X1,Compound Name,Clinical Phase,Mechanism of Action,Known Target,Disease Area,Indication
CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3,(R)-(-)-apomorphine,Launched,dopamine receptor agonist,ADRA2A|ADRA2B|ADRA2C|CALY|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A,neurology/psychiatry,Parkinson's Disease
COc1ccc([C@@H]2CNC(=O)C2)cc1OC1CCCC1,(R)-(-)-rolipram,Phase 1,phosphodiesterase inhibitor,PDE4A|PDE4B|PDE4C|PDE4D|PDE5A,,
NC[C@H](CC(=O)O)c1ccc(Cl)cc1,(R)-baclofen,Phase 3,benzodiazepine receptor agonist,GABBR1|GABBR2,,
COc1ccc([C@H]2CNC(=O)C2)cc1OC1CCCC1,(S)-(+)-rolipram,Phase 1,phosphodiesterase inhibitor,PDE4B|PDE4D,,
CC(C)C[C@H](NC(=O)CN(C)C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](CCS(C)(=O)=O)C(N)=O,"[sar9,met(o2)11]-substance-p",Preclinical,tachykinin antagonist,TACR1,,
Cl/C=C\C[N+]12CN3CN(CN(C3)C1)C2,"1-((Z)-3-chloroallyl)-1,3,5,7-tetraazaadamantan-1-ium",Preclinical,,,,
c1ccc(C[C@H](c2ccccc2)N2CCCCC2)cc1,"1-(1,2-diphenylethyl)piperidine-(+/-)",Preclinical,glutamate receptor antagonist,,,
Cc1ccc(Cl)c(OC[C@H](O)CNC(C)C)c1,1-(2-chloro-5-methylphenoxy)-3-(isopropylamino)-2-propanol,Preclinical,,,,
CC(=O)N1CCN(C)CC1,1-acetyl-4-methylpiperazine,Preclinical,acetylcholine receptor agonist,,,
O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ncccc2N1,1-azakenpaullone,Preclinical,glycogen synthase kinase inhibitor,CCNB1|CDK1|CDK5|GSK3B,,
OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O,1-deoxymannojirimycin,Preclinical,alpha mannosidase inhibitor,MAN2A1,,
CCn1c(=O)[nH]c2ccccc21,1-EBIO,Preclinical,potassium channel activator,KCNN1|KCNN2|KCNN3|KCNN4,,
CCN1CCCC1=O,1-ethyl-2-pyrrolidone,Preclinical,transdermal absorption-enhancing compound,,,
CCCCCCCCCCCCCCCC=O,1-hexadecanal,Preclinical,sphingosine 1-phosphate receptor substrate,DBI|RHO,,
CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc21,1-naphthyl-PP1,Preclinical,SRC inhibitor,SRC,,
CCCCCCCCCCCCCCCCCCCCCCCCCCCCO,1-octacosanol,Phase 2,,,,
N=C(N=C(N)N)Nc1ccccc1,1-phenylbiguanide,Preclinical,serotonin receptor agonist,HTR3A|HTR3B,,
CCNCCCNCCCCNCCCNCC,"1,12-Besm",Phase 2,polyamine biosynthesis inhibitor,,,
BrC1C(Br)C(Br)C(Br)C(Br)C1Br,"1,2,3,4,5,6-hexabromocyclohexane",Preclinical,JAK inhibitor,JAK2,,
CCCn1c(=O)c2[nH]c(-c3ccccc3)nc2n(CCC)c1=O,"1,3-dipropyl-8-phenylxanthine",Preclinical,adenosine receptor antagonist,,,
O=C(/C=C/c1ccc(O)c(O)c1)O[C@@H]1C[C@](OC(=O)/C=C/c2ccc(O)c(O)c2)(C(=O)O)C[C@@H](O)[C@H]1O,"1,5-dicaffeoylquinic-acid",Phase 1,,,,
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](O)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C,10-deacetylbaccatin,Preclinical,antitumor agent,,,
CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21,10-DEBC,Preclinical,AKT inhibitor,PIM1,,
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3cc(O)ccc3nc2-1,10-hydroxycamptothecin,Preclinical,topoisomerase inhibitor,TOP1,,
CCc1ccc(/C=C2/SC(=S)NC2=O)cc1,10058-F4,Preclinical,c-Myc inhibitor,,,
CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@@]2(O)[C@@H](C=C(CO)C[C@]3(O)C(=O)C(C)=C[C@@H]23)[C@@H]2C(C)(C)[C@]12OC(C)=O,12-O-tetradecanoylphorbol-13-acetate,Phase 2,PKC activator,KCNT2|TRPV4,,
CC(=N)NCc1cccc(CN)c1,1400W,Preclinical,nitric oxide synthase inhibitor,NOS1|NOS2|NOS3,,
CCCCC(C)(C)[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1C/C=C\CCCC(=O)O,"16,16-dimethylprostaglandin-e2",Phase 2,prostanoid receptor agonist,HPGD,,
CCCCCC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,17-hydroxyprogesterone-caproate,Launched,progesterone receptor agonist,AR|ESR1|ESR2|NR1H4|NR1I2|NR3C1|PGR,obstetrics/gynecology,spontaneous preterm birth
C[C@]12CC[C@@H](O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3ccccc3)=CC[C@@H]12,17-PA,Preclinical,glucocorticoid receptor agonist,,,
CCCCCCCCCCC[C@@H](N=O)c1cc(C)ccc1O,1E-1-(2-hydroxy-5-methylphenyl)-1-dodecanone-oxime,Preclinical,,,,
O=C(O)c1ccccc1NC(=O)C12CC3CC(CC(C3)C1)C2,2-(1-adamantylamino)benzoic-acid,Preclinical,,,,
O=C(O)CC[C@@H](CCCS)C(=O)O,2-(3-mercaptopropyl)pentanedioic-acid,Phase 1,glutamate carboxypeptidase inhibitor,FOLH1,,
O=C1NC(=CCl)Nc2sc3c(c21)CCCC3,"2-(chloromethyl)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one",Preclinical,,,,
c1ccc2sc(N3CCN(Cc4ccc5c(c4)OCO5)CC3)nc2c1,2-[1-(4-piperonyl)piperazinyl]benzothiazole,Preclinical,serotonin receptor agonist,HTR4,,
Nc1ccccc1S(N)(=O)=O,2-aminobenzenesulfonamide,Preclinical,carbonic anhydrase inhibitor,CA12|CA14|CA2|CA6|CA9,,
NCCOB(c1ccccc1)c1ccccc1,2-APB,Preclinical,"1,4,5-trisphosphate inhibitor",TRPC1|TRPC3|TRPC4|TRPC5|TRPC6|TRPC7|TRPM2|TRPM3|TRPM6|TRPV1|TRPV6,,
c1ccc2oc(C3=NCCN3)cc2c1,2-BFI,Preclinical,imidazoline receptor ligand,ADRA2A|ADRA2B|ADRA2C|MAOA|MAOB,,
OC[C@H]1O[C@@H](n2cnc3c(NC4CCCC4)nc(Cl)nc32)[C@H](O)[C@@H]1O,2-chloro-N6-cyclopentyladenosine,Preclinical,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,2-chloroadenosine,Preclinical,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B,,
Clc1cnccn1,2-chloropyrazine,Preclinical,,,,
CN1CCN(C2=Cc3ccccc3Oc3ccc(Cl)cc32)CC1,2-CMDO,Preclinical,dopamine receptor antagonist,DRD2|DRD4,,
CN([NH2+][O-])C(=O)N[C@@H](C=O)[C@@H](O)[C@@H](O)[C@@H](O)CO,2-deoxy-2-([methyl(nitroso)carbamoyl]amino)hexose,Preclinical,,,oncology|endocrinology,pancreatic cancer|hypoglycemia
OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O,2-deoxyglucose,Phase 2,glycolysis inhibitor,SLC2A1|SLC2A2|SLC2A3|SLC2A4,,
CCOc1ccccc1C(=O)O,2-ethoxybenzoic-acid,Phase 1,analgesic agent,,,
OC[C@H]1O[C@@H](O)[C@@H](F)[C@@H](O)[C@@H]1O,2-fluoro-2-deoxy-D-galactose,Phase 1,,LCT,,
C[C@@H]1O[C@H](O)[C@@H](F)[C@H](O)[C@@H]1O,2-fluorofucose,Phase 1,,,,
O=C1C(=C(O)/C=C/c2ccc(O)cc2)C(=O)[C@@](O)([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C(=O)[C@H]1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,"2-hydroxy-4-((E)-3-(4-hydroxyphenyl)acryloyl)-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-6-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)cyclohexane-1,3,5-trione",Preclinical,,,,
O=C(OCCO)c1ccccc1O,2-hydroxyethyl-salicylate,Launched,,,neurology/psychiatry,pain relief
CC(C)(O)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,2-hydroxyflutamide,Phase 2,androgen receptor antagonist,AR,,
NC[C@@](O)(CS(=O)(=O)O)c1ccc(Cl)cc1,2-hydroxysaclofen,Preclinical,GABA receptor antagonist,GABBR1|GABBR2,,
NC1=N[C@H]2CS[C@@H](CCCCC(=O)O)[C@H]2N1,2-iminobiotin,Phase 2,nitric oxide synthase inhibitor,NOS1|NOS2,,
O=C(O)CNC(=O)c1ccccc1I,2-iodohippuric-acid,Preclinical,,,,
COc1ccc2[nH]c(I)c(CCNC(C)=O)c2c1,2-iodomelatonin,Preclinical,melatonin receptor agonist,MTNR1A|MTNR1B|NQO2,,
COc1cc2c(cc1O)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,2-methoxyestradiol,Phase 2,hypoxia inducible factor inhibitor,COMT|CYP19A1|CYP1A1|CYP1B1|HIF1A|TUBB,,
Cc1[nH]c2ccc(O)cc2c1CCN,2-methyl-5-hydroxytryptamine,Preclinical,serotonin receptor agonist,HTR1B|HTR1D|HTR1E|HTR1F|HTR3A|HTR3B|HTR6,,
Cc1ccc([N+](=O)[O-])cc1O,2-methyl-5-nitrophenol,Preclinical,,,,
Cc1ncc[nH]1,2-methylimidazole,Preclinical,cholesterol inhibitor,,,
CCCCCCCC/C=C\CCCCCCCC(=O)OC(CO)CO,2-oleoylglycerol,Phase 1,glucose dependent insulinotropic receptor ligand,GPR119,,
C=C(O)C(=O)O,2-oxopropanoate,Preclinical,pyruvate dehydrogenase kinase inhibitor,ABAT,,
COc1ccc2[nH]c(-c3ccccc3)c(CCNC(C)=O)c2c1,2-phenylmelatonin,Preclinical,melatonin receptor agonist,MTNR1A|MTNR1B,,
O=C1Nc2ccccc2C2=N[C@@H](CN3CCN(c4ccccc4)CC3)CN12,2-PMDQ,Preclinical,adrenergic receptor antagonist,ADRA1A,,
NCCc1ccccn1,2-pyridylethylamine,Preclinical,histamine receptor agonist,HRH1,,
N#C/C(=C\c1ccc(O)c(O)c1)C(=O)OCCc1cccs1,2-TEDC,Preclinical,lipoxygenase inhibitor,ALOX12,,
O=c1cc[nH]c(=S)[nH]1,2-thiouracil,Preclinical,,,,
CC1(C)[C@@H]2CC[C@@]1(C)[C@H](O)[C@@H]2O,"2,3-cis/exo-camphanediol",Phase 1,,,,
CC1(C)C2CC1[C@](C)(O)[C@H](O)C2,"2,3-cis/exo-pinanediol",Phase 1,,,,
OCCNCCCOc1cccc(Cl)c1Cl,"2,3-DCPE",Preclinical,BCL-XL downregulator,BCL2L1,,
O=[N+]([O-])c1ccc(Cl)c([N+](=O)[O-])c1,"2,4-dinitrochlorobenzene",Phase 2,thioredoxin inhibitor,TXN,,
O=[N+]([O-])c1ccc(O)c([N+](=O)[O-])c1,"2,4-dinitrophenol",Preclinical,ATP synthase inhibitor,APP,,
OCc1ccc(CO)o1,"2,5-furandimethanol",Phase 2,hemoglobin modulator,HBB,,
C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(=O)nc(N)[nH]c21,2'-C-methylguanosine,Preclinical,HCV inhibitor,,,
C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc21,2'-MeCCPA,Preclinical,adenosine receptor agonist,ADORA1,,
O=C(O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCCO,20-HETE,Preclinical,ion channel antagonist,,,
CC(C)(O)CC[C@@H](O)[C@](C)(O)[C@@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@@H]3CC[C@]12C,20-hydroxyecdysone,Phase 2,ecdysone receptor modulator,,,
Cc1ccc(/C=C2\C(=O)[C@]3(C)CC[C@H]2C3(C)C)cc1,3-(4-methylbenzylidene)camphor,Launched,endocrine disruptor,,dermatology,sunscreen lotion
CN1[C@@H]2CC[C@H]1C[C@@H](OC(c1ccc(F)cc1)c1ccc(F)cc1)C2,3-alpha-bis-(4-fluorophenyl)-methoxytropane,Preclinical,dopamine uptake inhibitor,CHRM1|SLC6A2|SLC6A3|SLC6A4,,
C[C@]12CC[C@@H](O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12,3-alpha-hydroxy-5-beta-androstan-17-one,Preclinical,,HSD17B11|IGHG2|SULT2A1,,
NC(=O)c1cccc(N)c1,3-amino-benzamide,Phase 2,PARP inhibitor,PARP1,,
OCCCNc1ccccc1,3-anilinopropan-1-ol,Preclinical,,,,
C=CCN1CCN(c2nc3ccccc3nc2C#N)CC1,3-AQC,Preclinical,serotonin receptor agonist,HTR3A,,
O=[N+]([O-])c1cccc2c(Br)[nH]nc12,3-bromo-7-nitroindazole,Preclinical,nitric oxide synthase inhibitor,NOS1|NOS2|NOS3,,
CC1(C)[C@H]2CC[C@@]1(C)C(=O)[C@H]2Br,3-bromocamphor,Launched,,,,
O=C(O)C(O)=CBr,3-bromopyruvate,Preclinical,hexokinase inhibitor,HK2,,
N[C@@H](C(=O)O)c1ccc(O)c(C(=O)O)c1,3-carboxy-4-hydroxyphenylglycine-(R),Preclinical,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B|GRIN2C,,
N[C@H](C(=O)O)c1ccc(O)c(C(=O)O)c1,3-carboxy-4-hydroxyphenylglycine-(S),Preclinical,glutamate receptor antagonist,GRM1|GRM5,,
CN1[C@@H]2CC[C@H]1C[C@@H](O[C@H](c1ccccc1)c1ccc(Cl)cc1)C2,3-CPMT,Preclinical,dopamine reuptake inhibitor,,,
Nc1nccc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,3-deazaadenosine,Phase 2,adenosylhomocysteinase inhibitor,AHCY,,
Nc1nccc2c1ncn2[C@@H]1C=C(CO)[C@@H](O)[C@H]1O,3-deazaneplanocin-A,Preclinical,histone lysine methyltransferase inhibitor,EZH2,,
O=c1cc(O)ccn1[C@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,3-deazauridine,Preclinical,cytidine deaminase inhibitor,,,
CC[C@@](O)(CC(N)=O)c1ccccc1,3-hydroxy-3-phenylpentanamide,Phase 1,GABA receptor modulator,,,
O=C(O)CCCc1c[nH]c2ccccc12,3-indolebutyric-acid,Preclinical,,B2M|HLA-A|TRAC|TRBC1,,
Cc1cc(C(=O)O)sc1[C@@H](N)C(=O)O,3-MATIDA,Preclinical,glutamate receptor antagonist,GRM1,,
C[C@@H](CN)CC(=O)O,3-methyl-GABA,Preclinical,GABA aminotransferase activator,ABAT,,
Cn1cnc(=N)c2[nH]cnc21,3-methyladenine,Preclinical,PI3K inhibitor,PI3,,
COc1ccccc1N1CCN(CCn2c(=O)[nH]c3c([nH]c4ccccc43)c2=O)CC1,3-MPPI,Preclinical,adrenergic receptor ligand,ADRA1A,,
Clc1cccc(/C=N/N=C/c2cccc(Cl)c2)c1,"3,3'-dichlorobenzaldazine",Preclinical,glutamate receptor modulator,GRM5,,
c1ccc2c(Cc3c[nH]c4ccccc34)c[nH]c2c1,"3,3'-diindolylmethane",Phase 3,"CHK inhibitor|cytochrome P450 activator|indoleamine 2,3-dioxygenase inhibitor",AR|HIF1A|IFNG|PI3,,
N[C@@H](C(=O)O)c1ccc(C(=O)O)c(C(=O)O)c1,"3,4-DCPG-(+/-)",Preclinical,glutamate receptor agonist,GRM8,,
N[C@@H](C(=O)O)c1ccc(C(=O)O)c(C(=O)O)c1,"3,4-DCPG-(R)",Preclinical,glutamate receptor antagonist,,,
N[C@H](C(=O)O)c1ccc(C(=O)O)c(C(=O)O)c1,"3,4-DCPG-(S)",Preclinical,glutamate receptor agonist,GRM8,,
O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2,"3,4-methylenedioxy-beta-nitrostyrene",Preclinical,SRC inhibitor|SYK inhibitor,SRC|SYK,,
N[C@H](C(=O)O)c1cc(O)cc(O)c1,"3,5-DHPG-(S)",Preclinical,glutamate receptor agonist,GRM1,,
O=C(CCCN1CCC2(CC1)C(=O)N(Cc1cccc(F)c1)CN2c1ccccc1)c1ccc(F)cc1,3'-fluorobenzylspiperone,Preclinical,dopamine receptor ligand,DRD2,,
O=C(/C=C/c1cccnc1)c1ccncc1,3PO,Preclinical,phosphofructokinase inhibitor,PFKFB3,,
O=C(c1ccc(F)cc1)C1CCN(CCCCc2ccccc2)CC1,4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine,Preclinical,serotonin receptor antagonist,HTR2A,,
NCc1ccc(C(=O)O)cc1,4-(aminomethyl)benzoic-acid,Preclinical,hemostatic agent,,,
CC(=O)N1CC[N+](C)(C)CC1,"4-acetyl-1,1-dimethylpiperazinium",Preclinical,acetylcholine receptor agonist,,,
Nc1ccc(C(=O)NCC(=O)O)cc1,4-aminohippuric-acid,Launched,,SLC22A6,nephrology,renal diagnostic agent
N[C@@H](C(=O)O)c1ccc(C(=O)O)c(O)c1,4-carboxy-3-hydroxyphenylglycine-(RS),Preclinical,glutamate receptor agonist|glutamate receptor antagonist,GRM1,,
N[C@H](C(=O)O)c1ccc(C(=O)O)c(O)c1,4-carboxy-3-hydroxyphenylglycine-(S),Preclinical,glutamate receptor agonist|glutamate receptor antagonist,GRM1|GRM2,,
N=C(N)Nc1ccc(Cl)cc1,4-chlorophenylguanidine,Preclinical,urokinase inhibitor,PLAUR,,
CC(C)[C@@H](C(=O)Nc1nccs1)c1ccc(Cl)cc1,4-CMTB,Preclinical,free fatty acid receptor agonist,FFAR2,,
C[N+]1(C)CCC(OC(=O)C(c2ccccc2)c2ccccc2)CC1,4-DAMP,Preclinical,cholinergic receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,,
OC[C@H]1O[C@@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)O[C@@H]3CO)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O,4-galactosyllactose,Preclinical,,,,
O=c1nc[nH]c2ccccc12,4-HQN,Preclinical,PARP inhibitor,PARP1,,
Cc1c(O)c(=O)n(-c2ccccc2)n1C,4-hydroxy-phenazone,Preclinical,,,,
O=C(NC1CCN(Cc2ccccc2)CC1)c1ccc(I)cc1,4-IBP,Preclinical,sigma receptor agonist,SIGMAR1,,
Ic1cc(-c2ccccc2)ncn1,4-iodo-6-phenylpyrimidine,Preclinical,macrophage migration inhibiting factor inhibitor,MIF,,
N[C@H](Cc1ccc(I)cc1)C(=O)O,4-iodo-L-phenylalanine,Preclinical,,DPP4,,
COc1ccc(-c2coc3cc(O)cc(O)c3c2=O)cc1,4-methylgenistein,Preclinical,protein tyrosine kinase inhibitor,CYP19A1|ESRRA|ESRRB|ESRRG|FASN,,
Cc1nc[nH]c1CCN,4-methylhistamine,Preclinical,histamine receptor agonist,HRH4,,
Cc1cc(=O)oc2c(C=O)c(O)ccc12,4-mu-8C,Preclinical,IRE1 inhibitor,ERN1,,
CCC(=O)N[C@@H]1Cc2ccccc2[C@H](c2ccccc2)C1,4-P-PDOT,Preclinical,melatonin receptor antagonist,MTNR1A|MTNR1B,,
O=S(=O)(O)c1ccc(O)cc1,4-phenolsulfonic-acid,Preclinical,,,,
c1ccc([C@@H]2CNCc3ccccc32)cc1,"4-phenyl-1,2,3,4-tetrahydroisoquinoline",Preclinical,dopamine release inhibitor,,,
c1ccc(CCCCN2CCC(c3ccccc3)CC2)cc1,4-PPBP,Preclinical,sigma receptor ligand,SIGMAR1,,
CCCc1ccc(C(=O)O)cc1,4-propylbenzoic-acid,Preclinical,,,,
N#Cc1ccncn1,4-pyrimidinecarbonitrile,Preclinical,,,,
CC(C)(C)c1ccc(O)cc1,4-tert-butylphenol,Preclinical,,,,
C1CCC2(CC1)CCNCC2,"4,4-pentamethylenepiperidine",Preclinical,M2 channel blocker,,,
Clc1ccc(C(c2ccc(Cl)cc2)C(Cl)(Cl)Cl)cc1,"4,4'-DDT",Preclinical,,,,
Brc1c(Br)c(Br)c2n[nH]nc2c1Br,"4,5,6,7-tetrabromobenzotriazole",Preclinical,casein kinase inhibitor,AKT1|CHEK1|CSNK2A1|GSK3B|LCK|MAP2K1|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|ROCK1|RPS6KB1|SGK1,,
NS(=O)(=O)c1ccc2c(c1)[C@H]1C=CC[C@@H]1[C@@H](c1ccc(Br)cc1)N2,4BP-TQS,Preclinical,nicotinic receptor agonist,CHRNA7,,
O=C(O)c1ccc(N2C(=O)/C(=C/c3ccc(-c4ccc([N+](=O)[O-])cc4)o3)C=C2c2ccccc2)cc1,4E1RCat,Preclinical,protein synthesis inhibitor,EIF4E|EIF4G1,,
O=C(O)C(Cc1ccccc1[N+](=O)[O-])=NNc1nc(-c2ccc(Cl)c(Cl)c2)cs1,4EGI-1,Preclinical,protein synthesis inhibitor,EIF4E,,
Cn1cc(-c2ccc(S(=O)(=O)n3ccc(/C=C/C(=O)Nc4ccccc4N)c3)cc2)cn1,4SC-202,Phase 1,HDAC inhibitor,HDAC1,,
CCn1c(-c2ccc(Cl)cc2)n[nH]c1=O,"5-(4chlorophenyl)-4-ethyl-2,4-dihydro-3H-1,2,4-triazol-3-one",Preclinical,,,,
Nc1nc(=O)c2sc(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1,"5-amino-3-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione",Preclinical,,TLR7,,
NCC(=O)CCC(=O)O,5-aminolevulinic-acid,Launched,oxidizing agent,ALAD,oncology|dermatology,glioma|actinic keratosis (AK)
O=C1CN=C(c2cccc(Br)c2)c2oc3ccccc3c2N1,5-BDBD,Preclinical,purinergic receptor antagonist,P2RX4,,
NCCc1c[nH]c2ccc(C(N)=O)cc12,5-carboxamidotryptamine,Preclinical,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7,,
OCc1cncc(F)c1,5-fluoro-3-pyridyl-methanol,Preclinical,,,,
Fc1cncnc1,5-fluoropyrimidine,Phase 3,kinase inhibitor,,,
O=c1[nH]cc(F)c(=O)[nH]1,5-fluorouracil,Launched,thymidylate synthase inhibitor,DPYD|TYMS,oncology,colorectal cancer|breast cancer|pancreatic cancer|gastric adenocarcinoma
O=c1ncc(F)c[nH]1,5-FP,Phase 1,thymidylate synthase inhibitor,TYMS,,
O=Cc1ccc(CO)o1,5-HMF,Phase 2,,,,
CCCCC[C@@H](O)CCCC(=O)O,5-hydroxydecanoic-acid,Preclinical,,,,
CC1=NC[C@H](O)[C@@H](C(=O)O)N1,5-hydroxyectoine,Preclinical,,,,
CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C,5-hydroxymethyl-tolterodine,Phase 1,acetylcholine receptor antagonist,CHRM3,,
N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(=O)O,5-hydroxytryptophan,Launched,neurotransmitter,SLC36A1|SLC36A2,neurology/psychiatry,insomnia
Ic1cncc(OC[C@@H]2CCN2)c1,5-iodo-A-85380,Phase 2,acetylcholine receptor agonist,,,
Cc1ccc(C[N+](C)(C)C)o1,5-methylfurmethiodide,Preclinical,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4,,
C[C@H]1NC(=O)NC1=O,5-methylhydantoin-(D),Preclinical,,,,
C[C@@H]1NC(=O)NC1=O,5-methylhydantoin-(L),Preclinical,,,,
CCCCCCCC(=O)c1ccc(O)c(C(=O)O)c1,5-octanoylsalicylic-acid,Preclinical,protein kinase activator,,,
O=C(O)c1cc(=O)c2c(Cl)cc(Cl)cc2[nH]1,"5,7-dichlorokynurenic-acid",Preclinical,glutamate receptor antagonist,GLRA2|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,,
O[C@@H]1[C@H](O)[C@@H](CCl)O[C@H]1n1cnc2c(N[C@H]3C[C@@H]4CC[C@H]3C4)ncnc21,5'-chloro-5'-deoxy-ENBA-(+/-),Preclinical,adenosine receptor agonist,ADORA1,,
Nc1cc2c3ccccc3ccc2c2ccccc12,6-aminochrysene,Phase 2,transferase inhibitor,,,
CC1(C)S[C@@H]2[C@H](N)C(=O)N2[C@H]1C(=O)O,6-aminopenicillanic-acid,Preclinical,,,,
c1ccc(CNc2ncnc3nc[nH]c23)cc1,6-benzylaminopurine,Preclinical,purinergic receptor activator,,,
COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl,6-chloromelatonin,Preclinical,melatonin receptor agonist,MTNR1A|MTNR1B,,
N#[N+]CC(=O)CC[C@H](N)C(=O)O,6-diazo-5-oxo-L-norleucine,Preclinical,glutamate receptor antagonist|glutaminase inhibitor,,,
CCCCCCCCC(=O)NCc1cc(OC)c(O)cc1I,6-iodo-nordihydrocapsaicin,Preclinical,TRPV antagonist,TRPV1,,
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,"6,7-dehydro-17-acetoxy-progesterone",Preclinical,steroidal progestin,,,
CC(=O)OCC1=C(C(=O)O)N2C(=O)[C@@H](N)[C@H]2SC1,7-aminocephalosporanic-acid,Preclinical,beta lactamase inhibitor,,,
O=C(O)c1cc(=O)c2ccc(Cl)cc2[nH]1,7-chlorokynurenic-acid,Preclinical,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B|GRIN2C,,
CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1,7-hydroxy-DPAT,Preclinical,dopamine receptor agonist,DRD2|DRD3,,
CCCN(C/C=C/I)[C@H]1CCc2ccc(O)cc2C1,7-hydroxy-PIPAT,Preclinical,dopamine receptor ligand,DRD3,,
CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O,7-hydroxystaurosporine,Phase 2,CDK inhibitor|CHK inhibitor|PKC inhibitor,CDK1|CHEK1|CHEK2|GSK3B|LCK|MAPK14|MARK1|MARK3|PDPK1|PRKCA|PRKCB|PRKCD|PRKCE|PRKCG,,
CC(=O)O[C@H]1CC[C@@]2(C)C(=CC(=O)[C@@H]3[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]32)C1,7-keto-DHEA,Launched,steroid,,,
COc1ccc2nc3c(c(N)c2c1)CCCC3,7-methoxytacrine,Phase 2,acetylcholinesterase inhibitor,ACHE,,
Cn1cnc2[nH]c(=O)[nH]c(=O)c21,7-methylxanthine,Phase 2,adenosine receptor antagonist,,,
O=[N+]([O-])c1cccc2c[nH]nc12,7-nitroindazole,Preclinical,nitric oxide synthase inhibitor,NOS1|NOS2|NOS3,,
O=C1c2ccccc2NC2=CCCCCN12,"7,8,9,10-tetrahydroazepino[2,1-b]quinazolin-12(6H)-one",Preclinical,,,,
Nc1ncnc2c1nc(Br)n2[C@@H]1O[C@@H]2CO[P@@](=O)(O)O[C@H]2[C@H]1O,8-bromo-cAMP,Preclinical,PKA activator,,,
Nc1nc(=O)c2nc(Br)n([C@@H]3O[C@@H]4CO[P@@](=O)(O)O[C@H]4[C@H]3O)c2[nH]1,8-bromo-cGMP,Preclinical,PKA activator,PRKG1,,
CCCN(CCC)[C@H]1CCc2cccc(O)c2C1,8-hydroxy-DPAT,Preclinical,serotonin receptor agonist,HTR5A|HTR7,,
CCCN(C/C=C/I)[C@H]1CCc2cccc(O)c2C1,8-hydroxy-PIPAT,Preclinical,dopamine receptor ligand,DRD2|DRD3,,
CCC(=O)N[C@H]1CCc2cccc(OC)c2C1,8-M-PDOT,Preclinical,melatonin receptor agonist,MTNR1A|MTNR1B,,
Cc1oc(=O)oc1CCl,80841-78-7,Preclinical,,,,
Nc1c2ccccc2nc2ccccc12,9-aminoacridine,Preclinical,,,,
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(N)cccc3nc2-1,9-aminocamptothecin,Phase 2,topoisomerase inhibitor,TOP1,,
O=C(O)c1c2ccccc2cc2ccccc12,9-anthracenecarboxylic-acid,Preclinical,,ANO1|CLCN1,,
COc1ccc2c(NC(=O)Nc3cccc(C(F)(F)F)n3)ccnc2c1,A-1070722,Preclinical,glycogen synthase kinase inhibitor,GSK3A|GSK3B,,
O=C(O)c1ccccc1NC(=O)N1CCC(c2ccccc2C(F)(F)F)CC1,A-1120,Preclinical,retinoid receptor ligand,RBP4,,
O=C(O)c1cc(C(=O)O)c(C(=O)N(Cc2cccc(Oc3ccccc3)c2)[C@H]2CCCc3ccccc32)cc1C(=O)O,A-317491,Preclinical,purinergic receptor antagonist,P2RX3,,
CC(=O)N[C@@H]1N=C(c2ccccc2)c2ccccc2NC1=O,A-33903,Phase 2,,,,
COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1,A-366,Preclinical,histone lysine methyltransferase inhibitor,EHMT1|EHMT2,,
Cc1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)cc1C,A-381393,Preclinical,dopamine receptor antagonist,,,
Cc1cccc(NC(=O)CN2CCC(c3ccccn3)CC2)c1,A-412997,Preclinical,dopamine receptor agonist,DRD4,,
Clc1cccc(-c2nnnn2Cc2cccnc2)c1Cl,A-438079,Preclinical,purinergic receptor antagonist,P2RX7,,
CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O,A-485,Preclinical,histone acetyltransferase inhibitor,,,
CN1C[C@@H]2CN(c3ccc(-c4ccccc4)nn3)C[C@@H]2C1,A-582941,Preclinical,nicotinic receptor agonist,CHRNA7,,
CS(=O)(=O)Nc1c(O)ccc2c1CCC[C@@H]2C1=NCCN1,A-61603,Preclinical,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D,,
Cc1[nH]nc2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12,A-674563,Preclinical,AKT inhibitor,AKT1|PKIA|PRKACA,,
NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12,A-7,Preclinical,calmodulin antagonist,,,
N#Cc1c(O)c2c(-c3ccc(-c4ccccc4O)cc3)csc2[nH]c1=O,A-769662,Preclinical,AMPK activator,,,
O=C(Nc1ccc(S(=O)(=O)C(F)(F)F)cc1)C1=CCN(c2ncccc2C(F)(F)F)CC1,A-784168,Preclinical,transient receptor potential channel antagonist,TRPV1,,
COc1cc(NC(=O)c2ccc(-c3ccc(Cl)cc3)o2)cc(OC)c1,A-803467,Preclinical,sodium channel blocker,SCN10A,,
C[C@H](N/C(=N\c1cccc2ncccc12)NC#N)c1ccccc1,A-804598,Preclinical,purinergic receptor antagonist,P2RX7,,
C[C@H](/N=C(/NC#N)Nc1cccc2ncccc12)c1ccccc1,A-804598,Preclinical,purinergic receptor antagonist,P2RX7,,
Clc1cccc(-n2nnnc2NCc2ccccc2Oc2ccccn2)c1Cl,A-839977,Preclinical,purinergic receptor antagonist,P2RX7,,
CCC(=O)c1cc(-c2ccc(Cl)cc2)n(-c2ccc(S(N)(=O)=O)cc2)c1C,A-867744,Preclinical,acetylcholine receptor allosteric modulator,CHRNA3|CHRNA4|CHRNA7,,
CCCCOc1ccc(-c2cncc(C(=O)NCc3cccnc3N3CCOCC3)c2)cc1Cl,A-887826,Preclinical,sodium channel blocker,SCN10A,,
O=C(Nc1ccccc1)Nc1ccc(-c2ccc(C(=O)[C@@H]3CCC[C@H]3C(=O)O)cc2)cc1,A-922500,Preclinical,diacylglycerol O acyltransferase inhibitor,DGAT1,,
CNC(=O)c1cccc(NC(=O)N2CCC(Oc3ccccc3Cl)CC2)c1,A-939572,Preclinical,stearoyl-CoA desaturase inhibitor,SCD,,
CCC(=N\O)/C(C)=C/c1ccc(F)cc1,A-967079,Preclinical,transient receptor potential channel antagonist,TRPA1,,
Nc1nc2c(c(N3CCNCC3)n1)CCC1=C2[C@@H]2CCCC[C@@H]2O1,A-987306,Preclinical,histamine receptor antagonist,ADORA1|AVPR1A|CCR1|CHRM1|CHRM2|CHRM3|CHRM4|DRD3|HTR1A|HTR1B|HTR2A|HTR2B|HTR3A|TACR2,,
CC1=C(C)C(=O)C(CC[C@](C)(O)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C1=O,A0001,Phase 2,,,,
CCCCCCCCCC[C@@H](O)[C@H]1C=C[C@@H]2C(=O)N(c3ccccc3)C(=O)[C@@H]2N1Nc1ccc([N+](=O)[O-])cc1,A12B4C3,Preclinical,polynucleotide kinase/phosphatase inhibitor,PNKP,,
Cc1ccc(Sc2cncc3sc(C(N)=O)cc23)cc1,A205804,Preclinical,ICAM1 expression inhibitor,ICAM1|SELE,,
CS(=O)(=O)Nc1c(O)ccc2c1CCC[C@H]2C1=NCCN1,A61603,Preclinical,adrenergic receptor agonist,ADRA1A,,
Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(C(C)(C)C)n1,A66,Preclinical,PI3K inhibitor,PIK3CA,,
COc1ccc(CC(=O)N[C@@H](N/C(=N/C#N)Nc2cccc3ncccc23)C(C)(C)C)cc1OC,A740003,Preclinical,purinergic receptor antagonist,P2RX7,,
NC[C@@H]1O[C@H](C23CC4CC(CC(C4)C2)C3)Cc2c1ccc(O)c2O,A77636,Preclinical,dopamine receptor agonist,CALY,,
O=C(Nc1ccccc1)Nc1ccc(-c2ccc(C(=O)[C@@H]3CCC[C@@H]3C(=O)O)cc2)cc1,A922500,Preclinical,diacylglycerol O acyltransferase inhibitor,DGAT1,,
CCOC(=O)Nc1ccc(NCc2c(C)cc(C)cc2C)cc1N,AA-29504,Preclinical,GABA receptor positive allosteric modulator,GABRA1|GABRA4|GABRB3,,
C[n+]1ccn(C[C@@]2(C)[C@H](C(=O)O)N3C(=O)C[C@H]3S2(=O)=O)n1,AAI101,Phase 3,lactamase inhibitor,,,
CC[C@@H](C)NS(=O)(=O)c1ccc(F)c(C(=O)Nc2ccc(F)c(F)c2)c1,AB-423,Preclinical,HBV capsid assembly inhibitor,,,
Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,abacavir,Launched,nucleoside reverse transcriptase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)
Cc1ccc(Oc2ccccc2-c2csc(NC3=NCCCN3)n2)c(C)c1,abafungin,Phase 3,sterol methyltransferase inhibitor,,,
CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(C=C[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@]54O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,abamectin,Launched,benzodiazepine receptor agonist,GABBR1|GABBR2,infectious disease,gastrointestinal parasites
Cc1ccc(-c2ccc(C)cn2)nc1,abametapir,Phase 3,metalloproteinase inhibitor,MMP9,,
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N(C)[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,abarelix,Phase 3,gonadotropin releasing factor hormone receptor antagonist,GNRHR,,
CCNC(=O)c1cc2c(-c3cc(C(C)(C)O)ccc3Oc3c(C)cc(F)cc3C)cn(C)c(O)c-2n1,ABBV-744,Phase 1,bromodomain inhibitor,,,
O=C(NCc1ccncc1)[C@@]12C[C@H]3C[C@@H](C1)C[C@](c1ccc(Cl)cc1)(C3)C2,ABC-294640,Phase 2,sphingosine kinase inhibitor,SPHK2,,
CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,abemaciclib,Launched,CDK inhibitor,CDK4|CDK6,oncology,breast cancer
C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,abiraterone,Launched,androgen biosynthesis inhibitor,CYP11B1|CYP17A1,oncology,prostate cancer
CC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@@H]3[C@@H]2CC[C@]2(C)C(c4cccnc4)=CC[C@@H]32)C1,abiraterone-acetate,Launched,androgen biosynthesis inhibitor,CYP17A1,oncology,prostate cancer
COc1c(/C=C/c2ccc(NS(C)(=O)=O)cc2)cc(-n2ccc(=O)[nH]c2=O)cc1C(C)(C)C,ABT-072,Phase 2,RNA polymerase inhibitor,,,
N[C@H]1CCN(c2cccnc2)C1,ABT-202,Phase 1,acetylcholine receptor agonist,,,
C[C@@H]1CCCN1CCc1cc2cc(-c3ccc(C#N)cc3)ccc2o1,ABT-239,Phase 1,histamine receptor antagonist,HRH1|HRH2|HRH3,,
C#Cc1cccc2c1c(C(=O)c1ccc(Cn3c(C)nc4cnccc43)c(F)c1)cn2C(=O)N(C)C,ABT-491,Phase 1,platelet activating factor receptor antagonist,PTAFR,,
O=C(c1cc(S(=O)(=O)Nc2ccccc2F)c(F)cc1Cl)N1CCN2CCC[C@@H]2C1,ABT-639,Phase 2,calcium channel blocker,CACNA1G|CACNA1H|CACNA1I,,
Nc1ncnc2nc(-c3ccc(N4CCOCC4)nc3)cc(-c3cccc(Br)c3)c12,ABT-702,Preclinical,adenosine kinase inhibitor,ADK,,
c1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)nc1,ABT-724,Phase 2,dopamine receptor agonist,DRD4,,
CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-],ABT-737,Phase 1/Phase 2,BCL inhibitor,BCL2|BCL2L1|BCL2L2,,
COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1,ABT-751,Phase 2,tubulin polymerization inhibitor,TUBB,,
O=C(OC(C(F)(F)F)C(F)(F)F)N1CCN(Cc2ccc(C(F)(F)F)cc2N2CCCC2)CC1,ABX-1431,Phase 2,monoacylglycerol lipase inhibitor,,,
FC(F)(F)Oc1ccc(Nc2ccc3cccc(Cl)c3n2)cc1,ABX464,Phase 2,antiviral,,,
Oc1ccc(C2(c3ccccc3F)CCC(F)(F)CC2)cc1,AC-186,Preclinical,estrogen receptor agonist,ESR2,,
CCCCOCCOc1nc(-c2ccc(C(=O)O)c(F)c2)sc1C,AC-261066,Preclinical,retinoid receptor agonist,RARB,,
C/C(=N\NC(=O)[C@@H]1C(=O)NC[C@H]1c1ccccc1)c1cccc(Br)c1,AC-264613,Preclinical,PAR agonist,F2RL1,,
C/C(=N\NC(=O)[C@@H](NC(=O)c1ccccc1)c1n[nH]c(=O)c2ccccc12)c1cccc(Br)c1,AC-55541,Preclinical,PARP inhibitor,PARP2,,
CCCCCCCCc1ccc(-c2ccc(C(=O)O)cc2)cc1,AC-55649,Preclinical,retinoid receptor agonist,RARA|RARB,,
CCN1C(C)(C)CC(Oc2ccc(C(=O)Nc3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)nc2)CC1(C)C,AC-710,Preclinical,PDGFR tyrosine kinase receptor inhibitor,CSF1R|FLT3|KIT|PDGFRA|PDGFRB,,
CN(C)CC[C@@]1(c2ccc(Cl)cc2)Cc2ccccc2C(=O)O1,AC-7954-(+/-),Preclinical,urotensin receptor agonist,UTS2R,,
CCCCCCCCCCCCCCCCCC[S+](CCC)c1ccccc1C(=O)OCC,AC1NDSS5,Phase 1,,,,
CCCCC1CCN(CCCN2C(=O)COc3cc(F)ccc32)CC1,AC260584,Preclinical,cholinergic receptor agonist,,,
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N,acadesine,Phase 3,AMPK activator,,,
CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,acalabrutinib,Launched,Bruton's tyrosine kinase (BTK) inhibitor,BTK,hematologic malignancy,mantle cell lymphoma (MCL)
C[C@H](Nc1ncnc2nc[nH]c12)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1,acalisib,Phase 1,PI3K inhibitor,PIK3CB|PIK3CD,,
C[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)O[C@@H]3CO)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,acarbose,Launched,glucosidase inhibitor,AMY2A|MGAM,endocrinology,diabetes mellitus
CN(C)c1nc(N)c(C(=O)Nc2cccnc2)nc1Cl,ACDPP,Preclinical,glutamate receptor antagonist,GRM5,,
O=C(O)c1ccc(CN2C[C@@H]3C[C@H]2CN3Cc2ccc(Oc3ccc(-c4ncco4)cc3)cc2)cc1,acebilustat,Phase 2,leukotriene inhibitor,,,
CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(C(C)=O)c1,acebutolol,Launched,adrenergic receptor antagonist,ADRB1,cardiology,hypertension|ventricular arrhythmias
CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1,acecainide,Phase 3,polarization inhibitor,SCN5A,,
CC(=O)O[C@H]1CN2CCC1CC2,aceclidine,Launched,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,ophthalmology,glaucoma
O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl,aceclofenac,Launched,prostanoid receptor antagonist,PTGS2,rheumatology,rheumatoid arthritis|ankylosing spondylitis|osteoarthritis|periarthritis|lumbago|ischiadynia
CC(=O)Nc1ccc(S(=O)(=O)c2ccc(NC(C)=O)cc2)cc1,acedapsone,Launched,,,infectious disease,leprosy
CC(=O)Nc1ccc(C(=O)O)cc1,acedoben,Phase 2,,,,
Cn1c(=O)c2c(ncn2CC(=O)O)n(C)c1=O,acefylline,Launched,adenosine receptor agonist,ADORA1,pulmonary,asthma
CC(=O)N[C@@H](CCC(N)=O)C(=O)O,aceglutamide,Launched,,,gastroenterology,peptic ulcer disease (PUD)
C[C@H](N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O)Oc1ccccc1)C(=O)OCc1ccccc1,acelarin,Phase 2/Phase 3,anticancer agent,,,
COc1ccc2c(c1)c(CC(=O)OCC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,acemetacin,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,osteoarthritis
CC(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CO)O[C@](O)(C(=O)O)C[C@@H]1O,aceneuramic-acid,Phase 3,,CES1|SELE|SELP,,
CC(=O)C[C@@H](c1ccc([N+](=O)[O-])cc1)c1c(O)c2ccccc2oc1=O,acenocoumarol,Launched,vitamin K antagonist,VKORC1,hematology,deep vein thrombosis (DVT)
CC(=O)c1ccc2c(c1)N(CCCN(C)C)c1ccccc1S2,acepromazine,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|DRD1|DRD2|HTR1A|HTR2A,neurology/psychiatry,sedative
CC1=CC(=O)NS(=O)(=O)O1,acesulfame-potassium,Phase 3,,,,
CC(=O)Nc1ccccc1,acetanilide,Preclinical,hydrogen peroxide decomposition inhibitor,,,
CC(=O)Nc1cc([As](=O)(O)O)ccc1O,acetarsol,Launched,,,gastroenterology,diarrhea
CC(=O)Nc1nnc(S(N)(=O)=O)s1,acetazolamide,Launched,carbonic anhydrase inhibitor,AQP1|CA1|CA12|CA14|CA2|CA3|CA4|CA7,ophthalmology,glaucoma
CC(=O)c1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,acetohexamide,Launched,ATP channel blocker,ABCC8|KCNJ1|KCNJ10|KCNJ11,endocrinology,diabetes mellitus
CC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2,acetophenazine,Launched,dopamine receptor antagonist,DRD1|DRD2,neurology/psychiatry,psychosis
CC(=O)Nc1c(I)cc(I)c(C(=O)O)c1I,acetriazoic-acid,Preclinical,,,,
CC(=O)O[C@@H]1CC[C@@]2(C)[C@@H](CC[C@]3(C)[C@H]2C(=O)C=C2[C@@H]4[C@@H](C)[C@H](C)CC[C@]4(C)CC[C@]23C)[C@@]1(C)C(=O)O,acetyl-11-keto-beta-boswellic-acid,Phase 2,lipoxygenase inhibitor,HSD11B1|HSD11B2,,
CC(=O)N[C@@H](CSC/C=C(\C)CC/C=C(\C)CCC=C(C)C)C(=O)O,acetyl-farnesyl-cysteine,Launched,methyltransferase inhibitor,PPARG,dermatology,acne vulgaris (AV)
CC(=O)N[C@@H](CC(C)C)C(=O)O,acetyl-l-leucine,Launched,,,neurology/psychiatry,vertigo
CC(=O)OCC[N+](C)(C)C,acetylcholine,Launched,acetylcholine receptor agonist,ACHE|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|CHRNA2,neurology/psychiatry|gastroenterology|pulmonary,drowsiness|fatigue|headache|indigestion|chest congestion
CC(=O)N[C@@H](CS)C(=O)O,acetylcysteine,Launched,mucolytic agent,ACY1|CHUK|GRIN1|GRIN2A|GRIN2B|GRIN2D|GRIN3A|GSS|IKBKB|RELA|SLC7A11,gastroenterology,acetaminophen overdose|hepatic injury
CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(=O)O,acetylsalicylsalicylic-acid,Preclinical,cyclooxygenase inhibitor,,,
CO[C@@H]1[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O[C@H]2CC[C@H](N(C)C)[C@@H](C)O2)/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]1OC(C)=O,acetylspiramycin,Preclinical,other antibiotic,,,
CC(=O)NCCCCCC(=O)O,acexamic-acid,Launched,5 alpha reductase inhibitor,GAST,dermatology,wound healing
C[C@@]1(c2ccccc2)OC(C(=O)O)=CC1=O,acifran,Phase 3,cholesterol inhibitor,HCAR2|HCAR3,,
Cc1cnc(C(=O)O)c[n+]1[O-],acipimox,Launched,cholesterol inhibitor,HCAR2,endocrinology,hyperlipidemia
O=C(O)C(=O)Nc1cccc(-c2nn[nH]n2)c1,acitazanolast,Launched,mediator release inhibitor,,allergy,allergic rhinitis
COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C,acitretin,Launched,retinoid receptor agonist,RARA|RARB|RARG|RBP1|RXRA|RXRB|RXRG|STAT3,dermatology,psoriasis
N[C@@H](C(=O)O)[C@@H]1CC(Cl)=NO1,acivicin,Phase 2,gamma glutamyltransferase inhibitor,CTPS1,,
CC[C@@]1(O)C[C@H](O[C@H]2C[C@H](N(C)C)[C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)c2c(cc3c(c2O)C(=O)c2c(O)cccc2C3=O)[C@H]1C(=O)OC,aclarubicin,Launched,topoisomerase inhibitor,TOP1|TOP2A,hematologic malignancy,acute myeloid leukemia (AML)
O=C(O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)C(O)(c1cccs1)c1cccs1,aclidinium,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,pulmonary,bronchitis|emphysema|chronic obstructive pulmonary disease (COPD)
CC1=C(c2ccc(O)cc2)[C@H](c2ccc(OCCN3CCCCC3)cc2)Oc2cc(O)ccc21,acolbifene,Phase 3,estrogen receptor antagonist,,,
CC1(C)OB(O)c2cc(NC(=O)c3ccc(F)cc3C(F)(F)F)ccc21,acoziborole,Preclinical,antitrypanosomal,,,
NC1(C(=O)O)CC1,ACPC,Phase 1,glutamate receptor antagonist,,,
C[n+]1c2cc(N)ccc2cc2ccc(N)cc21.Nc1ccc2cc3ccc(N)cc3nc2c1,acriflavine,Launched,hypoxia inducible factor inhibitor,HIF1A,infectious disease,fungal infection
C[n+]1c2cc(N)ccc2cc2ccc(N)cc21,acriflavinium,Launched,hypoxia inducible factor inhibitor,HIF1A,infectious disease,fungal infection
CCCCCCc1ccc(O)cc1O.Nc1c2ccccc2nc2ccccc12,acrisorcin,Launched,other antifungal,,infectious disease,fungal infection
Cc1ccc(/C(=C\CN2CCCC2)c2cccc(/C=C/C(=O)O)n2)cc1,acrivastine,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis
NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1,ACT-132577,Launched,endothelin receptor antagonist,EDNRA|EDNRB,pulmonary,pulmonary arterial hypertension (PAH)
COc1ccc(S(=O)(=O)N2CCC[C@H]2C(=O)Nc2cc(C)cc(C)c2)cc1,ACT-462206,Phase 1,orexin receptor antagonist,HCRTR1|HCRTR2,,
CC(=O)Nc1ccc(CC(=O)O)cc1,actarit,Launched,interleukin receptor agonist,,rheumatology,rheumatoid arthritis
COCc1c(-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)c(F)c2)c2c(N)ncnn2c1CN1CCOCC1,ACTB-1003,Phase 1,FGFR inhibitor|VEGFR inhibitor,KDR|TEK,,
Cc1c2oc3c(C)ccc(C(=O)N[C@@H]4C(=O)N[C@@H](C(C)C)C(=O)N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)c3nc-2c(C(=O)N[C@@H]2C(=O)N[C@@H](C(C)C)C(=O)N3CCC[C@H]3C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]2C)c(N)c1=O,actinomycin-d,Launched,RNA polymerase inhibitor,,oncology,Wilm's tumor|Ewing's sarcoma|rhabdomyosarcoma|testicular carcinoma
CCOc1ccc(S(=O)(=O)O)c2cccnc12,actinoquinol,Preclinical,,,,
Cc1ccc(C(=O)NC2CC2)cc1-n1ncc(C(=O)c2cccc(C#N)c2)c1N,acumapimod,Phase 1,p38 MAPK inhibitor,,,
O=C(CCCCCCNC(=O)c1cnc(N(c2ccccc2)c2ccccc2)nc1)NO,ACY-1215,Phase 1/Phase 2,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC6|HDAC8,,
Nc1nc(=O)c2ncn(COCCO)c2[nH]1,acyclovir,Launched,DNA polymerase inhibitor,PNP,infectious disease,genitial herpes|shingles|chicken pox
CC(C)c1cccc2c1O[C@H](C(C)C)C(=S)N2CC(=O)O,AD-5467,Phase 2,aldose reductase inhibitor,AKR1B1,,
COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2,adapalene,Launched,retinoid receptor agonist,RARA|RARB|RARG|RXRA|RXRB|RXRG,dermatology,acne vulgaris (AV)
O=P(O)(O)OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O,adaprev,Phase 3,TGF beta receptor inhibitor,AKR1B1|GPI|HK1|M6PR|PYGM,,
C[C@@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(N)=O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O,adaptavir,Phase 2,CC chemokine receptor antagonist,CCR5,,
O=C(O)/C=C/c1ccc(-c2ccc(O)c(C34CC5CC(CC(C5)C3)C4)c2)cc1,adarotene,Phase 1,retinoid receptor agonist,RARB|RARG,,
O=C(NCCN1CCN(c2ncccn2)CC1)C12CC3CC(CC(C3)C1)C2,adatanserin,Phase 2,serotonin receptor agonist|serotonin receptor antagonist,HTR1A|HTR2A,,
CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,adavivint,Phase 1,WNT pathway inhibitor,,,
O=c1[nH]c(N2CCOCC2)cn1-c1ccc(Cl)cc1,ADD-233089,Phase 1,benzodiazepine receptor agonist,,,
Nc1ncnc2c1ncn2CCOCP(=O)(O)O,adefovir,Launched,DNA polymerase inhibitor,,infectious disease,hepatitis B
CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc21)OCOC(=O)C(C)(C)C,adefovir-dipivoxil,Launched,DNA polymerase inhibitor,,infectious disease,hepatitis B
O=C(CCCCCCCC(=O)NCCO)NCCO,adelmidrol,Launched,anti-inflammatory agent,,dermatology,dermatitis
C[S+](CC[C@H](N)C(=O)O)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O,ademetionine,Launched,methyltransferase stimulant|phosphodiesterase inhibitor,,neurology/psychiatry,depression|attention-deficit/hyperactivity disorder (ADHD)
Nc1ncnc2nc[nH]c12,adenine,Preclinical,protein synthesis stimulant,ACACB|ACP1|APRT|MTAP|PECR|SRPK2,,
Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,adenosine,Launched,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3|PI4K2A|PI4K2B|TRPM4,cardiology,Wolff-Parkinson-White Syndrome (WPW)
Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O,adenosine-phosphate,Launched,adenosine receptor agonist,ACSL1|ACSS1|ACSS2|ADCY1|ADK|CREB1|FBP1|HINT1|PDE4B|PDE4D|PIM1|PRKAA1|PRKAB1|PRKAB2|PYGL|TRPM4,,
Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O,adenosine-triphosphate,Phase 2,adenosine receptor agonist,ABCA1|ABCB1|ABCB11|ABCC2|ABCC8|ABCC9|ABCG1|ABL1|ABL2|ACSL1|ACSS1|ACSS2|ACVR1|ACVR1B|ACVRL1|ADCY1|ADRBK1|ADRBK2|AFG3L2|AKT1|ALK|AMHR2|APAF1|ARAF|ASNA1|ASNS|ASS1|CDK15|GPR17|ITPR1|NAE1|NT5C2|P2RY1|P2RY11|P2RY13|P2RY2|P2RY4|PRKAA1|RYR1|RYR2|RYR3|SLC25A4|TNK2|TRPM4|TRPM7,,
CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1,adiphenine,Launched,acetylcholine receptor antagonist,CHRNA1,neurology/psychiatry,spasms
O=C(O)CCCCC(=O)O,adipic-acid,Preclinical,solute carrier family member inhibitor,SLC22A6,,
O=C(COc1ccc(C(=O)c2ccccc2)cc1)NC1CCN(Cc2ccccc2)CC1,adiporon,Preclinical,adiponectin receptor agonist,ADIPOR1|ADIPOR2,,
CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3cccc(O)c32)cc1,ADL5859,Phase 2,opioid receptor agonist,OPRD1,,
Cc1cc(O[C@@H](CCC(F)(F)F)c2ccc(C(=O)NCCC(=O)O)cc2)cc(C)c1-c1ccc(C(C)(C)C)cc1,adomeglivant,Preclinical,glucagon receptor antagonist,,,
Fc1ccc(-c2cncc(CN3CCN(c4cccc5c4OCCO5)CC3)c2)cc1,adoprazine,Phase 2,dopamine receptor antagonist|serotonin receptor agonist,DRD2|HTR1A,,
O=C(C[S@@](=O)C(c1ccccc1)c1ccccc1)NO,adrafinil,Launched,adrenergic receptor agonist,,neurology/psychiatry,fatigue
CNCC(=O)c1ccc(O)c(O)c1,adrenalone,Launched,adrenergic receptor agonist,ADRA1A,hematology,hemorrhage
C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@]2(C)C(=O)CC[C@@H]12,adrenosterone,Preclinical,11-beta hydroxysteroid dehydrogenase inhibitor,HSD11B1|HSD11B2,,
Cc1cc(C)c(N)c(C#Cc2cccc(F)c2)n1,ADX-10059,Phase 2,glutamate receptor negative allosteric modulator,GRM5,,
O=C(c1ccc(F)cc1)N1CCC[C@H](c2nc(-c3ccc(F)cc3)no2)C1,ADX-47273,Preclinical,glutamate receptor modulator,GRM5,,
CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1,AEE788,Phase 1/Phase 2,EGFR inhibitor|VEGFR inhibitor,EGFR|ERBB2|ERBB4|FGFR2|FGFR3|KDR,,
NS(=O)(=O)c1nn2cc(-c3ccccc3)nc2s1,AEG3482,Preclinical,HSP inducer,,,
Cc1cccc(NC(=O)c2ccc(C(F)(F)F)cc2C(=O)O)n1,AF38469,Preclinical,sortilin inhibitor,SORT1,,
CC(=O)N[C@@H](Cc1ccccc1)C(=O)O,afalanine,Phase 3,dopamine receptor agonist,DRD2,,
CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(N)=O)C(C)C,afamelanotide,Launched,melanocyte-stimulating hormone mimetic,,,
CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,afatinib,Launched,EGFR inhibitor,EGFR|ERBB2|ERBB4,oncology,non-small cell lung cancer (NSCLC)
CC/C(=C(\c1ccc(O)cc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,afimoxifene,Phase 2,estrogen receptor antagonist,ESR1|ESR2|ESRRG|PLD1|PRKCD|PRKCE|PRKCQ|PRKCZ,,
Cc1ccccc1-n1c(CF)nc2ccc(N)cc2c1=O,afloqualone,Launched,acetylcholine receptor antagonist,,neurology/psychiatry,sedative
Cc1c(CN(C)C(=O)/C=C/c2cnc3c(c2)CCC(=O)N3)oc2ccccc12,AFN-1252,Phase 2,FABI inhibitor,,,
CCOc1ccc2nc(SCCN3CCOCC3)[nH]c2c1,afobazole,Launched,anxiolytic,,neurology/psychiatry,anxiety
CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O,AG-1024,Preclinical,insulin growth factor receptor inhibitor,IGF1R,,
CN(C)Cc1ccc(-c2nc3cccc4c3n2CCNC4=O)cc1,AG-14361,Preclinical,PARP inhibitor,PARP1,,
N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1,AG-490,Preclinical,EGFR inhibitor|JAK inhibitor,EGFR|JAK2|JAK3,,
N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCCc1ccccc1,AG-555,Preclinical,tyrosine kinase inhibitor,CDK2,,
N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCCCc1ccccc1,AG-556,Preclinical,tyrosine kinase inhibitor,,,
Cc1ccccc1[C@H](C(=O)NC1CCCCC1)N(C(=O)Cn1ccnc1C)c1cccc(F)c1,AGI-5198,Preclinical,isocitrate dehydrogenase inhibitor,IDH1,,
O=C(Nc1cccc(C(F)(F)F)c1)Nc1cc(S(=O)(=O)NC2CC2)ccc1-c1ccsc1,AGI-6780,Preclinical,isocitrate dehydrogenase inhibitor,IDH2,,
CO[C@H]1[C@@H]([C@@]2(C)O[C@@H]2CC=C(C)C)[C@]2(CC[C@H]1OC(=O)NC(=O)CCl)CO2,AGM-1470,Phase 2,cell cycle inhibitor,METAP2,,
CC(C)[C@@H]1[C@H]2CC[C@@H](C2)[C@H]1N,AGN-192403,Preclinical,imidazoline receptor ligand,NISCH,,
CCc1ccc(C2=CC(C)(C)Sc3ccc(C#Cc4ccc(C(=O)O)cc4)cc32)cc1,AGN-194310,Phase 3,retinoid receptor antagonist,RXRA|RXRB|RXRG,,
CC1(C)CCC(C)(C)c2c1cc(C(=O)Nc1cc(F)c(C(=O)O)c(F)c1)c(O)c2Cl,AGN-195183,Phase 1/Phase 2,retinoid receptor agonist,RARA,,
COc1ccc2cccc(CCNC(C)=O)c2c1,agomelatine,Launched,melatonin receptor agonist|serotonin receptor antagonist,HTR2A|HTR2B|HTR2C|MTNR1A|MTNR1B,neurology/psychiatry,depression
CCCCCCCCCCCCCCCCCCCCCC(=O)O,AGP-103,Launched,membrane permeability inhibitor,,,
Cc1ccc(S(=O)(=O)NC2c3ccccc3Oc3ccccc32)cc1,AH-7614,Preclinical,free fatty acid receptor antagonist,FFAR4,,
N=C(C[C@@H](O)COc1ccccc1-c1ccccc1)N1CCCCC1,AH11110,Preclinical,adrenergic receptor ligand,ADRA1B,,
CC(C)Oc1ccc2c(=O)c3cc(C(=O)O)ccc3oc2c1,AH6809,Preclinical,prostanoid receptor antagonist,PTGDR|PTGER1|PTGER2|PTGER3,,
FC(F)(F)Oc1ccc2nc(-c3ccc(OCCOCCOc4ccc(-c5nc6ccc(OC(F)(F)F)cc6[nH]5)nc4)cn3)[nH]c2c1,AI-10-49,Preclinical,core binding factor inhibitor,CBFB,,
c1ccc(-c2oc3ncnc(NC[C@@H]4CCCO4)c3c2-c2ccccc2)cc1,AIM-100,Preclinical,tyrosine kinase inhibitor,TNK2,,
CCCN[C@@H]1CCc2c(OC)cccc2[C@@H]1C,AJ76-(+),Preclinical,dopamine receptor antagonist,DRD2|DRD3|DRD4,,
CC[C@H]1[C@H]2C[C@H]3[C@@H]4N(C)c5ccccc5[C@]45C[C@@H]([C@H]2[C@H]5O)N3[C@@H]1O,ajmaline,Launched,sodium channel blocker,,cardiology,Wolff-Parkinson-White Syndrome (WPW)
O=C(Nc1cccc(Br)c1)c1cccc(S(=O)(=O)N2CCCCCC2)c1,AK-7,Preclinical,SIRT inhibitor,SIRT2,,
CC(=O)O[C@@H]1CC[C@@]2(C)[C@@H](CC[C@]3(C)[C@@H]2C(=O)C=C2[C@@H]4[C@@H](C)[C@H](C)CC[C@]4(C)CC[C@]23C)[C@@]1(C)C(=O)O,AKBA,Phase 3,lipoxygenase inhibitor,ALOX5,,
NC(=O)c1ccc([N+](=O)[O-])cc1Cl,aklomide,Launched,,,infectious disease,coccidiosis
Cc1c(F)cc(C(=O)NC2CC2)cc1-c1c(F)cn2c(C(C)(C)C)nnc2c1F,AL-8697,Preclinical,p38 MAPK inhibitor,MAPK14,,
CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O,alacepril,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension
C[C@H](N)C(=O)N[C@@H](C)P(=O)(O)O,alafosfalin,Phase 1,bacterial cell wall synthesis inhibitor,,,
Cc1sc[n+](CC(=O)c2ccccc2)c1C,alagebrium,Phase 2/Phase 3,glycosylation inhibitor,,,
C[C@@H](N)C(=O)O,alanine,Launched,,,,
N[C@@H](CN(O)[N+][O-])C(=O)O,alanosine,Phase 2,antimetabolite,,,
C=C1C(=O)O[C@@H]2C[C@@]3(C)CCC[C@H](C)C3=C[C@H]12,alantolactone,Preclinical,apoptosis stimulant|STAT inhibitor,STAT3,,
C[C@@H](N)C(=O)OC(C)(C)Cc1ccc(Cl)cc1,alaproclate,Phase 2,serotonin receptor antagonist,SLC6A4,,
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1,alarelin,Launched,gonadotropin releasing factor hormone receptor antagonist,GNRH1,,
CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1,albendazole,Launched,tubulin polymerization inhibitor,TUBA1A|TUBB|TUBB4B,infectious disease,cystic hydatid disease|parenchymal neurocysticercosis
CCC[S@@](=O)c1ccc2nc(NC(=O)OC)[nH]c2c1,albendazole-oxide,Launched,anthelmintic agent,,infectious disease,cystic hydatid disease|parenchymal neurocysticercosis
CC(C)(C)NC[C@@H](O)c1ccc(O)c(CO)c1,albuterol,Launched,adrenergic receptor agonist,ADRB2,pulmonary,asthma
CN1CCC(=C2c3ccccc3CCn3c(C=O)cnc32)CC1,alcaftadine,Launched,histamine receptor antagonist,HRH1,allergy,allergic conjunctivitis
C=CCOc1ccc(CC(=O)O)cc1Cl,alclofenac,Launched,cyclooxygenase inhibitor,PTGS1,rheumatology,rheumatoid arthritis
CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@H]2[C@@H]3[C@H]([C@@H](O)C[C@@]21C)[C@@]1(C)C=CC(=O)C=C1C[C@H]3Cl,alclometasone-dipropionate,Launched,glucocorticoid receptor agonist,CYP3A4|NR3C1|SERPINA6,dermatology,corticosteroid-responsive dermatoses
C=CC[N@@+]12CC[C@@]34c5ccccc5N5/C=C6/[C@H]7C[C@H]8[C@@]9(CC[N@@+]8(CC=C)C/C7=C\CO)c7ccccc7N(/C=C(/[C@@H](C[C@@H]31)/C(=C/CO)C2)[C@@H]54)[C@H]69,alcuronium,Launched,muscle relaxant,CHRM1|CHRM2|CHRM3|CHRM4|CHRNA7,neurology/psychiatry,muscle relaxant
O=C(NCc1ccc2c(c1)OCO2)c1c(Cl)cccc1Cl,alda-1,Preclinical,aldehyde dehydrogenase activator,ALDH2,,
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(/C(CO)=N/NC(=O)CCCCCN1C(=O)C=CC1=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,aldoxorubicin,Phase 3,topoisomerase inhibitor,TOP2A,,
CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O,alectinib,Launched,ALK tyrosine kinase receptor inhibitor,ALK|MET,oncology,non-small cell lung cancer (NSCLC)
CCCC[C@@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@@H](CC)CCCC,alexidine,Preclinical,phosphatidylglycerophosphatase inhibitor,PTPMT1,,
C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O,alfacalcidol,Launched,vitamin D receptor agonist,CYP27B1|VDR,endocrinology,vitamin D deficiency
CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C,alfadolone-acetate,Phase 2,benzodiazepine receptor agonist,,,
COc1cc2nc(N(C)CCCNC(=O)[C@H]3CCCO3)nc(N)c2cc1OC,alfuzosin,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,urology,benign prostatic hyperplasia (BPH)
CC(=O)[C@@]12O[C@](C)(c3ccccc3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]12C,algestone-acetophenide,Launched,,,endocrinology,contraceptive
C=CCc1cc(OC)c(O)c(C(=O)NCCO)c1,alibendol,Launched,antispasmodic,,gastroenterology,bile stimulation
C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccccc21,alimemazine,Launched,histamine receptor agonist|histamine receptor antagonist,HRH1,neurology/psychiatry|allergy|pulmonary,sedative|urticaria|itching|cough suppressant
C=CCN(C1=NCCN1)c1c(Cl)cccc1Cl,alinidine,Phase 3,bradycardic effect ,,,
COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O,alisertib,Phase 3,Aurora kinase inhibitor,AURKA,,
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,aliskiren-hemifumarate,Launched,renin inhibitor,REN,cardiology,hypertension
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)[C@H](C)C(=O)N(CC)[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,alisporivir,Phase 3,cyclophilin inhibitor,,,
C=CCN1CCC[C@@H]1CNC(=O)c1cc2nn[nH]c2cc1OC,alizapride,Launched,dopamine receptor antagonist,,gastroenterology,nausea
O=C1c2ccccc2C(=O)c2c1ccc(O)c2O,alizarin,Preclinical,,,,
NC(=O)N[C@H]1NC(=O)NC1=O,allantoin,Launched,cosmetic,,dermatology,skin protectant
O=c1nc[nH]c2n[nH]cc12,allopurinol,Launched,xanthine oxidase inhibitor,XDH,rheumatology|urology,gout|kidney stones
OC[C@H]1O[C@@H](n2ncc3c(O)ncnc32)[C@H](O)[C@@H]1O,allopurinol-riboside,Phase 2,anti-leishmanial agent|phosphorylase inhibitor,,,
O=c1nc[nH]c2c1cnn2[C@@H]1O[C@H](CO)[C@H](O)[C@@H]1O,allopurinol-riboside,Phase 2,anti-leishmanial agent|phosphorylase inhibitor,,,
C=CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3CC[C@@]21C,allylestrenol,Launched,steroidal progestin,ESR1|PGR|SLC6A9,obstetrics/gynecology,premature labor
C=CCNC(N)=S,allylthiourea,Preclinical,nitrification inhibitor,,,
C=CCNc1nc(NCC=C)nc(N2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)n1,almitrine,Launched,neurotransmitter agonist,ATP1A1,pulmonary,chronic obstructive pulmonary disease (COPD)
CNC(=O)[C@@H](c1ccccc1)N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(C(F)(F)F)cc1,almorexant,Phase 3,orexin receptor antagonist,HCRTR1|HCRTR2,,
CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12,almotriptan,Launched,serotonin receptor agonist,HTR1B|HTR1D,neurology/psychiatry,migraine headache
O=C1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc21,aloe-emodin,Preclinical,anticancer agent,CASP8,,
Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O,alogliptin,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus
O=C1c2c(O)cccc2[C@H]([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)c2cc(CO)cc(O)c21,aloin,Preclinical,angiogenesis inhibitor,,,
C1=C2CCCN[C@H]2[C@@H]2C[C@H]1[C@H]1CCCCN1C2,aloperine,Preclinical,,,,
Cc1cn([C@H]2C[C@H](F)[C@@H](CO)O2)c(=O)[nH]c1=O,alovudine,Phase 2,DNA synthesis marker,,,
CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C,aloxistatin,Phase 3,protease inhibitor,CTSG,,
Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,alpelisib,Launched,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,oncology,breast cancer
C/C=C/c1cc(OC)c(OC)cc1OC,alpha-asarone,Preclinical,cytochrome P450 inhibitor|HMGCR inhibitor,HMGCR,,
OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O,alpha-D-glucopyranose,Preclinical,,,,
COc1ccc([C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O[C@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)cc3O2)cc1O,alpha-glucosyl-hesperidin,Preclinical,antioxidant,,,
CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)O,alpha-linolenic-acid,Phase 3,omega 3 fatty acid stimulant,ELOVL4|FADS1|FADS2|FFAR1|FFAR4|PTGS2|SLC8A1|TRPV1,,
C[C@@H](N)Cc1cnc[nH]1,alpha-methylhistamine-dihydrobromide-(R)-(-),Preclinical,histamine receptor agonist,HRH3,,
C[C@H](N)Cc1cnc[nH]1,alpha-methylhistamine-dihydrobromide-(S)-(+),Preclinical,histamine receptor agonist,HRH3,,
C[C@@H](N)Cc1c[nH]c2ccc(O)cc12,alpha-methylserotonin,Preclinical,serotonin receptor agonist,HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR4,,
Cc1c(C)c2c(c(C)c1O)CC[C@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2,alpha-tochopherol,Launched,antioxidant,,endocrinology,vitamin E deficiency
CC(=O)Oc1c(C)c(C)c2c(c1C)CC[C@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2,alpha-tochopheryl-acetate,Launched,antioxidant,,endocrinology,vitamin E deficiency
C=CCc1ccccc1OC[C@H](O)CNC(C)C,alprenolol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2,cardiology,angina pectoris
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O,alprostadil,Launched,prostanoid receptor agonist,CATSPER1|CATSPER2|CATSPER3|CATSPER4|PTGDR|PTGER1|PTGER2|PTGER4|PTGIR,cardiology,congenital heart defects
O=C(O)CN1C(=O)c2cccc3cccc(c23)C1=O,alrestatin,Preclinical,aldose reductase inhibitor,AKR1B1,,
Nc1ccn([C@@H]2O[C@@](CO)(CCl)[C@@H](O)[C@H]2F)c(=O)n1,ALS-8112,Phase 1,,,,
CC(C)C(=O)OC[C@@]1(CCl)O[C@@H](n2ccc(N)nc2=O)[C@H](F)[C@@H]1OC(=O)C(C)C,ALS-8176,Phase 1,RNA polymerase inhibitor,,,
O=C(c1ccc(F)cc1)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1,altanserin,Phase 2,serotonin receptor antagonist,HTR2A,,
C=CCSC[C@@H]1Nc2cc(Cl)c(S(N)(=O)=O)cc2S(=O)(=O)N1,althiazide,Launched,diuretic,,cardiology,hypertension
C#Cc1cncc([C@@H]2CCCN2C)c1,altinicline,Phase 2,nicotinic receptor agonist,CHRNA4|CHRNB2,,
O=C(Nc1cc(Oc2cc(F)c(NC(=O)C3(C(=O)Nc4ccc(F)cc4)CC3)cc2F)ccn1)C1CC1,altiratinib,Phase 1,MET inhibitor|VEGFR inhibitor,KDR|MET|TEK,,
C=CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3C=C[C@@]21C,altrenogest,Launched,progestogen hormone,PGR,endocrinology,estrus
CN(C)c1nc(N(C)C)nc(N(C)C)n1,altretamine,Launched,DNA synthesis inhibitor,,oncology,ovarian cancer
CCN(CCCc1ccccc1)CCCc1ccccc1,alverine,Launched,muscle relaxant,HTR1A,gastroenterology,irritable bowel syndrome|diverticular disease
CO[C@H]1/C=C\C=C(/C)C(=O)NC2=CC(=O)C(NCCN(C)C)=C(C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O)C2=O,alvespimycin,Phase 2,HSP inhibitor,HSP90AA1,,
C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(=O)O)CC[C@@]1(C)c1cccc(O)c1,alvimopan,Launched,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,gastroenterology,postoperative ileus
CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,alvocidib,Phase 2,CDK inhibitor,CDK1|CDK2|CDK4|CDK5|CDK6|CDK7|CDK8|CDK9|EGFR|PYGM,,
CC(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(N)=O,ALX-40-4C,Preclinical,CC chemokine receptor antagonist,,,
CN(CC[C@@H](Oc1ccc(-c2ccccc2)cc1)c1ccc(F)cc1)CC(=O)O,ALX-5407,Phase 1,glycine transporter inhibitor,SLC6A9,,
CN1CCCC[C@@H]1Cn1cc(C(=O)c2cc([N+](=O)[O-])ccc2I)c2ccccc21,AM-1241,Preclinical,cannabinoid receptor agonist,CNR1|CNR2,,
Oc1c(I)cc(I)cc1I,AM-24,Phase 2,lipoxygenase inhibitor,ALOX5,,
Cc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(I)cc1,AM-251,Preclinical,cannabinoid receptor antagonist,CNR1|GPR18|GPR55,,
Cc1c(C(=O)NN2CCOCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(I)cc1,AM-281,Preclinical,cannabinoid receptor antagonist,CNR1|CNR2|GPR55,,
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)Nc1ccc(O)cc1,AM-404,Preclinical,cyclooxygenase inhibitor|FAAH inhibitor|TRPV antagonist,CNR1|CNR2|FAAH|TRPV1,,
CC1(C)CCC(C)(C)c2cc(C(=O)Nc3ccc(C(=O)O)cc3)ccc21,AM-580,Preclinical,retinoid receptor agonist,RARA,,
COc1ccc(C(=O)c2c(C)n(CCN3CCOCC3)c3cc(I)ccc23)cc1,AM-630,Preclinical,cannabinoid receptor antagonist,CNR1|CNR2,,
CN(CCc1ccc(Cl)c(Cl)c1)C[C@@H](O)COc1ccc(NS(C)(=O)=O)cc1,AM-92016,Preclinical,potassium channel blocker,GRIN1,,
Cc1noc(-c2ccc(-c3ccc(CC(=O)O)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1,AM095,Preclinical,lysophosphatidic acid receptor antagonist,,,
CCN(Cc1cc(C(F)(F)F)ccc1-c1cc(CC(=O)O)ccc1OC)C(=O)NCc1ccccc1,AM211,Preclinical,prostaglandin inhibitor,,,
COc1cnc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OC[C@@H]5Cc6ccccc6N5C(C)=O)ccc43)cc2)nc1,AM679,Preclinical,cannabinoid receptor agonist|lipoxygenase inhibitor,ALOX5AP|CNR1|CNR2,,
NC12CC3CC(CC(C3)C1)C2,amantadine,Launched,glutamate receptor antagonist,DRD2|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A,infectious disease|neurology/psychiatry,influenza A virus infection|Parkinson's Disease
N=C(N)N=Nc1ccc(NNC(N)=S)cc1,ambazone,Phase 1,DNA damage inducer,,,
CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl,ambenonium,Launched,cholinesterase inhibitor,ACHE,neurology/psychiatry,myasthenia gravis
COC(c1ccccc1)(c1ccccc1)[C@H](Oc1nc(C)cc(C)n1)C(=O)O,ambrisentan,Launched,endothelin receptor antagonist,EDNRA|EDNRB,pulmonary,pulmonary arterial hypertension (PAH)
Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1,ambroxol,Launched,sodium channel blocker,CYP3A4,pulmonary,bronchitis
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2/C(=O)Nc3ccc(-c4csc(-c5ccccc5)n4)cc32)c1C,amcasertib,Phase 2,kinase inhibitor,,,
CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1C[C@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C,amcinonide,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses
c1ccc(CNCc2ccc(CN3CCCNCCNCCCNCC3)cc2)nc1,AMD-3465,Preclinical,CC chemokine receptor antagonist,CXCR4,,
NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc21,AMD11070,Phase 3,CC chemokine receptor antagonist,CCR5|CXCR4,,
CC1(C)S[C@@H]2[C@H](/N=C/N3CCCCCC3)C(=O)N2[C@H]1C(=O)O,amdinocillin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,urinary tract infections|gram-negative bacterial infections
Cc1cccc(C)c1NC(=O)c1ccc(N)cc1,ameltolide,Preclinical,anticonvulsant,,,
Cc1cccc(C)c1N(CC(=O)Nc1ccc(-c2ncon2)cc1)C(=O)C1CCS(=O)(=O)CC1,amenamevir,Phase 1,helicase primase inhibitor,,,
O=C1c2ccccc2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,ametantrone,Preclinical,anticancer agent,,,
COc1cc(N)cn[n+]1-c1ccccc1,amezinium,Launched,adrenergic receptor agonist,ADRB2,cardiology,hypotension
Nc1c(CC(=O)O)cccc1C(=O)c1ccccc1,amfenac,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief
Nc1c(-c2cccc(C(F)(F)F)c2)nsc1C(=O)O,amflutizole,Phase 2,xanthine oxidase inhibitor,XDH,,
CO[C@H]1/C=C/C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)c2ccc3c(c2)N(C[C@@H]2CC[C@H]21)C[C@@]1(CCCc2cc(Cl)ccc21)CO3,AMG-176,Phase 1,MCL1 inhibitor,,,
COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1,AMG-208,Phase 1,tyrosine kinase inhibitor,MET,,
CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1,AMG-232,Phase 2,MDM inhibitor,MDM2,,
C[C@H](Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1,AMG-319,Phase 2,PI3K inhibitor,PIK3CD,,
COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(-c5cnn(C)c5)cn34)c(=O)c2c1,AMG-337,Phase 2,MET inhibitor,MET,,
CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1,AMG-487,Phase 2,CC chemokine receptor antagonist,,,
CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1,AMG-487-(+/-),Phase 2,CC chemokine receptor antagonist,CXCR3,,
C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,AMG-510,Phase 1/Phase 2,K-Ras inhibitor,,,
CC(=O)Nc1nc2c(Oc3cc(-c4ccc(C(F)(F)F)cc4)ncn3)cccc2s1,AMG-517,Phase 1,TRPV antagonist,TRPV1,,
Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O,AMG-548,Phase 1,MAP kinase inhibitor,MAPK11|MAPK12|MAPK13|MAPK14,,
CC#C[C@@H](CC(=O)O)c1ccc(OCc2cccc(-c3ccc(C(F)(F)F)cc3)c2)cc1,AMG-837,Phase 1,free fatty acid receptor agonist,FFAR1,,
C[C@H]1CC[C@H](n2c3cnccc3c3cnc(Nc4ccc5c(n4)CCN(C(=O)CO)C5)nc32)CC1,AMG-925,Phase 1,CDK inhibitor|FLT3 inhibitor,CDK4|CDK6|FLT3,,
CC(C)(C)c1ccc(/C=C/C(=O)Nc2ccc3c(c2)OCCO3)cc1,AMG-9810,Preclinical,TRPV antagonist,TRPV1,,
Cc1ccc2cc(-c3c(C)ccc(C(=O)c4c(-c5ccccc5)n(C)n(-c5ccccc5)c4=O)c3N)ccc2n1,AMG-PERK-44,Preclinical,PERK inhibitor,EIF2AK4,,
C[C@@H](Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1,AMG319,Phase 2,PI3K inhibitor,PIK3CD,,
COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1,AMG458,Preclinical,MET inhibitor,MET,,
Cc1csc(-c2nnc(Nc3ccc(Oc4ncccc4-c4ccnc(N)n4)cc3)c3ccccc23)c1,AMG900,Phase 1,Aurora kinase inhibitor,AURKA|AURKB|AURKC,,
O=C(Nc1ccc2c(O)cc(S(=O)(=O)O)cc2c1)Nc1ccc2c(O)cc(S(=O)(=O)O)cc2c1,AMI-1,Preclinical,protein arginine N-methyltransferase inhibitor,PRMT1,,
CCOC(=O)COc1ccc2c(c1)C[C@@H](NC[C@H](O)c1cccc(Cl)c1)CC2,amibegron,Phase 3,adrenergic receptor agonist,ADRB3,,
Cc1c(N(C)C)c(=O)n(-c2ccccc2)n1C,amidopyrine,Launched,analgesic agent,,dermatology,dermatitis herpetiformis (DH)
Nc1ccncc1N,amifampridine,Launched,potassium channel blocker,,neurology/psychiatry,Lambert-Eaton myasthenic syndrome (LEMS)
Cc1cc(N(C)C)ccc1C[C@@H](C)N,amiflamine,Phase 1,monoamine oxidase inhibitor,MAOA|SLC6A2,,
NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,amikacin,Launched,bacterial 30S ribosomal subunit inhibitor,,infectious disease,gram-negative bacterial infections
N=C(N)NC(=O)c1nc(Cl)c(N)nc1N,amiloride,Launched,sodium channel blocker,AOC1|ASIC1|ASIC2|ASIC3|PKD2|PKD2L1|PLAU|SCNN1A|SCNN1B|SCNN1D|SCNN1G|SLC9A1|TRPC7|TRPV2,cardiology,hypertension|congestive heart failure
NCCCCCC(=O)O,aminocaproic-acid,Launched,plasminogen activator inhibitor,LPA|PLAT|PLG,hematology,fibrinolytic bleeding
CC[C@@]1(c2ccc(N)cc2)CCC(=O)NC1=O,aminoglutethimide,Launched,glucocorticoid receptor antagonist,CYP11A1|CYP19A1,endocrinology|oncology,Cushing's syndrome|breast cancer
NN=C(N)N,aminoguanidine,Phase 3,nitric oxide synthase inhibitor,AKR1B1|NOS2|TIMP3,,
NC[C@@H](O)CC(=O)O,aminohydroxybutyric-acid,Launched,,,neurology/psychiatry,epilepsy
NCC(=O)CCC(=O)OCc1ccccc1,aminolevulinic-acid-benzyl-ester,Phase 1,,,,
C[C@H]1CCN=C(N)S1,aminomethyltransferase,Preclinical,nitric oxide synthase inhibitor,NOS2,,
CC(CC(C(N)=O)(c1ccccc1)c1ccccc1)N(C)C,aminopentamide,Launched,acetylcholine receptor antagonist,CHRM1,gastroenterology,acute abdominal visceral spasm|hypertrophic gastritis (GHG)|nausea
Cn1c(=O)c2[nH]cnc2n(C)c1=O,aminophylline,Launched,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3|HDAC2|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A,pulmonary,asthma|bronchitis|emphysema
Nc1nc(N)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2n1,aminopterin,Phase 3,dihydrofolate reductase inhibitor,DHFR|SLC46A1,,
CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1,aminopurvalanol-a,Preclinical,CDK inhibitor|tyrosine kinase inhibitor,CDK1|CDK2|CDK5,,
Nc1ccc(C(=O)O)c(O)c1,aminosalicylate,Launched,cyclooxygenase inhibitor,ALOX5|CHUK|PLA2G2E|PTGS1|PTGS2,gastroenterology,inflammatory bowel disease|ulcerative colitis
Nc1nncs1,aminothiadiazole,Phase 2,inosine monophosphate dehydrogenase inhibitor,ADORA3|IMPDH1,,
Nc1nccs1,aminothiazole,Preclinical,cyclin D inhibitor,NOS2,,
CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1,amiodarone,Launched,potassium channel blocker,ADRB1|CACNA1H|CACNA2D2|KCNA7|KCNH2,cardiology,ventricular arrhythmias
CN(C)CCCO[C@@H]1[C@H]2OC(C)(C)O[C@H]2O[C@@H]1[C@H](O)CO,amiprilose,Phase 3,CD antagonist,,,
CCCCCCCOc1ccc(CCC(N)(CO)CO)cc1C(F)(F)F,amiselimod,Phase 2,sphingosine 1-phosphate receptor modulator,,,
CCN1CCC[C@@H]1CNC(=O)c1cc(S(=O)(=O)CC)c(N)cc1OC,amisulpride,Launched,dopamine receptor antagonist,DRD2,neurology/psychiatry,psychosis|bipolar disorder|schizophrenia
Clc1ccc([C@]23CNC[C@H]2C3)cc1Cl,amitifadine,Phase 3,serotonin transporter (SERT) inhibitor,SLC6A2|SLC6A3|SLC6A4,,
Cc1ccc(/N=C/N(C)/C=N/c2ccc(C)cc2C)c(C)c1,amitraz,Launched,adrenergic receptor agonist,ADRA1A|ADRA2A,infectious disease,generalized demodicosis
CN(C)CCC=C1c2ccccc2CCc2ccccc21,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ__orepinephrine reuptake inhibitor (SNRI),ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRB1|ADRB2|ADRB3|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HRH1|HRH2|HRH4|HTR1A|HTR1B|HTR1D|HTR2A|HTR2C|HTR6|HTR7|KCNA1|KCND2|KCND3|KCNQ2|KCNQ3|NTRK1|NTRK2|OPRD1|OPRK1|OPRM1|SIGMAR1|SLC6A2|SLC6A4,neurology/psychiatry,depression
CC(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1,amlexanox,Launched,histamine receptor modulator,FGF1|IL3|PDE4A|PDE4B|PDE4C|PDE4D|S100A12|S100A13,dental|pulmonary|ophthalmology|allergy,aphthous ulcers|asthma|conjunctivitis|allergic rhinitis
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@H]1c1ccccc1Cl,amlodipine,Launched,calcium channel blocker,CACNA1C|CACNA1D|CACNA1F|CACNA1S|CACNA2D1,cardiology,hypertension|chronic stable angina|vasospastic angina|coronary artery disease (CAD)
CC1(C)[C@@H](O[C@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@@](C)(C(=O)O)CC[C@]5(C)CC[C@@]4(C)[C@]3(C)CC[C@@H]12,ammonium-glycyrrhizinate,Launched,thrombin inhibitor,HSD11B1|HSD11B2|SLCO1B1|SLCO1B3,dermatology,cosmetic
O=C(O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F,ammonium-perfluorocaprylate,Phase 1,Pim kinase inhibitor,PIM1,,
c1ccc(C(NCCNC(c2ccccc2)c2ccccc2)c2ccccc2)cc1,AMN-082,Preclinical,glutamate receptor modulator,GRM7,,
CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O,amodiaquine,Launched,histamine receptor agonist,HNMT,infectious disease,malaria
CN(C)CCN1C(=O)c2cccc3cc(N)cc(c23)C1=O,amonafide,Phase 3,topoisomerase inhibitor,TOP2A|TOP2B,,
CCC(C)(C)c1ccc(C[C@@H](C)CN2C[C@@H](C)O[C@@H](C)C2)cc1,amorolfine,Launched,membrane integrity inhibitor,,infectious disease,onychomycosis
Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2,amoxapine,Launched,norepinephrine reputake inhibitor,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|HRH1|HRH4|HTR1A|HTR1B|HTR2A|HTR2B|HTR2C|HTR3A|HTR6|HTR7|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,depression
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,amoxicillin,Launched,penicillin binding protein inhibitor,CYP2C19|SLC15A1|SLC15A2|SLC22A6,infectious disease|gastroenterology,skin infections|duodenal ulcer disease|gonorrhea|ear infections|throat infections|genitourinary tract infections|respiratory tract infections
Cc1o[nH]c(=O)c1C[C@@H](N)C(=O)O,AMPA-(RS),Preclinical,glutamate receptor agonist,GRIN1,,
Cc1o[nH]c(=O)c1C[C@H](N)C(=O)O,AMPA-(S),Preclinical,glutamate receptor agonist,GRIA2|GRIN1,,
O=C(c1ccc2nccnc2c1)N1CCCCC1,ampalex,Phase 2,glutamate receptor agonist,GRIA1|GRIA2|GRIA3|GRIA4,,
CCNC(=O)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,amperozide,Launched,dopamine receptor antagonist,FAAH|HTR2A,neurology/psychiatry,psychosis
C[C@@H]1[C@H](O)[C@@H](C)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)C[C@@H]2O[C@](O)(C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@H]1C)C[C@H](O)[C@H]2C(=O)O,amphotericin-b,Launched,membrane permeability enhancer,,infectious disease,fungal infection
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)O,ampicillin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,respiratory tract infections|meningitis|bacterial septicemia|endocarditis|urinary tract infections|gastrointestinal infections
CCOC(=O)O[C@@H](C)OC1=C(C(=O)Nc2ccccn2)N(C)S(=O)(=O)c2ccccc21,ampiroxicam,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief
CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1,amprenavir,Launched,HIV protease inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)
CCCc1ncc(C[n+]2ccccc2C)c(N)n1,amprolium,Launched,thiamine uptake blocker,,infectious disease,coccidiosis
Cc1c(N)c(=O)n(-c2ccccc2)n1C,ampyrone,Preclinical,cyclooxygenase inhibitor,,,
Nc1cc(-c2ccncc2)c[nH]c1=O,amrinone,Launched,phosphodiesterase inhibitor,PDE3A|PDE3B|PDE4B|TNF,cardiology,congestive heart failure
CC(=O)[C@]1(N)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C1)C(=O)c1ccccc1C3=O,amrubicin,Launched,topoisomerase inhibitor,TOP2A|TOP2B,oncology,small cell lung cancer
COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12,amsacrine,Launched,topoisomerase inhibitor,KCNH2|TOP2A,hematologic malignancy,acute lymphoblastic leukemia (ALL)
Cc1nc(N)sc1CCN,amthamine,Preclinical,histamine receptor agonist,HRH2,,
COc1ccccc1OC(=O)CNC(=O)Cc1ccc(C(=O)c2ccc(C)cc2)n1C,amtolmetin-guacil,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,rheumatoid arthritis|osteoarthritis
S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1,amuvatinib,Phase 2,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAD51 inhibitor|RET tyrosine kinase inhibitor,KIT|MET,,
N#C[C@H](O[C@@H]1O[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)c1ccccc1,amygdalin,Phase 2,caspase activator,CASP3,,
CCCCCO[NH2+][O-],amyl-nitrite,Preclinical,atrial natriuretic peptide receptor agonist,,,
CC[C@@](C)(CN(C)C)OC(=O)c1ccccc1,amyleine,Preclinical,local anesthetic,,,
N#C/C(=C\c1cccn1S(=O)(=O)c1cccc([N+](=O)[O-])c1)S(=O)(=O)c1ccc(F)cc1,AMZ30,Preclinical,protein phosphatase inhibitor,,,
OB1OCc2cc(Cl)ccc21,AN2718,Phase 1,leucyl-tRNA synthetase inhibitor,,,
O=C(Nc1ccccc1C(=O)N[C@H]1CCCCNC1=O)c1cc2ccccc2s1,ANA-12,Preclinical,tropomyosin receptor kinase inhibitor,NTRK2,,
c1cncc([C@H]2CCCCN2)c1,anabasine,Preclinical,acetylcholine receptor agonist,,,
COc1cc(F)c(C(C)C)cc1-c1ccc(C(F)(F)F)cc1CN1C(=O)O[C@H](c2cc(C(F)(F)F)cc(C(F)(F)F)c2)[C@@H]1C,anacetrapib,Phase 3,cholesteryl ester transfer protein inhibitor,CETP,,
Cc1cc2ncc(C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N)cn2n1,anagliptin,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus
O=C1CN2Cc3c(ccc(Cl)c3Cl)N=C2N1,anagrelide,Launched,phosphodiesterase inhibitor,PDE3A,hematology|hematologic malignancy,thrombocythemia|myeloproliferative neoplasms
CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)C(C)(C)N)C1,anamorelin,Phase 3,growth hormone secretagogue receptor agonist,GHSR,,
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)NCCO,anandamide,Phase 2,cannabinoid receptor agonist,CACNA1G|CACNA1H|CACNA1I|CNR1|CNR2|GLRA1|GPR18|GPR55|KCNA2|KCNK3|KCNK9|TRPM8|TRPV1,,
CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,anastrozole,Launched,aromatase inhibitor,CYP19A1,oncology,breast cancer
CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc([N+](=O)[O-])c(C(F)(F)F)c2)cc1,andarine,Phase 1,androgen receptor modulator,AR,,
C=C1CC[C@@H]2[C@](C)(CO)[C@H](O)CC[C@@]2(C)[C@@H]1C/C=C1/C(=O)OC[C@H]1O,andrographolide,Phase 2,tumor necrosis factor production inhibitor,IL1B|IL6|NFKB1|NFKB2|TNF,,
C[C@@]12CCC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)C=CC[C@@H]12,androstenone,Preclinical,steroid,,,
C[C@]12CC[C@@H](O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12,androsterone,Preclinical,androgen receptor agonist,,,
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@@]21C,anecortave-acetate,Launched,angiogenesis inhibitor,,ophthalmology,macular degeneration
C/C=C/c1ccc(OC)cc1,anethole,Launched,glutathione transferase stimulant,,,
COc1ccc(-c2cc(=S)ss2)cc1,anethole-trithione,Launched,glutathione transferase stimulant,,dental,xerostomia
CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]12CO2,anguidine,Phase 2,protein synthesis inhibitor,SLC5A1,,
CCCCCOc1ccc(-c2ccc(-c3ccc(C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@H](O)[C@@H](O)c5ccc(O)cc5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)cc3)cc2)cc1,anidulafungin,Launched,"fungal 1,3-beta-D-glucan synthase inhibitor",,infectious disease,candidemia|fungal infection|esophageal candidiasis
COc1ccc(C(=O)N2CCCC2=O)cc1,aniracetam,Launched,glutamate receptor agonist,DRD2|GRIA1|GRIA2|GRIA3|GRIA4|HTR2A,,
COc1ccc(C2C(=O)c3ccccc3C2=O)cc1,anisindione,Launched,vitamin K antagonist,GGCX,hematology,deep vein thrombosis (DVT)
CN1[C@@H]2C[C@H](OC(=O)[C@H](CO)c3ccccc3)C[C@@H]1[C@@H](O)C2,anisodamine,Phase 3,lipid peroxidase inhibitor,ADRA1A,,
COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1,anisomycin,Preclinical,DNA synthesis inhibitor,NHP2L1|RPL10L|RPL11|RPL13A|RPL15|RPL19|RPL23|RPL23A|RPL26L1|RPL3|RPL37|RPL8|RSL24D1,,
CCCC(CCC)C(=O)O[C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C,anisotropine,Launched,acetylcholine receptor antagonist,,gastroenterology,peptic ulcer disease (PUD)
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,anlotinib,Launched,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,KDR|PDGFRB,,
Clc1cccc(SC2CCNCC2)n1,anpirtoline,Phase 1,serotonin receptor agonist,HTR1B,,
CCOc1nc2c(N)ncnc2n1CC,ANR-94,Preclinical,adenosine receptor antagonist,ADORA2A,,
COc1cc2cc(c1Cl)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]1(C)O[C@H]1[C@H](C)[C@@H]1C[C@@](O)(NC(=O)O1)[C@H](OC)/C=C/C=C(\C)C2,ansamitocin-p-3,Preclinical,apoptosis stimulant,,,
CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCNC(=N)N)C(N)=O,antagonist-g,Phase 1,neuropeptide receptor antagonist,MAPK8,,
CCCCN(CC)c1nc(C)nc2c1c(C)c(C)n2-c1c(C)cc(C)cc1C,antalarmin,Preclinical,corticotropin releasing factor receptor antagonist,CRHR1,,
c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1,antazoline,Launched,antihistamine,HRH1,ophthalmology|otolaryngology,conjunctivitis|nasal congestion
O=C1c2c(O)cccc2Cc2cccc(O)c21,anthralin,Launched,DNA synthesis inhibitor,,dermatology,psoriasis
O=C1c2ccccc2C(=O)c2ccccc21,anthraquinone,Preclinical,CDC inhibitor,CDC25B,,
O=C1O[SbH]23OC(=O)[C@H](O2)[C@H]2O[SbH]4(OC(=O)[C@H](O4)[C@H]1O3)OC2=O,antimony-potassium,Phase 2,,,,
CCCCCC[C@H]1C(=O)O[C@H](C)[C@H](NC(=O)c2cccc(NC=O)c2O)C(=O)O[C@@H](C)[C@@H]1OC(=O)CC(C)C,antimycin-A,Preclinical,ATP synthase inhibitor,CYCS,,
Cc1ccc(C(C)C)cc1O,antioxine,Launched,,,,
CC(=C\c1ccc(Cl)cc1)/C(C)=N/O,AP-18,Preclinical,transient receptor potential channel antagonist,TRPA1,,
CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc([C@@H](CCc3ccc(OC)c(OC)c3)OC(=O)[C@@H]3CCCCN3C(=O)[C@@H](CC)c3cc(OC)c(OC)c(OC)c3)c2)c1)c1cc(OC)c(OC)c(OC)c1,AP1903,Phase 1/Phase 2,,MTOR,,
COc1cc(N2CCC(N(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,AP26113,Phase 2,ALK tyrosine kinase receptor inhibitor,ALK|EGFR,,
COc1cc(OC)c2c(=O)nc(-c3cc(C)c(OCCO)c(C)c3)[nH]c2c1,apabetalone,Phase 3,apolipoprotein expression enhancer,BRD3,,
Cc1nnc2n1-c1sc(CCC(=O)N3CCOCC3)cc1C(c1ccccc1Cl)=NC2,apafant,Phase 3,platelet activating factor receptor antagonist,PTAFR,,
CNC(=O)c1ccc(N2C(=S)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=O)C23CCC3)cc1F,apalutamide,Launched,androgen receptor antagonist,,oncology,prostate cancer
CC1(C)Oc2cc(NS(C)(=O)=O)ccc2N(c2ccc(F)cc2)C1=O,apararenone,Preclinical,mineralocorticoid receptor antagonist,,,
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,apatinib,Phase 3,RET tyrosine kinase inhibitor,CSK|KDR|KIT|RET,,
Cc1c(C)c2c(c(C)c1O)CCC(C)(C)O2,APC-100,Phase 1/Phase 2,androgen receptor antagonist|anti-inflammatory agent,AR,,
COc1cc(OC)cc(-c2ccc3c(-c4ccc(F)cc4)[nH]nc3n2)c1,APcK-110,Preclinical,KIT inhibitor,KIT|STAT3,,
COc1c(Nc2ccc(S(C)(=O)=O)nc2C)ncnc1OC1CCN(C(=O)OC(C)C)CC1,APD597,Phase 1,glucose dependent insulinotropic receptor agonist,GPR119,,
CC(C)OC(=O)N1CCC(Oc2ncnc3c2cnn3-c2ccc(S(C)(=O)=O)cc2F)CC1,APD668,Phase 1,glucose dependent insulinotropic receptor agonist,GPR119,,
C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@@]12CC[C@]3(O)CO,aphidicolin,Phase 1,RNA synthesis inhibitor,,,
Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1,API-001,Phase 2,sigma receptor antagonist,SIGMAR1,,
NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c2c1=O,API-1,Preclinical,AKT inhibitor,AKT1|AKT2|AKT3,,
O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12,apigenin,Preclinical,casein kinase inhibitor|cell proliferation inhibitor,AKR1B1|AR|CDK6|CFTR|CYP19A1|CYP1B1|HSD17B1,,
COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,apixaban,Launched,coagulation factor inhibitor,F10,neurology/psychiatry|hematology|cardiology,stroke|systemic embolism|pulmonary embolism (PE)|atrial fibrillation (AF)|deep vein thrombosis (DVT)
COc1cc(C(C)=O)ccc1O,apocynin,Phase 1,NADPH oxidase inhibitor,NOX4,,
O=C1C(=O)N(Cc2ccc(Cl)c(Cl)c2)c2ccccc21,apoptosis-activator-II,Preclinical,carboxylesterase inhibitor,BCHE|CES1,,
COC[C@]1(CO)C(=O)C2CCN1CC2,APR-246,Phase 3,p53 activator,TP53,,
Nc1cc(Cl)c(NC2=NCCN2)c(Cl)c1,apraclonidine,Launched,adrenergic receptor agonist,ADRA1A|ADRA2A|ADRA2B|ADRA2C,ophthalmology,glaucoma|intraocular pressure
CN[C@@H]1[C@@H](O[C@H]2O[C@H](CO)[C@@H](N)[C@H](O)[C@H]2O)O[C@H]2C[C@@H](N)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N)C[C@@H]3N)O[C@@H]2[C@@H]1O,apramycin,Launched,bacterial 30S ribosomal subunit inhibitor,,infectious disease,gram-negative bacterial infections
CC1(C)SCCN(S(=O)(=O)c2ccc(OCC#CCO)cc2)[C@H]1C(=O)NO,apratastat,Phase 2,matrix metalloprotease inhibitor|tumor necrosis factor production inhibitor,ADAM17|MMP1|MMP13|MMP9,,
CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,apremilast,Launched,phosphodiesterase inhibitor,PDE4A|PDE4B|PDE4C|PDE4D,dermatology|rheumatology,psoriasis|psoriatic arthritis
C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,aprepitant,Launched,tachykinin antagonist,TACR1,gastroenterology,nausea|vomiting
Nc1ccn([C@H]2CO[C@@H](CO)S2)c(=O)n1,apricitabine,Phase 3,nucleoside reverse transcriptase inhibitor,,,
CCN(CC)CCCN(c1ccccc1)C1Cc2ccccc2C1,aprindine,Launched,voltage-gated sodium channel blocker,CALM1|SCN5A,cardiology,cardiac arrythmia
C=CC[C@H](C(=O)NC(N)=O)C(C)C,apronal,Preclinical,cytochrome P450 modulator,,,
CCc1cccc(N(C)C(=N)Nc2cccc3ccccc23)c1,aptiganel,Phase 3,glutamate receptor antagonist,GRIN1,,
Cc1[nH]c2ccc(F)cc2c1-c1nc2c3cccnc3c3ncccc3c2[nH]1,APTO-253,Phase 1,kr_¼ppel-like factor expression enhancer,KLF4,,
c1cc(Nc2cc(C3CC3)n[nH]2)nc(Nc2ccc3nc[nH]c3c2)n1,APY-29,Preclinical,serine/threonine kinase inhibitor,ERN1,,
Cc1cccc(/C=N/Nc2cc(N3CCOCC3)n3nc(-c4ccncc4)cc3n2)c1,APY0201,Preclinical,phosphoinositide dependent kinase inhibitor,IL12A|IL12B|PIKFYVE,,
COc1ccc2c(c1)c(CC(=O)Oc1ccc(NC(C)=O)cc1)c(C)n2C(=O)c1ccc(Cl)cc1,apyramide,Preclinical,cyclooxygenase inhibitor,,,
CCN(CC)CCCNc1ccnc2cc(Cl)ccc12,AQ-13,Phase 2,antimalarial agent,,,
CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc32)CC1,AQ-RA741,Preclinical,acetylcholine receptor antagonist,CHRM2,,
Cc1ccc(-c2ccc(O[C@H]3CN4CCC3CC4)cn2)cc1,AQW-051,Preclinical,nicotinic receptor agonist,,,
NCC(=O)Nc1ccc(-n2nc(C(F)(F)F)cc2-c2ccc3c(ccc4ccccc43)c2)cc1,AR-12,Phase 1,phosphoinositide dependent kinase inhibitor,PDPK1,,
CC(C)[C@H](C(=O)Nc1ccc(C(=O)NO)cc1)c1ccccc1,AR-42,Phase 1,HDAC inhibitor,HDAC1,,
COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1,AR-A014418,Preclinical,glycogen synthase kinase inhibitor,GSK3B,,
Cc1n[nH]c(C)c1Cc1sc2c(c1C(=O)N1C[C@H](O)CO1)c(=O)n(C)c(=O)n2CC(C)C,AR-C155858,Preclinical,monocarboxylate transporter inhibitor,SLC16A1|SLC16A7,,
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O,arachidonic-acid,Phase 1,cytochrome P450 inhibitor,CLCN2|KCNJ4|KCNK10|KCNK18|KCNK2|PRKCZ|PTGS1|TRPC6|TRPM2,,
CCCCCCCCCCCCCCCCCCCC(=O)N[C@H]1CC[C@@]2(C)[C@@H](C1)C[C@@H](O)[C@@H]1[C@@H]2C[C@H](O)[C@]2(C)[C@@H]([C@H](C)CCC(=O)O)CC[C@@H]12,aramchol,Phase 2/Phase 3,stearoyl-CoA desaturase inhibitor,,,
CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12,arbidol,Launched,cytochrome P450 inhibitor,CYP3A4,infectious disease,influenza A virus infection
OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O,arbutin,Phase 2/Phase 3,melanin inhibitor,TYR,,
COc1ccccc1N1CCN(CCN2C(=O)c3ccccc3C(C)(C)C2=O)CC1,ARC-239,Preclinical,adrenergic receptor antagonist,ADRA2A|ADRA2B|ADRA2C,,
COc1cc(C[C@H]2C(=O)OC[C@@H]2Cc2ccc(OC)c(OC)c2)ccc1O,arctigenin,Preclinical,MEK inhibitor,CHUK|MAP2K1,,
O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21,arcyriaflavin-a,Preclinical,CDK inhibitor,CCND1|CDK4,,
CC#CCOC(=O)C1=CCCN(C)C1,arecaidine-but-2-ynyl-ester,Preclinical,acetylcholine receptor agonist,CHRM2,,
C#CCOC(=O)C1=CCCN(C)C1,arecaidine-propargyl-ester,Preclinical,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4,,
COC(=O)C1=CCCN(C)C1,arecoline,Phase 1,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4,,
C[C@@H]1CCN(C(=O)[C@H](CCCNC(=N)N)NS(=O)(=O)c2cccc3c2NC[C@H](C)C3)[C@@H](C(=O)O)C1,argatroban,Launched,thrombin inhibitor,F2,hematology,heparin-induced thrombocytopenia (HIT)
CSCC[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(C)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O,argireline,Phase 3,neurotransmitter release inhibitor,,,
C=C1C(=O)O[C@@H]2[C@H]3C(C)=CC[C@@]34O[C@@]4(C)CC[C@@H]12,arglabin,Launched,farnesyltransferase inhibitor,FNTA|NFKB1,,
O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,aripiprazole,Launched,serotonin receptor agonist|serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR3A|HTR6|HTR7,neurology/psychiatry,depression|schizophrenia|bipolar disorder
CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc21,aripiprazole-lauroxil,Launched,serotonin receptor agonist,,neurology/psychiatry,schizophrenia
CCCn1c(=O)c2[nH]cnc2n(-c2ccc(Cl)cc2)c1=O,arofylline,Phase 3,phosphodiesterase inhibitor,PDE4A,,
CC(C)(C)NC[C@@H](O)CSc1nc(-c2ccc(C(N)=O)s2)cs1,arotinolol,Launched,adrenergic receptor antagonist,ADRB3,cardiology|neurology/psychiatry,hypertension|tremors
Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1,ARQ-092,Phase 1,AKT inhibitor,AKT2,,
C#CC[C@H](c1nc2cc(Cl)ccc2c(=O)n1Nc1ccccc1)N(CCCN)C(=O)c1cccc(Cl)c1F,ARQ-621,Phase 1,kinesin-like spindle protein inhibitor,KIF11,,
C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1,ARRY-334543,Phase 2/Phase 3,EGFR inhibitor,ERBB2,,
Nc1ccc([As](=O)(O)O)cc1,arsanilic-acid,Phase 1,,LYZ,,
O=[As]O[As]=O,arsenic-trioxide,Launched,apoptosis stimulant,AKT1|CCND1|IKBKB|JUN|MAPK1|MAPK3|TXNRD1,gastroenterology,diarrhea
CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3,artemether,Launched,antimalarial agent,ATP1A1,infectious disease,malaria
C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4,artemisinin,Launched,DNA synthesis inhibitor,CYP2B6,infectious disease,malaria
CCO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3,artemotil,Launched,,,infectious disease,malaria
C[C@H]1[C@H](OC(=O)CCC(=O)O)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3,artesunate,Launched,DNA synthesis inhibitor,,infectious disease,malaria
CCCN[C@@H](C)C(=O)Nc1c(C)csc1C(=O)OC,articaine,Launched,local anesthetic,,neurology/psychiatry,local anesthetic
CCCCCC[C@@H](CCC)C(=O)O,arundic-acid,Phase 2/Phase 3,astrocyte modulating agent,PTGS2|S100B,,
Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@@H](CC(=O)Nc1ccc(OCCOCCOCCOCCNc3cccc4c3C(=O)N([C@H]3CCC(=O)NC3=O)C4=O)cc1)c1nnc(C)n1-2,ARV-825,Preclinical,bromodomain inhibitor,BRD4,,
Cc1cc(NCCO)nc(-c2ccc(Br)cc2)n1,AS-1269574,Preclinical,glucose dependent insulinotropic receptor agonist,GPR119,,
O=C(Nc1ccc(-c2ccncc2)cc1)N[C@H](CO)c1ccccc1,AS-1892802,Preclinical,rho associated kinase inhibitor,ROCK1,,
C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1,AS-1949490,Preclinical,SHIP2 phosphatase inhibitor,INPP5D,,
O=C(O)CCc1ccc(NCc2cccc3c2CCCN3CCOc2ccccc2)cc1F,AS-2034178,Preclinical,free fatty acid receptor agonist,FFAR1,,
Cc1cc(-c2nc(C(=O)Nc3cn(C4CCOCC4)nc3C(N)=O)co2)ccn1,AS-2444697,Preclinical,interleukin inhibitor,IRAK4,,
O=C1NC(=O)/C(=C/c2ccc(-c3ccc(F)cc3O)o2)S1,AS-252424,Preclinical,PI3K inhibitor,PIK3CG,,
O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1,AS-604850,Preclinical,PI3K inhibitor,PIK3CA|PIK3CG,,
O=C(NC[C@H](O)CO)c1ccncc1Nc1ccc(I)cc1F,AS-703026,Phase 2,MEK inhibitor,MAP2K1|MAP2K2,,
O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1,AS-77,Phase 1,potassium channel blocker,KCNA3|KCNA5|KCNN4,,
Cc1ccc2c(=O)c3cccc(CC(=O)O)c3oc2c1C,ASA-404,Phase 3,angiogenesis inhibitor,,,
CC(C)Oc1ccc(S(=O)(=O)N2CCN(c3ccc(-c4ncco4)c(OCC(=O)O)c3)CC2)cc1,asapiprant,Preclinical,prostaglandin inhibitor,,,
COc1cc(OC)c(OC)cc1C=O,asaraldehyde,Preclinical,cyclooxygenase inhibitor,PTGS2,,
COc1ccc(/C=C/C(=O)C=C(O)/C=C/c2ccc(OC)c(OC)c2)cc1OC,ASC-J9,Phase 2,androgen receptor enhancer,AR,,
O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1,asciminib,Phase 2,Bcr-Abl kinase inhibitor,,,
CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,ascomycin,Preclinical,calcineurin inhibitor,FKBP1A,,
O=C1O[C@H]([C@@H](O)CO)[C@@H](O)C1=O,ascorbic-acid,Launched,antioxidant,SLC23A1|SLC23A2,endocrinology,scurvy
CN1C[C@@H]2c3ccccc3Oc3ccc(Cl)cc3[C@H]2C1,asenapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,DRD2|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A,neurology/psychiatry,schizophrenia|bipolar disorder
C[C@H]1[C@H](C)CC[C@]2(C(=O)O)CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@]43C)[C@H]12,asiatic-acid,Preclinical,apoptosis stimulant,PYGM,,
CN(C(=O)C(c1ccccc1)c1ccccc1)[C@H](CN1CC[C@H](O)C1)c1ccccc1,asimadoline,Phase 3,opioid receptor agonist,OPRK1,,
CCCc1nc(C(F)(F)F)ccc1/C=C/C(=O)N[C@H](C)c1cc(F)c(NS(C)(=O)=O)c(F)c1,asivatrep,Phase 3,transient receptor potential channel antagonist,,,
CC(C)c1nnc(-c2ccc(-c3ccccc3)nc2)n1-c1cccc2nonc12,ASP-2535,Phase 1,glycine transporter inhibitor,SLC6A9,,
COc1ccc(-c2nc(OC)nn2-c2ccc(OC)cc2)cc1,ASP-6537,Preclinical,cyclooxygenase inhibitor,,,
COc1ccc2[nH]c(C(=O)N3CCC(CC(C)(C)O)CC3)cc2c1,ASP-9521,Preclinical,aldo-keto reductase inhibitor,,,
COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1,ASP3026,Phase 1,ALK tyrosine kinase receptor inhibitor,ALK,,
COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(=O)O,aspartame,Launched,,TAS1R2|TRPV1,,
CC(=O)Oc1ccccc1C(=O)O,aspirin,Launched,cyclooxygenase inhibitor,AKR1C1|ASIC3|EDNRA|HSPA5|IKBKB|NFKB1|NFKB2|NFKBIA|PRKAA1|PRKAA2|PRKAB1|PRKAB2|PRKAG1|PRKAG2|PRKAG3|PTGS1|PTGS2|RPS6KA3|TP53,neurology/psychiatry|endocrinology|dental,headache|fever|toothache|muscle pain
C=CC(=O)Nc1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1,AST-1306,Phase 1,EGFR inhibitor,EGFR|ERBB2,,
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)C(=O)[C@@H](O)CC2(C)C)C(C)(C)C[C@H](O)C1=O,astaxanthin,Launched,antioxidant,,,
C[C@@H]1O[C@@H](O[C@H]2C(=O)c3c(O)cc(O)cc3O[C@@H]2c2ccc(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O,astilbin,Preclinical,nuclear factor erythroid derived|like (NRF2) activator,,,
CC(C)(O)[C@H]1CC[C@@](C)([C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@H]5C(C)(C)[C@@H](O[C@@H]6OC[C@@H](O)[C@H](O)[C@H]6O)CC[C@@]56C[C@@]46CC[C@]23C)O1,astragaloside-a,Preclinical,anti-inflammatory agent,,,
C[C@@H]1CN(CC(=O)N2CC(C)(C)c3nc(CO)c(Cc4ccc(F)cc4)cc32)[C@@H](CN2CCOC[C@H]2C)CN1,ASTX660,Phase 1/Phase 2,apoptosis inhibitor,,,
C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2ncc(OC)c3ccc(Cl)cc23)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,asunaprevir,Phase 3,HCV inhibitor,,,
CN(C)C(=N)NCCC[C@H](N)C(=O)O,asymmetrical-dimethylarginine,Phase 1,nitric oxide synthase inhibitor,NOS2|NOS3,,
O=CN1CCC(C(=O)NCCN2CCC(=C3c4ccccc4C=Cc4ccccc43)CC2)CC1,AT-1015,Preclinical,serotonin receptor antagonist,HTR2A,,
CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CC(C)C)CC[C@H]2CC[C@@H](C(=O)NC(c3ccccc3)c3ccccc3)N2C1=O,AT-406,Phase 1,IAP antagonist ,,,
O=C(NC1CCNCC1)c1[nH]ncc1NC(=O)c1c(Cl)cccc1Cl,AT-7519,Phase 2,CDK inhibitor,CDK1|CDK2|CDK4|CDK5|CDK6|CDK9,,
O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1,AT-9283,Phase 2,Aurora kinase inhibitor|JAK inhibitor,AURKA|AURKB|JAK2|JAK3|RPS6KA6|STK17A,,
NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1,AT13148,Phase 1,protein kinase inhibitor,AKT1|AKT2|AKT3|ROCK1|ROCK2|SGK3,,
CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O,AT13387,Phase 2,HSP inhibitor,HSP90AA1,,
Clc1ccc(C2(c3ccc(-c4cn[nH]c4)cc3)CCNCC2)cc1,AT7867,Preclinical,AKT inhibitor,AKT2|GSK3B|PKIA|PRKACA,,
O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1,ataluren,Launched,CFTR channel agonist|dystrophin stimulant,DMD,genetics|pulmonary,duchenne muscular dystrophy (DMD)|cystic fibrosis
COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,atazanavir,Launched,HIV protease inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)
COc1ccc2cc([C@@H](C)C(=O)Oc3ccc(C(N)=S)cc3)ccc2c1,ATB-346,Phase 2,cyclooxygenase inhibitor,PTGER2,,
CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1,atenolol-(-),Launched,adrenergic receptor antagonist,,cardiology,hypertension
CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1,atenolol-(+),Preclinical,adrenergic receptor antagonist,,,
CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1,atenolol-(+/-),Launched,adrenergic receptor antagonist,ADRB1|ADRB2|LTF|PLA2G2E,cardiology,hypertension|angina pectoris
CN(C)C(=O)Nc1cccc(-c2ccc(N(C)C)cc2)c1,atglistatin,Preclinical,adipose triglyceride lipase inhibitor,,,
Cc1cc(C)cc([C@@H]2CCCN2Cc2ccc(Oc3ccc(C(N)=O)cc3F)cc2)c1,aticaprant,Phase 2,opioid receptor antagonist,,,
CCC1(c2cnc[nH]2)Cc2ccccc2C1,atipamezole,Launched,adrenergic receptor antagonist,,neurology/psychiatry,reverse sedative
CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1,atiprimod,Phase 2,JAK inhibitor|STAT inhibitor,JAK2|STAT3,,
COc1ccc(C2CNC(=O)NC2)cc1O[C@H]1C[C@@H]2CC[C@H]1C2,atizoram,Phase 2,phosphodiesterase inhibitor,PDE4A|PDE4B|PDE4C|PDE4D,,
CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O,ATN-161,Phase 2,integrin antagonist,ITGA5|ITGAV|ITGB1|ITGB3,,
CNCC[C@@H](Oc1ccccc1C)c1ccccc1,atomoxetine,Launched,norepinephrine transporter inhibitor,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,attention-deficit/hyperactivity disorder (ADHD)
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,atorvastatin,Launched,HMGCR inhibitor,AHR|DPP4|HMGCR,neurology/psychiatry|cardiology,stroke|heart attack
CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)CC)NC2=O)cc1,atosiban,Launched,oxytocin receptor antagonist,AVPR1A|AVPR1B|AVPR2|OXTR,neurology/psychiatry|cardiology|endocrinology,stroke|angina pectoris|myocardial infarction|hyperlipidemia
O=C1C(=O)[C@H]([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21,atovaquone,Launched,mitochondrial electron transport inhibitor,,infectious disease,pneumonia
CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(=O)O,ATPA,Preclinical,glutamate receptor agonist,GRIK1,,
C=C1CCC[C@]2(C)C=C3OC(=O)C(C)=C3C[C@@H]12,atractylenolide-i,Preclinical,JAK inhibitor,,,
COc1ccc(C[C@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@+]2(C)CCc3cc(OC)c(OC)cc3[C@@H]2Cc2ccc(OC)c(OC)c2)cc1OC,atracurium,Launched,acetylcholine receptor antagonist,,critical care|neurology/psychiatry,endotracheal intubation|muscle relaxant
CCCCN(CCCC)C(=O)CN1C[C@H](c2ccc3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1c1ccc(OC)cc1,atrasentan,Phase 3,endothelin receptor antagonist,EDNRA,,
CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)[C@@H](CO)c1ccccc1)C2,atropine,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3,ophthalmology,cycloplegia|mydriasis|amblyopia
C[N@+]1([O-])[C@@H]2CC[C@H]1C[C@@H](OC(=O)[C@H](CO)c1ccccc1)C2,atropine-oxide,Preclinical,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,,
COc1cc(F)ccc1-c1ncnc(Nc2cccc(C[S@](C)(=N)=O)c2)n1,atuveciclib,Phase 1,CDK9 inhibitor,,,
CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O,auranofin,Launched,NFkB pathway inhibitor,IKBKB|PRDX5|TRPA1,rheumatology,rheumatoid arthritis
CCN1CCN(C(=O)Cc2ccc(Nc3ncc(F)c(Nc4ccc(C(=O)Nc5ccccc5Cl)cc4)n3)cc2)CC1,aurora-a-inhibitor-i,Preclinical,Aurora kinase inhibitor,AURKA,,
OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O,aurothioglucose,Launched,PKC inhibitor,PRKCI,rheumatology,rheumatoid arthritis
CC[C@H]1NC(=O)N(c2ccc(Oc3ccc(C)c(OC)c3)nc2)C1=O,AUT-1,Preclinical,potassium channel activator,,,
C[C@H](c1ccc2ccc(O[C@H]3CC[C@@H](C(F)(F)F)CC3)c(C(F)(F)F)c2c1)N1[C@@H]2CC[C@H]1C[C@@H](C(=O)O)C2,autotaxin-modulator-1,Preclinical,autotaxin inhibitor,ENPP2,,
C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1C#CC(C)(C)N1CCN(C)CC1,AV-412,Phase 1,protein tyrosine kinase inhibitor,EGFR|ERBB2,,
O=C(N[C@H]1CCN(C(=O)c2cc(C(F)(F)F)cc(C(F)(F)F)c2)[C@H](Cc2ccc(Cl)cc2)C1)c1ccnc2ccccc12,AV-608,Phase 2,tachykinin antagonist,TACR1,,
Cc1ccc(NC(=O)[C@H]2CCCN(C(=O)c3c(C)cccc3F)[C@H]2c2ccc(NC3CCCC3)cc2)cc1C(F)(F)F,avacopan,Phase 2,complement inhibitor,,,
Cc1nc2cccc(N)c2c(=O)n1[C@H]1CCC(=O)NC1=O,avadomide,Phase 2,antitumor agent,,,
NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(-c2ncon2)cc1F)S(=O)(=O)c1ccc(Cl)cc1,avagacestat,Phase 2,gamma secretase inhibitor,PSEN1,,
COc1ccc(CNc2nc(N3CCC[C@H]3CO)ncc2C(=O)NCc2ncccn2)cc1Cl,avanafil,Launched,phosphodiesterase inhibitor,PDE5A,urology,erectile dysfunction
Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1,avapritinib,Launched,KIT inhibitor,,,
CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(C(C)C)cccc2C(C)C)c(C(C)C)c1,avasimibe,Phase 3,ACAT inhibitor,CES1,,
O=C(Nc1nc(-c2cc(Cl)cs2)c(N2CCN(C3CCCCC3)CC2)s1)c1cnc(N2CCC(C(=O)O)CC2)c(Cl)c1,avatrombopag,Launched,thrombopoietin receptor agonist,MPL,hematology,thrombocytopenia
CCNC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2c(-c3ccccc3)nc(OC)c2C=O)cc1,AVE-0991,Preclinical,angiotensin receptor agonist,MRGPRX1,,
O=C(NC1Cc2ccccc2C1)c1ccc2c(c1)OC(F)(F)O2,AVE-3085,Preclinical,nitric oxide synthase stimulant,,,
CN(C)C[C@H]1CCOC1(c1ccccc1)c1ccccc1,AVex-73,Preclinical,sigma receptor agonist,,,
NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O,avibactam,Launched,beta lactamase inhibitor,,infectious disease,intra-abdominal infections|urinary tract infections|pyelonephritis
C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)c(F)c3)nc3[nH]ccc23)c1,avitinib,Phase 2,EGFR inhibitor,,,
C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1,AVL-292,Phase 2,Bruton's tyrosine kinase (BTK) inhibitor,BTK|YES1,,
CNc1nn2c(C)c(N(C)C)c(C)nc2c1S(=O)(=O)c1ccccc1,AVN-492,Preclinical,serotonin receptor antagonist,,,
CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1,AVN-944,Phase 2,inosine monophosphate dehydrogenase inhibitor,IMPDH1|IMPDH2,,
COc1ccc(C(=O)C=C(O)c2ccc(C(C)(C)C)cc2)cc1,avobenzone,Launched,topical sunscreen agent,,dermatology,cosmetic|sunscreen lotion
C=Cc1cc(C(=O)Nc2ccc(C(=N)N)cc2)c(-c2ccc(C(=O)NCC3CC3)nc2C(=O)O)cc1OC,avoralstat,Phase 3,kallikrein inhibitor,,,
CCCCCCCCCCCCCCCCCCN(CCCCCCCCCCCCCCCCCC)CCCN(CCO)CCO,avridine,Preclinical,immunostimulant,,,
COc1ccc2c(c1)C(c1ccc(F)cc1)=C(CN1CCCC1)CO2,AX-024,Preclinical,cytokine production inhibitor,,,
CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)[nH]nc2c1,axitinib,Launched,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,CSF1|FLT1|FLT4|KDR|PLK4,oncology,renal cell carcinoma (RCC)
Clc1ccccc1CNC[C@H]1CC[C@H](CNCc2ccccc2Cl)CC1,AY-9944,Preclinical,hedgehog pathway modulator,,,
C=CCNC(=O)c1cc([N+](=O)[O-])cc2c(=O)nc(Nc3ccc(Cl)c(Cl)c3)[nH]c12,AZ-10417808,Preclinical,caspase inhibitor,CASP3,,
O=C(CC12CC3CC(CC(C3)C1)C2)Nc1cccc2nc(NCCNCCO)ccc12,AZ-10606120,Preclinical,purinergic receptor antagonist,P2RX7,,
Cc1ccc(-c2ncc[nH]2)cc1NC(=O)c1ccc(OCc2ccccn2)cc1,AZ-12080282,Preclinical,hedgehog pathway inhibitor,DHH,,
Cc1ccc(NC(=O)c2cccc(C(C)(C)C#N)c2)cc1Nc1ccc2ncn(C)c(=O)c2c1,AZ-628,Preclinical,RAF inhibitor,BRAF|RAF1,,
COc1ncnc(Cn2cc(C(=O)NCCO)c3ncc(C)cc32)c1C,AZ-7371,Preclinical,antibacterial ,,,
COc1cc(N2CCN(C)CC2)ccc1Nc1nccc(-c2cn(C)c3cnccc23)n1,AZ191,Preclinical,DYRK inhibitor,DYRK1B,,
C[C@@H]1COCCN1c1cc(C2(S(C)(=O)=O)CC2)nc(-c2cccc3[nH]ccc23)n1,AZ20,Preclinical,ATR kinase inhibitor,ATR|MTOR,,
COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2c(n1)n(C1CCCC1)c(=O)n2C,AZ3146,Preclinical,monopolar spindle 1 kinase inhibitor,,,
O=C1COc2c(CCNCCN(C(=O)CCNCCc3ccc(Cl)c(Cl)c3)C3CCCCC3)ccc(O)c2N1,AZ505,Preclinical,histone lysine methyltransferase inhibitor,SMYD2,,
C=CC(=O)Nc1cc(Nc2nccc(-c3c[nH]c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,AZ5104,Preclinical,EGFR inhibitor,EGFR,,
C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCNC,AZ7550,Phase 1,insulin growth factor receptor inhibitor,,,
Cc1cc(Nc2nc(N[C@@H](C)c3ccc(F)cc3)c(C#N)cc2F)[nH]n1,AZ960,Preclinical,JAK inhibitor,JAK2,,
Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,azacitidine,Launched,DNA methyltransferase inhibitor,DNMT1|DNMT3A,hematologic malignancy|hematology,myelodysplastic diseases (MDS)|anemia|chronic myelomonocytic leukemia (CMMoL)
OC(c1ccccc1)(c1ccccc1)C1CCNCC1,azacyclonol,Preclinical,histamine receptor antagonist,HRH1,,
Nc1nc2nn[nH]c2c(=O)[nH]1,azaguanine-8,Preclinical,purine antagonist,PNP,,
CC[C@@H]1[C@@H](C)O[C@@](O)([C@@H](C)[C@H](O)[C@H](C)[C@H]2OC(=O)/C=C/C=C/[C@H](C)[C@@H]([C@@H](C)[C@@H](O)[C@H](C)[C@@]3(O)C[C@@H](O[C@H]4C[C@H](O)[C@H](O)[C@H](C)O4)[C@H](CC)[C@@H](C)O3)OC(=O)/C=C/C=C/[C@@H]2C)C[C@H]1O[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1,azalomycin-B,Preclinical,bacterial 50S ribosomal subunit inhibitor,,,
O=C(CCCN1CCN(c2ccccn2)CC1)c1ccc(F)cc1,azaperone,Launched,dopamine receptor antagonist,DRD2|DRD3,neurology/psychiatry,sedative
N#[N+]CC(=O)OC[C@H](N)C(=O)O,azaserine,Preclinical,purine antagonist,,,
CN1C(=O)COc2c(C(=O)N[C@H]3CN4CCC3CC4)cc(Cl)cc21,azasetron,Launched,serotonin receptor antagonist,HTR3A|HTR3B,infectious disease,genitial herpes
CN1CCC(=C2c3ccccc3CCc3cccnc32)CC1,azatadine,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,azathioprine,Launched,dehydrogenase inhibitor,HPRT1|IMPDH1|PPAT,transplant|rheumatology,renal homotransplantation|rheumatoid arthritis
CN(C)CCCOc1ccc(-c2ccc3ncc4c(c3c2)n(C2CCOCC2)c(=O)n4C)cn1,AZD0156,Phase 1,ATM kinase inhibitor,,,
N#Cc1ccc2c(c1)C(c1ccc(CN3CCOCC3)cn1)C(=O)N2,AZD1080,Phase 1,glycogen synthase kinase inhibitor,GSK3A|GSK3B,,
N[C@@H]1CCCN(c2c(/C=C3\SC(=O)NC3=O)cccc2-c2ccccc2)C1,AZD1208,Phase 1,Pim kinase inhibitor,PIM1|PIM2|PIM3,,
CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccccc3)CC2)nc1C,AZD1283,Preclinical,purinergic receptor antagonist,P2RY12,,
CC(C)n1c(=O)n(C)c2cnc3cc(F)c(-c4ccc(OCCCN5CCCCC5)nc4)cc3c21,AZD1390,Phase 1,ATM kinase inhibitor,,,
O=C(c1ccc(Cl)o1)N1C[C@H]2CNC[C@@H]2C1,AZD1446,Phase 2,acetylcholine receptor agonist,CHRNA4|CHRNB2,,
Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1,AZD1480,Phase 1,JAK inhibitor,JAK1|JAK2|JAK3,,
CC(=O)Nc1cccc2c1c(Sc1ccc(Cl)cc1)c(C)n2CC(=O)O,AZD1981,Phase 2,CRTH receptor antagonist,PTGDR2,,
CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1,AZD2014,Phase 2,mTOR inhibitor,MTOR,,
COC1CCN(C(=O)c2cc(Cc3n[nH]c(=O)c4ccccc34)ccc2F)CC1,AZD2461,Phase 1,PARP inhibitor,,,
CN1CCN(S(=O)(=O)c2ccc(-c3cnc(N)c(C(=O)Nc4cccnc4)n3)cc2)CC1,AZD2858,Preclinical,glycogen synthase kinase inhibitor,GSK3B,,
Cc1noc(C)c1-c1ccc(-c2cc(C(N)=O)c(NC(N)=O)s2)c(O[C@H]2CCNC2)c1,AZD3264,Preclinical,IKK inhibitor,IKBKB,,
COc1cc(N2CCC(N)CC2)ccc1Nc1ncc(Cl)c(-c2c[nH]c3ccccc23)n1,AZD3463,Preclinical,ALK tyrosine kinase receptor inhibitor|insulin growth factor receptor inhibitor,ALK|IGF1R,,
CC(=O)N1CCN(CCOc2ccc(C3CCN(C4=Nn5c(nnc5C(F)(F)F)CC4)CC3)cc2)CC1,AZD3514,Phase 1,androgen receptor modulator,AR,,
COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C,AZD3759,Phase 2/Phase 3,EGFR inhibitor,EGFR,,
NC1=N[C@@](c2cccc(-c3cncnc3)c2)(c2ccnc(C(F)F)c2)c2cccc(F)c21,AZD3839,Phase 1,beta-secretase inhibitor,BACE1,,
Cc1[nH]nc(C(F)(F)F)c1Cc1sc2c(c1C(=O)N1C[C@](C)(O)CO1)c(=O)n(C)c(=O)n2C(C)C,AZD3965,Phase 1,monocarboxylate transporter inhibitor,SLC16A1,,
O=C(O)C[C@H]1CC[C@H](c2ccc(NC(=O)c3nnc(Nc4ccc(F)c(F)c4)o3)cc2)CC1,AZD3988,Preclinical,diacylglycerol kinase inhibitor,DGAT1,,
COc1cc(CCc2cc(NC(=O)c3ccc(N4C[C@@H](C)N[C@@H](C)C4)cc3)[nH]n2)cc(OC)c1,AZD4547,Phase 2/Phase 3,FGFR inhibitor,FGFR1|FGFR2|FGFR3|FGFR4|IGF1R|KDR,,
CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(Cl)cn2)C1,AZD4573,Phase 1,CDK9 inhibitor,,,
Cc1cc(-c2nnc(N)nc2-c2ccc(F)cc2)cc(Cl)n1,AZD4635,Phase 1/Phase 2,adenosine receptor antagonist,,,
C[C@@H](Oc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO,AZD5069,Phase 2,CC chemokine receptor antagonist,CXCR2,,
COc1nnc2ccc(N3CCC(c4ccc(OCCN5CCN(C)C(=O)[C@H]5C)cc4)CC3)nn12,AZD5153,Phase 1,bromodomain inhibitor,,,
NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,AZD5363,Phase 3,AKT inhibitor,AKT1|AKT2|AKT3,,
Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C,AZD5438,Phase 1,CDK inhibitor,KCNH2,,
CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@H]1c2ccccc2C[C@H]1OCC#CC#CCO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC)C1CCCCC1)C1CCCCC1,AZD5582,Preclinical,XIAP inhibitor,BIRC2|BIRC3|XIAP,,
Cc1c2c(nn1C)CSCc1cc(n(C)n1)CSc1cc(c3ccccc3c1)OCCCc1c(C(=O)O)n(C)c3c-2c(Cl)ccc13,AZD5991,Phase 1,MCL1 inhibitor,,,
Cc1cc([C@@H](C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1,AZD6482,Phase 1,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,,
C[C@@H]1COCCN1c1cc(C2([S@@](C)(=N)=O)CC2)nc(-c2ccnc3[nH]ccc23)n1,AZD6738,Phase 2,ATR kinase inhibitor,ATR,,
N[C@@H](Cc1ccccn1)c1ccccc1,AZD6765,Phase 2,glutamate receptor antagonist,GRIN1,,
CN(C)C(=O)c1ccc(S(=O)(=O)c2ccc(NC(=O)[C@@](C)(O)C(F)(F)F)c(Cl)c2)cc1,AZD7545,Phase 1,pyruvate dehydrogenase kinase inhibitor,PDK1,,
C[C@H](NC(=O)C(C)(F)F)[C@H](Oc1ccc2c(cnn2-c2cccc(C(=O)N[C@@H]3CCOC3)c2)c1)c1ccc2c(c1)OCCO2,AZD7594,Phase 2,glucocorticoid receptor modulator,,,
Cc1nc(C)c(-c2ccc([C@H]3CC[C@H](CC(=O)O)CC3)cc2)nc1C(N)=O,AZD7687,Phase 1,diacylglycerol O acyltransferase inhibitor,DGAT1,,
NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1,AZD7762,Phase 1,CHK inhibitor,CHEK1|CHEK2,,
Cn1c(=O)oc2ccc(-c3ccc(C[C@@H](C#N)NC(=O)[C@@H]4CNCCCO4)cc3)cc21,AZD7986,Phase 1,dipeptidyl peptidase inhibitor,,,
COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO,AZD8055,Phase 1,mTOR inhibitor,MTOR,,
C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,AZD8186,Phase 1,PI3K inhibitor,PIK3CB|PIK3CD,,
Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O,AZD8330,Phase 1,MEK inhibitor,MAP3K1,,
CC(C)C[C@H](CO)Nc1nc(S[C@@H](C)c2ccccc2)nc2nc(N)sc12,AZD8797,Preclinical,CC chemokine receptor antagonist,,,
CCn1nc(C2CCN(C(=O)CCO)CC2)nc1-c1cnc(N)c(-c2nnc(C(C)(C)C)o2)n1,AZD8835,Phase 1,PI3K inhibitor,PIK3CA|PIK3CD,,
CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1,AZD8931,Phase 2,EGFR inhibitor,EGFR|ERBB2|ERBB3,,
O=C(NCC12CC3CC(CC(C3)C1)C2)c1cc(CCCNCCCO)ccc1Cl,AZD9056,Phase 2,purinergic receptor antagonist,,,
N#Cc1cc(F)cc(-c2nc(-c3ccc(F)cn3)no2)c1,AZD9272,Preclinical,glutamate receptor antagonist,GRM5,,
C[C@@H]1Cc2c([nH]c3ccccc23)[C@@H](c2c(F)cc(/C=C/C(=O)O)cc2F)N1CC(C)(C)F,AZD9496,Phase 1,estrogen receptor agonist,ESR1,,
Cc1c(-c2ccnn2C)cc(C(=O)NCc2ccc(S(C)(=O)=O)cn2)c(=O)n1-c1cccc(C(F)(F)F)c1,AZD9668,Phase 2,elastase inhibitor,ELANE,,
O=C(O)CCCCCCCC(=O)O,azelaic-acid,Launched,tyrosinase inhibitor,AKR1D1|SRD5A2|TYR,dermatology,rosacea
CN1CCC[C@H](n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1,azelastine,Launched,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis
CCCCc1nc(-c2ccc(OCCCN(CC)CC)cc2)cn1-c1ccc(Oc2ccc(Cl)cc2)cc1,azeliragon,Phase 3,RAGE receptor antagonist,AGER,,
CC1=C(C(=O)OC(C)C)[C@@H](c2cccc([N+](=O)[O-])c2)C(C(=O)OC2CN(C(c3ccccc3)c3ccccc3)C2)=C(N)N1,azelnidipine,Launched,calcium channel blocker,CACNA1C,cardiology,hypertension
CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nc(=O)o[nH]2)cc1,azilsartan,Launched,angiotensin receptor antagonist,AGTR1|AGTR2,cardiology,hypertension
CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(-c2ccccc2-c2nc(=O)o[nH]2)cc1,azilsartan-medoxomil,Launched,angiotensin receptor antagonist,AGTR1|AGTR2,cardiology,hypertension
CN1CCN(CCCCN2C(=O)CN(/N=C/c3ccc(-c4ccc(Cl)cc4)o3)C2=O)CC1,azimilide,Phase 3,potassium channel blocker,KCNA5,,
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,azithromycin,Launched,bacterial 50S ribosomal subunit inhibitor,MLNR,infectious disease,pelvic inflammatory disease|pneumonia
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(=O)O,azlocillin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections|gram-negative bacterial infections
COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1,AZM-475271,Preclinical,SRC inhibitor,SRC,,
O=[N+]([O-])c1ncc[nH]1,azomycin-(2-nitroimidazole),Preclinical,protein synthesis inhibitor,,,
NS(=O)(=O)c1cc(-c2nn[nH]n2)c(NCc2cccs2)cc1Cl,azosemide,Launched,electrolyte reabsorption inhibitor,SLC12A1|SLC12A2,cardiology,edema
C[C@H]1[C@H](NC(=O)/C(=N\OC(C)(C)C(=O)O)c2csc(N)n2)C(=O)N1S(=O)(=O)O,aztreonam,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,urinary tract infections|respiratory tract infections|bacterial septicemia|skin infections|intra-abdominal infections|gynecologic infections
CCOC(=O)O[C@@H](C)OC(=O)[C@@H]1N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1(C)C,bacampicillin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections|gram-negative bacterial infections
CC[C@H](C)[C@H](N)C1=N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCCN)NC2=O)[C@@H](C)CC)CS1,bacitracin,Launched,bacterial cell wall synthesis inhibitor,IDE,infectious disease,first-aid antibiotic
CC[C@H](C)[C@H](N)C1=N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]2CCC(=O)O[Zn]OC(=O)C[C@H]3NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@@H](Cc4ccccc4)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCCN)NC(=O)[C@H](CCCCNC(=O)[C@H](CC(N)=O)NC3=O)NC(=O)[C@H]([C@@H](C)CC)NC2=O)CS1,bacitracin-zinc,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,first-aid antibiotic
NC[C@@H](CC(=O)O)c1ccc(Cl)cc1,baclofen,Launched,benzodiazepine receptor agonist,GABBR1|GABBR2|KCTD12|KCTD16|KCTD8,neurology/psychiatry,multiple sclerosis|spasms
CC(C)(c1ccc(OC[C@H]2CO2)cc1)c1ccc(OC[C@H]2CO2)cc1,BADGE,Preclinical,PPAR receptor antagonist,PPARG,,
Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1,bafetinib,Phase 2,Bcr-Abl kinase inhibitor|LYN tyrosine kinase inhibitor,ABL1|BCR|LYN,,
CO/C1=C\C(C)=C/[C@@H](C)[C@@H](O)[C@@H](C)C/C(C)=C/C=C/[C@H](OC)[C@@H]([C@@H](C)[C@@H](O)[C@H](C)[C@@]2(O)C[C@@H](O)[C@H](C)[C@@H](C(C)C)O2)OC1=O,bafilomycin-a1,Preclinical,ATPase inhibitor,,,
Cc1nc2cnc3ccc(C#Cc4cccnc4)cc3c2n1-c1ccc(C(C)(C)C#N)cc1,BAG-956,Preclinical,phosphoinositide dependent kinase inhibitor,PIK3CG,,
O=c1c(O)c(O)cc2oc(-c3ccccc3)cc(O)c1-2,baicalein,Preclinical,lipoxygenase inhibitor,ALOX5|GLO1|PREP|SELL|SELP|TNF|XDH,,
O=C(O)[C@H]1O[C@@H](Oc2cc3oc(-c4ccccc4)cc(O)c-3c(=O)c2O)[C@H](O)[C@@H](O)[C@@H]1O,baicalin,Launched,beta glucuronidase inhibitor,PREP,neurology/psychiatry,anxiety
C=C[C@@](C)(/C=C/c1ccc(O)cc1)CCC=C(C)C,bakuchiol,Phase 2,DNA polymerase inhibitor,HIF1A,,
Cn1c(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc2ccccc2c1=O,balaglitazone,Phase 3,insulin sensitizer|PPAR receptor partial agonist,PPARG,,
CC(C)C(=O)OC[C@@]1(N=[N+]=[N-])O[C@@H](n2ccc(N)nc2=O)[C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C,balapiravir,Phase 2,RNA polymerase inhibitor,,,
CCCN1CCN(c2ccc(C(=O)NC3(C(=O)NCC#N)CCCCC3)cc2)CC1,balicatib,Phase 2,cathepsin inhibitor,CTSK,,
CN[C@H]1CCCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2OC)C1,balofloxacin,Launched,bacterial DNA gyrase inhibitor,,infectious disease,gram-negative bacterial infections
O=C1c2c(O)c(=O)ccn2N([C@@H]2c3ccccc3SCc3c2ccc(F)c3F)[C@@H]2COCCN12,baloxavir,Phase 3,endonuclease inhibitor,,,
COC(=O)OCOc1c2n(ccc1=O)N([C@@H]1c3ccccc3SCc3c1ccc(F)c3F)[C@@H]1COCCN1C2=O,baloxavir-marboxil,Launched,endonuclease inhibitor,,infectious disease,influenza A virus infection
O=C(O)CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)O)c2)cc1,balsalazide,Launched,cyclooxygenase inhibitor,ALOX5|PPARG|PTGS1|PTGS2,gastroenterology,ulcerative colitis
CCOc1ccccc1N/N=C1/C(=O)N(c2nc(-c3ccccc3)cs2)N=C1C,BAM7,Preclinical,BAX activator,BAX,,
CCCn1c(=O)c(CCCOC(=O)NC)nc2ccccc21,bamaquimast,Preclinical,proton pump inhibitor,,,
CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(C(O)CNC(C)(C)C)c1,bambuterol,Launched,adrenergic receptor agonist,ADRB2|BCHE,pulmonary,asthma
O=C(NCCCN1CCC2(CC1)OCc1ccccc12)[C@H]1CCCN1Cc1ccccc1,BAN-ORL-24,Preclinical,nociceptin/orphanin FQ receptor antagonist,OPRL1,,
C[N+](C)([O-])CCNc1ccc(NCC[N+](C)(C)[O-])c2c1C(=O)c1c(O)ccc(O)c1C2=O,banoxantrone,Phase 1/Phase 2,topoisomerase inhibitor,TOP2A,,
CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1)CCOP(=O)(O)O,barasertib,Phase 2/Phase 3,Aurora kinase inhibitor,AURKA|AURKB,,
CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1,barasertib-HQPA,Phase 2/Phase 3,Aurora kinase inhibitor,AURKB,,
CC1(C)CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](C(=O)C=C4[C@@]5(C)C=C(C#N)C(=O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]2C1,bardoxolone,Phase 1,nuclear factor erythroid derived|like (NRF2) activator,NOS2|PPARG,,
COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2,bardoxolone-methyl,Phase 3,nuclear factor erythroid derived|like (NRF2) activator,PPARG|STAT3,,
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,baricitinib,Launched,JAK inhibitor,JAK1|JAK2,rheumatology,rheumatoid arthritis
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O,barium-6-O-phosphonato-D-glucose,Preclinical,,,,
COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@H]2CCN(Cc3ccccc3)C2)[C@H]1c1cccc([N+](=O)[O-])c1,barnidipine,Launched,calcium channel blocker,,cardiology,hypertension
CC1=CC(=C(c2ccc(N)cc2)c2ccc(N)cc2)C=CC1=N,basic-fuchsin,Preclinical,,,,
Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(F)cc1,basimglurant,Phase 2,glutamate receptor antagonist,GRM5,,
Cc1onc(-c2ccc(F)cc2)c1COc1ccc(C(=O)N2CCS(=O)(=O)CC2)cn1,basmisanil,Phase 2,GABA receptor inverse agonist,,,
COc1cc(NC(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2nc(O)ccc12,batefenterol,Phase 2,acetylcholine receptor antagonist|adrenergic receptor agonist,,,
CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO,batimastat,Phase 3,matrix metalloprotease inhibitor,ADAM28|ADAMTS5|MMP12|MMP16|MMP2|MMP8,,
O=C(c1ccc(CN2CCOCC2)cc1)N1CCN(C2CC2)CC1,bavisant,Phase 2,histamine receptor antagonist,HRH3,,
O[C@@H](CN1CCNCC1)Cn1c2ccc(Br)cc2c2cc(Br)ccc21,BAX-channel-blocker,Preclinical,cytochrome C release inhibitor,BAX,,
Cc1ccc(S(=O)(=O)/C=C/C#N)cc1,BAY-11-7082,Preclinical,NFkB pathway inhibitor,RELA,,
CC(C)(C)c1ccc(S(=O)(=O)/C=C/C#N)cc1,BAY-11-7085,Preclinical,NFkB pathway inhibitor,NFKBIA,,
COc1cc(F)ccc1-c1cc(Nc2cc(C[S@](C)(=N)=O)ccn2)ncc1F,BAY-1251152,Phase 1,CDK9 inhibitor,,,
C[C@H]1C[C@@H](n2c(Nc3ccc(OC(F)(F)F)cc3)nc3cc(CCC(=O)O)ccc32)CC(C)(C)C1,BAY-1436032,Phase 1,isocitrate dehydrogenase inhibitor,,,
C[C@@H]1COCCN1c1cc(-c2ccnn2C)c2ccnc(-c3ccn[nH]3)c2n1,BAY-1895344,Phase 1,ATR kinase inhibitor,,,
CCn1c(CO)nn(-c2cc(O[C@@H](C)C(F)(F)F)c(C(=O)Nc3c(F)cccc3Cl)cc2F)c1=O,BAY-2402234,Phase 1,dihydroorotate dehydrogenase inhibitor,,,
Nc1nc(-c2nn(Cc3ccccc3F)c3ncccc23)ncc1C1CC1,BAY-41-2272,Preclinical,guanylyl cyclase activator,GUCY1A3|GUCY1B3,,
N#Cc1c(N)nc(SCC(N)=O)c(C#N)c1-c1ccc(OCC2CC2)cc1,BAY-60-6583,Preclinical,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
COc1ccc(Cc2nc(=O)c3c(C)nc([C@@H](CCCc4ccccc4)[C@@H](C)O)n3[nH]2)cc1OC,BAY-60-7550,Preclinical,phosphodiesterase inhibitor,PDE2A,,
COc1ccc(-c2cc3nccn3c(Nc3ncccc3C(N)=O)n2)cc1OC,BAY-61-3606,Preclinical,SYK inhibitor,SYK,,
O=C(Nc1ccccc1C(=O)O)c1cc(S(=O)(=O)c2ccccc2)ccc1Cl,BAY-8002,Preclinical,monocarboxylate transporter inhibitor,,,
N[C@@H](C[C@@H](F)C(=O)O)C(=O)O,BAY-85-8050,Phase 1,,,,
Cc1cc(-c2nc(-c3ccc(OC(F)(F)F)cc3)no2)nn1Cc1ccnc(N2CCN(C3CC3)CC2)c1,BAY-87-2243,Phase 1,hypoxia inducible factor inhibitor,HIF1A,,
COC(=O)C1=C(C)NC(C)=C([N+](=O)[O-])[C@@H]1c1ccccc1C(F)(F)F,BAY-K-8644-(+/-),Preclinical,L-type calcium channel blocker,,,
COC(=O)C1=C(C)NC(C)=C([N+](=O)[O-])[C@H]1c1ccccc1C(F)(F)F,BAY-K-8644-(s)-(-),Preclinical,L-type calcium channel activator,CACNA1C,,
COC(=O)C1=C(C)N(C)C(C)=C(C(=O)OC)C1c1ccc(C(F)(F)F)cc1,BAY-W-9798,Phase 2,antioxidant,,,
NC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2n1,BAY1125976,Phase 1,AKT inhibitor,,,
COc1ccc(Oc2cc(NCCC(F)(F)F)c3ncc(-c4ccc(C(=O)NC5CC5)c(C)c4)n3n2)c(F)c1F,BAY1217389,Phase 1,kinase inhibitor,,,
Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(C#N)cc2)cn1,BAZ2-ICR,Preclinical,bromodomain inhibitor,ZNF215,,
Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12,bazedoxifene,Launched,selective estrogen receptor modulator (SERM),ESR1|ESR2,orthopedics|endocrinology,osteoporosis|menopause
N=C(N)SCc1ccc(B(O)O)cc1,BC-11,Preclinical,urokinase inhibitor,PLAU,,
Cc1oc2nc3c(c(NC(=O)CN4CCCC4=O)c2c1C)CCCC3,BCI-540,Phase 2,glutamate receptor agonist,,,
CC(C)(C)c1ccc(NC(=O)N2CCN(c3ncccc3Cl)CC2)cc1,BCTC,Preclinical,TRPV antagonist,TRPV1,,
N=C(N)c1cc2ccc(OC(=O)c3cccs3)cc2s1,BCX-1470,Phase 1,complement inhibitor|serine protease inhibitor,CFD,,
CN(CCc1ccc(Cl)c(Cl)c1)CCN1CCCC1,BD-1008,Preclinical,sigma receptor antagonist,,,
CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1,BD-1047,Preclinical,adrenergic receptor antagonist,SIGMAR1,,
CN1CCN(CCc2ccc(Cl)c(Cl)c2)CC1,BD-1063,Preclinical,sigma receptor antagonist,SIGMAR1,,
O=C1c2ccccc2CC[C@@H]1CNCCc1ccc(O)cc1,BE-2254,Phase 2,adrenergic receptor antagonist,ADRA1A,,
CNc1ccc(-c2nc(N3CCOCC3)c3sc(CN(C)c4ncc(C(=O)NO)cn4)cc3n2)cn1,BEBT-908,Preclinical,PI3K inhibitor,,,
COc1ccc2c(c1)[C@@H]1C[C@]1(C(=O)N1[C@@H]3CC[C@H]1CN(C)C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21,beclabuvir,Phase 2,antiviral,,,
O=C(CCCl)NCc1ccccc1,beclamide,Launched,anticonvulsant,,neurology/psychiatry,sedative|seizures
C[C@H]1C[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]2(C)[C@@]1(O)C(=O)CO,beclomethasone,Launched,glucocorticoid receptor agonist,NR3C1|SERPINA6,allergy,allergic rhinitis
CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]21C,beclomethasone-dipropionate,Launched,glucocorticoid receptor agonist,GPR97|NR3C1,allergy,allergic rhinitis
COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12,bedaquiline,Launched,ATPase inhibitor,,infectious disease,tuberculosis
O=C(c1cc2ccccc2o1)N1CCN(Cc2ccccc2)CC1,befuraline,Phase 2,,,,
O=S(=O)(N[C@H](CO)C(C(F)(F)F)C(F)(F)F)c1ccc(Cl)s1,begacestat,Phase 1,gamma secretase inhibitor,PSEN1,,
NC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](N)[C@@H](O)[C@@H]1O,bekanamycin,Launched,bacterial 30S ribosomal subunit inhibitor,,infectious disease,gram-negative bacterial infections
O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO,belinostat,Launched,HDAC inhibitor,HDAC1|HDAC10|HDAC11|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9,hematologic malignancy,peripheral T-cell lymphoma (PTCL)
CC(C)NC(=O)[C@H]1CC[C@@H](n2c(NC(=O)c3ccc(F)cc3)nc3ccc(CN4CCC(C(C)(C)O)CC4)cc32)CC1,belizatinib,Preclinical,receptor tyrosine protein kinase inhibitor,,,
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1ccccc1c2CCNC(C)C,belotecan,Phase 3,topoisomerase inhibitor,,,
CCC1(C)CC(=O)NC(=O)C1,bemegride,Launched,chemoreceptor agonist,GABRA1,critical care,poison antidote
CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)c1cc(Cl)cc(Cl)c1)C2,bemesetron,Phase 3,serotonin receptor antagonist,HTR3A|HTR3B,,
CCCC[C@@H](CC)COc1ccc(-c2nc(-c3ccc(OC)cc3)nc(-c3ccc(OC[C@@H](CC)CCCC)cc3O)n2)c(O)c1,bemotrizinol,Launched,,,dermatology,sunscreen lotion
CC(C)(CCCCCC(O)CCCCCC(C)(C)C(=O)O)C(=O)O,bempedoic-acid,Launched,AMPK inhibitor,ACLY,,
CCN(CC)CCOC(=O)C(O)(c1ccccc1)c1ccccc1,benactyzine,Preclinical,butyrylcholinesterase inhibitor,,,
O=C(O)c1ccc(N[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1,benaxibine,Phase 1,,,,
CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O,benazepril,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension
Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,bendamustine,Launched,DNA inhibitor,,hematologic malignancy,chronic lymphocytic leukemia (CLL)|non-Hodgkin lymphoma (NHL)
O=C(O)COc1nn(Cc2ccccc2)c2ccccc12,bendazac,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry|rheumatology,muscle pain|joint pain
c1ccc(Cc2nc3ccccc3[nH]2)cc1,bendazol,Launched,nitric oxide synthase stimulant,,,
NS(=O)(=O)c1cc2c(cc1C(F)(F)F)N[C@@H](Cc1ccccc1)NS2(=O)=O,bendroflumethiazide,Launched,sodium/potassium/chloride transporter inhibitor,SLC12A1|SLC12A3,cardiology,hypertension
c1ccc(CCNCc2ccccc2)cc1,benethamine,Preclinical,,,,
CCCCN(CC)c1c([N+](=O)[O-])cc(C(F)(F)F)cc1[N+](=O)[O-],benfluralin,Phase 3,,CYP1A1|CYP1A2|CYP2B6|CYP3A4|ESR1|MMP1|SULT2A1|UGT1A1,,
C/C(=C(\CCOP(=O)(O)O)SC(=O)c1ccccc1)N(C=O)Cc1cnc(C)nc1N,benfotiamine,Launched,antioxidant,AGER,rheumatology,lumbago
COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@@H]2CCCN(Cc3ccccc3)C2)[C@@H]1c1cccc([N+](=O)[O-])c1,benidipine,Launched,calcium channel blocker,CACNA1C|CACNA1G,cardiology,hypertension
O=C(CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1,benperidol,Launched,dopamine receptor antagonist,DRD2,neurology/psychiatry,schizophrenia
C[C@@H](COc1ccccc1Cc1ccccc1)N1CCCCC1,benproperine,Launched,antitussive,SCN5A,pulmonary,cough suppressant
NC(CO)C(=O)NNCc1ccc(O)c(O)c1O,benserazide,Launched,DOPA decarboxylase inhibitor,DDC,neurology/psychiatry,Parkinson's Disease
O=C(O)c1ccc(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1,bentiromide,Launched,,HPN,gastroenterology,pancreas diagnostic agent
O=C(CNC(=O)c1ccc(Cl)cc1)NO,benurestat,Phase 1,urease inhibitor,,,
CCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1,benzalkonium,Launched,cationic surfactant,,dermatology,abrasions|superficial cuts
NC(=NC(=O)c1nc(Cl)c(N)nc1N)NCc1ccccc1,benzamil,Phase 2,sodium channel blocker,ASIC1|PKD2L1|SCNN1A|SCNN1B|SCNN1D|SCNN1G|SLC8A1,,
CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1,benzbromarone,Launched,chloride channel blocker,ABCC1,rheumatology,gout
Cc1ccc(C)c([C@H](O)CNC(C)C)c1,"benzenemethanol,-2,5-dimethyl-[[(1-methylethyl)amino]methyl]",Preclinical,,,,
CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1,benzethonium,Launched,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic
O=C(Cn1ccnc1[N+](=O)[O-])NCc1ccccc1,benznidazole,Launched,DNA synthesis inhibitor,,infectious disease,Chagas disease
S=c1[nH]c2ccccc2s1,benzo[d]thiazole-2(3H)-thione,Phase 1,,,,
CCOC(=O)c1ccc(N)cc1,benzocaine,Launched,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic
O=C(O[C@H]1CN2CCC1CC2)c1ccccc1,benzoclidine,Preclinical,,,,
O=C(O)Cc1ccc(OCc2ccccc2)c(Cl)c1,benzofenac,Phase 1,,,,
O=C(O)c1ccccc1,benzoic-acid,Launched,food preservative,DAO|HRSP12|PRDX5|RAB9A,infectious disease,tinea pedis
O=C(c1ccccc1)[C@H](O)c1ccccc1,benzoin,Preclinical,,CES1,,
CCCCNc1ccc(C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC)cc1,benzonatate,Launched,local anesthetic,SCN5A,pulmonary,cough suppressant
CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)Cc2ccccc2)=CC1=O)Cc1ccccc1,benzoquinonium-dibromide,Preclinical,cholinergic receptor antagonist,CHRNA1,,
O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O)c1ccc(Cl)cc1,benzotript,Phase 1,CCK receptor antagonist,CCKAR|CCKBR,,
O=C(Oc1cccc2cccnc12)c1ccccc1,benzoxiquine,Preclinical,antiinfective drug,,,
O=C(OOC(=O)c1ccccc1)c1ccccc1,benzoyl-peroxide,Launched,oxidizing agent,,dermatology,acne vulgaris (AV)
O=C(Nc1ccc(C(=O)O)c(O)c1)c1ccccc1,benzoylpas,Preclinical,,,,
NS(=O)(=O)c1cc2c(cc1Cl)NC(=CSCc1ccccc1)NS2(=O)=O,benzthiazide,Launched,carbonic anhydrase inhibitor,CA2,cardiology,hypertension|edema
CN1[C@@H]2CC[C@H]1C[C@@H](OC(c1ccccc1)c1ccccc1)C2,benztropine-mesylate,Launched,acetylcholine receptor antagonist,CHRM1|HRH1|SLC6A3,neurology/psychiatry,extrapyramidal symptoms (EPS)|Parkinson's Disease
CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12,benzydamine,Launched,prostanoid receptor antagonist,,dental|otolaryngology,mouth inflammation|throat inflammation
OCc1ccccc1,benzyl-alcohol,Launched,local anesthetic,,infectious disease,virus herpes simplex (HSV)
O=C(OCc1ccccc1)c1ccccc1,benzyl-benzoate,Launched,lipase inhibitor,LIPE,allergy,sweet itch
S=C=NCc1ccccc1,benzyl-isothiocyanate,Preclinical,methylazoxymethanol acetate inhibitor,,,
CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1,benzyldimethylhexadecylammonium,Preclinical,cationic surfactant,,,
CCCCCCCC[N+](C)(C)Cc1ccccc1,benzyldimethyloctylammonium,Preclinical,,,,
CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(=O)O,benzylpenicillin,Launched,penicillin binding protein inhibitor,,infectious disease,celluitis|meningitis|endocarditis|syphilis|pneumonia|bacterial septicemia
C[N+](C)(CCOc1ccccc1)Cc1ccccc1,bephenium-hydroxynaphthoate,Launched,anthelmintic agent,,infectious disease,ascariasis
O=C(O)CCCN1CCC(O[C@@H](c2ccc(Cl)cc2)c2ccccn2)CC1,bepotastine,Launched,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis
CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1,bepridil,Launched,calcium channel blocker,KCNQ4,cardiology,angina pectoris
COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2,berberine,Launched,LDL receptor activator,LDLR,,
COc1c2ccoc2cc2oc(=O)ccc12,bergapten,Phase 3,,,,
COc1c(O)cc2c(c1O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1OC2=O,bergenin,Preclinical,interleukin inhibitor,IL1B|TNF,,
N[C@@H]1CCCCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2Cl)C1,besifloxacin,Launched,bacterial DNA gyrase inhibitor,,ophthalmology,conjunctivitis
Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc32)o1,BET-BAY-002,Preclinical,bromodomain inhibitor,,,
Oc1cccc(Nc2ccc(Nc3cccc(O)c3)nn2)c1,beta-amyloid-synthesis-inhibitor,Preclinical,beta amyloid synthesis inhibitor,APP,,
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)CCCC2(C)C)C(C)(C)CCC1,beta-carotene,Launched,,,,
CCCCOC(=O)c1cc2c(cn1)[nH]c1ccccc12,beta-CCB,Launched,benzodiazepine receptor ligand,GABRA1|GABRG2,,
C=C[C@]1(C)CC[C@@H](C(=C)C)C[C@H]1C(=C)C,beta-elemene,Launched,apoptosis stimulant,MMP2|MMP9,,
COC(=O)/C=C/C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,beta-funaltrexamine,Preclinical,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,,
CC(C)(O)CC(=O)O.CC(C)(O)CC(=O)O,beta-hydroxy-beta-methylbutyrate,Launched,protein synthesis stimulant,MTOR,,
CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O,beta-lapachone,Phase 2,topoisomerase inhibitor,TOP1,,
Oc1ccc2ccccc2c1,beta-naphthol,Preclinical,,,,
CNCCc1ccccn1,betahistine,Launched,histamine receptor agonist|histamine receptor antagonist,HRH1|HRH3,neurology/psychiatry,Meniere's disease
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,betamethasone,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses
CC(=O)OCC(=O)[C@@]1(O)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,betamethasone-acetate,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses
CCCC(=O)O[C@]1(C(=O)COC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,betamethasone-butyrate-propionate,Launched,,,rheumatology,rheumatoid arthritis
CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,betamethasone-dipropionate,Launched,anti-inflammatory agent,NR3C1,dermatology,corticosteroid-responsive dermatoses
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O,betamethasone-phosphate,Launched,,,rheumatology,rheumatoid arthritis
CCCCC(=O)O[C@]1(C(=O)CO)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,betamethasone-valerate,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses
O=C(O)CCNC(=O)c1ccccc1,betamipron,Launched,panipenem uptake inhibitor,,nephrology,renal toxicity
CC(C)NC[C@@H](O)COc1ccc(CCOCC2CC2)cc1,betaxolol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2,ophthalmology,intraocular pressure|glaucoma|ocular hypertension
NCCc1ccn[nH]1,betazole,Launched,histamine receptor agonist,HRH2,gastroenterology,gastric hypersecretion diagnostic
C[C@@H](C[N+](C)(C)C)OC(N)=O,bethanechol,Launched,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4,urology,urinary retention
CC[S@](=O)c1nc(-c2cccc(OCc3ccccc3)c2)cc(C(F)(F)F)n1,BETP,Preclinical,GLP receptor positive allosteric modulator,GLP1R,,
COc1ccc(NC(=O)c2ccc(C(=N)N(C)C)cc2)c(C(=O)Nc2ccc(Cl)cn2)c1,betrixaban,Launched,coagulation factor inhibitor,KCNH2,hematology,deep vein thrombosis (DVT)
C=C(C)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12,betulinic-acid,Phase 1/Phase 2,apoptosis stimulant|NFkB pathway inhibitor,GPBAR1,,
COc1ccc(CCNC[C@@H](O)COc2cccc(C)c2)cc1OC,bevantolol,Launched,adrenergic receptor antagonist,,cardiology,angina pectoris|hypertension
COc1cc(CNCCC2CCOCC2)ccc1Oc1cnc(C(N)=O)cn1,bevenopran,Phase 1,opioid receptor antagonist,,,
C=C(C)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(=O)O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12,bevirimat-dimeglumine,Phase 2,HIV capsid assembly inhibitor,,,
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(OCCOC4CC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,bexagliflozin,Phase 3,solute carrier family member inhibitor,,,
C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C,bexarotene,Launched,retinoid receptor agonist,RXRA|RXRB|RXRG,hematologic malignancy,cutaneous T-cell lymphoma (CTCL)
CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(=O)O,bezafibrate,Launched,PPAR receptor agonist,PPARA|PPARD|PPARG,cardiology,cholesterol
O=C(Nc1cccc(C(F)(F)F)c1)c1cccc2cc(Oc3cc(CO)ncn3)ccc12,BFH772,Phase 2,VEGFR inhibitor,,,
N=C(NOC[C@@H](O)CN1CCCCC1)c1cccnc1,BGP-15,Phase 2,PARP inhibitor,,,
COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cn1,BGT226,Phase 1/Phase 2,PI3K inhibitor,MTOR|PIK3CA|PIK3CB|PIK3CG,,
CC(C)(C)c1cc(O)c(C(C)(C)C)cc1O,BHQ,Preclinical,ATPase inhibitor,ATP2A1,,
Cc1nc2ccccc2c(-c2ccc3c4c(ccnc24)CCO3)c1[C@H](OC(C)(C)C)C(=O)O,BI-224436,Phase 1,HIV integrase inhibitor,,,
CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1,BI-2536,Phase 2,PLK inhibitor,BRD4|PLK1|PLK2|PLK3,,
Oc1nc(Cc2ccccn2)nc2c1cnn2C1CCOCC1,BI-409306,Phase 1,phosphodiesterase inhibitor,,,
O=c1[nH]nc(Sc2ncc([N+](=O)[O-])s2)n1-c1ccc2c(c1)OCCO2,BI-78D3,Preclinical,JNK inhibitor,MAPK8,,
CCNC(=O)C#Cc1ccc2c(c1)NC(=O)/C2=C(/Nc1ccc(CN(C)C)cc1)c1ccccc1,BI-847325,Phase 1,Aurora kinase inhibitor|MEK inhibitor,AURKA|AURKB|AURKC|MAP2K1|MAP2K2,,
CC(C)CCN1c2nc(Nc3cc(F)c(O)c(F)c3)ncc2N(C)C(=O)[C@@H]1C,BI-D1870,Preclinical,ribosomal protein inhibitor,RPS6KA1|RPS6KA2|RPS6KA3|RPS6KA6,,
CN(C(=O)n1cnc(-c2ccc[n+]([O-])c2)c1)C1CCCCC1,BIA-10-2474,Preclinical,Fatty acid hydrolase inhibitor,,,
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SC3Cn4cnc[n+]4C3)[C@H](C)[C@H]12,biapenem,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,bacterial septicemia|pneumonia|urinary tract infections
NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(N2Cc3ccccc3NC2=O)CC1)C(=O)N1CCN(c2ccncc2)CC1,BIBN4096,Phase 2,calcitonin antagonist,CALCA|CALCRL|RAMP1,,
C/C(=C\C(=O)Nc1ccccc1C(=O)O)c1ccc2ccccc2c1,BIBR-1532,Preclinical,telomerase inhibitor,TERT,,
CCN(CC)CC1CCN(c2ncc3ncnc(Nc4ccc(F)c(Cl)c4)c3n2)CC1,BIBU-1361,Preclinical,EGFR inhibitor,EGFR,,
CN1CCC(Nc2ncc3ncnc(Nc4ccc(F)c(Cl)c4)c3n2)CC1,BIBX-1382,Phase 1,EGFR inhibitor,EGFR|ERBB2,,
CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,bicalutamide,Launched,androgen receptor antagonist,AR,oncology,prostate cancer
Cc1ccc([C@@]23CNC[C@@H]2C3)cc1,bicifadine,Phase 3,dopamine reuptake inhibitor|serotonin receptor antagonist,,,
O=C(NCc1c(F)cc(F)cc1F)c1cn2c(c(O)c1=O)C(=O)N1[C@H]3CC[C@H](C3)O[C@@H]1C2,bictegravir,Launched,HIV integrase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)
CN1CCc2cc3c(cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1c2OCO1)OCO3,bicuculline-(+),Preclinical,GABA receptor antagonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|KCNN1,,
C[N+]1(C)CCc2cc3c(cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1c2OCO1)OCO3,bicuculline-methochloride-(-),Preclinical,GABA receptor antagonist,,,
COC(=O)c1cc(OC)c2c(c1-c1c(CO)cc(OC)c3c1OCO3)OCO2,bicyclol,Launched,NFkB pathway inhibitor,HSPA1A|HSPB1,infectious disease,hepatitis B|hepatitis C
CNCCCCOc1ccccc1Cc1ccccc1,bifemelane,Launched,acetylcholine release enhancer,MAOA|MAOB,ophthalmology|neurology/psychiatry,glaucoma|senile dementia
COC(=O)c1cc(OC)c2c(c1-c1c(C(=O)OC)cc(OC)c3c1OCO3)OCO2,bifendate,Launched,,,infectious disease,hepatitis B|hepatitis C
c1ccc(-c2ccc([C@H](c3ccccc3)n3ccnc3)cc2)cc1,bifonazole,Launched,sterol demethylase inhibitor,,infectious disease,tinea pedis|tinea cruris
COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc32)c1C,BIIB021,Phase 2,HSP inhibitor,HSP90AA1,,
CCOCCn1c(C2CCN(CCc3ccc(C(C)(C)C(=O)O)cc3)CC2)nc2ccccc21,bilastine,Launched,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis
CC(C)(C)[C@]1(O)C[C@@H]2OC(=O)C[C@@]23C(=O)O[C@@H]2OC(=O)[C@H](O)[C@]213,bilobalide,Preclinical,GABA receptor modulator,GLRA1|GLRA2|GLRB|HTR3A|HTR3B,,
CCNC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O,bimatoprost,Launched,prostanoid receptor agonist,AKR1C3|PTGER1|PTGER3|PTGFR,ophthalmology,intraocular pressure|glaucoma|ocular hypertension
CC(C)n1c(=O)n(C(=O)N[C@H]2C[C@H]3CC[C@@H](C2)N3C)c2ccccc21,BIMU-8,Preclinical,serotonin receptor agonist,HTR4,,
Cc1c(OCc2cccc(-c3ccc(C(=O)O)cc3)c2)cc2c(c1C)C(=O)[C@@H](C1CCCC1)C2,BINA,Preclinical,glutamate receptor positive allosteric modulator,GRM2,,
CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(=O)O,bindarit,Phase 2,NFkB pathway inhibitor,CCL2|CCL7|CCL8,,
Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21,binimetinib,Launched,MEK inhibitor,MAP2K1|MAP2K2,oncology,melanoma
Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)O)C(C)C)cc1,BIO-1211,Phase 2,integrin antagonist,ITGA4|ITGB1,,
Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N(C)[C@@H](CC(C)C)C(=O)NCC[C@H](NC(=O)[C@@H]2CCCN2S(=O)(=O)c2cc(Cl)cc(Cl)c2)C(=O)O)cc1,BIO-5192,Preclinical,integrin inhibitor,ITGA4|ITGB1,,
O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21,biotin,Launched,vitamin B,ACACA|ACACB|HLCS|MCCC1|MCCC2|PC|PCCA|PCCB|SLC5A6,,
NCc1ccccc1Sc1ccccc1CO,bipenamol,Phase 2,dipeptidyl peptidase inhibitor,CTSC,,
O[C@](CCN1CCCCC1)(c1ccccc1)[C@@H]1C[C@H]2C=C[C@@H]1C2,biperiden,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,neurology/psychiatry,Parkinson's Disease
CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c(-c2[nH]c3cc(F)ccc3c2C[C@@H]2C[C@H](O)CN2C(=O)[C@H](CC)NC(=O)[C@H](C)NC)[nH]c2cc(F)ccc12,birinapant,Phase 2,XIAP inhibitor,BIRC2|XIAP,,
CN1C(=O)N(c2cc(Cl)cc(Cl)c2)C(=O)[C@@]1(C)Cc1ccc(Br)cc1,BIRT-377,Preclinical,lymphocyte function-associated antigen negative modulator,ICAM1,,
Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O,bis(maltolato)oxovanadium(IV),Phase 2,tyrosine phosphatase inhibitor,PTPN1,,
CC(=O)Oc1ccc(C(c2ccc(OC(C)=O)cc2)c2ccccn2)cc1,bisacodyl,Launched,laxative,,gastroenterology,constipation
C(=N/NC1=NCCN1)\c1c2ccccc2c(/C=N/NC2=NCCN2)c2ccccc12,bisantrene,Phase 2,topoisomerase inhibitor,,,
Cn1cc(C2=C(c3cn(CCCSC(=N)N)c4ccccc34)C(=O)NC2=O)c2ccccc21,bisindolylmaleimide-IX,Preclinical,PKC inhibitor,AKT1|GSK3B|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|ROCK1|RPS6KB1|SIRT1,,
O=C(O)C[C@](O)(CC(=O)O[Bi]1OC(=O)C[C@@](O)(CC(=O)O)C(=O)O1)C(=O)O,bismuth-subcitrate-potassium,Launched,,,gastroenterology,duodenal ulcer disease
O=C1O[Bi](O)Oc2ccccc21,bismuth-subsalicylate,Launched,antacid,,gastroenterology,diarrhea
O=S(=O)(O)C(F)(F)F.O=S(=O)(O)C(F)(F)F.O=S(=O)(O)C(F)(F)F.[Bi],bismuth(III)-trifluoromethanesulfonate,Preclinical,direct substitution catalyst,,,
CC(C)(C)CC(C)(C)c1cc(Cc2cc(C(C)(C)CC(C)(C)C)cc(-n3nc4ccccc4n3)c2O)c(O)c(-n2nc3ccccc3n2)c1,bisoctrizole,Phase 2,,,,
CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1,bisoprolol,Launched,adrenergic receptor antagonist,ADRB1,cardiology,hypertension
CC(C)(c1ccc(O)cc1)c1ccc(O)cc1,bisphenol-A,Phase 1,synthetic estrogen,AR|ESR1|ESR2|ESRRG|PPARG,,
C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1CCN(c2ncc(C(F)(F)F)cc2F)CC1)C(F)(F)F,bitopertin,Phase 3,glycine transporter inhibitor,SLC6A5|SLC6A9,,
S=C=Nc1ccc(N=C=S)cc1,bitoscanate,Preclinical,anthelmintic agent,,,
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)O,bivalirudin,Launched,thrombin inhibitor,F2,cardiology,angina pectoris
COc1cc2nc(N3CCCN(C)CC3)nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC,BIX-01294,Preclinical,histone lysine methyltransferase inhibitor,EHMT1|EHMT2,,
CN(C)Cc1cccc(N/C(=C2\C(=O)Nc3cc(C(N)=O)ccc32)c2ccccc2)c1,BIX-02188,Preclinical,MEK inhibitor,MAP2K5,,
CN(C)Cc1cccc(N/C(=C2\C(=O)Nc3cc(C(=O)N(C)C)ccc32)c2ccccc2)c1,BIX-02189,Preclinical,MEK inhibitor,MAP2K5|MAPK7,,
O=C(O)c1cc2ccccc2s1,BL-5583,Preclinical,hypercalcaemic agent,,,
Cc1ccc2c(c1)C(=O)[C@]1(O)CCN(c3ccccc3)C1=N2,blebbistatin-(-),Preclinical,ATPase inhibitor,,,
Cc1ccc2c(c1)C(=O)[C@]1(O)CCN(c3ccccc3)C1=N2,blebbistatin-(+/-),Preclinical,ATPase inhibitor,MYH14|MYH2,,
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCCNCCCCN)cs2)cs1)[C@@H](C)O)[C@@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1,bleomycetin,Launched,EGFR expression inhibitor,,,
Cc1c(N)nc([C@H](CC(N)=O)NC[C@@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@@H](C)[C@H](O)[C@@H](C)C(=O)N[C@@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](O[C@H]1O[C@H](CO)[C@H](O)[C@@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1,bleomycin,Launched,DNA synthesis inhibitor,,hematologic malignancy|pulmonary|oncology,non-Hodgkin lymphoma (NHL)|Hodgkin's lymphoma|pleural effusion|testicular carcinoma|squamous cell carcinoma
CCN1CCN(c2cc(-c3ccc(F)cc3)c3c(n2)CCCCCC3)CC1,blonanserin,Launched,dopamine receptor antagonist|serotonin receptor antagonist,DRD2|HTR2A,neurology/psychiatry,schizophrenia
C=CC(=O)Nc1cccc(C)c1Nc1ncc2cc(-c3c(Cl)c(OC)cc(OC)c3Cl)ccc2n1,BLU9931,Preclinical,FGFR inhibitor,FGFR4,,
CNC(=O)c1cc(Oc2ccc3nc(N[C@@H]4CCCC[C@H]4O)sc3c2)ccn1,BLZ945,Phase 1/Phase 2,CSF1R inhibitor,,,
COc1ccc2c(c1)c(CC(=O)N1CCOCC1)c(C)n2C(=O)c1ccc(Cl)cc1,BML-190,Preclinical,cannabinoid receptor inverse agonist,CNR2,,
COc1cccc(-c2cc(NCc3ccc4c(c3)OCO4)nc(N)n2)c1,BML-284,Preclinical,WNT agonist,,,
Cc1noc(NS(=O)(=O)c2cccc3c(N(C)C)cccc23)c1C,BMS-182874,Phase 2,endothelin receptor antagonist,EDNRA,,
O=c1oc(-c2ccc(C(F)(F)F)cc2)nn1Cc1cc(Cl)ccc1O,BMS-191011,Preclinical,potassium channel activator,KCNMA1,,
CC1(C)Oc2ccc(C#N)cc2[C@H](N(Cc2ncc[nH]2)c2ccc(Cl)cc2)[C@H]1O,BMS-191095,Phase 1,KATP activator|potassium channel agonist,,,
Cc1onc(NS(=O)(=O)c2ccccc2-c2ccc(-c3ncco3)cc2CN(C)C(=O)CC(C)(C)C)c1C,BMS-207940,Preclinical,endothelin receptor antagonist,,,
N#Cc1ccc2c(c1)CN(S(=O)(=O)c1cccs1)[C@H](Cc1ccccc1)CN2Cc1cnc[nH]1,BMS-214662,Phase 1,farnesyltransferase inhibitor,,,
CCCCOc1c(C(=O)c2c(F)cc(C)cc2F)cnc2n[nH]cc12,BMS-265246,Preclinical,CDK inhibitor,CDK1|CDK2,,
C[C@H](c1ccc(F)cc1CCCC(=O)O)N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1,BMS-299897,Phase 1,gamma secretase inhibitor,,,
CCc1c(-c2ccccc2)c(-c2ccccc2)nn1-c1ccccc1-c1cccc(OCC(=O)O)c1,BMS-309403,Preclinical,fatty acid binding protein inhibitor,FABP4,,
Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1,BMS-345541,Preclinical,IKK inhibitor,CHUK|IKBKB,,
CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,BMS-387032,Phase 1,CDK inhibitor|cell cycle inhibitor|MCL1 inhibitor,CDK2|CDK7|CDK9,,
CCCC(=O)C1(c2ccccc2)CCN(C(=O)[C@@H](Cc2ccc(OC)cc2)NC(=O)[C@@H](N)Cc2cncn2C)CC1,BMS-470539,Preclinical,melanocortin receptor agonist,MC1R,,
Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,BMS-536924,Preclinical,IGF-1 inhibitor,AKT1|CCNE1|CDK2|CYP3A4|ERBB2|IGF1R|KDR|LCK|MAPK1|MET|PDGFRA|PDGFRB,,
CCN1CCN(c2ccc(C(C)(C)NC(=O)c3cc4[nH]c5ccccc5c(=O)c4cc3F)cn2)CC1,BMS-566419,Preclinical,inosine monophosphate dehydrogenase inhibitor,IMPDH1|IMPDH2,,
CCCNC(=O)c1cn2ncnc(Nc3cc(C(=O)NC4CC4)ccc3C)c2c1C,BMS-582949,Phase 2,p38 MAPK inhibitor,,,
CN1C(=O)N(c2cc(Cl)cc(Cl)c2)C(=O)[C@]12CN(Cc1cc(C(=O)O)cs1)C[C@H]2c1ccc(C#N)cc1,BMS-587101,Phase 2,integrin antagonist,ITGAL|ITGB2,,
Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,BMS-599626,Phase 1,EGFR inhibitor|protein tyrosine kinase inhibitor,EGFR|ERBB2|ERBB4,,
COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c12,BMS-626529,Phase 3,HIV attachment inhibitor,,,
Cc1ccc(C(=O)NC2CC2)cc1NC(=O)c1cnn(-c2ncccc2C(F)(F)F)c1C,BMS-626531,Phase 1,p38 MAPK inhibitor,,,
CC1(C)CCC(C)(C)c2cc(C3(c4ccc(C(=O)O)cc4)OCCO3)ccc21,BMS-649,Preclinical,retinoid receptor agonist,RXRA,,
CN1C(=O)N(c2cc(Cl)cc(Cl)c2)C(=O)[C@]12CN(c1ccc(C(=O)O)cn1)C[C@H]2c1ccc(C#N)cc1,BMS-688521,Preclinical,ICAM1 antagonist|leukocyte function-associated antigen receptor antagonist,ICAM1,,
COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1,BMS-690514,Phase 2,EGFR inhibitor|VEGFR inhibitor,EGFR|ERBB2|FLT3|KDR,,
Cn1c(N2CCCCS2(=O)=O)nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O,BMS-707035,Phase 2,HIV integrase inhibitor,,,
C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1,BMS-754807,Phase 2,IGF-1 inhibitor,AKT1|IGF1R,,
O[C@]12CC[C@](c3nnc4c(Oc5ccccc5Cl)cccn43)(CC1)C2,BMS-770767,Phase 2,11-beta-HSD1 inhibitor,,,
CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1,BMS-777607,Phase 1/Phase 2,AXL kinase inhibitor|c-Met inhibitor|FLT3 inhibitor|hepatocyte growth factor receptor inhibitor|macrophage migration inhibiting factor inhibitor|tyrosine kinase inhibitor,AXL|MERTK|MET|MST1R|TYRO3,,
CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2ccccc2Cl)n1,BMS-779788,Phase 1,LXR agonist,,,
COc1ccnc2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)C[C@H]3C)c12,BMS-806,Phase 1,HIV attachment inhibitor,,,
CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1CC[C@H](Nc2ncnc3cc(C(C)(C)C)nn23)C1=O,BMS-813160,Phase 2,CC chemokine receptor antagonist,,,
Nc1nccc(Oc2ccc(NC(=O)c3cn(COP(=O)(O)O)cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl,BMS-817378,Phase 1,c-Met inhibitor|VEGFR inhibitor,KDR|MET,,
CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1,BMS-833923,Phase 2,smoothened receptor antagonist,SMO,,
O=c1[nH]c([C@@H]2CCCN2)nc2c1oc1ccc(Cl)cc12,BMS-863233,Phase 1/Phase 2,CDC inhibitor,CDC7|PIM1,,
CN1C(=O)[C@@H](NC(=O)[C@H](CCC(F)(F)F)[C@H](CCC(F)(F)F)C(N)=O)N=C(c2ccccc2)c2ccccc21,BMS-906024,Phase 1,gamma secretase inhibitor,,,
CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21,BMS-911543,Phase 1/Phase 2,JAK inhibitor,,,
Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O,BMS-935177,Preclinical,Bruton's tyrosine kinase (BTK) inhibitor,,,
NC(=O)[C@@H](CC1CC1)[C@@H](CCC(F)(F)F)C(=O)N[C@H]1N=C(c2ccccc2)c2cccc(F)c2NC1=O,BMS-983970,Phase 1,notch signaling inhibitor,,,
Cc1noc(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1,BMS-986020,Phase 2,lysophosphatidic acid receptor antagonist,LPAR1,,
Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O,BMS-986142,Phase 2,Bruton's tyrosine kinase (BTK) inhibitor,,,
Cc1nnn(C)c1-c1cnc2c3ccc(C(C)(C)O)cc3n([C@H](c3ccccc3)C3CCOCC3)c2c1,BMS-986158,Phase 1/Phase 2,bromodomain inhibitor,,,
CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1,BMS-986195,Phase 1,Bruton's tyrosine kinase (BTK) inhibitor,,,
C[C@@H](C(=O)Nc1ccc(Cl)cc1)[C@H]1CC[C@@H](c2ccnc3ccc(F)cc32)CC1,BMS-986205,Phase 3,"indoleamine 2,3-dioxygenase inhibitor",,,
CSc1ccc(C(=O)N[C@@H]2CCCC[C@@H]2NC(=O)CNC(=O)c2cc(C(F)(F)F)ccc2NC(=O)NC(C)C)cc1,BMS-CCR2-22,Preclinical,CC chemokine receptor antagonist,CCR2,,
O[C@@H](CCCN1CCN(c2ncc(F)cn2)CC1)c1ccc(F)cc1,BMY-14802,Phase 2,sigma receptor antagonist,HTR1A,,
O=C(O)COc1cccc(-c2ocnc2-c2nc(-c3ccccc3)c(-c3ccccc3)o2)c1,BMY-45778,Preclinical,IP1 prostacyclin receptor agonist,PTGIR,,
COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1,BMY-7378,Preclinical,adrenergic receptor antagonist|serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|HTR1A,,
COc1cc(C(=O)c2c(C)oc3c(O)c(OC)ccc23)cc(OC)c1OC,BNC105,Phase 2,tubulin polymerization inhibitor,,,
O=C1/C(=C/c2ccccc2)C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,BNTX,Preclinical,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,,
CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@@H](CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C,boceprevir,Launched,HCV inhibitor,CMA1|CTSA|CTSF|CTSK|CTSL|CTSS,infectious disease,hepatitis C
O=C1C=Cc2cc(Br)ccc2C1=O,bonaphthone,Phase 3,,,,
Cc1cc2c(OC[C@@H](CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1,bopindolol,Launched,adrenergic receptor antagonist,,cardiology,hypertension|coronary artery disease (CAD)
N[C@@H](Cc1ccc(B(O)O)cc1)C(=O)O,boronophenylalanine,Phase 2,,,,
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,bortezomib,Launched,NFkB pathway inhibitor|proteasome inhibitor,PSMA1|PSMA2|PSMA3|PSMA4|PSMA5|PSMA6|PSMA7|PSMA8|PSMB1|PSMB10|PSMB11|PSMB2|PSMB3|PSMB4|PSMB5|PSMB6|PSMB7|PSMB8|PSMB9|PSMD1|PSMD2|RELA,hematologic malignancy,multiple myeloma|mantle cell lymphoma (MCL)
CCOc1cc(-c2nncn2C)ccc1Nc1ncc2cc(C)nc(NCC(C)(C)C)c2n1,BOS-172722,Phase 1,monopolar spindle 1 kinase inhibitor,,,
COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO,bosentan,Launched,endothelin receptor antagonist,EDNRA|EDNRB,pulmonary,pulmonary arterial hypertension (PAH)
COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,bosutinib,Launched,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,ABL1|BCR|CAMK1D|CAMK2G|CDK2|FRK|FYN|HCK|LYN|MAP2K1|MAP2K2|MAP3K2|MAP4K5|SRC|STK10|STK24|STK4|TNK2|TXK,hematologic malignancy,chronic myeloid leukemia (CML)
c1ccc(N2CCN(CCCOc3ccc4c(c3)OCO4)CC2)cc1,BP-554,Preclinical,serotonin receptor agonist,HTR1A,,
COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1,BP-897,Phase 2,dopamine receptor agonist,ADRA1A|ADRA1D|ADRA2A|DRD1|DRD2|DRD3|DRD4|HTR1A|HTR2B,,
CC(C)C[C@@H]1NC(=O)[C@@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC1=O,BQ-123,Phase 2,endothelin receptor antagonist,EDNRA,,
CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@H](C)CCC[C@@H]1C)C(=O)O,BQ-788,Phase 1,endothelin receptor antagonist,EDNRB,,
Cc1nn(C)c2c1[C@@H](c1ccc(C(F)(F)F)cc1)C(C#N)C(=N)O2,BQU57,Preclinical,Ras GTPase inhibitor,RALA|RALB,,
COC(=O)c1ccc2c(c1)nc(NC(=O)c1ccccc1)n2CCCc1ccccc1,BRD4770,Preclinical,histone lysine methyltransferase inhibitor,EHMT2,,
O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23,BRD7389,Preclinical,ribosomal protein inhibitor,RPS6KA1|RPS6KA2|RPS6KA3,,
CC(C)(C)c1ccc2cc(C#N)c(C#N)cc2c1,BRD9876,Preclinical,kinesin inhibitor,KIF11,,
C[C@H]1CCC/C=C/[C@@H]2C[C@H](O)C[C@H]2[C@H](O)/C=C/C(=O)O1,brefeldin-A,Preclinical,protein synthesis inhibitor,ARF1|CYTH2,,
CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@@H](C(=O)O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O,bremelanotide,Launched,melanocortin receptor agonist,MC1R|MC2R|MC3R|MC4R|MC5R,neurology/psychiatry,hypoactive sexual desire disorder
Cc1c(-c2ccc(-c3ccccc3F)cc2)nc2ccc(F)cc2c1C(=O)O,brequinar,Phase 2,dihydroorotate dehydrogenase inhibitor,DHODH,,
CC(C)(C)OC(=O)c1ncn2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc1-2,bretazenil,Phase 2,GABA benzodiazepine site receptor partial agonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6,,
CC[N+](C)(C)Cc1ccccc1Br,bretylium,Launched,norepinephrine inhibitor,ATP1A1,cardiology,ventricular arrhythmias|ventricular fibrillation (VF)|ventricular tachycardia (VT)
O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1,brexpiprazole,Launched,dopamine receptor partial agonist,DRD2,neurology/psychiatry,depression|schizophrenia
COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(OP(=O)(O)O)c2)c(OC)c1,briciclib,Phase 1,cyclin D inhibitor,CCND1,,
COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,brigatinib,Launched,ALK tyrosine kinase receptor inhibitor|EGFR inhibitor,ALK|EGFR,oncology,non-small cell lung cancer (NSCLC)
CCN(CC)c1ccc([C+](c2ccccc2)c2ccc(N(CC)CC)cc2)cc1,brilliant-green,Launched,,,infectious disease,antiseptic
Brc1c(NC2=NCCN2)ccc2nccnc12,brimonidine,Launched,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C,ophthalmology,intraocular pressure|glaucoma|ocular hypertension
CCCCCCCCCCCCCCCCOCCCOP(=O)(O)CO[C@H](CO)Cn1ccc(N)nc1=O,brincidofovir,Phase 3,antiviral,,,
CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,brinzolamide,Launched,carbonic anhydrase inhibitor,CA1|CA12|CA14|CA2|CA4|CA5A|CA7,ophthalmology,intraocular pressure|glaucoma|ocular hypertension
Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1,brivanib,Phase 3,FGFR inhibitor|VEGFR inhibitor,CYP3A4|FGFR1|FLT1|KCNH2|KDR,,
Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1,brivanib-alaninate,Phase 3,FGFR inhibitor|VEGFR inhibitor,FGFR3,,
O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1/C=C/Br,brivudine,Launched,DNA directed DNA polymerase inhibitor,,infectious disease,shingles
O[C@@H](CN1CCN(c2cccc(Cl)c2)CC1)C(c1ccccc1)c1ccccc1,BRL-15572,Preclinical,serotonin receptor antagonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR6,,
O=C(O)[C@@H](Cc1ccccc1)NCc1ccc(Cl)cc1,BRL-26314,Phase 1,cholesterol inhibitor,LPL,,
C[C@H](Cc1ccc(OCC(=O)O)cc1)NC[C@H](O)c1cccc(Cl)c1,BRL-37344,Phase 2,adrenergic receptor agonist,ADRB1|ADRB2|ADRB3,,
C[C@@H]1c2ccccc2CN1CC1=NCCN1,BRL-44408,Preclinical,adrenergic receptor antagonist,ADRA2A|ADRA2B|ADRA2C,,
Cc1ccc([N+](=O)[O-])cc1S(=O)(=O)N(C)C,BRL-50481,Preclinical,phosphodiesterase inhibitor,PDE7A|PDE7B,,
O=C(Cc1ccc(Cl)c(Cl)c1)N1CCCC[C@@H]1CN1CCCC1,BRL-52537,Preclinical,opioid receptor agonist,OPRK1,,
CN1CCC(c2c[nH]c3ccc(O)cc23)CC1,BRL-54443,Preclinical,serotonin receptor agonist,HTR1E|HTR1F,,
O=C(/C=C/c1ccccc1)NCCO,brolitene,Launched,muscle relaxant,RYR1,rheumatology,lumbago
Brc1ccc(NC2C3CC4CC(C3)CC2C4)cc1,bromantan,Launched,dopamine reuptake inhibitor|serotonin reuptake inhibitor,,neurology/psychiatry,neurasthenia
COc1ccc(C(=O)/C(Br)=C/C(=O)O)cc1,bromebric-acid,Preclinical,DNA synthesis inhibitor|purine antagonist,,,
CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1,bromhexine,Launched,mucolytic agent,,pulmonary,chest congestion
O=C1c2ccccc2C(=O)C1c1ccc(Br)cc1,bromindione,Phase 2,anticoagulant,,,
CC(C)[C@@H](Br)C(=O)NC(N)=O,bromisoval,Preclinical,anti-inflammatory agent,,,
CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,bromocriptine,Launched,dopamine receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR6|HTR7,endocrinology|neurology/psychiatry,hyperprolactinemia|Parkinson's Disease|acromegaly
CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC,bromopride,Launched,dopamine receptor antagonist,DRD2,gastroenterology,nausea|vomiting|gastroesophageal reflux disease (GERD)
CCOC(=O)Nc1cc(-c2ccc(C)c(NS(C)(=O)=O)c2)nn2c(C)nnc12,bromosporine,Preclinical,bromodomain inhibitor,,,
O=C(CCCN1CCC(O)(c2ccc(Br)cc2)CC1)c1ccc(F)cc1,bromperidol,Launched,dopamine receptor antagonist,DRD2,neurology/psychiatry,schizophrenia
CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1,brompheniramine,Launched,histamine receptor antagonist,HRH1,allergy|otolaryngology,allergic rhinitis|common cold
Nc1nc(=O)c(Br)c(-c2ccccc2)[nH]1,bropirimine,Phase 3,interferon inducer,,,
Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1,broxaldine,Preclinical,,,,
CC(C)(C)NC[C@@H](O)c1cc(Br)no1,broxaterol,Phase 3,adrenergic receptor agonist,ADRB2,,
O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1Br,broxuridine,Phase 2,antimetabolite,,,
Oc1c(Br)cc(Br)c2cccnc12,broxyquinoline,Phase 1,antiprotozoal agent,,,
COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(=O)[C@H](C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)/C=C(\C)C(C)C)[C@@H]24,bruceantin,Phase 2,protein synthesis inhibitor,,,
COc1cc2c(cc1OC)[C@@]13CCN4CC5=CCO[C@H]6CC(=O)N2[C@H]1[C@H]6[C@H]5C[C@H]43,brucine,Preclinical,glycine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,,
CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12,BS-181,Preclinical,CDK inhibitor,CDK7,,
O=C(c1cccc(-c2nc3ccccc3[nH]2)n1)N1CCN(C(=O)c2cccc(-c3nc4ccccc4[nH]3)n2)CC1,BT-11,Phase 2,cAMP stimulant,,,
O=C(Oc1cc(S(=O)(=O)c2ccccc2)ccc1[N+](=O)[O-])c1ccc(Cl)cc1,BTB06584,Preclinical,ATPase inhibitor,ATP5F1,,
O=[N+]([O-])c1cc(Cl)ccc1S(=O)(=O)c1ccccc1,BTB1,Preclinical,mitotic kinesin inhibitor,KIF18A,,
O=C(CNc1cccc(Cl)c1)N[C@@H]1CCCN(c2ncnc3[nH]ccc23)C1,BTK-IN-1,Preclinical,Bruton's tyrosine kinase (BTK) inhibitor,,,
Cc1ccc(S(=O)(=O)NCc2ccccc2)cc1,BTS,Preclinical,,,,
CC(C)(NCCCn1ccnc1)c1ccc(Cl)cc1,BTS-71321,Phase 2,,,,
C[C@@H](Oc1ccc(Cl)cc1)c1ccnc2ncnn12,BTS-72664,Phase 1,GABA receptor antagonist,GABBR1,,
CN(c1ccc(NC(=O)Nc2ccccc2)cc1)S(=O)(=O)c1cnn(-c2ccc(F)cc2)c1,BTT-3033,Preclinical,integrin inhibitor,ITGA2|ITGB1,,
C[C@H]1COC2(CCN(c3nc(=O)c4cc(C(F)(F)F)cc([N+](=O)[O-])c4s3)CC2)O1,BTZ043-racemate,Phase 1/Phase 2,DPRE1 inhibitor,,,
c1ccc2nc(C3=NCCN3)ccc2c1,BU-224,Preclinical,imidazoline receptor ligand,MAOA|MAOB,,
c1ccc2nc(C3=NCCN3)cnc2c1,BU-239,Preclinical,imidazoline receptor agonist|imidazoline receptor ligand,,,
c1ccc2cc(C3=NCCN3)ncc2c1,BU226,Preclinical,imidazoline receptor ligand,,,
CCCC(=O)Nc1ncnc2c1ncn2[C@@H]1O[C@@H]2CO[P@@](=O)(O)O[C@H]2[C@H]1OC(=O)CCC,bucladesine,Launched,adenosine receptor agonist|cAMP stimulant,PRKACA,dermatology,skin ulcer
CC(C)(C)c1ccc(CN2CCN([C@@H](c3ccccc3)c3ccc(Cl)cc3)CC2)cc1,buclizine,Launched,histamine receptor antagonist,HRH1,neurology/psychiatry,migraine headache
CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,budesonide,Launched,glucocorticoid receptor agonist,NR3C1,gastroenterology,Crohn's disease
CC(C)(C)N1CCC(c2ccccc2)(c2ccccc2)CC1,budipine,Launched,glutamate receptor antagonist,GRIN1,neurology/psychiatry,Parkinson's Disease
COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1,buflomedil,Launched,adrenergic receptor antagonist|calcium channel blocker,ADRA1A,cardiology,peripheral artery disease (PAD)
CCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1,bumetanide,Launched,solute carrier family member inhibitor,CFTR|GPR35|SLC12A1|SLC12A2|SLC12A4|SLC12A5,cardiology,edema|congestive heart failure
CCCC(=O)N1CCCN(c2nc(N)c3cc(OC)c(OC)cc3n2)CC1,bunazosin,Launched,adrenergic receptor antagonist,ADRA1A,ophthalmology,glaucoma|intraocular pressure
Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,buparlisib,Phase 3,PI3K inhibitor,PIK3CA|PIK3CG,,
CC(C)(C)C1CCC(C[C@H]2C(=O)C(=O)c3ccccc3C2=O)CC1,buparvaquone,Launched,antiprotozoal agent,,infectious disease,protozoan infection
CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1,buphenine,Launched,adrenergic receptor agonist,ADRB2,rheumatology,Raynaud's disease
CCCCc1ccc(C(N)=O)nc1,bupicomide,Phase 1,adrenergic receptor antagonist,ADRB1,,
CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,bupivacaine,Launched,sodium channel blocker,KCNA5|SCN10A,neurology/psychiatry,peripheral nerve block|caudal epidural block|lumbar epidural block
Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1,bupranolol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,cardiology|ophthalmology,hypertension|glaucoma
C[C@@H](NC(C)(C)C)C(=O)c1cccc(Cl)c1,bupropion,Launched,dopamine reuptake inhibitor,SLC6A2|SLC6A3,neurology/psychiatry,depression
O=C(NCc1ccccc1)OCCO,buramate,Preclinical,antiepileptic,,,
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,buserelin,Launched,gonadotropin releasing factor hormone receptor agonist,,oncology|obstetrics/gynecology,prostate cancer|endometriosis
O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1,buspirone,Launched,serotonin receptor agonist,DRD2|HTR1A,neurology/psychiatry,generalized anxiety disorder (GAD)
CS(=O)(=O)OCCCCOS(C)(=O)=O,busulfan,Launched,DNA inhibitor,,hematologic malignancy,chronic myeloid leukemia (CML)
CCCCNC(=O)[C@@H]1Cc2ccccc2N1C(=O)[C@@H](N)CC,butabindide,Preclinical,tripeptidyl peptidase inhibitor,TPP2,,
CCCCN(CCCC)CCCOC(=O)c1ccc(N)cc1,butacaine,Launched,local anesthetic,,neurology/psychiatry,local anesthetic
CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc(c43)[C@@H]2C1,butaclamol,Phase 2,dopamine receptor antagonist,DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR2A,,
C=CCC1(CC(C)C)C(=O)NC(=O)NC1=O,butalbital,Launched,GABA receptor antagonist,CHRNA4|CHRNA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA2|GRIK2,neurology/psychiatry,headache|muscle relaxant
CCCC1([C@H](O)C/C=C/[C@H]2[C@H](O)CC(=O)[C@@H]2CCCCCCC(=O)OC)CCC1,butaprost,Preclinical,prostaglandin receptor agonist,,,
O=C(/C=C/c1ccc(O)c(O)c1)c1ccc(O)cc1O,butein,Preclinical,EGFR inhibitor|SRC inhibitor,ACE,,
CN(Cc1ccc(C(C)(C)C)cc1)Cc1cccc2ccccc12,butenafine,Launched,fungal squalene epoxidase inhibitor,SQLE,infectious disease,tinea pedis|tinea cruris|tinea corporis
CCCCS(=N)(=O)CC[C@H](N)C(=O)O,buthionine-sulfoximine,Phase 1,glutathione transferase inhibitor,GCLM,,
Clc1ccc(CC[C@@H](Cn2ccnc2)Sc2c(Cl)cccc2Cl)cc1,butoconazole,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,vulvovaginal candidiasis
CCCC(=O)c1cc(F)ccc1OC[C@@H](O)CNC(C)(C)C,butofilolol,Phase 2,adrenergic receptor antagonist,,,
CCCCOC(=O)c1ccc(O)cc1,butyl-paraben,Preclinical,DNA synthesis inhibitor,,,
COc1ccc(O)c(C(C)(C)C)c1,butylated-hydroxyanisole,Preclinical,antioxidant,,,
Cc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1,butylated-hydroxytoluene,Phase 1,carbonic anhydrase inhibitor,CA2,,
CCC/C=C1\OC(=O)c2ccccc21,butylidenephthalide,Phase 1/Phase 2,cyclooxygenase inhibitor,,,
CCCC[C@H]1OC(=O)c2ccccc21,butylphthalide,Launched,potassium channel antagonist,KCNK2,neurology/psychiatry,stroke
CCCC[N@+]1(C)[C@@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12,butylscopolamine-bromide,Launched,cholinergic receptor antagonist,,gastroenterology,abdominal pain
CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1,BVD-523,Phase 2,MAP kinase inhibitor,,,
Cc1c(Cl)cccc1S(=O)(=O)Nc1nc(CC(=O)N2CCN(C)CC2)cs1,BVT-2733,Preclinical,11-beta hydroxysteroid dehydrogenase inhibitor,HSD17B1,,
CC1(C)C(=O)NC2=C1C(=O)C(=O)c1ccccc12,BVT-948,Preclinical,tyrosine phosphatase inhibitor,PTPN1|PTPN11|PTPN2,,
CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O,BW-180C,Phase 2,opioid receptor agonist,OPRD1|OPRM1,,
C/C(=N\NC(=S)NNC(=S)Nc1ccccc1Cl)c1ccccn1,BW-348U87,Preclinical,antiviral,,,
C=CCN1C[C@H](C)N([C@H](c2ccc(C(=O)N(CC)CC)cc2)c2cccc(O)c2)C[C@H]1C,BW-373U86,Preclinical,opioid receptor agonist,OPRD1,,
CNC(=O)c1ccc2c(c1)S(=O)(=O)c1ccccc1C2=O,BW-616U,Preclinical,monoamine oxidase inhibitor,MAOA,,
C[C@@H](N)Cc1c[nH]c2ccc(OCc3cccs3)cc12,BW-723C86,Preclinical,serotonin receptor agonist,HTR2A|HTR2B|HTR2C,,
CC(=O)N(O)C/C=C/c1cccc(Oc2ccccc2)c1,BW-A4C,Phase 1,lipoxygenase inhibitor,ALOX5,,
C[C@@H](/C=C/c1cccc(Oc2ccc(F)cc2)c1)N(O)C(N)=O,BW-B70C,Preclinical,lipoxygenase inhibitor,ALOX5,,
O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1,BX-795,Preclinical,IKK inhibitor,CDK2|CHEK1|GSK3B|KDR|PDK1|PDPK1,,
O=C(Nc1cccc(Nc2ncc(Br)c(NCCc3cnc[nH]3)n2)c1)N1CCCC1,BX-912,Preclinical,pyruvate dehydrogenase kinase inhibitor,CDK2|CHEK1|GSK3B|KDR|PDK1|PDPK1,,
Cn1cccc1/C=C1\C(=O)NC(=O)c2ccccc21,BYK-204165,Preclinical,PARP inhibitor,PARP1,,
COc1cc2nc(N3CCC(N4CCCCC4)CC3)nc(NC3CCCCCC3)c2cc1OC,C-021,Preclinical,CC chemokine receptor antagonist,CCR4,,
O=S(=O)(c1cccc2cnccc12)N1CCNCC1,C-1,Preclinical,protein kinase inhibitor,PRKCA,,
CCOC(=O)c1cnc[nH]1,C-751,Preclinical,,,,
CN1CCC[C@@H]1c1cccnc1.Cc1ccc(C(=O)O[C@H](C(=O)O)[C@@H](OC(=O)c2ccc(C)cc2)C(=O)O)cc1,C106,Phase 3,,,,
COc1ccc(S(=O)(=O)Nc2cc(-c3c(O)ccc4ccccc34)c(O)c3ccccc23)cc1,C188-9,Preclinical,STAT inhibitor,,,
CC(=O)N[C@H]1[C@@H](OC(C)C)O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O,C34,Preclinical,toll-like receptor inhibitor,TLR4,,
CC1=NN(c2ccc(C(=O)O)cc2)C(=O)C1=Cc1ccc(-c2cc(C)c(C)cc2[N+](=O)[O-])o1,C646,Preclinical,histone acetyltransferase inhibitor,EP300,,
Nc1ccc(-c2cccc(C(=O)Nc3cnc4nc(N5CCOCC5)oc4c3)n2)cn1,CA-4948,Phase 1,kinase inhibitor,,,
OC[C@H]1O[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,cabaletta,Phase 2,pharmacological chaperone,,,
CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,cabazitaxel,Launched,microtubule inhibitor,TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,oncology,prostate cancer
C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,cabergoline,Launched,dopamine receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR7,endocrinology,hyperprolactinemia
C[C@H]1CO[C@@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,cabotegravir,Phase 3,HIV integrase inhibitor,,,
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,cabozantinib,Launched,RET tyrosine kinase inhibitor|VEGFR inhibitor,KDR|MET|RET,oncology,medullary thyroid cancer (MTC)
CC(C)(C)[C@H]1CCc2c(sc(NC(=O)c3ccco3)c2C(=O)O)C1,CaCCinh-A01,Preclinical,calcium-activated chloride channel inhibitor,CLCA1,,
O=C(O)c1cn(C2CC2)c2cc(N3CCC(O)(COc4ccc(N5C[C@H](CO)OC5=O)cc4F)CC3)c(F)cc2c1=O,cadazolid,Phase 3,antibacterial ,,,
CCOC(=O)NNc1ccc(N(CC)C[C@@H](C)O)nn1,cadralazine,Launched,adrenergic receptor antagonist,,cardiology,hypertension
C[C@@]12CCc3occc3[C@H]1CC[C@@]13C[C@@H](CC[C@H]12)[C@@](O)(CO)C3,cafestol,Launched,pregnane X receptor agonist,,,
O=C(O)/C=C/c1ccc(O)c(O)c1,caffeic-acid,Preclinical,HIV integrase inhibitor|lipoxygenase inhibitor|nitric oxide production inhibitor|tumor necrosis factor production inhibitor,ALOX5|MIF,,
O=C(/C=C/c1ccc(O)c(O)c1)OCCc1ccccc1,caffeic-acid-phenethyl-ester,Preclinical,HIV integrase inhibitor,RELA,,
Cn1c(=O)c2c(ncn2C)n(C)c1=O,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,ADORA1|ADORA2A|ADORA2B|ADORA3|ATM|ITPR1|ITPR2|ITPR3|PDE10A|PDE11A|PDE1A|PDE1B|PDE1C|PDE2A|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A|PDE6A|PDE6B|PDE6C|PDE7A|PDE7B|PDE8A|PDE8B|PDE9A|PIK3CA|PIK3CB|PIK3CD|PRKDC|RYR1|RYR2|RYR3,neurology/psychiatry,fatigue|drowsiness
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]12,calcifediol,Launched,vitamin D receptor agonist,VDR,endocrinology,hyperparathyroidism
C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@@H](O)C4CC4)CC[C@@H]23)C[C@@H](O)C[C@@H]1O,calcipotriol,Launched,vitamin D receptor agonist,VDR,dermatology,psoriasis
CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@H](C(=O)N1CCC[C@H]1C(N)=O)[C@@H](C)O)C(C)C)[C@@H](C)O)[C@@H](C)O,calcitonin,Launched,calcitonin agonist,,orthopedics,osteoporosis
C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)C[C@@H]1O,calcitriol,Launched,vitamin D receptor agonist,VDR,endocrinology|orthopedics,hypocalcemia|hypoparathyroidism|osteoporosis
O=C(O)[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,calcium-gluceptate,Launched,,,,
Nc1nc(=O)c2c([nH]1)NC[C@H](CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O,calcium-levofolinate,Launched,,,,
C[C@@H](N[C@H]1CCCC[C@@H]1NC(=O)c1ccc(Cl)cc1)c1cccc2ccccc12,Calhex-231,Preclinical,calcium sensing receptor negative allosteric modulator,CASR,,
CCCC[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1,calpeptin,Preclinical,calpain inhibitor,,,
C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1,camicinal,Phase 2,motilin receptor agonist,MLNR,,
Cc1c(Cl)cccc1S(=O)(=O)Nc1nc(NCCc2ccccc2)nc2c1CN(Cc1ccccc1)CC2,CaMKII-IN-1,Preclinical,calcium/calmodulin dependent protein kinase inhibitor,AKT1|CAMK2A|CAMK4|MYLK,,
CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(OCC(=O)O)c(C(C)(C)C)c1,camobucol,Preclinical,anti-inflammatory agent,,,
CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(=N)N)cc2)cc1,camostat-mesilate,Launched,protease inhibitor,PRSS1,gastroenterology,pancreatitis
CC1(C)[C@@H]2CC[C@@]1(C)C(=O)C2,camphor-(+),Phase 2,,,,
CC1(C)[C@@H]2CC[C@]1(C)C(=O)C2,camphor-(1R),Phase 1,TRPV activator,TRPV1,,
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3ccccc3nc2-1,camptothecin,Phase 3,topoisomerase inhibitor,TOP1,,
CCN(CC)CCN[C@@H](C(=O)OCCC(C)C)c1ccccc1,camylofine-chlorhydrate,Launched,,,gastroenterology,abdominal pain
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,canagliflozin,Launched,sodium/glucose cotransporter inhibitor,SLC5A1|SLC5A2,endocrinology,diabetes mellitus
CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,candesartan,Launched,angiotensin receptor antagonist,AGTR1,cardiology,hypertension|congestive heart failure
CCOc1nc2cccc(C(=O)O[C@@H](C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,candesartan-cilexetil,Launched,angiotensin receptor antagonist,,cardiology,hypertension|congestive heart failure|hypertension
C[C@H](C[C@H](C)[C@@H](O)CC(=O)c1ccc(N)cc1)[C@H]1OC(=O)CC(=O)CCCC(=O)C[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)C[C@@H](O)[C@H](C(=O)O)[C@@H](O)C[C@@H](O[C@@H]2O[C@H](C)[C@H](O)[C@@H](O)[C@@H]2N)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@@H]1C,candicidin,Launched,fungal ergosterol inhibitor,,infectious disease,vulvovaginal candidiasis
C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,canertinib,Phase 3,EGFR inhibitor,AKT1|EGFR|ERBB2|ERBB4,,
CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)C(Cl)(Cl)P(=O)(O)O)[C@@H](O)[C@H]1O,cangrelor,Launched,purinergic receptor antagonist,,cardiology,myocardial infarction
C[C@@]12C(=O)OC(=O)[C@]1(C)[C@H]1CC[C@@H]2O1,cantharidin,Launched,protein phosphatase inhibitor,,dermatology,blisters
N#Cc1c(N)nc(SCc2csc(-c3ccc(Cl)cc3)n2)c(C#N)c1-c1ccc(OCCO)cc1,capadenoson,Phase 2,adenosine receptor agonist,ADORA1,,
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,capecitabine,Launched,DNA synthesis inhibitor|thymidylate synthase inhibitor,TYMS,oncology,breast cancer|colorectal cancer
COc1cc(C(=O)NCCCCCC(=O)O)cc(OC)c1OC,capobenic-acid,Preclinical,,,,
C[C@@H]1NC(=O)[C@@H](N)CNC(=O)[C@H]([C@H]2CCN=C(N)N2)NC(=O)/C(=C\NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC1=O,capreomycin,Launched,protein synthesis inhibitor,,infectious disease,tuberculosis
CN1N=C2CCN(C(=O)[C@@H](COCc3ccccc3)NC(=O)C(C)(C)N)C[C@@]2(Cc2ccccc2)C1=O,capromorelin,Preclinical,growth hormone secretagogue receptor agonist,,,
COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,capsaicin,Launched,TRPV agonist,CFTR|TRPV1,neurology/psychiatry|rheumatology,muscle pain|rheumatoid arthritis
Oc1cc2c(cc1O)CN(C(=S)NCCc1ccc(Cl)cc1)CCC2,capsazepine,Preclinical,TRPV agonist,TRPV1|TRPV4,,
O=C1[C@H]2CC=CC[C@@H]2C(=O)N1SC(Cl)(Cl)Cl,captan,Phase 1,,,,
C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O,captopril,Launched,angiotensin converting enzyme inhibitor,ACE|LTA4H|MMP2|MMP9,cardiology|endocrinology|nephrology,hypertension|congestive heart failure|myocardial infarction|diabetes mellitus|diabetic nephropathy
CNC(=O)ON(C(C)=O)C(=O)NC,caracemide,Phase 2,ribonucleotide reductase inhibitor,RRM1,,
CCN(CC)CCOC(=O)C1(c2ccccc2)CCCC1,caramiphen,Launched,cholinergic receptor antagonist,CHRM1|CHRM2,neurology/psychiatry,Parkinson's Disease
CC(C)NC[C@@H](O)COc1cccc2[nH]c3ccccc3c12,carazolol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,cardiology,angina pectoris|cardiac arrythmia|hypertension|myocardial infarction
C[N+](C)(C)CCOC(N)=O,carbachol,Launched,cholinergic receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|CHRNA2,ophthalmology,intraocular pressure
COC(=O)N/N=C/c1c[n+]([O-])c2ccccc2[n+]1[O-],carbadox,Launched,other antibiotic,,infectious disease|gastroenterology,dysentry|enteritis
NC(=O)N1c2ccccc2C=Cc2ccccc21,carbamazepine,Launched,carboxamide antiepileptic,SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,seizures
CNC(=O)Oc1cccc2ccccc12,carbaril,Launched,acetylcholinesterase inhibitor,,,
NC(=O)Nc1ccc([As](=O)(O)O)cc1,carbarsone,Launched,antiprotozoal agent,,infectious disease,amebiasis
CN1C2=CC(=O)/C(=N\NC(N)=O)C=C2C[C@H]1S(=O)(=O)O,carbazochrome,Launched,,,hematology,hemorrhage
COC(=O)Nc1nc2ccccc2[nH]1,carbendazim,Launched,microtubule inhibitor|tubulin polymerization inhibitor,TP53|TUBB,infectious disease,fungicide
CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C(=O)O)c3ccccc3)C(=O)N2[C@H]1C(=O)O,carbenicillin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections
CC1(C)[C@@H](OC(=O)CCC(=O)O)CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@@](C)(C(=O)O)CC[C@]5(C)CC[C@@]4(C)[C@]3(C)CC[C@@H]12,carbenoxolone,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,GJA1|GJA10|GJA3|GJA4|GJA5|GJA8|GJA9|GJB1|GJB2|GJB3|GJB4|GJB5|GJB6|GJB7|GJC1|GJC2|GJC3|GJD2|GJD3|GJD4|GJE1|HSD11B1|PANX1|PANX2|PANX3,gastroenterology|dental,peptic ulcer disease (PUD)|mouth inflammation
CCN(CC)CCOCCOC(=O)C1(c2ccccc2)CCCC1,carbetapentane,Launched,acetylcholine receptor antagonist,CHRM2,otolaryngology|pulmonary,common cold|nasal congestion|bronchitis
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(OC)cc2)NC(=O)CCCSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,carbetocin,Launched,oxytocin receptor agonist,OXTR,hematology,hemorrhage
C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O,carbidopa,Launched,aromatic L-amino acid decarboxylase inhibitor,DDC,neurology/psychiatry,Parkinson's Disease
CCOC(=O)n1ccn(C)c1=S,carbimazole,Launched,antithyroid agent,TPO,endocrinology,hyperthyroidism
CN(C)CCO[C@@H](c1ccc(Cl)cc1)c1ccccn1,carbinoxamine,Launched,histamine receptor antagonist,HRH1,allergy|ophthalmology|otolaryngology|dermatology,allergic rhinitis|conjunctivitis|vasomotor rhinitis|dermatographism
NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N,carboxyamidotriazole,Phase 3,calcium channel blocker,CXCL8,,
CCCCc1nc(Cl)c(C(=O)O)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,carboxylosartan,Phase 1,angiotensin antagonist,AGTR1,,
O=C(O)c1ccc(SSc2ccc(C(=O)O)cn2)nc1,carboxypyridine-disulfide,Phase 2,,,,
COc1ccc(Nc2nccc(NCCO)n2)cc1,cardiogenol-C,Preclinical,cardiomyogenesis inducer,,,
c1coc(-c2nnc3sc(C4CCCCC4)nn23)c1,cardionogen-1,Preclinical,WNT signaling inhibitor,CTNNB1,,
CC(C)(C(=O)O)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1,carebastine,Phase 1,histamine receptor antagonist,HRH1,,
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,carfilzomib,Launched,proteasome inhibitor,PSMA1|PSMA2|PSMA3|PSMA4|PSMA5|PSMA6|PSMA7|PSMA8|PSMB1|PSMB10|PSMB11|PSMB2|PSMB3|PSMB4|PSMB5|PSMB6|PSMB7|PSMB8|PSMB9,hematologic malignancy,multiple myeloma
NC(=O)N[C@@H](CCC(=O)O)C(=O)O,carglumic-acid,Launched,carbamoyl phosphate synthase activator,CPS1,metabolism,hyperammonemia
NC(=O)CN1C=CCC(C(N)=O)=C1,caricotamide,Phase 2,NADPH quinone oxidoreductase inhibitor,NQO2,,
CC(C)c1ccc(C(=O)N=C(N)N)cc1S(C)(=O)=O,cariporide,Phase 3,sodium/hydrogen exchanger inhibitor,SLC9A1,,
CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1,cariprazine,Launched,dopamine receptor antagonist,DRD2|DRD3,neurology/psychiatry,schizophrenia
CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O,carmofur,Launched,thymidylate synthase inhibitor,TYMS,oncology,breast cancer|colorectal cancer
COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1,carmoterol,Phase 2,adrenergic receptor agonist,ADRB2,,
O=C(O)c1ccc2[nH]cc(CCCCN3CC=C(c4ccccc4)CC3)c2c1,carmoxirole,Phase 2,dopamine receptor agonist,DRD2,,
C[N+](C)(C)C[C@@H](O)CC(=O)O,carnitine-(D/L),Phase 3,,,,
NCCC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)O,carnosine,Phase 2,antiglycating agent,,,
CCN(CC)CCn1c(=O)c(Cc2ccc(OC)cc2)nc2ccccc21,caroverin,Phase 3,cytochrome P450 inhibitor,,,
C[C@@H](C(=O)O)c1ccc2c(c1)[nH]c1ccc(Cl)cc12,carprofen,Launched,cyclooxygenase inhibitor,PTGS2,rheumatology,osteoarthritis
O=c1[nH]c(=O)c2ccccc2o1,carsalam,Preclinical,analgesic agent,,,
CC(C)(C)NCC(O)COc1cccc2c1CCC(=O)N2,carteolol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,ophthalmology,intraocular pressure|glaucoma|ocular hypertension
NC(=O)OC[C@@H]1[C@H](NC(=O)/C(=N\OCC(=O)O)c2csc(N)n2)C(=O)N1S(=O)(=O)O,carumonam,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,urinary tract infections|gram-negative bacterial infections
COc1ccccc1OCCNC[C@@H](O)COc1cccc2[nH]c3ccccc3c12,carvedilol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,cardiology,myocardial infarction|hypertension
NS(=O)(=O)c1ccc(C(=O)O)cc1,carzenide,Preclinical,,CA1|CA12|CA14|CA2|CA6|CA9,,
OCc1cc(O)c2c(O)c3c(O)cccc3c(O[C@@H]3O[C@H](CO)[C@H](O)[C@@H](O)[C@H]3O)c2c1,casanthranol-variant,Launched,,,gastroenterology,constipation
OCCN[C@H]1CCCc2c1[nH]c1ccc(-c3ccccc3)cc21,casin,Preclinical,GTPase inhibitor,CDC42,,
CC[C@H](C)C[C@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@H]([C@H](O)CCN)NC(=O)[C@H]([C@H](O)[C@@H](O)c2ccc(O)cc2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]([C@@H](C)O)NC1=O,caspofungin,Launched,"bacterial cell wall synthesis inhibitor|fungal 1,3-beta-D-glucan synthase inhibitor",,infectious disease,candidemia|esophageal candidiasis|aspergillosis|peritonitis|fungal infection
O[C@H]1[C@H](O)[C@@H](O)CN2CC[C@H](O)[C@H]12,castanospermine,Phase 2,glucosidase inhibitor,GAA|GBA,,
CCC1=C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@](C(=O)OC)(C2)[C@@H]13,catharanthine,Preclinical,tubulin polymerization inhibitor,,,
Cn1nc(C(C)(C)C)cc1C(=O)N[C@@H](Cc1cccc(Cl)c1)C(=O)NCC#N,cathepsin-inhibitor-1,Preclinical,cathepsin inhibitor,CTSB|CTSL|CTSV,,
O=C1NC(=O)/C(=C\c2ccc(-c3ccc(F)cc3)o2)S1,CAY10505,Preclinical,PI3K inhibitor,PIK3CG,,
CCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,CB-03-01,Phase 3,androgen receptor antagonist,AR,,
CN(C)/N=N/c1ccc(C(=O)O)cc1,CB-10-277,Phase 1,DNA synthesis inhibitor,,,
Cc1cc2c(C(N)=O)cccc2n1-c1nc2c(c(NCc3ccccc3)n1)COCC2,CB-5083,Phase 1,valosin-containing protein inhibitor,VCP,,
O=C(Cc1cccc(OC(F)(F)F)c1)Nc1ccc(CCCCc2nnc(NC(=O)Cc3ccccn3)s2)nn1,CB-839,Phase 2,glutaminase inhibitor,GLS,,
CCS(=O)(=O)N(Cc1cccnc1)c1cccc(-c2ccc(C#N)cc2)c1,CBiPES,Preclinical,glutamate receptor positive allosteric modulator,GRM2,,
CC(=O)c1ccc2c(c1)c1cc(C(C)=O)ccc1n2CCNC(C)C,cbl0137,Phase 1,histone chaperone inhibitor,,,
NC(=NNc1ccccc1)c1ccccc1,CBS-1114,Phase 1,lipoxygenase inhibitor,ALOX5,,
CCN1C(=O)CN=C2NC=C(c3ccc(-c4nnc[nH]4)nc3C)N=C21,CC-115,Phase 2,DNA protein kinase inhibitor|mTOR inhibitor,MTOR,,
CO[C@H]1CC[C@H](N2C(=O)CNc3ncc(-c4ccc(C(C)(C)O)nc4)nc32)CC1,CC-223,Phase 2,mTOR inhibitor,MTOR,,
c1cc(OCCN2CCCCC2)cc(-c2n[nH]c3ccc(-c4nnc[nH]4)cc23)c1,CC-401,Phase 1,JNK inhibitor,MAPK8,,
C=CC(=O)Nc1cc(C)ccc1Nc1nc(Nc2cc(OC)ncc2C)ncc1C(F)(F)F,CC-90003,Phase 1,MAP kinase inhibitor,,,
O[C@H]1CC[C@H](Nc2ncc3nc(Nc4c(F)cc(F)cc4F)n([C@H]4CCOC4)c3n2)CC1,CC-930,Phase 2,JNK inhibitor,,,
O=c1cccc2n1C[C@H]1C[C@@H]2CN(CCN2C[C@@H]3C[C@H](C2)c2cccc(=O)n2C3)C1,CC4,Preclinical,nicotinic receptor agonist,CHRNB2,,
C[C@@H](ONC(=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1)C(=O)Nc1ccc(Cl)cc1,CCG-1423,Preclinical,apoptosis stimulant,RHOC|SRF,,
Cc1ccc(-n2sc(=O)n(Cc3ccc(F)cc3)c2=O)cc1,CCG-50014,Preclinical,G protein signaling inhibitor,RGS4|RGS8,,
Cc1cccc(Oc2nc3c(C)cccn3c(=O)c2/C=C(\C#N)c2nc3ccccc3s2)c1,CCG-63802,Preclinical,G protein signaling inhibitor,RGS4,,
Cc1cccn2c(=O)c(/C=C(\C#N)c3nc4ccccc4s3)c(Oc3ccc(F)cc3)nc12,CCG-63808,Preclinical,G protein signaling inhibitor,RGS4,,
Cc1cc(C(=CNc2ccc(Cl)cc2)C(=O)Nc2ccc(Cl)cc2)on1,CCMI,Preclinical,acetylcholine receptor allosteric modulator,CHRNA7,,
O=C(O)Cc1cc2ccccc2nc1C(=O)O,CCMQ,Preclinical,homoquinolinic acid binding inhibitor,,,
O=C(CN1C2=NCCN2c2ccccc21)c1ccc(-c2ccccc2)cc1,CCT-031374,Preclinical,WNT signaling inhibitor,CTNNB1,,
CCc1cc(-c2n[nH]c(C)c2-c2ccc3c(c2)OCCO3)c(O)cc1O,CCT018159,Preclinical,HSP inhibitor,HSP90AA1|HSP90AB1,,
NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,CCT128930,Preclinical,AKT inhibitor,,,
CN(C)c1ccc(-c2nc3ncc(Cl)c(N4CCN(CC(=O)Nc5nccs5)CC4)c3[nH]2)cc1,CCT129202,Preclinical,Aurora kinase inhibitor,AURKA|AURKB|AURKC,,
Cc1cc(CN2CCN(c3c(Br)cnc4nc(-c5ccc(N6CCN(C)CC6)cc5)[nH]c34)CC2)no1,CCT137690,Preclinical,Aurora kinase inhibitor,AURKA|AURKB|AURKC,,
CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc4nc(O)cnc34)cc2F)n(-c2ccccc2)n1,CCT196969,Preclinical,RAF inhibitor,,,
N#Cc1cnc(Nc2cc(NC[C@H]3CNCCO3)c(C(F)(F)F)cn2)cn1,CCT245737,Preclinical,kinase inhibitor,,,
O=C(O)c1ccc(-c2ccc3cc(O)c(C45CC6CC(CC(C6)C4)C5)cc3c2)cc1,CD-1530,Preclinical,retinoid receptor agonist,RARG,,
O=C(O)c1ccc2cc(-c3ccc(O)c(C45CC6CC(CC(C6)C4)C5)c3)ccc2c1,CD-437,Preclinical,retinoid receptor agonist,RARG,,
OC[C@H]1O[C@H]2O[C@@H]3[C@@H](O)[C@H](O)[C@H](O[C@@H]4[C@@H](O)[C@H](O)[C@H](O[C@@H]5[C@@H](O)[C@H](O)[C@H](O[C@@H]6[C@@H](O)[C@H](O)[C@H](O[C@@H]7[C@@H](O)[C@H](O)[C@H](O[C@@H]8[C@@H](O)[C@H](O)[C@H](O[C@@H]1[C@@H](O)[C@@H]2O)O[C@@H]8CO)O[C@@H]7CO)O[C@@H]6CO)O[C@@H]5CO)O[C@@H]4CO)O[C@@H]3CO,CDBA,Phase 3,,,,
Nc1[nH]nc2nc3ccccc3nc12,CDK1-5-inhibitor,Preclinical,CDK inhibitor|glycogen synthase kinase inhibitor,CDK1|CDK5|GSK3B,,
COC[C@H](C)N[C@H]1CC[C@H](Nc2cc(-c3cccc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1,CDK9-IN-6,Preclinical,CDK inhibitor,CDK9,,
N#Cc1cccc(C(=O)Nc2cc(-c3ccccc3)nn2-c2ccccc2)c1,CDPPB,Preclinical,glutamate receptor positive allosteric modulator,GRM5,,
C[C@H]1CCc2c(cc(Br)c(F)c2Br)N1C=O,CE3F4,Preclinical,rap guanine nucleotide exchange factor inhibitor,RAPGEF3,,
CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3cc(F)ccc3[nH]c12,cebranopadol,Phase 3,opioid receptor agonist,OPRL1|OPRM1,,
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,cediranib,Phase 3,KIT inhibitor|VEGFR inhibitor,CSF1R|FLT1|FLT3|FLT4|KDR|KIT|PDGFRA|PDGFRB,,
C[C@H]1CC[C@H]2C(C)(C)[C@H]3C[C@@]12CC[C@@]3(C)O,cedrol,Phase 2,,,,
C[C@@H]1CC[C@H]2C(C)(C)[C@H]3C[C@@]12CC[C@@]3(C)O,cedrol-(+),Phase 2,sedative,,,
N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cl)CS[C@H]12)c1ccccc1,cefaclor,Launched,bacterial cell wall synthesis inhibitor,,infectious disease|otolaryngology,pneumonia|skin infections|urinary tract infections|respiratory tract infections|tonsillitis|pharyngitis
CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccc(O)cc3)[C@H]2SC1,cefadroxil,Launched,bacterial cell wall synthesis inhibitor,SLC15A1|SLC15A2|SLC22A6|SLC22A8,infectious disease|otolaryngology,urinary tract infections|skin infections|tonsillitis|pharyngitis
NC(=O)c1cc[n+](CC2=C(C(=O)O)N3C(=O)[C@@H](NC(=O)Cc4cccs4)[C@H]3SC2)cc1,cefalonium,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections
Cn1nnnc1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](O)c3ccccc3)[C@H]2SC1,cefamandole,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,skin infections|urinary tract infections|respiratory tract infections
Cn1nnnc1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](OC=O)c3ccccc3)[C@H]2SC1,cefamandole-nafate,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,skin infections|urinary tract infections|respiratory tract infections
CC(=O)OCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)CS/C(=N/C(C)C)NC(C)C)[C@H]2SC1,cefathiamidine,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections
Cc1nnc(SCC2=C(C(=O)O)N3C(=O)[C@@H](NC(=O)Cn4cnnn4)[C@H]3SC2)s1,cefazolin,Launched,bacterial cell wall synthesis inhibitor,PON1,infectious disease,urinary tract infections|skin infections|bacterial septicemia|endocarditis|surgical prophylaxis|bone and joint infections
CC/C=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)OCOC(=O)C(C)(C)C)=C(COC(N)=O)CS[C@H]12)c1csc(N)n1,cefcapene-pivoxil,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,skin infections|pneumonia|urinary tract infections
C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\O)c3csc(N)n3)[C@H]2SC1,cefdinir,Launched,bacterial cell wall synthesis inhibitor,MPO,infectious disease|otolaryngology|pulmonary,pneumonia|tonsillitis|pharyngitis|bronchitis|skin infections|otitis|sinusitis
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)OCOC(=O)C(C)(C)C)=C(/C=C\c3scnc3C)CS[C@H]12)c1csc(N)n1,cefditoren-pivoxil,Launched,bacterial cell wall synthesis inhibitor,,infectious disease|pulmonary|otolaryngology,pneumonia|bronchitis|skin infections|tonsillitis|pharyngitis
CO/N=C(/C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(C[N+]3(C)CCCC3)CS[C@H]12)c1csc(N)n1,cefepime,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,pneumonia|urinary tract infections|skin infections|intra-abdominal infections
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(C)CS[C@H]12)c1csc(N)n1,cefetamet,Launched,bacterial cell wall synthesis inhibitor,,infectious disease|otolaryngology|pulmonary,ear infections|pneumonia|otitis|sinusitis|bronchitis|urinary tract infections
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)OCOC(=O)C(C)(C)C)=C(C)CS[C@H]12)c1csc(N)n1,cefetamet-pivoxil,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections
CC(C)(O/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(C[N+]3(CCNC(=O)c4ccc(O)c(O)c4Cl)CCCC3)CS[C@H]12)c1csc(N)n1)C(=O)O,cefiderocol,Launched,antibacterial ,,,
C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OCC(=O)O)c3csc(N)n3)[C@H]2SC1,cefixime,Launched,bacterial cell wall synthesis inhibitor,,infectious disease|otolaryngology|pulmonary,urinary tract infections|otitis|pharyngitis|tonsillitis|gonorrhea|bronchitis
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CS[C@H]12)c1csc(N)n1,cefmenoxime,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections
CO[C@@]1(NC(=O)CSCC#N)C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CS[C@@H]21,cefmetazole,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,urinary tract infections|skin infections
CO[C@@]1(NC(=O)CSC[C@@H](N)C(=O)O)C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CS[C@@H]21,cefminox,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(C)c(CC(=O)O)s3)CS[C@H]12)c1csc(N)n1,cefodizime,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,respiratory tract infections|skin infections|gonorrhea
O=C(O)C1=C(CSc2nnnn2CS(=O)(=O)O)CS[C@@H]2[C@H](NC(=O)[C@H](O)c3ccccc3)C(=O)N12,cefonicid,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections
CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSc4nnnn4C)CS[C@H]23)c2ccc(O)cc2)C(=O)C1=O,cefoperazone,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections
NCc1ccccc1CC(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nnnn3CC(=O)O)CS[C@H]12,ceforanide,Launched,penicillin binding protein inhibitor,,infectious disease,gram-negative bacterial infections
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cn3ccc(=N)n3CCO)CS[C@H]12)c1csc(N)n1,cefoselis,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections|gram-positive bacterial infections
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(C)=O)CS[C@H]12)c1csc(N)n1,cefotaxime,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,respiratory tract infections|bone and joint infections|pelvic inflammatory disease|intra-abdominal infections|skin infections|meningitis|urinary tract infections|bacterial septicemia|gynecologic infections
CO[C@@]1(NC(=O)C2SC(=C(C(N)=O)C(=O)O)S2)C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CS[C@@H]21,cefotetan,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,urinary tract infections|respiratory tract infections|skin infections|gynecologic infections|chlamydia|intra-abdominal infections|bone and joint infections|surgical prophylaxis
CN(C)CCn1nnnc1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3csc(N)n3)[C@H]2SC1,cefotiam,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,bacterial septicemia|bone and joint infections|respiratory tract infections|skin infections|urinary tract infections
C[C@@H](OC(=O)OC1CCCCC1)OC(=O)C1=C(CSc2nnnn2CCN(C)C)CS[C@H]2[C@@H](NC(=O)Cc3csc(N)n3)C(=O)N12,cefotiam-cilexetil,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections|gram-positive bacterial infections
CO[C@@]1(NC(=O)Cc2cccs2)C(=O)N2C(C(=O)O)=C(COC(N)=O)CS[C@@H]21,cefoxitin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,respiratory tract infections|urinary tract infections|intra-abdominal infections|gynecologic infections|bacterial septicemia|bone and joint infections|skin infections
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(C[n+]3ccn4ncccc43)CS[C@H]12)c1nsc(N)n1,cefozopran,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections|gram-positive bacterial infections
Cc1cc(=O)c(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSc4nnnn4C)CS[C@H]23)c2ccc(O)cc2)c[nH]1,cefpiramide,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections
CO/N=C(/C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(C[n+]3cccc4c3CCC4)CS[C@H]12)c1csc(N)n1,cefpirome,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections
COCC1=C(C(=O)O[C@@H](C)OC(=O)OC(C)C)N2C(=O)[C@@H](NC(=O)/C(=N\OC)c3csc(N)n3)[C@H]2SC1,cefpodoxime,Launched,bacterial cell wall synthesis inhibitor,,otolaryngology|infectious disease|pulmonary,pharyngitis|pneumonia|bronchitis|gonorrhea|skin infections|urinary tract infections|sinusitis|tonsillitis
C/C=C/C1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccc(O)cc3)[C@H]2SC1,cefprozil,Launched,bacterial cell wall synthesis inhibitor,,otolaryngology|infectious disease|pulmonary,pharyngitis|tonsillitis|otitis|sinusitis|respiratory tract infections|skin infections|bronchitis
CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)C3=CCC=CC3)[C@H]2SC1,cefradine,Launched,bacterial cell wall synthesis inhibitor,CYP3A4,infectious disease|otolaryngology,respiratory tract infections|otitis|skin infections|urinary tract infections|tonsillitis|pharyngitis|pneumonia
NC(=O)c1cc[n+](CC2=C(C(=O)O)N3C(=O)[C@@H](NC(=O)[C@@H](c4ccccc4)S(=O)(=O)O)[C@H]3SC2)cc1,cefsulodin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections
CCO/N=C(/C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Sc3nc(-c4cc[n+](C)cc4)cs3)CS[C@H]12)c1nc(=NP(=O)(O)O)s[nH]1,ceftaroline-fosamil,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,skin infections|pneumonia
CC(C)(O/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(C[n+]3ccccc3)CS[C@H]12)c1csc(N)n1)C(=O)O,ceftazidime,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,respiratory tract infections|skin infections|bacterial septicemia|bone and joint infections|gynecologic infections|intra-abdominal infections|meningitis
Nc1nc(/C(=C/CC(=O)O)C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=CCS[C@H]23)cs1,ceftibuten,Launched,bacterial cell wall synthesis inhibitor,,pulmonary|otolaryngology,bronchitis|otitis|pharyngitis|tonsillitis
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSC(=O)c3ccco3)CS[C@H]12)c1csc(N)n1,ceftiofur,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,pneumonia|respiratory tract infections
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=CCS[C@H]12)c1csc(N)n1,ceftizoxim,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,respiratory tract infections|urinary tract infections|gonorrhea|pelvic inflammatory disease|intra-abdominal infections|bacterial septicemia|skin infections|bone and joint infections|meningitis
Nc1nc(/C(=N/O)C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(/C=C4\CCN([C@@H]5CCNC5)C4=O)CS[C@H]23)ns1,ceftobiprole,Phase 3,antiinfective drug,,,
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(O)nn3C)CS[C@H]12)c1csc(N)n1,ceftriaxone,Launched,bacterial cell wall synthesis inhibitor,,infectious disease|otolaryngology,gonorrhea|pneumonia|otitis|skin infections|urinary tract infections|pelvic inflammatory disease|bacterial septicemia|bone and joint infections|intra-abdominal infections|meningitis|surgical prophylaxis
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(N)=O)CS[C@H]12)c1ccco1,cefuroxime,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O[C@@H](C)OC(C)=O)=C(COC(N)=O)CS[C@H]12)c1ccco1,cefuroxime-axetil,Launched,bacterial cell wall synthesis inhibitor,,otolaryngology,pharyngitis|tonsillitis|otitis|sinusitis
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,celecoxib,Launched,cyclooxygenase inhibitor,CA12|PDPK1|PTGS2,rheumatology|endocrinology,osteoarthritis|rheumatoid arthritis|ankylosing spondylitis|primary dysmenorrhea (PD)
CCCC(=O)O[C@H]1CN2CC[C@H](O)[C@@H]2[C@@H](O)[C@@H]1O,celgosivir,Phase 2,glucosidase inhibitor,,,
CCN(CC)C(=O)Nc1ccc(OC[C@@H](O)CNC(C)(C)C)c(C(C)=O)c1,celiprolol,Launched,adrenergic receptor antagonist,ADRA2A|ADRB1|ADRB2,genetics,Ehlers-Danlos syndrome (EDS)
CCc1cc(-c2noc(-c3cc(OC)nc(C4CCCC4)c3)n2)cc(C)c1OC[C@@H](O)CO,cenerimod,Phase 2,sphingosine 1-phosphate receptor modulator,,,
CCCCOCCOc1ccc(-c2ccc3c(c2)/C=C(/C(=O)Nc2ccc([S@@](=O)Cc4cncn4CCC)cc2)CCCN3CC(C)C)cc1,cenicriviroc,Phase 3,CC chemokine receptor antagonist,,,
NC(=O)O[C@@H](Cn1ncnn1)c1ccccc1Cl,cenobamate,Launched,GABA receptor modulator|voltage-gated sodium channel blocker,,,
c1ccc2cc([C@]34CNC[C@H]3C4)ccc2c1,centanafadine,Phase 3,dopamine reuptake inhibitor,,,
Nn1cnc2cc3ccccc3cc2c1=O,centazolone,Phase 1,monoamine oxidase inhibitor,,,
Cc1cccc(N2CCN(CCc3ccc4ccccc4n3)CC2)c1,centhaquin,Phase 1,analgesic agent,,,
CCC(=O)c1ccc(OC[C@@H](O)CN2CCN(c3ccccc3)CC2)cc1,centpropazine,Phase 3,inositol monophosphatase inhibitor,,,
COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC,CEP-32496,Phase 1/Phase 2,RAF inhibitor,BRAF|RAF1,,
CN1CCN(c2cccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4n3)c2)CC1,CEP-33779,Preclinical,JAK inhibitor,JAK2,,
CNC(=O)c1ccccc1Nc1nc(Nc2ccc3c(c2OC)CCC[C@H](N2CCN(CCO)CC2)C3)ncc1Cl,CEP-37440,Phase 1,ALK tyrosine kinase receptor inhibitor,ALK,,
COc1cc2nccc(Oc3ccc(NC(=O)c4cn(C(C)C)c(=O)n(-c5ccc(F)cc5)c4=O)cc3F)c2cc1OC,CEP-40783,Preclinical,AXL kinase inhibitor,,,
CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1,cephalexin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease|otolaryngology,respiratory tract infections|otitis|skin infections|bone and joint infections|genitourinary tract infections
C/C=C(\C)C(=O)N[C@@H](c1ccccc1)[C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C,cephalomannine,Preclinical,DNA polymerase inhibitor,,,
CC(=O)OCC1=C2C(=O)O[Zn]OC(=O)[C@@H](N)CCCC(=O)N[C@@H]3C(=O)N2[C@@H]3SC1,cephalosporin-c-zn,Preclinical,bacterial cell wall synthesis inhibitor,,,
CC(=O)OCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3cccs3)[C@H]2SC1,cephalothin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,skin infections|surgical prophylaxis
CC(=O)OCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)CSc3ccncc3)[C@H]2SC1,cephapirin,Launched,bacterial cell wall synthesis inhibitor,,obstetrics/gynecology,mastitis
COc1ccc2cc1Oc1ccc(cc1)C[C@H]1c3c(cc4c(c3Oc3cc5c(cc3OC)CCN(C)[C@@H]5C2)OCO4)CCN1C,cepharanthine,Phase 2,NFkB pathway inhibitor,,,
CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)C3=CCC=CC3)[C@@H]2SC1,cephradine,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,skin infections|respiratory tract infections|urinary tract infections
CCCCCCCCCCCCC/C=C/[C@@H](O)[C@H](CO)NC(C)=O,ceramide,Launched,phosphoenolpyruvate carboxylase activator|serine/threonine protein phosphatase activator,,dermatology,cosmetic
Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,ceritinib,Launched,ALK tyrosine kinase receptor inhibitor,ALK|FLT3|IGF1R|INSR|TSSK1B,oncology,non-small cell lung cancer (NSCLC)
C/C=C/C/C=C/CCC(=O)[C@H]1O[C@H]1C(N)=O,cerulenin,Launched,fatty acid synthase inhibitor,FASN,infectious disease,fungal infection
CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(OS(=O)(=O)O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)[C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,ceruletide,Preclinical,CCK receptor agonist,CCKAR,,
CCCCCCCCCCCCCCCCNc1ccc(C(=O)O)cc1,cetaben,Phase 2,ACAT inhibitor|cholesterol inhibitor,PPARA,,
CCCCCCCCCCCCCCCCOc1nc2ccc(C)cc2c(=O)o1,cetilistat,Phase 3,triacylglycerol lipase inhibitor,PNLIP,,
O=C(O)COCCN1CCN([C@@H](c2ccccc2)c2ccc(Cl)cc2)CC1,cetirizine,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis
CCCCCCCCCCCCCCCC[N+](C)(C)C,cetrimonium,Launched,,,dermatology,cosmetic
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,cetrorelix,Launched,gonadotropin releasing factor hormone receptor antagonist,GNRHR|LHCGR,endocrinology,premature luteinizing hormone surges
CCCCCCCCCCCCCCCC[n+]1ccccc1,cetylpyridinium,Launched,,,dental,gingivitis|mouth inflammation
C[C@H]1O[C@]2(CS1)CN1CCC2CC1,cevimeline,Launched,acetylcholine receptor agonist,CHRM3,rheumatology,sjogren's syndrome
CNCCCOc1cc(F)c(-c2c(Cl)nc3ncnn3c2N[C@@H](C)C(F)(F)F)c(F)c1,cevipabulin,Phase 1,microtubule stimulant|tubulin polymerization inhibitor,TUBB,,
CNC(=O)[C@H]1O[C@@H](n2cnc3c(NCc4cccc(I)c4)nc(Cl)nc32)[C@H](O)[C@@H]1O,CF102,Phase 2,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5C[C@@H](C)O[C@@H](C)C5)cc4)[nH]nc3c1)C(=O)N2,CFI-400945,Phase 2,serine/threonine kinase inhibitor,,,
Cc1cc(-c2cnn3c(NC[C@H]4C[C@@](C)(O)C4)cc(Oc4cccnc4)nc23)ccc1C(=O)NC1CC1,CFI-402257,Phase 1/Phase 2,dual specificity protein kinase inhibitor,,,
COc1ccc(NC(=O)c2cc(OCCCN(C)C)nn2Cc2ccccc2)cc1,CFM-1571,Preclinical,guanylate cyclase activator,,,
COc1cc2c(cc1OC)C(c1ccc(N)cc1)=NNC(=O)C2,CFM-2,Preclinical,glutamate receptor antagonist,,,
O=C(O)c1ccc(/C=C2/SC(=S)N(c3cccc(C(F)(F)F)c3)C2=O)cc1,CFTRinh-172,Preclinical,chloride channel blocker,CFTR,,
Cc1c(N)cccc1Cn1ccc(OCCc2cccs2)cc1=O,CG-400549,Phase 2,FABI inhibitor,,,
Nc1nc(-c2ccc(Cl)c(Cl)c2)c(-c2ccncc2)s1,CGH2466,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2B|ADORA3,,
O=C(N[C@H](NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1,CGK-733,Preclinical,ATM kinase inhibitor|ATR kinase inhibitor,ATM|ATR,,
COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N4CCN(C)C(=O)C4)CC3)cc1)C(=O)C2,CGM097,Phase 1,MDM inhibitor,MDM2,,
CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(=O)[nH]c12,CGP-12177,Phase 1,adrenergic receptor agonist,ADRB1|ADRB2|ADRB3,,
CC(C)(C=O)Cc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1,CGP-13501,Preclinical,GABA receptor modulator,GABBR1,,
CS(=O)(=O)O.Cn1cc(C(F)(F)F)nc1-c1ccc(OC[C@H](O)CNCCOc2ccc(O)c(C(N)=O)c2)cc1,CGP-20712A,Preclinical,adrenergic receptor antagonist,ADRB1|ADRB3,,
CCN(CC)CCNC(=O)c1cc(C#N)c(Cl)cc1OC,CGP-25454A,Preclinical,dopamine receptor antagonist,,,
O=C1CS[C@@H](c2ccccc2Cl)c2cc(Cl)ccc2N1,CGP-37157,Preclinical,mitochondrial Na+/Ca2+ exchanger antagonist|sodium/calcium exchange inhibitor,SLC8A1,,
CCOC(=O)[C@H](N)/C=C(\C)CP(=O)(O)O,CGP-39551,Preclinical,NMDA receptor antagonist,,,
O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc21,CGP-52411,Preclinical,EGFR inhibitor,EGFR,,
O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21,CGP-53353,Preclinical,EGFR inhibitor|PKC inhibitor,EGFR|PRKCB,,
C[C@H](NC[C@H](O)CP(=O)(O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1,CGP-54626,Preclinical,GABA receptor antagonist,GABBR1|GABBR2|KCTD12|KCTD16|KCTD8,,
C[C@H](NC[C@H](O)CP(=O)(O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1,CGP-55845,Preclinical,GABA receptor antagonist,GABBR1|GABBR2|KCTD12|KCTD16|KCTD8,,
Nc1ncnc2n[nH]c(Nc3ccc(F)cc3)c12,CGP-57380,Preclinical,MAP kinase inhibitor,AURKB|LCK|MKNK1|MKNK2|SGK1,,
OCCCNc1cc(-c2ccnc(Nc3cccc(Cl)c3)n2)ccn1,CGP-60474,Preclinical,CDK inhibitor,CDK1|CDK2,,
Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12,CGP-71683,Preclinical,neuropeptide receptor antagonist,NPY5R,,
CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21,CGP-74514,Preclinical,CDK inhibitor,CDK1,,
C[C@@H](NCc1cc(Br)cc2[nH]c(=O)c(=O)[nH]c12)P(=O)(O)O,CGP-78608,Preclinical,glutamate receptor antagonist,,,
CC(C)(CO)Cc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1,CGP-7930,Preclinical,GABA receptor modulator,GABBR1,,
Nc1nc2ccc(Cl)cc2c2nc(-c3ccco3)nn12,CGS-15943,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
COc1ccc(-n2[nH]c3c4c(ncc3c2=O)CCCCC4)cc1,CGS-20625,Phase 1,benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6,,
CCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)nc(NCCc4ccc(CCC(=O)O)cc4)nc32)[C@H](O)[C@@H]1O,CGS-21680,Preclinical,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
O=c1c2cnc3ccccc3c2[nH]n1-c1ccc(Cl)cc1,CGS-9896,Preclinical,GABA receptor antagonist,GABRA1|GABRB2|GABRG2,,
Cc1nc(Cn2cnc3c2c(=O)n(C)c(=O)n3C)no1,CH-170,Phase 1,,,,
Cc1nc2ccc(-n3ncc(C(=O)c4cc5ccccc5[nH]4)c3N)cc2[nH]1,CH-5183284,Phase 2,fibroblast growth factor inhibitor,FGFR1|FGFR2|FGFR3,,
Cc1ccccc1/N=N/c1ccc(NC(=O)c2ccnn2C)c(C)c1,CH223191,Preclinical,aryl hydrocarbon receptor antagonist,AHR,,
CS(=O)(=O)N1CCc2c(-c3cnc(N)nc3)nc(N3CCOCC3)nc21,CH5132799,Phase 1,PI3K inhibitor,MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG,,
CC(C)(C)c1cc(C(=O)/C=C/c2ccc(C(=O)O)cc2)cc(C(C)(C)C)c1,CH55,Preclinical,retinoid receptor binder,RARA|RARB,,
N#C/C(=C\c1ccc(O)cc1)C(=O)O,CHC,Preclinical,monocarboxylate transporter inhibitor,SLC16A1,,
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,chenodeoxycholic-acid,Launched,11-beta hydroxysteroid dehydrogenase inhibitor|FXR agonist,HSD11B1|NR1H4,cardiology|gastroenterology,cerebral cholesterosis|gallstones
O=C(O)C1(c2ccc(-c3ccc(Cl)c(Cl)c3)c(F)c2)CC1,CHF5074,Phase 2,gamma secretase modulator,PSEN1,,
COc1cc(-c2ccc(NN=C3C=Cc4c(S(=O)(=O)O)cc(S(=O)(=O)O)c(N)c4C3=O)c(OC)c2)ccc1NN=C1C=Cc2c(S(=O)(=O)O)cc(S(=O)(=O)O)c(N)c2C1=O,chicago-sky-blue-6b,Preclinical,glutamate inhibitor|macrophage migration inhibiting factor inhibitor,MIF,,
Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)/C=C/c2cccnc2)cc1,chidamide,Launched,HDAC inhibitor,HDAC10|HDAC3,hematologic malignancy,peripheral T-cell lymphoma (PTCL)
O=S(=O)(O)c1cc(I)c(O)c2ncccc12,chiniofon,Launched,antiprotozoal agent,,infectious disease,amebiasis
O=c1[nH]c2ccc(Cl)cc2c(N[C@@H]2CN3CCC2CC3)c1-c1nc2ccccc2[nH]1,CHIR-124,Preclinical,CHK inhibitor,CHEK1,,
Nc1nc(NCCNc2ncc(-n3ccnc3)c(-c3ccc(Cl)cc3Cl)n2)ccc1[N+](=O)[O-],CHIR-98014,Preclinical,glycogen synthase kinase inhibitor,GSK3A|GSK3B,,
Cc1c[nH]c(-c2cnc(NCCNc3ccc(C#N)cn3)nc2-c2ccc(Cl)cc2Cl)n1,CHIR-99021,Preclinical,glycogen synthase kinase inhibitor,CDK1|GSK3A|GSK3B|MAPK1,,
OC[C@@H](O)[C@H]1O[C@@H]2O[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@H]1O,chloralose,Preclinical,,,,
O=C(O)CCCc1ccc(N(CCCl)CCCl)cc1,chlorambucil,Launched,DNA inhibitor,,hematologic malignancy,chronic lymphocytic leukemia (CLL)|Hodgkin's lymphoma
Cc1ccc(S(=O)(=O)NCl)cc1,chloramine-T,Launched,,,infectious disease,bacterial gill disease
O=C(N[C@H](CO)[C@H](O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl,chloramphenicol,Launched,bacterial 50S ribosomal subunit inhibitor,CD55,infectious disease|endocrinology,meningitis|fever|cholera
CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc([N+](=O)[O-])cc1,chloramphenicol-palmitate,Launched,protein synthesis inhibitor,,infectious disease|endocrinology,meningitis|fever|cholera
O=C(O)CCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc([N+](=O)[O-])cc1,chloramphenicol-sodium-succinate,Launched,protein synthesis inhibitor,,infectious disease,gram-negative bacterial infections
Nc1ncnc(Nc2ccc(Cl)cc2)n1,chlorazanil,Preclinical,,,,
CN1CCN([C@@H](c2ccccc2)c2ccc(Cl)cc2)CC1,chlorcyclizine,Launched,histamine receptor antagonist,,allergy,allergic rhinitis
O=S(=O)(Oc1ccc(Cl)cc1)c1ccc(Cl)cc1,chlorfenson,Phase 2,other antifungal,,,
N=C(N=C(N)Nc1ccc(Cl)cc1)NCCCCCCNC(=N)N=C(N)Nc1ccc(Cl)cc1,chlorhexidine,Launched,membrane integrity inhibitor,,dermatology|infectious disease|dental,cosmetic|skin infections|gingivitis
Oc1ccc(Cl)c2c1CCC2,chlorindanol,Preclinical,,,,
O=C1c2ccccc2C(=O)C1c1ccc(Cl)cc1,chlorindione,Preclinical,,,,
C[N+](C)(C)CC[N+]1(C)Cc2c(Cl)c(Cl)c(Cl)c(Cl)c2C1,chlorisondamine-diiodide,Preclinical,acetylcholine receptor antagonist,CHRNA1,,
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,chlormadinone-acetate,Launched,5 alpha reductase inhibitor,PGR,endocrinology,hypermenorrhea|amenorrhea|oligomenorrhea|polymenorrhea
Cc1nc2ccccc2n1Cc1ccc(Cl)cc1,chlormidazole,Launched,fungal lanosterol demethylase inhibitor,,infectious disease,fungal infection
Cc1cc(O)ccc1Cl,chlorocresol,Launched,ryanodine receptor activator,,infectious disease,first-aid antiseptic
O=C(/C=C/c1ccc(O)c(O)c1)O[C@@H]1C[C@](O)(C(=O)O)C[C@@H](O)[C@H]1O,chlorogenic-acid,Launched,antioxidant,SLC37A4,neurology/psychiatry|pulmonary|allergy,headache|chest congestion|allergic rhinitis
C=CC1=C(C)c2cc3[nH]c(c(CC(=O)O)c4[nH]c(cc5nc(cc1n2)C(C)=C5CC)c(C)c4C(=O)O)[C@@H](CCC(=O)O)[C@@H]3C,chlorophyllin,Preclinical,,,urology,urinary incontinence
C=Cc1c(C)c2n3c1/C=C1\N=C(/C=c4/c(C)c(C(=O)O)/c(n4[Cu]3)=C(\CC(=O)O)C3=N/C(=C\2)[C@@H](C)[C@@H]3CCC(=O)O)C(CC)=C1C,chlorophyllin-copper,Phase 1,cytochrome P450 inhibitor,,,
CCN(CC)CCOC(=O)c1ccc(N)cc1Cl,chloroprocaine,Launched,sodium channel blocker,ATP1A1|CHRNA10|GRIN3A|HTR3A|SCN10A|SLC6A3,neurology/psychiatry,local anesthetic
CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1,chloropyramine,Launched,histamine receptor antagonist,HRH1,cardiology|ophthalmology|allergy|pulmonary,edema|conjunctivitis|allergic rhinitis|asthma
CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12,chloroquine,Launched,antimalarial agent,MRGPRX1,infectious disease,malaria|amebiasis
NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O,chlorothiazide,Launched,diuretic,CA1|CA2|CA4|SLC12A3,cardiology,hypertension
Cc1cc(O)c(C(C)C)cc1Cl,chlorothymol,Launched,,,,
COc1ccc(C(Cl)=C(c2ccc(OC)cc2)c2ccc(OC)cc2)cc1,chlorotrianisene,Launched,estrogenic hormone,ESR1|ESR2,endocrinology|oncology,menopause|prostate cancer
Oc1c(Cl)cc(Cl)c2cccnc12,chloroxine,Launched,opioid receptor antagonist,OPRK1,gastroenterology|infectious disease|dermatology,diarrhea|inflammatory bowel disease|giardiasis|dandruff
O=c1cc[nH]c2cc(Cl)ccc12,chloroxoquinoline,Launched,,,,
Cc1cc(O)cc(C)c1Cl,chloroxylenol,Launched,ATP synthase inhibitor,,infectious disease,skin infections
CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1,chlorphenamine,Launched,histamine receptor antagonist,,allergy,allergic rhinitis|urticaria
OC[C@@H](O)COc1ccc(Cl)cc1,chlorphenesin,Launched,muscle relaxant,,neurology/psychiatry,muscle relaxant|sedative
CN(C)CCO[C@@](C)(c1ccccc1)c1ccc(Cl)cc1,chlorphenoxamine,Preclinical,histamine receptor antagonist,,,
NC(=O)OC[C@@H](O)COc1ccc(Cl)cc1,chlorphensin-carbamate,Launched,muscle relaxant,,neurology/psychiatry,spasms
CC(C)NC(=N)N=C(N)Nc1ccc(Cl)c(Cl)c1,chlorproguanil,Launched,dihydrofolate reductase inhibitor,DHFR,infectious disease,malaria
CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21,chlorpromazine,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CALM1|CHRM1|CHRM3|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HRH4|HTR1A|HTR2A|HTR2B|HTR2C|HTR6|HTR7|KCNH2|ORM1|ORM2|SMPD1|TRPC5,neurology/psychiatry|gastroenterology|hematology|infectious disease,schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus
CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1,chlorpropamide,Launched,ATP channel blocker,ABCC8|KCNJ10,endocrinology,diabetes mellitus
CC(C)OC(=O)Nc1cccc(Cl)c1,chlorpropham,Phase 1,antiviral,,,
CN(C)CC/C=C1/c2ccccc2Sc2ccc(Cl)cc21,chlorprothixene,Launched,dopamine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|HRH1|HTR2A|HTR2B|HTR2C,neurology/psychiatry,schizophrenia|bipolar disorder
CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl,chlorpyrifos,Launched,acetylcholinesterase inhibitor,ACHE,,
Cc1ccc2c(Cl)cc(Cl)c(O)c2n1,chlorquinaldol,Launched,other antibiotic,,infectious disease,fungal infection
CN(C)[C@@H]1C(=O)[C@@H](C(N)=O)C(=O)[C@@]2(O)C(=O)[C@H]3C(=O)c4c(O)ccc(Cl)c4[C@@](C)(O)[C@H]3C[C@@H]12,chlortetracycline,Launched,protein synthesis inhibitor,,ophthalmology,conjunctivitis
NS(=O)(=O)c1cc([C@@]2(O)NC(=O)c3ccccc32)ccc1Cl,chlorthalidone,Launched,carbonic anhydrase inhibitor,CA1|CA12|CA14|CA2|CA4|CA7|SLC12A1,cardiology|gastroenterology|rheumatology|nephrology,hypertension|edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|acute glomerulonephritis (AGN)|chronic renal failure
O=c1[nH]c2cc(Cl)ccc2o1,chlorzoxazone,Launched,bacterial 30S ribosomal subunit inhibitor,KCNMA1|KCNN4,neurology/psychiatry,muscle relaxant
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]12,cholecalciferol,Launched,,VDR,endocrinology,vitamin D deficiency
CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,cholesterol,Preclinical,,RORA,,
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C,cholic-acid,Launched,bile acid,ADH1C|CES1|COX4I1|COX5A|COX5B|COX6A2|COX6B1|COX6C|COX7A1|COX7B|COX7C|COX8A|ESRRG|FABP6|FECH|GPBAR1|MT-CO1|MT-CO2|MT-CO3|PLA2G1B,gastroenterology|neurology/psychiatry|genetics,bile acid synthesis disorders|peroxisomal disorders|Zellweger syndrome
C[N+](C)(C)CCO,choline,Phase 3,acetylcholine precursor,ACHE|BCHE|CHRNA2|PCYT1A|PCYT1B|PHOSPHO1|PLD1|PLD2,,
C[N+](C)(C)CCOP(=O)(O)OC[C@H](O)CO,choline-alfoscerate,Launched,acetylcholine precursor,,,
N[C@@H](C(=O)O)c1cc(O)ccc1Cl,CHPG,Preclinical,glutamate receptor agonist,GRM5,,
CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1,CHR-6494,Preclinical,serine/threonine kinase inhibitor,GSG2,,
CCS(=O)(=O)N(C)[C@@H]1c2cc(C#N)ccc2OC(C)(C)[C@H]1O.CCS(=O)(=O)N(C)[C@H]1c2cc(C#N)ccc2OC(C)(C)[C@@H]1O,chromanol-(+/-),Preclinical,potassium channel blocker,,,
CCS(=O)(=O)N(C)[C@H]1c2cc(C#N)ccc2OC(C)(C)[C@@H]1O,"chromanol-293B-(-)-[3R,4S]",Preclinical,potassium channel blocker,,,
O=C(O[Cr](OC(=O)c1ccccn1)OC(=O)c1ccccn1)c1ccccn1,chromium-picolinate,Launched,insulin sensitizer,,endocrinology,diabetes mellitus
O=C(O)c1cc(=O)c2ccccc2o1,chromocarb,Launched,antispasmodic,,,
O=c1cc(-c2ccccc2)oc2cc(O)cc(O)c12,chrysin,Phase 1,breast cancer resistance protein inhibitor,AKR1B1|CDK6|CYP19A1|CYP1B1,,
Cc1cc(O)c2c(c1)C(=O)c1cccc(O)c1C2=O,chrysophanic-acid,Preclinical,EGFR inhibitor,EGFR|MTOR,,
Cc1nc(C)c(C)nc1C,chuanxiongzine,Phase 2,,,,
c1ccc(Oc2cccnc2)cc1,CI-844,Phase 2,,,,
CCN[C@@H](C)CN1CCc2c(c(=O)oc3ccccc23)C1,CI-923,Phase 1,acetylcholine receptor antagonist,,,
Cc1cccc(Cl)c1NC(=O)Nc1ccncc1,CI-953,Phase 1,voltage-gated sodium channel blocker,,,
O=C(O)C1=CCCN(CCOC(c2ccc(C(F)(F)F)cc2)c2ccc(C(F)(F)F)cc2)C1,CI-966,Phase 1,GAT inhibitor,SLC6A1,,
CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC,CI-976,Phase 1,ACAT inhibitor,ACAT1|CES1,,
c1ccc2c(c1)C1=N/C2=N\c2c3ccccc3c3n2[Zn]n2/c(c4ccccc4/c2=N/C2=N/C(=N\3)c3ccccc32)=N\1,ciaftalan-zinc,Phase 1,reactive oxygen species stimulant,,,
c1ccc(C2(c3ccccc3)C[C@H]2C2=NCCN2)cc1,cibenzoline,Launched,sodium channel blocker,,cardiology,cardiac arrythmia
CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C,ciclesonide,Launched,glucocorticoid receptor agonist,NR3C1|SERPINA6,allergy,allergic rhinitis
Cc1cc(C2CCCCC2)n(O)c(=O)c1,ciclopirox,Launched,membrane integrity inhibitor,ATP1A1,infectious disease,onychomycosis
C[C@@H](C(=O)O)c1ccc2c(c1)Cc1ccccc1-2,cicloprofen,Preclinical,cyclooxygenase inhibitor,PTGS1|PTGS2,,
Cc1ccc(-c2n[nH]c3c2[C@H](c2cccc(O)c2)N(c2ccc(C(=O)O)cc2)C3=O)cc1,CID-16020046,Preclinical,G protein-coupled receptor antagonist,GPR55,,
O=C(Nc1ccc(CN2CCOCC2)cc1)c1ccc(-c2cccc(Cl)c2)o1,CID-2011756,Preclinical,protein kinase inhibitor,PKD1,,
COC(=O)c1cnn(-c2ccc(F)cc2F)c1/C=N/NC(=S)NC(C)(C)C,CID-2745687,Preclinical,G protein-coupled receptor antagonist,GPR35,,
OC1=c2ccccc2=C(NC2CCCCC2)/C1=C\c1ccccc1,CID-5458317,Preclinical,MAP kinase phosphatase inhibitor,MAPK3,,
Nc1ccn(C[C@@H](CO)OCP(=O)(O)O)c(=O)n1,cidofovir,Launched,DNA polymerase inhibitor,,infectious disease,acquired immunodeficiency syndrome (AIDS)|cytomegalovirus retinitis
CC1(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)CCCCC1,ciglitazone,Phase 2,PPAR receptor agonist,PPARG,,
CC1(C)C[C@@H]1C(=O)N/C(=C\CCCCSC[C@H](N)C(=O)O)C(=O)O,cilastatin,Launched,dehydropeptidase inhibitor,DPEP1,,
CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@@H](C(=O)O)N2C1=O,cilazapril,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|congestive heart failure
CC(C)[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](Cc2ccccc2)C(=O)N1C,cilengitide,Phase 3,integrin antagonist,ITGAV|ITGB3,,
COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC/C=C/c2ccccc2)[C@@H]1c1cccc([N+](=O)[O-])c1,cilnidipine,Launched,calcium channel blocker,CACNA1B,cardiology,hypertension
O=C(O)c1ccnc(N2CC(O)(c3ccc(OCc4c(-c5c(Cl)cccc5Cl)noc4C4CC4)cc3Cl)C2)c1,cilofexor,Phase 3,FXR agonist,,,
COc1ccc([C@]2(C#N)CC[C@@H](C(=O)O)CC2)cc1OC1CCCC1,cilomilast,Phase 3,phosphodiesterase inhibitor,PDE4A|PDE4B|PDE4D,,
CN(C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1)C1CCCCC1,cilostamide,Preclinical,phosphodiesterase inhibitor,PDE3A|PDE3B,,
O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1,cilostazol,Launched,phosphodiesterase inhibitor,PDE3A|PDE3B,cardiology,claudication
COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)O)C[C@H]5/C=C\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(NC(C)C)n3)nc2c1,ciluprevir,Preclinical,serine protease inhibitor,,,
Cc1cc(NC(=O)[C@H](c2ccccc2)N2CCCc3ccccc32)no1,CIM-0216,Preclinical,transient receptor potential channel agonist,TRPM3,,
CC(C)NC[C@@H](O)c1ccc(N)c(C#N)c1,cimaterol,Preclinical,adrenergic receptor agonist,ADRB1|ADRB2|ADRB3,,
CN/C(=N\C#N)NCCSCc1[nH]cnc1C,cimetidine,Launched,histamine receptor antagonist,HRH2|SLC29A4|SLC47A1|SLC47A2,gastroenterology|hematologic malignancy|endocrinology,duodenal ulcer disease|peptic ulcer disease (PUD)|gastroesophageal reflux disease (GERD)|aggressive systemic mastocytosis (ASM)|Zollinger-Ellison syndrome|endocrine adenoma
C[N@+]1(CC2CC2)[C@@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12,cimetropium,Launched,acetylcholine receptor antagonist,CHRM1,gastroenterology,irritable bowel syndrome
C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,cinacalcet,Launched,calcium channel activator,CASR,endocrinology|nephrology|oncology,hyperparathyroidism|chronic kidney disease (CKD)|parathyroid carcinoma|hypercalcemia
O=C(O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(C(=O)O)cc1,cinaciguat,Phase 2,guanylate cyclase activator,GUCY1A3|GUCY1B3,,
CCC(CC)(CC(=O)Nc1cccc(/C=C/c2nc(C3CCC3)cs2)c1)C(=O)O,cinalukast,Phase 2,leukotriene receptor antagonist,CYSLTR1,,
CN(C)CCCSc1ccccc1NC(=O)/C=C/c1ccccc1,cinanserin,Preclinical,serotonin receptor antagonist,HTR2A,,
CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1,cinchocaine,Launched,sodium channel blocker,CALM1|SCN10A|SCN5A,neurology/psychiatry,local anesthetic
C=C[C@H]1C[N@@]2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccccc12,cinchonidine,Phase 1,P glycoprotein inhibitor,,,
C=C[C@H]1C[N@@]2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccccc12,cinchonine,Preclinical,P glycoprotein inhibitor,CYP2D6,,
O=C(O)c1cc(-c2ccccc2)nc2ccccc12,cinchophen,Launched,analgesic agent,,rheumatology,gout
CCOC(=O)CN1CCN(C(=O)/C=C/c2cc(OC)c(OC)c(OC)c2)CC1,cinepazet,Launched,vasodilator,,,
O=C(/C=C/c1cccc(F)c1)NC1CC1,cinflumide,Phase 2,muscle relaxant,,,
O=C/C=C/c1ccccc1,cinnamaldehyde,Preclinical,aldose reductase inhibitor|TRPV agonist,TRPA1,,
C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1,cinnarazine,Launched,calcium channel blocker,,neurology/psychiatry|gastroenterology|ophthalmology,Meniere's disease|nausea|vomiting|Cogan's syndrome
CC(=O)O[C@H]1[C@H]2O[C@]23[C@@H]2CC[C@]4(O)C[C@@H](O)CC[C@]4(C)[C@H]2CC[C@]3(C)[C@H]1c1ccc(=O)oc1,cinobufotalin,Phase 1,anticancer agent,,,
COc1cc(/C=C/C(=O)N2CCCCCCC2)cc(OC)c1OC,cinoctramide,Preclinical,,,,
CCn1nc(C(=O)O)c(=O)c2cc3c(cc21)OCO3,cinoxacin,Launched,topoisomerase inhibitor,,infectious disease,urinary tract infections
CCOCCOC(=O)/C=C/c1ccc(OC)cc1,cinoxate,Launched,,,dermatology,sunscreen lotion
CCOC(=O)Nc1ccc2c(c1)N(C(=O)CN(CC)CC)c1ccccc1CC2,CINPA-1,Preclinical,CAR antagonist,NR1H4|NR1I3|PPARG,,
CCNC(=O)/C=C/c1cccc(Br)c1,cinromide,Phase 3,,,,
CC(C)(C[C@H]1CN(S(=O)(=O)c2cccc(C(F)(F)F)c2)c2cc(-c3cc(F)cc(OC(F)F)c3)ccc2O1)C(=O)O,cintirorgon,Phase 1/Phase 2,ROR agonist,,,
COc1cc(/C=C/C(N)=O)cc(OC)c1OC,cintriamide,Preclinical,,,,
Nc1nc2c([nH]1)c(=O)n(CC1CC1)c(=O)n2CC1CC1,cipamfylline,Phase 2,phosphodiesterase inhibitor,,,
C[C@H]1Cc2c([nH]c3cc(Cl)c(F)cc23)[C@@]2(N1)C(=O)Nc1ccc(Cl)cc12,cipargamin,Phase 2,antimalarial agent,,,
CN1C(=O)N(C[C@H](C(=O)NO)[C@@H](CC2CCCC2)C(=O)N2CCCCC2)C(=O)C1(C)C,cipemastat,Phase 3,metalloproteinase inhibitor,ADAM17|MMP1|MMP13|MMP2|MMP3|MMP8|MMP9,,
CC(C)(Oc1ccc([C@H]2CC2(Cl)Cl)cc1)C(=O)O,ciprofibrate,Launched,PPAR receptor agonist,PPARA,endocrinology,hyperlipidemia
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,ciprofloxacin,Launched,bacterial DNA gyrase inhibitor,TOP2A,otolaryngology,otitis
O=C(c1ccc(OCCCc2cnc[nH]2)cc1)C1CC1,ciproxifan,Preclinical,histamine receptor antagonist,ADRA2A|ADRA2C|HRH3|HRH4|HTR3A,,
COc1ccc(OC[C@@H]2c3cc(OC)c(OC)cc3CCN2C(=O)c2cccc(Cl)c2)cc1,CIQ,Preclinical,glutamate receptor potentiator,GRIN2C|GRIN2D,,
c1ccc(C2CC2)c(OCC2=NCCN2)c1,cirazoline,Preclinical,adrenergic receptor agonist,ADRA1A,,
CCCCCC/C=C/C=C\CCCCCCCC(=O)O,"cis-9,trans-11-conjugated-linoleic-acid",Launched,,,,
N[C@]1(C(=O)O)CC[C@@H](C(=O)O)C1,cis-ACPD,Preclinical,glutamate receptor agonist,GRM2|GRM3|GRM6|GRM7|GRM8,,
CC1(C)[C@H]2CC[C@]1(C)[C@@H](O)[C@H]2O,"cis-exo-camphanediol-2,3",Phase 1,nitric oxide stimulant,NOS3,,
O=C(O)/C=C\c1cnc[nH]1,cis-urocanic-acid,Phase 2,serotonin receptor agonist,HTR2A,,
O=C(O)/C=C/c1cnc[nH]1,cis-urocanic-acid,Phase 2,serotonin receptor agonist,HTR2A,,
COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC,cisatracurium,Launched,acetylcholine receptor antagonist,CHRNA2,neurology/psychiatry|critical care,muscle relaxant|endotracheal intubation
CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,citalopram,Launched,selective serotonin reuptake inhibitor (SSRI),ADRA1A|CHRM1|HRH1|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,depression
O=C(CCCCCCNC(=O)c1cnc(N(c2ccccc2)c2ccccc2Cl)nc1)NO,citarinostat,Phase 1,HDAC inhibitor,,,
Clc1ccc(-c2nc3sccn3c2/C=N/OCc2ccc(Cl)c(Cl)c2)cc1,CITCO,Preclinical,constitutive androstane receptor (CAR) agonist,NR1I3,,
C[N+](C)(C)CCOP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@H](O)[C@@H]1O,citicoline,Launched,glutathione transferase stimulant|membrane permeability enhancer,ACHE|SLC1A2,neurology/psychiatry|ophthalmology,stroke|Alzheimer's disease|senile dementia|Parkinson's Disease|attention-deficit/hyperactivity disorder (ADHD)|glaucoma
CC(=O)N[C@H]1CCSC1=O,citiolone,Preclinical,lipotropic|mucolytic agent,,,
O=C(O)CC(O)(CC(=O)O)C(=O)O,citric-acid,Preclinical,coagulation factor inhibitor,AKR1B1|ANG|APRT|BHMT|C8G|CA4|CPB1|CS|CTDSP1|GNMT|HGS|HS3ST3A1|IL4I1|ITPA|LSM6|MDH2|MIF|PDE5A|PKD2L1|PLEKHA1|RNASE1|RNASE3|SRC|TNFSF13B|UCK2,,
Cc1cn2c(N)c(Cl)cc(C(=O)NCC3CCN(CC(C)C)CC3)c2n1,CJ-033466,Preclinical,serotonin receptor agonist,HTR4,,
Cc1nccn1-c1ccc(Sc2cccc(C3(C(N)=O)CCOCC3)c2)cc1,CJ-13610,Phase 2,lipoxygenase inhibitor,,,
C=CC(=O)Nc1cccc(-c2cccc3cnc(Nc4ccc(N5CCN(CCO)CC5)c(F)c4F)nc23)c1,CK-101,Preclinical,EGFR inhibitor,,,
Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1,CK-636,Preclinical,actin related protein inhibitor,ACTR2|ACTR3|ARPC1B|ARPC2|ARPC3|ARPC4|ARPC5,,
Oc1cc2c(cc1O)[C@H](Cc1cccc3ccccc13)NCC2,CKD-712,Phase 1,NFkB pathway inhibitor,JAK2|STAT1,,
NCCNS(=O)(=O)c1ccc(Cl)c2ccncc12,CKI-7,Preclinical,casein kinase inhibitor,CSNK1G2,,
Cc1nnc2ccc(-c3cccc(C(F)(F)F)c3)nn12,CL-218872,Phase 1,benzodiazepine receptor agonist,GABRA1|GABRA2|GABRA3|GABRA5|GABRB2|GABRG2,,
N#CCC(=O)c1ccccc1,CL-225385,Phase 2,,,,
C[C@H](Cc1ccc2c(c1)OC(C(=O)O)(C(=O)O)O2)NC[C@H](O)c1cccc(Cl)c1,CL316243,Phase 2,adrenergic receptor agonist,ADRB3|UCP1|UCP2|UCP3,,
Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1,cladribine,Launched,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor,ADA|PNP|POLA1|POLE|POLE2|POLE3|POLE4|RRM1|RRM2|RRM2B,hematologic malignancy,hairy cell leukemia
CNC(=S)NS(=O)(=O)c1cc(CCNC(=O)c2cc(Cl)ccc2OC)ccc1OC,clamikalant,Preclinical,ATP-sensitive potassium channel antagonist,,,
CN(C)c1cccc(F)c1C(=O)NC(=O)Nc1ccc(Cl)cc1,clanfenur,Preclinical,anticancer agent,,,
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,clarithromycin,Launched,bacterial 50S ribosomal subunit inhibitor,CYP3A4,otolaryngology|pulmonary|infectious disease,pharyngitis|tonsillitis|sinusitis|bronchitis|pneumonia|skin infections|otitis
O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21,clavulanate,Launched,beta lactamase inhibitor,,otolaryngology,otitis
COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1,clebopride,Launched,dopamine receptor antagonist,ACHE|DRD2,gastroenterology,nausea
CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1,clemastine,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis|urticaria
Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc32)cc1,clemizole,Launched,HCV inhibitor,,allergy,allergic rhinitis
CC(C)(C)NC[C@@H](O)c1cc(Cl)c(N)c(Cl)c1,clenbuterol,Launched,adrenergic receptor agonist,ABCC8|ADRB2|KCNJ11,pulmonary,chronic obstructive pulmonary disease (COPD)|asthma
CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1c1cccc(Cl)c1Cl,cleviprex,Launched,calcium channel blocker,CACNA1C|CACNA1D|CACNA1F|CACNA1S,cardiology,hypertension
Cc1cn([C@H]2O[C@@H](CO)[C@H](O)[C@H]2F)c(=O)[nH]c1=O,clevudine,Launched,DNA polymerase inhibitor,,infectious disease,hepatitis B
C[N+]12CCC(CC1)[C@H](OC(=O)C(O)(c1ccccc1)c1ccccc1)C2,clidinium,Launched,acetylcholine receptor antagonist,CHRM1|CHRM3,gastroenterology,peptic ulcer disease (PUD)|irritable bowel syndrome|enterocolitis
CC(C)(C)C(=O)[C@@H](Oc1ccc(Cl)cc1)n1ccnc1,climbazole,Launched,enzyme inducer,,dermatology,dandruff|eczema
N[C@H]1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2Cl)C1,clinafloxacin,Phase 3,bacterial DNA gyrase inhibitor,,,
CCC[C@@H]1C[C@@H](C(=O)N[C@@H]([C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)[C@H](C)Cl)N(C)C1,clindamycin,Launched,protein synthesis inhibitor,,infectious disease,respiratory tract infections|pneumonia|skin infections|gynecologic infections|intra-abdominal infections|bacterial septicemia|bone and joint infections
CCCCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](O)[C@@H](O)[C@@H]([C@H](NC(=O)[C@@H]2C[C@@H](CCC)CN2C)[C@H](C)Cl)O[C@@H]1SC,clindamycin-palmitate,Launched,bacterial 50S ribosomal subunit inhibitor,,infectious disease,intra-abdominal infections|skin infections|pneumonia|peritonitis|gynecologic infections
CCC[C@@H]1C[C@@H](C(=O)N[C@@H]([C@H]2O[C@H](SC)[C@H](OP(=O)(O)O)[C@@H](O)[C@H]2O)[C@H](C)Cl)N(C)C1,clindamycin-phosphate,Launched,protein synthesis inhibitor,,obstetrics/gynecology,bacterial vaginosis
CCC(C)(Oc1ccc(C2(c3ccc(O[C@](C)(CC)C(=O)O)cc3)CCCCC2)cc1)C(=O)O,clinofibrate,Launched,lipase clearing factor inhibitor,LPL,endocrinology,hypertriglyceridemia
N=C(NCc1ccc(Cl)cc1)SCCCc1cnc[nH]1,clobenpropit,Preclinical,histamine receptor antagonist,HRH1|HRH2|HRH3|HRH4,,
CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,clobetasol-propionate,Launched,glucocorticoid receptor agonist,NR3C1|PLA2G1B,dermatology,corticosteroid-responsive dermatoses
CCCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@@]21C,clobetasone-butyrate,Launched,corticosteroid agonist,NR3C1,dermatology,eczema|psoriasis|dermatitis
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C,clocortolone-pivalate,Launched,steroid,NR3C1|PLA2G1B,dermatology,corticosteroid-responsive dermatoses
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,clofarabine,Launched,ribonucleotide reductase inhibitor,POLA1|POLD1|POLE|RRM1|RRM2|RRM2B,hematologic malignancy,acute lymphoblastic leukemia (ALL)
CC(C)/N=c1\cc2n(-c3ccc(Cl)cc3)c3ccccc3nc-2cc1Nc1ccc(Cl)cc1,clofazimine,Launched,GK0582 inhibitor,,infectious disease,leprosy
CN(C)CC[C@@](O)(c1ccccc1)c1ccccc1Cl,clofedanol,Launched,histamine receptor antagonist,HRH1,pulmonary,cough suppressant
CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1,clofibrate,Launched,PPAR receptor agonist,LPL|PPARA,endocrinology|cardiology,hyperlipidemia|cholesterol
CC(C)(Oc1ccc(Cl)cc1)C(=O)O,clofibric-acid,Launched,PPAR receptor agonist,PPARA,endocrinology,hyperlipidemia
CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1,clofilium,Phase 2,potassium channel blocker,KCNA5|KCNH1,,
CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1,clofoctol,Launched,protein synthesis inhibitor,,infectious disease,gram-positive bacterial infections
CS(=O)(=O)CS(=O)(=O)OCCCl,clomesone,Phase 1,DNA inhibitor,,,
Cc1ncsc1CCCl,clomethiazole,Launched,GABA receptor antagonist|GABA receptor modulator,GABRA1,neurology/psychiatry,Parkinson's Disease|sedative|muscle relaxant
CCN(CC)CCOc1ccc(/C(=C(\Cl)c2ccccc2)c2ccccc2)cc1,clomifene,Launched,estrogen receptor antagonist,ESR1,obstetrics/gynecology,infertility
CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21,clomipramine,Launched,serotonin transporter (SERT) inhibitor,GSTP1|HTR2A|HTR2B|HTR2C|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,obsessive compulsive disorder (OCD)
Clc1cccc(Cl)c1NC1=NCCN1,clonidine,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C,cardiology|neurology/psychiatry,hypertension|attention-deficit/hyperactivity disorder (ADHD)
Cc1c(Cl)cccc1Nc1ncccc1C(=O)O,clonixin,Preclinical,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology|infectious disease,rheumatoid arthritis|soft tissue infection
C[C@@H]1CCC[C@H](C)N1NC(=O)c1ccc(Cl)c(S(N)(=O)=O)c1,clopamide,Launched,sodium/chloride cotransporter inhibitor,,cardiology,hypertension
Clc1ccc([C@@H](OCCN2CCCCC2)c2ccccc2)cc1,cloperastine,Launched,antitussive,,pulmonary,cough suppressant
Clc1ccc(C(OCCN2CCCCC2)c2ccccc2)cc1,cloperastine-fendizoate,Preclinical,potassium channel antagonist,,,
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,clopidogrel,Launched,purinergic receptor antagonist,P2RY12,cardiology|neurology/psychiatry,myocardial infarction|stroke|peripheral artery disease (PAD)|acute coronary syndrome (ACS)
Cc1[nH]c(C)c(Cl)c(=O)c1Cl,clopidol,Launched,,,infectious disease,coccidiosis
O=C(O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)COc2cccc(Cl)c2)[C@H](O)C[C@@H]1O,cloprostenol-(+/-),Launched,prostaglandin receptor agonist,PTGDR|PTGER1|PTGER3|PTGFR|TBXA2R,obstetrics/gynecology,endometriosis
CC(C)(C)NC[C@@H](O)COc1cc(Cl)ccc1Cl,cloranolol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,cardiology,hypertension
C#CCN(C)CCCOc1ccc(Cl)cc1Cl,clorgiline,Phase 2,monoamine oxidase inhibitor,MAOA,,
CN1CCN([C@H]2Cc3ccccc3Sc3ccc(Cl)cc32)CC1,clorotepine,Launched,adrenergic receptor antagonist|dopamine receptor antagonist,ADRA1A|ADRA1B|ADRA1D|DRD2|HRH1|HTR2C|HTR6,neurology/psychiatry,psychosis
CC(C)NC[C@@H](O)c1ccccc1Cl,clorprenaline,Launched,adrenergic receptor agonist,ADRB1|ADRB2,pulmonary,asthma
Nc1cc(C(Cl)=C(Cl)Cl)c(S(N)(=O)=O)cc1S(N)(=O)=O,clorsulon,Launched,glycolysis inhibitor,,infectious disease,gastrointestinal roundworms|lungworms|liver flukes|lice|mites
Cc1cc([C@@H](C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O,closantel,Launched,chitinase inhibitor|NFkB pathway inhibitor,,infectious disease,liver flukes
CN1CCN(C2=Nc3ccccc3Sc3ccc(Cl)cc32)CC1,clotiapine,Launched,,,neurology/psychiatry,psychosis
Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1,clotrimazole,Launched,cytochrome P450 inhibitor|imidazoline receptor ligand,CYP3A4|KCNN4|NR1I2|NR1I3|TRPM2|TRPM4|TRPM8,infectious disease,vulvovaginal candidiasis|oropharyngeal candidiasis
Cc1onc(-c2ccccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O,cloxacillin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections
Oc1ccc(Cl)c2cccnc12,cloxyquin,Preclinical,potassium channel activator,KCNK18,,
CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1,clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CALY|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HRH4|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR3A|HTR5A|HTR6|HTR7,neurology/psychiatry,schizophrenia
Cc1cccc(F)c1C(=O)Nc1cnc(-c2cc3c(cc2Cl)OC(F)(F)O3)cn1,CM-4620,Phase 2,calcium release activated channel modulator,,,
O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1,CMPD-1,Preclinical,p38 MAPK inhibitor,GNRHR|MAPK14,,
N#Cc1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+](=O)[O-],CNQX,Phase 1,glutamate receptor antagonist,GRIA1|GRIA2|GRIA3|GRIA4,,
C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(NC4CN(CCF)C4)cc3OC)ncc2C(F)(F)F)c1,CNX-2006,Preclinical,EGFR inhibitor,EGFR,,
C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(Oc4ccnc(C(=O)NC)c4)cc3)ncc2F)c1,CNX-774,Preclinical,Bruton's tyrosine kinase (BTK) inhibitor,BTK,,
Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1,CO-101244,Preclinical,glutamate receptor antagonist,GRIN2B,,
NC(=O)N/N=C/c1ccc(Oc2ccc(F)cc2)cc1,CO-102862,Phase 1,sodium channel blocker,SCN4A|SCN9A,,
CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,cobicistat,Launched,cytochrome P450 inhibitor,CYP3A4|CYP3A43|CYP3A5|CYP3A7,infectious disease,human immunodeficiency virus (HIV-1)
O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1,cobimetinib,Launched,MEK inhibitor,MAP2K1,oncology,melanoma
CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCS,coenzyme-A,Launched,,ACAT2|CRAT|CS|DBI|HMGCR|KAT2A|KAT2B|KAT5,,
NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1,coenzyme-I,Phase 2,,AASS|ACADS|ADH1A|ADH1B|ADH1C|ADH4|ADH5|ADH7|AKR1B1|AKR1C1|AKR1C2|AKR1C3|AKR1C4|ALDH1A1|ALDH1A2|ALDH1A3|ALDH1B1|ALDH2|ALDH3A1|ALDH3A2|ALDH3B1|ALDH3B2|ALDH4A1|ALDH5A1|ALDH6A1|ALDH7A1|ALDH9A1|AMT|BDH1|BLVRA|BLVRB|CDO1|CYB5R3|CYP17A1|CYP4A11|DHCR7|DHFR|DLAT|DLD|EHHADH|GAPDH|GAPDHS|GLUD1|GLUD2|GPD1|GSR|H6PD|HADH|HADHA|HIBADH|HMGCR|HMOX1|HMOX2|HPGD|HSD11B1|HSD11B2|HSD17B1|HSD17B10|HSD17B2|HSD17B3|HSD17B4|HSD17B7|HSD17B8|HSD3B1|HSD3B2|IDH3A|IDH3B|IDH3G|IMPDH1|IMPDH2|LDHA|LDHAL6A|LDHAL6B|LDHB|LDHC|MDH1|MDH2|ME1|ME2|ME3|MSMO1|MT-ND1|MT-ND2|MT-ND3|MT-ND4|MT-ND4L|MT-ND5|MT-ND6|MTHFD1|MTHFD2|NDUFA1|NDUFA10|NDUFA11|NDUFA12|NDUFA13|NDUFA2|NDUFA3|NDUFA4|NDUFA4L2|NDUFA5|NDUFA6|NDUFA7|NDUFA8|NDUFA9|NDUFAB1|NDUFB1|NDUFB10|NDUFB2|NDUFB3|NDUFB4|NDUFB5|NDUFB6|NDUFB7|NDUFB8|NDUFB9|NDUFC1|NDUFC2|NDUFS1|NDUFS2|NDUFS3|NDUFS4|NDUFS5|NDUFS6|NDUFS7|NDUFS8|NDUFV1|NDUFV2|NDUFV3|NNT|NQO2|NSDHL|OGDH|PDHA1|PDHA2|PDHB|PHGDH|PYCR1|PYCR2|QDPR|RDH5|SORD|TSTA3|TYR|UGDH,,
COC1=C(OC)C(=O)C(C/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C)=C(C)C1=O,coenzyme-Q10,Launched,,,,
O=C(Nc1nc(-c2ccc(O)c(O)c2)c(-c2ccccc2)s1)c1ccc(O)c(O)c1,COH29,Phase 1,ribonucleotide reductase inhibitor,,,
COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2,colchicine,Launched,microtubule inhibitor,GLRA1|GLRA2|TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,rheumatology|endocrinology,gout|fever
C=C[C@@]1(C)CC(=O)[C@]2(O)[C@@]3(C)[C@@H](O)CCC(C)(C)[C@@H]3[C@H](O)[C@H](OC(C)=O)[C@@]2(C)O1,colforsin,Phase 2,adenylyl cyclase activator,ADCY2|ADCY5,,
C=C[C@@]1(C)CC(=O)[C@]2(O)[C@@]3(C)[C@@H](O)CCC(C)(C)[C@@H]3[C@H](OC(=O)CCN(C)C)[C@H](OC(C)=O)[C@@]2(C)O1,colforsin-daproate,Launched,adenylyl cyclase activator,,,
CCCCCCCCCCCCCCCC(=O)OC[C@H](CO[P@@](=O)(O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC,colfosceril-palmitate,Launched,pulmonary surfactant,,pulmonary,respiratory distress syndrome (RDS)
CC(C)CCCC(=O)N[C@@H](CCNCS(=O)(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCNCS(=O)(=O)O)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCNCS(=O)(=O)O)NC(=O)[C@H](CCNCS(=O)(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCNCS(=O)(=O)O)NC1=O)[C@@H](C)O,colistimethate,Launched,bacterial permeability inducer,,infectious disease,gram-negative bacterial infections
CC[C@@H](C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@H](C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O,colistin,Launched,bacterial permeability inducer,,infectious disease,gram-negative bacterial infections|gram-negative bacterial infections
COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1O,combretastatin-A-4,Phase 2,tubulin polymerization inhibitor,,,
O=c1cc(N2CCOCC2)nc2c3ccccc3ccn12,compound-401,Preclinical,DNA dependent protein kinase inhibitor,MTOR|PRKDC,,
COc1cccc(CN2C[Si](C)(C)O[Si](C)(C)C2)c1,compound-58112,Preclinical,,,,
O=C(O)c1cc(Oc2ccc([N+](=O)[O-])cc2)cc(Oc2ccc([N+](=O)[O-])cc2)c1,compound-w,Preclinical,beta-secretase inhibitor,BACE1,,
Cc1nc2c([nH]1)CCN(C(=O)c1ccc(NC(=O)c3ccccc3-c3ccccc3)cc1)c1ccccc1-2,conivaptan,Launched,vasopressin receptor antagonist,AVPR1A|AVPR2,endocrinology,hyponatremia
C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C=O)[C@H]4CC[C@]5(C)[C@@H](C6=CC(=O)OC6)CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)[C@H](O)[C@H](O)[C@H]1O,convallatoxin,Preclinical,cardiac glycoside,,,
COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21,copanlisib,Launched,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,hematologic malignancy,follicular lymphoma
N[C@H](Cc1cnc[nH]1)C(=O)O,copper-histidine,Phase 3,,SLC15A3|SLC15A4|SLC38A5,,
CCCCCn1cc(C(=O)NC23CC4CC(CC(C4)C2)C3)c(=O)c2cc(-c3ccccc3)ccc21,COR-170,Preclinical,cannabinoid receptor inverse agonist,CNR2,,
Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)C[C@H]1O,cordycepin,Phase 1/Phase 2,DNA inhibitor,,,
C[C@H]1[C@H](C)CC[C@]2(C(=O)O)CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@]43C)[C@H]12,corosolic-acid,Phase 2,PKC inhibitor|protein tyrosine kinase inhibitor,HSD11B1|PTPN1,,
CCOC[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCN(S(=O)(=O)c1ccc(C(F)(F)F)cc1)C2,CORT-108297,Preclinical,glucocorticoid receptor antagonist,,,
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2C(=O)CO,corticosterone,Preclinical,mineralocorticoid receptor agonist,HSD11B1|NCOA1|NR3C2,,
C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO,cortisone,Launched,glucocorticoid receptor agonist,NR3C1,gastroenterology|rheumatology|dermatology,ulcerative colitis|rheumatoid arthritis|psoriasis|joint inflammation|eczema
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C,cortisone-acetate,Launched,glucocorticoid receptor agonist,NR3C1,pulmonary|rheumatology|allergy|dermatology|ophthalmology|gastroenterology|infectious disease,asthma|rheumatoid arthritis|urticaria|osteoarthritis|psoriasis|allergic rhinitis|conjunctivitis|ulcerative colitis|meningitis
C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO,cortodoxone,Phase 3,androgen receptor antagonist,AR,,
C=C1C(=O)O[C@@H]2/C=C(\C)CC/C=C(\C)CC[C@@H]12,costunolide,Preclinical,telomerase inhibitor,,,
N#Cc1cnc2c(Cl)cc(NCc3cn(CCN4CCCCCC4)nn3)cc2c1Nc1ccc(F)c(Cl)c1,cot-inhibitor-1,Preclinical,MAPK-interacting kinase inhibitor,MAP3K8,,
CCN1CCC(n2cc(CNc3cc(Cl)c4ncc(C#N)c(Nc5ccc(F)c(Cl)c5)c4c3)nn2)CC1,cot-inhibitor-2,Preclinical,MAPK-interacting kinase inhibitor,MAP3K8,,
S=C(N/N=C1\CCCc2cccnc21)N1CCN(c2ccccn2)CC1,COTI-2,Phase 1,anticancer agent,,,
CN1C(=O)CC[C@H]1c1cccnc1,cotinine,Phase 2,nicotine metabolite,,,
O=c1ccc2ccccc2o1,coumarin,Launched,vitamin K antagonist,CA1|CA12|CA14|CA2|CA4|CA6|CA9|CYP2A6,gastroenterology|pulmonary,ulcerative colitis|asthma|celiac disease
CCOP(=S)(OCC)Oc1ccc2c(C)c(Cl)c(=O)oc2c1,coumophos,Preclinical,cholinesterase inhibitor,,,
O=C(O)C1(c2ccc3c(c2)OC[C@H](Cc2ccc(-c4ccccc4)cc2)[C@H]3O)CCCC1,"CP-105,696",Preclinical,leukotriene receptor antagonist,,,
CON(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1,CP-316819,Preclinical,glycogen phosphorylase inhibitor,PYGL,,
CCCCC/N=c1\ccn(Cc2ccccc2)c2ccccc12,CP-339818,Preclinical,potassium channel blocker,KCNA3,,
CCC(CC)Nc1cc(C)nc(Oc2c(C)cc(C)cc2C)c1C,CP-376395,Phase 1,corticotropin releasing factor receptor antagonist,CRHR1,,
CC(C)(NS(=O)(=O)c1ccc(Oc2ccc(F)cc2)cc1)C(=O)NO,CP-471474,Preclinical,matrix metalloprotease inhibitor,MMP1|MMP13|MMP2|MMP3|MMP9,,
CC[C@@H]1C[C@H](N(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)C(C)=O)c2cc(C(F)(F)F)ccc2N1C(=O)OC(C)C,CP-532623,Phase 1,cholesteryl ester transfer protein inhibitor,CETP,,
NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1,CP-547632,Phase 2,kinase inhibitor,,,
O=C(c1c2ccccc2cc2ccccc12)N1CCC(N2CCC[C@@H](C(=O)N3CCOCC3)C2)CC1,CP-640186,Preclinical,acetyl-CoA carboxylase inhibitor,ACACA|ACACB,,
COCCOc1ccc2c(c1)ncn2-c1ccc2cccc(N3CCC(N)CC3)c2n1,CP-673451,Preclinical,PDGFR tyrosine kinase receptor inhibitor,KIT|PDGFRA|PDGFRB,,
COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,CP-724714,Phase 2,EGFR inhibitor|protein tyrosine kinase inhibitor,ERBB2,,
CC(C)c1ccc(CC(=O)N2CCC[C@@H](c3cccc(OC(C)(C)C(=O)O)c3)C2)cc1,CP-775146,Preclinical,PPAR receptor agonist,PPARA,,
CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1,CP-91149,Preclinical,glycogen phosphorylase inhibitor,PYGL,,
O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1,CP-93129,Preclinical,serotonin receptor agonist,HTR1A,,
CCCOc1ccc2[nH]cc(C3=CCNCC3)c2n1,CP-94253,Preclinical,serotonin receptor agonist,HTR1B,,
CCNC1(C(N)=O)CCN(c2ncnc3c2nc(-c2ccccc2Cl)n3-c2ccc(Cl)cc2)CC1,"CP-945,598",Phase 3,cannabinoid receptor antagonist,CNR1,,
COc1ccccc1CN[C@H]1CCCN[C@H]1c1ccccc1,CP-99994,Phase 2,tachykinin antagonist,TACR1,,
O=C(O)[C@H](Cc1ccccc1)CN(O)C(=O)Cc1ccccc1,CPA-inhibitor,Preclinical,carboxypeptidase inhibitor,CPA1|CPA2,,
CCOC(=O)[C@]12C[C@H]1/C(=N\O)c1ccccc1O2,CPCCOEt,Preclinical,glutamate receptor antagonist,GRM1,,
Cc1noc2c1-c1ccccc1C(c1ccc(Cl)cc1)=N[C@H]2CC(N)=O,CPI-0610,Phase 2,bromodomain inhibitor,BRD4,,
CC(=O)Nc1ccc(C(=O)NC(C)(C)C)cc1,CPI-1189,Phase 2,tumor necrosis factor release inhibitor,TNF,,
COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCN(CC(F)(F)F)CC2)c2ccccc12,CPI-1205,Phase 1/Phase 2,EZH2 inhibitor,,,
CCS(=O)(=O)N1CCC([C@@H](C)n2c(C)c(C(=O)NCc3c(OC)cc(C)[nH]c3=O)c3ccccc32)CC1,CPI-169,Preclinical,histone lysine methyltransferase inhibitor,EZH2,,
Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@@H](CC(N)=O)c1nnc(C)n1-2,CPI-203,Preclinical,bromodomain inhibitor,BRD4,,
COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCOCC2)c2ccccc12,CPI-360,Preclinical,histone lysine methyltransferase inhibitor,EZH2,,
Cc1ccc(-c2nc(N)nc3c2nnn3Cc2cccc(CO[C@H]3CCOC3)n2)o1,CPI-444,Phase 1/Phase 2,adenosine receptor antagonist,,,
O=C(O)CCCC[C@@H](CCSCc1ccccc1)SCc1ccccc1,CPI-613,Phase 3,pyruvate dehydrogenase inhibitor,PDHA1,,
O=C(O)[C@H]1CN(CCCP(=O)(O)O)CCN1,CPP,Phase 2,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,,
O=C(C[C@H]1CC(c2ccc(F)cc2F)=NO1)N1CCOCC1,CPSI-1306-(+/-),Preclinical,macrophage migration inhibiting factor inhibitor,MIF,,
Nc1ccc(S(=O)(=O)Nc2cnc3c(Cl)cccc3n2)cc1,CQS,Preclinical,,,,
CC[C@H](CO)Nc1nc(NCc2ccc(-c3ccccn3)cc2)c2ncn(C(C)C)c2n1,CR8-(R),Preclinical,CDK inhibitor,CCNA2,,
CN(CC(=O)O)C(=N)N,creatine,Launched,,CKB|CKM|CKMT1A|CKMT2|GAMT|SLC6A8,,
CN1CC(=O)NC1=N,creatinine,Preclinical,,,,
C[C@H](NC(=O)CCC(F)(F)F)C(=O)N[C@@H]1C(=O)N(CCO)c2ncccc2-c2ccccc21,crenigacestat,Preclinical,notch signaling inhibitor,,,
CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1,crenolanib,Phase 3,PDGFR tyrosine kinase receptor inhibitor,CSF1R|FLT3|KIT|PDGFRA|PDGFRB,,
Cc1ccc(O)cc1,cresol,Launched,,,,
CC(=O)Oc1c(C)cccc1C(=O)O,cresopirine,Preclinical,,,,
O=C(O)Cn1c2ccccc2c(=O)c2ccccc21,cridanimod,Launched,progesterone receptor agonist,PGR,infectious disease,influenza A virus infection
N#Cc1ccc(Oc2ccc3c(c2)COB3O)cc1,crisaborole,Launched,phosphodiesterase inhibitor,PDE4A|PDE4B|PDE4C|PDE4D,dermatology,dermatitis
O=C(O)c1cc(NCCc2ccc(C(F)(F)F)cc2)ccc1O,crisdesalazine,Preclinical,free radical scavenger,,,
C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,crizotinib,Launched,ALK tyrosine kinase receptor inhibitor,ALK|MET,oncology,non-small cell lung cancer (NSCLC)
C[C@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,crizotinib-(S),Preclinical,MTH1 inhibitor,NUDT1,,
C=C(c1ccccc1OCc1cccc(Cl)c1)n1ccnc1,croconazole,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,fungal infection
COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC,crolibulin,Phase 1/Phase 2,tubulin polymerization inhibitor,,,
CC1(C)Oc2ccc(C#N)cc2[C@@H](N2CCCC2=O)[C@@H]1O.CC1(C)Oc2ccc(C#N)cc2[C@H](N2CCCC2=O)[C@H]1O,cromakalim,Phase 2,,KCNJ8,,
O=C(O)c1cc(=O)c2c(OCC(O)COc3cccc4oc(C(=O)O)cc(=O)c34)cccc2o1,cromoglicic-acid,Launched,immunosuppressant,KCNMA1|S100P,pulmonary|ophthalmology|allergy|gastroenterology,asthma|conjunctivitis|urticaria|ulcerative colitis
C/C=C/C(=O)N(CC)c1ccccc1C,crotamiton,Launched,antipruritic,,infectious disease,scabies
O=C(O)c1cc2cccc([N+](=O)[O-])c2[nH]1,CRT0044876,Preclinical,,,,
C[C@H]1COC2=C1C(=O)C(=O)c1c2ccc2c1CCCC2(C)C,cryptotanshinone,Preclinical,acetylcholinesterase inhibitor|STAT inhibitor,STAT3,,
CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1,crystal-violet,Launched,other antibiotic,,,
c1ccc2sc(C3(N4CCCCC4)CCCCC3)cc2c1,CS-110266,Preclinical,dopamine receptor agonist,SLC6A3,,
CC(C)Cc1sc(N)nc1-c1ccc(P(=O)(O)O)o1,CS-917,Phase 2,fructose biphosphate inhibitor,FBP1,,
O=C(O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C12CCCCC2,CT-7758,Phase 2,integrin antagonist,ITGA4,,
CC(C)c1cnn2c(NCc3ccccc3)cc(NC[C@H]3CCNC[C@@H]3O)nc12,CT7001,Phase 1/Phase 2,CDK inhibitor,,,
Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1,CTEP,Preclinical,glutamate receptor antagonist,GRM5,,
O=C(NO)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1,CTS-1027,Phase 2,metalloproteinase inhibitor,MMP1|MMP13|MMP2|MMP3|MMP9,,
CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(=O)O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O,CTS21166,Phase 1,beta-secretase inhibitor,BACE1,,
O=C(N[C@H](Cc1ccccc1)C(=O)O)c1sc2cc(F)ccc2c1Cl,CU-CPT-4a,Preclinical,toll-like receptor inhibitor,TLR3,,
CNc1ccc([N+](=O)[O-])cc1-n1cnc(-c2ccc(C(F)(F)F)cc2)c1,CU-T12-9,Preclinical,toll-like receptor agonist,TLR1|TLR2,,
C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCC(=O)NO)cc23)c1,CUDC-101,Phase 1,EGFR inhibitor,EGFR|ERBB2,,
CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1sc(-c2ncco2)nc1-c1ccccc1)C1CCCCC1,CUDC-427,Phase 1,apoptosis inhibitor,XIAP,,
COc1ccc(-c2nc(N3CCOCC3)c3sc(CN(C)c4ncc(C(=O)NO)cn4)cc3n2)cn1,CUDC-907,Phase 2,PI3K inhibitor,HDAC2|PIK3R1,,
COc1cccc(CN(C(=O)CC(C)(C)C)[C@H]2C[C@@H](C(=O)N3CCNCC3)N(Cc3ccc4c(c3)OCO4)C2)c1,CUR-61414,Phase 1,smoothened receptor antagonist,DHH|IHH|SMO,,
COc1cc(/C=C/C(=O)C=C(O)/C=C/c2ccc(O)c(OC)c2)ccc1O,curcumin,Launched,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,APP|CA1|CA12|CA14|CA2|CA4|CA6|CA9|CHRM3|CYP3A4|DNMT3B|EP300|MMP13|MMP9|NOS2|PTGS1|PTGS2|XDH,,
C=C1C[C@@]2(O)O[C@@]3(C[C@H]2C(C)C)[C@@H](C)CC[C@@H]13,curcumol,Phase 1,JAK inhibitor,JAK1|JAK2|JAK3,,
COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC,cutamesine,Phase 2,sigma receptor agonist,SIGMAR1,,
Nc1nc(Nc2ccccc2)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,CV-1808,Preclinical,adenosine receptor agonist,ADORA2A,,
CS(=O)(=O)Nc1ccc(-c2coc3cc(OCc4cccc(C(=O)O)c4)ccc3c2=O)cc1,CVT-10216,Phase 1,aldehyde dehydrogenase inhibitor,ALDH2,,
COc1ccn2ncc(-c3nc4n[nH]c(NC(=O)c5ccc(F)cc5)c4cc3F)c2c1,CW-008,Preclinical,PKA activator,PRKACA,,
O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12,CX-4945,Phase 1/Phase 2,casein kinase inhibitor,CSNK2A1|CSNK2A2|DAPK3|HIPK3,,
O=C(c1ccc2c(c1)OCO2)N1CCCCC1,CX-516,Phase 2/Phase 3,glutamate receptor modulator,,,
Cc1cnc(CNC(=O)c2c(=O)c3ccc(N4CCCN(C)CC4)nc3n3c2sc2ccccc23)cn1,CX-5461,Phase 1,RNA polymerase inhibitor,,,
Cc1nn(C)cc1CN1CCC(c2ccc(C(=O)Nc3ccccc3N)cc2)CC1,CXD101,Phase 1/Phase 2,HDAC inhibitor,,,
CN1Cc2ccccc2[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,CY208-243,Phase 2,dopamine receptor agonist,CALY,,
N#CCC(=O)NN,cyacetacide,Preclinical,,,,
C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccc(C#N)cc21,cyamemazine,Launched,serotonin receptor antagonist,HTR1A|HTR2A|HTR2C|HTR7,neurology/psychiatry,schizophrenia|anxiety
C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4/[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)O[P@](=O)(O)O[C@H]1[C@@H](O)[C@@H](n6cnc7cc(C)c(C)cc76)O[C@@H]1CO)[C@H]5CC(N)=O)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O,cyanocobalamin,Launched,methylmalonyl CoA mutase stimulant|vitamin B,MUT,hematology|infectious disease|gastroenterology,anemia|fish tapeworm infestation|celiac disease
CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(C#N)cc12,cyanopindolol,Phase 2,adrenergic receptor antagonist,ADRB1|HTR1A|HTR1D,,
CC[C@H](Nc1nc(NCc2cnc(C)cc2C)c2ncn(C(C)C)c2n1)[C@@H](C)O,CYC065,Phase 1,CDK inhibitor,,,
Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1,CYC116,Phase 1,Aurora kinase inhibitor,AURKA|AURKB|KDR,,
O=S(=O)(O)NC1CCCCC1,cyclamic-acid,Preclinical,,,,
C[C@H]1C[C@H](OC(=O)[C@@H](O)c2ccccc2)CC(C)(C)C1,cyclandelate,Launched,calcium channel blocker,,cardiology|rheumatology,claudication|arteriosclerosis|Raynaud's disease
Nc1ncnc2c1ncn2[C@H]1O[C@H]2CO[P@@](=O)(O)O[C@@H]2[C@@H]1O,cyclic-AMP,Preclinical,,CNGA3|TRPM7,,
CN1CCN(C(c2ccccc2)c2ccccc2)CC1,cyclizine,Launched,histamine receptor modulator,HRH1|SULT1E1,gastroenterology|neurology/psychiatry,nausea|vomiting|vertigo|motion sickness
CN(C)CCC=C1c2ccccc2C=Cc2ccccc21,cyclobenzaprine,Launched,adrenergic receptor agonist|serotonin receptor agonist,HTR2A,neurology/psychiatry,spasms
NC1=NCCN1CC(=O)O,cyclocreatine,Phase 1,creatine kinase substrate,,,
N=c1ccn2c(n1)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]12,cyclocytidine,Preclinical,DNA synthesis inhibitor|RNA synthesis inhibitor,,,
C[C@@H]1C[C@@H]([C@H](O)CC2CC(=O)NC(=O)C2)C(=O)[C@@H](C)C1,cycloheximide,Preclinical,protein synthesis inhibitor,RPL3,,
CC1=C2C[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]2CC[C@]12O[C@@H]1C[C@H](C)CN[C@H]1[C@H]2C,cyclopamine,Preclinical,hedgehog pathway inhibitor,,,
NS(=O)(=O)c1cc2c(cc1Cl)N[C@@H](CC1CCCC1)NS2(=O)=O,cyclopenthiazide,Launched,thiazide diuretic,,cardiology,hypertension|congestive heart failure
CN(C)CCOC(=O)[C@@H](c1ccccc1)C1(O)CCCC1,cyclopentolate,Launched,acetylcholine receptor antagonist,,ophthalmology,mydriasis|cycloplegia
O=[P@]1(N(CCCl)CCCl)NCCCO1,cyclophosphamide,Launched,DNA alkylating agent,CYP2A6|CYP2B6|CYP2C18|CYP2C19|CYP2C8|CYP2C9|CYP2D6|CYP3A4|CYP3A5|CYP3A7,hematologic malignancy|oncology,Hodgkin's lymphoma|small lymphocytic lymphoma (SLL)|breast cancer|neuroblastoma|Burkitt's lymphoma|multiple myeloma|chronic lymphocytic leukemia (CLL)|acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)|chronic myeloid leukemia (CML)|true histiocytic lymphoma (THL)|retinoblastoma|ovarian cancer
CC(=O)C1=C(O)[C@@H]2[C@H]3c4c[nH]c5cccc(c45)C[C@H]3C(C)(C)N2C1=O,cyclopiazonic-acid,Preclinical,ATPase inhibitor,ATP2A1,,
N[C@@H]1CONC1=O,cycloserine-(D),Launched,bacterial cell wall synthesis inhibitor,GRIN1,infectious disease,tuberculosis|tuberculosis
C/C=C/C[C@H](C)[C@H](O)[C@@H]1C(=O)N[C@H](CC)C(=O)N(C)CC(=O)N(C)[C@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@H](CC(C)C)C(=O)N[C@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@H](CC(C)C)C(=O)N(C)[C@H](CC(C)C)C(=O)N(C)[C@H](C(C)C)C(=O)N1C,cyclosporin-A,Launched,calcineurin inhibitor,ABCB11|CAMLG|FPR1|PPIA|PPIF|PPP3CA|PPP3R2|SLC10A1|SLCO1B1|SLCO1B3,rheumatology|dermatology,rheumatoid arthritis|psoriasis
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,cyclosporin-A,Launched,calcineurin inhibitor,ABCB11|CAMLG|FPR1|PPIA|PPIF|PPP3CA|PPP3R2|SLC10A1|SLCO1B1|SLCO1B3,rheumatology|dermatology,rheumatoid arthritis|psoriasis
NS(=O)(=O)c1cc2c(cc1Cl)N[C@H]([C@H]1C[C@@H]3C=C[C@H]1C3)NS2(=O)=O,cyclothiazide,Launched,glutamate receptor modulator,CA2|GRIA1|GRIA2|GRIA3|GRIA4|SLC12A3,cardiology,hypertension
COc1cc(/C=C2\CCC/C(=C\c3ccc(O)c(OC)c3)C2=O)ccc1O,cyclovalone,Launched,breast cancer resistance protein inhibitor,ABCG2,gastroenterology,bile stimulation
CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](NC)CC[C@@]45C[C@@]35CC[C@]12C,cyclovirobuxin-D,Preclinical,calcium channel modulator,,,
O=C(O)[C@H]1CSC(c2nc3cc4c(cc3s2)NCC4)=N1,CycLuc1,Preclinical,,,,
FCc1ccc(OCCOc2ccc(Cl)cc2Cl)c(Cl)n1,CYM-50260,Preclinical,sphingosine 1-phosphate receptor agonist,S1PR4,,
Cc1cc(CN)cc(C)c1NC(=O)c1ccc(-c2cc(Cl)ccc2Cl)o1,CYM-50358,Preclinical,sphingosine 1-phosphate receptor antagonist,S1PR4,,
COc1ccc(Oc2c(Cl)cnn(C3c4ccccc4-c4ccccc43)c2=O)cc1,CYM-50769,Preclinical,neuropeptide receptor antagonist,NPBWR1,,
CCOc1ccc(-c2nc(-c3cccc4c3CC[C@H]4NCCO)no2)cc1OCC,CYM-5442,Preclinical,sphingosine 1-phosphate receptor agonist,S1PR1,,
Cc1cc(C(=O)Cn2cc(C#N)ccc2=O)c(C)n1Cc1ccccc1,CYM-5520,Preclinical,sphingosine 1-phosphate receptor agonist,S1PR2,,
O=C(c1cc(C2CC2)on1)N(C1CCCCC1)C1CCCCC1,CYM-5541,Preclinical,sphingosine 1-phosphate receptor agonist,S1PR3,,
CC1(C)[C@@H](C=C(Cl)Cl)[C@@H]1C(=O)O[C@@H](C#N)c1cccc(Oc2ccccc2)c1,cypermethrin,Launched,,,infectious disease,flea control
CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1,cyproheptadine,Launched,histamine receptor antagonist,ADRA1A|ADRA1B|ADRA1D|CHRM1|CHRM2|CHRM3|HRH1|HTR2A|HTR2C|HTR6|HTR7,allergy|otolaryngology|ophthalmology|dermatology,allergic rhinitis|vasomotor rhinitis|conjunctivitis|urticaria|dermatographism
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C,cyproterone-acetate,Launched,androgen receptor antagonist,ADORA1|AR,oncology,prostate cancer
Nc1nc(N)nc(NC2CC2)n1,cyromazine,Launched,,,,
CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1,CYT-997,Phase 2,tubulin polymerization inhibitor,TUBB,,
N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1,cyt387,Phase 3,JAK inhibitor,JAK1|JAK2|JAK3,,
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,cytarabine,Launched,ribonucleotide reductase inhibitor,POLA1|POLB|POLD1|POLE,hematologic malignancy,acute lymphoblastic leukemia (ALL)|chronic lymphocytic leukemia (CLL)|acute myeloid leukemia (AML)|non-Hodgkin lymphoma (NHL)
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,cytidine,Launched,,,,
O=c1cccc2n1C[C@@H]1CNC[C@H]2C1,cytisine,Launched,acetylcholine receptor agonist,CHRNA2|CHRNA3|CHRNA4|CHRNA6|CHRNA7|CHRNB2|CHRNB4,neurology/psychiatry,nicotinism
C=C1[C@@H](C)[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]23OC(=O)/C=C/[C@H](O)CCC[C@@H](C)C/C=C/[C@H]3[C@@H]1O,cytochalasin-B,Phase 2,microtubule inhibitor,ACTB,,
Nc1nc(=O)n([C@H]2C[C@@H](O)[C@@H](CO)O2)cc1Cl,cytochlor,Phase 1,,,,
COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1,CZC-54252,Preclinical,leucine rich repeat kinase inhibitor,LRRK2,,
CC(C)(C)NS(=O)(=O)c1cncc(-c2cc(F)c3nc(N)nn3c2)c1,CZC24832,Preclinical,PI3K inhibitor,PIK3CG,,
OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O,D-(+)-maltose,Preclinical,,MGAM,,
Nc1nc(N)c2c(OCC3CCN(Cc4c(Cl)cccc4Cl)CC3)cccc2n1,D-157495,Preclinical,decapping scavenger enzyme inhibitor,,,
COc1ccc2c(c1)n(CCN)c(=O)n2C(=O)[C@@H]1C[C@H](C)CC[C@H]1C(C)C,D-3263,Phase 1,transient receptor potential channel agonist,,,
NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCCO4)[nH]2)cc1,D-4476,Preclinical,TGF beta receptor inhibitor,CSNK1A1|CSNK1D|TGFB1,,
COc1ccc2[nH]c(C(=O)c3ccccc3)cc2c1,D-64131,Preclinical,microtubule inhibitor,TUBB,,
Cc1c(C)c2c(c(C)c1OC(=O)CCC(=O)O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2,D-alpha-tocopheryl-succinate,Launched,,,,
Cc1cc(O)cc2c1O[C@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC2,D-delta-tocopherol,Launched,,,,
C=C(C)[C@H]1CC=C(C)CC1,D-limonene,Phase 1,,,,
N[C@H](Cc1ccccc1)C(=O)O,D-phenylalanine,Preclinical,enkephalinase inhibitor,CCBL1|CRH|HCAR3,,
N[C@H](CO)C(=O)O,D-serine,Launched,glutamate receptor agonist,GLRA1|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|SERPINB3,,
S=C(S)OC1CC2CC1C1CCCC21,D609,Preclinical,phospholipase inhibitor,,,
COc1ccc(OC)c(CN(C(C)=O)c2cc(F)ccc2Oc2ccccc2)c1,DAA-1106,Preclinical,benzodiazepine receptor agonist,TSPO,,
Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,dabigatran,Launched,thrombin inhibitor,F2,neurology/psychiatry|hematology,stroke|systemic embolism|pulmonary embolism (PE)|deep vein thrombosis (DVT)
CCCCCCOC(=O)/N=C(/N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1,dabigatran-etexilate,Launched,thrombin inhibitor,F2,neurology/psychiatry|hematology,stroke|systemic embolism|pulmonary embolism (PE)|deep vein thrombosis (DVT)
CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,dabrafenib,Launched,RAF inhibitor,BRAF|LIMK1|NEK11|RAF1|SIK1,oncology,melanoma
CN(C)/N=N/c1nc[nH]c1C(N)=O,dacarbazine,Launched,DNA alkylating agent,PGD|POLA2,oncology|hematologic malignancy,melanoma|Hodgkin's lymphoma
O=C(/C=C/c1ccc(CN(CCO)CCc2c[nH]c3ccccc23)cc1)NO,dacinostat,Phase 1,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9,,
COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc(-c2ccc(-c3ccc(-c4c[nH]c([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)n4)cc3)cc2)c[nH]1)C(C)C,daclatasvir,Launched,HCV inhibitor,,infectious disease,hepatitis C
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1,dacomitinib,Launched,EGFR inhibitor,EGFR|ERBB2|ERBB4,,
Cc1c2oc3c(C)ccc(C(=O)N[C@@H]4C(=O)N[C@H](C(C)C)C(=O)N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)c3nc-2c(C(=O)N[C@@H]2C(=O)N[C@H](C(C)C)C(=O)N3CCC[C@H]3C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]2C)c(N)c1=O,dactinomycin,Launched,RNA polymerase inhibitor,POLR2A,oncology,testicular carcinoma|Wilm's tumor|rhabdomyosarcoma|Ewing's sarcoma|gestational trophoblastic disease (GTD)
O=c1c(-c2ccc(O)cc2)coc2cc(O)ccc12,daidzein,Phase 2,estrogen receptor agonist,ESRRA|ESRRB|ESRRG|TRPC5,,
O=c1c(-c2ccc(O)cc2)coc2cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc12,daidzin,Phase 1,antioxidant,ALDH2,,
CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(=N)N)C(=O)O,dalargin,Phase 2,opioid receptor agonist,OPRM1,,
CN[C@H]1C(=O)N[C@@H]2Cc3ccc(cc3)Oc3cc4cc(c3O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3NC(=O)CCCCCCCCC(C)C)Oc3ccc(cc3Cl)[C@@H](O)[C@@H]3NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@@H](NC2=O)c2cc(cc(O)c2Cl)Oc2cc1ccc2O)c1ccc(O)c(c1)-c1c(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)cc(O)cc1[C@@H](C(=O)NCCCN(C)C)NC3=O,dalbavancin,Launched,bacterial cell wall synthesis inhibitor,PNLIP,infectious disease,skin infections
CCC(CC)CC1(C(=O)Nc2ccccc2SC(=O)C(C)C)CCCCC1,dalcetrapib,Phase 3,cholesteryl ester transfer protein inhibitor,CETP,,
Nc1ccncc1,dalfampridine,Launched,potassium channel blocker,KCNA1|KCNA10|KCNA2|KCNA3|KCNA4|KCNA5|KCNA6|KCNA7|KCNB1|KCNB2|KCNC1|KCNC2|KCNC3|KCNC4|KCND1|KCND2|KCND3|KCNF1|KCNG1|KCNG2|KCNG3|KCNG4|KCNH1|KCNH2|KCNH3|KCNH4|KCNH5|KCNH6|KCNH7|KCNH8|KCNJ13|KCNJ5|KCNQ1|KCNQ2|KCNQ3|KCNQ4|KCNQ5|KCNS1|KCNS2|KCNS3|KCNV1|KCNV2,neurology/psychiatry,multiple sclerosis
CCN(CC)CCS(=O)(=O)[C@@H]1CCN2C(=O)c3coc(n3)CC(=O)C[C@H](O)/C=C(C)/C=C\CNC(=O)/C=C/[C@@H](C)[C@H](C(C)C)OC(=O)[C@@H]12,dalfopristin,Preclinical,antibacterial ,,,
O=C(O)Cc1ccc(CCNS(=O)(=O)c2ccc(Cl)cc2)cc1,daltroban,Phase 3,thromboxane receptor antagonist,TBXA2R,,
CN(C)NC(=O)CCC(=O)O,daminozide,Preclinical,KDM2A inhibitor,KDM2A|KDM7A|PHF8,,
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C,danazol,Launched,estrogen receptor antagonist|progesterone receptor agonist,AR|CCL2|ESR1|GNRHR|GNRHR2|PGR,obstetrics/gynecology|cardiology,endometriosis|angioedema
NCC(=O)N1C[C@H](NC(=O)c2ccccc2)C[C@H]1C(=O)O,danegaptide,Phase 2,gap junction modulator,,,
Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@H]2CCCNC2)c1O,danirixin,Phase 2,CC chemokine receptor antagonist,CXCR2,,
CN1C[C@@H]2C[C@H]1CN2c1cc2c(cc1F)c(=O)c(C(=O)O)cn2C1CC1,danofloxacin,Launched,bacterial DNA gyrase inhibitor,,pulmonary,bovine respiratory disease (BRD)
CC(C)(C)OC(=O)N[C@H]1CCCCC/C=C\[C@@H]2C[C@@]2(C(=O)NS(=O)(=O)C2CC2)NC(=O)[C@@H]2C[C@@H](OC(=O)N3Cc4cccc(F)c4C3)CN2C1=O,danoprevir,Phase 3,HCV inhibitor,,,
O=C1CN(/N=C/c2ccc(-c3ccc([N+](=O)[O-])cc3)o2)C(=O)N1,dantrolene,Launched,calcium channel blocker,RYR1|RYR3,neurology/psychiatry|endocrinology,spasms|malignant hyperthermia (MH)
CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1,danusertib,Phase 2,Aurora kinase inhibitor|growth factor receptor inhibitor,AURKA|AURKB|AURKC|FGFR1|NTRK1|RET|SLK,,
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,dapagliflozin,Launched,sodium/glucose cotransporter inhibitor,SLC5A1|SLC5A2,endocrinology,diabetes mellitus
CS(=O)(=O)CCC#N,dapansutrile,Phase 2,anti-inflammatory agent,,,
O=c1ccc2ccc(O)c(O)c2o1,daphnetin,Preclinical,protein kinase inhibitor,,,
Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1,dapiprazole,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D,ophthalmology,mydriasis
Cc1cc(C)c(Nc2ccnc(Nc3ccc(C#N)cc3)n2)c(C)c1,dapivirine,Phase 3,non-nucleoside reverse transcriptase inhibitor,CYP3A4|CYP3A5,,
CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1,dapoxetine,Launched,selective serotonin reuptake inhibitor (SSRI),HTR1A|HTR1B|HTR2C|SLC6A4,urology,premature ejaculation (PE)
O=C(O)CNC(=O)c1c(O)n(C2CCCCC2)c(=O)n(C2CCCCC2)c1=O,daprodustat,Phase 3,hypoxia inducible factor inhibitor,EGLN1,,
Nc1ccc(S(=O)(=O)c2ccc(N)cc2)cc1,dapsone,Launched,bacterial antifolate,DHFR,dermatology|infectious disease,dermatitis herpetiformis (DH)|leprosy
C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1,DAPT,Preclinical,gamma secretase inhibitor,,,
CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@@H]([C@H](C)CC(=O)O)C(=O)N[C@@H](CC(=O)c2ccccc2N)C(=O)O[C@@H]1C,daptomycin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,skin infections|endocarditis
CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c2c1CCC2,darapladib,Phase 3,phospholipase inhibitor,PLA2G7,,
Cc1oc(-c2ccccc2)nc1CCC(=O)c1ccc(CC2SC(=O)NC2=O)cc1,darglitazone,Phase 2,PPAR receptor antagonist,PPARG,,
NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(CCc2ccc3c(c2)CCO3)C1,darifenacin,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,urology,urinary incontinence
C[C@@H](Cn1ccc(-c2ccc(C#N)c(Cl)c2)n1)NC(=O)c1cc([C@@H](C)O)n[nH]1,darolutamide,Launched,androgen receptor antagonist,AR,oncology,prostate cancer
CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,darunavir,Launched,HIV protease inhibitor,CYP3A4,infectious disease,human immunodeficiency virus (HIV-1)
COc1cc(OC)nc(O[C@H](C(=O)O)C(OC)(c2ccccc2)c2ccccc2)n1,darusentan,Phase 3,endothelin receptor antagonist,EDNRA,,
COc1c(-c2ccc3cc(NS(C)(=O)=O)ccc3c2)cc(-n2ccc(=O)[nH]c2=O)cc1C(C)(C)C,dasabuvir,Launched,HCV inhibitor,,infectious disease,hepatitis C
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,dasatinib,Launched,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,ABL1|ABL2|BLK|EPHA2|FGR|FRK|FYN|HCK|KIT|LCK|LYN|PDGFRB|SRC|SRMS|STAT5B|YES1,hematologic malignancy,chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
N[C@@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,dasotraline,Phase 3,dopamine-norepinephrine-serotonin reuptake inhibitor,,,
CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)N1Cc3ccccc3NC1=O)C2,DAU-5884,Preclinical,acetylcholine receptor antagonist,CHRM3,,
CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C,daucosterol,Phase 2,apoptosis stimulant,,,
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,daunorubicin,Launched,RNA synthesis inhibitor|topoisomerase inhibitor,TOP2A|TOP2B,hematologic malignancy,acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)
Cc1c(Cn2ccnc2)c2ccccc2n1CCC(=O)O,dazmegrel,Phase 2,thromboxane synthase inhibitor,TBXAS1,,
O=C(O)c1ccc(OCCn2ccnc2)cc1,dazoxiben,Phase 2,thromboxane synthase inhibitor,TBXAS1,,
c1ccc(CNc2nc(NCc3ccccc3)c3ccccc3n2)cc1,DBeQ,Preclinical,ATPase inhibitor,CASP3,,
O=C(NN1CCCCC1)c1nn(-c2ccc(Cl)cc2Cl)c(-c2ccc(C#Cc3ccc(C(F)(F)F)cc3)s2)c1CNS(=O)(=O)N1CCCC1,DBPR-211,Preclinical,cannabinoid receptor antagonist,,,
CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N,DBPR108,Phase 1,dipeptidyl peptidase inhibitor,DPP4,,
CCCCc1ccc(NS(=O)(=O)c2ccc(F)cc2)cc1,DC-260126,Preclinical,free fatty acid receptor antagonist,FFAR1,,
Cn1cc(-c2cc(Oc3cc(F)c(NC(=O)C4(C(=O)Nc5ccccc5)CC4)cc3F)ccn2)cn1,DCC-2618,Phase 1,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,KIT|PDGFRA,,
CCn1c(=O)[nH]c2cc(Cl)c(Cl)cc21,DCEBIO,Preclinical,potassium channel activator,KCNN2|KCNN3|KCNN4,,
CCCCC[C@H]1C[C@H]1C[C@H]1C[C@H]1CCCCCCCC(=O)O,DCP-LA,Preclinical,protein kinase activator,,,
CCCC[C@@]1(C2CCCC2)Cc2cc(OCCCC(=O)O)c(Cl)c(Cl)c2C1=O,DCPIB,Preclinical,chloride channel blocker|gap junction modulator|glutamate inhibitor,SLC1A2,,
CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(Oc4ccc5c(c4)CC(=O)N5)c3)cc2C(F)(F)F)CC1,DDR1-IN-1,Preclinical,discoidin domain receptor inhibitor,DDR1|DDR2,,
Nc1cc2[nH]cnc2c(O)n1,deazaguanine,Preclinical,DNA synthesis inhibitor,,,
CN(C)c1cc2c(cc1Sc1nc3c(N)nccc3n1CCNCC(C)(C)C)OCO2,Debio-0932,Phase 1,HSP inhibitor,,,
N=C(N)N1CCc2ccccc2C1,debrisoquin,Launched,adrenergic neuron blocker,SLC6A2,cardiology,hypertension
C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C,decamethonium,Launched,acetylcholine receptor agonist,ACHE|CHRNA2,neurology/psychiatry,muscle relaxant
CC(C)[C@H]1CC[C@@H](C)C[C@@H]1OC(=O)C[N+](C)(C)CCCCCCCCCC[N+](C)(C)CC(=O)O[C@H]1C[C@@H](C)CC[C@@H]1C(C)C,decamethoxine,Phase 2,antiseptic,,,
CC[C@@](C)(Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(=O)NCC(F)(F)F,decernotinib,Phase 2/Phase 3,JAK inhibitor,JAK3,,
Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,decitabine,Launched,DNA methyltransferase inhibitor,DNMT1|DNMT3A,hematologic malignancy|hematology,myelodysplastic diseases (MDS)|anemia|chronic myeloid leukemia (CML)
CCN(CC)CCNC(=O)c1ccc(N)c(Cl)c1,declopramide,Preclinical,cell cycle inhibitor,,,
OCCOCCN1CCN(C(c2ccccc2)c2ccccc2)CC1,decloxizine,Preclinical,histamine receptor antagonist,,,
CCCCCCCCCCOc1cc2c(=O)c(C(=O)OCC)c[nH]c2cc1OCC,decoquinate,Launched,antiprotozoal agent,,infectious disease,coccidiosis
CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1,defactinib,Phase 2,focal adhesion kinase inhibitor,PTK2,,
O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1,deferasirox,Launched,chelating agent,CYP3A4,hematology,transfusional hemosiderosis|thalassemia|iron overload
O=C(O)c1ccc(-n2nc3nc2-c2ccccc2O[Fe]Oc2ccccc2-3)cc1,deferasirox-iron-chelate,Launched,,,,
Cc1c(O)c(=O)ccn1C,deferiprone,Launched,chelating agent,UGT1A6,hematology,transfusional hemosiderosis|thalassemia|iron overload
CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN,deferoxamine-mesylate,Launched,chelating agent,,hematology,acute iron intoxication|iron overload
CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C,deflazacort,Launched,glucocorticoid receptor agonist,NR3C1,rheumatology,joint inflammation
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,deforolimus,Phase 3,mTOR inhibitor,MTOR,,
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)C(=O)N[C@H](Cc1ccc(NC(N)=O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,degarelix,Launched,gonadotropin releasing factor hormone receptor antagonist,GNRHR,oncology,prostate cancer
CC(=O)c1c(O)cc(C)oc1=O,dehydroacetic-acid,Preclinical,,,,
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3C(=O)C[C@H]4CC(=O)CC[C@]4(C)[C@@H]3CC(=O)[C@]12C,dehydrocholate,Preclinical,,,,
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3C(=O)C[C@@H]4CC(=O)CC[C@]4(C)[C@H]3CC(=O)[C@]12C,dehydrocholate-acid,Preclinical,,,,
COc1cc2c(cc1OC)-c1c(C)c3ccc(OC)c(OC)c3c[n+]1CC2,dehydrocorydaline,Phase 3,acetylcholinesterase inhibitor,ACHE,,
C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12,dehydroepiandrosterone,Launched,protein synthesis stimulant,ESR1|ESR2|G6PD|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B|HSD17B1|NR1I2|NR1I3|PPARA|SIGMAR1|SULT2A1|SULT2B1,endocrinology,menopause
C[C@]12CC[C@H](OS(=O)(=O)O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12,dehydroepiandrosterone-sulfate,Launched,androgen receptor agonist|estrogen receptor agonist,AR|ESR1|ESR2,endocrinology,menopause
Nc1nc(-n2cc(C(=O)O)c(=O)c3cc(F)c(N4CC(O)C4)c(Cl)c32)c(F)cc1F,delafloxacin,Phase 3,antiinfective drug,,,
C[C@]1(COc2ccc(N3CCC(Oc4ccc(OC(F)(F)F)cc4)CC3)cc2)Cn2cc([N+](=O)[O-])nc2O1,delamanid,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,tuberculosis
CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(-c2ccccc2)n1)[C@@H](C)O)B(O)O,delanzomib,Phase 1/Phase 2,proteasome inhibitor,CMA1|CTSG|CYP3A4|ELANE,,
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(=O)O)C1Cc2ccccc2C1,delapril,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension
CC(C)Nc1cccnc1N1CCN(C(=O)c2cc3cc(NS(C)(=O)=O)ccc3[nH]2)CC1,delavirdine,Launched,non-nucleoside reverse transcriptase inhibitor,CYP3A4,infectious disease,human immunodeficiency virus (HIV-1)
CC(C)C[C@H](NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C(=O)O,delcasertib,Phase 1,PKC inhibitor,,,
C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2,delgocitinib,Phase 2,JAK inhibitor,,,
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@@H]1C(=O)N[C@H](Cc1ccccc1)C(=O)O,delivert,Launched,angiotensin receptor agonist,AGTR1|AGTR2,critical care,sepsis
CN1CCN(c2ccc(N3C[C@H](CO)OC3=O)cc2F)C=N1,delpazolid,Phase 2,antibacterial,,,
Oc1cc(O)c2cc(O)c(-c3cc(O)c(O)c(O)c3)[o+]c2c1,delphinidin,Phase 2,membrane permeability inhibitor,GLO1,,
CC(C)=CCC/C(C)=C/CC/C(C)=C/CC[C@]1(C)CCc2cc(O)cc(C)c2O1,delta-tocotrienol,Phase 1,HMGCR inhibitor,HMGCR,,
c1ccc(Cn2c(-c3ccc(OC[C@H](C4CCNCC4)n4c(-c5ccccc5)nc5ccccc54)cc3)nc3ccccc32)cc1,deltarasin,Preclinical,phosphodiesterase inhibitor,KRAS,,
CN(CCCCCCCCCCN(C)C(=O)Oc1cccc([N+](C)(C)C)c1)C(=O)Oc1cccc([N+](C)(C)C)c1,demecarium,Launched,acetylcholinesterase inhibitor,ACHE|BCHE,ophthalmology,intraocular pressure|glaucoma
CN(C)[C@@H]1C(=O)[C@@H](C(N)=O)C(=O)[C@@]2(O)C(=O)[C@H]3C(=O)c4c(O)ccc(Cl)c4[C@@H](O)[C@H]3C[C@@H]12,demeclocycline,Launched,bacterial 30S ribosomal subunit inhibitor,,endocrinology|infectious disease|ophthalmology|urology,fever|respiratory tract infections|psittacosis|trachoma|conjunctivitis|urethritis|chancroid|cholera|syphilis|listeria|anthrax|actinomycosis|tularemia|brucellosis
CC[N+](CC)(CC(=O)Nc1c(C)cccc1C)Cc1ccccc1,denatonium-benzoate,Preclinical,,,,
COc1ccc(CCNC[C@H](O)c2ccc(O)cc2)cc1OC,denopamine,Launched,adrenergic receptor agonist,,cardiology,angina pectoris
Cc1nsc(NC(=O)c2ccccc2)c1C(=O)Nc1ccc(Cl)cc1,denotivir,Launched,antiviral,,infectious disease,virus herpes simplex (HSV)|skin infections
Oc1ccc(O[C@H]2CCCCO2)cc1,deoxyarbutin,Preclinical,tyrosinase inhibitor,,,
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C,deoxycholic-acid,Launched,biliverdin reductase A activator|G protein-coupled receptor agonist,FPR1|GPBAR1,endocrinology,submental fat
CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,deoxycorticosterone-acetate,Preclinical,progestogen hormone,NR3C2,,
CNCCc1ccc(O)c(O)c1,deoxyepinephrine,Preclinical,adrenergic receptor agonist|dopamine receptor agonist,ADRA1A|DRD1|DRD2,,
CN1[C@@H]2CC[C@H]1C[C@@H](OC1c3ccccc3CCc3ccccc31)C2,deptropine,Preclinical,histamine receptor antagonist,HRH1,,
Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc21,dequalinium,Launched,PKC inhibitor,KCNN1|KCNN3,infectious disease,first-aid antiseptic
COc1ccc(-c2cc(C(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1F,deracoxib,Launched,cyclooxygenase inhibitor,PTGS2,rheumatology,osteoarthritis
COCCNCCc1cccc(Nc2ncc3c(n2)-c2ccccc2[C@H](c2ccccc2F)C3)c1,derazantinib,Phase 2,tyrosine kinase inhibitor,,,
COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5ccccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC,deserpidine,Launched,angiotensin converting enzyme inhibitor,ACE|SLC18A2,cardiology,hypertension
O=C(O)CNC(=O)c1c(O)c2ccccc2n(OCC2CC2)c1=O,desidustat,Preclinical,hypoxia inducible factor prolyl hydroxylase inhibitor,,,
CNCCCN1c2ccccc2CCc2ccccc21,desipramine,Launched,tricyclic antidepressant,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD2|HRH1|HTR1A|HTR2A|HTR2C|SLC6A2|SLC6A4|SMPD1,neurology/psychiatry,depression
C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1C[C@@H]1O[C@@H](C3CCCCC3)O[C@]12C(=O)CO,desisobutyryl-ciclesonide,Launched,cytochrome P450 inhibitor,,allergy,allergic rhinitis
C[C@H]1O[C@@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3C[C@@H](O)[C@]3(C)[C@@H](C5=CC(=O)OC5)CC[C@]43O)C2)C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1,deslanoside,Launched,Na/K-ATPase inhibitor,ATP1A1|ATP1A2|ATP1A3|ATP1A4|ATP1B1|ATP1B2|ATP1B3|FXYD2,cardiology,congestive heart failure|cardiac arrythmia
Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,desloratadine,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis|urticaria
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,deslorelin,Phase 2,gonadotropin releasing factor hormone receptor agonist,,,
Clc1ccc2c(c1)N=C(N1CCNCC1)c1ccccc1N2,desmethylclozapine,Phase 2,acetylcholine receptor agonist,HTR2C,,
N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,desmopressin-acetate,Launched,vasopressin receptor agonist,AVPR1A|AVPR1B|AVPR2|OXTR,endocrinology|urology,central diabetes insipidus|nocturnal enuresis
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3C(=C)C[C@@]21CC,desogestrel,Launched,progesterone receptor agonist,ESR1|PGR,endocrinology,contraceptive
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,desonide,Launched,glucocorticoid receptor agonist,NR3C1|PLA2G1B,gastroenterology,Crohn's disease
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO,desoximetasone,Launched,glucocorticoid receptor agonist,NR3C1|PLA2G1B,dermatology,corticosteroid-responsive dermatoses
CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,desoxycorticosterone-pivalate,Launched,corticosteroid agonist,NR3C2,endocrinology,Addison's disease
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2C(=O)CO,desoxycortone,Preclinical,mineralocorticoid receptor agonist,NR3C1|NR3C2,,
c1ccc2c(c1)CN1CCCC1=N2,desoxypeganine,Phase 1,acetylcholinesterase inhibitor|monoamine oxidase inhibitor,ACHE,,
CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1,desvenlafaxine,Launched,serotoninâ__orepinephrine reuptake inhibitor (SNRI),SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,depression
Cc1cccc(Cc2cnc[nH]2)c1C,detomidine,Launched,adrenergic receptor agonist,ADRA2A,neurology/psychiatry,sedative
CN1C(=O)[C@@H](NC(=O)c2cc3ccccc3[nH]2)N=C(c2ccccc2)c2ccccc21,devazepide,Preclinical,CCK receptor antagonist,,,
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,dexamethasone,Launched,glucocorticoid receptor agonist,ANXA1|NOS2|NR0B1|NR3C1|NR3C2,endocrinology|rheumatology|allergy|gastroenterology|hematology|neurology/psychiatry|dermatology,hypercalcemia|rheumatoid arthritis|psoriatic arthritis|osteoarthritis|allergic rhinitis|ulcerative colitis|anemia|multiple sclerosis|enteritis|lupus|dermatitis herpetiformis (DH)|nephrotic syndrome|psoriasis
CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,dexamethasone-acetate,Launched,glucocorticoid receptor agonist,,endocrinology|rheumatology|allergy|gastroenterology|hematology|neurology/psychiatry|dermatology,hypercalcemia|rheumatoid arthritis|psoriatic arthritis|osteoarthritis|allergic rhinitis|ulcerative colitis|anemia|multiple sclerosis|enteritis|lupus|dermatitis herpetiformis (DH)|nephrotic syndrome|psoriasis
CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1,dexchlorpheniramine,Launched,histamine receptor antagonist,,allergy|cardiology,allergic conjunctivitis|allergic rhinitis|urticaria|angioedema
Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1,dexlansoprazole,Launched,ATPase inhibitor,ATP4A,gastroenterology,gastroesophageal reflux disease (GERD)|erosive esophagitis (EE)
CCCCCN(CCCOC)C(=O)[C@@H](CCC(=O)O)NC(=O)c1ccc(Cl)c(Cl)c1,dexloxiglumide,Phase 3,CCK receptor antagonist,CCKAR,,
Cc1cccc([C@H](C)c2cnc[nH]2)c1C,dexmedetomidine,Launched,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C,neurology/psychiatry,sedative
COC(=O)C1=C(C)NC(C)=C(C(=O)OCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)[C@@H]1c1cccc([N+](=O)[O-])c1,dexniguldipine,Phase 2,calmodulin antagonist,ADORA3,,
CC(C)(CO)[C@@H](O)C(=O)NCCCO,dexpanthenol,Launched,,,gastroenterology,paralytic ileus
C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1,dexrazoxane,Launched,chelating agent|topoisomerase inhibitor,TOP2A|TOP2B,cardiology,cardiomyopathy
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O,dextran,Launched,,,hematology|critical care,thrombosis|hypovolemia
COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,dextromethorphan,Launched,glutamate receptor antagonist|sigma receptor agonist,CHRNA2|CHRNA3|CHRNA4|CHRNA7|CHRNB2|CHRNB4|CYBA|CYBB|GRIN3A|NCF1|NCF2|NCF4|OPRD1|OPRK1|OPRM1|PGRMC1|RAC1|RAC2|SIGMAR1|SLC6A2|SLC6A4,pulmonary,cough suppressant
Cc1ncc([N+](=O)[O-])n1C[C@@H](CN1CCOCC1)OP(=O)(O)O,dextrorotation-nimorazole-phosphate-ester,Preclinical,antiinfective drug,,,
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,dextrose,Launched,,,endocrinology,hypoglycemia
Fc1cccc(/C=N/N=C/c2cccc(F)c2)c1,DFB,Preclinical,glutamate receptor agonist,GRM5,,
CN1CCN(c2ccc(/C=C(\C#N)c3ccccc3Br)cc2)CC1,DG-172,Preclinical,PPAR receptor inverse agonist,PPARD,,
O=C(O)CCCN1CCC[C@H]1COc1ccc(Oc2ccc(Cl)cc2)cc1,DG051,Preclinical,leukotriene synthesis inhibitor,,,
CCCCC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12,DH-97,Preclinical,melatonin receptor antagonist,MTNR1B,,
CCCCCCC[n+]1ccc(-c2cc[n+](CCCCCCC)cc2)cc1,DHBP,Preclinical,ryanodine receptor blocker,,,
CC(=O)Oc1cccc2c1C(=O)c1c(OC(C)=O)cc(C(=O)O)cc1C2=O,diacerein,Launched,interleukin inhibitor,IL1B,rheumatology,osteoarthritis
CC(=O)Nc1ccc(OC(C)=O)cc1,diacetamate,Preclinical,,,,
Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]2O[C@@H](n3cnc4c(N)ncnc43)[C@H](O)[C@@H]2O)[C@@H](O)[C@H]1O,diadenosine-tetraphosphate,Phase 1,adenosine kinase inhibitor,P2RY13|P2RY2,,
N#C[C@H](Cc1ccc(O)cc1)c1ccc(O)cc1,diarylpropionitrile,Preclinical,estrogen receptor agonist,ESR2,,
CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I,diatrizoic-acid,Launched,,,radiology,contrast agent
COc1ccc(Cc2cnc(N)nc2N)cc1OC,diaveridine,Launched,dihydrofolate reductase inhibitor,,infectious disease,coccidiosis
CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1,diazoxide,Launched,potassium channel activator,ATP1A1|CA1|CA2|KCNJ11|KCNJ8|KCNMA1|SLC12A3,endocrinology,hypoglycemia
NC[C@@H]1CC[C@@H](N)[C@@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)O1,dibekacin,Launched,bacterial 30S ribosomal subunit inhibitor,,infectious disease,gram-negative bacterial infections
CN(C)CCN1C(=O)c2ccccc2N(C)c2ccccc21,dibenzepine,Preclinical,norepinephrine reputake inhibitor,,,
c1ccc2c(c1)sc1ccccc12,dibenzothiophene,Preclinical,,,,
CCCCOC(=O)c1ccccc1C(=O)OCCCC,dibutyl-phthalate,Preclinical,,TRPA1,,
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@@]21C,dichlorisone-acetate,Phase 2,,,,
Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O,dichlorophen,Launched,anticestodal agent,,infectious disease,hookworm|tapeworm
N#C[C@H](c1ccc(Cl)cc1)c1c(Cl)cc(-n2ncc(=O)[nH]c2=O)cc1Cl,diclazuril,Launched,antiprotozoal agent,,infectious disease,equine protozoal myeloencephalitis (EPM)
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,diclofenac,Launched,cyclooxygenase inhibitor,AKR1C3|ALOX5|ASIC1|ASIC3|KCNQ2|KCNQ3|PLA2G2A|PPARG|PTGS1|PTGS2|SCN4A,rheumatology|neurology/psychiatry,rheumatoid arthritis|osteoarthritis|migraine headache
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1,diclofenamide,Launched,carbonic anhydrase inhibitor,CA1|CA12|CA2|CA4|CA7,ophthalmology|neurology/psychiatry,glaucoma|epilepsy
COc1ccc2c(c1)CN(C)C[C@H]2c1ccc(Cl)c(Cl)c1,diclofensine,Phase 3,dopamine reuptake inhibitor,DRD1|MAOA|MAOB,,
Cc1onc(-c2c(Cl)cccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O,dicloxacillin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections
O=c1oc2ccccc2c(O)c1Cc1c(O)c2ccccc2oc1=O,dicoumarol,Launched,NADPH inhibitor,CRYZ|NQO1|VKORC1,hematology,deep vein thrombosis (DVT)
C1CCC(NC2CCCCC2)CC1,dicyclohexylamine,Preclinical,,,,
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1,dicycloverine,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3,gastroenterology,irritable bowel syndrome
O=c1nc[nH]c2c1ncn2[C@H]1CC[C@@H](CO)O1,didanosine,Launched,nucleoside reverse transcriptase inhibitor,PNP,infectious disease,human immunodeficiency virus (HIV-1)
Nc1ncnc2c1ncn2[C@H]1CC[C@@H](CO)O1,dideoxyadenosine,Phase 1,nucleoside reverse transcriptase inhibitor,,,
O=C(NO)c1ccc(O)c(O)c1,didox,Launched,ribonucleotide reductase inhibitor,RRM1,oncology,breast cancer
C/C=C(C(=C/C)/c1ccc(O)cc1)\c1ccc(O)cc1,dienestrol,Launched,estrogen receptor agonist,ESR1,endocrinology,menopause
C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N,dienogest,Launched,progesterone receptor agonist,PGR,endocrinology|obstetrics/gynecology,contraceptive|endometriosis
CCN(CC)C(=O)N1CCN(C)CC1,diethylcarbamazine,Launched,lipoxygenase inhibitor,ALOX5|PTGS1,infectious disease,filariasis
CCN(CC)C(=O)c1cccc(C)c1,diethyltoluamide,Launched,ionotropic receptor IR40a activator,,dermatology,sunscreen lotion
O=C(Cc1ccc(-c2ccccc2)cc1)Nc1ccccn1,difenpiramide,Launched,cyclooxygenase inhibitor|prostaglandin inhibitor,,neurology/psychiatry,pain relief
CC(=O)OCC(=O)[C@@]1(OC(C)=O)[C@@H](C)C[C@H]2[C@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,diflorasone-diacetate,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses
CN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2)CC1,difloxacin,Launched,bacterial DNA gyrase inhibitor,,infectious disease,skin infections|urinary tract infections
O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O,diflunisal,Launched,prostanoid receptor antagonist,PTGS1|PTGS2,rheumatology,rheumatoid arthritis|osteoarthritis
CCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,difluprednate,Launched,glucocorticoid receptor agonist,NR3C1,ophthalmology,endogenous uveitis
O=C1c2ccccc2CN2C(=O)c3ccccc3CN12,diftalone,Launched,cyclooxygenase inhibitor,,endocrinology,thyroiditis
C[C@]12CC[C@H](O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](C3=CC(=O)OC3)CC[C@]12O,digitoxigenin,Preclinical,ATPase inhibitor,ATP1A1,,
C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5CC[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O,digitoxin,Launched,ATPase inhibitor,ATP1A1|ATP1A2|ATP1A3|ATP1A4|ATP1B1|ATP1B2|ATP1B3|FXYD2,cardiology,congestive heart failure|cardiac arrythmia
C[C@]12CC[C@H](O)C[C@H]1CC[C@@H]1[C@@H]2C[C@@H](O)[C@]2(C)[C@@H](C3=CC(=O)OC3)CC[C@]12O,digoxigenin,Preclinical,steroid,,,
C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O,digoxin,Launched,ATPase inhibitor,ATP1A1,cardiology,congestive heart failure|atrial fibrillation (AF)
CCCCC/C=C\C/C=C\C/C=C\CCCCCCC(=O)O,dihomo-gamma-linolenic-acid,Phase 2,prostanoid receptor agonist,PTGS1|PTGS2,,
Oc1cc2c(cc1O)[C@H]1c3ccccc3CN[C@@H]1CC2,dihydrexidine,Phase 2,dopamine receptor agonist,DRD1|DRD2|DRD3|DRD4|DRD5,,
C[C@H]1[C@@H](O)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3,dihydroartemisinin,Launched,antimalarial agent,,infectious disease,malaria
CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O,dihydroergocristine,Launched,adrenergic receptor antagonist|prolactin inhibitor,ADRA1A|ADRB1|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR2A|HTR3A|HTR4|HTR5A|HTR6|HTR7,neurology/psychiatry,senile dementia|cerebrovascular insufficiency
CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,dihydroergotamine,Launched,serotonin receptor agonist,ADRA2A|DRD2|HTR1B|HTR1D|HTR1E|HTR1F|HTR2B|HTR7,neurology/psychiatry,migraine headache
O=C1c2c(O)cc(O)cc2O[C@H](c2cc(O)c(O)c(O)c2)[C@H]1O,dihydromyricetin,Preclinical,,,,
CC(C)[C@@H](C)/C=C/[C@@H](C)[C@H]1CC[C@@H]2/C(=C/C=C3\C[C@@H](O)CC[C@@H]3C)CCC[C@]21C,dihydrotachysterol,Launched,vitamin analog,VDR,orthopedics|endocrinology,rickets|hypocalcemia|osteomalacia
N[C@@H](C(=O)O)c1cc(O)cc(O)c1,dihydroxyphenylglycine,Preclinical,glutamate receptor agonist,GRM1|GRM5,,
O=C(O)CCc1cc(I)c(Oc2ccc(O)cc2)c(I)c1,diiodothyropropionic-acid,Phase 2,thyroid hormone stimulant,,,
COc1cc(C(=O)OCCCN2CCCN(CCCOC(=O)c3cc(OC)c(OC)c(OC)c3)CC2)cc(OC)c1OC,dilazep,Launched,adenosine reuptake inhibitor,SLC29A1,cardiology,coronary heart disease
Cc1cc(F)ccc1-c1nc(NC(CO)CO)nc2c1ccc(=O)n2-c1c(F)cccc1F,dilmapimod,Phase 1,p38 MAPK inhibitor,,,
CN(C(=O)C(Cl)Cl)c1ccc(OC(=O)c2ccco2)cc1,diloxanide,Launched,protein synthesis inhibitor,,infectious disease,amebiasis
COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,diltiazem,Launched,calcium channel blocker,CACNA1C|CACNA1S|CACNA2D1|CACNG1|HTR3A|KCNA5,cardiology,hypertension|angina pectoris
COC(=O)c1ccc(C(c2c[nH]c3ccccc23)c2c[nH]c3ccccc23)cc1,DIM-C-pPhCO2Me,Preclinical,nuclear receptor antagonist,,,
CN(C)CCCSC(=N)N,dimaprit,Preclinical,histamine receptor agonist,HRH2|HRH3|HRH4,,
Cc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,dimemorfan,Launched,sigma receptor agonist,SIGMAR1,pulmonary,cough suppressant
CN(C)CCOC(c1ccccc1)c1ccccc1.Cn1c(=O)c2[nH]c(Cl)nc2n(C)c1=O,dimenhydrinate,Launched,histamine receptor antagonist,HRH1,neurology/psychiatry|gastroenterology,motion sickness|nausea|vomiting
O=S(=O)(O)CCSSCCS(=O)(=O)O,dimesna,Phase 3,tubulin polymerization inhibitor,,,
CC1(C)OC(=O)NC1=O,dimethadione,Preclinical,oxazolidine antiepileptic,,,
C[Si](C)(C)O[Si](C)(C)C,dimethicone,Launched,,,dermatology,cosmetic
C[C@@H](C1=C(CCN(C)C)Cc2ccccc21)c1ccccn1,dimethindene-(S)-(+),Preclinical,acetylcholine receptor antagonist,HRH1,,
CCCCc1cc2ccccc2c(OCCN(C)C)n1,dimethisoquin,Launched,local anesthetic,,neurology/psychiatry,local anesthetic
COC(=O)/C=C/C(=O)OC,dimethyl-fumarate,Launched,nuclear factor erythroid derived|like (NRF2) activator,KEAP1,neurology/psychiatry,multiple sclerosis
CO[C@H]1CO[C@@H]2[C@H]1OC[C@H]2OC,dimethyl-isosorbide,Preclinical,cosmetic moisturizer,,,
C[C@@H](C1=C(CCN(C)C)Cc2ccccc21)c1ccccn1,dimetindene,Launched,cholinergic receptor antagonist|histamine receptor antagonist,HRH1,allergy,allergic rhinitis
Cc1ncc([N+](=O)[O-])n1C,dimetridazole,Launched,bacterial DNA inhibitor,,infectious disease,protozoan infection
N=C(N)c1ccc(/N=N/Nc2ccc(C(=N)N)cc2)cc1,diminazene-aceturate,Phase 3,angiotensin converting enzyme activator,AOC1|PRDX5|PRSS1,,
CCOP(=S)(OCC)Oc1cc(C)nc(C(C)C)n1,dimpylate,Launched,acetylcholinesterase inhibitor,ACHE,infectious disease,flea control
CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12,dinaciclib,Phase 3,CDK inhibitor,CDK1|CDK2|CDK5|CDK9,,
Cc1c(C(N)=O)cc([N+](=O)[O-])cc1[N+](=O)[O-],dinitolmide,Launched,,,infectious disease,coccidiosis
CCCCC[C@H](O)/C=C/[C@@H]1[C@@H](C/C=C\CCCC(=O)O)[C@@H](O)C[C@H]1O,dinoprost,Launched,prostacyclin analog,PTGDR|PTGDR2|PTGER1|PTGER2|PTGER3|PTGER4|PTGFR|TBXA2R,obstetrics/gynecology,labor induction
C[C@@H]1CC[C@@]2(OC1)O[C@H]1C[C@H]3[C@@H]4CC=C5C[C@@H](O[C@@H]6O[C@H](CO)[C@@H](O[C@@H]7O[C@@H](C)[C@H](O)[C@@H](O)[C@H]7O)[C@H](O)[C@H]6O[C@@H]6O[C@@H](C)[C@H](O)[C@@H](O)[C@H]6O)CC[C@]5(C)[C@H]4CC[C@]3(C)[C@H]1[C@@H]2C,dioscin,Preclinical,apoptosis stimulant,CXCR3,,
C[C@@H]1CC[C@@]2(OC1)O[C@H]1C[C@H]3[C@@H]4CC=C5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]3(C)[C@H]1[C@@H]2C,diosgenin,Preclinical,steroid,,,
COc1ccc(-c2cc(=O)c3c(O)cc(O)cc3o2)cc1O,diosmetin,Launched,aryl hydrocarbon receptor agonist,CYP1B1,dermatology,cosmetic
COc1ccc(-c2cc(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3o2)cc1O,diosmin,Launched,aryl hydrocarbon receptor agonist|capillary stabilizing agent,AHR,cardiology|hematology|dermatology,chronic venous insufficiency (CVI)|edema|deep vein thrombosis (DVT)|statis dermatitis|heavy leg syndrome
COc1ccc(C(=O)c2ccccc2O)c(O)c1,dioxybenzone,Preclinical,topical sunscreen agent,,,
O=C(Nc1ccccc1)OC[C@@H](CN1CCCCC1)OC(=O)Nc1ccccc1,diperodon,Preclinical,local anesthetic,,,
C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1,diphemanil,Launched,acetylcholine receptor antagonist,CHRM3,neurology/psychiatry,spasms
O=c1c(-c2ccccc2)c1-c1ccccc1,diphencyprone,Phase 2,immunostimulant,,,
CN(C)CCOC(c1ccccc1)c1ccccc1,diphenhydramine,Launched,histamine receptor antagonist,HRH1,neurology/psychiatry,headache
OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1,diphenidol,Launched,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4,neurology/psychiatry,vertigo
c1ccc2c(c1)[I]c1ccccc1-2,diphenyleneiodonium,Preclinical,nitric oxide synthase inhibitor,NOS2|NOS3,,
N=C(Nc1ccccc1)Nc1ccccc1,diphenylguanidine,Preclinical,,,,
CN1CCC(OC(c2ccccc2)c2ccccc2)CC1,diphenylpyraline,Launched,dopamine reuptake inhibitor,HRH1|SLC6A3,allergy,allergic rhinitis
CNC[C@@H](O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1,dipivefrine,Launched,adrenergic receptor agonist,,ophthalmology,glaucoma|intraocular pressure
Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1,dipraglurant,Phase 2,glutamate receptor negative allosteric modulator,GRM5,,
CC(C)N(CCc1c[nH]c2ccccc12)C(C)C,DIPT,Launched,dopamine reuptake inhibitor|serotonin reuptake inhibitor,HTR1A|HTR2A|HTR2C,,
OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1,dipyridamole,Launched,phosphodiesterase inhibitor,ADA|PDE10A|PDE1A|PDE1B|PDE1C|PDE2A|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A|PDE6A|PDE6B|PDE6C|PDE6D|PDE6G|PDE6H|PDE7A|PDE7B|PDE8A|PDE8B|PDE9A|SLC29A1,cardiology,coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension
CC(=O)Oc1cccc(C(=O)O)c1OC(C)=O,dipyrocetyl,Launched,chelating agent,,endocrinology|neurology/psychiatry,fever|pain relief
O=c1ccn([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4ccc(=O)[nH]c4=O)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)c(=O)[nH]1,diquafosol,Phase 3,purinergic receptor activator,,,
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O,dirithromycin,Launched,bacterial 50S ribosomal subunit inhibitor,,pulmonary,bronchitis
COC(=O)/C=C/C(=O)OCCN1C(=O)CCC1=O,diroximel-fumarate,Phase 3,anti-inflammatory agent,,,
O=C(O)CCCCCCCCC(=O)O,disodium-sebacate,Phase 1,,HBB,,
CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C,disopyramide,Launched,sodium channel blocker,CHRM1|CHRM2|CHRM3|KCND2|KCND3|KCNH2|SCN5A,cardiology,ventricular tachycardia (VT)|ventricular arrhythmias
CCN(CC)C(=S)SSC(=S)N(CC)CC,disulfiram,Launched,aldehyde dehydrogenase inhibitor|DNA methyltransferase inhibitor|TRPV agonist,ALDH2|DBH,neurology/psychiatry,abstinence from alcohol
Oc1cccc2cc3cccc(O)c3c(O)c12,dithranol,Launched,DNA synthesis inhibitor,,dermatology,psoriasis
Cc1ccccc1NC(=N)Nc1ccccc1C,ditolylguanidine,Preclinical,sigma receptor agonist,GRIN1|GRIN2A|GRIN2B|SIGMAR1,,
C[C@H](CN1CCN(CCOCCO)CC1)CN1c2ccccc2Sc2ccccc21,dixyrazine,Preclinical,antipsychotic,,,
C[C@@]12N[C@@H](Cc3ccccc31)c1ccccc12,dizocilpine-(-),Phase 1,glutamate receptor antagonist,,,
C[C@]12N[C@H](Cc3ccccc31)c1ccccc12,dizocilpine-(+),Preclinical,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,,
CN(C)c1ccc(/C=C2\CCCN=C2c2cccnc2)cc1,DMAB-anabaseine,Preclinical,adrenergic receptor agonist,CHRNA7,,
COc1cccc(/C=N/N=C/c2cccc(OC)c2)c1,DMeOB,Preclinical,glutamate receptor modulator,GRM5,,
CC(C)Oc1ccc(-c2cnc3c(-c4ccnc5ccccc45)cnn3c2)cc1,DMH1,Preclinical,ALK tyrosine kinase receptor inhibitor,ACVR1,,
c1ccc(-c2cnn3cc(-c4ccc(OCCN5CCOCC5)cc4)cnc23)cc1,DMH4,Preclinical,VEGFR inhibitor,KDR,,
COc1cc(C=O)c([N+](=O)[O-])cc1OC,DMNB,Preclinical,DNA dependent protein kinase inhibitor,,,
O=C1c2ccccc2C(Cc2ccnc(F)c2)(Cc2ccnc(F)c2)c2ccccc21,DMP-543,Phase 2,acetylcholine release enhancer,,,
CCC[C@@H](NC(=O)N1C(=O)C(CC)(CC)[C@@H]1Oc1ccc(C(=O)N2CCN(C)CC2)cc1)c1ccc2c(c1)OCO2,DMP-777,Phase 2,elastase inhibitor,MPO,,
CS(C)=O.CS(C)=O,DMSO,Preclinical,control vehicle,,,
O=c1[nH]c2cc([N+](=O)[O-])c([N+](=O)[O-])cc2[nH]c1=O,DNQX,Preclinical,glutamate receptor antagonist,GRIA1|GRIA2|GRIK1|GRIN1|GRIN2A|GRIN2B,,
CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1,dobutamine,Launched,adrenergic receptor agonist,ADRB1|ADRB2,cardiology,congestive heart failure
CC1=C(C)C(=O)C(CCCCC#CCCCC#CCO)=C(C)C1=O,docebenone,Phase 2,lipoxygenase inhibitor,ALOX5,,
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C,docetaxel,Launched,tubulin polymerization inhibitor,BCL2|MAP2|MAP4|MAPT|NR1I2|TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,oncology,breast cancer|non-small cell lung cancer (NSCLC)|prostate cancer|gastric adenocarcinoma|head and neck squamous cell carcinoma (HNSCC)
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O,doconexent,Launched,PPAR receptor agonist,FFAR1|PTGS1|PTGS2,,
CCCC[C@@H](CC)COC(=O)C[C@@H](C(=O)OC[C@@H](CC)CCCC)S(=O)(=O)O,docusate,Launched,laxative,,gastroenterology,constipation
CCCCCCCCCCCCOS(=O)(=O)O,dodecyl-sulfate,Preclinical,,LYZ,,
O=C(C(c1ccccc1)c1ccccc1)N1CCN(CC(O)COc2cccc3ncccc23)CC1,dofequidar,Phase 3,MRP inhibitor|P glycoprotein inhibitor,ABCB1,,
O=C(O[C@@H]1C[C@@H]2C[C@@H]3C[C@H](C1)N2CC3=O)c1c[nH]c2ccccc12,dolasetron,Launched,serotonin receptor antagonist,HTR3A,gastroenterology,nausea|vomiting
CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C,dolastatin-10,Phase 2,tubulin polymerization inhibitor,TUBB,,
C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,dolutegravir,Launched,HIV integrase inhibitor,CYP3A4|CYP3A5|CYP3A7|POU2F2|UGT1A1,infectious disease,human immunodeficiency virus (HIV-1)
CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1,domiphen,Preclinical,,,,
O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1,domperidone,Launched,dopamine receptor antagonist,DRD2|DRD3,infectious disease,fescue toxicosis
COc1cc2c(cc1OC)C(=O)[C@H](CC1CCN(Cc3ccccc3)CC1)C2,donepezil,Launched,acetylcholinesterase inhibitor,ACHE,neurology/psychiatry,Alzheimer's disease
N#Cc1ccc(N2CCN(C(=O)COc3ccc4[nH]cc(CCN)c4c3)CC2)cc1,donitriptan,Phase 2,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR5A|HTR6,,
NCCc1ccc(O)c(O)c1,dopamine,Launched,dopamine receptor agonist,DBH|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR7|SLC6A2|SLC6A3|SLC6A4,cardiology|neurology/psychiatry,ventricular arrhythmias|depression|headache|tremors
Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1,doramapimod,Phase 2,p38 MAPK inhibitor,MAPK11|MAPK12|MAPK13|MAPK14,,
CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(C=C[C@H](C)[C@@H](C6CCCCC6)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@]54O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,doramectin,Launched,,,infectious disease,gastrointestinal roundworms
Cn1c(Cn2ccc(C(F)(F)F)c(Oc3cc(Cl)cc(C#N)c3)c2=O)n[nH]c1=O,doravirine,Launched,non-nucleoside reverse transcriptase inhibitor,,,
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)[C@H](C)[C@H]12,doripenem,Launched,bacterial cell wall synthesis inhibitor,DPEP1,infectious disease,intra-abdominal infections|urinary tract infections|pyelonephritis
c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1,dorsomorphin,Preclinical,AMPK inhibitor,ACVR1|BMPR1A|BMPR1B|EPHA2|FKBP1A|FLT1|FLT3|KDR|LCK|MKNK1|PRKAA1|RPS6KA1|SRC,,
CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,dorzolamide,Launched,carbonic anhydrase inhibitor,CA1|CA12|CA14|CA2|CA4|CA7,ophthalmology,intraocular pressure|glaucoma
CN(C)CC/C=C1\c2ccccc2CSc2ccccc21,dosulepin,Launched,norepinephrine reuptake inhibitor|serotoninâ__orepinephrine reuptake inhibitor (SNRI)|tricyclic antidepressant,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HRH1|SLC6A2|SLC6A4,neurology/psychiatry,depression
O=P(O)(O)CN1CCN(CP(=O)(O)O)CCN(CP(=O)(O)O)CCN(CP(=O)(O)O)CC1,DOTMP,Preclinical,,,,
CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1,dovitinib,Phase 3,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,CSF1R|EGFR|FGFR1|FGFR2|FGFR3|FLT1|FLT3|FLT4|INSR|KDR|KIT|PDGFRA|PDGFRB,,
CCN1C[C@@H](CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O,doxapram,Launched,potassium channel blocker,,pulmonary|neurology/psychiatry,respiratory depression|central nervous system depression|acute hypercapnia (AHC)
COc1cc2nc(N3CCN(C(=O)[C@H]4COc5ccccc5O4)CC3)nc(N)c2cc1OC,doxazosin,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D,urology|cardiology,benign prostatic hyperplasia (BPH)|hypertension
CN(C)CC/C=C1/c2ccccc2COc2ccccc21,doxepin,Launched,histamine receptor antagonist,HRH1|SLC6A2|SLC6A4,neurology/psychiatry,depression|anxiety
C=C1/C(=C/C=C2\CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O,doxercalciferol,Launched,vitamin D receptor agonist,VDR,nephrology|endocrinology,chronic kidney disease (CKD)|hyperparathyroidism
C[C@H]1O[C@@H](n2cc(F)c(=O)[nH]c2=O)[C@H](O)[C@@H]1O,doxifluridine,Launched,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer
Cn1c(=O)c2c(ncn2CC2OCCO2)n(C)c1=O,doxofylline,Launched,adenosine receptor antagonist,ADORA1|PDE4A|PDE4B|PDE4C|PDE4D,pulmonary,asthma
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,doxorubicin,Launched,topoisomerase inhibitor,TOP2A,hematologic malignancy|oncology,acute lymphoblastic leukemia (ALL)|acute myeloid leukemia (AML)|Wilm's tumor|breast cancer|ovarian cancer|Hodgkin's lymphoma|bladder cancer|multiple myeloma
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,doxycycline,Launched,bacterial 30S ribosomal subunit inhibitor|metalloproteinase inhibitor,MMP8,dental,periodontitis
CN(C)CCOC(C)(c1ccccc1)c1ccccn1,doxylamine,Launched,histamine receptor antagonist,HRH1,neurology/psychiatry,sedative
CN(C(=S)NN=C(c1ccccn1)c1ccccn1)C1CCCCC1,DpC,Phase 1,,,,
CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNCc1cccc(F)c1)C(C)(C)C)S(=O)(=O)c1cccc(N)c1,DPC-681,Phase 1,HIV protease inhibitor,,,
CCCn1c(=O)c2[nH]c(C3CCCC3)nc2n(CCC)c1=O,DPCPX,Phase 1,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
N#Cc1cc2c(OC[C@H](O)CN3CCN(C(c4ccccc4)c4ccccc4)CC3)cccc2[nH]1,DPI-201106,Phase 2,sodium channel activator,ADRB2,,
CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1P(=O)(c1ccccc1)c1ccccc1,DPO-1,Preclinical,potassium channel blocker,KCNA5,,
CCN(CC)CCOc1ccc(Cc2ccccc2)cc1,DPPE,Phase 3,histamine receptor antagonist,ABCB1|HRH1,,
Cc1ccc2[nH]c(=O)c(C3=NN(C(=O)CCC(=O)O)[C@H](c4ccc(Br)cc4)C3)c(-c3ccccc3)c2c1,DQP-1105,Preclinical,glutamate receptor antagonist,GRIN2C|GRIN2D,,
Cc1nc(=O)c2c([nH]1)CCSC2,DR-2313,Preclinical,PARP inhibitor,PARP1|PARP3,,
O=C1Nc2ccc(Cl)c3c2[C@@]1(CCCCN1CC=C(c2ccc(Cl)cc2)CC1)CCC3,DR-4485,Preclinical,serotonin receptor antagonist,HTR7,,
CC[C@H](CO)Nc1nc(Nc2cccc(-c3ccccn3)c2)c2ncn(C(C)C)c2n1,DRF053-(R),Preclinical,CDK inhibitor,CSNK1A1,,
CCN(CC)CCOC(=O)[C@H](c1ccccc1)C1CCCCC1,drofenine,Launched,,,neurology/psychiatry,spasms
CC/C(=C(/c1ccc(OCCN(C)C)cc1)c1cccc(O)c1)c1ccccc1,droloxifene,Phase 3,selective estrogen receptor modulator (SERM),ESR1,,
CCC(=O)O[C@H]1CC[C@H]2[C@H]3CC[C@H]4CC(=O)[C@@H](C)C[C@@]4(C)[C@@H]3CC[C@@]12C,dromostanolone-propionate,Launched,androgen receptor modulator,AR,oncology,breast cancer
CCCCc1oc2ccc(NS(C)(=O)=O)cc2c1C(=O)c1ccc(OCCCN(CCCC)CCCC)cc1,dronedarone,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|CACNA1C|CACNA1D|CACNA1F|CACNA1S|CACNB1|CACNB2|CACNB3|CACNB4|KCNA5|KCNH2|KCNK2|SCN1A,cardiology,atrial fibrillation (AF)
O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1,droperidol,Launched,dopamine receptor antagonist,ADRA1A|DRD2|DRD3|DRD4|HTR2A,gastroenterology,nausea|vomiting
OC[C@@H](O)CN1CCN(c2ccccc2)CC1,dropropizine,Launched,antitussive,,pulmonary,cough suppressant
C[C@]12CCC(=O)C=C1[C@@H]1C[C@@H]1[C@H]1[C@@H]3[C@@H]4C[C@@H]4[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@@H]12,drospirenone,Launched,mineralocorticoid receptor antagonist,AR|NR3C2|PGR,endocrinology,contraceptive
CCOc1ccc(CC2=NCCc3cc(OCC)c(OCC)cc32)cc1OCC,drotaverine,Launched,phosphodiesterase inhibitor,,obstetrics/gynecology,labor induction
CN1c2c(oc(=O)n(-c3ccccn3)c2=O)-c2ccccc2S1(=O)=O,droxicam,Launched,cyclooxygenase inhibitor,PTGS1,rheumatology,rheumatoid arthritis|osteoarthritis
N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1,droxidopa,Launched,norepinephrine precursor,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|PAH,cardiology|neurology/psychiatry,hypertension|Parkinson's Disease
Cc1cc(Cl)ccc1OCCCC(=O)NO,droxinostat,Preclinical,HDAC inhibitor,HDAC6|HDAC8,,
O=C(Nc1c(-c2cccs2)nc2ccccn12)c1ccc(Cl)cc1,DS2-(806622),Preclinical,,,,
Cc1cc(Nc2ccc(S(F)(F)(F)(F)F)cc2)n2nc(C(C)(F)F)nc2n1,DSM265,Phase 2,dihydroorotate dehydrogenase inhibitor,,,
CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COP(=O)(O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,DSPC,Preclinical,,,,
CCCCNc1nc(N)c2[nH]c(=O)n(Cc3ccc(OCCN(C)C)nc3)c2n1,DSR-6434,Preclinical,toll-like receptor agonist,TLR7,,
N=C(N)NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)O,DU-728,Phase 1,structural glycoprotein antagonist,ITGA2B|ITGB3,,
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,duloxetine,Launched,norepinephrine reuptake inhibitor|serotoninâ__orepinephrine reuptake inhibitor (SNRI),HTR2A|HTR2C|HTR6|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,depression|generalized anxiety disorder (GAD)|muscle pain|peripheral neuropathy
CS(=O)(=O)c1ccc(-c2cc(Br)sc2-c2ccc(F)cc2)cc1,DUP-697,Phase 1,cyclooxygenase inhibitor,PTGS2,,
C[C@]12C=CC(=O)N[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](C(=O)Nc3cc(C(F)(F)F)ccc3C(F)(F)F)CC[C@@H]12,dutasteride,Launched,5 alpha reductase inhibitor,SRD5A1|SRD5A2|SRD5A3,urology,benign prostatic hyperplasia (BPH)
C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,duvelisib,Launched,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,,
CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1,DVD-111,Phase 2,,,,
COCCCc1ccc2oc(-c3ccc(OC)c(OC)c3)cc2c1,DWK-1339,Preclinical,beta amyloid aggregation inhibitor,,,
CCN(CC)c1ccc(/C=N/NC(=O)c2ccc(O)cc2)cc1,DY131,Preclinical,estrogen-related receptor agonist,ESRRB|ESRRG,,
CCCCOc1ccc(C(=O)CCN2CCCCC2)cc1,dyclonine,Launched,sodium channel blocker,SCN10A|SCN5A,neurology/psychiatry,local anesthetic
CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C,dydrogesterone,Launched,progesterone receptor agonist,PGR,obstetrics/gynecology,infertility
O=C(N/N=C/c1ccc(O)c(O)c1)c1cc2ccccc2cc1O,dynasore,Preclinical,dynamin inhibitor,DNM1|DNM1L|DNM2,,
CCCCCCCCNC(=O)/C(C#N)=C/c1cn(CCCN(C)C)c2ccccc12,dynole-34-2,Preclinical,dynamin inhibitor,DNM1,,
Cn1c(=O)c2c(ncn2C[C@@H](O)CO)n(C)c1=O,dyphylline,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,PDE4A,pulmonary,asthma|bronchitis|emphysema
O=C(CN1CCC(C(=O)c2ccc(F)cc2)CC1)c1ccc2ccccc2c1,E-2001,Preclinical,antioxidant,,,
COc1cc(/C=C2\CCCN([C@@H](C)c3ccc(F)cc3)C2=O)ccc1-n1cnc(C)c1,E-2012,Phase 1,gamma secretase modulator,APH1A|APH1B|PSENEN,,
Cc1cccc(CCN2CCC(C(=O)c3ccc(NS(C)(=O)=O)cc3)CC2)n1,E-4031,Phase 1,potassium channel blocker,KCNH1|KCNH2,,
CC(C)C[C@H](NC(=O)[C@H]1O[C@@H]1C(=O)O)C(=O)NCCCCNC(=N)N,E-64,Preclinical,calpain inhibitor|cysteine protease inhibitor,CTSS,,
CCCCCCCCC/C(=C\C1=C(C)C(=O)C(OC)=C(OC)C1=O)C(=O)O,E3330,Preclinical,NFkB pathway inhibitor,,,
C[C@H](NC(=O)c1c(C(F)F)nn(C)c1Oc1cccc(C(F)(F)F)c1)c1ccc(C(=O)O)cc1,E7046,Phase 1,prostanoid receptor antagonist,,,
O=C1NNc2nc(CN3Cc4ccccc4C3)nc3cccc1c23,E7449,Phase 2,PARP inhibitor,PARP1|PARP2|TNKS|TNKS2,,
Cc1ccc(NS(=O)(=O)c2cccc(C#N)c2)c2[nH]cc(C#N)c12,E7820,Phase 2,angiogenesis inhibitor,,,
COCCN(C(=O)c1cc(OC)c(OC)c(OC)c1)c1nc(-c2ccccc2)cs1,eact,Preclinical,calcium-activated chloride channel inhibitor,ANO1,,
Nc1ncnc2c1ncn2[C@H]1O[C@@H](C(=O)N2CCN(CC(=O)Nc3cccc4c3CNC4=O)CC2)[C@H](O)[C@@H]1O,EB-47,Preclinical,PARP inhibitor,PARP1,,
CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1,ebastine,Launched,histamine receptor antagonist,CYP3A4|HRH1,allergy,allergic rhinitis|urticaria
CCOC(=O)[C@@H]1CN(Cc2ccccc2)C(=O)C1=O,EBPC,Preclinical,aldose reductase inhibitor,AKR1B1,,
O=c1c2ccccc2[se]n1-c1ccccc1,ebselen,Phase 2/Phase 3,cyclooxygenase inhibitor|glutathione peroxidase agonist|H+/K+-ATPase inhibitor|nitric oxide synthase inhibitor,ALB,,
COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc32)c1C,EC-144,Preclinical,HSP inhibitor,HSP90AA1|HSP90AB1,,
CC1(C)CCC(C)(C)c2cc(C#Cc3ccc(C(=O)O)cc3)ccc21,EC-23,Preclinical,retinoid receptor agonist,RARA|RARB|RARG,,
CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1,ecabapide,Phase 3,,,,
CC(C)c1cc2c(cc1S(=O)(=O)O)[C@@]1(C)CCC[C@@](C)(C(=O)O)[C@@H]1CC2,ecabet,Launched,gastrin inhibitor|urease inhibitor,NOXO1,ophthalmology,dry eye syndrome
CC1(C)[C@H]2CC[C@]1(CS(=O)(=O)O)C(=O)C2=Cc1ccc(C=C2C(=O)[C@@]3(CS(=O)(=O)O)CC[C@@H]2C3(C)C)cc1,ecamsule-triethanolamine,Launched,,,dermatology,skin protectant|sunscreen lotion
CS[C@H]1SC[C@H]2C(=O)N(C)[C@@H](C(C)C)C(=O)OC[C@@H](NC(=O)c3cnc4ccccc4n3)C(=O)N[C@@H](C)C(=O)N(C)[C@H]1C(=O)N(C)[C@@H](C(C)C)C(=O)OC[C@@H](NC(=O)c1cnc3ccccc3n1)C(=O)N[C@@H](C)C(=O)N2C,echinomycin,Phase 2,DNA intercalating agent,,,
Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1,econazole,Launched,lanosterol demethylase inhibitor|sterol demethylase inhibitor,NPY1R|NPY2R|TRPM2|TRPV5,infectious disease,tinea pedis|tinea cruris|tinea corporis|tinea versicolor|cutaneous candidiasis
CC1=NCC[C@@H](C(=O)O)N1,ectoine,Launched,anti-inflammatory agent,,,
Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H]2SC(=O)NC2=O)c2sccc12,edaglitazone,Phase 2,PPAR receptor agonist,PPARG,,
Cc1cc(=O)n(-c2ccccc2)[nH]1,edaravone,Launched,nootropic agent,BCL2,neurology/psychiatry,stroke
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)NCCNC(=O)c1ccccc1O,edasalonexent,Phase 3,NFkB pathway inhibitor,,,
CCCCCCCCCCCCCCCCCCOC[C@H](COP(=O)(O)OCC[N+](C)(C)C)OC,edelfosine,Phase 2,phospholipase inhibitor,,,
C[C@@H](O)CN(CCN(C[C@@H](C)O)C[C@@H](C)O)C[C@@H](C)O,editol,Preclinical,,,,
Cn1c(CCCCCCC(=O)NO)nc2cc(N(CCCl)CCCl)ccc21,EDO-S101,Phase 1/Phase 2,HDAC inhibitor,,,
OC1CN(CCCOCCc2ccc3sccc3c2)C1,edonerpic-maleate,Preclinical,beta amyloid inhibitor,,,
CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1,edoxaban,Launched,coagulation factor inhibitor,F10,neurology/psychiatry|hematology|cardiology,stroke|pulmonary embolism (PE)|systemic embolism|deep vein thrombosis (DVT)|atrial fibrillation (AF)
CCc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O,edoxudine,Launched,DNA directed DNA polymerase inhibitor,,infectious disease,virus herpes simplex (HSV)
CC[N+](C)(C)c1cccc(O)c1,edrophonium,Launched,acetylcholinesterase inhibitor,ACHE|BCHE,neurology/psychiatry,myasthenia gravis
O=P(O)(O)CN(CCN(CP(=O)(O)O)CP(=O)(O)O)CP(=O)(O)O,EDTMP,Preclinical,chelating agent,,,
CS(=O)(=O)c1ccc(-c2cnc(NCc3ccco3)n3cnnc23)cc1,EED226,Preclinical,polycomb protein inhibitor,EED,,
O=C(Cn1ccnc1[N+](=O)[O-])NCC(F)(F)C(F)(F)F,EF5,Phase 2,cytochrome P450 activator,,,
Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(=O)O)cc2)c1,efaproxiral,Phase 3,hemoglobin oxygen release stimulant,HBA1|HBB,,
CCC1(C2=NCCN2)Cc2ccccc2O1,efaroxan,Phase 2,adrenergic receptor antagonist,ADORA2A,,
Cc1cc(Oc2ccc3nc(COc4ccc(C[C@H]5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N,efatutazone,Phase 2,PPAR receptor agonist,PPARG,,
O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1,efavirenz,Launched,HIV protease inhibitor,CYP1A2|CYP2B6|CYP2C19|CYP2C9|CYP2D6|CYP3A4,infectious disease,human immunodeficiency virus (HIV-1)
C=C1CCN([C@H](C)[C@@](O)(Cn2cncn2)c2ccc(F)cc2F)CC1,efinaconazole,Launched,lanosterol demethylase inhibitor,CYP51A1,infectious disease,onychomycosis
O=C(O)COCCN1CCN(C(c2ccc(F)cc2)c2ccc(F)cc2)CC1,efletirizine,Phase 3,antihistamine,,,
NCCCC(N)(C(=O)O)C(F)F,eflornithine,Launched,ornithine decarboxylase inhibitor,ARG2|ODC1,dermatology,facial hair reduction
CCOC(=O)COc1ccc2c(=O)cc(-c3ccccc3)oc2c1,efloxate,Preclinical,vasodilator,,,
CC1=C(C(=O)OCCN(Cc2ccccc2)c2ccccc2)[C@H](c2cccc([N+](=O)[O-])c2)C(P2(=O)OCC(C)(C)CO2)=C(C)N1,efonidipine,Launched,calcium channel blocker,,cardiology,hypertension
N=C(N)NCCC[C@H](NC(=O)c1sccc1NS(=O)(=O)c1cccc2nsnc12)C(=O)O,EG00229,Preclinical,neuropilin receptor antagonist,NRP1,,
Cc1cc(C(=O)Nc2nc3cccc(Cl)c3n2[C@@H]2CCCCN(C(=O)/C=C/CN(C)C)C2)ccn1,EGF816,Phase 2,EGFR inhibitor,EGFR,,
N[C@@]1(C(=O)O)CC[C@H]2[C@H](C(=O)O)[C@H]21,eglumetad,Phase 2,glutamate receptor agonist,GRM2|GRM3|GRM6|GRM8,,
CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc21,EHop-016,Preclinical,Ras GTPase inhibitor,RAC1|RAC3,,
CCC(CC)n1ccc2c(C(=O)NCc3c(C)cc(C)[nH]c3=O)cc(C#N)cc21,EI1,Preclinical,histone lysine methyltransferase inhibitor,EZH2,,
CCN(c1nc(N)c(C(=O)N=C(N)N)nc1Cl)C(C)C,EIPA,Preclinical,sodium/hydrogen exchanger inhibitor|transient receptor potential polycystic inhibitor,ADRA2A|ASIC1|PKD2L1,,
CCSC(=N)N,EIT-hydrobromide,Preclinical,nitric oxide synthase inhibitor,NOS2|NOS3,,
CCNCCc1ccc(CN(CC)c2cc(OC)ccc2[C@@H]2CCc3cc(O)ccc3C2)cc1,elacestrant,Phase 3,estrogen receptor degrader,,,
COc1cc2c(cc1OC)CN(CCc1ccc(NC(=O)c3cccc4c(=O)c5cccc(OC)c5[nH]c34)cc1)CC2,elacridar,Phase 1,P glycoprotein inhibitor,ABCB1,,
CCC(=C/[C@H](C)C/C=C/C(C)=C/[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C/C(C)=C/C(=O)O)/C=C/[C@H]1OC(=O)C=C[C@@H]1C,elactocin,Phase 1,exportin antagonist,XPO1,,
CCCCCCCC/C=C/CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@@H](O)[C@@H]1O,elacytarabine,Phase 3,antineoplastic agent,DCK,,
CSc1ccc(C(=O)/C=C/c2cc(C)c(OC(C)(C)C(=O)O)c(C)c2)cc1,elafibranor,Phase 3,PPAR receptor agonist,PPARA|PPARD|PPARG,,
COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F,elagolix,Launched,gonadotropin releasing factor hormone receptor antagonist,GNRHR,,
COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc(-c2ccc3c(c2)O[C@@H](c2ccccc2)n2c-3cc3cc(-c4c[nH]c([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)n4)ccc32)c[nH]1)C(C)C,elbasvir,Launched,HCV inhibitor,,infectious disease,hepatitis C
C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)[C@@H](OCCCO)[C@@H]1O,eldecalcitol,Phase 3,bone formation stimulant,VDR,,
O=C1c2cc(-c3ccc(OC(F)(F)F)cc3)ccc2OCCN1Cc1ncccn1,eleclazine,Phase 3,late sodium current inhibitor,,,
C=C[C@]1(C)CC[C@@H](C(=C)C)C[C@@H]1C(=C)C,elemene,Phase 3,VEGFR inhibitor,,,
CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1,elesclomol,Phase 3,oxidative stress inducer,HSPA1A,,
CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12,eletriptan,Launched,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2B|HTR7,neurology/psychiatry,migraine headache
CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2c(c1)OCCO2,eliglustat,Launched,glycosyl transferase inhibitor,UGCG,hematology,Gaucher disease
CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F,elinogrel,Phase 2,purinergic receptor antagonist,P2RY12,,
O[C@@H](CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1,eliprodil,Phase 3,glutamate receptor antagonist,GRIN1|GRIN2B,,
O=c1oc2c(O)c(O)cc3c(=O)oc4c(O)c(O)cc1c4c23,ellagic-acid,Phase 2,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,CA1|CA12|CA14|CA2|CA3|CA4|CA5A|CA5B|CA6|CA7|CA9|CSNK2A1|GSK3B|PRKACA|PRKCA|PRKCB|SQLE|SYK,,
O=C(c1cccc(N2Cc3cccc(Cl)c3C2=O)c1)N1CCC2(CC1)CCN(c1ccncc1)CC2,ELN-441958,Preclinical,bradykinin receptor antagonist,BDKRB1,,
NC(=O)/C(=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)c1cncnc1,eltanexor,Preclinical,exportin inhibitor,,,
CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,eltanolone,Phase 3,GABA receptor positive allosteric modulator,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB2|GABRG2,,
c1cc2c(c(N3CCNCC3)c1)OCCO2,eltoprazine,Phase 2,serotonin receptor agonist,HTR1A|HTR1B,,
CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O,eltrombopag,Launched,thrombopoietin receptor agonist,MPL,hematology|infectious disease,anemia|hepatitis C|thrombocytopenia
COc1ccc(CN(C(=O)[C@@H](N)Cc2c(C)cc(C(N)=O)cc2C)[C@@H](C)c2nc(-c3ccccc3)c[nH]2)cc1C(=O)O,eluxadoline,Launched,opioid receptor agonist|opioid receptor antagonist,OPRD1|OPRK1|OPRM1,gastroenterology,irritable bowel syndrome
COc1cc2c(cc1Cc1cccc(Cl)c1F)c(=O)c(C(=O)O)cn2[C@H](CO)C(C)C,elvitegravir,Launched,HIV integrase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)
CN[C@@H]1[C@@H](C)O[C@@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(C=C[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@]54O)C[C@@H]2OC)C[C@H]1OC,emamectin,Preclinical,GABA receptor agonist,,,
CCCCCCCCCCCC1C(=O)C(=O)C=C(O)C1=O,embelin,Preclinical,HCV inhibitor|XIAP inhibitor,XIAP,,
CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1,EMD-1214063,Phase 2,hepatocyte growth factor receptor inhibitor,MET,,
Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1,EMD-386088,Preclinical,serotonin receptor agonist,HTR6,,
COc1ccc(C(=O)N2CCCc3cc(C4=NNC(=O)S[C@@H]4C)ccc32)cc1OC,EMD-53998,Phase 1,phosphodiesterase inhibitor,TNNC1,,
CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,EMD-66684,Preclinical,angiotensin receptor antagonist,AGTR1,,
CN(C)CCNC(=O)NC[C@H]1CC[C@@H]2[C@H](O1)c1cc(C(F)(F)F)ccc1N[C@H]2c1ccccc1,EMD534085,Preclinical,kinesin inhibitor,,,
CCOCCn1c(N2CCCN(C)CC2)nc2ccccc21,emedastine,Launched,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis
O=C(NCCS)c1cccc(C(=O)NCCS)c1,emeramide,Phase 2,antioxidant,,,
CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21,emetine,Phase 2,protein synthesis inhibitor,RPS2,,
CCOC(=O)c1ccc(OCCN2C[C@H](O)[C@@H](O)[C@H](O)[C@H]2CO)cc1,emiglitate,Preclinical,alpha glucoside inhibitor,,,
NCC[C@@H](O)c1cccc(OCC2CCCCC2)c1,emixustat,Phase 3,retinoid isomerohydrolase inhibitor,,,
CC(C)C[C@@H]1C(=O)O[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](Cc2ccc(N3CCOCC3)cc2)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](Cc2ccc(N3CCOCC3)cc2)C(=O)N1C,emodepside,Phase 1,nematocide,,,
Cc1cc(O)c2c(c1)C(=O)c1cc(O)cc(O)c1C2=O,emodin,Preclinical,11-beta hydroxysteroid dehydrogenase inhibitor,CSNK2A1,,
CCOc1c(N2CCOCC2)cnn(C)c1=O,emorfazone,Launched,anti-inflammatory agent|cyclooxygenase inhibitor,,dental,mouth inflammation
CCc1nc(C)ccc1O,emoxipin,Phase 3,,,,
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,empagliflozin,Launched,sodium/glucose cotransporter inhibitor,SLC5A1|SLC5A2,endocrinology,diabetes mellitus
C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)COc1c(F)c(F)cc(F)c1F,emricasan,Phase 2,caspase inhibitor,CASP1|CASP3|CASP7,,
Nc1nc(=O)n([C@@H]2CS[C@H](CO)O2)cc1F,emtricitabine,Launched,nucleoside reverse transcriptase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)
O=C(O)c1cc(N2N=C(C(F)(F)F)/C(=C/c3ccc(-c4ccccc4)o3)C2=O)ccc1Cl,EN460,Preclinical,endoplasmic reticulum oxidation inhibitor,ERO1A,,
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O,enalapril,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|congestive heart failure|left ventricular systolic dysfunction (LVSD)
C[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O,enalaprilat,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension
CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1,enasidenib,Launched,isocitrate dehydrogenase inhibitor,IDH1,hematologic malignancy,acute myeloid leukemia (AML)
C=C(C#N)C(=O)OCCCC,enbucrilate,Launched,,,dermatology,skin lacerations|tissue adhesive
COc1ccccc1N1CCN(C[C@@H](O)COc2cc(OC)c(OC)c(OC)c2)CC1,enciprazine,Phase 3,GABA receptor modulator,GABRA1,,
COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1,encorafenib,Launched,RAF inhibitor,BRAF,oncology,melanoma
O=C(Nc1cccc2cccnc12)c1ccc(N2C(=O)[C@@H]3[C@H](C2=O)[C@@H]2C=C[C@H]3C2)cc1,endo-IWR-1,Preclinical,PARP inhibitor,TNKS|TNKS2,,
CC/C(=C(\c1ccc(O)cc1)c1ccc(OCCNC)cc1)c1ccccc1,endoxifen,Phase 2,estrogen receptor antagonist,ESR1,,
C=CCO[C@H](Cn1ccnc1)c1ccc(Cl)cc1Cl,enilconazole,Launched,sterol demethylase inhibitor,CYP19A1|CYP1A2|CYP2B6|CYP2C9|CYP2J2|CYP3A4|CYP3A5|NR1I2|PPARA|PTGER2,infectious disease,skin infections
C#Cc1c[nH]c(=O)[nH]c1=O,eniluracil,Phase 3,dihydropyrimidine dehydrogenase inhibitor,AOX1|DPYD|XDH,,
Cc1cc(-n2cccc2)c(S(C)(=O)=O)cc1C(=O)NC(=N)N,eniporide,Preclinical,sodium/hydrogen antiport inhibitor,,,
C[n+]1ccc(C(=O)NCc2ccccc2)cc1,enisamium-iodide,Launched,,,,
Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)[nH]n1,ENMD-2076,Phase 2,Aurora kinase inhibitor|FLT3 inhibitor|VEGFR inhibitor,AURKA|FLT3|KDR|PDGFRA|PTK2|SRC,,
CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,enocitabine,Launched,DNA synthesis inhibitor,CMPK1|RRM1|TYMS,hematologic malignancy,acute myeloid leukemia (AML)
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)nc21,enoxacin,Launched,topoisomerase inhibitor,TOP2A,infectious disease,urinary tract infections|gonorrhea
CSc1ccc(C(=O)c2[nH]c(=O)[nH]c2C)cc1,enoximone,Launched,phosphodiesterase inhibitor,PDE3A,cardiology,congestive heart failure
CC1(C)[C@@H](O)CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@@](C)(C(=O)O)CC[C@]5(C)CC[C@@]4(C)[C@]3(C)CC[C@@H]12,enoxolone,Launched,gap junction modulator,HSD11B1,gastroenterology|otolaryngology,peptic ulcer disease (PUD)|common cold
CCCn1c(=O)[nH]c(=O)c2[nH]cnc21,enprofylline,Phase 3,phosphodiesterase inhibitor,ADORA1|ADORA2A|ADORA2B|ADORA3|PDE4A|PDE4B,,
CCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1,enrofloxacin,Launched,bacterial DNA gyrase inhibitor,,infectious disease,gram-negative bacterial infections
CCN(CC)C(=O)/C(C#N)=C/c1cc(O)c(O)c([N+](=O)[O-])c1,entacapone,Launched,catechol O methyltransferase inhibitor,COMT,neurology/psychiatry,Parkinson's Disease
O=C(Nc1ccc2ncccc2c1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12,entasobulin,Preclinical,tubulin polymerization inhibitor,,,
C=C1[C@H](CO)[C@@H](O)C[C@@H]1n1cnc2c(=O)nc(N)[nH]c21,entecavir,Launched,DNA replication inhibitor|nucleoside reverse transcriptase inhibitor,,infectious disease,hepatitis B
Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,entinostat,Phase 3,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC9,,
CN1CCN(c2ccc(C(=O)Nc3[nH]nc4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1,entrectinib,Launched,ALK tyrosine kinase receptor inhibitor|proto-oncogene tyrosine protein kinase inhibitor,ALK|NTRK1|NTRK2|NTRK3|ROS1,oncology,non-small cell lung cancer (NSCLC)
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,enzalutamide,Launched,androgen receptor antagonist,AR,oncology,prostate cancer
Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21,enzastaurin,Phase 3,PKC inhibitor,AKT1|GSK3B|PRKCA|PRKCB|PRKCD|PRKCG,,
Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl,EO-1428,Preclinical,p38 MAPK inhibitor,MAPK11|MAPK14,,
NS(=O)(=O)NCCNc1nonc1C(=Nc1ccc(F)c(Br)c1)NO,epacadostat,Phase 3,"indoleamine 2,3-dioxygenase inhibitor",IDO1,,
CC(/C=C1\SC(=S)N(CC(=O)O)C1=O)=C\c1ccccc1,epalrestat,Launched,aldose reductase inhibitor,AKR1B1,nephrology,diabetic nephropathy
CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,eperezolid,Phase 1,bacterial 30S ribosomal subunit inhibitor,,,
CCc1ccc(C(=O)[C@@H](C)CN2CCCCC2)cc1,eperisone,Launched,acetylcholine receptor antagonist,CYP2J2,neurology/psychiatry,amyotrophic lateral sclerosis (ALS)|spasms|head injury|spinal injury
NC[C@H]1OB(O)c2c(OCCCO)cccc21,epetraborole,Preclinical,leucyl-tRNA synthetase inhibitor,,,
CN[C@@H](C)[C@H](O)c1ccccc1,ephedrine,Launched,adrenergic receptor agonist,ACHE|ADRA1A|ADRB2|SLC18A2|SLC6A2,cardiology|pulmonary|neurology/psychiatry|endocrinology,hypotension|asthma|narcolepsy|obesity
CN[C@@H](C)[C@@H](O)c1ccccc1,ephedrine-(racemic),Launched,adrenergic receptor agonist,ADRA1A|ADRA2A|ADRB1|ADRB2|ATF1|ATF2|ATF3|ATF4|ATF5|ATF6|ATF7|FOS|IL2|JDP2|JUN|NFATC1|SLC6A2|SLC6A3|SLC6A4|TNF,cardiology|pulmonary|neurology/psychiatry|endocrinology,hypotension|asthma|narcolepsy|obesity
C[C@]12CC[C@H](O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12,epiandrosterone,Preclinical,steroid,G6PD,,
O=C(O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1ccc(O)c(O)c1)c1cc(O)c(O)c(O)c1,epicatechin-gallate-(-),Phase 2,bacterial DNA gyrase inhibitor,BACE1|FASN,,
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@H](O)[C@@H]2O,epiestriol,Preclinical,,,,
Oc1cc(O)c2c(c1)O[C@H](c1cc(O)c(O)c(O)c1)[C@H](O)C2,epigallocatechin-(-),Phase 2,,,,
O=C(O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(O)c(O)c1)c1cc(O)c(O)c(O)c1,epigallocatechin-gallate-(-),Phase 2/Phase 3,bacterial DNA gyrase inhibitor,ELANE|EP300|FASN|KAT2B|MMP14|MMP2,,
NC1=NC[C@@H]2c3ccccc3Cc3ccccc3N12,epinastine,Launched,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis
CNC[C@H](O)c1ccc(O)c(O)c1,epinephrine,Launched,adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|PAH|TNF,cardiology|allergy|pulmonary,cardiac arrest|anaphylactic shock|asthma
COc1cc(C)nc(-n2nc(C)cc2OC)n1,epirizole,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1,epirubicin,Launched,topoisomerase inhibitor,CHD1|TOP2A,oncology,breast cancer
C[C@]12C[C@H]3S[C@H]3C[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,epitiostanol,Launched,androgen receptor agonist,AR,oncology,breast cancer
COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@H]13,eplerenone,Launched,cytochrome P450 inhibitor,NR3C2,cardiology,congestive heart failure|hypertension
CC1(C)OC2(C)[C@@H](O)CC1C[C@@H]2O,epomediol,Launched,cholesterol inhibitor,CYP7A1,neurology/psychiatry,itching
CCCCC[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)O[C@H]2C[C@H]1O,epoprostenol,Launched,prostacyclin analog,P2RY12|PTGER1|PTGER4|PTGIR|PTGIS,cardiology,hypertension
C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@@H]2CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1,epothilone-A,Preclinical,microtubule stabilizing agent,,,
C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1,epothilone-B,Phase 3,microtubule stabilizing agent|tubulin polymerization inhibitor,TUBB,,
C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1,epothilone-D,Phase 2,microtubule stabilizing agent|tubulin polymerization inhibitor,TUBB,,
CCOc1cccc(NC(=O)c2ccc(N3CCCC3)c(C(F)(F)F)c2)c1,EPPTB,Preclinical,trace amine associated receptor antagonist,TAAR1,,
CCO[C@@H](CN1CCN(C[C@@H](C)C(=O)c2ccccc2)CC1)c1ccccc1,eprazinone,Launched,mucolytic agent,,pulmonary,bronchospasm
CC[C@H](C)[C@H]1O[C@]2(C=C[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](NC(C)=O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2,eprinomectin,Launched,benzodiazepine receptor agonist,,infectious disease,gastrointestinal roundworms|lungworms
CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C=C(C(=O)O)CC[C@]4(C)[C@H]3CC[C@]12C,epristeride,Preclinical,5 alpha reductase inhibitor,,,
O=C(NCCCN1CCOCC1)c1ccc(Cl)cc1,eprobemide,Launched,monoamine oxidase inhibitor,MAOA,neurology/psychiatry,depression
O=S(=O)(O)CCCS(=O)(=O)O,eprodisate,Phase 3,amyloid protein inhibitor|antiamyloidogenic agent,SAA1,,
CCCCc1ncc(/C=C(\Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1,eprosartan,Launched,angiotensin receptor antagonist,AGTR1,cardiology,hypertension
N=C(N)NCCCC[C@@H]1NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(=O)O)NC(=O)CNC1=O,eptifibatide,Launched,platelet aggregation inhibitor,ITGA2B|ITGB3,cardiology,acute coronary syndrome (ACS)|percutaneous coronary intervention (PCI)
CC(C)N(C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)[C@H]1C[C@@H](CCc2nc3ccc(C(C)(C)C)cc3[nH]2)C1,EPZ-5676,Phase 1,histone lysine methyltransferase inhibitor,DOT1L,,
CC(C)N(CCCNC(=O)Nc1ccc(C(C)(C)C)cc1)C[C@H]1O[C@@H](n2ccc3c(N)ncnc32)[C@H](O)[C@@H]1O,EPZ004777,Preclinical,histone lysine methyltransferase inhibitor,DOT1L,,
Cc1cc(C)c(CNC(=O)c2cc(-c3ccc(CN4CCOCC4)cc3)cc3c2cnn3C2CCCC2)c(=O)[nH]1,EPZ005687,Preclinical,histone lysine methyltransferase inhibitor,EZH2,,
CCN(c1cc(C#CCN2CCOCC2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)[C@H]1CC[C@H](N(C)CCOC)CC1,EPZ011989,Preclinical,histone lysine methyltransferase inhibitor,EZH2,,
O=C(NC[C@H](O)CN1CCc2ccccc2C1)c1cc(NC2COC2)ncn1,EPZ015666,Preclinical,protein arginine N-methyltransferase inhibitor,PRMT5,,
CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@H](OCCC3CCOCC3)C2)cc1,EPZ020411,Preclinical,protein arginine N-methyltransferase inhibitor,PRMT6,,
C[C@@]12CC[C@H]3C(=CCc4cc(O)ccc43)[C@@H]1CCC2=O,equilin,Preclinical,estrogen receptor agonist,HSD17B1,,
Oc1ccc([C@H]2COc3cc(O)ccc3C2)cc1,equol,Launched,estrogen receptor agonist,ESR1|ESR2,,
Cc1ccc2c(=O)c3ccccc3n(CCCN)c2c1C,ER-27319,Preclinical,mediator release inhibitor|SYK inhibitor,SYK,,
CC(C)c1cccc2c(-c3ccccc3)cc(-c3ccc(-c4ccc(C(=O)O)cc4)[nH]3)nc12,ER-50891,Preclinical,retinoid receptor antagonist,RARA,,
CCOc1ccccc1-n1c([C@@H](C)N2CCN(C(=O)COc3ccc(Cl)cc3)CC2)nc2ccccc2c1=O,erastin,Preclinical,ion channel antagonist,VDAC2,,
CN(C)[C@@H]1C(=O)[C@@H](C(N)=O)C(=O)[C@@]2(O)C(=O)[C@@H]3C(=O)c4c(O)c(NC(=O)CN5CCCC5)cc(F)c4C[C@H]3C[C@@H]12,eravacycline,Launched,antibacterial,,,
COC(=O)/C=C/c1cc(O)ccc1O,erbstatin-analog,Preclinical,EGFR inhibitor|tyrosine kinase inhibitor,EGFR,,
C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@H](C)C(C)(C)O)CC[C@@H]23)C[C@@H](O)C[C@@H]1O,ercalcitriol,Phase 1,vitamin D receptor agonist,VDR,,
COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1,erdafitinib,Launched,FGFR inhibitor,FGFR1|FGFR2|FGFR3|FGFR4,,
O=C(O)CSCC(=O)N[C@H]1CCSC1=O,erdosteine,Launched,mucolytic agent,,pulmonary|infectious disease,bronchitis|cough suppressant|chronic obstructive pulmonary disease (COPD)|respiratory tract infections
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@@H]12,ergocalciferol,Launched,vitamin analog,VDR,endocrinology|orthopedics,hypoparathyroidism|rickets|hypophosphatemia
C[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,ergonovine,Launched,adrenergic receptor agonist|serotonin receptor agonist,ADRA1A|HTR1E,hematology,postpartum hemorrhage (PPH)
CC(C)[C@@H](C)/C=C/[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,ergosterol,Preclinical,vitamin D precursor,,,
CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21,ergotamine,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|DRD1|DRD2|DRD5|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|SLC6A2,neurology/psychiatry,migraine headache
C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C,eribulin,Launched,microtubule inhibitor,,oncology,breast cancer
COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C,ERK5-IN-1,Preclinical,MAP kinase inhibitor,MAPK7,,
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,erlotinib,Launched,EGFR inhibitor,EGFR|NR1I2,oncology,non-small cell lung cancer (NSCLC)|pancreatic cancer
C[C@@H](O)[C@@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)Nc4cccc(C(=O)O)c4)C3)[C@H](C)[C@H]12,ertapenem,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,intra-abdominal infections|skin infections|pneumonia|urinary tract infections|gynecologic infections|postpartum endomyometritis
Oc1ccc([C@@H]2Oc3ccc(O)cc3[C@@H]3CCC[C@@H]32)cc1,erteberel,Phase 2,estrogen receptor agonist,ESR1|ESR2,,
CCOc1ccc(Cc2cc([C@]34OC[C@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1,ertugliflozin,Launched,sodium/glucose cotransporter inhibitor,SLC5A2,endocrinology,diabetes mellitus
OC[C@@H](O)[C@@H](O)CO,erythritol,Launched,,,,
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,erythromycin,Launched,NFkB pathway inhibitor,MLNR,infectious disease,listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma
CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C,erythromycin-estolate,Launched,bacterial 50S ribosomal subunit inhibitor,ABCB1|ALB|CYP3A4|CYP51A1|KCNH2|MLNR|SLC47A1,infectious disease,listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma
CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C,erythromycin-ethylsuccinate,Launched,cytochrome P450 inhibitor|protein synthesis inhibitor,ABCB1|ALB|CYP3A4|CYP51A1|KCNH2|MLNR|SLC47A1,infectious disease,listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma
O=C1OC2(c3ccccc31)c1cc(I)c(O)c(I)c1Oc1c2cc(I)c(O)c1I,erythrosine,Preclinical,coloring agent,,,
O=C(CN1CCNCC1)NC1CCCCC1,esaprazole,Phase 2,,,,
Cc1c(C(=O)Nc2ccc(S(C)(=O)=O)cc2)cn(CCO)c1-c1ccccc1C(F)(F)F,esaxerenone,Preclinical,mineralocorticoid receptor antagonist,,,
CC=C(C)C(=O)O[C@H]1[C@H](OC(C)=O)[C@]2(CO)[C@H](O)C[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O[C@@H]6O[C@H](C(=O)O)[C@@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)[C@](C)(CO)[C@@H]5CC[C@]43C)[C@@H]2CC1(C)C,escin,Launched,nitric oxide synthase stimulant,,dermatology,varicose veins
CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21.O=C(O)C(=O)O,escitalopram,Launched,selective serotonin reuptake inhibitor (SSRI),SLC6A4,neurology/psychiatry,depression|generalized anxiety disorder (GAD)
CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,escitalopram,Launched,selective serotonin reuptake inhibitor (SSRI),SLC6A4,neurology/psychiatry,depression|generalized anxiety disorder (GAD)
O=c1ccc2cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c(O)cc2o1,esculin,Phase 1,antioxidant,,,
CN1CC[C@@]2(C)c3cc(O)ccc3N(C)[C@@H]12,eseroline-(-),Preclinical,acetylcholinesterase inhibitor,OPRD1|OPRM1,,
CC(C)(C)c1cc(C(=O)/C(C#N)=N/Nc2cccc(Cl)c2)no1,ESI-09,Preclinical,EPAC inhibitor,RAPGEF3|RAPGEF4,,
CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc21,eslicarbazepine-acetate,Launched,sodium channel blocker,SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,seizures
COC(=O)CCc1ccc(OC[C@@H](O)CNC(C)C)cc1,esmolol,Launched,adrenergic receptor antagonist,ADRB1,cardiology,ventricular tachycardia (VT)|hypertension
COc1ccc2nc([S@@](=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,esomeprazole,Launched,ATPase inhibitor,ATP4A,gastroenterology,gastroesophageal reflux disease (GERD)|Zollinger-Ellison syndrome|peptic ulcer disease (PUD)
CC(=O)SC[C@H](CC(=O)c1ccc(C)cc1)C(=O)O,esonarimod,Preclinical,antirheumatic drug,,,
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O,estetrol,Phase 3,selective estrogen receptor modulator (SERM),ESR1,,
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,estradiol,Launched,estrogen receptor agonist,ESR1|ESR2|GPER1|KCNMA1|NR1I2,endocrinology,contraceptive
C[C@]12CC[C@@H]3c4ccc(OS(N)(=O)=O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,estradiol-3-O-sulfamate,Phase 2,steryl sulfatase inhibitor,,,
CC(=O)Oc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,estradiol-acetate,Launched,estrogen receptor agonist,ESR1,endocrinology|obstetrics/gynecology,menopause|vaginal atrophy
C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,estradiol-benzoate,Preclinical,contraceptive agent,ESR1,,
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1,estradiol-cypionate,Launched,estrogen receptor agonist,ESR1,endocrinology,hypoestrogenism|menopause
CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C,estradiol-valerate,Launched,estrogen receptor agonist,ESR1,oncology|endocrinology|obstetrics/gynecology,prostate cancer|hypoestrogenism|menopause|vaginal atrophy
C[C@]12CC[C@@H]3c4ccc(OC(=O)N(CCCl)CCCl)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,estramustine,Launched,DNA alkylating agent,ESR1|ESR2|MAP1A|MAP2,oncology,prostate cancer
C[C@]12CC[C@@H]3c4ccc(OC(=O)N(CCCl)CCCl)cc4CC[C@H]3[C@@H]1CC[C@@H]2OP(=O)(O)O,estramustine-phosphate,Launched,DNA synthesis inhibitor|microtubule inhibitor,ESR1|ESR2|MAP1A|MAP2,oncology,prostate cancer
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@@H](O)[C@@H]2O,estriol,Launched,estrogen receptor agonist,ESR1|ESR2,endocrinology|obstetrics/gynecology|infectious disease,menopause|vaginal atrophy|urinary tract infections
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CCC2=O,estrone,Launched,estrogen receptor agonist|estrogenic hormone,ESR1|ESR2,endocrinology,menopause
C[C@]12CC[C@@H]3c4ccc(OS(=O)(=O)O)cc4CC[C@H]3[C@@H]1CCC2=O,estropipate,Launched,estrogen receptor agonist,ESR1|ESR2,orthopedics|endocrinology|obstetrics/gynecology,osteoporosis|menopause|vaginal atrophy|hypoestrogenism
C=C(CC)C(=O)c1ccc(OCC(=O)O)c(Cl)c1Cl,etacrynic-acid,Launched,sodium/potassium/chloride transporter inhibitor,ATP1A1|SLC12A1,cardiology|gastroenterology|nephrology|rheumatology,hypertension|congestive heart failure|edema|hepatic cirrhosis|chronic renal failure|nephrotic syndrome
CCN(CC)CCOc1ccccc1C(=O)CCc1ccccc1,etafenone,Launched,calcium channel blocker,,,
O=S(=O)(O)c1cc(O)ccc1O,etamsylate,Launched,hemostatic agent,,hematology,hemorrhage
O=C(Cn1ccnc1[N+](=O)[O-])NCCO,etanidazole,Phase 3,bacterial cell wall synthesis inhibitor,,,
CCOC(=O)c1cnc2c(cnn2CC)c1NN=C(C)C,etazolate,Phase 2,phosphodiesterase inhibitor,GABRB3|PDE4A,,
Cn1c(=O)c2c(ncn2CC(=O)Nc2ccc(-c3ccccc3)nn2)n(C)c1=O,ETC-159,Phase 1,beta catenin inhibitor|porcupine inhibitor,PORCN,,
N#Cc1ccc(-c2cnc3ccc(-c4ccc(C(=O)N5CCOCC5)cc4)cn23)cc1,ETC-206,Phase 1,MAPK-interacting kinase inhibitor,,,
CCN(CC)S(=O)(=O)c1ccc(C(=O)O)cc1,etebenecid,Preclinical,uricosuric blocker,,,
CCC1(c2ccccc2)C(=O)N(COC)C(=O)N(COC)C1=O,eterobarb,Phase 2,anticonvulsant,,,
CCOC(=O)Nc1ccc2c(c1)N(C(=O)CCN(CC)CC)c1ccccc1S2,ethacizin,Launched,anticonvulsant,,cardiology,ventricular tachycardia (VT)|Wolff-Parkinson-White Syndrome (WPW)
CCOc1ccc2nc3cc(N)ccc3c(N)c2c1,ethacridine-lactate-monohydrate,Preclinical,DNA intercalating agent,,,
CC[C@@H](CO)NCCN[C@@H](CC)CO,ethambutol,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,tuberculosis
CCN(CC)C(=O)c1ccc(O)c(OC)c1,ethamivan,Preclinical,respiratory stimulant,,,
CCOc1ccc(Cc2nccc3cc(OCC)c(OCC)cc23)cc1OCC,ethaverine,Launched,calcium channel blocker,,neurology/psychiatry,muscle relaxant|spasms
CCOc1ccccc1C(N)=O,ethenzamide,Launched,analgesic agent,,neurology/psychiatry|endocrinology|otolaryngology,headache|fever|common cold
CCn1cnc(C(=O)NC)c1C(=O)NC,ethimizol,Phase 1,,,,
C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,ethinyl-estradiol,Launched,estrogen receptor agonist|estrogenic hormone,ESR1|ESR2|NR1I2,endocrinology,contraceptive
CCc1cc(C(N)=S)ccn1,ethionamide,Launched,mycolic synthesis inhibitor,,infectious disease,tuberculosis
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,ethisterone,Launched,progestogen hormone,TYR,endocrinology,amenorrhea
CCOc1cc(NC(C)=O)ccc1C(=O)OC,ethopabate,Launched,antiprotozoal agent,,infectious disease,coccidiosis
CC[C@@]1(C)CC(=O)NC1=O,ethosuximide,Launched,succinimide antiepileptic,CACNA1G|CACNA1H|CACNA1I,neurology/psychiatry,epilepsy
CCN1C(=O)N[C@H](c2ccccc2)C1=O,ethotoin,Launched,hydantoin antiepileptic,SCN5A,neurology/psychiatry,seizures
CCOc1ccc2c(c1)C(C)=CC(C)(C)N2,ethoxyquin,Preclinical,antioxidant,,,
CCOc1ccc2nc(S(N)(=O)=O)sc2c1,ethoxzolamide,Launched,carbonic anhydrase inhibitor,CA1|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|CA5B|CA6|CA7|CA9,ophthalmology|gastroenterology,glaucoma|duodenal ulcer disease
CCOC(=O)c1ccccc1OC(N)=O,ethyl-2-(carbamoyloxy)benzoate,Phase 1,,,,
CCOC(=O)c1ccc(O)cc1,ethyl-paraben,Preclinical,,,,
C=C(O)C(=O)OCC,ethyl-pyruvate,Phase 2,tumor necrosis factor production inhibitor,,,
CCOc1cc(C=O)ccc1O,ethyl-vanillin,Preclinical,,,,
O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O,ethylenediaminetetraacetic-acid,Launched,PKC inhibitor,,neurology/psychiatry,metal toxicity
CC[C@@H](N)[C@@H](O)c1ccc(O)c(O)c1,ethylnorepinephrine,Preclinical,bronchodilator,,,
C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=C[C@@H](OC(C)=O)CC[C@@H]4[C@H]3CC[C@@]21C,ethynodiol-diacetate,Launched,,ESR1|PGR,endocrinology,contraceptive
C#C[C@@]1(O)[C@@H](CO)O[C@@H](n2ccc(N)nc2=O)[C@@H]1O,ethynylcytidine,Preclinical,antimetabolite,,,
CCc1cc(Cl)c(OC)c(C(=O)NC[C@@H]2CCCN2CC)c1O,eticlopride,Preclinical,dopamine receptor antagonist,DRD2|DRD3|DRD4,,
CCc1cccc(CC)c1NC(=O)CN(CC(=O)O)CC(=O)O,etifenin,Preclinical,renal function diagnostic agent,,,
CCNC1=Nc2ccc(Cl)cc2[C@](C)(c2ccccc2)O1,etifoxine,Launched,GABA receptor modulator,GABRA1|GABRA2|GABRA3|GABRA5,neurology/psychiatry,anxiety
CCNCC(O)c1cccc(O)c1,etilefrine,Launched,adrenergic receptor agonist,ADRA1A|ADRB1,neurology/psychiatry|otolaryngology|endocrinology|pulmonary,headache|nasal congestion|fever|cough suppressant|common cold
CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1,etilevodopa,Phase 3,dopamine receptor agonist,DRD3,,
CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl,etizolam,Launched,benzodiazepine receptor agonist,GABRA1,neurology/psychiatry,insomnia|anxiety
CCc1cccc2c3c([nH]c12)[C@](CC)(CC(=O)O)OCC3,etodolac,Launched,cyclooxygenase inhibitor,PTGS2,rheumatology,osteoarthritis|rheumatoid arthritis
O=C(OCCOCCO)c1ccccc1Nc1cccc(C(F)(F)F)c1,etofenamate,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry|rheumatology,muscle pain|joint pain
CC(C)(Oc1ccc(Cl)cc1)C(=O)OCCOC(=O)c1cccnc1,etofibrate,Launched,PPAR receptor agonist,PPARA,endocrinology,hypertriglyceridemia
Cn1c(=O)c2c(ncn2CCO)n(C)c1=O,etofylline,Launched,adenosine receptor antagonist,ADORA1,pulmonary,asthma|bronchitis
Cn1c(=O)c2c(ncn2CCOC(=O)C(C)(C)Oc2ccc(Cl)cc2)n(C)c1=O,etofylline-clofibrate,Launched,platelet aggregation inhibitor,PPARA,endocrinology,hyperlipidemia
CCOC(=O)c1cncn1[C@H](C)c1ccccc1,etomidate,Launched,GABA receptor modulator,ADRA2B|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ,neurology/psychiatry,general anaesthetic
CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1,etomoxir,Phase 2,carnitine palmitoyltransferase inhibitor,CPT1A,,
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3C(=C)C[C@@]21CC,etonogestrel,Launched,progesterone receptor agonist,ESR1|PGR,endocrinology,contraceptive
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,etoposide,Launched,topoisomerase inhibitor,TOP2A|TOP2B,oncology,non-small cell lung cancer (NSCLC)
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OP(=O)(O)O,etoposide-phosphate,Launched,topoisomerase inhibitor,TOP2A,oncology,testicular carcinoma|small cell lung cancer
Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1,etoricoxib,Launched,cyclooxygenase inhibitor,PTGS2,rheumatology,rheumatoid arthritis|psoriatic arthritis|osteoarthritis|gout|ankylosing spondylitis
CCOCCOc1ccccc1C(N)=O,etosalamide,Preclinical,anti-inflammatory agent,,,
O=C(CCCO)NCCO,etoxybamide,Phase 2,,,,
Cn1ncc2c(N3CCOCC3)nc(-c3cccc(O)c3)nc21,ETP-45658,Preclinical,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,,
CC(C)(C#N)c1ccc(N2C(=O)OCc3cnc4ccc(-c5cnc6ccccc6c5)cc4c32)cc1,ETP-46464,Preclinical,ATR kinase inhibitor,,,
CN[C@H]1CCc2ncsc2C1,etrabamine,Phase 2,dopamine receptor agonist,,,
O=C(O)C[C@H]1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(C(F)(F)F)c3)cc21,etrasimod,Phase 3,sphingosine 1-phosphate receptor antagonist,,,
Cc1cc(C#N)cc(C)c1Oc1nc(Nc2ccc(C#N)cc2)nc(N)c1Br,etravirine,Launched,non-nucleoside reverse transcriptase inhibitor,CYP2C19|CYP2C9|CYP3A4,infectious disease,human immunodeficiency virus (HIV-1)
CC12CCC(CC1)C(C)(C)O2,eucalyptol,Launched,acetylcholinesterase inhibitor,ACHE,dental,gingivitis
C[C@H]1C[C@H](OC(=O)[C@@H](O)c2ccccc2)CC(C)(C)N1C,eucatropine,Preclinical,acetylcholine receptor antagonist,,,
C=CCc1ccc(O)c(OC)c1,eugenol,Launched,androgen receptor antagonist,AR,dental,toothache
COc1ccc(-c2cc(=O)c3c(O)c(OC)c(O)cc3o2)cc1OC,eupatilin,Launched,mucus protecting agent,,,
Cc1cc(C)c2c(c1)[C@@H](N(Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1nnn(C)n1)CCCN2C[C@H]1CC[C@H](C(=O)O)CC1,evacetrapib,Phase 3,cholesteryl ester transfer protein inhibitor,CETP,,
Cc1cc(-c2ccc(NN=C3C=Cc4c(S(=O)(=O)O)cc(S(=O)(=O)O)c(N)c4C3=O)c(C)c2)ccc1NN=C1C=Cc2c(S(=O)(=O)O)cc(S(=O)(=O)O)c(N)c2C1=O,evans-blue,Launched,glutamate receptor negative allosteric modulator,GRIA1|PTPN1,,
CC(C)(C)c1ccc(CN(Cc2cccc(OCC(=O)O)c2)S(=O)(=O)c2cccnc2)cc1,evatanepag,Phase 2,prostaglandin inhibitor,PTGER2|PTGER4,,
CCCCOc1cccc(CCNCC(=O)N(C)C)c1,evenamide,Phase 2,voltage-gated sodium channel blocker,,,
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,everolimus,Launched,mTOR inhibitor,MTOR,oncology|neurology/psychiatry|genetics|urology,breast cancer|neuroendocrine tumors of pancreatic origin (PNET)|renal cell carcinoma (RCC)|subependymal giant cell astrocytoma (SEGA)|tuberous sclerosis complex (TSC)|renal angiomyolipoma
C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1,evobrutinib,Phase 2,Bruton's tyrosine kinase (BTK) inhibitor,,,
C[C@@H](N[C@H]1CCN(c2ccc(CC(=O)O)cc2)C1)c1cccc2ccccc12,evocalcet,Phase 3,calcium sensitizer,,,
CN1c2ccccc2C(=O)N2CCc3c([nH]c4ccccc34)[C@H]21,evodiamine,Preclinical,ATPase inhibitor|TRPV agonist,TRPV1,,
O=C(N[C@H]1CN2CCC1CC2)c1cc2cccc(Cl)c2s1,EVP-6124,Phase 3,acetylcholine receptor agonist,CHRNA7,,
Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1,EVP4593,Preclinical,NFkB pathway inhibitor,,,
Cc1cccc(-c2nc(CNc3ccccc3F)[nH]c2-c2ccc3ncnn3c2)n1,EW-7197,Phase 2,TGF beta receptor inhibitor,ACVR1B|TGFBR1,,
NC(=O)[C@H]1CCCc2c1[nH]c1ccc(Cl)cc21,EX-527,Phase 2,SIRT inhibitor,SIRT1,,
CCCCCCOc1ccccc1C(N)=O,exalamide,Launched,membrane permeability inhibitor,,,
Cc1[nH]c2ccccc2c1C[C@@H](NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O,examorelin,Phase 2,growth hormone releasing factor agonist,GHRHR|GHSR,,
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1cc(F)c(C)c3c1c2[C@@H](N)CC3,exatecan-mesylate,Phase 3,topoisomerase inhibitor,TOP1,,
C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,exemestane,Launched,aromatase inhibitor,CYP19A1,oncology,breast cancer
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,exenatide,Launched,GLP receptor agonist,GLP1R,endocrinology,diabetes mellitus
CC(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O,exherin,Phase 2,cadherin antagonist,CDH2,,
CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc(S(C)(=O)=O)cc1,exisulind,Phase 3,phosphodiesterase inhibitor,PDE5A,,
COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1,EXO-1,Preclinical,ARF inhibitor,,,
O=C(Nc1cccc2cccnc12)c1ccc(N2C(=O)[C@@H]3[C@H](C2=O)[C@H]2C=C[C@@H]3C2)cc1,exo-IWR-1,Preclinical,WNT signaling inhibitor negative control,TNKS,,
CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1,ezatiostat,Phase 2,glutathione transferase inhibitor,GSTP1,,
O=C1[C@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1,ezetimibe,Launched,cholesterol inhibitor|Niemann-Pick C1-like 1 protein antagonist,ANPEP|NPC1L1|SOAT1,endocrinology|metabolism,hyperlipidemia|hypercholesterolemia|sitosterolemia
CCN(CC)c1ccc(-n2nc3cc(C)c(N)cc3n2)cc1,ezutromid,Phase 2,utrophin enhancer,UTRN,,
Cn1c(=O)cnn(CCCCN2CCN(c3ncccn3)CC2)c1=O,F-11440,Phase 2,serotonin receptor agonist,HTR1A,,
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OCc1cccnc1,F-16915,Preclinical,,,,
Cc1ccc(=O)n(-c2ccc(O)cc2)c1,F351,Phase 2,TGF beta receptor inhibitor,TGFB1,,
N#Cc1ccc([C@H]2CCCc3cncn32)cc1,fadrozole,Launched,aromatase inhibitor,CYP11B1|CYP19A1,oncology,breast cancer
OC[C@H]1NCC[C@@H](O)[C@@H]1O,fagomine,Phase 2,glucosidase inhibitor,GLB1,,
C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(O)(C(F)(F)F)C(F)(F)F)CC[C@@H]23)C[C@@H](O)C[C@@H]1O,falecalcitriol,Launched,vitamin D receptor agonist,VDR,endocrinology,hyperparathyroidism
CC(=O)OCC(CCn1cnc2cnc(N)nc21)COC(C)=O,famciclovir,Launched,DNA polymerase inhibitor,,dental|infectious disease,cold sore|genitial herpes|shingles
N=C(N)Nc1nc(CSCC/C(N)=N\S(N)(=O)=O)cs1,famotidine,Launched,histamine receptor antagonist,HRH2,gastroenterology,heartburn
CC(C)c1c(CN(C)[C@@H](C)Cc2ccccc2)n(C)n(-c2ccccc2)c1=O,famprofazone,Preclinical,cyclooxygenase inhibitor,,,
O=S1(=O)c2cccc3cccc(c23)N1CCCN1CCN(c2ccc(F)cc2)CC1,fananserin,Phase 2,dopamine receptor antagonist|serotonin receptor antagonist,HTR2A,,
c1ccc(CCNc2nc(-c3ccccc3)cs2)cc1,fanetizole,Phase 3,neutrophil superoxide production,,,
COc1ccc(CCN(C)CCCOc2ccc(S(=O)(=O)c3c(C(C)C)cn4ccccc34)cc2)cc1OC,fantofarone,Preclinical,calcium channel blocker,,,
O=C(c1ccc2nonc2c1)N1CCCCC1,farampator,Preclinical,ionotropic glutamate receptor agonist,,,
CC(C)=CCC/C(C)=C/CC/C(C)=C/CSc1ccccc1C(N)=O,farnesyl-thiosalicylic-acid-amide,Phase 1,Ras GTPase inhibitor,HRAS,,
C[C@@H](O)[C@@H]1C(=O)N2C(C(=O)O)=C([C@H]3CCCO3)S[C@H]12,faropenem,Launched,lactamase inhibitor,,infectious disease|pulmonary|otolaryngology,pneumonia|bronchitis|skin infections|urinary tract infections|sinusitis
Cc1oc(=O)oc1COC(=O)C1=C([C@H]2CCCO2)S[C@@H]2[C@@H]([C@@H](C)O)C(=O)N12,faropenem-medoxomil,Launched,lactamase inhibitor,,otolaryngology|infectious disease|pulmonary,sinusitis|pneumonia|bronchitis|skin infections|urinary tract infections
O=C1CC[C@H](C(=O)N2CCCCC2)N1,fasoracetam,Preclinical,GABA receptor antagonist,,,
O=S(=O)(c1cccc2cnccc12)N1CCCNCC1,fasudil,Launched,rho associated kinase inhibitor,PKIA|PRKACA|ROCK1|ROCK2,neurology/psychiatry,cerebral vasospasm
NC(=O)c1nc(F)c[nH]c1=O,favipiravir,Phase 3,RNA polymerase inhibitor,,,
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N=C/N5CCCCC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,FCE-22250,Phase 1,DNA directed DNA polymerase inhibitor,,,
Nc1nc(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1F,fdcyd,Phase 2,DNA methyltransferase inhibitor,,,
CCCCOC[C@@H](O)COc1ccccc1,febuprol,Launched,choleretic agent,,,
Cc1nc(-c2ccc(OCC(C)C)c(C#N)c2)sc1C(=O)O,febuxostat,Launched,xanthine oxidase inhibitor,XDH,nephrology,hyperuricemia
Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1,fedratinib,Launched,FLT3 inhibitor|JAK inhibitor,BRD4|JAK1|JAK2|JAK3|TYK2,hematologic malignancy,myelofibrosis
NC(=O)OCC(COC(N)=O)c1ccccc1,felbamate,Launched,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B,neurology/psychiatry,epilepsy
O=C(O)Cc1ccc(-c2ccccc2)cc1,felbinac,Launched,cyclooxygenase inhibitor,CTSL,rheumatology|neurology/psychiatry,rheumatoid arthritis|muscle pain
CCOC(=O)Cc1ccc(-c2ccccc2)cc1,felbinac-ethyl,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,,
CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1c1cccc(Cl)c1Cl,felodipine,Launched,calcium channel blocker,CFTR,cardiology,hypertension
NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,felypressin,Preclinical,vasopressin receptor agonist,,,
O=C(CCCl)NCCc1ccccc1,fenaclon,Preclinical,,,,
COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1,fenbendazole,Launched,tubulin polymerization inhibitor,TUBB,infectious disease,gastrointestinal parasites|gastrointestinal roundworms
O=C(O)CCC(=O)c1ccc(-c2ccccc2)cc1,fenbufen,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief
N[C@@H](Cc1ccc(Cl)cc1)C(=O)O,fenclonine-(+/-),Preclinical,tryptophan hydroxylase inhibitor,PAH|TPH1|TPH2,,
C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1,fendiline,Preclinical,calcium channel blocker,HTR2B,,
C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1,fenebrutinib,Phase 2,Bruton's tyrosine kinase (BTK) inhibitor,,,
NC[C@@H](CC(=O)O)c1ccccc1,fenigam,Launched,benzodiazepine receptor agonist,GABBR1|GABBR2,neurology/psychiatry,posttraumatic stress disorder|anxiety|depression
CCCC[C@@H](O)c1ccccc1,fenipentol,Launched,choleretic agent,,gastroenterology,bile stimulation
CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1,fenobam,Phase 2,glutamate receptor antagonist,GRM5,,
CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1,fenofibrate,Launched,PPAR receptor agonist,MMP25|PPARA,endocrinology,hypercholesterolemia|hypertriglyceridemia
CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)O,fenofibric-acid,Launched,cytochrome P450 inhibitor,CLCN1|PPARA,cardiology,dyslipidemia
Oc1ccc([C@H]2CNCCc3c2cc(O)c(O)c3Cl)cc1,fenoldopam,Launched,dopamine receptor agonist,DRD1|DRD4,cardiology,hypertension
C[C@@H](C(=O)O)c1cccc(Oc2ccccc2)c1,fenoprofen,Launched,prostaglandin inhibitor,PTGS1|SLC5A8,rheumatology,rheumatoid arthritis|osteoarthritis
O=C(CN1CCN(Cc2ccc3c(c2)OCO3)CC1)N1c2ccccc2Sc2ccccc21,fenoverine,Launched,acetylcholine receptor antagonist,,neurology/psychiatry,spasms
CCOC(=O)[C@@H](C)Oc1ccc(Oc2nc3ccc(Cl)cc3o2)cc1,fenoxaprop-p-ethyl,Preclinical,,NOS3,,
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)Nc2ccc(O)cc2)C(C)(C)CCC1,fenretinide,Phase 3,apoptosis stimulant|retinoid receptor agonist,RARA,,
O=C1NCC2(CCN(CCc3ccccc3)CC2)O1,fenspiride,Launched,bronchodilator,,pulmonary|otolaryngology,asthma|otitis|sinusitis|rhinopharyngitis|laryngitis
COP(=S)(OC)Oc1ccc(SC)c(C)c1,fenthion,Launched,cholinesterase inhibitor,,,
O=C(O)Cc1sc(-c2ccccc2)nc1-c1ccc(Cl)cc1,fentiazac,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry|rheumatology,muscle pain|joint pain
Clc1ccc([C@@H](Cn2ccnc2)OCc2ccc(Sc3ccccc3)cc2)c(Cl)c1,fenticonazole,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,vulvovaginal candidiasis
O/N=C/c1ccc(-c2ccc(O)c(F)c2)c(Cl)c1O,FERb-033,Preclinical,EGFR inhibitor,ERBB2,,
CN(C)CC1=CC=C[C@@]1(CNc1ccnc2cc(Cl)ccc12)[Fe]C1C=CC=C1,ferroquine,Phase 2,antimalarial agent,,,
CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1,ferrostatin-1,Preclinical,ferroptosis inhibitor,,,
COc1cc(/C=C/C(=O)O)ccc1O,ferulic-acid,Phase 2,antioxidant,CA1|CA12|CA14|CA2|CA4|CA6|CA9,,
CC(C)C(=O)Oc1ccc(CO)cc1[C@H](CCN(C(C)C)C(C)C)c1ccccc1,fesoterodine,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,urology,urinary incontinence
Cc1c(CC(=O)O)c2cccnc2n1Cc1ccc(S(C)(=O)=O)cc1C(F)(F)F,fevipiprant,Phase 2,prostaglandin inhibitor,,,
COC(=O)/C=C/c1cccc(N(Cc2ccc(-c3ccc(N(C)C)cc3)cc2)C(=O)C2CCCCC2)c1,fexaramine,Preclinical,FXR agonist,NR1H4,,
CSc1ccc(OCc2ncc([N+](=O)[O-])n2C)cc1,fexinidazole,Phase 3,,,,
CC(C)(C(=O)O)c1ccc([C@@H](O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,fexofenadine,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis|urticaria
Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3C)n1,fezolinetant,Phase 2,neurokinin receptor antagonist,,,
O=C(O)CNC(=O)c1nc(Cl)c2ccccc2c1O,FG-2216,Phase 2,hypoxia inducible factor prolyl hydroxylase inhibitor,EGLN1|EGLN2|HIF1A,,
Cc1nc(C(=O)NCC(=O)O)c(O)c2ccc(Oc3ccccc3)cc12,FG-4592,Phase 3,hypoxia inducible factor prolyl hydroxylase inhibitor,EGLN1|EGLN2|EGLN3,,
CNC(=O)c1cc2c(cn1)[nH]c1ccccc12,FG-7142,Preclinical,GABA benzodiazepine site receptor inverse agonist,,,
CCCCCCN(CCCCCC)C(=O)Cc1c(-c2ccc(F)cc2)[nH]c2ccccc12,FGIN-1-27,Preclinical,inositol monophosphatase inhibitor,TSPO,,
CCCCCCN(CCCCCC)C(=O)Cc1c(-c2ccc(Cl)cc2)[nH]c2ccc(Cl)cc12,FGIN-1-43,Preclinical,benzodiazepine receptor agonist,TSPO,,
Cc1cc([N+](=O)[O-])ccc1NS(=O)(=O)c1cc(Cl)ccc1Cl,FH-535,Preclinical,PPAR receptor antagonist|WNT signaling inhibitor,PPARD|PPARG,,
CC(=O)Nc1ccc(Cc2ccc(NC(C)=O)cc2)cc1,FH1,Preclinical,hepatocyte function enhancer,,,
Nc1nc(=O)n([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2F)cc1I,fiacitabine,Phase 2,DNA synthesis inhibitor,,,
NC(=O)[C@H]1C[C@]2(NC(=O)NC2=O)c2cc(F)ccc2O1,fidarestat,Phase 3,aldose reductase inhibitor,AKR1B1,,
CCc1c(Cl)c(O)c(Cl)c(O)c1C(=O)O[C@H]1[C@H](O)[C@H](OC)[C@H](OC/C2=C\C=C\C[C@H](O)/C(C)=C/[C@H](CC)[C@@H](O[C@@H]3OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]3O)/C(C)=C/C(C)=C/C[C@@H]([C@@H](C)O)OC2=O)O[C@@H]1C,fidaxomicin,Launched,RNA polymerase inhibitor,,gastroenterology,diarrhea
CON(C)C(=O)N1N=C(c2cc(F)ccc2F)S[C@@]1(CCCN)c1ccccc1,filanesib,Phase 3,kinesin inhibitor|kinesin-like spindle protein inhibitor,KIF11,,
O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1,filgotinib,Phase 3,JAK inhibitor,JAK1|JAK2|JAK3|TYK2,,
CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,fimasartan,Launched,angiotensin receptor antagonist,AGTR1,cardiology,hypertension|congestive heart failure
N#Cc1c(N2C[C@@H]3NCCO[C@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,finafloxacin,Launched,bacterial DNA gyrase inhibitor,,infectious disease|pulmonary,intra-abdominal infections|chronic obstructive pulmonary disease (COPD)|cystic fibrosis
CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C,finasteride,Launched,5 alpha reductase inhibitor,AKR1D1|SRD5A1|SRD5A2,endocrinology,androgenetic alopecia
CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1,fingolimod,Launched,immunosuppressant|sphingosine 1-phosphate receptor agonist,S1PR1|S1PR5,neurology/psychiatry,multiple sclerosis
O=C(NCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1)c1cc2cc(F)ccc2[nH]1,FIPI,Preclinical,phospholipase inhibitor,PLD1|PLD2,,
N#Cc1nn(-c2c(Cl)cc(C(F)(F)F)cc2Cl)c(N)c1[S@@](=O)C(F)(F)F,fipronil,Launched,chloride channel blocker|GABA gated chloride channel blocker,,infectious disease,flea control
CCOCc1cc(OC)c(-c2ccc(C[C@H](NC(=O)c3c(F)cccc3F)C(=O)O)cc2)c(OC)c1,firategrast,Phase 2,integrin antagonist,ITGA4,,
CC1(C)OC(=O)C(OCC2CC2)=C1c1ccc(S(C)(=O)=O)cc1,firocoxib,Launched,cyclooxygenase inhibitor,PTGS2,rheumatology,osteoarthritis
COc1ccccc1[C@H](Cn1c(=O)n(C(C)(C)C(=O)O)c(=O)c2c(C)c(-c3ncco3)sc21)OC1CCOCC1,firsocostat,Phase 2,acetyl-CoA carboxylase inhibitor,,,
O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)ccc12,fisetin,Preclinical,Aurora kinase inhibitor,CDK6|FASN,,
C=CC(=O)N[C@H]1CCOC[C@H]1Nc1ncc2cc(-c3c(Cl)c(OC)cc(OC)c3Cl)ccc2n1,fisogatinib,Phase 1,fibroblast growth factor inhibitor,,,
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccc(N=C=S)cc2)CC1,FIT,Preclinical,opioid receptor agonist,OPRD1,,
C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N[C@H](CO)CC[S@@](C)=O,FK-33-824,Phase 2,opioid receptor agonist,OPRM1,,
CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1,FK-3311,Phase 2,cyclooxygenase inhibitor,PTGS2,,
CC/C(=C\C(=N\O)C(N)=O)[C@@H](C)[N+](=O)[O-],FK-409,Phase 2,guanylyl cyclase activator,,,
O=C(/C=C/c1cccnc1)NCCCCC1CCN(C(=O)c2ccccc2)CC1,FK-866,Phase 2,niacinamide phosphoribosyltransferase inhibitor,NAMPT,,
CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12,FK-888,Phase 2,tachykinin antagonist,TACR1|TACR2,,
CC(=O)N1CCC(NC(=O)c2ccc(F)cc2)CC1,FK-962,Phase 2,somatostatin receptor agonist,,,
Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@H](O)[C@H](O)[C@H](O)CO[P@](=O)(O)O[P@](=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](O)[C@@H]3O)c2cc1C,flavin-adenine-dinucleotide,Preclinical,,ACAD8|ACADM|ACADS|ACOX1|AIFM1|CYB5R1|CYB5R3|DAO|DLD|DPYD|ERO1LB|FDXR|GCDH|GFER|GSR|IL4I1|IVD|MAOA|MAOB|NOS1|NQO1|NQO2|POR|TXNRD1|XDH,,
Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O,flavoxate,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2,urology,urinary incontinence|interstitial cystitis (IC)|urethritis|prostatitis
O=C(NCC1CCCCN1)c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F,flecainide,Launched,sodium channel blocker,KCNA5|KCNA7|SCN5A,cardiology,ventricular tachycardia (VT)|atrial fibrillation (AF)|ventricular arrhythmias
CN1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn(CCF)c3c2F)CC1,fleroxacin,Launched,topoisomerase inhibitor,TOP2A,infectious disease|gastroenterology,gonorrhea|enteritis|diarrhea|respiratory tract infections
CC1=NC2=C(C(=O)CC(C)(C)C2)[C@H](c2ccc([N+](=O)[O-])cc2)C1C(=O)OC1CCCCC1,FLI-06,Preclinical,notch signaling inhibitor,,,
O=c1[nH]c2ccccc2n1CCN1CCN(c2cccc(C(F)(F)F)c2)CC1,flibanserin,Launched,serotonin receptor agonist,DRD4|HTR1A|HTR2A,neurology/psychiatry,hypoactive sexual desire disorder
COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(C(F)(F)F)ccc21,flindokalner,Phase 3,potassium channel agonist,KCNMA1|KCNN4|KCNQ2|KCNQ4|KCNQ5,,
O=C(OC[C@H](O)CO)c1ccccc1Nc1ccnc2c(C(F)(F)F)cccc12,floctafenine,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief
CCC(=O)c1c(O)cc(O)cc1O,flopropione,Launched,serotonin receptor antagonist,HTR1A,neurology/psychiatry,spasms
CS(=O)(=O)c1ccc([C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)cc1,florfenicol,Launched,protein synthesis inhibitor,,pulmonary,bovine respiratory disease (BRD)
O=C(OCCN1CCCC1)c1ccccc1Nc1ccnc2cc(C(F)(F)F)ccc12,florifenine,Preclinical,anti-inflammatory agent,,,
O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1F,floxuridine,Launched,DNA synthesis inhibitor,TYMS,oncology,colorectal cancer
CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C,FLT3-IN-1,Preclinical,FLT3 inhibitor,,,
COC(=O)Nc1nc2ccc(C(=O)c3ccc(F)cc3)cc2[nH]1,flubendazole,Launched,tubulin polymerization inhibitor,TUBB,infectious disease,gastrointestinal parasites
Cc1onc(-c2c(F)cccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O,flucloxacillin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease|otolaryngology|dermatology|gastroenterology,gram-positive bacterial infections|tonsillitis|sinusitis|pneumonia|eczema|endocarditis|meningitis|enteritis|bacterial septicemia
OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,fluconazole,Launched,sterol demethylase inhibitor,CYP51A1,infectious disease,esophageal candidiasis|meningitis
Nc1nc(=O)[nH]cc1F,flucytosine,Launched,other antifungal,DNMT1,infectious disease,bacterial septicemia|endocarditis|urinary tract infections|meningitis
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,fludarabine,Launched,ribonucleotide reductase inhibitor,ADA|DCK|POLA1|RRM1|RRM2,hematologic malignancy,chronic lymphocytic leukemia (CLL)
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O,fludarabine-phosphate,Launched,ribonucleotide reductase inhibitor,POLA1|POLD1|POLE|RRM1|RRM2|RRM2B,hematologic malignancy,chronic lymphocytic leukemia (CLL)
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,fludrocortisone-acetate,Launched,,NR3C2,endocrinology,Addison's disease|adrenogenital syndrome
CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,fludroxycortide,Launched,glucocorticoid receptor agonist,NR3C1|SERPINA6,infectious disease|dermatology,skin infections|psoriasis
O=C(O)c1ccccc1Nc1cccc(C(F)(F)F)c1,flufenamic-acid,Preclinical,chloride channel blocker,AKR1C3|ANO1|AR|GJA1|GJA10|GJA3|GJA4|GJA5|GJA8|GJA9|GJB1|GJB2|GJB3|GJB4|GJB5|GJB6|GJB7|GJC1|GJC2|GJC3|GJD2|GJD3|GJD4|GJE1|PANX1|PANX2|PANX3|PKD2L1|PTGS1|PTGS2|TRPC5|TRPM2|TRPM5,,
Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1,flumatinib,Phase 3,Bcr-Abl kinase inhibitor,ABL1|PDGFRB,,
CCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(F)ccc1-2,flumazenil,Launched,benzodiazepine receptor antagonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ,neurology/psychiatry,sedative
CC[C@@](O)(c1ccccc1)c1cccc(C(F)(F)F)c1,flumecinol,Launched,,,,
C[C@H]1CCc2cc(F)cc3c(=O)c(C(=O)O)cn1c23,flumequine,Launched,topoisomerase inhibitor,,infectious disease,urinary tract infections
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,flumethasone,Launched,glucocorticoid receptor agonist,NR3C1|PLA2G1B,otolaryngology|infectious disease|dermatology,otitis|ear infections|corticosteroid-responsive dermatoses
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C,flumethasone-pivalate,Launched,glucocorticoid receptor agonist,NR3C1|SERPINA6,allergy,allergic rhinitis
FC(F)(F)c1cccc([C@H]2CNCCO2)c1,flumexadol,Preclinical,,,,
Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1,flunarizine,Launched,calcium channel blocker,CACNA1G|CACNA1H|CACNA1I|CALM1|HRH1,neurology/psychiatry|cardiology,migraine headache|vertigo|peripheral artery disease (PAD)
CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,flunisolide,Launched,cytochrome P450 inhibitor,NR3C1,allergy,allergic rhinitis
Cc1c(Nc2ncccc2C(=O)O)cccc1C(F)(F)F,flunixin-meglumin,Launched,prostanoid receptor antagonist,,pulmonary,bovine respiratory disease (BRD)
CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,fluocinolone-acetonide,Launched,glucocorticoid receptor agonist,NR3C1|SERPINA6,dermatology,seborrheic dermatitis
CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C,fluocinonide,Launched,glucocorticoid receptor agonist,NR3C1|SERPINA6|SMO,dermatology,seborrheic dermatitis|eczema
O=C1OC2(c3ccc(O)cc3Oc3cc(O)ccc32)c2ccccc21,fluorescein,Launched,,SLC22A6,ophthalmology,ophthalmology diagnostic
CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,fluorometholone,Launched,glucocorticoid receptor agonist,NR3C1,ophthalmology,eye inflammation
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,fluorometholone-acetate,Launched,,NR3C1,ophthalmology,eye inflammation
C[N+](C)(CF)CCO,fluoromethylcholine,Launched,,,,
CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,fluoxetine,Launched,selective serotonin reuptake inhibitor (SSRI),ANO1|HTR2B|SLC6A4,neurology/psychiatry,depression|obsessive compulsive disorder (OCD)|bulimia nervosa|panic disorders|bipolar disorder
OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,flupentixol,Launched,dopamine receptor antagonist,ADRA1A|CHRM1|DRD1|DRD2|DRD3|DRD5|HTR2A,neurology/psychiatry,schizophrenia|depression
OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,fluphenazine,Launched,dopamine receptor antagonist,CALM1|DRD1|DRD2|DRD5|HRH1|HTR2A|HTR6|HTR7,neurology/psychiatry,schizophrenia
CCCCCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,fluphenazine-decanoate,Launched,dopamine receptor antagonist,DRD2|HTR1B|HTR4,neurology/psychiatry,schizophrenia
CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N,flupirtine,Launched,glutamate receptor antagonist,ADRA2A|KCNQ1|KCNQ2,neurology/psychiatry,pain relief
NC(=O)NCCN1CCN(c2cccc(C(F)(F)F)c2)CC1,fluprazine,Phase 1,serotonin receptor agonist,HTR1A|HTR1B,,
Cc1cc(C2=NO[C@](c3cc(Cl)cc(Cl)c3)(C(F)(F)F)C2)ccc1C(=O)NCC(=O)NCC(F)(F)F,fluralaner,Preclinical,GABA receptor antagonist,,,
C[C@@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1,flurbiprofen-(+/-),Launched,cyclooxygenase inhibitor,,rheumatology,rheumatoid arthritis|osteoarthritis
C[C@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1,flurbiprofen-(S)-(+),Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,rheumatoid arthritis|osteoarthritis
CC(=O)O[C@@H](C)OC(=O)[C@H](C)c1ccc(-c2ccccc2)c(F)c1,flurbiprofen-axetil,Launched,analgesic agent,,,
C[C@@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1,flurizan,Phase 3,gamma secretase inhibitor,APH1B|BACE1|IKBKG|PSEN1|PSEN2|PTGS1|PTGS2,,
NP(N)(=O)NC(=O)c1ccc(F)cc1,flurofamide,Preclinical,urease inhibitor,,,
O=C1NCN(c2ccccc2)C12CCN(CCCC(c1ccc(F)cc1)c1ccc(F)cc1)CC2,fluspirilene,Launched,dopamine receptor antagonist,CACNG1|DRD2|HRH1|HTR1A|HTR1D|HTR1E|HTR2A,neurology/psychiatry,schizophrenia
CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,flutamide,Launched,androgen receptor antagonist,AHR|AR,oncology,prostate cancer
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,fluticasone-propionate,Launched,glucocorticoid receptor agonist,NR3C1|NR3C2|PGR|PLA2G4A,dermatology,corticosteroid-responsive dermatoses
Fc1ccc(C(c2ccccc2)(c2ccccc2F)n2ccnc2)cc1,flutrimazole,Launched,sterol demethylase inhibitor,,infectious disease,mycosis
CC(C)n1c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21,fluvastatin,Launched,HMGCR inhibitor,HMGCR,endocrinology|cardiology,hypercholesterolemia|congenital heart defects
COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1,fluvoxamine,Launched,selective serotonin reuptake inhibitor (SSRI),SLC6A4,neurology/psychiatry,obsessive compulsive disorder (OCD)
CC(C)C[C@H](NC(=O)OCC1c2ccccc2-c2ccccc21)C(=O)O,fmoc-L-leucine,Phase 2,PPAR receptor agonist,,,
CN1CCN(Cc2ccc(NC(=O)c3[nH]ncc3Nc3ncnc4[nH]ccc34)cc2)CC1,FN-1501,Phase 1,tyrosine kinase inhibitor,,,
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,folic-acid,Launched,folate receptor ligand,FOLR2|FOLR3|SLC19A1|SLC46A1,hematology,megaloblastic anemia
Cc1cn[nH]c1,fomepizole,Launched,alcohol dehydrogenase inhibitor,ADH1A|ADH1B|ADH1C|AKR1A1|CAT,critical care,poison antidote
c1ccc(OCc2ccc(CCCN3CCOCC3)cc2)cc1,fomocaine,Launched,voltage-gated sodium channel modulator,,neurology/psychiatry,local anesthetic
CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]4O[C@H](C(=O)O)[C@@H](O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)O)[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)O)[C@H]3NS(=O)(=O)O)[C@H](O)[C@H]2OS(=O)(=O)O)[C@H](O)[C@H]1NS(=O)(=O)O,fondaparinux,Launched,coagulation factor inhibitor,F10|SERPINC1,hematology,deep vein thrombosis (DVT)
COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1,foretinib,Phase 2,VEGFR inhibitor,FLT1|FLT4|KDR|MET,,
C[C@]12CCC(=O)C(=O)[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12,formestane,Launched,aromatase inhibitor,CYP19A1,oncology,breast cancer
COc1ccc(-c2coc3cc(O)ccc3c2=O)cc1,formononetin,Preclinical,alcohol dehydrogenase inhibitor,ADH1C|SLC5A2,,
COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1,formoterol,Launched,adrenergic receptor agonist,ADRB2,pulmonary,asthma|chronic obstructive pulmonary disease (COPD)|bronchospasm
O=c1nc[nH]c2c([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)c[nH]c12,forodesine,Launched,purinergic receptor antagonist,PNP,hematologic malignancy,peripheral T-cell lymphoma (PTCL)
CC(C)c1cc(C(C)C)c(-c2csc(N(CCN(C)C)Cc3cccnc3)n2)c(C(C)C)c1,foropafant,Phase 3,platelet activating factor receptor antagonist,PTAFR,,
C=C[C@@]1(C)CC(=O)[C@]2(O)[C@@]3(C)[C@@H](O)CCC(C)(C)[C@@H]3[C@H](O)[C@H](OC(C)=O)[C@@]2(C)O1,forskolin,Launched,adenylyl cyclase activator,ADCY2|ADCY5|GNAS,,
CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1,fosamprenavir,Launched,HIV protease inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)
C[C@@H](O[C@H]1OCCN(Cc2nn(P(=O)(O)O)c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,fosaprepitant-dimeglumine,Launched,tachykinin antagonist,TACR1,gastroenterology,nausea|vomiting
COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O,fosbretabulin,Phase 3,tubulin polymerization inhibitor|VE-cadherin antagonist,CDH5,,
CC/C(=C(/CC)c1ccc(OP(=O)(O)O)cc1)c1ccc(OP(=O)(O)O)cc1,fosfestrol,Launched,synthetic estrogen,ESR1|ESR2,oncology,prostate cancer
O=P(O)(O)OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,fosfluconazole,Preclinical,other antifungal,,,
C[C@@H]1O[C@@H]1P(=O)(O)O,fosfomycin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,urinary tract infections
O=C(O)c1ccccc1OP(=O)(O)O,fosfosal,Launched,phosphodiesterase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief
O=C(COP(=O)(O)O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O,fosfructose,Phase 3,fructose diphosphate stimulant,,,
CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)O)C(C)C,fosinopril,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|congestive heart failure
O=C(O)[C@@H]1C[C@@H](C2CCCCC2)CN1C(=O)C[P@@](=O)(O)CCCCc1ccccc1,fosinoprilat,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension
O=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1COP(=O)(O)O,fosphenytoin,Launched,sodium channel blocker,SCN5A,neurology/psychiatry,epilepsy|seizures
COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC,fostamatinib,Launched,SYK inhibitor,SYK,hematology,chronic immune thrombocytopenia (ITP)
COc1cnc(-n2cnc(C)n2)c2c1c(C(=O)C(=O)N1CCN(C(=O)c3ccccc3)CC1)cn2COP(=O)(O)O,fostemsavir,Phase 3,antiviral,,,
CCOP(=O)(OCC)[C@@H](C)NC(=O)N(CCCl)[NH2+][O-],fotemustine,Launched,thioredoxin inhibitor,,oncology,melanoma
CSCC[C@H](NC=O)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)O,foxy-5,Phase 2,WNT5a peptide mimetic,WNT5A,,
Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O,FPH1-(BRD-6125),Preclinical,hepatocyte function enhancer,,,
CC(N)(Cc1ccccc1)c1ccccc1,FPL-12495,Phase 1,glutamate receptor antagonist,,,
CCCc1c(OC[C@@H](O)COc2ccc3c(=O)cc(C(=O)O)oc3c2CCC)ccc(C(C)=O)c1O,FPL-55712,Phase 1,leukotriene receptor antagonist,,,
COc1ccc(Nc2ccn(-c3ccccc3)n2)cc1,FPL-62064,Phase 2,cyclooxygenase inhibitor|lipoxygenase inhibitor,,,
COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1,FPL-64176,Preclinical,calcium channel activator,CACNA1C|CACNA1S,,
O=C(c1ccc(Cl)cc1)N(Cc1ccccc1)C1CCCCC1,FPS-ZM1,Preclinical,RAGE receptor antagonist,AGER,,
COc1ccc(-c2nc(C(=O)N3CCN(C)CC3)sc2-c2ccc(OC)cc2)cc1,FR-122047,Preclinical,cyclooxygenase inhibitor,,,
CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(=O)O,FR-139317,Phase 1,endothelin receptor antagonist,EDNRA,,
Nc1[nH]nc2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12,FR-180204,Preclinical,MAP kinase inhibitor,MAPK1|MAPK3,,
CCn1c(=O)c(-c2ccc(Cl)cc2Cl)cc2cnc(Nc3ccc(N4CCNCC4)c(F)c3)nc21,FRAX486,Preclinical,serine/threonine kinase inhibitor,PAK1|PAK2|PAK3|PAK4,,
COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1,frentizole,Phase 1,immunosuppressant,,,
CC(C)[C@@H](NC(=O)Cn1c(-c2ccccc2)ncc(N)c1=O)[C@@H](O)c1nnc(C(C)(C)C)o1,freselestat,Preclinical,elastase inhibitor,CELA1|ELANE,,
CN[C@@H]1CCc2[nH]c3ccc(C(N)=O)cc3c2C1,frovatriptan,Launched,serotonin receptor agonist,HTR1A|HTR1B|HTR1D,neurology/psychiatry,migraine headache
CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12,fruquintinib,Launched,VEGFR inhibitor,KDR,oncology,colorectal cancer
C#CCOc1ccc(/C=C/C(=O)Nc2ccccc2C(=O)O)cc1OC,FT011,Preclinical,TGF beta receptor inhibitor,,,
Cc1cccc(C)c1NC(=O)c1ccccc1C(=O)O,ftaxilide,Preclinical,,,,
O=c1[nH]c(=O)n([C@H]2CCCO2)cc1F,ftorafur,Launched,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer
CC(=O)O[C@H]1CC(C)(C)C(=C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(\C)C(=O)C[C@]23O[C@@]2(C)C[C@H](O)CC3(C)C)[C@](C)(O)C1,fucoxanthin,Phase 2,anticancer agent,,,
N[C@@H](CSCCCO)C(=O)O,fudosteine,Launched,mucolytic agent,,pulmonary,chest congestion
C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O,fulvestrant,Launched,estrogen receptor antagonist,ESR1|ESR2|GPER1,oncology,breast cancer
CO[C@H]1[C@@H]([C@@]2(C)O[C@@H]2CC=C(C)C)[C@]2(CC[C@H]1OC(=O)/C=C/C=C/C=C/C=C/C(=O)O)CO2,fumagillin,Launched,methionine aminopeptidase inhibitor,METAP2,infectious disease,microsporidiosis
CCCC[C@@H](C)[C@@H](OC(=O)C[C@@H](CC(=O)O)C(=O)O)[C@H](C[C@@H](C)C[C@H](O)CCCC[C@@H](O)C[C@H](O)[C@H](C)N)OC(=O)C[C@@H](CC(=O)O)C(=O)O,fumonisin-B1,Preclinical,,CERS1,,
O=C1N(Cc2ccc(C(F)(F)F)o2)c2ccccc2[C@]12COc1cc3c(cc12)OCO3,funapide,Preclinical,sodium channel blocker,,,
O=C1CN(/N=C/C=C/c2ccc([N+](=O)[O-])o2)C(=O)N1,furagin,Preclinical,antibacterial,,,
O=C1O[C@H](CN2CCOCC2)CN1/N=C/c1ccc([N+](=O)[O-])o1,furaltadone,Launched,bacterial DNA inhibitor,,infectious disease,gram-negative bacterial infections
N=C(N)c1ccc(-c2ccc(-c3ccc(C(=N)N)cc3)o2)cc1,furamidine,Preclinical,protein arginine N-methyltransferase inhibitor,PRMT1,,
O=C1OCCN1/N=C/c1ccc([N+](=O)[O-])o1,furazolidone,Launched,bacterial DNA inhibitor,,gastroenterology|infectious disease,diarrhea|enteritis|cholera
O=C(O)c1cc2cc(Cc3cccnc3)ccc2o1,furegrelate,Phase 1,thromboxane synthase inhibitor,TBXAS1,,
NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl,furosemide,Launched,diuretic,CA2|GPR35|SLC12A1|SLC12A2,cardiology|rheumatology,edema|hypertension|congestive heart failure|nephrotic syndrome
C/C(=C(/CCO)SSC[C@H]1CCCO1)N(C=O)Cc1cnc(C)nc1N,fursultiamine,Launched,vitamin B,,metabolism,thiamine deficiency
O=[N+]([O-])/C(Br)=C\c1ccc(Br)o1,furvina,Preclinical,quorum sensing signaling inhibitor,,,
CC(=O)O[C@H]1C[C@@]2(C)[C@@H](C[C@@H](O)[C@H]3[C@@]4(C)CC[C@@H](O)[C@@H](C)[C@@H]4CC[C@@]32C)/C1=C(\CCC=C(C)C)C(=O)O,fusidic-acid,Launched,bacterial 30S ribosomal subunit inhibitor,,dermatology,acne vulgaris (AV)
C=CC(=O)N1CC[C@H](n2nc(C#Cc3cc(OC)cc(OC)c3)c3c(N)ncnc32)C1,futibatinib,Phase 3,FGFR inhibitor,,,
CC(=O)c1ccc2c(c1)[C@@H]1C=CC[C@@H]1[C@H](c1cc3c(cc1Br)OCO3)N2,G-1,Preclinical,G protein-coupled receptor agonist,GPER1,,
Brc1cc2c(cc1[C@H]1Nc3ccccc3[C@H]3C=CC[C@H]31)OCO2,G-15,Preclinical,estrogen receptor antagonist,GPER1,,
CN1CCC(Nc2nc(Nc3ccc(Oc4ccccc4)cc3)c3c(O)ncc(Br)c3n2)CC1,G-749,Preclinical,tyrosine kinase inhibitor,,,
C=C1CC/C=C(\C)CC[C@@H]2[C@@H]1CC2(C)C,g-caryophyllene,Preclinical,acetylcholinesterase inhibitor,ACHE,,
CS(=O)(=O)c1ccc(-c2nnc(/C=C/c3nnc(-c4ccc(C#N)cc4)o3)n2-c2ccccc2Cl)nc1,G007-LK,Preclinical,tankyrase inhibitor,TNKS|TNKS2,,
NCC1(CC(=O)O)CCCCC1,gabapentin,Launched,calcium channel blocker,ADORA1|CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1E|CACNA1F|CACNA1G|CACNA1H|CACNA1I|CACNA1S|CACNA2D1|CACNA2D2|CACNA2D3|CACNA2D4|CACNB1|CACNB2|CACNB3|CACNB4|CACNG1|CACNG2|CACNG3|CACNG4|CACNG5|CACNG6|CACNG7|CACNG8|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B,infectious disease|neurology/psychiatry,virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
CC(C)C(=O)O[C@@H](C)OC(=O)NCC1(CC(=O)O)CCCCC1,gabapentin-enacarbil,Launched,adrenergic receptor agonist,CACNA1G,neurology/psychiatry,restless leg syndrome|postherpetic neuralgia
COc1ccc(-c2ccc(=N)n(CCCC(=O)O)n2)cc1,gabazine,Preclinical,GABA receptor antagonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRG2,,
CCOC(=O)c1ccc(OC(=O)CCCCCNC(=N)N)cc1,gabexate,Launched,serine protease inhibitor,PRSS1|TPSAB1,gastroenterology,pancreatitis
O=c1[nH]oc2c1CCNC2,gaboxadol,Phase 3,benzodiazepine receptor agonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRD|GABRR1|GABRR2|GABRR3,,
O=C1CN2CCN3CCN([C@@H](CO)[C@@H](O)CO)CCN(CC2)CC(=O)O[Gd](O1)OC(=O)C3,gadobutrol,Launched,radiopaque medium,,radiology,MRI contrast agent
CNC(=O)CN1CCN2CCN(CC(=O)NC)CC(=O)O[Gd](OC(=O)C2)OC(=O)C1,gadodiamide,Launched,radiopaque medium,,radiology,MRI contrast agent
O=C(O)CN1CCN2CCN(CC(=O)O)CC(=O)O[Gd](OC(=O)C2)OC(=O)C1,gadopentetic-acid,Launched,contrast agent,PGD,radiology,contrast agent
O=C(O)CN1CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC1,gadoterate-meglumine,Launched,radiopaque medium,,radiology,MRI contrast agent
C[C@@H](O)CN1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C3)OC(=O)C2,gadoteridol,Launched,radiopaque medium,,radiology,MRI contrast agent
CCCNc1nc(NCCC)nc(N(C)OC)n1,GAL-021,Preclinical,calcium channel blocker,,,
COc1ccc2c3c1O[C@H]1C[C@@H](O)C=C[C@@]31CCN(C)C2,galantamine,Launched,acetylcholinesterase inhibitor,ACHE|BCHE|CHRNA1|CHRNA10|CHRNA2|CHRNA3|CHRNA4|CHRNA5|CHRNA6|CHRNA7|CHRNA9|CHRNB1|CHRNB2|CHRNB3|CHRNB4|CHRND|CHRNE|CHRNG,neurology/psychiatry,senile dementia
C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(n3cnc4ccccc43)=CC[C@@H]12,galeterone,Phase 3,androgen receptor modulator,AR|CYP17A1,,
Nc1ncnc2c([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)c[nH]c12,galidesivir,Phase 1,antiviral,,,
CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC,gallamine-triethiodide,Launched,acetylcholine receptor antagonist,CHRM2|CHRNA1,neurology/psychiatry,muscle relaxant
O=C(O)c1cc(O)c(O)c(O)c1,gallic-acid,Preclinical,beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist,CA1|CA12|CA14|CA2|CA4|CA6|CA9|SELP,,
COc1ccc(CCN(C)CCCC(C#N)(c2cc(OC)c(OC)c(OC)c2)C(C)C)cc1OC,gallopamil,Launched,L-type calcium channel blocker,ATP2A2,cardiology,hypertension|cardiac arrythmia
CC(C)=CCC[C@]1(C)C=Cc2c(O)c3c(c(CC=C(C)C)c2O1)O[C@]12C(=C[C@@H]4C[C@H]1C(C)(C)O[C@@]2(C/C=C(/C)C(=O)O)C4=O)C3=O,gambogic-acid,Phase 2,caspase activator,BCL2,,
CCCN1C[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@H]1C,gamithromycin,Preclinical,antibacterial ,,,
NCCCC(=O)O,gamma-aminobutyric-acid,Preclinical,benzodiazepine receptor agonist,GABBR1|GABBR2|GABRA1|GABRA2|GABRA3|GABRA5|GABRB2|GABRG2|GATM|KCTD12|KCTD16|KCTD8|SLC6A1,,
CCCCC/C=C\C/C=C\C/C=C\CCCCC(=O)O,gamma-linolenic-acid,Phase 2,cyclooxygenase inhibitor|prostanoid receptor agonist,PTGS1|PTGS2,,
CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C,ganaxolone,Phase 3,GABA receptor modulator,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6,,
Nc1nc(=O)c2ncn(COC(CO)CO)c2[nH]1,ganciclovir,Launched,DNA polymerase inhibitor,,infectious disease,cytomegalovirus (CMV)
CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3c(ccn3C)c2)c(O)cc1O,ganetespib,Phase 3,HSP inhibitor,HSP90AA1,,
C[C@H](CC(=O)C[C@@H](C)[C@H]1C[C@H](O)[C@@]2(C)C3=C(C(=O)C[C@]12C)[C@@]1(C)CCC(=O)C(C)(C)[C@@H]1C[C@@H]3O)C(=O)O,ganoderic-acid-a,Preclinical,JAK inhibitor,,,
c1cc(-c2sc(-c3ccncc3)c(-c3ccncc3)c2-c2ccncc2)ccn1,GANT-58,Preclinical,GLI antagonist,GLI1,,
CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1,GANT-61,Preclinical,GLI antagonist,GLI1|GLI2,,
C[C@H]1NCc2cc(-c3ccc4c(=O)c(C(=O)O)cn(C5CC5)c4c3OC(F)F)ccc21,garenoxacin,Launched,topoisomerase inhibitor,TOP2A,infectious disease,respiratory tract infections
OCc1ccc(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1,gastrodin,Phase 2,,,,
O=C(/C=C/c1c(C(=O)O)[nH]c2cc(Cl)cc(Cl)c12)Nc1ccccc1,gavestinel,Phase 3,glutamate receptor antagonist,GLRB|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B,,
C(=C/c1ccccc1)\CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1,GBR-12783,Preclinical,dopamine reuptake inhibitor,,,
c1ccc(CCCN2CCN(CCOC(c3ccccc3)c3ccccc3)CC2)cc1,GBR-12935,Preclinical,dopamine reuptake inhibitor,AGTR1|SLC6A3,,
Fc1ccc(C(OCCN2CCN(C/C=C/c3ccccc3)CC2)c2ccc(F)cc2)cc1,GBR-13069,Preclinical,dopamine reuptake inhibitor,SLC6A3,,
CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@H]3O)CC1)c1ccc(Cl)cc1,GDC-0068,Phase 3,AKT inhibitor,AKT1|AKT2|AKT3|PRKG1,,
C[C@H](Nc1ccc2c(c1)OCCn1cc(N3C(=O)OC[C@H]3C(F)F)nc1-2)C(N)=O,GDC-0077,Phase 1,PI3K inhibitor,,,
CC1(C)OCCn2c1nc1c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,GDC-0084,Phase 2,mTOR inhibitor|PI3K inhibitor,,,
CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1)C1CCCCC1,GDC-0152,Phase 1,XIAP inhibitor,BIRC2|BIRC3|BIRC7|XIAP,,
CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(C2COC2)C3)cc1,GDC-0349,Phase 1,Pim kinase inhibitor,PIK3CA,,
N[C@@H]1CCCN(c2c(Br)cnc3[nH]cc(NC(=O)C4CC4)c23)C1,GDC-0575,Phase 1,CHK inhibitor,,,
O=C(NOCCO)c1ccc2cncn2c1Nc1ccc(I)cc1F,GDC-0623,Phase 1,MEK inhibitor,,,
CC/C(=C(/c1ccc(/C=C/C(=O)O)cc1)c1ccc2n[nH]cc2c1)c1ccc(F)cc1Cl,GDC-0810,Phase 2,selective estrogen receptor destabilizer,ESR1,,
Cc1c(NC(=O)c2cc3c(s2)CCCC3)cccc1-c1cn(C)c(=O)c(Nc2ccc([C@H]3C(=O)N(C)CCN3C)cc2)n1,GDC-0834,Phase 1,Bruton's tyrosine kinase (BTK) inhibitor,BTK,,
OCCn1cc(-c2ccc3c(c2)CC/C3=N\O)c(-c2ccncc2)n1,GDC-0879,Preclinical,RAF inhibitor,BRAF,,
CC1=C(c2cccc(O)c2)[C@H](c2ccc(OCCN3CC(CF)C3)cc2)Oc2ccc(O)cc21,GDC-0927,Phase 1,estrogen receptor antagonist,,,
CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5n[nH]cc45)nc(N4CCOCC4)c3s2)CC1,GDC-0941,Phase 2,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,,
Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,GDC-0980,Phase 2,mTOR inhibitor|PI3K inhibitor,FGR|MAP3K9|MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG|SYK,,
Cn1nccc1Nc1nccc(-c2ccn([C@@H](CO)c3ccc(Cl)c(F)c3)c(=O)c2)n1,GDC-0994,Phase 1,MAP kinase inhibitor,MAPK1|MAPK3,,
CC(=O)O[C@@H]1C[C@H]2C(C)(C)C(=O)C=C[C@]2(C)[C@H]2CC[C@@]3(C)[C@H](c4ccoc4)OC(=O)[C@H]4O[C@]43[C@@]21C,gedunin,Preclinical,HSP inhibitor,HSP90AA1,,
COc1cc(C(C)C)c(Oc2cnc(N)nc2N)cc1S(N)(=O)=O,gefapixant,Phase 3,purinergic receptor antagonist,,,
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,gefitinib,Launched,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC)
COC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C/C=C(\C)C(=O)NC(=CC1=O)C2=O,geldanamycin,Preclinical,HSP inhibitor,HSP90AA1,,
CC(C)(CO)CCCCCCC(C)(C)CO,gemcadiol,Phase 2,antilipemic,,,
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,gemcitabine,Launched,ribonucleotide reductase inhibitor,CMPK1|RRM1|RRM2|TYMS,oncology,ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)|pancreatic cancer
CCCCCCCC/C=C/CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O,gemcitabine-elaidate,Phase 1,apoptosis inhibitor|DNA synthesis inhibitor,CMPK1|RRM1|TYMS,,
Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1,gemfibrozil,Launched,lipoprotein lipase activator,LPL|PPARA|SLCO1B1|SLCO1B3|SLCO2B1,endocrinology|cardiology,hyperlipidemia|coronary heart disease
CO/N=C1\CN(c2nc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)C[C@@H]1CN,gemifloxacin,Launched,bacterial DNA gyrase inhibitor,,pulmonary|infectious disease,bronchitis|pneumonia
N[C@@H](CC(=O)N1CCc2c(nc(C(F)(F)F)nc2C(F)(F)F)C1)CN1CC(F)(F)CCC1=O,gemigliptin,Launched,dipeptidyl peptidase inhibitor,,,
COC(=O)C1=CO[C@@H](O)[C@@H]2C(CO)=CC[C@H]12,genipin,Preclinical,choleretic agent,,,
COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H]2C(CO)=CC[C@H]12,geniposide,Preclinical,GLP receptor agonist,GLP1R,,
O=C(O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H]2C(CO)=CC[C@H]12,geniposidic-acid,Preclinical,cyclooxygenase inhibitor,,,
O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,genistein,Phase 2/Phase 3,tyrosine kinase inhibitor,CFTR|ESR1|ESR2|ESRRA|ESRRB|ESRRG|NCOA1|NCOA2|PPARG|PTK2B|TOP2A|TRPC5,,
CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H]([C@@H](C)NC)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O,gentamycin,Launched,bacterial 50S ribosomal subunit inhibitor,HSPA8,infectious disease|critical care,bone and joint infections|endocarditis|pelvic inflammatory disease|meningitis|pneumonia|urinary tract infections|sepsis
C=C[C@@H]1C2=CCOC(=O)C2=CO[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,gentiopicrin,Phase 3,glutamate receptor downregulator,GRIN2B,,
CCCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2c(c1)OCCO2,genz-123346,Preclinical,glucosylceramidase inhibitor,UGCG,,
CNCCn1c(=O)c2cc(OC)c(OC)cc2c2cnc3cc4c(cc3c21)OCO4,genz-644282,Phase 1,topoisomerase inhibitor,TOP1,,
C[C@@H](N)Cc1cccc(O)c1,gepefrine,Launched,adrenergic receptor agonist,,cardiology,hypotension
CC(C)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](N)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)O,gepon,Phase 1,,,,
O=c1ccc2ncc(=O)n3c2n1C[C@H]3CN1CCC(NCc2cc3c(cn2)OCCC3)CC1,gepotidacin,Phase 2,topoisomerase inhibitor,,,
CC(C)=CCC/C(C)=C/CC/C(C)=C/CCC(=O)OC/C=C(\C)CCC=C(C)C,geranyl-farnesylacetate,Phase 2,mucin production enhancer,,,
C#C[C@]1(O)C=C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC,gestodene,Launched,contraceptive agent,,endocrinology,contraceptive
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3C=C[C@@]21CC,gestrinone,Launched,progesterone receptor antagonist,AR|ESR1|PGR,obstetrics/gynecology,endometriosis
CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21,GF109203X,Preclinical,PKC inhibitor,PDPK1|PIM1|PRKCI|PRKCZ,,
COP(=O)(CC[C@@H](N)C(=O)O)Oc1cccc(CC(=O)O)c1,GGsTop,Preclinical,gamma glutamyltransferase Inhibitor,GGT1,,
COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12,GGTI-298,Preclinical,GGTase inhibitor,CDKN1A,,
CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1,gilteritinib,Launched,FLT3 inhibitor,FLT3,,
O=c1cc(O)c(Cl)c[nH]1,gimeracil,Launched,dihydropyrimidine dehydrogenase inhibitor,DPYD,oncology,gastric adenocarcinoma
C[C@@H]1C(=O)O[C@H]2C[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@]36[C@@H](OC(=O)[C@@H]6O)O[C@@]4(C(=O)O5)[C@]21O,ginkgolide-A,Preclinical,GABA receptor antagonist,GLRA1|GLRB,,
C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@]36[C@@H](OC(=O)[C@@H]6O)O[C@@]4(C(=O)O5)[C@@]12O,ginkgolide-B,Phase 3,platelet activating factor receptor antagonist,GLRA1|GLRA2|GLRA3|GLRB|HTR3A|HTR3B,,
CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@]12C,ginsenoside-C-K,Phase 1,NFkB pathway inhibitor|nitric oxide synthase inhibitor,PTGS2,,
CC(C)=CCC[C@@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@]12C,ginsenoside-RD,Phase 3,calcium channel blocker,,,
CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3[C@@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)C[C@]12C,ginsenoside-RE,Phase 1,anti-inflammatory agent,,,
CC(C)=CCC[C@@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@]12C,ginsenoside-RE3,Launched,angiogenesis inhibitor|apoptosis stimulant,KCNH2,,
CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(C(=O)NO)cc3)ccc2c1,givinostat,Phase 3,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9,,
C(#Cc1nc2ncccc2nc1OCCN1CCCC1)c1ccccc1,GK921,Preclinical,transglutaminase inhibitor,TGM2,,
COC[C@H](C)Oc1cc(O[C@@H](C)Cc2ccccc2)cc(C(=O)Nc2ccc(C(=O)O)cn2)c1,GKA-50,Preclinical,glucokinase activator,GCK,,
CN(C)c1cccc(-c2c3c(=O)n(-c4ccccc4Cl)[nH]c3cc(=O)n2C)c1,GKT137831,Phase 2,NADPH oxidase inhibitor,NOX1|NOX4,,
CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1,glasdegib,Launched,hedgehog pathway inhibitor,SMO,hematologic malignancy,acute myeloid leukemia (AML)
CC(C)(C)[C@@H]1NC(=O)O[C@@H]2CCC[C@H]2OC/C=C\C(F)(F)c2nc3ccccc3nc2O[C@@H]2C[C@@H](C(=O)N[C@]3(C(=O)NS(=O)(=O)C4(C)CC4)C[C@H]3C(F)F)N(C2)C1=O,glecaprevir,Launched,serine protease inhibitor,,infectious disease,hepatitis C
COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1,glesatinib,Phase 2,tyrosine kinase inhibitor,,,
Cc1ccc(S(=O)(=O)NC(=O)NN2C[C@H]3CCC[C@@H]3C2)cc1,gliclazide,Launched,ATP channel blocker|insulin secretagogue,,endocrinology,diabetes mellitus
CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,glimepiride,Launched,insulin secretagogue,ABCC8|KCNJ1|KCNJ11,endocrinology,diabetes mellitus
Cc1cnc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)cn1,glipizide,Launched,sulfonylurea,ABCC8|KCNJ10|KCNJ11|PPARG,endocrinology,diabetes mellitus|hyperglycemia
COc1ccc2c(c1)C(=O)N(CCc1ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc1)C(=O)C2(C)C,gliquidone,Launched,sulfonylurea,ABCC8|KCNJ10|KCNJ8,endocrinology,diabetes mellitus
COc1ccc2c3c1O[C@H]1C[C@@H](OC(=O)c4ccccc4)C=C[C@@]31CCN(C)C2,Gln-1062,Preclinical,cholinesterase inhibitor,,,
COc1ccc(S(=O)(=O)N[C@@H](CNc2nc(C)nc(N3CCC(c4ccc5c(n4)NCCC5)CC3)c2C)C(=O)O)cc1,GLPG0187,Phase 1,integrin antagonist,,,
CN1C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=O)[C@@]1(CO)c1ccccc1,GLPG0492,Phase 1,androgen receptor modulator,AR,,
CN1C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=O)[C@]1(CO)c1ccccc1,GLPG0492-R-enantiomer,Phase 1,androgen receptor modulator,AR,,
CC1(C)Cc2c(sc(NC(=O)c3cc[nH]n3)c2C(N)=O)C(C)(C)O1,GLPG1837,Phase 2,CFTR channel potentiator,,,
O=C(O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)O,glucaric-acid,Phase 1,,,,
O=C1O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]1O,gluconolactone,Launched,,LCT,,
N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O,glucosamine,Launched,glycosylated protein precursor,IL1B,neurology/psychiatry|rheumatology,muscle pain|rheumatoid arthritis|joint pain|backache
CC(C)OC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(=O)O,glutathione-monoisopropyl-ester,Phase 2,lipid peroxidase inhibitor,,,
NCC(=O)N[C@@H](CCC(N)=O)C(=O)O,gly-gln,Phase 2,,,,
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,glyburide,Launched,ATP channel blocker|insulin secretagogue|sulfonylurea,ABCA1|ABCB11|ABCC8|ABCC9|CFTR|CPT1A|KCNJ1|KCNJ11|KCNJ5|KCNJ8|SLCO2B1,endocrinology,diabetes mellitus|hyperglycemia
CCCCCCCCCCCC(=O)OC[C@@H](O)CO,glycerol-monolaurate,Launched,beta lactamase inhibitor,,,
O=C(CCCc1ccccc1)OCC(COC(=O)CCCc1ccccc1)OC(=O)CCCc1ccccc1,glycerol-phenylbutyrate,Phase 1,sigma receptor ligand,,,
COc1cc2c(=O)c(-c3ccc(O)cc3)coc2cc1O,glycitein,Phase 3,tumor necrosis factor release inhibitor,TNF,,
C[N+]1(C)CC[C@H](OC(=O)[C@](O)(c2ccccc2)C2CCCC2)C1,glycopyrrolate,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,gastroenterology,peptic ulcer disease (PUD)
CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)O,GM-1485,Preclinical,immunophilin ligand,FKBP1A,,
N#CN/C(=N\c1ccncc1)NCCCCCCOc1ccc(Cl)cc1,GMX1778,Phase 1/Phase 2,NAMPT inhibitor,NAMPT,,
CCNc1nc(Nc2cc(F)c(C(=O)N3CCOCC3)cc2OC)ncc1C(F)(F)F,GNE-7915,Preclinical,leucine rich repeat kinase inhibitor,,,
NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1,GNF-2,Preclinical,Bcr-Abl kinase inhibitor,ABL1|BCR,,
O=C(NCCO)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1,GNF-5,Preclinical,Bcr-Abl kinase inhibitor,ABL1|BCR,,
Cc1ccc(NC(=O)Nc2cc(C(F)(F)F)ccc2F)cc1Nc1ccc2c(c1)NC(=O)/C2=C\c1ccc[nH]1,GNF-5837,Preclinical,growth factor receptor inhibitor,NTRK1|NTRK2|NTRK3,,
Cc1ccc(Nc2ncc3c(n2)N(C)C(=O)N(c2cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc2C)C3)cn1,GNF-7,Preclinical,glucokinase inhibitor|protein kinase inhibitor,GCK|TNK2,,
N=C(N)Nc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5,GNTI,Preclinical,opioid receptor antagonist,OPRK1|OPRM1,,
COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C,go-6983,Preclinical,protein kinase inhibitor,PRKCA|PRKCB|PRKCD|PRKCG|PRKCZ,,
Fc1cc(F)c2c(c1)[C@H]1C=CC[C@H]1[C@@H](c1cccnc1)N2,golgicide-A,Preclinical,ARF inhibitor,GBF1,,
CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1,golvatinib,Phase 2,VEGFR inhibitor,KDR|MET,,
CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,gonadorelin,Launched,gonadotropin releasing factor hormone receptor agonist,GNRHR,obstetrics/gynecology,cystic ovaries|reproductive synchrony
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,goserelin-acetate,Launched,gonadotropin releasing factor hormone receptor agonist,GNRHR|LHCGR,oncology|obstetrics/gynecology,prostate cancer|breast cancer|endometriosis
Cc1cc2c(C(C)C)c(O)c(O)c(C=O)c2c(O)c1-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O,gossypol,Phase 2,BCL inhibitor|MCL1 inhibitor,BCL2,,
Cc1ccc2c(c1)Cc1c(C(=O)NN3CCCCC3)nn(-c3ccc(Cl)cc3Cl)c1-2,GP1a,Preclinical,cannabinoid receptor agonist,CNR2,,
Cc1ccc2c(c1)Cc1c(C(=O)NC3CCCCC3)nn(-c3ccc(Cl)cc3Cl)c1-2,GP2a,Preclinical,cannabinoid receptor agonist,CNR2,,
O=C1COc2nccc(-c3ccccc3F)c2CN1Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1,GPBAR-A,Preclinical,G protein-coupled receptor agonist,GPBAR1,,
CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)OCCCc1cccnc1,GPI-1046,Preclinical,FKBP inhibitor,FKBP1A,,
O=C(N[C@@H]1Cc2ccccc2N(C[C@@H](O)CO)C1=O)c1cc2cc(Cl)sc2[nH]1,GPi-688,Preclinical,glycogen phosphorylase inhibitor,,,
O=C(CCCCCCCn1cc(-c2cccnc2)nn1)Nc1ccccc1-c1ccccc1,GPP-78,Preclinical,NAMPT inhibitor,NAMPT,,
Cc1cc(OCc2nc(-c3ccccc3Cl)cs2)ccc1OCC(=O)O,GPR120-modulator-1,Preclinical,G protein-coupled receptor modulator,FFAR4,,
COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(-c3ccc(C(C)=O)cc3)cc2)CC1,GR-103691,Preclinical,dopamine receptor antagonist,DRD3,,
Cn1cc(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)c2ccccc21,GR-113808,Preclinical,serotonin receptor antagonist,HTR4,,
COc1ccc(NC(=O)c2ccc(-c3ccc(-c4noc(C)n4)cc3C)cc2)cc1N1CCN(C)CC1,GR-127935,Preclinical,serotonin receptor antagonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR6,,
COC(=O)Nc1ccc2[nH]cc(CCNC(C)=O)c2c1,GR-135531,Preclinical,melatonin receptor agonist,,,
N=C(N)c1ccc(N2CCN(C3CCN(CC(=O)O)CC3)CC2)cc1,GR-144053,Preclinical,integrin antagonist,ITGA2B|ITGB3,,
COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1,GR-159897,Preclinical,tachykinin antagonist,TAC1|TACR2,,
CC=C1C(=O)C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,GR-235,Launched,estrogen receptor agonist|FXR antagonist|progesterone receptor agonist,NR1H4,,
OC[C@H]1O[C@@H](n2cnc3c(N[C@H]4CCC[C@@H]4O)ncnc32)[C@H](O)[C@@H]1O,GR-79236,Phase 1,adenosine receptor agonist,ADORA1|ADORA2A,,
COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1,GR125487,Preclinical,serotonin receptor antagonist,HTR4,,
COc1ccc(CNC(=O)/C=C/c2ccc3[nH]cc(CCN(C)C)c3c2)cc1,GR46611,Preclinical,serotonin receptor agonist,HTR1D,,
CC(C)C[C@@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCCO)C(C)C)C(C)C)C(C)C,gramicidin,Launched,bacterial permeability inducer,,infectious disease,first-aid antibiotic
CN(C)Cc1c[nH]c2ccccc12,gramine,Preclinical,norepinephrine reputake inhibitor,,,
CN1[C@@H]2CCC[C@H]1C[C@@H](NC(=O)c1nn(C)c3ccccc13)C2,granisetron,Launched,serotonin receptor antagonist,HTR3A,gastroenterology,nausea|vomiting
CCc1nc2c(C)nc(C)cc2n1-c1ccc(CCNC(=O)NS(=O)(=O)c2ccc(C)cc2)cc1,grapiprant,Launched,prostaglandin inhibitor,PTGER4,rheumatology,osteoarthritis
C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)O[C@@H]1C[C@H]1CCCCCc1nc3ccc(OC)cc3nc1O2)C(=O)NS(=O)(=O)C1CC1,grazoprevir,Launched,HCV inhibitor,,infectious disease,hepatitis C
COC1=CC(=O)C[C@@H](C)[C@]12Oc1c(Cl)c(OC)cc(OC)c1C2=O,griseofulvin,Launched,tubulin polymerization inhibitor,KRT12,infectious disease,ringworm|tinea pedis
O=C(O)c1ccc(N2N=C(Cc3ccccc3)/C(=C\c3ccc(-c4ccccc4F)o3)C2=O)cc1,GS-143,Preclinical,ubiquitin ligase inhibitor,BTRC|NFKBIA,,
CSc1nc(NC2CCCC2)c([N+](=O)[O-])c(NC2CCCC2)n1,GS-39783,Preclinical,GABA receptor modulator,GABBR1,,
CCCn1c(=O)c2[nH]c(-c3cnn(Cc4cccc(C(F)(F)F)c4)c3)nc2n(CC)c1=O,GS-6201,Phase 1,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
CCCCOc1nc(N)c2c(n1)N(Cc1cccc(CN3CCCC3)c1)CC(=O)N2,GS-9620,Phase 2,toll-like receptor agonist,TLR7,,
FC(F)(F)Oc1ccc(-c2ccc3nnc(C(F)(F)F)n3c2)cc1,GS-967,Preclinical,voltage-gated sodium channel blocker,,,
c1cn2cc(-c3ccc4c[nH]nc4c3)nc(Nc3ccc(N4CCOCC4)cc3)c2n1,GS-9973,Phase 2,SYK inhibitor,SYK,,
O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N/O,GSK-3-inhibitor-IX,Preclinical,glycogen synthase kinase inhibitor|lipoxygenase inhibitor,GSK3A|GSK3B,,
O=C(O)CCNc1cc(N2CCc3ccccc3CC2)nc(-c2ccccn2)n1,GSK-J1,Preclinical,histone demethylase inhibitor,KDM6B,,
O=C(O)CCNc1cc(N2CCc3ccccc3CC2)nc(-c2cccnc2)n1,GSK-J2,Preclinical,histone demethylase inhibitor,,,
CCOC(=O)CCNc1cc(N2CCc3ccccc3CC2)nc(-c2ccccn2)n1,GSK-J4,Preclinical,histone lysine demethylase inhibitor,KDM6A|KDM6B,,
CCOC(=O)CCNc1cc(N2CCc3ccccc3CC2)nc(-c2cccnc2)n1,GSK-J5,Preclinical,histone demethylase control,,,
c1ccc([C@@H]2C[C@H]2NC2CCNCC2)cc1,GSK-LSD-1,Preclinical,histone lysine demethylase inhibitor,KDM1A,,
COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC,GSK0660,Preclinical,PPAR receptor antagonist,PPARD,,
O=C1NC(=O)/C(=C/c2ccc3nccc(-c4ccncc4)c3c2)S1,GSK1059615,Phase 1,PI3K inhibitor,PIK3CG,,
CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1,GSK1070916,Phase 1,Aurora kinase inhibitor,AURKA|AURKB|AURKC|CYP2D6|CYP3A4,,
CC(C)c1noc(N2CCC(COc3ccc(-c4ccc(S(C)(=O)=O)cc4)nc3)CC2)n1,GSK1292263,Phase 2,glucose dependent insulinotropic receptor agonist,GRPR,,
CN(C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc21)[C@@H](CN1CCCC1)c1ccc(-c2cccc(C(N)=O)c2)cc1,GSK1562590,Preclinical,urotensin receptor antagonist,UTS2R,,
Cc1ccc2c(N3CCN(CCc4cccc(N5CCNC5=O)c4)CC3)cccc2n1,GSK163090,Phase 2,serotonin receptor antagonist,HTR1A|HTR1B|HTR1D,,
CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3c(cc2OC)CCN3C(=O)CN(C)C)nc2[nH]ccc12,GSK1838705A,Preclinical,insulin growth factor receptor inhibitor,ALK|IGF1R|INSR|RPS6KA1,,
CNC(=O)c1ccc(Oc2ccc3c(c2)CCN(C2CCC2)CC3)nc1,GSK189254,Phase 2,histamine receptor antagonist,,,
CCc1cc(Nc2nccc(-c3c(-c4ccc(OC)c(C(=O)Nc5c(F)cccc5F)c4)nc4ccccn34)n2)c(OC)cc1N1CCC(N2CCN(S(C)(=O)=O)CC2)CC1,GSK1904529A,Preclinical,IGF-1 inhibitor|insulin growth factor receptor inhibitor|insulin receptor ligand,IGF1R|INSR,,
Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl,GSK2110183,Phase 2,AKT inhibitor,AKT1|AKT2|AKT3,,
COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,GSK2126458,Phase 1,mTOR inhibitor|PI3K inhibitor,MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG,,
CCOc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)cn1,GSK2190915,Phase 2,lipoxygenase inhibitor,ALOX5AP,,
O=C(NC1(c2ccccc2)CC1)c1c(CN2CCC(N3CCCCC3)CC2)c(-c2cccc(C(F)(F)F)c2)nc2cc(Br)ccc12,GSK2193874,Preclinical,transient receptor potential channel antagonist,TRPV4,,
O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(-c3ccc4occc4c3)cc2)C1,GSK2194069,Preclinical,fatty acid synthase inhibitor,FASN,,
COc1cccc2c1c(NS(=O)(=O)c1ccc(Cl)s1)nn2Cc1cccc(CNC(=O)C(C)(C)O)c1,GSK2239633A,Preclinical,CC chemokine receptor antagonist,,,
CONC(=O)c1ccccc1Nc1cc(Nc2cc(C)nn2C(C)C)ncc1Cl,GSK2256098,Phase 2,kinase inhibitor,,,
CNc1nc(C)nc(N[C@H]2CCC[C@@H](C(=O)NCc3ccc(C#N)cc3C(F)(F)F)C2)n1,GSK2256294A,Phase 1,epoxide hydolase inhibitor,EPHX2,,
CCCC[C@]1(CC)CS(=O)(=O)c2cc(CNC(CC(=O)O)CC(=O)O)c(OC)cc2[C@@H](c2ccccc2)N1,GSK2330672,Phase 2,bile acid transporter inhibitor,SLC10A2,,
CNc1nc(-c2ccc3c(N)[nH]nc3c2)cc(N2C[C@@H](C(=O)NC3CCCCC3)CC[C@H]2C)n1,GSK2334470,Preclinical,phosphoinositide dependent kinase inhibitor,AURKA|AURKB|PDPK1,,
O=C1CCCN1c1ccc(Oc2ccc3c(c2)CCN(C2CCC2)CC3)nc1,GSK239512,Preclinical,histamine receptor antagonist,,,
COc1cccc(Nc2c(C(N)=O)cnc3c(C)cc(S(=O)(=O)c4cccc(C(=O)N(C)C)c4)cc23)c1,GSK256066,Phase 2,phosphodiesterase inhibitor,PDE4A,,
O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1,GSK2578215A,Preclinical,leucine rich repeat kinase inhibitor,LRRK2,,
Cn1cc(-c2ccc3c(c2)CCN3C(=O)Cc2cccc(C(F)(F)F)c2)c2c(N)ncnc21,GSK2606414,Preclinical,protein kinase inhibitor,EIF2AK3|MYLK2,,
Cc1c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc32)cccc1C(F)(F)F,GSK2636771,Phase 2,PI3K inhibitor,PIK3CB,,
Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1,GSK2656157,Preclinical,PERK inhibitor,,,
CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21,GSK269962,Preclinical,rho associated kinase inhibitor,ROCK1|ROCK2,,
CCCOc1ccn2c(C(C)=O)cc(-c3ccccc3S(C)(=O)=O)c2c1,GSK2801,Preclinical,bromodomain inhibitor,BAZ2A|BAZ2B,,
CC[C@H](C)n1cc(C)c2c(C(=O)NCc3c(C)cc(C)[nH]c3=O)cc(-c3ccc(N4CCNCC4)nc3)cc21,GSK2816126,Phase 1,histone lysine methyltransferase inhibitor,EZH2,,
Cc1ncc(Cl)cc1NCc1ccc(C(=O)N[C@@H](CC2CCCC2)C(=O)NC2CC2)s1,GSK2830371,Preclinical,protein phosphatase inhibitor,PPM1D,,
COc1ncc(-c2ccc3c(Nc4cc(Oc5cc(F)cc(F)c5)cc(C(=O)O)c4)c(S(=O)(=O)NC4CC4)cnc3c2)c(OC)n1,GSK2837808A,Preclinical,lactate dehydrogenase inhibitor,LDHA,,
CC(C)C1=C2[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(=O)O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@@]2([C@@H](O)CN(CCN(C)C)Cc2ccc(Cl)cc2)CC1=O,GSK2838232,Phase 2,HIV gag inhibitor,,,
O=C(O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1,GSK2879552,Phase 1/Phase 2,histone lysine demethylase inhibitor,KDM1A,,
C[C@H](CS(C)(=O)=O)n1ccc2c(C(F)(F)F)c(C#N)ccc21,GSK2881078,Phase 2,androgen receptor modulator,,,
CCc1ccc(N(CC(C)C)S(=O)(=O)c2ccc(OCC3CCOCC3)c(CO)c2)cc1,GSK2981278,Phase 1/Phase 2,ROR modulator,,,
CN1C(=O)[C@@H](NC(=O)c2nc(Cc3ccccc3)n[nH]2)COc2ccccc21,GSK2982772,Phase 2,RIPK inhibitor,,,
O=C(CCc1ccc(CN[C@H](C(=O)OC2CCCC2)C2CCCCC2)cn1)NO,GSK3117391,Phase 1/Phase 2,HDAC inhibitor,,,
CCOc1cc(=O)[nH]cc1-c1ccc(CC(=O)Nc2cc(C(C)(C)C(F)(F)F)on2)c(F)c1,GSK3179106,Phase 1,RET tyrosine kinase inhibitor,,,
CC(=O)N1CCC(Nc2cc(C(=O)NC[C@H](O)CN3CCc4ccccc4C3)ncn2)CC1,GSK3326595,Phase 1/Phase 2,protein arginine N-methyltransferase inhibitor,,,
CCn1ncc2c(NC3CCOCC3)c(-c3nnc(Cc4sc(C)nc4C)o3)cnc21,GSK356278,Preclinical,phosphodiesterase inhibitor,,,
CC(C)(C)NCc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O,GSK369796,Phase 1,potassium channel antagonist,,,
COc1ccc(S(=O)(=O)Nc2c(C)cc(C)cc2C)cc1,GSK37647,Preclinical,free fatty acid receptor agonist,FFAR4,,
O=C(NCCS(=O)(=O)c1ccc(C(F)(F)F)cn1)c1ccc(Cl)cc1,GSK3787,Preclinical,PPAR receptor antagonist,PPARD,,
CC1=C(C(=O)Nc2cc3c[nH]nc3cc2F)[C@H](c2ccc(C(F)(F)F)cc2)CC(=O)N1,GSK429286A,Preclinical,rho associated kinase inhibitor,ROCK1,,
C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F,GSK461364,Phase 1,PLK inhibitor,PLK1,,
Cc1cc(C)c(CNC(=O)c2cc(-c3ccc(N4CCN(C)CC4)nc3)cc3c2c(C)cn3C(C)C)c(=O)[nH]1,GSK503,Preclinical,histone lysine methyltransferase inhibitor,EZH2,,
O=C(O)c1ccc(-c2c[nH]c3ncc(-c4ccccc4)cc23)cc1C1CCCC1,GSK650394,Preclinical,serum/glucocorticoid regulated kinase inhibitor,SGK1|SGK2,,
NC[C@H]1OB(O)c2c(OCCO)ccc(Cl)c21,GSK656,Preclinical,leucyl-tRNA synthetase inhibitor,,,
CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21,GSK690693,Phase 1,AKT inhibitor,AKT1|AKT2|AKT3|PAK4|PAK6|PAK7|PRKCQ|PRKG1|PRKX,,
O=S(=O)(Cc1ccccc1)Nc1ccc(-c2ccc3c(cnn3-c3ccc(F)cc3)c2)c(C(F)(F)F)c1,GSK9027,Preclinical,glucocorticoid receptor agonist,NR3C1,,
CC(C)Oc1ccc(C(=O)N[C@H](CNC(=O)CN(C)C)Cc2ccc(-c3cn4cccc([C@H](C)O)c4n3)cc2)cc1Cl,GSK923295,Phase 1,centromere associated protein inhibitor,CENPE,,
c1ccc(-c2[nH]nc3c2oc2ccccc23)cc1,GTP-14564,Preclinical,FLT3 inhibitor|tyrosine kinase inhibitor,CSF1R|FLT3|KIT|PDGFRB,,
COc1ccc(/C=C2\CCCN=C2c2cccnc2)c(OC)c1,GTS21,Phase 1/Phase 2,cholinergic receptor agonist,CHRNA7,,
COc1ccccc1OC(=O)c1ccccc1OC(C)=O,guacetisal,Launched,immunosuppressant,,pulmonary,cough suppressant
Nc1ncn([C@H]2C[C@H](OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(=O)nc(N)[nH]c54)C[C@@H]3O)[C@@H](CO)O2)c(=O)n1,guadecitabine,Phase 3,DNA methyltransferase inhibitor,,,
COc1ccccc1O,guaiacol,Launched,local anesthetic,CA2,pulmonary,cough suppressant
COc1ccccc1OC[C@@H](O)CO,guaifenesin,Launched,expectorant,,pulmonary,cough suppressant
N=C(N)N/N=C/c1c(Cl)cccc1Cl,guanaben-acetate,Launched,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C,cardiology,hypertension
N=C(N)NC[C@H]1COC2(CCCCC2)O1,guanadrel,Launched,adrenergic inhibitor,,cardiology,hypertension
CCC(C)(C)NC(=N)NC#N,guancydine,Preclinical,antihypertensive agent,,,
N=C(N)NCCN1CCCCCCC1,guanethidine,Launched,adrenergic inhibitor,SLC6A2,cardiology,hypertension
N=C(N)NC(=O)Cc1c(Cl)cccc1Cl,guanfacine,Launched,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C,cardiology,hypertension
N=C(N)N,guanidine,Launched,HSP inhibitor,ALDH2|DLG4|GAMT|RNASE1,neurology/psychiatry,Lambert-Eaton myasthenic syndrome (LEMS)
N=C(N)NCCC(=O)O,guanidinopropionic-acid,Phase 2,creatine kinase inhibitor,CKM,,
Nc1nc(=O)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1,guanosine,Preclinical,,PNP,,
CSc1nc2ccc3nc(NC(=O)C(c4ccccc4)c4ccccc4)sc3c2s1,Gue-1654,Preclinical,oxoeicosanoid receptor modulator,OXER1,,
O=C(O)C1=CCCNC1,guvacine,Preclinical,GABA uptake inhibitor,SLC6A1|SLC6A11|SLC6A12|SLC6A13,,
Cc1cc(SCc2sc(-c3ccc(C(F)(F)F)c(F)c3)nc2C)ccc1OCC(=O)O,GW-0742,Preclinical,PPAR receptor agonist,PPARD,,
CCOC(=O)c1ccc(-n2cc(Cc3cnc(OCC)nc3)c(=O)nc2SCc2ccc(F)cc2)cc1,GW-1100,Preclinical,G protein-coupled receptor agonist,FFAR1,,
CN(CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(=O)O)cc1)c1ccccn1,GW-1929,Preclinical,PPAR receptor agonist,PPARG,,
COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1,GW-2580,Preclinical,cFMS kinase inhibitor,CSF1R,,
CC(C)[C@@H]1C(=O)N(S(C)(=O)=O)[C@@H]2CCN(C(=O)/C=C/CN3CCCCC3)[C@H]21,GW-311616,Phase 1,elastase inhibitor|leukocyte elastase inhibitor,ELANE,,
O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,GW-3965,Preclinical,LXR agonist,NR1H2|NR1H3,,
COc1ccc2c(c1)c(CCN1CCOCC1)c(C)n2C(=O)c1cccc(Cl)c1Cl,GW-405833,Preclinical,cannabinoid receptor agonist,CNR2,,
CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(/C=C/c2cccc(C(=O)O)c2)c(Cl)c1,GW-4064,Preclinical,FXR agonist,NR1H4,,
O=C(Nc1nc2ccccc2n1CCc1ccccc1)c1ccccc1,GW-438014A,Preclinical,neuropeptide receptor antagonist,NPY5R,,
Cn1cc(/C=C2\C(=O)Nc3cccnc32)c2ccccc21,GW-441756,Preclinical,growth factor receptor inhibitor,NTRK1,,
Cc1cc(SCc2sc(-c3ccc(C(F)(F)F)cc3)nc2C)ccc1OCC(=O)O,GW-501516,Phase 2,PPAR receptor agonist,PPARA|PPARD,,
O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1,GW-5074,Phase 1/Phase 2,leucine rich repeat kinase inhibitor|RAF inhibitor,NTRK1|RAF1,,
COc1ccccc1NC(=O)OCC1CCN(C(=O)OC(C)(C)C)CC1,GW-542573X,Preclinical,calcium channel activator,KCNN1,,
CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)cs1,GW-583340,Preclinical,EGFR inhibitor,EGFR|ERBB2,,
CCOc1c2c(c(OCC)c3ccccc13)C(=O)N(c1ccc(CC(=O)NS(=O)(=O)c3ccccc3)cc1)C2,GW-627368,Preclinical,prostanoid receptor antagonist,PTGER4,,
CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)cc1)N/C(C)=C\C(=O)c1ccc(C(F)(F)F)cc1,GW-6471,Preclinical,PPAR receptor antagonist,PPARA,,
CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(=O)O,GW-7647,Preclinical,PPAR receptor agonist,PPARA,,
O=C(NC1CCOCC1)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1,GW-788388,Preclinical,ALK tyrosine kinase receptor inhibitor,LCK|MAPK14|TGFBR1,,
COc1cc(-n2cnc3cc(-c4ccc(Cl)cc4)sc3c2=O)ccc1OCCN1CCCC1,GW-803430,Phase 1,melanin inhibitor,KCNH2|MCHR1,,
O=C(NCC1CCOCC1)c1cnc(Nc2ccc(Cl)cc2Cl)nc1C(F)(F)F,GW-842166,Phase 2,cannabinoid receptor agonist,CNR2,,
COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC,GW-843682X,Preclinical,PLK inhibitor,PLK1|PLK3,,
O=C(O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1,GW-9508,Preclinical,free fatty acid receptor agonist|G protein-coupled receptor agonist,FFAR1|FFAR4,,
O=C(Nc1ccccc1)c1cc([N+](=O)[O-])ccc1Cl,GW-9662,Preclinical,PPAR receptor antagonist,NCOA2|PPARG|RXRA,,
CC(=N)NCCSCC[C@H](N)C(=O)O,GW274150,Phase 2,nitric oxide synthase inhibitor,,,
CC1=NN=C(c2ccc(N)cc2)c2cc3c(cc2C1)OCO3,GYKI-52466,Preclinical,glutamate receptor antagonist,GRIA1|GRIA2|GRIA3|GRIA4,,
CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@]12C,gynostemma-extract,Phase 2,calcium channel modulator,,,
Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2n[nH]cc2c1,GZD824,Preclinical,Bcr-Abl kinase inhibitor,ABL1|BCR,,
CCc1ccc(NC(=O)Nc2c[nH]c3ccccc23)cc1,H-151,Preclinical,STING antagonist,,,
O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12,H-89,Preclinical,PKA inhibitor,GSG2|PKIA|PRKACA,,
O=C(O)c1ccc2c(c1)C(=O)N(c1cccc(Oc3ccc([N+](=O)[O-])cc3)c1)C2=O,H2L-5765834,Preclinical,lysophosphatidic acid receptor antagonist,LPAR1|LPAR3,,
N=C(N)NCCNS(=O)(=O)c1cccc2cnccc12,HA-1004,Phase 2,calcium channel blocker,,,
O=C1S/C(=C\c2ccc(OCc3cccc(B(O)O)c3)cc2)C(=O)N1Cc1ccc(F)cc1,HA-130,Preclinical,autotaxin inhibitor,ENPP2,,
N[C@@H]1CCN(O)C1=O,HA-966-(R)-(+),Preclinical,glutamate receptor agonist,GRIA1,,
N[C@H]1CCN(O)C1=O,HA-966-(S)-(-),Preclinical,glutamate receptor antagonist,GRIA1,,
CCOC(=O)C1=C(N)Oc2ccc(Br)cc2[C@H]1[C@H](C#N)C(=O)OCC,HA14-1,Preclinical,BCL inhibitor,BCL2,,
O=C(O)c1ccc(S(=O)(=O)N(Cl)Cl)cc1,halazone,Launched,,,infectious disease,disinfectant
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CCl)O1,halcinonide,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses
CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,halobetasol-propionate,Launched,glucocorticoid receptor agonist,NR3C1|PLA2G1B,dermatology,corticosteroid-responsive dermatoses
CCCCN(CCCC)CC[C@@H](O)c1cc2c(Cl)cc(Cl)cc2c2cc(C(F)(F)F)ccc12,halofantrine,Launched,antimalarial agent,KCNN4,infectious disease,malaria
O=C(C[C@H]1NCCC[C@@H]1O)Cn1cnc2cc(Br)c(Cl)cc2c1=O,halofuginone,Launched,collagenase inhibitor,COL1A1|MMP2,rheumatology,scleroderma
O=C(NCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1)c1ccc(F)cc1,halopemide,Phase 2,phospholipase inhibitor,PLD1|PLD2,,
O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,haloperidol,Launched,dopamine receptor antagonist,DRD1|DRD2|DRD3|DRD4|DRD5|GRIN2B|HRH1|HTR1A|HTR1D|HTR2A|HTR2B|HTR7|KCNH1,neurology/psychiatry,schizophrenia|Tourette's disorder
CCCCCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1,haloperidol-decanoate,Launched,psychoactive drug,DRD2|DRD3|DRD4|HTR2A,neurology/psychiatry,schizophrenia
Clc1cc(Cl)c(OCC#CI)cc1Cl,haloprogin,Launched,other antifungal,,infectious disease,tinea pedis
Cc1nccc2c1[nH]c1ccccc12,harmane,Preclinical,monoamine oxidase inhibitor,MAOA|MAOB,,
COC(=O)C[C@](O)(CCC(C)(C)O)C(=O)O[C@@H]1C(OC)=C[C@]23CCCN2CCc2cc4c(cc2[C@H]13)OCO4,harringtonine,Phase 3,protein synthesis inhibitor,,,
O=C(O)CN(CCN(CC(=O)O)Cc1ccccc1O)Cc1ccccc1O,HBED,Phase 3,chelating agent,,,
CC(C)c1ccc(NC(=O)Cn2cnc3c2c(=O)n(C)c(=O)n3C)cc1,HC-030031,Phase 1,TRPA1 channel blocker,TRPA1,,
Cc1c(C(=O)Nc2cccc(C(F)(F)F)c2)cc(-c2ccccc2)n1CCCN1CCOCC1,HC-067047,Preclinical,transient receptor potential channel antagonist,TRPV4,,
Cn1c(=O)n(CCCO)c(=O)c2c1nc(Oc1cccc(Cl)c1)n2Cc1ccc(Cl)cc1,HC-070,Preclinical,transient receptor potential channel antagonist,,,
CCc1ccc(/C=C/C(=O)Nc2ccc(C(C)=O)cc2)o1,heclin,Preclinical,ubiquitin ligase inhibitor,NEDD4|SMURF2|WWP1,,
CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1,HEMADO,Preclinical,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
CC1=C([C@@H](C)O)c2cc3nc(cc4[nH]c(cc5[nH]c(cc1n2)c(C)c5CCC(=O)O)c(CCC(=O)O)c4C)C([C@@H](C)O)=C3C,hematoporphyrin,Launched,,,neurology/psychiatry,depression|psychosis
Oc1cc2c(cc1O)[C@@H]1c3ccc(O)c(O)c3OC[C@]1(O)C2,hematoxylin,Preclinical,,,,
C=CC1=C(C)C2=N/C1=C\c1c(C)c(CCC(=O)O)c3n1[Fe](O)n1/c(c(C)c(C=C)/c1=C/2)=C\C1=N/C(=C\3)C(CCC(=O)O)=C1C,hemin,Launched,enzyme inducer,,hematology|cardiology,acute intermittent porphyria (AIP)|hypertension|ventricular tachycardia (VT)
CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3[C@@H](O)C[C@]12C,hemomex-s,Launched,,PPARG,,
NS(=O)(=O)OCCCCCCCOS(N)(=O)=O,hepsulfam,Preclinical,DNA cross-linking,,,
C[C@@H](N)CCCC(C)(C)O,heptaminol,Launched,vasoconstrictor,,cardiology,hypotension
Cc1cc(Nc2ncnc3ccc(-c4ccc(CNCCS(C)(=O)=O)o4)cc23)ccc1Oc1ccn2ncnc2c1,HER2-Inhibitor-1,Preclinical,EGFR inhibitor,,,
CCS(=O)(=O)Nc1ccc2c(c1)/C(=C(/Nc1ccc(CN3CCCCC3)cc1)c1ccccc1)C(=O)N2,hesperadin,Preclinical,Aurora kinase inhibitor,AURKB,,
COc1ccc([C@@H]2CC(=O)c3c(O)cc(O)cc3O2)cc1O,hesperetin,Launched,ACAT inhibitor,DGAT1|MTTP|SOAT1|SOAT2,,
COc1ccc([C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2)cc1O,hesperidin,Launched,flavanone glycoside,AURKB|CACNA1B,,
CC1(C)S[C@@H]2[C@H](N3C(=O)[C@@H](c4ccccc4)NC3(C)C)C(=O)N2[C@H]1C(=O)O,hetacillin,Launched,bacterial cell wall synthesis inhibitor,,obstetrics/gynecology,mastitis
Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl,hexachlorophene,Launched,potassium channel activator,GLUD1|SDHD,infectious disease,gram-positive bacterial infections
C[N+](C)(C)CCCCCC[N+](C)(C)C,hexamethonium,Preclinical,cholinergic receptor antagonist,CHRNA2|CHRNA3|CHRNA4|CHRNA6,,
CC(=O)NCCCCCCNC(C)=O,hexamethylenebisacetamide,Phase 2,AKT inhibitor|differentiation inducer|NFKB pathway inhibitor,AKT1,,
CCCCCCOC(=O)CCC(=O)CN,hexaminolevulinate,Launched,,,radiology,diagnostic agent
O=P(O)(O)O[C@H]1[C@H](OP(=O)(O)O)[C@@H](OP(=O)(O)O)[C@H](OP(=O)(O)O)[C@@H](OP(=O)(O)O)[C@H]1OP(=O)(O)O,hexasodium-phytate,Phase 2,,,,
CC[C@H](c1ccc(O)cc1)[C@@H](CC)c1ccc(O)cc1,hexestrol,Launched,synthetic estrogen,AKR1C1|ESR1|ESR2,endocrinology,hypoestrogenism
CCCC[C@@H](CC)CN1CN(C[C@@H](CC)CCCC)C[C@@](C)(N)C1,hexetidine,Launched,local anesthetic,,otolaryngology|infectious disease|dental|gastroenterology,pharyngitis|meningitis|laryngitis|gingivitis|ulcerative colitis
O=C(O)[C@H](O)[C@H](O)[C@H](O)[C@H](O)CO,hexonic-acid,Preclinical,,,,
Oc1ccc([C@H](O)CNCCCCCCNC[C@H](O)c2ccc(O)c(O)c2)cc1O,hexoprenaline,Launched,adrenergic receptor agonist,ADRB2,pulmonary,asthma
C[C@@H](CNC1CCCCC1)OC(=O)c1ccccc1,hexylcaine,Launched,sodium channel blocker,SCN5A,neurology/psychiatry,local anesthetic
C[C@@H](O)CC(C)(C)O,hexylene-glycol,Preclinical,,AKR1C3|CTPS1|DLG4|HSP90AA1|NOS3|PGF|PLA2G1B|PTPN1|SELP,,
CCCCCCc1ccc(O)cc1O,hexylresorcinol,Launched,local anesthetic,TYR,infectious disease,skin infections|first-aid antiseptic
Oc1ccc(C[C@H]2NCCc3cc(O)c(O)cc32)cc1,higenamine,Phase 1,adrenergic receptor agonist,ADRB2,,
O=C(O)CNC(=O)c1ccccc1,hippuric-acid,Preclinical,,,,
NCCc1cnc[nH]1,histamine,Launched,histamine receptor agonist,HRH1|HRH2|HRH3|HRH4,allergy,allergic rhinitis
Cc1cc(C)c(S(=O)(=O)n2cc(C)cc2C)c(C)c1,HJC-0350,Preclinical,GTPase inhibitor,RAPGEF4,,
CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,HKI-357,Phase 1,EGFR inhibitor,EGFR,,
CCn1c2ccccc2c2cc(CNCc3ccccc3OC)ccc21,HLCL-61,Preclinical,protein arginine N-methyltransferase inhibitor,PRMT5,,
COc1cc2c(cc1OC)CN(CCc1ccc(-n3nnc(-c4cc(OC)c(OC)cc4NC(=O)c4cc(=O)c5ccccc5o4)n3)cc1)CC2,HM-30181,Phase 1,P glycoprotein inhibitor,,,
COc1ccc(S(=O)(=O)N(C(C)=O)c2ccccc2/C=C/c2cc[n+]([O-])cc2)cc1,HMN-214,Phase 1,PLK inhibitor,PLK1,,
CC(C)(C)NC[C@H](O)c1ccc(O)cc1Cl,HOKU-81,Preclinical,bronchodilator,,,
CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)[C@@H](O)c1ccccc1)C2,homatropine,Launched,acetylcholine receptor antagonist,CHRM1,ophthalmology,uveal tract inflammation|pupil dilation
C[N+]1(C)[C@@H]2CC[C@H]1C[C@@H](OC(=O)[C@@H](O)c1ccccc1)C2,homatropine-methylbromide,Launched,acetylcholine receptor antagonist,CHRM5,ophthalmology,uveal tract inflammation
CC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc21,homidium,Preclinical,,,,
CN1CCCN([C@@H](c2ccccc2)c2ccc(Cl)cc2)CC1,homochlorcyclizine,Launched,antihistamine,HRH1,allergy,allergic rhinitis
COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@@H]1C(OC)=C[C@]23CCCN2CCc2cc4c(cc2[C@H]13)OCO4,homoharringtonine,Launched,protein synthesis inhibitor,RPL3,hematologic malignancy,chronic myeloid leukemia (CML)
O=C(O)Cc1cccnc1C(=O)O,homoquinolinic-acid,Preclinical,glutamate receptor agonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,,
C[C@H]1C[C@H](OC(=O)c2ccccc2O)CC(C)(C)C1,homosalate,Preclinical,HSP inducer,,,
COc1ccc(CCN)cc1OC,homoveratrylamine,Preclinical,monoamine oxidase inhibitor,,,
C=CCc1ccc(O)c(-c2ccc(O)c(CC=C)c2)c1,honokiol,Phase 3,AKT inhibitor,ALOX5|PTGS1|PTGS2,,
CN(C)CCc1ccc(O)cc1,hordenine,Preclinical,,,,
CCCC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)NCC(N)=O,HP-228,Preclinical,nitric oxide synthase inhibitor,,,
CC(C)(O)c1nc(-c2cccc(CNC(=O)c3cnc(-c4ccccn4)nc3)c2)no1,hPGDS-IN-1,Preclinical,prostaglandin inhibitor,,,
CCCCCCO[C@H](C)c1c(C)c2cc3nc(c4c5[nH]c(cc6nc(cc1[nH]2)C(C)=C6CC)c(C)c5C(=O)C4)[C@@H](CCC(=O)O)[C@@H]3C,HPPH,Phase 2,photosensitizing agent,,,
O=C(Nc1nnn[nH]1)c1cncc(N2CCCC2)n1,HSR6071,Preclinical,antiallergic agent,,,
O=C1/C(=N\c2cccc(C(F)(F)F)c2)c2ccccc2N1c1ccccc1,HT-2157,Phase 1/Phase 2,galanin receptor 3 antagonist,,,
Cc1nc(Nc2cnn(C3CCNCC3)c2)nc2c1N(C)C(=O)c1cc3ccccc3cc1N2C,HTH-01-015,Preclinical,protein kinase inhibitor,NUAK1,,
CCCCCCOc1cc(C)c(O)c(C)c1C,HTHQ,Preclinical,antioxidant,,,
C[C@@H](CCCCC(=O)Nc1ccc(C(F)(F)F)cc1)NCCc1cnc[nH]1,HTMT,Preclinical,histamine receptor agonist,HRH4,,
C/C=C1\[C@H]2C=C(C)C[C@]1(N)c1ccc(=O)[nH]c1C2,huperzine-A,Phase 2,acetylcholinesterase inhibitor,ACHE,,
CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1C(=O)O,hyaluronic-acid,Launched,,C1QBP|CD44|HABP2|HAPLN1|HAPLN3|HAPLN4|HMMR|ICAM1|NCAN|VCAN,rheumatology|urology,osteoarthritis|interstitial cystitis (IC)
CCN(CC)CCNc1ccc(CO)c2sc3ccccc3c(=O)c12,hycanthone,Launched,RNA synthesis inhibitor,,infectious disease,schistosomiasis
N/N=c1\[nH]ncc2ccccc12,hydralazine,Launched,vasodilator,,cardiology,hypertension
NNc1nncc2ccccc12,hydralazine,Launched,vasodilator,,cardiology,hypertension
COc1ccc2c(c1OC)C(=O)O[C@@H]2[C@H]1c2cc3c(cc2CCN1C)OCO3,"hydrastine-(1R,9S)",Preclinical,tyrosine hydroxylase inhibitor,,,
C[N+]1=Cc2cc3c(cc2CC1)OCO3,hydrastinine,Preclinical,hemostatic agent,,,
NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,hydrochlorothiazide,Launched,thiazide diuretic,CA1|CA12|CA2|CA4|CA9|KCNMA1|SLC12A3,cardiology,hypertension|congestive heart failure
C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO,hydrocortisone,Launched,glucocorticoid receptor agonist,ANXA1|NOS2|NR3C1|NR3C2,dermatology|neurology/psychiatry,eczema|psoriasis|seborrheic dermatitis|itching
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,hydrocortisone-acetate,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses
CCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,hydrocortisone-butyrate,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses|eczema
C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)O,hydrocortisone-hemisuccinate,Phase 2/Phase 3,,,,
C[C@@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)(O)O,hydrocortisone-phosphate,Launched,,,pulmonary|gastroenterology|hematologic malignancy|ophthalmology,asthma|nausea|vomiting|multiple myeloma|contact dermatitis|enteritis|colitis
CCCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,hydrocortisone-valerate,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses
NS(=O)(=O)c1cc2c(cc1C(F)(F)F)NCNS2(=O)=O,hydroflumethiazide,Launched,sodium/potassium/chloride transporter inhibitor,ATP1A1|CA1|CA12|CA2|CA4|CA9|KCNMA1|SLC12A1|SLC12A3,cardiology|gastroenterology|rheumatology|nephrology,edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|chronic renal failure|acute glomerulonephritis (AGN)|hypertension
CC[C@H]1C[N@@]2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12,hydroquinidine,Launched,antiarrhythmic,,cardiology,cardiac arrythmia
Oc1ccc(O)cc1,hydroquinone,Launched,melanin inhibitor,TYR,dermatology,dyschromia
C/C1=C2/N([Co+]O)[C@H]([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(=O)(O)O[C@H]2[C@@H](O)[C@@H](n3cnc4cc(C)c(C)cc43)O[C@@H]2CO)[C@]2(C)N=C(/C(C)=C3\N=C(/C=C4/N=C1[C@@H](CCC(N)=O)C4(C)C)[C@@H](CCC(N)=O)[C@]3(C)CC(N)=O)[C@@H](CCC(N)=O)[C@]2(C)CC(N)=O,hydroxocobalamin,Launched,vitamin B,,,
C[C@@H](N)Cc1ccc(O)cc1,hydroxyamphetamine,Launched,trace amine associated receptor agonist,TAAR1,ophthalmology,mydriasis
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,hydroxychloroquine,Launched,antimalarial agent,TLR7|TLR9,infectious disease,malaria
O=c1[nH]ccc2c(S(=O)(=O)N3CCCNCC3)cccc12,hydroxyfasudil,Preclinical,rho associated kinase inhibitor,PKIA|PRKACA|ROCK1,,
CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,hydroxyprogesterone,Launched,progesterone receptor agonist,PGR,obstetrics/gynecology,spontaneous preterm birth
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,hydroxyprogesterone-acetate,Launched,progesterone receptor agonist,PGR,,
C[C@@H](O)COC[C@H]1O[C@@H]2O[C@H]3[C@H](O)[C@@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@@H](O[C@H]5[C@H](O)[C@@H](O)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O[C@H]1[C@H](O)[C@H]2O)O[C@@H]8COC[C@@H](C)O)O[C@@H]7COC[C@@H](C)O)O[C@@H]6COC[C@@H](C)O)O[C@@H]5COC[C@@H](C)O)O[C@@H]4COC[C@@H](C)O)O[C@@H]3COC[C@@H](C)O,hydroxypropyl-beta-cyclodextrin,Phase 2/Phase 3,,,,
O=C(/C=C/c1ccc(O)cc1)[C@H]1C(=O)[C@H]([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C(=O)[C@@](O)([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C1=O,hydroxysafflor-yellow-A,Preclinical,antitumor agent,,,
N=C(N)c1ccc(/C=C/c2ccc(C(=N)N)cc2O)cc1,hydroxystilbamidine,Launched,,,,
Nc1c2c(nc3ccccc13)CCC[C@@H]2O,"hydroxytacrine-maleate-(R,S)",Preclinical,cholinesterase inhibitor,ACHE,,
Cc1cccc(C(=O)O)c1O,hydroxytoluic-acid,Preclinical,,,,
NC(=O)NO,hydroxyurea,Launched,ribonucleotide reductase inhibitor,RRM1|RRM2|RRM2B,hematologic malignancy|oncology,chronic myeloid leukemia (CML)|head and neck squamous cell carcinoma (HNSCC)
OCCOCCN1CCN([C@@H](c2ccccc2)c2ccc(Cl)cc2)CC1,hydroxyzine,Launched,antihistamine,HRH1,neurology/psychiatry|allergy|dermatology,anxiety|urticaria|itching|dermatosis
CN[C@H]1C[C@@H](N)[C@H](O)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@@H]3O[C@@]4(O[C@H]23)O[C@H]([C@@H](N)CO)[C@H](O)[C@H](O)[C@H]4O)[C@@H]1O,hygromycin-B,Preclinical,polypeptide synthesis inhibitor,,,
Cc1cc(=O)oc2cc(O)ccc12,hymecromone,Phase 2,monoamine oxidase inhibitor,MAOA|MAOB,,
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,hyodeoxycholic-acid,Phase 1,atherosclerosis formation inhibitor,,,
CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)[C@H](CO)c1ccccc1)C2,hyoscyamine,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4,gastroenterology|urology|neurology/psychiatry|allergy,peptic ulcer disease (PUD)|acute abdominal visceral spasm|ulcerative colitis|interstitial cystitis (IC)|enterocolitis|irritable bowel syndrome|tremors|allergic rhinitis
Cc1cc(O)c2c(=O)c3c(O)cc(O)c4c5c(O)cc(O)c6c(=O)c7c(O)cc(C)c8c1c2c(c34)c(c78)c65,hypericin,Phase 3,tyrosine kinase inhibitor,,,
O=c1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,hyperin,Preclinical,aldose reductase inhibitor,ACE|AKR1B1,,
C=C1C(=O)C[C@H]2C[C@@H]3O[C@@]3(C)CC[C@@H]3O[C@@]3(C)C[C@@H](OC(C)=O)[C@H]1C2(C)C,hypoestoxide,Phase 1,IKK inhibitor,IKBKB|IL1B|TNF,,
O=c1nc[nH]c2nc[nH]c12,hypoxanthine,Preclinical,PARP inhibitor,PNP,,
CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc21,I-BET-762,Phase 2,bromodomain inhibitor,BRD2|BRD3|BRD4,,
COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n([C@H](C)c3ccccn3)c12,I-BET151,Preclinical,bromodomain inhibitor,BRD2|BRD3|BRD4,,
CCn1cc(-c2cccc(C(F)(F)F)c2)c2sc(C(=N)NC3CCS(=O)(=O)CC3)cc2c1=O,I-BRD9,Preclinical,bromodomain inhibitor,BRD9,,
CCN(CC)CCNC(=O)c1ccc(I)cc1,I-BZA,Phase 2,,,,
CCN(CC)CCNC(=O)c1ccccc1I,I-BZA2,Phase 3,,,,
CCC(=O)N1CCOc2c(cc(-c3ccc(OC)c(OC)c3)cc2OC[C@H]2CCCN(C)C2)C1,I-CBP-112,Preclinical,bromodomain inhibitor,CREBBP|EP300,,
Cc1nc(-c2nc(-c3ccc(OC(F)(F)F)cc3)no2)nn1Cc1cccc(N2CCC(S(C)(=O)=O)CC2)c1,IACS-10759,Preclinical,mitochondrial complex I inhibitor,,,
CNC(=O)[C@H]1O[C@@H](n2cnc3c(NCc4cccc(I)c4)ncnc32)[C@H](O)[C@@H]1O,IB-MECA,Phase 3,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
CC(C)n1nnc2cc(C(=O)O)ccc21,IBC-293,Preclinical,hydroxycarboxylic acid receptor agonist,HCAR3,,
O=C1CC[C@H](N2Cc3c(OCc4ccc(CN5CCOCC5)cc4)cccc3C2=O)C(=O)N1,iberdomide,Preclinical,cereblon modulator,,,
CC(C)(NC(=O)O[C@@H]1CN2CCC1CC2)c1csc(-c2ccc(F)cc2)n1,ibiglustat,Preclinical,glucosylceramidase inhibitor,,,
CC(C)Cn1c(=O)n(C)c(=O)c2[nH]cnc21,IBMX,Preclinical,phosphodiesterase inhibitor,ADORA1|PDE2A|PDE3B|PDE4D|PDE5A|PDE6G|PDE7A|PDE8A|PDE9A,,
N[C@@H](C(=O)O)c1cc(=O)[nH]o1,ibotenic-acid,Preclinical,glutamate receptor agonist,GRIN1,,
CCOP(=O)(Cc1ccc(C(=O)Nc2ccc(Br)cc2C#N)cc1)OCC,ibrolipim,Phase 2,lipoprotein lipase activator,LPL,,
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,ibrutinib,Launched,Bruton's tyrosine kinase (BTK) inhibitor,BLK|BMX|BTK,hematologic malignancy,chronic lymphocytic leukemia (CLL)|mantle cell lymphoma (MCL)|Waldenstrom's macroglobulinemia (WM)
CC(C)C(=O)c1c(C(C)C)nn2ccccc12,ibudilast,Launched,leukotriene receptor antagonist|phosphodiesterase inhibitor,IL1B|IL6|PDE3A|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A,pulmonary|neurology/psychiatry,asthma|stroke
CC(C)Cc1ccc([C@@H](C)C(=O)O)cc1,ibuprofen,Launched,cyclooxygenase inhibitor,,neurology/psychiatry|rheumatology|otolaryngology|obstetrics/gynecology|endocrinology|dental,headache|muscle pain|rheumatoid arthritis|backache|common cold|menstrual pain|fever|toothache
CC(C)Cc1ccc([C@H](C)C(=O)O)cc1,ibuprofen-(S),Launched,cyclooxygenase inhibitor,ASIC1|PTGS1|PTGS2|SLC5A8,neurology/psychiatry,pain relief
CC(C)Cc1ccc([C@@H](C)C(=O)O)cc1.NCCCC[C@H](N)C(=O)O,ibuprofen-lysine,Launched,cyclooxygenase inhibitor,,cardiology,patent ductus arteriosus (PDA)
CC(C)Cc1ccc([C@@H](C)C(=O)OCc2ccccn2)cc1,ibuprofen-piconol,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief
CC(C)Cc1ccc([C@@H](C)C(=O)NO)cc1,ibuproxam,Launched,cyclooxygenase inhibitor|prostaglandin inhibitor,ALOX5,endocrinology|rheumatology|neurology/psychiatry,fever|joint inflammation|pain relief
CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CC1)CN(S(C)(=O)=O)c1ccccc12,ibutamoren,Phase 2,growth hormone secretagogue receptor agonist,GHR|GHSR,,
CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1,ibutilide,Launched,potassium channel blocker,CACNA1C|KCNH2,cardiology,atrial fibrillation (AF)
COc1cc(OC)c(/C=C2/C(=O)Nc3ccccc32)c(OC)c1,IC261,Preclinical,casein kinase inhibitor,CSNK1A1|CSNK1D|CSNK1E|CSNK1G2,,
O=C(Nc1cnc(Cl)nc1)c1ccc(F)c(F)c1,ICA-069673,Preclinical,voltage-gated potassium channel activator,KCNQ2|KCNQ3,,
O=C(Nc1ccc(Cl)nc1)c1ccc(Cl)cc1,ICA-110381,Preclinical,voltage-gated potassium channel activator,KCNQ2,,
O=C(Nc1ccc(S(=O)(=O)Nc2nccs2)cc1)C(c1ccccc1)c1ccccc1,ICA-121431,Preclinical,sodium channel blocker,SCN1A|SCN3A,,
COc1ccc(-c2oc3c(CC=C(C)C)c(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)cc(O)c3c(=O)c2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)cc1,icariin,Phase 3,phosphodiesterase inhibitor,PDE5A,,
COc1ccc(-c2oc3c(CC=C(C)C)c(O)cc(O)c3c(=O)c2O)cc1,icaritin,Phase 3,PPAR receptor antagonist,PDE5A,,
N=C(N)NCCC[C@@H](N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C[C@@H]2CCCC[C@@H]21,icatibant-acetate,Launched,bradykinin receptor antagonist,BDKRB2,cardiology,angioedema
O=C1[C@H](Cc2ccc(O)cc2)N2C(=O)CCN(C(=O)NCc3ccccc3)[C@H]2CN1Cc1cccc2ccccc12,ICG-001,Preclinical,beta-catenin inhibitor,CTNNB1,,
Cc1ccc(OC[C@@H](O)[C@H](C)NC(C)C)c2c1CCC2,"ICI-118,551",Phase 2,adrenergic receptor antagonist,ADRB2|ADRB3,,
N=C(NCC(F)(F)F)Nc1ccn(CCCCC(N)=O)n1,ICI-162846,Phase 1,histamine receptor antagonist,HRH2,,
CN(C)CCSc1nc2ccccc2cc1-c1ccccc1,ICI-169369,Phase 2,serotonin receptor antagonist,,,
O=C(O)CCC/C=C\C[C@@H]1CO[C@H](C(F)(F)F)O[C@@H]1c1ccccc1O,"ICI-185,282",Phase 1,thromboxane receptor antagonist,,,
O=C(O)CC/C=C\C[C@@H]1CO[C@H](c2ccccc2Cl)O[C@@H]1c1ccccc1O,ICI-192605,Phase 2,thromboxane receptor antagonist,TBXA2R,,
CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@H](CN1CCCC1)c1ccccc1,ICI-199441,Preclinical,opioid receptor agonist,CYP2D6|OPRD1|OPRK1|OPRM1|UTS2R,,
O=C(O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1,"ICI-215,001",Preclinical,adrenergic receptor agonist,ADRB3,,
CCCn1c(=O)c(C)cn2nc(N)nc12,ICI-63197,Preclinical,phosphodiesterase inhibitor,,,
N#Cc1ccccc1OC[C@@H](O)CNCCNC(=O)Nc1ccccc1,ICI-89406,Phase 1,adrenergic receptor antagonist,ADRB1|ADRB2,,
O=C1NC(c2cccc([N+](=O)[O-])c2)=CCN1c1ccccc1O,icilin,Phase 1,TRPV agonist,TRPA1|TRPM8,,
COc1cc(Cc2cnc(N)nc2N)c2c(c1OC)O[C@H](C1CC1)C=C2,iclaprim,Phase 3,dihydrofolate reductase inhibitor,,,
CCCCC[C@H](O)/C=C/C=C\C/C=C\C/C=C\CCCC(=O)O,icomucret,Phase 3,mucin production enhancer,LTB4R2,,
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O,icosapent,Launched,platelet aggregation inhibitor,ACSL3|ACSL4|FADS1|FFAR1|PPARD|PPARG|PTGS1|PTGS2|SLC8A1|TRPV1,endocrinology,hypertriglyceridemia
C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1,icotinib,Launched,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC)
Cc1cc(/C=C2\SC(=O)N(c3ccccc3)C2=O)c(C)n1-c1cccnc1,iCRT-14,Preclinical,beta catenin inhibitor|WNT signaling inhibitor,CTNNB1|TCF4,,
C[C@@H]([C@H](C)O)[C@H](N)C(=O)O,ID-1101,Phase 1,insulin sensitizer,INS,,
COc1ccc(-n2c(C)c([N+](=O)[O-])c3ccc(O)cc32)cc1,ID-8,Preclinical,,,,
Fc1ccc2c(CCNCc3cccc(OCC(F)(F)C(F)F)c3)c[nH]c2c1,idalopirdine,Phase 3,serotonin receptor antagonist,HTR6,,
CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O,idarubicin,Launched,topoisomerase inhibitor,TOP2A,hematologic malignancy,acute myeloid leukemia (AML)
COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F,idasanutlin,Phase 3,MDM inhibitor,MDM2|TP53,,
c1ccc2c(c1)OC[C@H](C1=NCCN1)O2,idazoxan,Phase 3,adrenergic receptor antagonist,ADRA2A|PTGS2,,
COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O,idebenone,Launched,calcium channel modulator,,neurology/psychiatry|ophthalmology,Alzheimer's disease|Friedreich's ataxia|Leber hereditary optic neuropathy (LHON)
CC[C@H](Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,idelalisib,Launched,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,hematologic malignancy,chronic lymphocytic leukemia (CLL)
CN1CCN(C(=O)COc2ccc(C34CC5CC(CC(C5)C3)C4)cc2)CC1,IDF-11774,Preclinical,hypoxia inducible factor inhibitor,,,
Cc1cc([C@H](C)Nc2nccc(N3C(=O)OC[C@@H]3[C@H](C)F)n2)ncc1-c1ccnc(C(F)(F)F)c1,IDH-305,Phase 2,isocitrate dehydrogenase inhibitor,,,
Nc1nonc1/C(=N\c1ccc(F)c(Cl)c1)NO,IDO5L,Preclinical,"indoleamine 2,3-dioxygenase inhibitor",IDO1,,
O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1I,idoxuridine,Launched,DNA directed DNA polymerase inhibitor|DNA synthesis inhibitor,,infectious disease,virus herpes simplex (HSV)
C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1,IDRA-21,Preclinical,glutamate receptor positive allosteric modulator,GRIA1|GRIA2|GRIA3|GRIA4,,
O=C1[C@@H]2C[C@@H]3C[C@H]1C[C@@](O)(C3)C2,idramantone,Preclinical,,,,
Oc1ccc(C2=Cc3ccc(O)cc3OC2)cc1,idronoxil,Phase 3,XIAP inhibitor,ENOX2|SPHK1,,
C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2,IEM1460,Preclinical,glutamate receptor antagonist,GRIA2,,
NCCCCCNCC12CC3CC(CC(C3)C1)C2,IEM1754,Preclinical,glutamate receptor antagonist,GRIA1,,
C[C@@H]([C@H](O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1,ifenprodil,Launched,adrenergic receptor antagonist|glutamate receptor antagonist,GRIN2B,,
O=[P@]1(NCCCl)OCCCN1CCCl,ifosfamide,Launched,DNA alkylating agent,CYP2A6|CYP2B6|CYP2C18|CYP2C19|CYP2C8|CYP2C9|CYP3A4|CYP3A5|CYP3A7|PTGS1,oncology|urology,testicular carcinoma|hemorrhagic cystitis
CCC(C/C=C/c1ccccc1)(c1ccccc1)N(C)CC1CC1,igmesine,Phase 2,sigma receptor agonist,SIGMAR1,,
CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1,iguratimod,Launched,cyclooxygenase inhibitor|NFkB pathway inhibitor,PTGS2,rheumatology,rheumatoid arthritis
O=C(c1ccc(Nc2nccc(-c3cc4ccccc4s3)n2)cc1)N1CCC(N2CCCC2)CC1,IKK-16,Preclinical,IKK inhibitor,IKBKB,,
NC(=O)c1sc(-c2ccsc2)cc1N,IKK-2-inhibitor,Preclinical,IKK inhibitor|SYK inhibitor,IKBKB,,
O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1O,IKK-2-inhibitor-V,Phase 1,IKK inhibitor|NFkB pathway inhibitor,IKBKB,,
COc1ccnc(C[S@@](=O)c2nc3ccc(-n4cccc4)cc3[nH]2)c1C,ilaprazole,Launched,proton pump inhibitor,,gastroenterology,gastroesophageal reflux disease (GERD)
O=C(/C=C/c1ccc2c(c1)OCO2)N1CCCCC1,ilepcimide,Phase 3,anticonvulsant,,,
CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](CC(=O)NO)CC(C)C,ilomastat,Phase 3,matrix metalloprotease inhibitor,ACAN|ADAM28|MMP1|MMP12|MMP13|MMP14|MMP2|MMP3|MMP8|MMP9,,
COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1,iloperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A|ADRA2C|DRD1|DRD2|DRD3|DRD4|HRH1|HTR1A|HTR2A|HTR6|HTR7,neurology/psychiatry,schizophrenia
CC#CC[C@@H](C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O,iloprost,Launched,platelet aggregation inhibitor|prostanoid receptor agonist,PTGDR|PTGER1|PTGER2|PTGER3|PTGER4|PTGFR|PTGIR|TBXA2R,pulmonary,pulmonary arterial hypertension (PAH)
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,imatinib,Launched,Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,ABL1|CSF1R|DDR1|KIT|NTRK1|PDGFRA|PDGFRB|RET,hematologic malignancy|oncology,chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)|myelodysplastic diseases (MDS)|aggressive systemic mastocytosis (ASM)|hypereosinophilic syndrome (HES)|chronic eosinophilic leukemia (CEL)|dermatofibrosarcoma protuberans (DFSP)|gastrointestinal stromal tumors (GIST)
O=C1CCC(c2ccc(-n3ccnc3)cc2)=NN1,Imazodan,Phase 1,phosphodiesterase inhibitor,,,
C[C@@H]1N=C(N)N=C(N(C)C)N1,imeglimin,Phase 2,gluconeogenesis inhibitor,,,
N=C(N)SCCc1cnc[nH]1,imetit,Preclinical,histamine receptor agonist,HRH3|HRH4,,
NC1=NC(=O)N2C[C@@H]12,imexon,Phase 2,apoptosis stimulant|ribonucleotide reductase inhibitor,,,
O=[N+]([O-])N=C1NCCN1Cc1ccc(Cl)nc1,imidacloprid,Launched,acetylcholine receptor antagonist,,,
Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1,imidafenacin,Launched,acetylcholine receptor antagonist,CHRM1|CHRM3,neurology/psychiatry,spasms
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1C(=O)N(C)C[C@H]1C(=O)O,imidapril,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|congestive heart failure
CCN(CC)CCNc1ccc2ncn3c4ccc(O)cc4c(=O)c1c23,imidazoacridinone,Preclinical,anticancer agent,,,
O=C(NCNC(=O)N[C@H]1C(=O)NC(=O)N1CO)N[C@H]1C(=O)NC(=O)N1CO,imidurea,Preclinical,other antibiotic,,,
CCn1ccnc1C[C@H]1COc2ccccc2O1,imiloxan,Phase 1,adrenergic receptor antagonist,ADRA2A|ADRA2B,,
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCCNC=N)C[C@H]12,imipenem,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,pneumonia|urinary tract infections|intra-abdominal infections|gynecologic infections|bacterial septicemia|bone and joint infections|skin infections|endocarditis
CN(C)CCCN1c2ccccc2CCc2ccccc21,imipramine,Launched,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,ADRA1A|ADRA1B|ADRA1D|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD5|HRH1|HTR1A|HTR2A|HTR2C|HTR6|HTR7|KCND2|KCND3|KCNH1|KCNH2|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry|urology,depression|nocturnal enuresis
CC(C)Cn1cnc2c(N)nc3ccccc3c21,imiquimod,Launched,interferon inducer|toll-like receptor agonist,TLR7|TLR8,dermatology|infectious disease|oncology,actinic keratosis (AK)|genital warts|basal cell carcinoma (BCC)
O=C1NC(=O)C2(N1)c1cc(F)ccc1-c1ccc(F)cc12,imirestat,Preclinical,aldose reductase inhibitor,,,
Cl[Mn]123(Cl)N4CCN1[C@@H]1CCCC[C@H]1N2Cc1cccc(n1)CN3[C@@H]1CCCC[C@H]14,imisopasem-manganese,Preclinical,superoxide dismutase mimetic,,,
c1ncc(CC2CCNCC2)[nH]1,immepip,Preclinical,histamine receptor agonist,HRH3|HRH4,,
c1cc(Cc2cnc[nH]2)ccn1,immethridine,Phase 1,histamine receptor agonist,HRH3,,
NCCCCCc1cnc[nH]1,impentamine,Preclinical,histamine receptor antagonist,HRH3,,
N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(=O)O,IMREG-1,Phase 3,,,,
CO[C@@H]1[C@H](O[P@@](=O)(S)OC[C@H]2O[C@@H](n3cnc4c(N)ncnc43)C[C@@H]2O)[C@@H](CO)O[C@H]1n1ccc(=O)[nH]c1=O,inarigivir,Phase 2,antiviral,,,
CO[C@@H]1[C@H](O[P@@](=O)(OC[C@H]2O[C@@H](n3cnc4c(N)ncnc43)C[C@@H]2O)SCOC(=O)OC(C)C)[C@@H](CO)O[C@H]1n1ccc(=O)[nH]c1=O,inarigivir-soproxil,Phase 2,antiviral,,,
CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F,INC-280,Phase 3,c-Met inhibitor,MET,,
O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc21,INCA-6,Preclinical,calcineurin inhibitor,NFATC1,,
COc1ccc(C2(O)CCC(N3CC[C@@H](NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)cn1,INCB-003284,Phase 2,CC chemokine receptor antagonist,,,
CN1C(=O)C(C)(C)Oc2c(-c3cn(C)c(O)c4nccc3-4)cc(S(C)(=O)=O)cc21,INCB-057643,Phase 1/Phase 2,bromodomain inhibitor,,,
COc1ccc([C@]2(O)CC[C@H](N3CC[C@@H](NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)cn1,INCB-3284,Phase 2,CC chemokine receptor antagonist,CCR2,,
NC(=O)[C@@H]1C(=O)C[C@@H]2C[C@@H]3Cc4cccc(O)c4C(=O)[C@@H]3C(=O)[C@]2(O)C1=O,incyclinide,Phase 2,matrix metalloprotease inhibitor,,,
CCc1cc2c(cc1CC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2,indacaterol,Launched,adrenergic receptor agonist,ADRB1|ADRB2,pulmonary,chronic obstructive pulmonary disease (COPD)
C[C@H]1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(S(N)(=O)=O)c1,indapamide,Launched,thiazide diuretic,CA2|HTR3A|KCNQ1,cardiology,hypertension|congestive heart failure
CN[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,indatraline,Preclinical,norepinephrine transporter inhibitor,MAOA|MAOB,,
COc1ccc(S(=O)(=O)n2cc(CCC(=O)O)c3cc(OC)ccc32)cc1,indeglitazar,Phase 2,PPAR receptor agonist,NCOA1|PPARA|PPARD|PPARG,,
O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12,indibulin,Phase 1/Phase 2,tubulin polymerization inhibitor,,,
CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O,indinavir,Launched,HIV protease inhibitor,CYP3A4|CYP3A5|CYP3A7,infectious disease,human immunodeficiency virus (HIV-1)
CC(=O)N(C)c1cccc(-c2ccnc3c(C(=O)c4cccs4)cnn23)c1,indiplon,Phase 3,benzodiazepine receptor agonist,GABRA1,,
O=C1Nc2ccccc2/C1=C1/Nc2ccccc2C1=O,indirubin,Phase 2/Phase 3,CDK inhibitor|glycogen synthase kinase inhibitor,CDK1|CDK5|GSK3A,,
O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\O,indirubin-3-monoxime,Preclinical,CDK inhibitor|glycogen synthase kinase inhibitor,CDK1|CDK2|CDK5|CDK5R1|GSK3B,,
NS(=O)(=O)c1ccc(S(=O)(=O)Nc2cccc3c(Cl)c[nH]c23)cc1,indisulam,Phase 2,CDK inhibitor,CA1|CA12|CA14|CA2|CA6|CA7|CA9,,
CC(C)O[In](OC(C)C)OC(C)C,indium-tri(2-propanolate),Preclinical,,,,
CC[C@@H](C(=O)O)c1ccc(N2Cc3ccccc3C2=O)cc1,indobufen,Launched,cyclooxygenase inhibitor|platelet aggregation inhibitor,PTGS1|PTGS2,hematology,thrombosis
CC1(C)C(/C=C/C=C/C=C/C=C2/N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,indocyanine-green,Launched,contrast agent,SLCO1B1,cardiology,vascular imaging agent
OCc1c[nH]c2ccccc12,indole-3-carbinol,Phase 2/Phase 3,"aryl hydrocarbon receptor agonist|indoleamine 2,3-dioxygenase inhibitor",AHR,,
O=C(O)C(O)=Cc1c[nH]c2ccccc12,indole-3-pyrubate,Phase 2,melatonin receptor agonist,,,
COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,indomethacin,Launched,cyclooxygenase inhibitor,GLO1|PLA2G2A|PPARA|PPARG|PTGDR2|PTGR2|PTGS1|PTGS2|SLC46A1,rheumatology|orthopedics,rheumatoid arthritis|ankylosing spondylitis|osteoarthritis|bursitis|tendinitis
O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1,indoramin,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2B|ADRA2C,urology|cardiology,benign prostatic hyperplasia (BPH)|hypertension
Cn1cc(C[C@@H](N)C(=O)O)c2ccccc21,indoximod,Phase 2,"indoleamine 2,3-dioxygenase inhibitor",IDO1,,
CC1=C[C@]23C(=O)[C@@H](C=C(CO)[C@@H](O)[C@]2(O)[C@H]1O)[C@H]1[C@@H](C[C@H]3C)C1(C)C,ingenol,Launched,PKC activator,PRKCD|PRKCE,dermatology,keratosis
C/C=C(/C)C(=O)O[C@H]1C(C)=C[C@]23C(=O)[C@@H](C=C(CO)[C@@H](O)[C@]12O)[C@H]1[C@@H](C[C@H]3C)C1(C)C,ingenol-mebutate,Launched,PKC activator,PRKCA|PRKCB|PRKCD|PRKCE|PRKCG,dermatology,actinic keratosis (AK)
Cc1ccc(-c2csc(NC(=O)c3ccccc3)n2)c(C)c1,INH1,Preclinical,Hec1 inhibitor,NDC80,,
CSC[C@H]1CN(/N=C/c2ccc([N+](=O)[O-])o2)C(=O)O1,inimur,Launched,other antifungal,,,
NC(=O)c1ccc(I)c([N+](=O)[O-])c1,iniparib,Phase 3,PARP inhibitor,PARP1,,
O=c1nc[nH]c2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,inosine,Launched,neurotrophic agent,PARP1|PNP,,
O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O,inositol,Launched,insulin sensitizer,CDIPT,obstetrics/gynecology,polycystic ovary syndrom (PCOS)
O=C(O[C@H]1[C@H](OC(=O)c2cccnc2)[C@@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@@H](OC(=O)c2cccnc2)[C@H]1OC(=O)c1cccnc1)c1cccnc1,inositol-hexanicotinate,Launched,,,dermatology|cardiology|rheumatology|neurology/psychiatry,statis dermatitis|claudication|Raynaud's disease|hypertension|insomnia|atherosclerosis|restless leg syndrome|schizophrenia|psoriasis|acne vulgaris (AV)
O=c1ccn([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@H](O)[C@H]2O)c(=O)[nH]1,INS316,Phase 2,purinergic receptor antagonist,,,
CC[C@H]1[C@@H](O)[C@@H]2[C@H](CC[C@]3(C)[C@@H]([C@H](C)CCC(=O)O)CC[C@@H]23)[C@@]2(C)CC[C@@H](O)C[C@@H]12,INT-747,Phase 3,FXR agonist,,,
CC[C@H]1[C@@H](O)[C@@H]2[C@H](CC[C@]3(C)[C@@H]([C@H](C)CCOS(=O)(=O)O)CC[C@@H]23)[C@@]2(C)CC[C@@H](O)C[C@@H]12,INT-767,Phase 1,FXR agonist,GPBAR1,,
Cc1cc(C)n(-c2cccc([C@H](CC(=O)O)CN3CC[C@@H](CCc4ccc5c(n4)NCCC5)C3)c2)n1,integrin-antagonist-1,Phase 1,integrin antagonist,ITGAV|ITGB6,,
COc1nc(N)nc2c1ncn2[C@@H]1O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OCC(C)(C)C)Oc2cccc3ccccc23)[C@@H](O)[C@@]1(C)O,INX-08189,Phase 2,antiviral,,,
N=C(N)NCc1cccc(I)c1,iobenguane,Launched,antineoplastic agent,,oncology|cardiology|endocrinology,neuroblastoma|congestive heart failure|pheochromocytoma
CC(=O)N(C[C@H](C)C(=O)O)c1c(I)cc(I)c(N)c1I,iocetamic-acid,Launched,radiopaque medium,,radiology,contrast agent
O=C(CCCCC(=O)Nc1c(I)cc(I)c(C(=O)O)c1I)Nc1c(I)cc(I)c(C(=O)O)c1I,iodipamide,Launched,radiopaque medium,ALB,radiology,contrast agent
CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I,iodixanol,Launched,radiopaque medium,,radiology,contrast agent
Cc1c(I)c(=O)n(-c2ccccc2)n1C,iodoantipyrine,Preclinical,,,,
O=C1CC[C@](c2ccccc2)(C2CCN(Cc3ccc(I)cc3)CC2)C(=O)N1,iododexetimide,Phase 2,acetylcholine receptor antagonist,,,
N=C(NCCc1ccc(I)cc1)SCCCc1cnc[nH]1,iodophenpropit,Preclinical,histamine receptor antagonist,HRH3|HRH4,,
Oc1c(I)cc(I)c2cccnc12,iodoquinol,Launched,antiseptic,,infectious disease,amebiasis
CC(=O)N(C[C@@H](O)CO)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I,iohexol,Launched,radiopaque medium,,radiology,contrast agent
C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I,iopamidol,Launched,radiopaque medium,,radiology,contrast agent
CN(C)/C=N/c1c(I)cc(I)c(CCC(=O)O)c1I,iopodic-acid,Launched,,,radiology,contrast agent
COCC(=O)Nc1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)N(C)C[C@@H](O)CO)c1I,iopromide,Launched,radiopaque medium,,radiology,contrast agent
CNC(=O)c1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I,iothalamic-acid-d3,Preclinical,radiopaque medium,,,
O=C(NC[C@@H](O)CO)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(N(CCO)C(=O)CO)c1I,ioversol,Launched,radiopaque medium,,radiology,contrast agent
O=C(NCc1ccc(Oc2ccccc2)cc1)c1nc(-c2cc(Br)c(O)c(Br)c2)no1,IOWH032,Phase 2,CFTR channel antagonist,CFTR,,
O=C(O)c1ccc(O)c2ncccc12,IOX1,Preclinical,histone demethylase inhibitor,EGLN1|KDM3A|KDM4C|KDM6B,,
O=C(O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O,IOX2,Preclinical,hypoxia inducible factor inhibitor,EGLN1|KDM2A|KDM5C,,
CNC(=O)c1c(I)c(C(=O)NCC(=O)Nc2c(I)c(C(=O)O)c(I)c(C(=O)NCCO)c2I)c(I)c(N(C)C(C)=O)c1I,ioxaglic-acid,Launched,radiopaque medium,,radiology,contrast agent
CC(=O)N(C[C@@H](O)CO)c1c(I)c(C(=O)NCCO)c(I)c(C(=O)NC[C@@H](O)CO)c1I,ioxilan,Launched,radiopaque medium,,radiology,angiography
Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12,IPA-3,Preclinical,p21 activated kinase inhibitor,PAK1,,
N=C(Nc1ccc(I)cc1)NC1C2CC3CC(C2)CC1C3,IPAG,Preclinical,,,,
C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cnn(C)c3)c2c(=O)n1-c1ccccc1,IPI549,Phase 2,PI3K inhibitor,,,
Nc1c2c(nc3c1CCC3)CCCC2,ipidacrine,Phase 3,acetylcholinesterase inhibitor,ACHE,,
OC[C@H]1O[C@@H](c2ccc(F)c(Cc3cc4ccccc4s3)c2)[C@H](O)[C@@H](O)[C@@H]1O,ipragliflozin-L-proline,Launched,sodium/glucose cotransporter inhibitor,SLC5A2,endocrinology,diabetes mellitus
CC(C)[N@+]1(C)[C@@H]2CC[C@H]1C[C@@H](OC(=O)[C@@H](CO)c1ccccc1)C2,ipratropium,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,pulmonary,bronchospasm|chronic obstructive pulmonary disease (COPD)|bronchitis|emphysema
CC(C)Oc1ccc2c(=O)c(-c3ccccc3)coc2c1,ipriflavone,Launched,bone resorption inhibitor,,orthopedics,osteoporosis
O=C1c2ccccc2S(=O)(=O)N1CCCCN1CCN(c2ncccn2)CC1,ipsapirone,Phase 3,serotonin receptor agonist,HTR1A,,
CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,irbesartan,Launched,angiotensin receptor antagonist,AGTR1|JUN|SLC10A1,cardiology|nephrology,hypertension|diabetic nephropathy
CC(C)(C)c1cc(CCC(=O)OCC(COC(=O)CCc2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)(COC(=O)CCc2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)COC(=O)CCc2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)cc(C(C)(C)C)c1O,irganox-1010,Preclinical,antioxidant,,,
N=C(N)NCCC[C@@H]1NC(=O)[C@@H](N)CSSC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)CNC1=O,iRGD-peptide,Preclinical,integrin signaling activator,,,
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,irinotecan,Launched,topoisomerase inhibitor,TOP1|TOP1MT,oncology,colorectal cancer
Cc1cc(C)cc(C(=O)N(C)[C@H](Cc2ccc(-c3ccccc3)cc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)O)c1,IRL-2500,Preclinical,endothelin receptor antagonist,EDNRB,,
NS(=O)(=O)Oc1ccc2c3c(c(=O)oc2c1)CCCCC3,irosustat,Phase 2,steroid sulfatase inhibitor,CA2|STS,,
Nc1nc(N)nc(-c2cc(Cl)ccc2Cl)n1,irsogladine,Launched,phosphodiesterase inhibitor,PDE4A,gastroenterology,peptic ulcer disease (PUD)
CC(C)NC[C@@H](O)COc1ccccc1-n1cccc1,isamoltane,Phase 1,adrenergic receptor antagonist,HTR1A|HTR1B,,
C[C@@H](c1nc(-c2ccc(C#N)cc2)cs1)[C@@](O)(Cn1cncn1)c1cc(F)ccc1F,isavuconazole,Phase 3,cytochrome P450 inhibitor,CYP3A4,,
CC(C)Cn1cnc2c1c(=O)n(C)c(=O)n2C,isbufylline,Phase 2,phosphodiesterase inhibitor,,,
CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](N)C[C@H]2NC(=O)[C@@H](O)CN)OC[C@]1(C)O,isepamicin,Launched,protein synthesis inhibitor,,infectious disease,pneumonia|peritonitis
COC(=O)C[C@H]1CC(c2ccc(O)cc2)=NO1,ISO-1,Preclinical,macrophage migration inhibiting factor inhibitor,MIF,,
CC(C)COC(=O)c1ccc(N)cc1,isobutamben,Preclinical,local anesthetic,,,
Cc1cc(C(=O)NNCc2ccccc2)no1,isocarboxazid,Launched,monoamine oxidase inhibitor,MAOA|MAOB,neurology/psychiatry,depression
Clc1ccc([C@@H](Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1,isoconazole,Launched,fungal lanosterol demethylase inhibitor,CYP17A1,infectious disease,gram-positive bacterial infections
O=C(O)CCCN1C(=O)c2cccc3cccc(c23)C1=O,isodibut,Phase 2,aldehyde reductase inhibitor,,,
CC[C@@H](NC(C)C)[C@@H](O)c1ccc(O)c(O)c1,isoetharine,Launched,adrenergic receptor agonist,,pulmonary,bronchospasm|asthma
CC(C)c1ccc2c(c1)[C@H](N1CCN(CCO)CC1)Cc1ccc(F)cc1S2,isofloxythepin,Phase 2,dopamine receptor antagonist,,,
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,isoflupredone-acetate,Preclinical,,NR3C1,,
O=C(O)C1=CCNCC1,isoguvacine,Preclinical,benzodiazepine receptor agonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRR1|GABRR2|GABRR3,,
CC[C@@H](C)[C@@H](N)C(=O)O,isoleucine,Launched,,,,
O=C(/C=C/c1ccc(O)cc1)c1ccc(O)cc1O,isoliquiritigenin,Preclinical,guanylate cyclase activator,GABBR1,,
CN[C@@H](C)CCC=C(C)C,isometheptene-mucate,Launched,,,neurology/psychiatry,headache
NNC(=O)c1ccncc1,isoniazid,Launched,FABI inhibitor,CYP1A2|CYP2C19|CYP2C8|CYP2E1|CYP3A4,infectious disease,tuberculosis
COc1ccc(/C=C/C(=O)OCCC(C)C)cc1,isopentyl-4-methoxycinnamate,Launched,,,dermatology,sunscreen lotion
CC(C)NC[C@@H](O)c1ccc(O)c(O)c1,isoprenaline,Launched,adrenergic receptor agonist,ADRB1|ADRB2|ADRB3,cardiology|pulmonary,bradycardia|heart block|asthma
CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C,isopropamide-iodide,Launched,acetylcholine receptor antagonist,CHRM3|CHRM4,gastroenterology,peptic ulcer disease (PUD)|gastrointestinal acidosis
O=c1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,isoquercitrin,Phase 2/Phase 3,antioxidant,,,
COc1cc2c(cc1OC)[C@H](C)NCC2,"Isoquinoline,-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro,",Preclinical,,,,
O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2O,isosorbide,Launched,nitric oxide stimulant,,cardiology,angina pectoris|coronary artery disease (CAD)
O=[N+]([O-])O[C@H]1CO[C@H]2[C@@H]1OC[C@H]2O[N+](=O)[O-],isosorbide-dinitrate,Launched,nitric oxide stimulant,GUCY1A2|GUCY1A3|GUCY1B2|GUCY1B3|NPR1,cardiology,angina pectoris|coronary artery disease (CAD)
O=[N+]([O-])O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2O,isosorbide-mononitrate,Launched,nitric oxide stimulant,GUCY1A2|GUCY1A3|GUCY1B2|GUCY1B3,cardiology,angina pectoris|coronary artery disease (CAD)
C[C@@]12CC[C@@H]3[C@@](CC[C@H]4[C@@]3(C)CCC[C@@]4(C)C(=O)O)(CC1=O)C2,isosteviol,Phase 2,,,,
Cc1ccnc2c1CCC[C@H]2C(N)=S,isotiquimide,Phase 1,,,,
CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1,isotretinoin,Launched,retinoid receptor agonist,RARA|RARB|RARG,dermatology,acne vulgaris (AV)
CC(C)CC(N)=O,isovaleramide,Phase 2,alcohol dehydrogenase inhibitor,,,
O=C(O)Cc1ccc2c(c1)C(=O)c1ccccc1CO2,isoxepac,Phase 2,anti-inflammatory agent,,,
C[C@@H](COc1ccccc1)N[C@H](C)[C@@H](O)c1ccc(O)cc1,isoxsuprine,Launched,adrenergic receptor agonist,ADRB2,rheumatology|cardiology,Raynaud's disease|arteriosclerosis|Buerger's disease
Cc1ccc(C(=O)N(CCCN)[C@@H](c2nc3cc(Cl)ccc3c(=O)n2Cc2ccccc2)C(C)C)cc1,ispinesib,Phase 2,kinesin inhibitor,KIF11,,
COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@@H]1c1cccc2nonc12,isradipine,Launched,calcium channel blocker,CACNA1D|CACNA1F|CACNA2D1,cardiology,hypertension
O=C(COc1ccc(Cl)cc1)N[C@H]1CC[C@H](NC(=O)COc2ccc(Cl)cc2)CC1,ISRIB,Preclinical,eukaryotic translation initiation factor inhibitor|PERK inhibitor,EIF2A|EIF2AK3,,
C[C@]12CC/C(=N\OCCN)C[C@@H]1C(=O)C[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12,istaroxime,Phase 2,ATPase inhibitor,ATP1A1,,
CCn1c(=O)c2c(nc(/C=C/c3ccc(OC)c(OC)c3)n2C)n(CC)c1=O,istradefylline,Launched,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,neurology/psychiatry,Parkinson's Disease|dyskinesia
O=C(NC1CC1)c1cc(-c2cccs2)on1,ISX-9,Preclinical,neural stem cell inducer,NEUROD1,,
CC1(C)CN2C(CS/C(=N/C3CCCCC3)NC3CCCCC3)=CSC2=N1,IT1t,Preclinical,CC chemokine receptor antagonist,CXCR4,,
N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1,itacitinib,Phase 3,JAK inhibitor,JAK1,,
CCOC(=O)C1=C(C)NC2=C(C(=O)CC(C)(C)C2)[C@@H]1c1ccc(-c2ccccc2)cc1,ITD-1,Preclinical,TGF beta receptor inhibitor,TGFBR2,,
COC(=O)c1csc(C(=O)c2c[nH]c3ccccc23)n1,ITE,Preclinical,aryl hydrocarbon receptor agonist,AHR,,
CN1C(=O)c2c(nn(Cc3ccc(-c4cccc(F)n4)cc3)c2Nc2ccccc2)N2C1=N[C@@H]1CCC[C@@H]12,ITI214,Phase 1/Phase 2,phosphodiesterase inhibitor,PDE1A,,
COc1ccc(C(=O)NCc2ccc(OCCN(C)C)cc2)cc1OC,itopride,Launched,dopamine receptor antagonist,CHRM3|DRD2,gastroenterology|neurology/psychiatry,dyspepsia|gastroparesis|heartburn|nausea|vomiting|anorexia
CC[C@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,itraconazole,Launched,cytochrome P450 inhibitor,,infectious disease,onychomycosis|histoplasmosis|blastomycosis|aspergillosis
Cc1cc(/C=c2/sc3nc4ccccc4n3c2=O)c(C)n1-c1ccccc1,ITX3,Preclinical,GEF inhibitor,TRIO,,
COc1c(NC(=O)C(=O)c2ccc(OCCN3CCOCC3)c3ccccc23)cc(C(C)(C)C)cc1NS(C)(=O)=O,ITX5061,Phase 1,SR-BI inhibitor,,,
Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1,IU1,Preclinical,ubiquitin C-terminal hydrolase inhibitor,USP14,,
COc1cc2c(cc1OC)CC(=O)N(CCCN(C)C[C@H]1Cc3cc(OC)c(OC)cc31)CC2,ivabradine,Launched,HCN channel blocker|potassium channel blocker|sodium channel blocker,HCN1|HCN3|HCN4,cardiology,angina pectoris
CC(C)(C)c1cc(C(C)(C)C)c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O,ivacaftor,Launched,CFTR channel potentiator,CFTR,pulmonary,cystic fibrosis
CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2,ivermectin,Launched,benzodiazepine receptor agonist,CHRNA7|P2RX7,infectious disease,gastrointestinal roundworms|lungworms|cattle grubs|mites|lice|horn flies
N#Cc1ccnc(N2C(=O)CC[C@H]2C(=O)N(c2cncc(F)c2)[C@H](C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1,ivosidenib,Launched,isocitrate dehydrogenase inhibitor,IDH1,hematologic malignancy,acute myeloid leukemia (AML)
O=C(CSc1nc2c(c(=O)n1-c1ccccc1)SCC2)Nc1ccc(-c2ccccc2)cn1,IWP-L6,Preclinical,porcupine inhibitor,PORCN,,
C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1,ixabepilone,Launched,microtubule stabilizing agent,TUBB,oncology,breast cancer
CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,ixazomib,Launched,proteasome inhibitor,,hematologic malignancy,multiple myeloma
CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C[C@](CC(=O)O)(C(=O)O)O1,ixazomib-citrate,Launched,proteasome inhibitor,,hematologic malignancy,multiple myeloma
COc1cccc(/C=N/N(C(=O)C(F)(F)F)c2ccc(C)cc2C)c1,J147,Phase 1,BDNF inducer,,,
C=CC(=O)c1ccc2ccccc2c1,JAK3-inhibitor-V,Preclinical,JAK inhibitor,JAK3,,
CC(C)[C@H](/N=C(/NS(=O)(=O)c1ccc(Cl)cc1)N1C[C@H](c2ccccc2)C(c2ccc(Cl)cc2)=N1)C(N)=O,JD-5037,Preclinical,cannabinoid receptor antagonist,,,
CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1,JDTic,Phase 1,opioid receptor antagonist,OPRK1,,
CCCCN1[C@@H]2CC[C@H]1C[C@@H](OC(c1ccc(F)cc1)c1ccc(F)cc1)C2,JHW-007,Preclinical,dopamine reuptake inhibitor,SLC6A3,,
COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1,JI-101,Phase 1/Phase 2,kinase inhibitor,,,
Clc1ccc(N/N=C(\c2ccccc2)c2ccccn2)nc1,JIB04,Preclinical,histone lysine demethylase inhibitor,KDM4E,,
CCOc1ccc(Nc2nc(-c3c(C)nc4ccccn34)cs2)cc1,JK-184,Preclinical,hedgehog pathway inhibitor,,,
COc1oc(=O)c2cc(N)ccc2c1Cl,JLK-6,Preclinical,gamma secretase inhibitor,PSEN1,,
CN1CCN(C(=O)c2nc3ccc(Cl)cc3[nH]2)CC1,JNJ-10191584,Preclinical,histamine receptor antagonist,HRH4,,
CC1(C)OC[C@H](NC(=O)Nc2ccc(Br)cc2Br)[C@H](c2ccccc2)O1,JNJ-10397049,Preclinical,orexin receptor antagonist,HCRTR1|HCRTR2,,
CO[C@H]1CC[C@@H](C(=O)c2ccc3nc4c(cc3c2)CCCO4)CC1,JNJ-16259685,Preclinical,glutamate receptor antagonist,GRM1,,
O=C(Nc1ccccc1)N1CCN(c2nc(-c3ccccc3)ns2)CC1,JNJ-1661010,Preclinical,FAAH inhibitor,FAAH,,
O=C(Nc1ccc(C(F)(F)F)cn1)N1CCN(c2ncccc2C(F)(F)F)CC1,JNJ-17203212,Preclinical,TRPV antagonist,TRPV1,,
Cn1cc(CNCC2CCN(c3ncc(C(=O)NO)cn3)CC2)c2ccccc21,JNJ-26481585,Phase 2,HDAC inhibitor,HDAC1|HDAC10|HDAC11|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9|MDM2,,
NS(=O)(=O)NCc1csc2ccccc12,JNJ-26990990,Phase 2,anticonvulsant,,,
CC[C@@H](c1ccc(F)c(F)c1)n1c(C(=O)OC)c(-c2ccno2)[nH]c1=S,JNJ-27141491,Preclinical,CC chemokine receptor antagonist,CCR2,,
Fc1ccc(CN2CCC(Nc3ccc(C(F)(F)F)nn3)CC2)cc1F,JNJ-37822681,Phase 2,dopamine receptor antagonist,DRD2,,
Cn1cc(-c2ccc3nnc(C(F)(F)c4ccc5ncccc5c4)n3n2)cn1,JNJ-38877605,Phase 1,tyrosine kinase inhibitor,MET,,
FC(F)(c1ccc2ncccc2c1)c1nnc2ccc(-c3ccncc3)nn12,JNJ-38877618,Phase 1,c-Met inhibitor,,,
CC(C)c1cc(N2CC[C@@H](N)C2)nc(N)n1,JNJ-39758979,Phase 2,histamine receptor antagonist,,,
CCCCn1ccc(N2CCC(c3ccccc3)CC2)c(Cl)c1=O,JNJ-40411813,Phase 2,glutamate receptor positive allosteric modulator,GRM2,,
O=C(O)c1cnn(-c2nc3cc(Cl)c(OC(F)(F)F)cc3[nH]2)c1,JNJ-42041935,Preclinical,hypoxia inducible factor prolyl hydroxylase inhibitor,PDK2,,
O=C(Nc1cnccc1Cl)N1CCN(Cc2ccc3c(c2)OC(F)(F)O3)CC1,JNJ-42165279,Phase 2,FAAH inhibitor,FAAH,,
O=C(NCC1(N2CCN(c3ccccc3)CC2)CCOCC1)c1cccnc1Sc1ccccc1,JNJ-47965567,Preclinical,purinergic receptor antagonist,P2RX7,,
C[C@@H]1c2nnn(-c3ncc(F)cn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl,JNJ-54175446,Phase 1,purinergic receptor antagonist,,,
C[C@H](NC(=O)CNC(=O)c1cccc(Cl)c1)c1ccccc1,JNJ-63533054,Preclinical,G protein-coupled receptor agonist,GPR139,,
Nc1nc2cc(CC[C@H]3C[C@@H](n4ccc5c(N)ncnc54)[C@H](O)[C@@H]3O)ccc2cc1Br,JNJ-64619178,Phase 1,protein arginine N-methyltransferase inhibitor,,,
CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21,JNJ-678,Phase 1,RSV fusion inhibitor,,,
Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F,JNJ-7706621,Preclinical,CDK inhibitor,AURKA|AURKB|CDK1|CDK2,,
CN1CCN(C(=O)c2cc3cc(Cl)ccc3[nH]2)CC1,JNJ-7777120,Preclinical,histamine receptor antagonist,HRH4,,
CO[C@@H]1[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O)/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]1OC(C)=O,josamycin,Launched,bacterial 50S ribosomal subunit inhibitor,,pulmonary,bronchitis
Nc1cc(COc2c(Cl)cc(C[C@H](N)C(=O)O)cc2Cl)c2oc(-c3ccccc3)nc2c1,JPH203,Preclinical,solute carrier family member inhibitor,,,
Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n1-2,JQ1-(+),Preclinical,bromodomain inhibitor,BRD4|BRDT,,
CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1,JTC-801,Phase 2,opioid receptor antagonist,OPRL1,,
Cc1nn(C)c2nc(NNC(=O)Nc3cc(Cl)nc(Cl)c3)cc(C(C)C)c12,JTE-013,Preclinical,lysophospholipid receptor antagonist,P2RY10|S1PR2,,
CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O,JTE-607,Phase 2,cytokine production inhibitor,IL10|IL1B|IL6|TNF,,
CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4c(c3)OCO4)c(=O)[nH]c12,JTE-907,Phase 1,cannabinoid receptor inverse agonist,CNR2,,
COc1ccc(C2(CNC(=O)c3ccc(NC(=O)c4ccco4)cc3)CCOCC2)cc1,JW-55,Preclinical,tankyrase inhibitor,TNKS|TNKS2,,
O=C(OC(C(F)(F)F)C(F)(F)F)N1CCN(Cc2cccc(Oc3ccccc3)c2)CC1,JW-642,Preclinical,monoacylglycerol lipase inhibitor,MGLL,,
O=C1Nc2ccccc2C12OCC1(CO2)COC2(OC1)C(=O)Nc1ccccc12,JW-67,Preclinical,WNT pathway inhibitor,APC|AXIN1|GSK3B,,
COc1ccc(-n2c(SCc3nc(-c4ccc(C)cc4)no3)nnc2-c2ccncc2)cc1,JW-74,Preclinical,tankyrase inhibitor|WNT signaling inhibitor,TNKS|TNKS2,,
COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1,JX-401,Preclinical,p38 MAPK inhibitor,MAPK14,,
O=C(Oc1ccc([N+](=O)[O-])cc1)N1CCC(C(O)(c2ccc3c(c2)OCO3)c2ccc3c(c2)OCO3)CC1,JZL-184,Preclinical,monoacylglucerol lipase inhibitor,MGLL,,
O=C(Oc1ccc([N+](=O)[O-])cc1)N1CCN(Cc2cccc(Oc3ccccc3)c2)CC1,JZL-195,Preclinical,FAAH inhibitor|monoacylglycerol lipase inhibitor,FAAH|MGLL,,
O=C(O)c1ccc(N[C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)cc1,K-247,Phase 1,,,,
CC(=O)NC1=NN(C(C)=O)[C@](C)(c2ccccc2)S1,K-858,Preclinical,kinesin-like spindle protein inhibitor,KIF11,,
O=C(O)c1ccc(N[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)cc1,K-MAP,Phase 2,,,,
C=CC(=O)N1CCN(C(=O)CNc2cc(I)c(Cl)cc2O)CC1,K-Ras(G12C)-inhibitor-12,Preclinical,K-Ras inhibitor,KRAS,,
O=C(CCCS)NC1CCN(C(=O)COc2ccc(Cl)cc2Cl)CC1,K-Ras(G12C)-inhibitor-6,Preclinical,K-Ras inhibitor,,,
C[C@]12CC[C@H]3[C@@H](CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1,K-strophanthidin,Phase 2,ATPase inhibitor,ATP1A1,,
COc1cc(-c2cc(-c3cccc(O)c3)cnc2N)cc(OC)c1OC,K02288,Preclinical,bone morphogenic protein inhibitor,BMP1,,
CCCCOc1ccc(CC/C=C2\SC(=O)N(CCN)C2=O)cc1,K145,Preclinical,sphingosine kinase inhibitor,SPHK2,,
O=c1c(O)c(-c2ccc(O)cc2)oc2cc(O)cc(O)c12,kaempferol,Preclinical,bone resorption inhibitor|estrogen-related receptor inverse agonist,AKR1B1|ALOX15B|ALOX5|AR|CYP1B1|GLO1|HSD17B1|UGT3A1,,
CC1(C)c2nc(-c3ccc(F)cc3)c(Nc3ccc(F)cc3)n2CCN1C(=O)CN,KAF-156,Preclinical,antimalarial agent,,,
C=C(C)[C@H]1CN[C@H](C(=O)O)[C@H]1CC(=O)O,kainic-acid,Preclinical,kainate receptor agonist,GRIA1|GRIK1|GRIK2|GRIK3|GRIK4|GRIK5,,
O=c1c(-c2ccc(O)cc2)coc2c([C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)c(O)ccc12,kakonein,Phase 2,GABA receptor antagonist|serotonin receptor antagonist,,,
NC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](O)[C@@H](O)[C@@H]1O,kanamycin,Launched,bacterial 30S ribosomal subunit inhibitor,,infectious disease,gram-negative bacterial infections
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1ccccc1c2CC[Si](C)(C)C,karenitecin,Phase 3,topoisomerase inhibitor,TOP1,,
O=C(O)c1ccccc1C(=O)Nc1ccc(-c2ccccc2)cc1,kartogenin,Preclinical,chondrocyte differentiation stimulator,FLNA,,
C[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H]2O)[C@@H](N)C[C@@H]1NC(=N)C(=O)O,kasugamycin,Preclinical,bacterial 30S ribosomal subunit inhibitor,,,
N=C(N)SCCc1ccc(OCc2ccc([N+](=O)[O-])cc2)cc1,KB-R7943,Preclinical,sodium/calcium exchange inhibitor,SLC8A1|TRPC3|TRPC5|TRPC6,,
Nc1ncnc2c1c(-c1ccc(Cl)cc1)nn2-c1cccc(-c2cnnn2Cc2cccc(-c3ccccc3)c2)c1,KB-SRC-4,Preclinical,SRC inhibitor,SRC,,
O[C@@H]1[C@@H](O)[C@@H](O)O[C@@H]2CO[C@H](c3ccccc3)O[C@@H]12,KBG,Phase 2,neprilysin inhibitor,MME,,
CCCCCCCCCCCCCCOc1ccc(C(=O)O)o1,KD-023,Phase 2,ACAT inhibitor,ACACA|ACACB,,
CC(C)NC(=O)COc1cccc(-c2nc(Nc3ccc4n[nH]cc4c3)c3ccccc3n2)c1,KD025,Phase 2,rho associated kinase inhibitor,ROCK2,,
O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1,kenpaullone,Preclinical,CDK inhibitor|glycogen synthase kinase inhibitor,CCNB1|CDK1|CDK5|GSK3B,,
O=C(c1ccc(F)cc1)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1,ketanserin,Launched,serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|DRD1|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A|HTR7|SLC18A1|SLC18A2,cardiology,hypertension
CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,ketoconazole,Launched,sterol demethylase inhibitor,KCNA10,dermatology,seborrheic dermatitis
C[C@H]1CCN1c1nc(N2C[C@@H]3[C@@H](CC(=O)O)[C@@H]3C2)cc(C(F)(F)F)n1,ketohexokinase-inhibitor-1,Preclinical,kinase inhibitor,,,
C[C@@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1,ketoprofen,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2|SLC5A8,rheumatology,rheumatoid arthritis|osteoarthritis
O=C(c1ccccc1)c1ccc2n1CC[C@@H]2C(=O)O,ketorolac,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief
CN1CCC(=C2c3ccccc3C=C(O)c3sccc32)CC1,ketotifen,Launched,histamine receptor agonist|leukotriene receptor antagonist|phosphodiesterase inhibitor,HRH1,neurology/psychiatry,itching
N#CCCCSC(=N)N,kevetrin,Phase 1,p53 activator,,,
COc1ccc([C@H]2CC(c3c(O)cc(C)oc3=O)=NCCS2)c(OC)c1,KF-38789,Preclinical,P selectin inhibitor,SELP,,
CSc1nc(N)cc(Oc2ccc(-c3nnc(Nc4cccc(C(F)(F)F)c4)[nH]3)cc2)n1,KG-5,Preclinical,RAF inhibitor,BRAF|FLT3|KIT|PDGFRB,,
CCOC(=O)c1c(C(C#N)C=N)c2ccc(Cl)c(Cl)c2n1C,KH-CB19,Preclinical,CDC inhibitor,CLK1|CLK3|DYRK1A,,
COc1c2occc2c(OC)c2c(=O)cc(C)oc12,khellin,Phase 2,vasodilator,,,
CSc1ccccc1Nc1nc(N2CCNCC2)nc2c(NCC3CC3)ncnc12,KHK-IN-1,Preclinical,hexokinase inhibitor,KHK,,
CC(C)CNc1ccnc(NCc2csc(-c3ccccc3)n2)n1,KHS-101,Preclinical,neural stem cell inducer,TACC3,,
Cc1noc(-c2ccc(CSCCC(=O)O)cc2)c1NC(=O)O[C@H](C)c1ccccc1Cl,KI-16425,Preclinical,lysophosphatidic acid receptor antagonist,LPAR1|LPAR3,,
COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)N[C@@H](C)c1nccs1,KI-20227,Preclinical,c-Fms inhibitor,CSF1R|KDR|KIT|PDGFRB,,
COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC,KI-8751,Preclinical,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,KDR,,
COC(=O)CCSCc1ccc(-c2onc(C)c2NC(=O)O[C@@H](C)c2ccccc2Cl)cc1,ki16198,Preclinical,lipoprotein antagonist,LPA,,
O=C1N[C@@H]2[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)N2C1=O,kifunensine,Phase 1,mannosidase inhibitor,MAN1B1|MAN2A1,,
c1coc(CNc2ncnc3nc[nH]c23)c1,kinetin,Launched,cell division inducer,,dermatology,sunburn
CS(=O)(=O)N(Cc1ccco1)C[C@@H](O)Cn1c2ccccc2c2ccccc21,KL-001,Preclinical,proteasome inhibitor,CRY1|CRY2,,
CN(C)CCNC(=O)COc1c2cccc1Cc1cccc(c1OCC(=O)NCCN(C)C)Cc1cccc(c1OCC(=O)NCCN(C)C)Cc1cccc(c1OCC(=O)NCCN(C)C)C2,KM-0118,Phase 1,anticancer agent,,,
CC(C)(C)c1cc(/C=C2\CCOC2=O)cc(C(C)(C)C)c1O,KME-4,Preclinical,prostaglandin inhibitor,,,
O=C(OC(C(F)(F)F)C(F)(F)F)N1CCC(C(O)(c2ccc3c(c2)OCO3)c2ccc3c(c2)OCO3)CC1,KML29,Preclinical,monoacylglucerol lipase inhibitor,MGLL,,
CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12,KN-62,Preclinical,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,AKT1|CAMK2A|CHEK1|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|P2RX7|PRKCA|ROCK1|RPS6KB1|SGK1,,
COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1,KN-93,Preclinical,calcium/calmodulin dependent protein kinase inhibitor,CAMK2A,,
COc1ccc2c3c([nH]c2c1)[C@H](CC(C)C)N1C(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)[C@@H]1C3,Ko143,Preclinical,BCRP inhibitor,ABCB1|ABCC1,,
NC1=NC(=O)N([C@H]2C[C@@H](O)[C@@H](CO)O2)CN1,KP-1212,Phase 2,,,,
COc1cc(-c2ncn(/C=C\C(=O)OC(C)C)n2)cc(C(F)(F)F)c1,KPT-185,Preclinical,exportin antagonist,XPO1,,
O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)N1CC(F)(F)C1,KPT-276,Preclinical,exportin antagonist,XPO1,,
Nc1ccc(/C=C/C(=O)NCc2cc3cc(-c4ccc(C(=O)N5CCC(F)(F)CC5)cc4)cc(-c4ccc(F)cc4)c3o2)cn1,KPT-9274,Phase 1,NAMPT inhibitor,,,
O=C(CSc1ccc(Br)cc1)Nc1cn(CCc2ccccc2)nc1C(=O)O,KR-33494,Preclinical,cell death inhibitor ,,,
COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccc(N3CCN(C(C)=O)CC3)cc2OC)n1,KRCA-0008,Preclinical,ALK inihibitor,ALK,,
CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl,KRN-633,Preclinical,VEGFR inhibitor,FLT1|FLT4|KDR,,
O=C(Nc1ccccc1C(=O)Nc1ccc(CCO)cc1)c1ccc([N+](=O)[O-])cc1,KS-176,Preclinical,BCRP inhibitor,ABCG2,,
CCc1oc2ccccc2c1C(=O)c1ccc(OCC(=O)O)cc1,KT-433,Phase 2,uricosuric agent,,,
COc1ccc(-c2ccc3c(N4CCOCC4)nc(N4C[C@@H](C)O[C@@H](C)C4)nc3n2)cc1CO,KU-0063794,Preclinical,mTOR inhibitor,MTOR,,
O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1,KU-55933,Preclinical,ATM kinase inhibitor,ATM|PRKDC,,
C[C@@H]1CN(CC(=O)Nc2ccc3c(c2)Cc2cccc(-c4cc(=O)cc(N5CCOCC5)o4)c2S3)C[C@H](C)O1,KU-60019,Preclinical,ATM kinase inhibitor,ATM,,
CC[C@@]1(c2ncc[nH]2)Cc2ccccc2O1,KU14R,Preclinical,imidazoline receptor antagonist,,,
OC[C@H]1O[C@@H](Oc2cc3c(O)cc(O)cc3[o+]c2-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O,kuromanin,Preclinical,ribosyl cyclase inhibitor,CD38,,
O=C(c1ccc(/C=C/c2[nH]nc3ccccc23)cc1)N1CCNCC1,KW-2449,Phase 1,Abl kinase inhibitor|Aurora kinase inhibitor|FLT3 inhibitor,ABL1|AURKA|AURKB|FLT3,,
CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC,KW-2478,Phase 1/Phase 2,HSP inhibitor,,,
CCCn1c(=O)c2[nH]c(C34C[C@@H]5C[C@@H](C[C@H]3C5)C4)nc2n(CCC)c1=O,KW-3902,Phase 3,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1,KX2-391,Phase 3,SRC inhibitor|tubulin polymerization inhibitor,SRC,,
COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC,KY02111,Preclinical,WNT pathway inhibitor,DKK1,,
O=C(O)c1cc(=O)c2ccccc2[nH]1,kynurenic-acid,Phase 1,glutamate receptor antagonist,GPR35|GRIN1|GRIN2A|GRIN2B,,
C[C@@H]1O[C@@H](O)[C@H](O)[C@H](O)[C@H]1O,L-(+)-rhamnose-monohydrate,Preclinical,,,,
CC1(C)CC(=O)C([C@@H]2C3=C(CC(C)(C)CC3=O)Oc3ccccc32)C(=O)C1,L-152804,Preclinical,neuropeptide receptor antagonist,NPY5R,,
CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(-c2ccccc2S(=O)(=O)NC(=O)c2sccc2C)cc1,L-161982,Preclinical,prostanoid receptor antagonist,PTGER4,,
CCCc1c(OCCCOc2ccc(OCC(=O)O)cc2)ccc(C(C)=O)c1O,L-165041,Preclinical,PPAR receptor agonist,PPARD,,
CCCOc1ccc(Br)cc1-c1cc(-c2ccc(Cl)cc2)[nH]c1-c1ccncc1,L-168049,Preclinical,glucagon receptor antagonist,GCGR,,
Cc1cccc(NC(=O)N[C@@H]2N=C(c3ccccc3)c3ccccc3N(C)C2=O)c1,L-365260,Phase 2,CCK receptor antagonist,CCKAR|CCKBR|KCNQ1,,
Cc1ccccc1N1CCN(S(=O)(=O)C[C@]23CC[C@H](C[C@@H]2NC(=O)[C@@H](N)CCS(C)(=O)=O)C3(C)C)CC1,L-368899,Phase 1,oxytocin receptor antagonist,AVPR1A|AVPR2|OXTR,,
CCOC(=O)c1ncn2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc1-2,"L-655,708",Preclinical,GABA receptor inverse agonist,GABRA1|GABRA2|GABRA3|GABRA5|GABRG2,,
Cc1c(CC(C)(C)C(=O)O)n(Cc2ccc(Cl)cc2)c2ccc(F)cc12,L-655240,Phase 1,thromboxane receptor antagonist,PTGES,,
CS(=O)(=O)c1ccc(Cn2c3c(c4cc(F)cc(F)c42)CCC[C@@H]3CC(=O)O)cc1,L-670596,Preclinical,prostanoid receptor antagonist,,,
O=C(Nc1ccccc1)N[C@H]1C[C@H](C(=O)O)Nc2cc(Cl)cc(Cl)c21,L-689560,Preclinical,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,,
CC(Oc1ccc(O)cc1)(P(=O)(O)O)P(=O)(O)O,L-690330,Preclinical,inositol monophosphatase inhibitor,IMPA1,,
c1ccc(CN2CCC3(CCc4ccccc43)CC2)cc1,L-693403,Preclinical,sigma receptor agonist|sigma receptor antagonist,DRD2|SIGMAR1,,
CS(=O)(=O)Nc1ccc(Cc2noc(-c3ccc4[nH]cc(CCN)c4c3)n2)cc1,L-694247,Preclinical,serotonin receptor agonist,HTR1A|HTR1B|HTR1D,,
O=C(c1c(O)c2ccc(Cl)cc2[nH]c1=O)C1CC1,L-701252,Preclinical,glutamate receptor antagonist,GRIN1,,
O=c1[nH]c2cc(Cl)ccc2c(O)c1-c1cccc(Oc2ccccc2)c1,L-701324,Preclinical,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,,
CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(C(F)(F)F)cc(C(F)(F)F)c1,"L-732,138",Preclinical,tachykinin antagonist,TACR1|TACR2,,
FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(C(F)(F)F)c1,L-733060,Preclinical,tachykinin antagonist,TACR1,,
Cc1c(C2CCN(CCc3ccccc3)CC2)noc1-c1ccc(Cl)cc1,L-741742,Preclinical,dopamine receptor antagonist,DRD3|DRD4|SCN1A|SCN3A,,
Clc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1,L-745870,Preclinical,dopamine receptor antagonist,DRD1|DRD2|DRD3|DRD4|HTR1A|HTR2A|HTR6|HTR7,,
CCCCCCNC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(O)cc3)cc2)cc1,L-755507,Preclinical,adrenergic receptor agonist,ADRB1|ADRB2|ADRB3,,
C[C@@H](O[C@H]1OCCN(Cc2n[nH]nc2CN(C)C)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,L-760735,Preclinical,tachykinin antagonist,TACR1,,
N#Cc1ccc(Cn2cncc2CN2CCN(c3cccc(Cl)c3)C(=O)C2)cc1,L-778123,Phase 1,farnesyltransferase inhibitor,FNTA|FNTB|PGGT1B,,
COc1ccc(Br)cc1S(=O)(=O)NC(=O)/C=C/c1ccccc1Cc1ccc2ccccc2c1,L-798106,Preclinical,prostanoid receptor antagonist,PTGER3,,
Cn1ncnc1COc1nn2c(-c3cc(F)ccc3F)nnc2cc1C(C)(C)C,L-838417,Preclinical,GABA receptor partial agonist,GABRA1|GABRA2|GABRA3|GABRA5,,
N=C(N)NCCC[C@H](N)C(=O)O,L-arginine,Launched,nitric oxide precursor,ARG2|ASL|ASS1|AZIN2|GPRC6A|NOS2|NOS3|SLC7A1|SLC7A3|SLC7A4,cardiology|neurology/psychiatry|urology|obstetrics/gynecology|otolaryngology,congestive heart failure|hypertension|coronary artery disease (CAD)|claudication|senile dementia|erectile dysfunction|infertility|common cold
CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O,L-ascorbyl-6-palmitate,Preclinical,,,,
NC(=O)C[C@H](N)C(=O)O,L-asparagine,Phase 3,,ASNS|ASRGL1|NARS|NARS2|SLC1A5|SLC38A3,,
N[C@@H](CC(=O)NO)C(=O)O,L-asparagine-N-hydroxy,Preclinical,,,,
N[C@@H](CC(=O)O)C(=O)O,L-aspartic-acid,Launched,metallic radical formation stimulant,ACY1|ACY3|ADSS|ADSSL1|ASNS|ASPA|ASPH|ASRGL1|ASS1|CAD|DARS|DARS2|GOT1|GOT2|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|LYZ|PAICS|RNASE1|SLC1A1|SLC25A12|SLC25A13,,
NC(=O)NCCC[C@H](N)C(=O)O,L-citrulline,Launched,nitric oxide stimulant,ASS1|DDAH1|DDAH2|GPRC6A|NOS1|NOS2|NOS3|OTC|PADI1|PADI2|PADI3|PADI4|PADI6,cardiology|urology,hypertension|erectile dysfunction
N[C@@H](CS)C(=O)O,L-cysteine,Launched,,CARS|CARS2|CBS|CDO-1|CDO1|CSAD|CTH|GCLC|GCLM|GOT1|GSS|MGMT|NFS1|SLC19A3,rheumatology,osteoarthritis|rheumatoid arthritis
N[C@@H](CSSC[C@H](N)C(=O)O)C(=O)O,L-cystine,Launched,,CTNS|SLC3A1|SLC7A11|SLC7A9,,
C[N+](C)(C)[C@@H](Cc1c[nH]c(=S)[nH]1)C(=O)O,L-ergothioneine,Phase 3,free radical scavenger,,,
N[C@@H](CCC(=O)O)C(=O)O,L-glutamic-acid,Launched,glutamate receptor agonist,AADAT|AASS|ABAT|ALDH18A1|ASNS|BCAT1|BCAT2|CCBL2|DNPEP|EARS2|ENPEP|EPRS|FOLH1|FPGS|FTCD|GAD1|GAD2|GATB|GCLC|GCLM|GGCX|GLS|GLS2|GLUD1|GLUD2|GLUL|GMPS|GOT1|GOT2|GPT|GPT2|GRIA1|GRIA2|GRIA3|GRIA4|GRID1|GRID2|GRIK1|GRIK2|GRIK3|GRIK4|GRIK5|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B|GRM1|GRM2|GRM3|GRM4|GRM6|GRM7|GRM8|LGSN|NADSYN1|NAGS|OPLAH|PFAS|PGCP|PSAT1|SLC1A1|SLC1A2|SLC1A3|SLC1A6|SLC1A7|SLC25A18|SLC25A22|SLC7A11|TAT,,
NC(=O)CC[C@H](N)C(=O)O,L-glutamine,Launched,,CTPS1|GLUL|GPRC6A|PPAT,gastroenterology|dental|neurology/psychiatry|rheumatology,diarrhea|mucositis|muscle pain|joint pain|peptic ulcer disease (PUD)|ulcerative colitis|Crohn's disease|anxiety|insomnia
Nc1ccccc1C(=O)C[C@H](N)C(=O)O,L-kynurenine,Phase 1,aryl hydrocarbon receptor agonist,,,
CC(C)C[C@H](N)C(=O)O,L-leucine,Phase 3,,BCAT1|BCAT2|LARS|LARS2|LCMT1|LCMT2,,
NCCCC[C@H](N)C(=O)O,L-lysine,Phase 2,serotonin receptor agonist,GPRC6A|KARS|SLC7A1|SLC7A2|SLC7A3|SLC7A4,,
CSCC[C@H](N)C(=O)O,L-methionine,Launched,voltage-gated calcium channel ligand,BHMT|BHMT2|METAP2|MTR|MTRR,pulmonary|allergy|neurology/psychiatry,asthma|allergic rhinitis|depression|Parkinson's Disease|schizophrenia
N[C@@H](CN1C=CC(=O)C(=O)C1)C(=O)O,L-mimosine,Preclinical,dopamine beta hydroxylase inhibitor|eukaryotic translation initiation factor inhibitor,DBH|EIF5A,,
CN[C@@H](CCCNC(=N)N)C(=O)O,L-monomethylarginine,Phase 3,nitric oxide synthase inhibitor,NOS1|NOS2,,
COC(=O)[C@@H](N)CCCNC(N)=N[N+](=O)[O-],L-NAME,Phase 2/Phase 3,nitric oxide synthase inhibitor,NOS3,,
CC(=N)NCCCC[C@H](N)C(=O)O,L-NIL,Preclinical,nitric oxide synthase inhibitor,NOS1|NOS2|NOS3,,
C[C@H](Cc1ccccc1)Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,L-phenylisopropyladenosine,Preclinical,,,,
O=C(O)[C@@H]1CCCN1,L-proline,Launched,glutamate receptor agonist,EPRS|L3HYPDH|P3H1|P3H2|P3H3|P4HA1|P4HA2|PARS2|PPIA|PPIB|PPIC|PPIF|PPIG|PPIH|PRODH|PROSC|PYCR1|PYCR2|PYCRL|SLC6A14|SLC6A7,,
N[C@@H](Cn1oc(=O)[nH]c1=O)C(=O)O,L-quisqualic-acid,Preclinical,glutamate receptor agonist,FOLH1|GRIA2|GRIK1|GRIK2|GRM1|GRM2|GRM3|GRM5|GRM7|GRM8,,
CCNC(=O)CC[C@H](N)C(=O)O,L-theanine,Launched,glutamate receptor antagonist,,,
C[C@@H](O)[C@H](N)C(=O)O,L-threonine,Phase 2,,TARS|TARS2|THNSL1,,
CC(C)[C@@H](N)C(=O)O,L-valine,Phase 2,,,,
C[C@@H](CCc1ccccc1)NC[C@@H](O)c1ccc(O)c(C(N)=O)c1,labetalol,Launched,adrenergic receptor antagonist,ADRA1D|ADRB1|ADRB2,cardiology,hypertension
CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1ccccc1/C=C/C(=O)OC(C)(C)C,lacidipine,Launched,calcium channel blocker,CACNA1C,cardiology,hypertension
OC[C@@H](O)[C@@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)CO,lacitol,Launched,laxative,,gastroenterology,constipation
OC[C@H]1O[C@@H](O[C@@H]2[C@@H](CO)O[C@](O)(CO)[C@H]2O)[C@H](O)[C@@H](O)[C@H]1O,lactulose,Launched,laxative,,gastroenterology,portal-systemic encephalopathy (PSE)
O=C(C[S@@](=O)Cc1ccco1)NC/C=C\COc1cc(CN2CCCCC2)ccn1,lafutidine,Launched,histamine receptor antagonist,HRH2,gastroenterology,duodenal ulcer disease|peptic ulcer disease (PUD)
Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,lamivudine,Launched,nucleoside reverse transcriptase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)|acquired immunodeficiency syndrome (AIDS)|hepatitis B
Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1,lamotrigine,Launched,serotonin receptor antagonist|sodium channel blocker,SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,epilepsy|bipolar disorder
CC#Cc1cncc(-c2ccc3c(c2)[C@@]2(N=C(C)C(N)=N2)[C@]2(CC[C@H](OC)CC2)C3)c1,lanabecestat,Phase 3,beta secretase inhibitor,,,
CC(=O)O[C@H]1C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@@H](CC[C@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)O[C@H](C)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,lanatoside-C,Preclinical,cardiac glycoside,,,
CC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1,landiolol,Launched,adrenergic receptor antagonist,ADRB1,cardiology,cardiac arrythmia
O=C(O)CCCc1cc2cc(Cl)ccc2n1S(=O)(=O)c1ccc2ncsc2c1,lanifibranor,Phase 2,PPAR receptor agonist,,,
N#C/C(=C1/SC[C@H](c2ccccc2Cl)S1)n1ccnc1,lanoconazole,Launched,sterol demethylase inhibitor,,infectious disease,fungal infection
Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1,lansoprazole,Launched,ATPase inhibitor,ATP4A|ATP4B,gastroenterology,heartburn
CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,lapatinib,Launched,EGFR inhibitor,EGFR|ERBB2,oncology,breast cancer
CCN1C[C@]2(OC(=O)c3ccccc3NC(C)=O)CC[C@H](OC)[C@@]34[C@@H]2C[C@@H]([C@@H]13)[C@@]1(O)C[C@H](OC)[C@H]2C[C@@H]4[C@]1(O)[C@H]2OC,lappaconite,Phase 2,sodium channel blocker,,,
CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1,laquinimod,Phase 3,immunosuppressant,CXCL2,,
CC(C)C[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN)C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)C(C)C,larazotide-acetate,Phase 2,tight junction regulator,,,
CS(=O)(=O)c1cc(F)cc2c3c(n(Cc4ccc(Cl)cc4)c12)[C@@H](CC(=O)O)CC3,laropiprant,Launched,prostanoid receptor antagonist,PTGDR|PTGDR2|PTGER1|PTGER2|PTGER3|PTGFR|PTGIR|TBXA2R,cardiology,cholesterol
O=C(Nc1cnn2ccc(N3CCC[C@@H]3c3cc(F)ccc3F)nc12)N1CC[C@H](O)C1,larotrectinib,Launched,tropomyosin receptor kinase inhibitor,NTRK1|NTRK2|NTRK3,,
CC[C@@H](C(=O)[C@@H](C)[C@@H](O)[C@H](C)CCc1ccc(C)c(O)c1C(=O)O)[C@H]1O[C@](CC)([C@H]2CC[C@](O)(CC)[C@H](C)O2)C[C@@H]1C,lasalocid,Launched,bacterial permeability inducer,,infectious disease,coccidiosis
CN1CCC(C(=O)c2cccc(NC(=O)c3c(F)cc(F)cc3F)n2)CC1,lasmiditan,Launched,serotonin receptor agonist,,,
O=C(O)[C@@H](O)[C@H](O)C(=O)O.Oc1ccc2c(c1)CC[C@H](c1ccccc1)[C@@H]2c1ccc(OCCN2CCCC2)cc1,lasofoxifene,Launched,selective estrogen receptor modulator (SERM),ESR1|ESR2,orthopedics|oncology,osteoporosis|breast cancer
CC(C)OC(=O)CCC/C=C\C[C@@H]1[C@@H](CC[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O,latanoprost,Launched,prostanoid receptor agonist,PTGFR,ophthalmology,ocular hypertension|glaucoma
Cc1ccc2c(c1)c1c(n2CCc2ccc(C)nc2)CCN(C)C1,latrepirdine,Phase 3,glutamate receptor antagonist,HRH1|HTR6,,
C/C1=C/C(=O)O[C@@H]2C[C@@H](CC[C@H](C)/C=C\CC1)O[C@@](O)([C@@H]1CSC(=O)N1)C2,latrunculin-B,Phase 1,actin polymerization inhibitor,ACTA1|MKL1|SPIRE2,,
CCCCCCCCCCCC(=O)O,lauric-acid,Phase 3,bacterial permeability inducer,GPR84|HNF4A|LTF|LY96|PLA2G2A|TLR4,,
CCCCCCCCCCCC(=O)N(CCO)CCO,lauric-diethanolamide,Preclinical,,,,
CCCCCCCCCCCCN1CCCCCC1=O,laurocapram,Phase 3,,,,
NCCNC(=O)c1ccc(Cl)cn1,lazabemide,Phase 3,monoamine oxidase inhibitor,MAOB,,
C=CC(=O)Nc1cc(Nc2nccc(-n3cc(CN(C)C)c(-c4ccccc4)n3)n2)c(OC)cc1N1CCOCC1,lazertinib,Phase 1/Phase 2,tyrosine kinase inhibitor,,,
CN1CCN(C(=O)[C@H]2[C@@H](C(=O)O)[C@@H]3CC[C@H]2O3)CC1,LB-100,Phase 2,protein phosphatase inhibitor,,,
O=C(c1cn(Cc2cncn2Cc2ccc(Br)cc2)cc1-c1cccc2ccccc12)N1CCOCC1,LB42708,Preclinical,farnesyltransferase inhibitor,,,
CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc(C(=O)c2ccc(F)cc2)cs1)C1CCCCC1,LCL-161,Phase 2,XIAP inhibitor,BIRC2|XIAP,,
O=C(O)C[C@H]1CC[C@H](c2ccc(-c3ccc(Nc4ccc(C(F)(F)F)nc4)cn3)cc2)CC1,LCQ908,Phase 3,diacylglycerol O acyltransferase inhibitor,DGAT1,,
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C.CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O,LCZ696,Launched,angiotensin receptor antagonist,,cardiology,angioedema|hypotension
CCOc1cn(-c2ccc(F)cc2C)nc1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)c(F)c1,LDC1267,Preclinical,protein tyrosine kinase inhibitor,AXL|MERTK|TYRO3,,
COc1ccc2nc3ccc(Cl)cc3c(SCCCN)c2c1,LDN-209929,Preclinical,haspin kinase inhibitor,GSG2,,
c1cc(-c2cnn3cc(-c4ccc(N5CCNCC5)cc4)cnc23)c2cccnc2c1,LDN-212854,Preclinical,bone morphogenic protein inhibitor,ABL1|ACVR1|RIPK2,,
NNC(=O)CSc1nc2scc(-c3ccccc3)c2c(=O)n1-c1ccccc1,LDN-27219,Preclinical,tissue transglutaminase inhibitor,TGM2,,
CC(=O)O/N=C1/C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc21,LDN-57444,Preclinical,ubiquitin C-terminal hydrolase inhibitor,,,
c1ccc2c(-c3cnn4cc(-c5ccc(N6CCNCC6)cc5)cnc34)ccnc2c1,LDN193189,Preclinical,bone morphogenic protein inhibitor,ACVR1|BMPR1A,,
CN1c2cc3c(cc2N=C(c2ccc(C(=O)O)cc2)c2ccccc21)C(C)(C)CCC3(C)C,LE-135,Preclinical,retinoid receptor agonist,RARB,,
COC(=O)N[C@H](C(=O)N1CC2(CC2)C[C@H]1c1nc(-c2ccc3c(c2)C(F)(F)c2cc(-c4ccc5nc([C@@H]6[C@H]7CC[C@H](C7)N6C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]c5c4)ccc2-3)c[nH]1)C(C)C,ledipasvir,Launched,HCV inhibitor,,infectious disease,hepatitis C
Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,leflunomide,Launched,dihydroorotate dehydrogenase inhibitor|PDGFR tyrosine kinase receptor inhibitor,AHR|DHODH|PTK2B,rheumatology,rheumatoid arthritis
Cc1ncc(OC[C@@]2(c3cccc(F)c3)C[C@H]2C(=O)Nc2ccc(F)cn2)c(C)n1,lemborexant,Launched,orexin receptor antagonist,HCRTR1|HCRTR2,,
Nc1cccc2c1CN([C@H]1CCC(=O)NC1=O)C2=O,lenalidomide,Launched,anticancer agent,TNF,hematologic malignancy,multiple myeloma|mantle cell lymphoma (MCL)|myelodysplastic diseases (MDS)
CCC(=O)N1CC[C@H](Nc2ncnc3c2CN(c2cnc(OC)c(C(F)(F)F)c2)CC3)C1,leniolisib,Phase 2/Phase 3,PI3K inhibitor,,,
COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,lenvatinib,Launched,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FLT4|KDR,oncology,thyroid cancer
COc1cc(C(=O)OCCCCNC(=N)N)cc(OC)c1O,leonurine,Preclinical,anti-inflammatory agent,,,
Cc1c(Cc2ccccc2)nnc(N2CCN(c3cnc(C(C)(C)O)cn3)[C@H](C)C2)c1C,LEQ506,Phase 1,G protein signaling inhibitor,,,
COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(c2ccccc2)c2ccccc2)[C@@H]1c1cccc([N+](=O)[O-])c1,lercanidipine,Launched,calcium channel blocker,CACNA2D1,cardiology,hypertension
c1ccc(Cn2c(N3CCNCC3)nc3ccccc32)cc1,lerisetron,Phase 3,serotonin receptor antagonist,HTR3A,,
CCc1nn(CCO)c(CC)c1Oc1cc(C#N)cc(C#N)c1,lersivirine,Phase 2,non-nucleoside reverse transcriptase inhibitor,,,
O=C(O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12,lesinurad,Launched,uric acid diuretic,SLC22A12,rheumatology,gout
C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O,lestaurtinib,Phase 3,FLT3 inhibitor|growth factor receptor inhibitor|JAK inhibitor,FLT3|NTRK1,,
O=C(CCn1cnc2c(=O)nc[nH]c21)Nc1ccc(C(=O)O)cc1,leteprinim,Phase 2,nerve growth factor agonist,,,
COc1cccc(N2CCN(C3=Nc4c(F)cccc4[C@H](CC(=O)O)N3c3cc(C(F)(F)F)ccc3OC)CC2)c1,letermovir,Launched,CMV terminase inhibitor,,infectious disease,cytomegalovirus (CMV)
CCOC(=O)CSCC[C@H]1N[C@H](C(=O)O)CS1,letosteine,Launched,mucolytic agent,,pulmonary|infectious disease,bronchitis|pneumonia
N#C[C@H](c1ccc(F)cc1)c1c(Cl)cc(-n2ncc(=O)[nH]c2=O)cc1Cl,letrazuril,Phase 1,antiinfective drug,,,
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,letrozole,Launched,aromatase inhibitor,CYP19A1,oncology,breast cancer
CN(C)c1ccc2c(c1)Sc1cc(N(C)C)ccc1N2,leucomethylene-blue,Phase 3,nitric oxide production inhibitor|tau aggregation inhibitor,MAPT,,
Nc1nc(=O)c2c([nH]1)NC[C@H](CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O,leucovorin,Launched,folate receptor ligand,,oncology,osteosarcoma
COC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C,leucylleucine-methyl-ester,Phase 2,,,,
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1,leuprolide,Launched,gonadotropin releasing factor hormone receptor agonist,GNRHR,oncology,prostate cancer
CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1,levalbuterol,Launched,adrenergic receptor agonist,ADRB2,pulmonary,bronchospasm
C=CCN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13,levallorphan,Launched,opioid receptor antagonist,CHRNA2|OPRM1,pulmonary,respiratory depression
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1c1ccccc1Cl,levamlodipine,Launched,calcium channel blocker,,cardiology,hypertension
CC1(C)Oc2ccc(C#N)cc2[C@@H](N2CCCC2=O)[C@@H]1O,levcromakalim,Phase 3,potassium channel activator,KCNJ5,,
CC[C@@H](C(N)=O)N1CCCC1=O,levetiracetam,Launched,calcium channel blocker,CACNA1B|SCN1A|SV2A,neurology/psychiatry,seizures
CN1C[C@H]2CCC[C@@H](C1)[C@@H]2OC(=O)[C@](O)(c1ccccc1)C1CCCC1,levo-phencynonate,Launched,acetylcholine receptor antagonist,CHRM1,,
CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1,levobetaxolol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2,ophthalmology,intraocular pressure|glaucoma
CC(C)(C)NC[C@H](O)COc1cccc2c1CCCC2=O,levobunolol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,ophthalmology,glaucoma|ocular hypertension
CC(C)(C)NC[C@@H](O)COc1cccc2c1CCCC2=O,levobunolol-(+),Preclinical,adrenergic receptor antagonist,,,
CC(C)(C)NC[C@@H](O)COc1cccc2c1CCCC2=O,levobunolol-(+/-),Preclinical,adrenergic receptor antagonist,,,
C[C@@H]1CN([C@H]2CC[C@](C#N)(c3ccc(F)cc3)CC2)CC[C@]1(C(=O)O)c1ccccc1,levocabastine,Launched,histamine receptor antagonist,HRH1|NTSR2,ophthalmology,conjunctivitis
C[N+](C)(C)C[C@H](O)CC(=O)O,levocarnitine,Launched,,CRAT|CROT,endocrinology,carnitine deficiency
CCC(=O)O[C@H](CC(=O)O)C[N+](C)(C)C,levocarnitine-propionate,Launched,carnitine palmitoyltransferase inhibitor,CRAT,neurology/psychiatry|endocrinology,peripheral neuropathy|carnitine deficiency
O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,levocetirizine,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis|urticaria
N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O,levodopa,Launched,dopamine precursor,DRD1|DRD2|DRD3|DRD4|DRD5|GPR143,neurology/psychiatry,Parkinson's Disease
OC[C@@H](O)CN1CCN(c2ccccc2)CC1,levodropropizine,Launched,antitussive,,pulmonary,cough suppressant
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,levofloxacin,Launched,bacterial DNA gyrase inhibitor,TOP2A,infectious disease|otolaryngology|pulmonary|urology,pneumonia|sinusitis|bronchitis|skin infections|prostatitis|urinary tract infections|pyelonephritis|anthrax|plague
CC(C)=CCC[C@](C)(O)[C@@H]1CC=C(C)CC1,levomenol,Launched,,,neurology/psychiatry|infectious disease,spasms|skin infections
CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,levomenthol,Launched,,OPRK1|TRPA1|TRPM8|TRPV3,neurology/psychiatry,pain relief
COc1ccc2c(c1)N(C[C@H](C)CN(C)C)c1ccccc1S2,levomepromazine,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR2A|HTR2C,neurology/psychiatry|gastroenterology,psychosis|schizophrenia|bipolar disorder|nausea|insomnia
c1ccc2c(c1)Sc1ccccc1N2C[C@H]1CN2CCC1CC2,levomequitazine,Phase 2,histamine receptor antagonist,HRH1,,
C[C@H](N)[C@H](O)c1ccc(O)c(O)c1,levonordefrin,Launched,vasodilator,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|SLC6A2,hematology,hemorrhage
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC,levonorgestrel,Launched,estrogen receptor agonist|glucocorticoid receptor antagonist|progesterone receptor agonist|progesterone receptor antagonist,PGR,endocrinology,contraceptive
CCC(=O)OC(Cc1ccccc1)(c1ccccc1)[C@@H](C)CN(C)C,levopropoxyphene,Launched,antitussive,,pulmonary,cough suppressant
C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1,levosimendan,Launched,calcium sensitizer,KCNJ11|KCNJ8|PDE3A|TNNC1,cardiology,congestive heart failure
CCN1CCC[C@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC,levosulpiride,Launched,dopamine receptor antagonist,CA1|CA12|CA7|DRD2|DRD3,neurology/psychiatry|gastroenterology|urology,schizophrenia|psychosis|anxiety|vertigo|dyspepsia|irritable bowel syndrome|premature ejaculation (PE)
N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O,levothyroxine,Launched,thyroid hormone stimulant,THRA|THRB,endocrinology,myxedema coma
CC(=O)[C@@H](C#N)C(=O)Nc1cc(Br)ccc1Br,LFM-A13,Preclinical,Bruton's tyrosine kinase (BTK) inhibitor,BTK,,
Cc1cc(C)c(-c2ccc(NC(=O)[C@H](Cc3ccc(C(=O)NCCS(=O)(=O)O)cc3)c3ccc(-c4ccc(C(C)(C)C)cc4)cc3)cc2)c(C)c1,LGD-6972,Phase 2,glucagon receptor antagonist,,,
Cc1cc(-c2ncc(CC(=O)Nc3ccc(-c4cnccn4)cn3)cc2C)ccn1,LGK-974,Phase 2,porcupine inhibitor,PORCN,,
Cc1cc2sc(NC(=O)Cc3ccccc3)nc2cc1Cl,LH846,Preclinical,casein kinase inhibitor,CSNK1D,,
Clc1cccc([C@H](c2ccc3nc[nH]c3c2)n2ccnc2)c1,liarozole,Phase 2/Phase 3,cytochrome P450 inhibitor,CYP19A1|CYP26A1,,
NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc21,licarbazepine,Phase 3,voltage-gated sodium channel blocker,SCN5A,,
C=CC(C)(C)c1cc(/C=C/C(=O)c2ccc(O)cc2)c(OC)cc1O,licochalcone-A,Phase 3,topoisomerase inhibitor,PTPN1,,
CC1(C)Cc2c(-c3ccccc3)c(-c3ccc(Cl)cc3)c(CC(=O)O)n2C1,licofelone,Phase 3,cyclooxygenase inhibitor|lipoxygenase inhibitor,ALOX5|PLA2G2E|PTGS2,,
CCc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc2c(c1)OCCO2,licogliflozin,Preclinical,sodium/glucose cotransporter inhibitor,,,
O=c1[nH]c2cc(Cl)c(Cl)c([N+](=O)[O-])c2[nH]c1=O,licostinel,Phase 1,NMDA receptor antagonist ,,,
CNC(=N)NC(=O)Nc1c(C)cccc1C,lidamidine,Launched,adrenergic receptor agonist,,gastroenterology,diarrhea
CCN(CC)CC(=O)Nc1c(C)cccc1C,lidocaine,Launched,histamine receptor agonist,EGFR|SCN10A|SCN5A|SCN9A,neurology/psychiatry|dermatology|hematology,itching|eczema|hemorrhage
Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,lidoflazine,Launched,calcium channel blocker,SCN1A|SCN3A|SLC29A1,cardiology,coronary artery disease (CAD)
O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4ccc(C(F)(F)F)cc4[nH]3)ccnc2N1,lifirafenib,Phase 1/Phase 2,RAF inhibitor,,,
CS(=O)(=O)c1cccc(C[C@H](NC(=O)c2c(Cl)cc3c(c2Cl)CCN(C(=O)c2ccc4ccoc4c2)C3)C(=O)O)c1,lifitegrast,Launched,lymphocyte function-associated antigen negative modulator,,ophthalmology,dry eye syndrome
CCC/C=C1\OC(=O)C2=C1CCC=C2,ligustilide,Preclinical,tumor necrosis factor production inhibitor,TNF,,
CCCC[C@H](C)C[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC/C=C/C(=O)O,limaprost-alfadex,Launched,prostanoid receptor agonist,PTGER1,cardiology,claudication
CC(C)C(=O)Nc1ncc(-c2cc(C(F)F)nn2-c2c(Cl)cccc2Cl)s1,LIMKi-3,Preclinical,LIM kinase inhibitor,LIMK1,,
CC1(C)O[C@H]2CC(=O)OC[C@]23[C@H]2CC[C@@]4(C)[C@H](c5ccoc5)OC(=O)[C@H]5O[C@]54[C@]2(C)C(=O)C[C@@H]13,limonin,Preclinical,HIV protease inhibitor,,,
C[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(N)=O)NC(=O)[C@@H]2CSSC[C@H](N)C(=O)N[C@H]3CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O)CSSC[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(=O)O)NC3=O)C(=O)N2,linaclotide,Launched,guanylate cyclase activator,GUCY2C,gastroenterology,irritable bowel syndrome|constipation
CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,linagliptin,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus
C=C[C@](C)(O)CCC=C(C)C,linalool,Phase 1,anticonvulsant,,,
Cc1cccc(C)c1CNc1cc(C(=O)NCCO)cn2c(C)c(C)nc12,linaprazan,Preclinical,ATP-sensitive potassium channel inhibitor,,,
CCC[C@@H]1C[C@@H](C(=O)N[C@@H]([C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)[C@@H](C)O)N(C)C1,lincomycin,Launched,bacterial 30S ribosomal subunit inhibitor,,gastroenterology,enteritis
Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl,lindane,Launched,,GABRB1|GLRA1|GLRA2|GLRA3|GLRB,infectious disease,scabies
CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,linezolid,Launched,bacterial 50S ribosomal subunit inhibitor,MAOA|MAOB,infectious disease,pneumonia|skin infections
Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4n[nH]c(N)c34)cc2)c1,linifanib,Phase 3,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,CSF1|CSF1R|FLT1|FLT3|FLT4|KDR|KIT|PDGFRB|RET|TEK,,
CCCCC/C=C\C/C=C\CCCCCCCC(=O)O,linoleic-acid,Phase 3,oxidative stress inducer,FABP4|FFAR1|FFAR4|HNF4A|KCNB1|PPARG|TRPM8,,
O=C1N(c2ccccc2)c2ccccc2C1(Cc1ccncc1)Cc1ccncc1,linopirdine,Phase 3,potassium channel blocker,KCNQ2|KCNQ3|KCNQ4|KCNQ5,,
Nc1c[n+](N2CCOCC2)no1,linsidomine,Launched,nitric oxide donor,,urology,erectile dysfunction
C[C@]1(O)C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1,linsitinib,Phase 3,IGF-1 inhibitor,IGF1R|INSR|INSRR,,
CCN1CCN=C1CNC(=O)c1cc(Cl)c(N)cc1OC,lintopride,Preclinical,serotonin receptor antagonist,,,
N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,liothyronine,Launched,thyroid hormone stimulant,THRA|THRB,endocrinology,hypothyroidism|myxedema coma
N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,liothyronine-(isomer),Preclinical,,,,
NC(=O)CCCC[C@H]1CCSS1,lipoamide,Preclinical,,,,
O=C1C[C@@H](c2ccc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc2)Oc2cc(O)ccc21,liquiritin,Preclinical,antioxidant,,,
CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C)[C@@H](C)CC)C(=O)O,liraglutide,Launched,GLP receptor agonist,GLP1R,endocrinology,weight-loss aid|diabetes mellitus
COc1cccc(N(C)C(=S)Oc2ccc3c(c2)CCCC3)n1,liranaftate,Launched,fungal squalene epoxidase inhibitor,,infectious disease,fungal infection
CS(=O)(=O)Oc1ccc2c(NC(N)=O)c(C(=O)c3ccc(Cl)cc3Cl)oc2c1,lirimilast,Phase 2,phosphodiesterase inhibitor,,,
Nc1ccc(C(=O)OC[C@@H](O)CO)cc1,lisadimate,Launched,topical sunscreen agent,,dermatology,sunscreen lotion
NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O,lisinopril,Launched,angiotensin converting enzyme inhibitor,ACE|ACE2,cardiology|endocrinology,hypertension|congestive heart failure|diabetes mellitus
C[C@@H](O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,lisofylline,Phase 2,interleukin receptor antagonist|STAT inhibitor,,,
CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,lisuride,Launched,dopamine receptor agonist,ADRA1A|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR6,neurology/psychiatry,Parkinson's Disease
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,lithocholic-acid,Preclinical,FXR antagonist|vitamin D receptor agonist,GPBAR1|NR1H4|NR1I2|VDR,,
CCNCCS(=O)(=O)NC[C@@]1(c2ccccc2)SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C,litronesib,Phase 2,kinesin-like spindle protein inhibitor,KIF11,,
Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc32)c(Cl)c1,lixivaptan,Phase 3,vasopressin receptor antagonist,AVPR2,,
O=C(NCCO)c1cc(C(=O)NCCO)cc(C(=O)NCCO)c1,LM-22A4,Preclinical,tropomyosin receptor kinase inhibitor,NTRK2,,
CC[C@@H](C)[C@@H](N)C(=O)NCCN1CCOCC1,LM11A-31,Phase 1,neurotrophic agent,NGFR,,
CC1(C)CC(Oc2ccc(-c3ccc(-c4cn[nH]c4)cc3O)nn2)CC(C)(C)N1,LMI070,Phase 1/Phase 2,survival motor neuron protein modulator,SMN1,,
Cc1cc(C)cc(C(=O)NOCCCCCC(=O)NO)c1,LMK-235,Preclinical,HDAC inhibitor,HDAC4|HDAC5,,
CN1[C@@H](CC(=O)c2ccccc2)CCC[C@H]1C[C@H](O)c1ccccc1,lobeline,Launched,acetylcholine receptor antagonist,CHRNA10|CHRNA9|SLC18A2,neurology/psychiatry,smoking cessation
CCOC(=O)Nc1nc2ccccc2[nH]1,lobendazole,Preclinical,anthelmintic agent,,,
O=C(O)c1ccccc1Nc1cc(Cl)ccc1C(=O)O,lobenzarit,Launched,immunosuppressant,,rheumatology,rheumatoid arthritis
Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)C[C@@H]1F,lodenosine,Phase 2,antiretroviral ,,,
N#Cc1cc(NC(=O)C(=O)O)c(Cl)c(NC(=O)C(=O)O)c1,lodoxamide,Launched,histamine receptor antagonist,,ophthalmology,vernal keratoconjunctivitis (VKC)
Cc1[nH]cnc1-c1ccc(Cl)cc1,lofemizole,Phase 3,cyclooxygenase inhibitor,,,
CN(CCCN1c2ccccc2CCc2ccccc21)CC(=O)c1ccc(Cl)cc1,lofepramine,Launched,norepinephrine reuptake inhibitor|serotoninâ__orepinephrine reuptake inhibitor (SNRI),HTR1A|SLC6A2|SLC6A4,neurology/psychiatry,depression
C[C@@H](Oc1c(Cl)cccc1Cl)C1=NCCN1,lofexidine,Launched,adrenergic receptor agonist,,neurology/psychiatry,opioid withdrawal
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN[C@@H](C)C3)c(F)c21,lomefloxacin,Launched,bacterial DNA gyrase inhibitor,,infectious disease,respiratory tract infections|urinary tract infections
Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1,lomeguatrib,Phase 2,O6-alkylguanine-DNA alkyltransferase inhibitor,MGMT,,
COc1ccc(CN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)c(OC)c1OC,lomerizine,Launched,calcium channel blocker,CACNA1B|SCN5A,neurology/psychiatry,migraine headache
Nc1nc(=O)c2c([nH]1)NC[C@H](CCc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)C2,lometrexol,Phase 2,glycinamide ribonucleotide formyltransferase inhibitor,GART,,
O=C(NC1CCN(CCCCC2(C(=O)NCC(F)(F)F)c3ccccc3-c3ccccc32)CC1)c1ccccc1-c1ccc(C(F)(F)F)cc1,lomitapide,Launched,microsomal trigylceride transfer protein inhibitor,MTTP,endocrinology,hypercholesterolemia
O=C(NC1CCCCC1)N(CCCl)[NH2+][O-],lomustine,Launched,DNA synthesis inhibitor,,hematologic malignancy|oncology,Hodgkin's lymphoma|brain tumors
NC(=O)N1CCC(CC(=O)N2CCC([C@H]3c4ncc(Br)cc4CCc4cc(Cl)cc(Br)c43)CC2)CC1,lonafarnib,Phase 3,farnesyltransferase inhibitor,FNTA|HRAS|KRAS|NRAS,,
O=C(O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12,lonidamine,Launched,glucokinase inhibitor,GCK,,
CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1,loperamide,Launched,opioid receptor agonist,CACNA1A|CALM1|OPRD1|OPRK1|OPRM1|POMC,gastroenterology,diarrhea
Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,lopinavir,Launched,HIV protease inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)
N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cl)CC[C@H]12)c1ccccc1,loracarbef,Launched,bacterial cell wall synthesis inhibitor,,infectious disease|otolaryngology|pulmonary,ear infections|laryngitis|bronchitis|pneumonia|urinary tract infections|skin infections
CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,loratadine,Launched,histamine receptor antagonist,HRH1,allergy|neurology/psychiatry,allergic rhinitis|itching
Cl/C(=C\n1cncn1)c1ccc(Cl)cc1Cl,loreclezole,Phase 2,benzodiazepine receptor agonist,GABRB2|GABRB3,,
CC(=O)N(C)c1cc(-c2ccnc3c(C(=O)c4cccs4)cnn23)ccc1F,lorediplon,Phase 2,GABA receptor modulator,GABRA1,,
CCCCCN(CCCCC)C(=O)[C@@H](CCC(=O)O)NC(=O)c1ccc(Cl)c(Cl)c1,lorglumide,Phase 1,CCK receptor antagonist,CCKAR|CCKBR,,
C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21,lorlatinib,Launched,ALK tyrosine kinase receptor inhibitor,ALK,oncology,non-small cell lung cancer (NSCLC)
CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O,lornoxicam,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology|neurology/psychiatry,osteoarthritis|sciata
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,losartan,Launched,angiotensin receptor antagonist,AGTR1,cardiology|nephrology,hypertension|diabetic nephropathy|hypertension
Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1,losmapimod,Phase 3,p38 MAPK inhibitor,MAPK14,,
CNc1nc(-c2cccc(NC(=O)c3ccc(C(=O)OC)cc3)c2)c2cc(OC)c(OC)cc2n1,lotamilast,Preclinical,phosphodiesterase inhibitor,,,
CCOC(=O)O[C@]1(C(=O)OCCl)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,loteprednol,Launched,glucocorticoid receptor agonist|phospholipase inhibitor,NR3C1,ophthalmology,conjunctivitis
CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,lovastatin,Launched,HMGCR inhibitor,HDAC2|HMGCR|ITGAL|NR1I2,cardiology|endocrinology,coronary heart disease|myocardial infarction|hypercholesterolemia
CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|ADRB1|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HRH2|HRH4|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR3A|HTR5A|HTR6|HTR7|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,schizophrenia
CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(=O)O,loxistatin-acid,Preclinical,cysteine peptidase inhibitor,CTSB,,
C[C@@H](C(=O)O)c1ccc(C[C@H]2CCCC2=O)cc1,loxoprofen,Launched,cyclooxygenase inhibitor|prostanoid receptor antagonist,PTGS2,neurology/psychiatry,pain relief
Nc1nc(O[C@@H](c2ccc(-c3cccc(F)c3)cc2)C(F)(F)F)cc(-c2ccc(C[C@H](N)C(=O)O)cc2)n1,LP-533401,Preclinical,tryptophan hydroxylase inhibitor,,,
Cc1csc2c(N[C@@H](C)CN3CCN(S(=O)(=O)c4ccc(Cl)c(Cl)c4)CC3)ncnc12,LPA2-antagonist-1,Preclinical,lysophosphatidic acid receptor antagonist,LPAR2,,
COc1cc(C(=O)N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C,LRRK2-IN-1,Preclinical,leucine rich repeat kinase inhibitor,LRRK2,,
CC(C)NC(=O)c1ccc(C#Cc2ccncc2)cn1,LSN-2463359,Preclinical,glutamate receptor positive allosteric modulator,GRM5,,
CC(F)(F)c1cc(F)ccc1-c1sc2cc(O)ccc2c1Oc1ccc(/C=C/C(=O)O)cc1,LSZ-102,Phase 1,selective estrogen receptor modulator (SERM),,,
N=C(Nc1ccccc1)c1cccs1,LTA,Phase 2,,,,
CCCCC/C=C\C[C@@H](O)/C=C/C=C/C=C\[C@@H](O)CCCC(=O)O,LTB4,Phase 2,leukocyte activator,LTB4R|LTB4R2,,
NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN)C(c1ccccc1)c1ccccc1)C(N)=O,LTX-315,Phase 2,anticancer agent,,,
CC(C)(C)CC(=O)Nc1c(F)cc(C(=O)/N=c2\sccn2COP(=O)(O)O)cc1F,Lu-AA-47070,Phase 2,adenosine receptor antagonist,ADORA2A,,
CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O,lubiprostone,Launched,chloride channel activator,CLCN2,gastroenterology,constipation|irritable bowel syndrome
CCN(CC)CCNc1ccc(C)c2sc3ccccc3c(=O)c12,lucanthone,Phase 2,endonuclease inhibitor,APEX1|TOP1|TOP2A,,
CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12,lucitanib,Phase 2,FGFR inhibitor|VEGFR inhibitor,FGFR1|FLT1|KDR|KIT|PDGFRA|PDGFRB|RET,,
N#Cc1c(N)nc(SCc2ncc[nH]2)c(C#N)c1-c1ccc(O)cc1,LUF-5834,Preclinical,adenosine receptor agonist,ADORA2A|ADORA2B,,
O=C(NC(=O)c1c(F)cccc1F)Nc1cc(Cl)c(OC(F)(F)[C@@H](F)C(F)(F)F)cc1Cl,lufenuron,Launched,chitin inhibitor,,infectious disease,flea control
N#C/C(=C1/SC[C@@H](c2ccc(Cl)cc2Cl)S1)n1ccnc1,luliconazole,Launched,sterol demethylase inhibitor,,infectious disease,tinea pedis|tinea cruris|tinea corporis
Cc1ccc(NC(=O)C2(c3ccc4c(c3)OC(F)(F)O4)CC2)nc1-c1cccc(C(=O)O)c1,lumacaftor,Launched,CFTR channel agonist,CFTR,pulmonary,cystic fibrosis
CN1CCN2c3c(cccc31)[C@@H]1CN(CCCC(=O)c3ccc(F)cc3)CC[C@@H]12,lumateperone,Launched,dopamine receptor modulator|serotonin receptor antagonist,DRD2|HTR2A,,
CCCCN(CCCC)C[C@@H](O)c1cc(Cl)cc2c1-c1ccc(Cl)cc1/C2=C/c1ccc(Cl)cc1,lumefantrine,Launched,antimalarial agent,ATP1A1,infectious disease,malaria
O=C1CCC[C@@H]2[C@H]3C[C@@H](CN12)[C@@H]1CCCCN1C3,lupanine,Phase 1,sodium channel blocker,INS,,
O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,lurasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,ADRA2A|ADRA2C|DRD2|HTR1A|HTR2A|HTR7,neurology/psychiatry,schizophrenia
COc1ccc2[nH]c3c(c2c1)CCN[C@]31CS[C@@H]2c3c(OC(C)=O)c(C)c4c(c3[C@H](COC1=O)N1[C@@H]2[C@H]2c3c(cc(C)c(OC)c3O)C[C@@H]([C@@H]1O)N2C)OCO4,lurbinectedin,Phase 3,DNA binding agent,,,
Cc1nc2ccccn2c(=O)c1CCN1CCc2oc3ccccc3c2C1,lusaperidone,Preclinical,adrenergic receptor antagonist,,,
CCCCCCO[C@@H](C)c1cccc(-c2csc(NC(=O)c3cc(Cl)c(/C=C(\C)C(=O)O)c(Cl)c3)n2)c1OC,lusutrombopag,Launched,thrombopoietin receptor agonist,,,
CC1=C[C@H](O)CC(C)(C)[C@H]1/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C,lutein,Launched,antioxidant,,ophthalmology,macular degeneration|cataracts|retinitis pigmentosa (RP)
O=c1cc(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,luteolin,Phase 2,glucosidase inhibitor,TOP1,,
CC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12,luzindole,Preclinical,melatonin receptor antagonist,MTNR1A|MTNR1B,,
COc1cccc(-c2ccc([C@@H](Oc3cc(-c4ccc(C[C@H](N)C(=O)O)cc4)nc(N)n3)C(F)(F)F)cc2)c1,LX1031,Phase 2,tryptophan hydroxylase inhibitor,TPH1,,
Cc1c[nH]c2ncnc(N3CCC(CN)(C(=O)Nc4cccc(OC(=O)N(C)C)c4)CC3)c12,LX7101,Phase 1/Phase 2,LIM kinase inhibitor|rho associated kinase inhibitor,LIMK2|ROCK1|ROCK2,,
Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1,LXH254,Phase 1,RAF inhibitor,,,
Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,LXR-623,Phase 1,LXR agonist,AR|NR1H2|NR1H3|NR1I2|NR3C1,,
CC1(N)CCN(c2cccnc2NC(=O)c2nc(-c3ncccc3C(F)(F)F)cnc2N)CC1,LXS196,Phase 1,PKC inhibitor,,,
O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2,LY2090314,Phase 2,glycogen synthase kinase inhibitor,GSK3B,,
c1ccc(-c2nn3c(c2-c2ccnc4cc(OCCN5CCOCC5)ccc24)CCC3)nc1,LY2109761,Preclinical,TGF beta receptor inhibitor,TGFBR1|TGFBR2,,
N[C@@]1(C(=O)O)CS(=O)(=O)[C@H]2[C@H](C(=O)O)[C@H]21,LY2140023,Phase 3,glutamate receptor agonist,GRM3,,
O=C(O)[C@@H]1C[C@H]2C[C@@H](CCc3nn[nH]n3)CC[C@H]2CN1,LY215490,Phase 1,glutamate receptor antagonist,GRIA1|GRIA2|GRIA3|GRIA4|GRIK1,,
Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1,LY2157299,Phase 2/Phase 3,TGF beta receptor inhibitor,TGFBR1,,
CN(C)C(=O)n1nnnc1Cc1ccc(-c2ccccc2)cc1,LY2183240,Preclinical,FAAH inhibitor|FAAH reuptake inhibitor,FAAH,,
CC(C)(C)Cn1c(N)nc2ccc(-c3nc(C(C)(C)C)[nH]c3-c3ccc(F)cc3)nc21,LY2228820,Phase 2,p38 MAPK inhibitor,MAPK14,,
COc1ccc(/C=C/CCCCOc2ccc(C(=O)c3cccc(C(=O)O)c3)cc2CCC(=O)O)cc1,LY223982,Phase 2,leukotriene receptor antagonist,LTB4R,,
CC(C)Oc1cccc(-n2c(CCc3c[nH]c4ccc(Br)cc34)nc3ccccc3c2=O)c1,LY225910,Preclinical,CCK receptor antagonist,CCKBR,,
CCNCc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1,LY231617,Preclinical,lipid peroxidase inhibitor,,,
CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,LY2334737,Phase 1,antitumor agent|ribonucleotide reductase inhibitor,,,
CN(CCOc1ccc(-c2ccc3c(c2)OCO3)cc1C(C)(C)C)CC(=O)O,LY2365109,Preclinical,glycine transporter inhibitor,SLC6A9,,
CC(C)OC(=O)N[C@H]1Cc2c(n(Cc3ccccn3)c3ccc(C#N)cc23)C1,LY2452473,Phase 2,androgen receptor modulator,AR,,
CC(C)NCCCC[C@H](NC(=O)[C@H]1CCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](Cc2ccc(O)cc2)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NCC(=O)N1)C(N)=O,LY2510924,Phase 2,CC chemokine receptor antagonist,,,
CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1,LY255283,Preclinical,leukotriene receptor antagonist,LTB4R|LTB4R2,,
Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc3n[nH]cc23)CC1,LY2584702,Phase 1,ribosomal protein inhibitor,RPS6KB1,,
Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1,LY2603618,Phase 2,CHK inhibitor,CHEK1,,
COc1cccc(OCCCN)c1-c1cc(Nc2cnc(C#N)cn2)[nH]n1,LY2606368,Phase 2,CHK inhibitor,CHEK1,,
O=C(Nc1ncc(SCCN2CCCC2)s1)[C@]1(c2ccc(S(=O)(=O)C3CC3)cc2)C[C@H]1C1CCCCC1,LY2608204,Phase 2,glucokinase activator,GCK,,
COc1ccc(C[C@H]2NCCc3c2[nH]c2ccc(C)cc32)c(Cl)c1OC,LY266097,Preclinical,serotonin receptor antagonist,HTR2B,,
Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1,LY2784544,Phase 2,JAK inhibitor,JAK2|JAK3,,
NC(=O)c1ccc(Oc2ccc(CN3CCC[C@H]3c3cccnc3)cc2)c(Cl)c1,LY2795050,Preclinical,opioid receptor antagonist,,,
Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1,LY2801653,Phase 2,MET inhibitor,MET,,
C[C@@]1(c2cc(-c3cncnc3)c(F)cc2F)CCSC(N)=N1,LY2811376,Phase 1,beta-secretase inhibitor,BACE1,,
Cc1nc(N2CCN(C)CC2)c2nc(-c3ccccc3Cl)n(C3CCOCC3)c2n1,LY2828360,Phase 2,cannabinoid receptor agonist,,,
CC(C)c1c2cc(-c3ccnc(N[C@H]4CC[C@H](NC5CCOCC5)CC4)n3)ccc2nn1C,LY2857785,Preclinical,CDK inhibitor,CDK9,,
C[C@@H](Oc1ccc2n[nH]c(/C=C/c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl,LY2874455,Phase 1,FGFR antagonist,FGFR1|FGFR2|FGFR3|FGFR4|KDR,,
O=C1NN(C(=O)Nc2ccc(Br)cc2)[C@@H](c2ccccc2)[C@@H]1c1ccccc1,LY288513,Preclinical,CCK receptor antagonist,CCKBR,,
NC1=N[C@@]2(c3cc(NC(=O)c4ccc(F)cn4)ccc3F)COC[C@H]2CS1,LY2886721,Phase 1/Phase 2,beta-secretase inhibitor,BACE1,,
O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,LY294002,Preclinical,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,AKT1|CHEK1|GSK3B|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG|PIM1|PLK1|PRKCA|PRKDC|ROCK1|RPS6KB1|SGK1,,
C[C@H](N)C(=O)N[C@@]1(C(=O)O)C[C@@H](Sc2nnc[nH]2)[C@H]2[C@H](C(=O)O)[C@H]21,LY2979165,Phase 1,glutamate receptor agonist,GRM2,,
CNC(=O)O[C@H]1COc2ccc(N3CCN(C4COC4)CC3)cc2[C@@H]1NC(=O)c1ccc(F)cc1,LY3000328,Phase 1,cathepsin inhibitor,CTSS,,
CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1,LY3009120,Phase 1,RAF inhibitor,BRAF|RAF1,,
CO[C@@H](C)Cn1c(=O)n(C)c2cnc3ccc(-c4cncc(C(C)(C)O)c4)cc3c21,LY3023414,Phase 2,mTOR inhibitor|PI3K inhibitor,MTOR,,
O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12,LY303511,Preclinical,casein kinase inhibitor|mTOR inhibitor|PI3K inhibitor,BRD2|BRD3|BRD4,,
CC1(C)C(=O)N(CCN2CCC(C(=O)c3ccc(F)cc3)CC2)c2ccccc21,LY310762,Preclinical,serotonin receptor antagonist,HTR1D,,
CCc1c(CC(N)=O)c2cc(OCCCP(=O)(O)O)ccc2n1Cc1ccccc1,LY311727,Preclinical,phospholipase inhibitor,,,
CC(C)(O)c1cc(Nc2cc(Oc3cn(C4CC4)nc3C3CCOCC3)ccn2)ccn1,LY3200882,Phase 1,TGF beta receptor inhibitor,,,
COc1ccc(-c2oc3cc(OC)ccc3c2C(=O)c2ccc(C#N)cc2)cc1,LY320135,Preclinical,cannabinoid receptor antagonist,CNR1,,
Cn1nccc1Nc1nccc(-c2cc3c(s2)C(C)(C)N(CCN2CCOCC2)C3=O)n1,LY3214996,Phase 1,ERK inhibitor,,,
Cc1cc(Nc2ccc(F)c(C[C@@]3(C(=O)O)CCN(Cc4cccc(Cl)c4F)[C@H](C)C3)n2)n[nH]1,LY3295668,Phase 1/Phase 2,Aurora kinase inhibitor,,,
CN1CCC(c2c[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc23)CC1,LY334370,Preclinical,serotonin receptor agonist,,,
CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1,LY344864,Preclinical,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR7,,
c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1,LY364947,Preclinical,p38 MAPK inhibitor|TGF beta receptor inhibitor,TGFBR1,,
CC(C)N1Cc2cc(S(C)(=O)=O)ccc2N(CCN2CC=C(c3c[nH]c4cc(F)ccc34)CC2)S1(=O)=O,LY393558,Preclinical,serotonin receptor antagonist,HTR1B|HTR1D|HTR2A|HTR2B,,
CC(C)S(=O)(=O)NC[C@H](C)c1ccc(-c2ccc(C#N)cc2)cc1,LY404187,Preclinical,glutamate receptor positive allosteric modulator,GRIA1|GRIA2|GRIA3|GRIA4,,
C[C@H](NC(=O)[C@@H](O)c1cc(F)cc(F)c1)C(=O)N[C@@H]1C(=O)N(C)c2ccccc2-c2ccccc21,LY411575,Preclinical,gamma secretase inhibitor,,,
CC(C)S(=O)(=O)NC[C@H](C)c1ccc(NC(=O)c2cc(F)cc(F)c2)cc1,LY450108,Phase 1,glutamate receptor modulator,,,
COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1,LY456236,Preclinical,glutamate receptor antagonist,GRM1,,
CC(C)c1ccc2c(c1)CC[C@H]1[C@](C)(CN)CCC[C@]21C,lylamine,Preclinical,cannabinoid receptor agonist,CNR1,,
CN(C)[C@@H]1C(=O)[C@@H](C(=O)NCNCCCC[C@H](N)C(=O)O)C(=O)[C@@]2(O)C(=O)[C@@H]3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12,lymecycline,Launched,bacterial 50S ribosomal subunit inhibitor,,dermatology,acne vulgaris (AV)
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3CC[C@@]21C,lynestrenol,Launched,progestogen hormone,,endocrinology,contraceptive
NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,lypressin,Launched,vasopressin receptor agonist,AVPR1A|AVPR1B|AVPR2,endocrinology,central diabetes insipidus
CCCC(CCC)C(=O)NCc1ccc2c(cnn2-c2ccccc2OC)c1,M-25,Preclinical,smoothened receptor antagonist,DHH|IHH|SMO,,
CN(C)c1ccc(C(=O)NCCCCCCC(=O)NO)cc1,M-344,Preclinical,HDAC inhibitor,HDAC8,,
Cc1cc(C)c(S(=O)(=O)Nc2cccc(C(F)(F)F)c2)c(C)c1,m-3M3FBS,Preclinical,phospholipase activator,PLCB2|PLCB3|PLCD1|PLCG1|PLCG2,,
N=C(N=C(N)N)Nc1cccc(Cl)c1,m-chlorophenylbiguanide,Preclinical,serotonin receptor agonist,HTR3A|HTR3B,,
Oc1cccc(-c2c3nc(c(-c4cccc(O)c4)c4ccc([nH]4)c(-c4cccc(O)c4)c4ccc([nH]4)c(-c4cccc(O)c4)c4nc2C=C4)C=C3)c1,m-THP,Phase 1,,,,
COc1cc(CN(CCN)C(=O)c2cccs2)ccc1OCc1ccccc1,M8-B,Preclinical,transient receptor potential channel antagonist,TRPM8,,
CC(C)Cc1ccc([C@@H](C)C(=O)NCCO)cc1,mabuprofen,Launched,cyclooxygenase inhibitor,,neurology/psychiatry,pain relief
CC(C)(C)NC[C@@H](O)c1cc(Cl)c(N)c(C(F)(F)F)c1,mabuterol,Launched,adrenergic receptor agonist,ADRB2,pulmonary,asthma
COc1cc(C[C@H](C)[C@H](C)Cc2ccc3c(c2)OCO3)ccc1O,macelignan,Preclinical,anti-inflammatory agent|antioxidant,,,
CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1,macitentan,Launched,endothelin receptor antagonist,EDNRA|EDNRB,endocrinology,contraceptive
CCCCS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1,macitentan-n-butyl-analogue,Preclinical,endothelin receptor antagonist,,,
O=c1nc(N2CCN(CC3CCCCC3)CC2)sc2c([N+](=O)[O-])cc(C(F)(F)F)cc12,macozinone,Preclinical,DPRE1 inhibitor,,,
C[C@H]1[C@H](C)CC[C@]2(C(=O)O[C@@H]3O[C@H](CO[C@@H]4O[C@H](CO)[C@@H](O[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5[C@H](O)C[C@]43C)[C@H]12,madecassoside,Preclinical,anti-inflammatory agent,,,
COc1ccc2c(C)nc(Nc3nc(=O)c(C)c(C)[nH]3)nc2c1,madrasin,Preclinical,cell splicing inhibitor,,,
NCc1ccc(S(N)(=O)=O)cc1,mafenide,Launched,carbonic anhydrase inhibitor,CA12|CA14|CA2|CA4|CA6|CA9,infectious disease,first-aid antibiotic|skin infections
C=CCc1ccc(O)c(-c2cc(CC=C)ccc2O)c1,magnolol,Preclinical,PPAR receptor agonist,GABRA1|PPARG,,
CCOC(=O)C[C@@H](SP(=S)(OC)OC)C(=O)OCC,malathion,Launched,cholinesterase inhibitor,ACHE,infectious disease,lice
CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1,malotilate,Launched,protein synthesis stimulant,,gastroenterology,hepatic cirrhosis
O=C(O)[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO,maltobionic-acid,Launched,matrix metalloprotease inhibitor,,dermatology,cosmetic
O=C(O)[C@H](O)c1ccccc1,mandelic-acid,Launched,,,,
Cc1nc(COP(=O)(O)O)cc2c1O[Mn]Oc1c(cc(COP(=O)(O)O)nc1C)CN(CC(=O)O)CCN(CC(=O)O)C2,mangafodipir,Launched,contrast agent,,radiology,contrast agent
COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(C(c3ccccc3)c3ccccc3)CC2)[C@@H]1c1cccc([N+](=O)[O-])c1,manidipine,Launched,calcium channel blocker,CACNA1C|CACNA1D,cardiology,hypertension
C#CCCC(=O)[C@@H](C#N)C(=O)Nc1ccc(C(F)(F)F)cc1,manitimus,Preclinical,dehydrogenase inhibitor,,,
OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,mannitol-D,Launched,diuretic,,neurology/psychiatry|ophthalmology|gastroenterology,intracranial pressure|intraocular pressure|constipation
CNCCC[C@]12CC[C@H](c3ccccc31)c1ccccc12,maprotiline,Launched,norepinephrine reputake inhibitor|tricyclic antidepressant,SLC6A2,neurology/psychiatry,depression|dysthymic disorder
Cc1nnc(C(C)C)n1[C@@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,maraviroc,Launched,CC chemokine receptor antagonist,CCR5,infectious disease,human immunodeficiency virus (HIV-1)
CN1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn4c3c2OCN4C)CC1,marbofloxacin,Launched,bacterial DNA gyrase inhibitor,,infectious disease,gram-negative bacterial infections
CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O,maribavir,Phase 3,cytomegalovirus inhibitor|protein kinase inhibitor,PYGM,,
CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C,marimastat,Phase 3,matrix metalloprotease inhibitor,MMP1|MMP10|MMP11|MMP12|MMP13|MMP14|MMP15|MMP16|MMP17|MMP19|MMP2|MMP20|MMP21|MMP23A|MMP24|MMP25|MMP26|MMP27|MMP28|MMP3|MMP7|MMP8|MMP9,,
COc1ccc(C(C)(C)C)cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1,maropitant,Launched,neurokinin receptor antagonist,TACR1,gastroenterology,vomiting
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1,masitinib,Launched,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor,FGFR3|KIT|PDGFRA|PDGFRB,dermatology,mastocytoma
C[C@@H](Cc1ccc(O)c(O)c1)[C@@H](C)Cc1ccc(O)c(O)c1,masoprocol,Launched,lipoxygenase inhibitor,ALOX5,dermatology,actinic keratosis (AK)
O=C1CCC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34,matrine,Phase 2,opioid receptor agonist,OPRK1,,
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O,mavacamten,Phase 3,myosin inhibitor ,,,
CC(C)(O)c1ccccc1-c1ccc2nc(/C=C/c3ccc(C(F)(F)F)cc3)[nH]c2c1,mavatrep,Preclinical,transient receptor potential channel antagonist,,,
COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc1cccc(C)c1,mavoglurant,Phase 2,glutamate receptor antagonist,GRM5,,
C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)OCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)C[C@@H]1O,maxacalcitol,Launched,vitamin D receptor agonist,VDR,endocrinology,hyperparathyroidism
COc1cc2cc(c1Cl)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]1(C)O[C@H]1[C@H](C)[C@@H]1C[C@@](O)(NC(=O)O1)[C@H](OC)/C=C/C=C(\C)C2,maytansinol-isobutyrate,Preclinical,,,,
CCc1cnc(N2CCC(c3nc(COc4ccc(-n5cnnn5)cc4)cs3)CC2)nc1,MBX-2982,Phase 2,glucose dependent insulinotropic receptor agonist,GPR119,,
Cc1ncc(COP(=O)(O)O)c(C=O)c1O,MC-1,Phase 3,,AADAT|ABAT|AGXT|AGXT2|ALAS1|AZIN2|BCAT1|BCAT2|CBS|CCBL1|CCBL2|CSAD|CTH|DDC|FTCD|GAD1|GAD2|GADL1|GCAT|GLDC|GOT1|GOT2|GPT|GPT2|HDC|IGSF10|KYNU|MOCOS|NFS1|OAT|ODC1|PDXDC1|PDXP|PHYKPL|PNPO|PROSC|PSAT1|PYGB|PYGL|PYGM|SCLY|SDS|SDSL|SEPSECS|SGPL1|SHMT1|SHMT2|SPTLC1|SPTLC2|SPTLC3|SRR|TAT|THNSL1,,
Cn1c(/C=C/C(=O)NO)ccc1/C=C/C(=O)c1cccc(F)c1,MC1568,Preclinical,HDAC inhibitor,HDAC2,,
CC(C)(O)c1coc(S(=O)(=O)NC(=O)Nc2c3c(cc4c2CCC4)CCC3)c1,MCC950,Preclinical,NOD like receptor inhibitor,NLRP3,,
CSc1ccc([C@H]2CN3CCC[C@H]3c3ccccc32)cc1,McN-5652-(+/-),Preclinical,selective serotonin reuptake inhibitor (SSRI),,,
CC1(N2CCC(n3c([C@@H]4CCCNC4)nc4ccccc43)CC2)CCCCCCC1,MCOPPB,Preclinical,nociceptin/orphanin FQ receptor agonist,OPRL1,,
Clc1cccc(N2CCNCC2)c1,mCPP,Phase 2,serotonin receptor agonist,HTR1A|HTR1D|HTR1E|HTR2A|HTR2B|HTR2C|HTR6,,
C=C1C[C@]23C[C@@]1(O)CC[C@H]2[C@@]12C=C[C@H](O)[C@@](C)(C(=O)O1)[C@H]2[C@@H]3C(=O)O,MD-920,Phase 1,NFkB pathway inhibitor,AADACL2,,
COc1cc(-n2c(=S)[nH]c3ccccc3c2=O)c(Cl)cc1Cl,mdivi-1,Preclinical,dynamin inhibitor,DNM1,,
O[C@H](c1ccccc1)C1CCN(CCc2ccccc2)CC1,MDL-11939,Phase 2,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,,
Cn1c(-c2ccccc2)nnc1S(C)(=O)=O,MDL-27531,Preclinical,glycine receptor agonist,,,
O=C(O)CCc1c(C(=O)O)[nH]c2cc(Cl)cc(Cl)c12,MDL-29951,Preclinical,glutamate receptor antagonist,FBP1,,
O=C1CC2(CCCC2)CC(=O)N1CCCCNC[C@H]1COc2ccccc2O1,MDL-72832,Preclinical,serotonin receptor agonist,HTR1A,,
O=C1CC2(CCCC2)CC(=O)N1CCNC[C@H]1COc2ccccc2O1,MDL-73005EF,Phase 1,serotonin receptor antagonist,HTR1A,,
CS(=O)(=O)OCOS(C)(=O)=O,MDMS,Phase 2,DNA inhibitor,,,
C[C@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1,ME-0328,Preclinical,PPAR receptor antagonist,PARP3,,
C[C@@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1,ME0328,Preclinical,PARP inhibitor,PARP3,,
COC(=O)Nc1nc2ccc(C(=O)c3ccccc3)cc2[nH]1,mebendazole,Launched,tubulin polymerization inhibitor,TUBA1A|TUBB|TUBB4B,infectious disease,pinworm|whipworm|hookworm|ascariasis
CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)[C@@H](C)Cc1ccc(OC)cc1,mebeverine,Launched,acetylcholine receptor antagonist,CHRM1,gastroenterology,irritable bowel syndrome
CN1CCc2c(c3ccccc3n2Cc2ccccc2)C1,mebhydrolin,Launched,antihistamine,,allergy,allergic rhinitis|urticaria
CN1C(=O)N(C)C2C1N(C)C(=O)N2C,mebicar,Launched,anxiolytic,,neurology/psychiatry,anxiety
Cc1cc(C)c(NC(=O)CN(CC(=O)O)CC(=O)O)c(C)c1Br,mebrofenin,Launched,,,radiology,diagnostic agent
CNC1(C)C2CCC(C2)C1(C)C,mecamylamine,Launched,acetylcholine receptor antagonist,CHRNA1|CHRNA2|CHRNA3|CHRNA4|CHRNA6|CHRNA7|CHRNB4,cardiology,hypertension
CCOC(=O)c1c(C)n(C)c2ccc(O)cc12,mecarbinate,Preclinical,,,,
COc1cccc(OC)c1-c1cc(C(=O)NC2(C(=O)O)C3CC4CC(C3)CC2C4)nn1-c1ccnc2cc(Cl)ccc12,meclinertant,Phase 2/Phase 3,neurotensin receptor antagonist,NTSR1|NTSR2,,
Cc1cccc(CN2CCN([C@@H](c3ccccc3)c3ccc(Cl)cc3)CC2)c1,meclizine,Launched,constitutive androstane receptor (CAR) agonist,NR1I3,gastroenterology|neurology/psychiatry,nausea|vomiting|motion sickness
C=C1c2c(Cl)ccc(O)c2C(=O)C2=C(O)[C@]3(O)C(O)=C(C(N)=O)C(=O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@H]12,meclocycline-sulfosalicylate,Launched,bacterial 50S ribosomal subunit inhibitor,,dermatology|infectious disease,acne vulgaris (AV)|skin infections
Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl,meclofenamic-acid,Launched,cyclooxygenase inhibitor|prostanoid receptor antagonist,ALOX5|CNR1|KCNQ2|KCNQ3|PTGS1|PTGS2,rheumatology|neurology/psychiatry|endocrinology,joint pain|muscle pain|rheumatoid arthritis|primary dysmenorrhea (PD)
CN(C)CCOC(=O)COc1ccc(Cl)cc1,meclofenoxate,Launched,nootropic agent,,neurology/psychiatry,senile dementia|Alzheimer's disease
COC(=O)[C@@H](N)CS,mecysteine,Launched,analgesic agent,,pulmonary,chest congestion
Cc1cccc([C@@H](C)c2cnc[nH]2)c1C,medetomidine,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C,neurology/psychiatry,sedative
CC(C)(CCCCCCCCCCC(C)(C)CC(=O)O)CC(=O)O,medica-16,Phase 2,ATP citrase lyase inhibitor,FFAR1,,
Cc1nccc2[nH]c(=O)ccc12,medorinone,Phase 1,,,,
O=P(O)(O)CP(=O)(O)O,medronic-acid,Launched,bone resorption inhibitor,,radiology,skeletal imaging agent
CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,medroxyprogesterone,Launched,progesterone receptor agonist,PGR,endocrinology,contraceptive
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,medroxyprogesterone-acetate,Launched,progesterone receptor agonist,ESR1|PGR,endocrinology,contraceptive
CC(=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C,medrysone,Launched,glucocorticoid receptor agonist,NR3C1,ophthalmology,conjunctivitis|episcleritis
Cc1cccc(Nc2ccccc2C(=O)O)c1C,mefenamic-acid,Launched,cyclooxygenase inhibitor,KCNQ1|PTGS1|PTGS2|TRPM3,endocrinology,primary dysmenorrhea (PD)
CCN(CC)CCNC(=O)COc1ccc(OC)cc1,mefexamide,Preclinical,psychoactive drug,,,
O[C@@H](c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)[C@H]1CCCCN1,mefloquine,Launched,adenosine receptor antagonist|hemoglobin antagonist,,infectious disease,malaria
CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,megestrol,Launched,progesterone receptor agonist,,oncology,breast cancer
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,megestrol-acetate,Launched,progesterone receptor agonist,NR3C1|PGR,neurology/psychiatry|endocrinology,anorexia|cachexia
COc1ccc(Cl)cc1C(=O)NCCc1ccc(C(=O)O)cc1,meglitinide,Phase 2,potassium channel blocker,CCR2,,
CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,meglumine,Launched,excipient,,,
CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21,meisoindigo,Phase 3,STAT inhibitor,STAT3,,
N#CC(C(=N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F,MEK1-2-inhibitor,Preclinical,MEK inhibitor,MAP2K2,,
CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@@H](C(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O,melanotan-ii,Launched,melanocortin receptor agonist,,,
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,melatonin,Launched,melatonin receptor agonist|nitric oxide synthase inhibitor,ASMT|CALM1|CALR|EPX|ESR1|HTR2B|MPO|MTNR1A|MTNR1B|NQO2|RORB,neurology/psychiatry,sleep cycle support
C[N+](C)(C)NCCC(=O)O,meldonium,Launched,gamma butyrobetaine hydroxylase inhibitor,BBOX1,cardiology,coronary artery disease (CAD)
C=C1C[C@H]2[C@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@@H]3CC[C@]2(C)[C@@]1(OC(C)=O)C(C)=O,melengestrol-acetate,Preclinical,progesterone receptor agonist,,,
COC(=O)[C@@H](N)Cc1ccc(O)c(O)c1,melevodopa,Launched,dopamine precursor|dopamine receptor agonist,DDC,neurology/psychiatry,Parkinson's Disease
Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1,meloxicam,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,osteoarthritis|rheumatoid arthritis
CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1,melperone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,DRD2|HTR2A,neurology/psychiatry,psychosis
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,melphalan,Launched,DNA alkylating agent|DNA inhibitor,,hematologic malignancy,multiple myeloma
N[C@@H](Cc1ccc([N+]([O-])(CCCl)CCCl)cc1)C(=O)O,melphalan-n-oxide,Phase 1,hypoxia inducible factor inhibitor,HIF1A,,
CC(C)(C)NC[C@@H](O)c1ccc(O)cc1Cl,meluadrine,Preclinical,,,,
C[C@]12C[C@@H]3C[C@](C)(C1)C[C@@](N)(C3)C2,memantine,Launched,glutamate receptor antagonist,,neurology/psychiatry,Alzheimer's disease|senile dementia
CC1=CC(=O)c2ccccc2C1=O,menadione,Launched,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,AOX1|BGLAP|F10|F2|F7|F9|GGCX|NQO1|NQO2|PROC|PROS1|PROZ|VKORC1|VKORC1L1,gastroenterology|neurology/psychiatry|dermatology|rheumatology,ulcerative colitis|diarrhea|headache|varicose veins|rheumatoid arthritis
C[C@@]1(S(=O)(=O)O)CC(=O)c2ccccc2C1=O,menadione-bisulfite,Phase 2,vitamin K,GGCX|VKORC1|VKORC1L1,,
CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC1=C(C)C(=O)c2ccccc2C1=O,menatetrenone,Launched,bone resorption inhibitor,,orthopedics,osteoporosis
COc1ccc(C(=O)CCC(=O)O)c2ccccc12,menbutone,Launched,,,gastroenterology,bile stimulation
CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12,mepacrine,Launched,cytokine production inhibitor|NFkB pathway inhibitor|TP53 activator,PLA2G1B,infectious disease,giardiasis
CN1CCC[C@@H](CN2c3ccccc3Sc3ccccc32)C1,mepazine,Phase 2,MALT1 inhibitor (JH),MALT1,,
C[N+]1(C)CCC[C@H](OC(=O)C(O)(c2ccccc2)c2ccccc2)C1,mepenzolate,Launched,acetylcholine receptor antagonist,,gastroenterology,peptic ulcer disease (PUD)
Cc1ccccc1OC[C@@H](O)CO,mephenesin,Launched,muscle relaxant,,neurology/psychiatry,muscle relaxant
CNC(C)(C)Cc1ccccc1,mephentermine,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3,cardiology,hypotension
CC[C@@]1(c2ccccc2)NC(=O)N(C)C1=O,mephenytoin,Launched,hydantoin antiepileptic,SCN5A,neurology/psychiatry,seizures
[O-][n+]1cccc(CO)c1,mepiroxol,Preclinical,,,,
Cc1cccc(C)c1NC(=O)[C@H]1CCCCN1C,mepivacaine,Launched,potassium channel blocker|sodium channel blocker,,neurology/psychiatry,local anesthetic
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO,meprednisone,Launched,,NR3C1,,
CCCNC(C)(C)COC(=O)c1ccccc1,meprylcaine,Preclinical,local anesthetic,,,
CC[C@@]1(c2cccc(O)c2)CCCCN(C)C1,meptazinol,Launched,opioid receptor agonist,BCHE,neurology/psychiatry,pain relief
COc1ccc(CN(CCN(C)C)c2ccccn2)cc1,mepyramine,Launched,histamine receptor antagonist,HRH1,otolaryngology|obstetrics/gynecology,common cold|menstrual pain
COc1ccc(O)cc1,mequinol,Launched,,TYR,dermatology,skin depigmentation
O=C(Nc1ccccc1)c1c(O)[nH]c(=S)[nH]c1=O,merbarone,Phase 2,topoisomerase inhibitor,TOP2A,,
S=c1nc[nH]c2nc[nH]c12,mercaptopurine,Launched,immunosuppressant|protein synthesis inhibitor|purine antagonist,HPRT1|IMPDH1|IMPDH2|PPAT,hematologic malignancy,acute lymphoblastic leukemia (ALL)
O=C(O)C[C@@H](S)C(=O)O,mercaptosuccinic-acid,Launched,,,,
CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1,Merck60,Preclinical,HDAC inhibitor,HDAC1|HDAC2,,
CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C,mericitabine,Phase 2,HCV inhibitor,,,
COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1,merimepodib,Phase 2,inosine monophosphate dehydrogenase inhibitor,IMPDH1,,
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)N(C)C)C3)[C@H](C)[C@H]12,meropenem,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,skin infections|intra-abdominal infections|meningitis
COc1cc2cc(c1Cl)N(C)C(=O)C[C@H](OC(=O)[C@H](C)N(C)C(=O)CCS)[C@]1(C)O[C@H]1[C@H](C)[C@@H]1C[C@@](O)(NC(=O)O1)[C@H](OC)/C=C/C=C(\C)C2,mertansine,Phase 2,microtubule inhibitor,,,
Nc1ccc(O)c(C(=O)O)c1,mesalazine,Launched,cyclooxygenase inhibitor|lipoxygenase inhibitor|prostanoid receptor antagonist,ALOX5|CHUK|IKBKB|MPO|PPARG|PTGS1|PTGS2,gastroenterology,ulcerative colitis|inflammatory bowel disease
O=S(=O)(O)CCS,mesna,Launched,antioxidant,,urology,hemorrhagic cystitis
CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc([S@@](C)=O)cc21,mesoridazine,Launched,dopamine receptor antagonist,DRD2|HTR2A,neurology/psychiatry,schizophrenia
CN(C)C(=O)Oc1ccc[n+](C)c1,mestinon,Launched,cholinesterase inhibitor,ACHE|BCHE,neurology/psychiatry,myasthenia gravis
C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(OC)ccc4[C@H]3CC[C@@]21C,mestranol,Launched,estrogen receptor agonist,ESR1,endocrinology,contraceptive
CN1C[C@@H](NS(=O)(=O)N(C)C)C[C@@H]2c3cccc4c3c(cn4C)C[C@H]21,mesulergine,Phase 2,dopamine receptor agonist,HTR2A|HTR2B|HTR2C|HTR3A|HTR3B|HTR6|HTR7,,
CC(=O)Oc1cccc(C)c1,meta-cresyl-acetate,Preclinical,,,,
CC(=O)Nc1cccc(O)c1,metacetamol,Preclinical,analgesic agent,,,
Cc1cccc(O)c1,metacresol,Launched,,INS,,
CN1c2c([nH]c(N)nc2=O)NC[C@@H]1CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,metafolin,Launched,,,,
S=C=Nc1cccc(C2(N3CCCCC3)CCCCC2)c1,metaphit,Preclinical,phencyclidine receptor acylator,,,
CC(C)NC[C@@H](O)c1cc(O)cc(O)c1,metaproterenol,Launched,adrenergic receptor agonist,ADRB2,pulmonary,bronchospasm|asthma|bronchitis|emphysema
C[C@H](N)[C@H](O)c1cccc(O)c1,metaraminol,Launched,adrenergic receptor agonist,ADRA1A,cardiology,hypotension
Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl,metatinib,Phase 1,Bcr-Abl kinase inhibitor,ABL1|BCR,,
Cc1cc(C)cc(OC[C@H]2CNC(=O)O2)c1,metaxalone,Launched,muscle relaxant,,neurology/psychiatry,muscle pain
COc1cc2nc(N3CCN(C(=O)[C@H](C)OC)CC3)nc(N)c2cc1OC,metazosin,Phase 2,adrenergic receptor antagonist,ADRA1A,,
CSCC[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O,metenkephalin,Phase 2,immunostimulant,OPRD1,,
CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@@H]2c3cccc4c3c(cn4C)C[C@H]21,metergoline,Launched,dopamine receptor agonist|serotonin receptor antagonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7,neurology/psychiatry|endocrinology,seasonal affective disorder|anxiety|hyperprolactinemia
CN(C)C(=N)N=C(N)N,metformin,Launched,insulin sensitizer,ACACB|PRKAB1,endocrinology,diabetes mellitus
CC(=O)O[C@@H](C)C[N+](C)(C)C,methacholine,Launched,acetylcholine receptor agonist,CHRM2|CHRM4,pulmonary,bronchial hyperresponsiveness diagnostic
C=C1c2cccc(O)c2C(=O)[C@@H]2C(=O)[C@]3(O)C(=O)[C@@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@H]12,methacycline,Preclinical,protein synthesis inhibitor,,pulmonary,bronchitis
CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc21,methantheline,Launched,acetylcholine receptor antagonist,CHRM1|HRH2,gastroenterology|neurology/psychiatry|urology,peptic ulcer disease (PUD)|irritable bowel syndrome|pancreatitis|dyskinesia|neurogenic bladder
CCC1(CC)C(=O)NC(=O)N(C)C1=O,metharbital,Launched,GABA receptor modulator,CHRNA4|CHRNA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA2|GRIK2,neurology/psychiatry,epilepsy
CC(=O)N=c1sc(S(N)(=O)=O)nn1C,methazolamide,Launched,carbonic anhydrase inhibitor,CA1|CA12|CA14|CA2|CA4|CA7,ophthalmology,glaucoma|intraocular pressure
C1N2CN3CN1CN(C2)C3,methenamine,Launched,bacterial DNA inhibitor,,infectious disease,urinary tract infections
COC(=O)Nc1nc2ccc(SC(C)C)cc2[nH]1,methiazole,Preclinical,anthelmintic agent,,,
COc1cccc(OC)c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O,methicillin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections|gram-positive bacterial infections
Cn1cc[nH]c1=S,methimazole,Launched,antithyroid agent,TPO,endocrinology,hyperthyroidism
CSCC[C@@H](N)C(=O)O,methionine,Launched,,METAP2,,
CC(=O)SCCC(=O)N1[C@H](C)CCC[C@@H]1C(=O)O,methiopril,Phase 2,angiotensin converting enzyme inhibitor,ACE,,
COc1ccccc1OC[C@@H](O)COC(N)=O,methocarbamol,Launched,muscle relaxant,CA1,neurology/psychiatry,muscle relaxant
COC(C)(C)CCC[C@H](C)C/C=C/C(C)=C/C(=O)OC(C)C,methoprene-(s),Preclinical,,,,
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,methotrexate,Launched,dihydrofolate reductase inhibitor,DHFR,oncology|hematologic malignancy|dermatology|rheumatology,gestational choriocarcinoma|hydatidiform mole|acute lymphoblastic leukemia (ALL)|psoriasis|rheumatoid arthritis
COc1ccc(OC)c(C(O)C(C)N)c1,methoxamine,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D,cardiology,hypotension
COc1c2occc2cc2ccc(=O)oc12,methoxsalen,Launched,DNA synthesis inhibitor,CYP1A1|CYP1A2|CYP2A13|CYP2A6|CYP3A4,dermatology,psoriasis
CN[C@@H](C)Cc1ccccc1OC,methoxyphenamine,Launched,adrenergic receptor agonist,,pulmonary,asthma
C[N+]1(C)[C@@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12,methscopolamine,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3,gastroenterology,peptic ulcer disease (PUD)
CN1C(=O)C[C@](C)(c2ccccc2)C1=O,methsuximide,Launched,T-type calcium channel blocker,CACNA1G|CACNA1H|CACNA1I,neurology/psychiatry,seizures
CN1[C@@H](CCl)Nc2cc(Cl)c(S(N)(=O)=O)cc2S1(=O)=O,methyclothiazide,Launched,chloride reabsorption inhibitor,SLC12A1|SLC12A3,cardiology,hypertension|edema
C[C@@H](N)Cc1c[nH]c2ccc(O)cc12,methyl-5-hydroxytryptamine,Preclinical,,,,
COC(=O)c1cccnc1,methyl-nicotinate,Phase 2,,,,
COC(=O)c1ccccc1O,methyl-salicylate,Launched,,,endocrinology|neurology/psychiatry,fever|pain relief
C[N+]1(C)[C@@H]2CC[C@H]1C[C@@H](OC(=O)[C@@H](CO)c1ccccc1)C2,methylatropine-nitrate,Preclinical,acetylcholine receptor antagonist,CHRM1,,
CC[N+](C)(CC)CCOC(=O)C(O)(c1ccccc1)c1ccccc1,methylbenactyzium-bromide,Preclinical,cholinergic receptor antagonist,,,
Cc1cc(C(C)(C)CC(C)(C)C)ccc1OCCOCC[N+](C)(C)Cc1ccccc1,methylbenzethonium-chloride,Preclinical,other antibiotic,,,
C[Co+]N1/C2=C(/C)C3=N/C(=C/C4=N/C(=C(/C)C5=N[C@@](C)([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(=O)(O)O[C@H]1[C@@H](O)[C@@H](n2cnc6cc(C)c(C)cc62)O[C@@H]1CO)[C@@](C)(CC(N)=O)[C@@H]5CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)C(C)(C)[C@@H]3CCC(N)=O,methylcobalamin,Phase 3,vitamin B,,,
C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O,methyldopa,Launched,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C|DDC,cardiology,hypertension
CCOC(=O)[C@@](C)(N)Cc1ccc(O)c(O)c1,methyldopate,Launched,,,cardiology,hypertension
CN(C)c1ccc2nc3ccc(=[N+](C)C)cc-3sc2c1,methylene-blue,Launched,guanylyl cyclase inhibitor|nitric oxide production inhibitor,ACHE,hematology,methemoglobinemia
CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,methylergometrine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,DRD1|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C,hematology|neurology/psychiatry,postpartum hemorrhage (PPH)|migraine headache
CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14,methyllycaconitine,Preclinical,acetylcholine receptor antagonist,CHRNA7,,
C[N@+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,methylnaltrexone,Launched,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,gastroenterology,constipation
COC(=O)c1ccc(O)cc1,methylparaben,Launched,other antifungal,,dermatology,cosmetic
C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)CO)[C@@]2(C)C=CC(=O)C=C12,methylprednisolone,Launched,glucocorticoid receptor agonist,NR3C1,endocrinology|rheumatology|dermatology|infectious disease|allergy|hematology|neurology/psychiatry|gastroenterology,hypercalcemia|thyroiditis|ankylosing spondylitis|bursitis|osteoarthritis|psoriatic arthritis|seborrheic dermatitis|mycosis|allergic rhinitis|psoriasis|anemia|multiple sclerosis|ulcerative colitis|enteritis
CCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,methylprednisolone-aceponate,Launched,anti-inflammatory agent|glucocorticoid receptor agonist,NR3C1,endocrinology|rheumatology|infectious disease|allergy|pulmonary|gastroenterology|dermatology|neurology/psychiatry|hematology,congenital adrenal hyperplasia|thyroiditis|hypercalcemia|rheumatoid arthritis|bursitis|epicondylitis|allergic rhinitis|asthma|ulcerative colitis|enteritis|osteoarthritis|psoriasis|multiple sclerosis|anemia
C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)O)[C@@]2(C)C=CC(=O)C=C12,methylprednisolone-sodium-succinate,Launched,glucocorticoid receptor agonist,,endocrinology|rheumatology|dermatology|pulmonary|allergy|infectious disease|ophthalmology|gastroenterology|hematology|neurology/psychiatry,hypercalcemia|thyroiditis|osteoarthritis|rheumatoid arthritis|seborrheic dermatitis|asthma|allergic rhinitis|shingles|conjunctivitis|ulcerative colitis|enteritis|anemia|multiple sclerosis|mycosis
Cc1cc(=O)[nH]c(=S)[nH]1,methylthiouracil,Launched,,,endocrinology,hyperthyroidism
CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1,methysergide,Launched,serotonin receptor antagonist,HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7,neurology/psychiatry,headache
Cc1cc2c(cc1S(N)(=O)=O)S(=O)(=O)CCC2,meticrane,Launched,diuretic,,cardiology,edema
C[C@](N)(Cc1ccc(O)cc1)C(=O)O,metirosine,Launched,tyrosine hydroxylase inhibitor,TH,cardiology,hypertension
CSc1ccc2c(c1)[C@H](N1CCN(C)CC1)Cc1ccccc1S2,metitepine,Preclinical,anti-HCVE2,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7,,
CN1CCC[C@@H](CC2c3ccccc3Sc3ccccc32)C1,metixene,Launched,acetylcholine receptor antagonist,CHRM5,neurology/psychiatry,Parkinson's Disease
CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,metoclopramide,Launched,dopamine receptor antagonist|serotonin receptor antagonist,CHRM1|DRD2|HTR3A|HTR3B|HTR4,gastroenterology,gastroparesis|nausea|vomiting
COc1ccc2cc1Oc1cc3c(cc1OC)CC[N+](C)(C)[C@H]3Cc1ccc(cc1)Oc1c(OC)c(OC)cc3c1[C@@H](C2)[N+](C)(C)CC3,metocurine,Launched,acetylcholine receptor antagonist,CHRM2|CHRNA2,neurology/psychiatry,muscle relaxant
Cc1ccccc1N1C(=O)c2cc(S(N)(=O)=O)c(Cl)cc2N[C@@H]1C,metolazone,Launched,carbonic anhydrase inhibitor,SLC12A3,cardiology,edema|hypertension
COCCc1ccc(OC[C@@H](O)CNC(C)C)cc1,metoprolol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2,cardiology,hypertension|angina pectoris|myocardial infarction
COc1ccccc1OC(=O)[C@@H](C)c1ccc(CC(C)C)cc1,metoxibutropate,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,,
COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl,metrifonate,Phase 3,acetylcholinesterase inhibitor,ACHE,,
CC(=O)Nc1c(I)c(C(=O)N[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]2O)c(I)c(N(C)C(C)=O)c1I,metrizamide,Launched,radiopaque medium,,radiology,contrast agent
CC(=O)Nc1c(I)c(C(=O)O)c(I)c(N(C)C(C)=O)c1I,metrizoic-acid,Launched,radiopaque medium,,radiology,contrast agent
Cc1ncc([N+](=O)[O-])n1CCO,metronidazole,Launched,DNA inhibitor,CYP2C9|CYP3A4,dermatology,rosacea
CC(C)(C(=O)c1cccnc1)c1cccnc1,metyrapone,Launched,cytochrome P450 inhibitor,CYP11B1,nephrology,adrenal diagnostic agent
CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,mevastatin,Preclinical,HMGCR inhibitor,HMGCR,,
COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1,mexeneone,Preclinical,,,,
Cc1cccc(C)c1OC[C@@H](C)N,mexiletine,Launched,sodium channel blocker,PLAU|SCN4A|SCN5A,cardiology,ventricular arrhythmias|ventricular tachycardia (VT)
CC1(C)S[C@H]2[C@@H](NC(=O)[C@@H](NC(=O)N3CCN(S(C)(=O)=O)C3=O)c3ccccc3)C(=O)N2[C@@H]1C(=O)O,mezlocillin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections|gram-positive bacterial infections
O=C1C[C@@H](c2ccc(O)cc2)Oc2cc(O)ccc21,MF-101,Phase 3,estrogen receptor agonist,CYP19A1|XDH,,
CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1,MG-132,Preclinical,proteasome inhibitor,PSMB1,,
CC[N+](CC)(CC)CCOc1ccc(/C=C/c2ccccc2)cc1,MG-624,Preclinical,acetylcholine receptor antagonist,CHRNA7,,
Cn1cnc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccccc5)cc4F)c3s2)c1,MGCD-265,Preclinical,VEGFR inhibitor,AXL|MET,,
CC(=O)NCCNc1cc(Cl)nn2c(-c3cccc(S(=O)(=O)N(C)C)c3)c(C)nc12,MI-14,Preclinical,PI4K inhibitor,PI4KB,,
CN1CCN2c3ccccc3Cc3ccccc3C2C1,mianserin,Launched,serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|HRH1|HRH2|HTR2A|HTR2B|HTR2C|HTR6|HTR7,neurology/psychiatry,depression
CC(C)S(=O)(=O)NC[C@H](C)c1ccc(-c2ccc(CCNS(C)(=O)=O)cc2)cc1,mibampator,Phase 2,glutamate receptor modulator,GRIA1,,
CCCCCOc1ccc(-c2cc(-c3ccc(C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@H](O)CC(N)=O)NC(=O)[C@H]([C@H](O)[C@@H](O)c5ccc(O)c(OS(=O)(=O)O)c5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)cc3)no2)cc1,micafungin,Launched,"fungal 1,3-beta-D-glucan synthase inhibitor",,infectious disease,candidemia|peritonitis|esophageal candidiasis
Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,miconazole,Launched,bacterial cell wall synthesis inhibitor,TRPM2|TRPV5,infectious disease|neurology/psychiatry,yeast infection|itching
CNC[C@@H]1CC[C@@H](N)[C@@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H](N)C[C@@H]2N)O1,micronomicin,Launched,protein synthesis inhibitor,,infectious disease,gram-negative bacterial infections
O=C(O)[C@H]1CN(C/C=C/P(=O)(O)O)CCN1,midafotel,Phase 3,glutamate receptor antagonist,GRIN2A|GRIN2B|GRIN2C|GRIN2D,,
CCC(=O)O[C@@H]1CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@H]1OC,midecamycin,Launched,protein synthesis inhibitor,,infectious disease,respiratory tract infections|ear infections|skin infections
COc1ccc(OC)c([C@@H](O)CNC(=O)CN)c1,midodrine,Launched,adrenergic receptor agonist,,cardiology,hypotension
CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,midostaurin,Launched,FLT3 inhibitor|KIT inhibitor|PKC inhibitor,FLT3|PRKCG,hematologic malignancy,acute myeloid leukemia (AML)
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,mifepristone,Launched,glucocorticoid receptor antagonist|progesterone receptor antagonist,AR|NR1I2|NR3C1|PGR,endocrinology,hyperglycemia|diabetes mellitus
COP(=O)(OC)O[C@@H](c1ccc(Cl)cc1)P(=O)(OC)OC,mifobate,Phase 2,PPAR receptor antagonist,PPARG,,
OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,miglitol,Launched,glucosidase inhibitor,GAA|GANAB|GANC|MGAM,endocrinology,diabetes mellitus
CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,miglustat,Launched,glycosyl transferase inhibitor,UGCG,hematology,Gaucher disease
CCCCCNCC(N)=O,milacemide,Phase 3,monoamine oxidase inhibitor,MAOB,,
CC1(C)CCC2(CC1)N[C@@H](C(=O)N[C@@H]1CC[C@@H](C(N)=O)OC1)[C@H](c1ccnc(Cl)c1F)[C@]21C(=O)Nc2cc(Cl)ccc21,milademetan,Phase 1,MDM inhibitor,,,
CCN(CC)C(=O)[C@@]1(c2ccccc2)C[C@H]1CN,milnacipran,Launched,serotoninâ__orepinephrine reuptake inhibitor (SNRI),SLC6A2|SLC6A4,rheumatology,fibromyalgia
Cc1[nH]c(=O)c(C#N)cc1-c1ccncc1,milrinone,Launched,phosphodiesterase inhibitor,PDE2A|PDE3A|PDE3B|PDE5A,cardiology,congestive heart failure
CCCCCCCCCCCCCCCCOP(=O)(O)OCC[N+](C)(C)C,miltefosine,Launched,membrane integrity inhibitor,PLA2G1B,infectious disease,leishmaniasis
N[C@@H](Cn1ccc(=O)c(O)c1)C(=O)O,mimosine,Preclinical,DNA replication inhibitor,CCL2|SHMT1|SHMT2|TYR,,
CCCCCCCC/C=C\CCCCCC[C@@H](O)C(=O)O,minerval,Phase 1/Phase 2,FAAH inhibitor,,,
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(=O)[C@@H](C(N)=O)C(=O)[C@@]3(O)C(=O)[C@H]1C2=O,minocycline,Launched,bacterial 30S ribosomal subunit inhibitor,,endocrinology|infectious disease|ophthalmology|urology,fever|respiratory tract infections|psittacosis|trachoma|conjunctivitis|urethritis|chancroid|tularemia|cholera|brucellosis
O=P(O)(O)C(O)(Cc1cnc2ccccn12)P(=O)(O)O,minodronic-acid,Launched,bone resorption inhibitor,FDPS|GGPS1,orthopedics,osteoporosis
Nc1cc(N2CCCCC2)nc(N)[n+]1[O-],minoxidil,Launched,KATP activator|Kir6 channel (KATP) activator|vasodilator,ABCC9|KCNJ1|KCNJ10|KCNJ11|KCNJ8|PTGS1,endocrinology,androgenetic alopecia
CCC(=O)O[C@@H]1CC(=O)O[C@H](C)C/C=C/C=C/[C@H](OC(C)=O)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(OC(C)=O)[C@@H](OC(=O)CC)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@H]1OC,miocamycin,Launched,other antibiotic,,infectious disease,urinary tract infections|chlamydia
CCC(=O)OCN1C(=O)C=CC1=O,MIRA-1,Preclinical,apoptosis stimulant,,,
Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1,mirabegron,Launched,adrenergic receptor agonist,ADRB1|ADRB2|ADRB3,urology,urinary incontinence
O=C(O)[C@H]1CCCN1C(=O)CCCCC(=O)N1CCC[C@@H]1C(=O)O,miridesap,Preclinical,amyloid protein inhibitor,,,
NC1=NC(=O)/C(=C/c2ccc(O)cc2)S1,mirin,Preclinical,MRE11A exonuclease inhibitor,MRE11A,,
CCCCCCCCCCCCCC(=O)O.CCCCCCCCCCCCCC(=O)O.N[C@H]1CCCC[C@@H]1N.[Pt+2],miriplatin,Launched,DNA synthesis inhibitor,,oncology,hepatocellular carcinoma (HCC)
CCCOc1ccc(S(=O)(=O)N2CCN(CCO)CC2)cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1,mirodenafil,Launched,phosphodiesterase inhibitor,PDE5A,urology,erectile dysfunction
CCC1=C[C@@H]2[C@H](C1)C[C@]2(CN)CC(=O)O,mirogabalin-besylate,Preclinical,calcium channel antagonist,,,
CN1CCN2c3ncccc3Cc3ccccc3[C@@H]2C1,mirtazapine,Launched,adrenergic receptor antagonist|serotonin receptor antagonist,ADRA2A|ADRA2B|ADRA2C|HTR2A|HTR2C,neurology/psychiatry,depression
COC[C@@H](O)Cn1ccnc1[N+](=O)[O-],misonidazole,Phase 3,,,,
CCCCC(C)(O)C/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC,misoprostol,Launched,prostanoid receptor agonist,PTGER2|PTGER3|PTGER4|PTGIR,gastroenterology,duodenal ulcer disease
O=C(c1ccc(NS(=O)(=O)c2cccc3cccnc23)cc1)N1CCN(CC2CC2)CC1,mitapivat,Preclinical,pyruvate kinase isozyme activator,,,
O=C(O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1,mitiglinide,Launched,insulin secretagogue,ABCC8|KCNJ10|PPARG,endocrinology,diabetes mellitus
O=C(O)Cc1cccc2c(=O)cc(-c3ccccc3)oc12,mitoflaxone,Phase 2,antitumor agent,VWF,,
CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12,mitomycin-C,Launched,DNA alkylating agent|DNA synthesis inhibitor,,oncology,pancreatic cancer|gastric adenocarcinoma
COC1=C(OC)C(=O)C(CCCCCCCCCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)=C(C)C1=O,mitoquinone,Launched,antioxidant,,,
Clc1ccc([C@@H](c2ccccc2Cl)C(Cl)Cl)cc1,mitotane,Launched,antineoplastic agent,CYP11A1|CYP11B1|ESR1,oncology,adrenal cortical carcinoma
O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,mitoxantrone,Launched,topoisomerase inhibitor,TOP2A,neurology/psychiatry|oncology|hematologic malignancy,multiple sclerosis|prostate cancer|acute myeloid leukemia (AML)
COc1cc2c(cc1OC)[C@@H](Cc1cc(OC)c(OC)c(OC)c1)[N@@+](C)(CCCOC(=O)CC/C=C/CCC(=O)OCCC[N@+]1(C)CCc3cc(OC)c(OC)cc3[C@H]1Cc1cc(OC)c(OC)c(OC)c1)CC2,mivacurium,Launched,acetylcholine receptor antagonist,CHRNA2,critical care|neurology/psychiatry,endotracheal intubation|muscle relaxant
CCS(=O)(=O)Nc1ccc(Oc2ccc(F)cc2F)c(-c2cn(C)c(=O)c3[nH]ccc23)c1,mivebresib,Phase 1,bromodomain inhibitor,,,
CCOC(=O)Nc1cc2c(c(N)n1)NC(c1ccccc1)C(C)=N2,mivobulin,Phase 2,microtubule inhibitor,,,
Nc1ncnc2c1ncn2[C@@H]1O[C@@H]2CO[P@@](=O)(S)O[C@@H]3[C@H](O)[C@@H](CO[P@@](=O)(S)O[C@H]2[C@H]1O)O[C@H]3n1cnc2c(N)ncnc21,MIW-815,Preclinical,interferon inducer,,,
CN(c1nc(=O)cc[nH]1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1,mizolastine,Launched,histamine receptor antagonist,HRH1,allergy,urticaria|allergic rhinitis
NC(=O)C1N=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1=O,mizoribine,Launched,immunosuppressant|inosine monophosphate dehydrogenase inhibitor,IMPDH1,transplant|rheumatology,organ rejection|nephrotic syndrome
Cc1c(C(=O)NCc2cccnc2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1,MJ-15,Preclinical,cannabinoid receptor antagonist,CNR1,,
C1Cc2[nH]nc(-c3nn[nH]n3)c2C1,MK-0354,Phase 2,niacin receptor agonist,HCAR2|HCAR3,,
O=C1O[C@]2(CC[C@@H](C(=O)Nc3ccn(-c4ccccc4F)n3)CC2)c2cnccc21,MK-0557,Phase 3,neuropeptide receptor antagonist,,,
C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1ccc2c(N)ncnc21,MK-0608,Phase 1,antiviral,,,
O=C(O)CC[C@H]1CC[C@@](c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1,MK-0752,Phase 1/Phase 2,gamma secretase inhibitor,,,
CN1C(=O)C(F)=C[C@]2(C)[C@H]3CC[C@]4(C)[C@@H](C(=O)NCc5nc6ncccc6[nH]5)CC[C@H]4[C@@H]3CC[C@@H]12,MK-0773,Phase 2,androgen receptor modulator,AR,,
CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2CCc3ncc(C(F)(F)F)cc3C2)(C(C)C)C1,MK-0812,Phase 2,CC chemokine receptor antagonist,CCR2,,
COc1ccc2cc(-c3cc(-c4cc(Cl)cc(Cl)c4)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1,MK-0893,Phase 2,glucagon receptor antagonist,GCGR,,
COc1ccc(CNC(=O)c2cc(-c3cncc(Cl)c3)cnc2-c2ccccn2)nc1OC,MK-1064,Phase 1,orexin receptor antagonist,,,
C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1,MK-1775,Phase 2,WEE1 kinase inhibitor,WEE1,,
O=C(O)c1n[nH]c2c1C[C@H]1C[C@@H]21,MK-1903,Phase 2,niacin receptor agonist,,,
CCN1C[C@H](C)n2c(c(O)c3c(=O)n(Cc4ccc(F)c(Cl)c4)nc(C(=O)NC)c32)C1=O,MK-2048,Preclinical,HIV integrase inhibitor,,,
NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1,MK-2206,Phase 2,AKT inhibitor,AKT1|AKT2|AKT3,,
FC(F)(F)c1ccc(Nc2ncnc3cc(-c4ncccc4C(F)(F)F)ccc23)cc1,MK-2295,Phase 2,TRPV antagonist,TRPV1,,
CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1,MK-2461,Phase 1/Phase 2,FGFR inhibitor|VEGFR inhibitor,FGFR1|FGFR2|FGFR3|FLT1|FLT3|FLT4|KDR|MERTK|MET|MST1R|NTRK1|NTRK2|PDGFRB,,
Cc1sc(C)c(C(=O)NC2(c3ccc(C(=O)O)cc3)CC2)c1Cc1ccc(C(F)(F)F)cc1,MK-2894,Preclinical,prostaglandin inhibitor,PTGER4,,
O=C(CN1C(=O)C2(CCCC2)NC[C@H]1c1cc(F)cc(F)c1)Nc1ccc2c(c1)C[C@@]1(C2)C(=O)Nc2ncccc21,MK-3207,Phase 2,calcitonin antagonist,CALCA,,
COc1ccc(CNC(=O)c2cc(-c3cncc(C)c3)ncc2-c2nccs2)nc1OC,MK-3697,Phase 2,orexin receptor antagonist,HCRTR2,,
COc1cc(C(=O)N2CCC3(CC2)CC(=O)c2cc(-c4cncc(C(=O)O)c4)ccc2O3)cc2c1c(C)cn2C1CC1,MK-4074,Phase 1,acetyl-CoA carboxylase inhibitor,,,
O[C@@](Cc1ncc(CC2(C(F)(F)F)CC2)[nH]1)(c1ccc(-n2cccn2)cc1)C(F)(F)F,MK-5046,Preclinical,bombesin receptor agonist,BRS3|GRPR|NMBR,,
O=C(O)[C@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](Oc2cccc(Cl)c2F)CC1,MK-5108,Phase 1,Aurora kinase inhibitor,AURKA|AURKB|AURKC,,
CN(C)C(=O)CCS[C@@H](SCCC(=O)O)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,MK-571,Phase 2,leukotriene receptor antagonist,ABCC2|CYSLTR1,,
Cc1ccc(-c2ncccn2)c(C(=O)N2C[C@H](COc3ccc(F)cn3)CC[C@H]2C)c1,MK-6096,Phase 2,orexin receptor antagonist,HCRTR1|HCRTR2,,
CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1,MK-7246,Preclinical,CRTH receptor antagonist,,,
Cc1ccc(Cc2cc3c(=O)n([C@H]4CCCC[C@@H]4O)cnc3c3ccccc23)cn1,MK-7622,Phase 2,cholinergic receptor agonist,,,
Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1,MK-8033,Phase 1,c-Met inhibitor,MET,,
O=C(O)Cn1nnc(-c2cc(N3CCC(Oc4cc(F)ccc4Br)CC3)no2)n1,MK-8245,Phase 2,stearoyl-CoA desaturase inhibitor,SCD,,
COc1ccc(C(NC(=O)c2cnc(-c3cccnn3)nc2O)c2ccc(OC)cc2)cc1,MK-8617,Preclinical,hypoxia inducible factor prolyl hydroxylase inhibitor,,,
O=C(c1cccc(Cl)c1F)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1,MK-8745,Preclinical,Aurora kinase inhibitor,AURKA,,
CC(C)c1ccc2c(c1)c(SC(C)(C)C)c(CC(C)(C)C(=O)O)n2Cc1ccc(Cl)cc1,MK-886,Preclinical,lipoxygenase inhibitor,,,
CC(C)c1ccc(CC(=O)N[C@H](C)c2ccc(OCC(F)(F)F)cn2)cc1,MK-8998,Phase 2,T-type calcium channel blocker,,,
O=C(c1ccc(-c2ccc(Cl)cc2)o1)N(Cc1ccccn1)c1ccc(N2CCNCC2)cc1,MK2-IN-1,Preclinical,MAP kinase inhibitor,MAPKAPK2,,
CCn1c(=O)/c(=C2\Sc3ccccc3N2C)s/c1=C/c1cccc[n+]1CC,MKT-077,Phase 1,HSP inhibitor,,,
COc1cc(N)c(Cl)cc1C(=O)OCCN1CCCCC1,ML10302,Preclinical,serotonin receptor partial agonist,HTR3A|HTR3B|HTR4,,
Cc1ccc(S(=O)(=O)n2c(N)nc3ccccc32)cc1,ML130,Preclinical,NOD1 inhibitor,,,
COc1ccc(CNCc2cccc3ccccc23)cc1,ML133,Preclinical,potassium channel blocker,,,
COc1ccc([C@H]2CC(c3ccccc3)=NN2c2ccc(S(N)(=O)=O)cc2)cc1,ML141,Preclinical,GTPase inhibitor,CDC42,,
CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1,ML161,Preclinical,protease-activated receptor inhibitor,,,
Cc1ccc(CNc2ncnc3ccc(-c4ccc(CO)o4)cc23)o1,ML167,Preclinical,CLK inhibitor|DYRK inhibitor,CLK4|DYRK1B,,
O=c1cc(N2CCN(c3cccc(C(F)(F)F)c3)CC2)[nH]c(=O)n1C1CCCCC1,ML179,Preclinical,liver receptor homolog inverse agonist,NR5A2,,
Cc1cc(C)c2nc(-c3ccccn3)cc(C(=O)Nc3ccc(S(=O)(=O)Nc4onc(C)c4C)cc3)c2c1,ML193,Preclinical,G protein-coupled receptor antagonist,GPR55,,
Cc1cc(N2CCCCC2)nc2ccccc12,ML204,Preclinical,transient receptor potential channel antagonist,TRPC4|TRPC5,,
Cc1cc(C)c(NC(=O)[C@@H]2C[C@H]3CC[C@@H]2C3)c(C)c1,ML213,Preclinical,potassium channel activator,KCNQ4,,
CC(C)(C)CCN1C[C@@H]2[C@@H](CNC(=O)c3cc(Cl)cc(Cl)c3)[C@@H]2C1,ML218,Preclinical,T-type calcium channel blocker,CACNA1G|CACNA1H|CACNA1I,,
c1ccc(-c2ccc(CNc3nc(-c4ccccn4)nnc3-c3ccccc3)cc2)cc1,ML228,Preclinical,hypoxia inducible factor activator,HIF1A,,
COc1ccc(-c2csc(NC(=O)[C@H]3CCCCN3S(=O)(=O)c3ccc(C)cc3)n2)cc1,ML277,Preclinical,potassium channel activator,KCNQ1,,
CC(C)c1ccc(NC(=O)c2cccs2)c(-c2nc3ccccc3[nH]c2=O)c1,ML281,Preclinical,serine/threonine kinase inhibitor,STK33,,
Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(-c2ccccc2)n1,ML297,Preclinical,inward rectifier potassium channel activator,KCNJ3,,
O=C(NCCN1CCC2(CC1)C(=O)NCN2c1cccc(F)c1)c1ccc(F)c(F)c1,ML298,Preclinical,phospholipase inhibitor,PLD2,,
COc1cc2nc(C3CC3)nc(N3CCN(c4ccccc4OC)CC3)c2cc1OC,ML314,Preclinical,neurotensin agonist,NTSR1,,
Cc1cnc(-c2ccccc2C(C)C)nc1NCc1ccc(-n2ccnn2)cc1,ML323,Preclinical,ubiquitin specific protease inhibitor,USP1,,
CN(C)CCCNC(=O)c1ccc(-c2cc(O)c3ncccc3c2)cc1,ML324,Preclinical,histone lysine demethylase inhibitor,KDM4A,,
CSc1nc(-c2ccnc(N[C@@H](C)c3ccccc3)c2)c(-c2ccc(F)cc2)[nH]1,ML3403,Preclinical,MAP kinase inhibitor,CYP3A4|MAPK11|MAPK12|MAPK14,,
COc1ccc(-c2cnc3c(-c4cccc5ncccc45)cnn3c2)cc1,ML347,Preclinical,ALK tyrosine kinase receptor inhibitor,ACVR1|ACVRL1|BMPR1A,,
O=C(CN1CCN(C(=O)c2ccco2)CC1)Nc1cc(C(F)(F)F)ccc1Cl,ML348,Preclinical,lysophospholipase inhibitor,LYPLA1,,
COc1ccccc1C(=O)Nc1cccc(NC(=O)c2cccc(C)c2)c1,ML365,Preclinical,potassium channel blocker,KCNK3|KCNK9,,
CC(C)(N)c1cc(C(=O)N[C@@H]2CCc3ccc(Oc4ccnc5c4CCC(=O)N5)cc3C2)cc(C(F)(F)F)c1,ML786,Preclinical,RAF inhibitor,BRAF|RAF1,,
O=S(=O)(c1cccc2c(Cl)cccc12)N1CCCNCC1,ML9,Preclinical,myosin light chain kinase inhibitor,TRPC6,,
CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21,MLN0128,Phase 2,mTOR inhibitor,MTOR|PIK3CA|PIK3CD|PIK3CG,,
Nc1nc2cc(-c3ccc4ncc(C(=O)N5CCOCC5)n4c3)ccc2o1,MLN1117,Phase 2,PI3K inhibitor,PIK3CA,,
C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1,MLN2480,Phase 1/Phase 2,RAF inhibitor,,,
O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1,MLN8054,Phase 1,Aurora kinase inhibitor,AURKA,,
CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(=O)O)(CC(=O)O)O1,MLN9708,Phase 3,proteasome inhibitor,,,
CCC(CC)(NC(=O)C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NC1(C(=O)NC(c2ccc(F)cc2)c2ccc(F)cc2)CCCC1,MM-102,Preclinical,WDR5/MLL interaction inhibitor,,,
CC1(C)CCC(C)(C)c2cc(C3(c4ccc5cc(C(=O)O)ccc5c4)SCCS3)ccc21,MM-11253,Preclinical,retinoid receptor antagonist,RARG,,
O=S(=O)(Nc1cc(Sc2ccccc2)c(O)c2ccccc12)c1c(F)c(F)c(F)c(F)c1F,MM-206,Preclinical,STAT inhibitor,,,
COc1ccccc1N1CCN(CCCCN2C(=O)CCC2=O)CC1,MM77,Preclinical,serotonin receptor antagonist,HTR1A,,
COCc1nc2c([nH]1)c(=O)n(C)c(=O)n2CC(C)C,MMPX,Preclinical,phosphodiesterase inhibitor,,,
CS(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc(C(F)(F)F)nc3)c2)cc1,MMV-390048,Preclinical,PI4K inhibitor,,,
CC(C)c1ccc(-c2cc(=O)c3ccccc3o2)cc1,MN-64,Preclinical,tankyrase inhibitor,TNKS,,
Cn1cnnc1Sc1c([N+](=O)[O-])ncn1C,MNITMT,Preclinical,lymphocyte inhibitor,,,
Nc1ccccc1NC(=O)c1ccc(CNc2nccc(-c3cccnc3)n2)cc1,mocetinostat,Phase 2,HDAC inhibitor,HDAC1|HDAC11|HDAC2|HDAC3,,
O=C(NCCN1CCOCC1)c1ccc(Cl)cc1,moclobemide,Launched,monoamine oxidase inhibitor,MAOA|MAOB,neurology/psychiatry,depression|anxiety
Cc1nccnc1N1CCCCC1,modaline,Preclinical,,,,
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(=O)O,moexipril,Launched,angiotensin converting enzyme inhibitor,ACE|ACE2,cardiology,hypertension
NC/C(=C/F)CCc1ccc(F)cc1,mofegiline,Phase 1,monoamine oxidase inhibitor,MAOA|MAOB,,
COc1ccc(-c2noc(CC(=O)O)c2-c2ccc(OC)cc2)cc1,mofezolac,Launched,cyclooxygenase inhibitor,PTGS1,rheumatology|orthopedics,rheumatoid arthritis|osteoporosis
CCOC(=O)CC(=O)N1CCS[C@@H]1COc1ccccc1OC,moguisteine,Phase 2,ATP-sensitive potassium channel inhibitor,,,
O=c1c(-n2ccnn2)c[nH]n1-c1cc(N2CCOCC2)ncn1,molidustat,Phase 3,hypoxia inducible factor inhibitor,EGLN2,,
CCc1c(C)[nH]c2c1C(=O)[C@H](CN1CCOCC1)CC2,molindone,Launched,dopamine receptor antagonist,DRD2|HRH1|HTR2A,neurology/psychiatry,schizophrenia
CCOC(=O)Nc1c[n+](N2CCOCC2)no1,molsidomine,Launched,guanylate cyclase stimulant,GUCY1A3,cardiology,coronary artery disease (CAD)
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,mometasone,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,mometasone-furoate,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses
CCOC(=O)C1=C(C)NC(=S)N[C@@H]1c1cccc(O)c1,monastrol,Preclinical,kinesin inhibitor,KIF11,,
CC[C@@]1([C@@H]2O[C@@H]([C@H]3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)C[C@@H]2C)CC[C@H]([C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(=O)O)O3)O2)O1,monensin,Launched,bacterial permeability inducer,,infectious disease,gastrointestinal parasites
C[C@](C#N)(COc1cc(C#N)ccc1C(F)(F)F)NC(=O)c1ccc(SC(F)(F)F)cc1,monepantel,Preclinical,mTOR inhibitor,,,
Oc1ccc(OCc2ccccc2)cc1,monobenzone,Launched,melanin inhibitor,TYR,dermatology,skin depigmentation
C[C@H]1C(=O)O[C@@H]2CCN3CC=C(COC(=O)[C@](C)(O)[C@]1(C)O)[C@H]23,monocrotaline,Preclinical,antitumor agent,,,
CCCCCCCC(=O)OC[C@@H](O)CO,monoctanoin,Launched,,,gastroenterology,gallstones
COC(=O)/C=C/C(=O)O,monomethyl-fumarate,Launched,,,neurology/psychiatry,multiple sclerosis
Nc1cccc2c(=O)[nH][nH]c(=O)c12,monosodium-alpha-luminol,Launched,,,,
CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)CO,monostearin,Preclinical,,,,
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,montelukast,Launched,leukotriene receptor antagonist,ALOX5|CYSLTR1,pulmonary|allergy,asthma|allergic rhinitis|exercise-induced bronchoconstriction (EIB)
COc1ccccc1OC[C@@H](O)CNC(C)C,moprolol,Launched,adrenergic receptor antagonist,,cardiology|ophthalmology|neurology/psychiatry,hypertension|glaucoma|anxiety
Cc1ccsc1/C=C/C1=NCCCN1C,morantel,Launched,acetylcholine receptor agonist,,infectious disease,tapeworm
O=c1c(O)c(-c2ccc(O)cc2O)oc2cc(O)cc(O)c12,morin,Preclinical,cytochrome P450 inhibitor,ADORA2A|ESR2|FASN|MCL1|SLC22A12,,
Cc1ncc([N+](=O)[O-])n1C[C@@H](O)CN1CCOCC1,morinidazole,Launched,other antibiotic,CYP51A1,,
O=C(OCCN1CCOCC1)c1cccnc1Nc1cccc(C(F)(F)F)c1,morniflumate,Launched,anti-inflammatory agent,,neurology/psychiatry,pain relief
N=C(N)/N=C(\N)N1CCOCC1,moroxydine,Launched,antiviral,,infectious disease,influenza A virus infection
CCOC(=O)C1=C(CN2CCOCC2)NC(c2nccs2)=N[C@@H]1c1ccc(F)cc1Br,morphothiadin,Preclinical,antiinfective drug,,,
CCOc1cc(N)c(Cl)cc1C(=O)NC[C@H]1CN(Cc2ccc(F)cc2)CCO1,mosapride,Launched,serotonin receptor agonist,HTR4,gastroenterology,hypertrophic gastritis (GHG)|gastroesophageal reflux disease (GERD)|dyspepsia|irritable bowel syndrome
CC1=C(c2cc(-n3ccnc3)cs2)NNC(=O)C1,motapizone,Preclinical,phosphodiesterase inhibitor,,,
CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21,motesanib,Phase 3,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FLT1|FLT4|KDR|KIT,,
CCCN(CCC)C(=O)C1=Cc2ccc(-c3ccc(C(=O)N4CCCC4)cc3)cc2N=C(N)C1,motolimod,Phase 2,toll-like receptor agonist,TLR8,,
CO[C@@]1(NC(=O)[C@@H](C(=O)O)c2ccc(O)cc2)C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CO[C@@H]21,moxalactam,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections|gram-negative bacterial infections|skin infections|bone and joint infections|pneumonia|urinary tract infections|meningitis
CCc1cc2cc(OC)c(OC)cc2c(Cc2ccccc2)n1,moxaverine,Launched,phosphodiesterase inhibitor,,neurology/psychiatry,spasms
CO/N=C1\C[C@]2(C[C@@H]3C[C@@H](C/C=C(\C)C[C@@H](C)/C=C/C=C4\CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@H](/C(C)=C/C(C)C)[C@H]1C,moxidectin,Launched,chloride channel antagonist,,infectious disease,gastrointestinal parasites
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,moxifloxacin,Launched,bacterial DNA gyrase inhibitor,TOP2A,otolaryngology|pulmonary|infectious disease,sinusitis|bronchitis|pneumonia|skin infections|intra-abdominal infections
COc1nc(C)nc(Cl)c1NC1=NCCN1,moxonidine,Launched,imidazoline receptor agonist,ADRA2A|ADRA2B|ADRA2C,cardiology,hypertension
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@H](N(C)C)c3ccccc32)cc1,mozavaptan,Launched,vasopressin receptor antagonist,AVPR1A|AVPR1B|AVPR2,endocrinology,hyponatremia
Cc1cccc(C#Cc2ccccc2)n1,MPEP,Preclinical,glutamate receptor antagonist,GRM1|GRM4|GRM5,,
Cc1cc(N2CCOCC2)ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1,MPI-0479605,Preclinical,mitotic kinase inhibitor,TTK,,
CC(C)CNc1nc(-c2cccc3ncccc23)cn2c(-c3ccc(C(=O)NC4CC4)cc3)cnc12,Mps-BAY-2a,Preclinical,monopolar spindle 1 kinase inhibitor,TTK,,
COc1cc(N2CCC(O)CC2)ccc1Nc1cc(Nc2ccccc2S(=O)(=O)C(C)C)c2cc[nH]c2n1,Mps1-IN-1,Preclinical,monopolar spindle 1 kinase inhibitor,TTK,,
COc1cc(S(C)(=O)=O)ccc1Nc1nc2ccc(-c3ccc(NC(=O)[C@H](C)c4ccc(F)cc4)cc3)cn2n1,Mps1-IN-5,Phase 1,protein kinase inhibitor,,,
O=C(NCCCN1CCCCCC1)[C@H](c1ccccc1)C1CCCCC1,MR-16728,Preclinical,acetylcholine release enhancer,,,
OCCc1ccc(OCCn2ccnc2)cc1,MR-948,Phase 1,thromboxane synthase inhibitor,TBXAS1,,
Cc1cc(-c2nncc3c(C(C)(C)C)c(OCc4ncnn4C)nn23)no1,MRK-016,Phase 1,GABA receptor inverse agonist,GABRA1|GABRA2|GABRA3|GABRA5,,
Cn1ncnc1COc1nn2c(-c3c(F)cccc3F)nnc2cc1C1CCC1,MRK-409,Phase 1,benzodiazepine receptor agonist,,,
O=S(=O)(N[C@H]1CC[C@@](c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F,MRK-560,Preclinical,gamma secretase inhibitor,APP,,
O=C(Cc1ccccc1)Nc1nc2ccc(Cl)cc2c2nc(-c3ccco3)nn12,MRS-1220,Preclinical,adenosine receptor antagonist,ADORA2B|ADORA3,,
CCOC(=O)C1=C(C)NC(c2ccccc2)=C(C(=O)OCc2ccc([N+](=O)[O-])cc2)[C@@H]1C#Cc1ccccc1,MRS-1334,Preclinical,adenosine receptor antagonist,ADORA3,,
C#CCN1C(C)=C(C(=O)OC)[C@H](c2cccc([N+](=O)[O-])c2)C(C(=O)OCC)=C1C,MRS-1845,Preclinical,calcium channel blocker,,,
S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(N=C=S)c2)c1,MRS-2578,Preclinical,purinergic receptor antagonist,P2RY6,,
c1ccc(Oc2nc(NC3CCCCC3)c3[nH]cnc3n2)cc1,MRS-3777,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
c1ccc(Oc2nc(NC3CCCCC3)c3[nH]cnc3n2)cc1.c1ccc(Oc2nc(NC3CCCCC3)c3[nH]cnc3n2)cc1,MRS-3777,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
CN1CCN(Cc2ccc(-c3cn([C@H]4CC[C@H](O)CC4)c4nc(NCCC5CC5)ncc34)cc2)CC1,MRX-2843,Phase 1,MER tyrosine kinase inhibitor,,,
C[C@@H]1C=CNN1C(=O)c1cccnc1,MS-424,Phase 2,glutamate transporter modulator,,,
CCc1ccc(C(=O)COc2ccc(C[C@@H]3SC(=O)NC3=O)cc2)nc1,MSDC-0160,Phase 2,insulin sensitizer,,,
COc1cccc(C(=O)COc2ccc(Cc3sc(O)nc3O)cc2)c1,MSDC-0602K,Phase 2,mitochondrial pyruvate carrier modulator,,,
c1cnc(NCc2ccc(CNc3ncccn3)cc2)nc1,MSX-122,Phase 2,CC chemokine receptor antagonist,CXCR4,,
C[C@@](N)(C(=O)O)c1ccc(-c2nn[nH]n2)cc1,MTPG,Preclinical,glutamate receptor antagonist,GRM2|GRM3,,
FC(F)(F)c1ccc(/C=C/c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1,mubritinib,Phase 1,protein tyrosine kinase inhibitor,EGFR|ERBB2,,
C/C(=C\C(=O)OCCCCCCCCC(=O)O)C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O,mupirocin,Launched,isoleucyl-tRNA synthetase inhibitor,,infectious disease,impetigo
NCc1cc(=O)[nH]o1,muscimol,Phase 1,benzodiazepine receptor agonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRR1|GABRR2|GABRR3,,
CCc1cc(O)c(Oc2ccc(C(N)=O)cc2F)cc1F,MUT056399,Phase 1,FABI inhibitor,,,
Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1,MY-5445,Preclinical,phosphodiesterase inhibitor|platelet aggregation inhibitor,PDE5A,,
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,mycophenolate-mofetil,Launched,dehydrogenase inhibitor|inositol monophosphatase inhibitor,IMPDH1|IMPDH2,transplant,organ rejection
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)O)C(=O)OC2,mycophenolic-acid,Launched,dehydrogenase inhibitor|inositol monophosphatase inhibitor,IMPDH1|IMPDH2,transplant,organ rejection
O=c1c(O)c(-c2cc(O)c(O)c(O)c2)oc2cc(O)cc(O)c12,myricetin,Preclinical,androgen receptor agonist|cytochrome P450 inhibitor,PIK3CG,,
C[C@@H]1O[C@@H](Oc2c(-c3cc(O)c(O)c(O)c3)oc3cc(O)cc(O)c3c2=O)[C@H](O)[C@H](O)[C@H]1O,myricitrin,Preclinical,PKC inhibitor,NOS1|PRKCA,,
CCCCCCCCCCCCCCOC(=O)c1cccnc1,myristyl-nicotinate,Phase 1,topical sunscreen agent,,,
CC(=NNC(=S)NNC(=S)Nc1ccccc1Cl)c1ccccn1,N-(2-chlorophenyl)-2-({(2E)-2-[1-(2-pyridinyl)ethylidene]hydrazino}carbothioyl)hydrazinecarbothioamide,Preclinical,,,,
CCCCCc1ccc(/C=C/C(=O)Nc2ccccc2C(=O)O)cc1,N-(p-amylcinnamoyl)-anthranilic-acid,Preclinical,phospholipase inhibitor,,,
O=C(NCCN1CCCCC1)c1ccc(I)cc1,N-[2-(piperidinylamino)ethyl]-4-iodobenzamide,Preclinical,sigma receptor ligand,,,
CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO,N-acetyl-D-glucosamine,Phase 2/Phase 3,,B4GALT1|B4GALT2|B4GALT3|B4GALT4|NAGK|NAGLU|NAGPA|RENBP,,
CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O,N-acetyl-tyrosine,Launched,,,,
CC(=O)NCCC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)O,N-acetylcarnosine,Launched,,,,
CC(=O)NCC(=O)N[C@H](CCC(=O)O)C(=O)O,N-acetylglycyl-D-glutamic-acid,Preclinical,glutamate receptor agonist,,,
CC(=O)N[C@@H]1[C@H](O)[C@H](O)[C@H](CO)O[C@@H]1O,N-acetylmannosamine,Phase 2,,,,
CC(=O)NCCc1c[nH]c2ccccc12,N-acetyltryptamine,Preclinical,melatonin receptor agonist,,,
CNCCc1cnc[nH]1,N-alpha-methylhistamine-dihydrochloride,Phase 3,histamine receptor agonist,HRH4,,
Oc1ccc2c3c1O[C@H]1c4c(c5ccccc5n4Cc4ccccc4)C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314,N-benzylnaltrindole,Preclinical,opioid receptor antagonist,,,
c1ccc2sc(SNC3CCCCC3)nc2c1,N-cyclohexyl-2-benzothiazolesulfenamide,Preclinical,,,,
O=C(NO)c1cccnc1,N-hydroxynicotinamide,Preclinical,,,,
C[C@@H]([C@H](O)c1ccccc1)N(C)C,"N-methyl-(-)ephedrine-[1R,2S]",Preclinical,,,,
CC[N+](C)(CC)CC(=O)Nc1c(C)cccc1C,N-methyllidocaine-iodide,Preclinical,antiarrhythmic medication,,,
CN1CCCC1=O,N-methylpyrrolidone,Phase 1,,,,
CN1CCN(c2ccc3ccccc3n2)CC1,N-methylquipazine,Preclinical,serotonin receptor agonist,,,
CN(C(=O)Cc1ccccc1)[C@H](CN1CCCC1)c1ccccc1,N-MPPP,Preclinical,opioid receptor agonist,,,
c1ccc2sc(SN3CCOCC3)nc2c1,N-oxydiethylenebenzothiazole-2-sulfenamide,Preclinical,,,,
O=C(Nc1ccc(O)cc1)c1ccccc1O,N-salicoylaminophenol,Phase 1/Phase 2,ribonucleotide reductase inhibitor,,,
NC(=O)CNCCC(c1ccccc1)c1ccccc1,N20C,Preclinical,glutamate receptor antagonist,,,
OC[C@H]1O[C@@H](n2cnc3c(NC4CCCC4)ncnc32)[C@H](O)[C@@H]1O,N6-cyclopentyladenosine,Preclinical,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3|SLC29A1,,
CNc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,N6-methyladenosine,Preclinical,,,,
Cc1cc(C(N)=O)ccc1-n1c(CCC(=O)O)ccc1-c1ccc(-n2ccnc2)cc1,N6022,Phase 1/Phase 2,alcohol dehydrogenase inhibitor,ADH5,,
Cc1ccc(C)c(-n2cnc3cc(C(=O)NCc4ccccc4Cl)ccc32)c1,NAB-2,Preclinical,ubiquitin ligase transport promoter,NEDD4,,
COc1ccc2cc(CCC(C)=O)ccc2c1,nabumetone,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,rheumatoid arthritis|osteoarthritis
NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)c1,nadide,Launched,free radical scavenger,AHCY|AKR1A1|ALDH2|BLVRA|DHPS|DLD|GALE|HMGCR|HSD17B1|HSD17B4|IMPDH2|MGAM|P2RY11|SORD|TRPM2,,
C[C@H]1CCc2c(N3CCC(O)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,nadifloxacin,Launched,bacterial DNA gyrase inhibitor,,dermatology|infectious disease,acne vulgaris (AV)|skin infections
CC(C)(C)NC[C@@H](O)COc1cccc2c1C[C@H](O)[C@H](O)C2,nadolol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,cardiology,angina pectoris|hypertension
NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1.NC1CCCCC1.NC1CCCCC1.NC1CCCCC1.NC1CCCCC1,NADPH,Preclinical,,DRD2|DRD3|DRD4|GHSR|HTR2A|HTR2C,,
CCCCN1CCC[C@@H]1CNC(=O)c1cc(C#N)c2ccccc2c1OC,nafadotride,Preclinical,dopamine receptor antagonist,DRD2|DRD3|HTR1A,,
N=C(N)Nc1ccc(C(=O)Oc2ccc3cc(C(=N)N)ccc3c2)cc1,nafamostat,Launched,serine protease inhibitor,ASIC1|ASIC2|ASIC3|C1R|PRSS1|TPSAB1|TRPM7,cardiology,anticoagulent
CCOc1ccc2ccccc2c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O,nafcillin,Launched,bacterial cell wall synthesis inhibitor,CYP1A2|CYP3A4|SLC22A6,infectious disease,gram-positive bacterial infections
CCN(CC)CCOC(=O)[C@H](Cc1cccc2ccccc12)C[C@H]1CCCO1,naftidrofuryl,Launched,adrenergic receptor antagonist,,cardiology,claudication
CN(C/C=C/c1ccccc1)Cc1cccc2ccccc12,naftifine,Launched,fungal squalene epoxidase inhibitor,,infectious disease,tinea pedis|tinea cruris|tinea corporis
COc1ccccc1N1CCN(C[C@@H](O)COc2cccc3ccccc23)CC1,naftopidil,Launched,adrenergic receptor antagonist,ADRA1A,urology,benign prostatic hyperplasia (BPH)
Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314,nalbuphine,Launched,opioid receptor agonist|opioid receptor antagonist,OPRD1|OPRK1|OPRM1,neurology/psychiatry,pain relief
CN(C(=O)/C=C/c1ccoc1)[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,nalfurafine,Launched,opioid receptor agonist,OPRK1|OPRM1,nephrology,uremic pruritus
CCn1cc(C(=O)O)c(=O)c2ccc(C)nc21,nalidixic-acid,Launched,bacterial DNA gyrase inhibitor,,infectious disease,urinary tract infections
C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,nalmefene,Launched,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,pulmonary,respiratory depression
C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](OCCOCCOCCOCCOCCOCCOCCOC)CC[C@@]3(O)[C@H]1C5,naloxegol,Launched,opioid receptor antagonist,OPRM1,gastroenterology,constipation
C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,naloxone,Launched,opioid receptor antagonist,CREB1|ESR1|OPRD1|OPRK1|OPRM1|TLR4,pulmonary,respiratory depression
C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2/C(=N/NC(=O)c2ccccc2)CC[C@@]3(O)[C@H]1C5,naloxone-benzoylhydrazone,Preclinical,opioid receptor antagonist,OPRK1|OPRM1,,
O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,naltrexone,Launched,opioid receptor antagonist,OPRD1|OPRK1|OPRM1|SIGMAR1,neurology/psychiatry,abstinence from alcohol
Oc1ccc2c3c1O[C@H]1c4oc5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314,naltriben,Preclinical,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,,
Oc1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314,naltrindole,Preclinical,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,,
CC(C)(O)CS(=O)(=O)Nc1ccc2c(c1)CCN(C(=O)COc1cccnc1)C2,Nampt-IN-1,Preclinical,,,,
COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1,NAN-190,Preclinical,serotonin receptor agonist,ADRA1A|ADRA1B|ADRA1D|HTR1A|HTR1F,,
CO[C@H]1CC[C@@H](O[C@H]2C[C@H]([C@]3(C)CC[C@]4(C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)/C=C(\C)C(=O)[C@H](C)C[C@H](C)C(=O)O)O4)O3)O[C@]3(O[C@@H]([C@H]4O[C@@](O)(CO)[C@H](C)C[C@@H]4C)C[C@@H]3C)[C@@H]2C)O[C@@H]1C,nanchangmycin,Preclinical,other antibiotic,,,
CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O,napabucasin,Phase 3,STAT inhibitor,STAT3,,
C1=C(CC2=NCCN2)CCc2ccccc21,napamezole,Preclinical,adrenergic receptor antagonist|monoamine reuptake inhibitor,,,
c1ccc2c(CC3=NCCN3)cccc2c1,naphazoline,Launched,adrenergic receptor agonist,ADRA1A|ADRA2A,ophthalmology,eye irritation
CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)c2c(c1O)CCCC2,naphthoquine-phosphate,Launched,antimalarial agent,,infectious disease,malaria
Cn1cc(C(=O)c2cccc3ccccc23)cc1C(=O)O,napirimus,Phase 1,immunosuppressant,,,
COc1ccc2cc([C@H](C)C(=O)O)ccc2c1,naproxen,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry|rheumatology|dental|otolaryngology|endocrinology,pain relief|rheumatoid arthritis|headache|toothache|backache|muscle pain|common cold|fever
C=CC(=O)N1CC[C@@H](Oc2nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3)c(C(N)=O)nc2CC)C1,naquotinib,Phase 3,EGFR inhibitor,,,
CC[C@@H](C(=O)O)[C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@]3(C=C[C@@H](O)[C@]4(CC[C@@](C)([C@H]5CC[C@](O)(CC)[C@H](C)O5)O4)O3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C,narasin,Launched,antiprotozoal agent,,infectious disease,coccidiosis
CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1,naratriptan,Launched,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F,neurology/psychiatry,migraine headache
O=C1C[C@@H](c2ccc(O)cc2)Oc2cc(O)cc(O)c21,naringenin,Phase 1,aromatase inhibitor|TRPV antagonist,CYP19A1|CYP1B1|ESR2|GLO1|HSD17B1,,
O=C(O)/C=C/c1ccc(O)cc1,naringeninic-acid,Phase 1,,HCAR2|PTGR1,,
C[C@@H]1O[C@@H](O[C@H]2[C@H](Oc3cc(O)c4c(c3)O[C@H](c3ccc(O)cc3)CC4=O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O,naringin,Preclinical,cytochrome P450 inhibitor,SLCO1A2,,
C[C@@H]1O[C@@H](O[C@H]2[C@H](Oc3cc(O)c(C(=O)CCc4ccc(O)cc4)c(O)c3)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O,naringin-dihydrochalcone,Preclinical,cytochrome P450 inhibitor,,,
CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1,narlaprevir,Phase 3,HCV inhibitor,,,
C1=C(CN2CCOCC2)COc2c1cccc2OC[C@H]1CNCCO1,NAS-181,Preclinical,serotonin receptor antagonist,HTR1B,,
CC(C)(C)C(=O)CN1C(=O)[C@H](NC(=O)Nc2cccc(C(=O)O)c2)CN(C2CCCCC2)c2ccccc21,nastorazepide,Phase 2,CCK receptor antagonist,CCKBR,,
C[C@@H]1C/C=C/C=C/C=C/C=C/[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)C[C@@H]2O[C@](O)(C[C@@H](O)C[C@H]3O[C@@H]3/C=C/C(=O)O1)C[C@H](O)[C@H]2C(=O)O,natamycin,Launched,fungal ergosterol inhibitor,,ophthalmology|infectious disease,conjunctivitis|fungal keratosis|blepharitis
CC(C)[C@H]1CC[C@H](C(=O)N[C@H](Cc2ccccc2)C(=O)O)CC1,nateglinide,Launched,insulin secretagogue,ABCC8|KCNJ10|KCNJ11|PPARG,endocrinology,diabetes mellitus
O=C(NCc1ccc(OC(F)(F)F)cc1)[C@@H]1c2ccccc2C(=O)N1C1CCOCC1,NAV-26,Preclinical,voltage-gated sodium channel blocker,SCN9A,,
CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1,navarixin,Phase 2,CC chemokine receptor antagonist,CXCR1|CXCR2,,
CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,navitoclax,Phase 2,BCL inhibitor,BCL2|BCL2L1|BCL2L2,,
CCCN1CCO[C@@H]2c3cc(O)ccc3CC[C@H]21,naxagolide,Phase 3,dopamine receptor agonist,,,
Nc1ncnc2c1ncn2CCNCCCCCO,NB-001,Preclinical,antiviral,,,
CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl,NBI-27914,Preclinical,corticotropin releasing factor receptor antagonist,CRHR1,,
CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(F)c(C(F)(F)F)c3)nc3ncccc3c2=O)cc1,NBI-74330-(+/-),Preclinical,CC chemokine receptor antagonist,CXCR3,,
COc1cc2c(cc1OC)[C@H]1C[C@@H](O)[C@H](CC(C)C)CN1CC2,NBI-98782,Preclinical,vesicular monoamine transporter inhibitor,,,
NS(=O)(=O)c1cccc2c1c([N+](=O)[O-])cc1[nH]c(=O)c(=O)[nH]c12,NBQX,Preclinical,glutamate receptor antagonist,GRIA1|GRIA2|GRIA3|GRIA4|GRIK1|GRIN1|GRIN2A|GRIN2B,,
O=C(O)/C=C1\CCCc2ccccc2[C@H]1O,NCS-382,Preclinical,GABA receptor antagonist,GABBR1|GABBR2|SLC52A2,,
C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)c1ccc(CO[N+](=O)[O-])cc1,NCX-1015,Preclinical,interleukin sythesis stimulator,,,
Cc1nccn1Cc1ccccn1,NDD-094,Preclinical,,,,
CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc2c(c1)OCO2)Cc1ccc2c(c1)OCO2,NDT-9513727,Preclinical,complement antagonist,C5AR1,,
CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1,NE-100,Phase 2,sigma receptor antagonist,SIGMAR1,,
O[C@H](CNC[C@@H](O)[C@H]1CCc2cc(F)ccc2O1)[C@@H]1CCc2cc(F)ccc2O1,nebivolol,Launched,adrenergic receptor antagonist,ADRB1,cardiology,hypertension
NC[C@@H]1CC(=O)N(Cc2ccccc2)C1,nebracetam,Phase 3,acetylcholine receptor agonist,CHRM1,,
CCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O,NECA,Launched,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
CN1C(=O)[C@H](Cc2c[nH]c3ccccc23)NC1=S,necrostatin-1,Preclinical,RIPK inhibitor,RIPK1,,
CN1C(=O)N[C@H](Cc2c[nH]c3c(Cl)cccc23)C1=O,necrostatin-2,Preclinical,necroptosis inhibitor|RIPK inhibitor,RIPK2,,
CCCc1c2oc(C(=O)O)cc(=O)c2cc2c(=O)cc(C(=O)O)n(CC)c12,nedocromil,Launched,histamine receptor antagonist,CYSLTR1|CYSLTR2|FPR1|HSP90AA1|PTGDR,neurology/psychiatry|ophthalmology,itching|conjunctivitis
Cc1cccc(C)c1NC(=O)CN1CCCC1=O,nefiracetam,Phase 3,acetylcholine receptor agonist|benzodiazepine receptor agonist,CHRM1,,
CN1CCO[C@@H](c2ccccc2)c2ccccc2C1,nefopam,Launched,cyclooxygenase inhibitor,,neurology/psychiatry,pain relief
COc1nc(N)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,nelarabine,Launched,DNA synthesis inhibitor|T cell inhibitor,POLA1,hematologic malignancy,acute lymphoblastic leukemia (ALL)
Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,nelfinavir,Launched,HIV protease inhibitor,CYP1A2|CYP2B6|CYP2C19|CYP2C9|CYP2D6|CYP3A4|CYP3A7,infectious disease,human immunodeficiency virus (HIV-1)
COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncccc23)nc1N,nelociguat,Preclinical,guanylate cyclase stimulant,,,
COc1ccc(NC(=O)Nc2ccc(F)cc2F)cc1-c1c(Br)cnn1C,nelotanserin,Phase 2,serotonin receptor inverse agonist,,,
Nc1c(Cl)cc(C=C2NCCN2)cc1Cl,nemazoline,Phase 2,adrenergic receptor agonist|adrenergic receptor antagonist,,,
CC(C)N1CCN(Cc2cnc(-c3cc(-c4cccc5[nH]ccc45)cc4[nH]ncc34)o2)CC1,nemiralisib,Phase 2,,,,
CNc1cc(OC)c(C(=O)N[C@@H]2CCN(Cc3ccccc3)[C@@H]2C)cc1Cl,nemonapride,Launched,dopamine receptor antagonist,DRD2|DRD3|DRD4,neurology/psychiatry,schizophrenia
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3ccc(Cl)c(C)c3[nH]2)c1,nemorexant,Preclinical,orexin receptor antagonist,,,
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N2CCO[C@H](OC)C2)[C@H](O)[C@H](C)O1,nemorubicin,Phase 2,topoisomerase inhibitor,TOP1|TOP2A,,
CCC[N@+]12[C@H](O)[C@@H](CC)[C@@H]3C[C@@H]1[C@@H]1N(C)c4ccccc4[C@]14C[C@H]2[C@@H]3[C@@H]4O,neo-gilurytmal,Launched,,,cardiology,cardiac arrythmia
COc1ccc([C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)cc3O2)cc1O,neohesperidin,Preclinical,,,,
COc1ccc(CCC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)cc2O)cc1O,neohesperidin-dihydrochalcone,Preclinical,,,,
NC[C@@H]1O[C@H](O[C@H]2[C@@H](O)[C@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)O[C@@H]2CO)[C@H](N)[C@@H](O)[C@@H]1O,neomycin,Launched,bacterial 30S ribosomal subunit inhibitor,CXCR4,infectious disease|gastroenterology,first-aid antibiotic|hepatic encephalopathy (HE)|intra-abdominal infections
CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1,neostigmine,Launched,acetylcholinesterase inhibitor,ACHE,neurology/psychiatry,myasthenia gravis
NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N,nepafenac,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,ophthalmology,eye inflammation
NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1,nepicastat,Phase 2,dopamine beta hydroxylase inhibitor,DBH,,
CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,neratinib,Launched,EGFR inhibitor,EGFR|ERBB2|KDR,oncology,breast cancer
Cc1oncc1C(=O)N1CCCCC1,nerbacadol,Phase 3,cyclooxygenase inhibitor,,,
CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(CCO)S(C)(=O)=O)c(C3CC3)cc12,nesbuvir,Phase 2,RNA polymerase inhibitor,,,
CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O,netilmicin,Launched,protein synthesis inhibitor,,infectious disease,gram-negative bacterial infections
Cc1ccccc1-c1cc(N2CCN(C)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,netupitant,Launched,tachykinin antagonist,TACR1,gastroenterology,nausea|vomiting
O=C(O)c1cc(NCc2c(F)c(F)c(C(F)(F)F)c(F)c2F)ccc1O,Neu2000,Phase 2,ionotropic glutamate receptor antagonist,,,
COc1ccc(-c2nc(-c3ccc(-c4cccc(Cl)c4)o3)[nH]c2-c2ccc(OC)cc2)cc1,neurodazine,Preclinical,neurogenesis of non-pluripotent C2C12 myoblast inducer,,,
CCOC(=O)c1ccc(N(C)c2csc(-c3ccccc3)n2)cc1,neuropathiazol,Preclinical,neural stem cell inducer,BMP2|LIF,,
Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1,nevirapine,Launched,non-nucleoside reverse transcriptase inhibitor,CYP1A2|CYP2A6|CYP2B6|CYP2C9|CYP2D6|CYP3A4|CYP3A5,infectious disease,human immunodeficiency virus (HIV-1)
CCCCN(Cc1ccc(C(=O)NO)cc1)C(=O)Nc1ccccc1,nexturastat-A,Preclinical,HDAC inhibitor,HDAC1|HDAC6,,
Cc1ccc(NCCCc2ccccc2)c(N)c1,NFKB-activation-inhibitor-II,Preclinical,NFkB pathway inhibitor,RELA,,
NC(=N[N+](=O)[O-])NCCC[C@H](N)C(=O)O,NG-nitro-arginine,Phase 1,nitric oxide synthase inhibitor,NOS1|NOS2|NOS3,,
O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2c(c1)Cc1ccccc1-2,NGB-2904,Preclinical,dopamine receptor antagonist,DRD3,,
c1ccc(-c2ncc(CN3CCN(c4ncccn4)CC3)[nH]2)cc1,NGD-94-1,Phase 1,dopamine receptor antagonist,DRD4,,
CCC(CC)Nc1nc(C)c(-c2ccc(OC(F)(F)F)cc2OC)nc1OC,NGD-98-2,Preclinical,corticotropin releasing factor receptor antagonist,CRHR1,,
CCc1cc(Nc2nc(-c3ccc(-n4cnc(C)c4)c(F)c3)cs2)c(C)cc1C,NGP555,Phase 1,gamma secretase modulator,,,
CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C,NH125,Preclinical,eukaryotic translation elongation factor 2 inhibitor,,,
COC(=O)c1cc2c(C(F)(F)F)cc(-c3ccccc3)cc2n1O,NHI-2,Preclinical,lactate dehydrogenase inhibitor,LDHA,,
COc1cc(C#N)ccc1S(=O)(=O)Nc1ccc2c(c1)cc(C)c(=O)n2C,NI-57,Preclinical,bromodomain inhibitor,BRD1|BRPF1|BRPF3,,
O=C(O)c1cccnc1,niacin,Launched,NAD precursor|vitamin B,DGAT2|HCAR1|HCAR2|HCAR3|NNMT|QPRT,endocrinology,hypertriglyceridemia
CCN(CC)CCCC[C@@H](NC(=O)c1ccc([N+](=O)[O-])cc1)c1ccccc1,nibentan,Phase 2,potassium channel blocker,,,
CC(C)NC[C@H](O)COc1cccc2c1N(C(=O)c1cccnc1)CCC2,nicainoprol,Preclinical,angiotensin converting enzyme inhibitor,,,
C[C@@H](CNC(=O)c1cccnc1)NC(=O)c1cccnc1,nicaraven,Phase 3,free radical scavenger,,,
COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)[C@@H]1c1cccc([N+](=O)[O-])c1,nicardipine,Launched,calcium channel blocker,ADORA3,cardiology,chronic stable angina|hypertension
CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13,nicergoline,Launched,adrenergic receptor antagonist,ADRA1A,rheumatology|neurology/psychiatry|cardiology|hematology,Raynaud's disease|migraine headache|atherosclerosis|thrombosis
O=C(OCC(COC(=O)c1cccnc1)(COC(=O)c1cccnc1)COC(=O)c1cccnc1)c1cccnc1,niceritrol,Launched,NAD precursor,,endocrinology,hyperlipidemia
O=C(Nc1ccc([N+](=O)[O-])cc1Cl)c1cc(Cl)ccc1O,niclosamide,Launched,DNA replication inhibitor|STAT inhibitor,STAT3,infectious disease,tapeworm
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)NCCNC(=O)c1cccnc1,nicodicosapent,Preclinical,sterol regulatory element binding protein (SREBP) inhibitor,,,
O=C(NCCO[N+](=O)[O-])c1cccnc1,nicorandil,Launched,nitric oxide donor|potassium channel activator,KCNJ11,cardiology,angina pectoris
NC(=O)c1cccnc1,nicotinamide,Launched,protein synthesis stimulant,BST1|LDHA|PARP1|SIRT5,dermatology,acne vulgaris (AV)
CN1CCC[C@H]1c1cccnc1,nicotine,Launched,acetylcholine receptor agonist,CHAT|CHRNA10|CHRNA2|CHRNA3|CHRNA4|CHRNA5|CHRNA6|CHRNA7|CHRNA9|CHRNB2|CHRNB3|CHRNB4|CYP19A1|TBXAS1|TRPA1,neurology/psychiatry,smoking cessation
OCc1cccnc1,nicotinyl-alcohol-tartrate,Launched,,,cardiology|neurology/psychiatry,vascular spasm|vertigo
COc1ccc(-c2c(C)c(C(=O)NN3CCCCC3)nn2-c2ccc(Cl)cc2Cl)cc1,NIDA-41020,Preclinical,cannabinoid receptor antagonist,CNR1,,
COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-],nifedipine,Launched,calcium channel blocker,CACNA1C|CACNA1D|CACNA1F|CACNA1H|CACNA1S|CACNA2D1|CACNB2|CALM1|GLRA1|GLRA3|GLRB|KCNA1|KCNA5|NR1I2|TRPM3,cardiology,vasospastic angina|chronic stable angina
Cn1c(NCCN(CCO)CCCc2ccc([N+](=O)[O-])cc2)cc(=O)n(C)c1=O,nifekalant,Launched,potassium channel blocker,,cardiology,ventricular arrhythmias|ventricular tachycardia (VT)
CC(C)NC[C@@H](O)c1ccc([N+](=O)[O-])cc1,nifenalol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2,,
Cc1c(NC(=O)c2cccnc2)c(=O)n(-c2ccccc2)n1C,nifenazone,Launched,analgesic agent,,neurology/psychiatry,pain relief
O=C(O)c1cccnc1Nc1cccc(C(F)(F)F)c1,niflumic-acid,Launched,cyclooxygenase inhibitor,ANO1|CLCN1|CLCNKA|CLCNKB|KCNQ1|PLA2G1B|PLA2G4A|PTGS1|PTGS2|UGT1A9,rheumatology|neurology/psychiatry,joint pain|muscle pain
O=C(N/N=C/c1ccc([N+](=O)[O-])o1)c1ccc(O)cc1,nifuroxazide,Launched,bacterial DNA inhibitor,,gastroenterology,colitis|diarrhea
O=C(N/N=C/c1ccc([N+](=O)[O-])o1)c1cc([N+](=O)[O-])cc([N+](=O)[O-])c1O,nifursol,Launched,bacterial DNA inhibitor,,,
C[C@H]1CS(=O)(=O)CCN1/N=C/c1ccc([N+](=O)[O-])o1,nifurtimox,Launched,DNA inhibitor,,infectious disease,Chagas disease|African trypanosomiasis
COC(=O)C1=C(C)NC(C)=C(C(=O)OCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)[C@@H]1c1cccc([N+](=O)[O-])c1,niguldipine-(R)-(-),Preclinical,,,,
COC(=O)C1=C(C)NC(C)=C(C(=O)OCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)[C@H]1c1cccc([N+](=O)[O-])c1,niguldipine-(S)-(+),Preclinical,adrenergic receptor antagonist,ADRA1A,,
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,nilotinib,Launched,Abl kinase inhibitor|Bcr-Abl kinase inhibitor,ABL1|KIT,hematologic malignancy,chronic myeloid leukemia (CML)
CC1(C)NC(=O)N(c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)C1=O,nilutamide,Launched,androgen receptor antagonist,AR,oncology,prostate cancer
COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)[C@@H]1c1cccc([N+](=O)[O-])c1,nilvadipine,Launched,calcium channel blocker,CACNA1C|CACNA1D,cardiology,hypertension|cerebral artery occlusion
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,NIM811,Phase 2,mitochondrial permeability transition inhibitor,,,
CS(=O)(=O)Nc1ccc([N+](=O)[O-])cc1Oc1ccccc1,nimesulide,Launched,cyclooxygenase inhibitor,LTF|PLA2G2E|PTGS1|PTGS2,rheumatology|obstetrics/gynecology,osteoarthritis|menstrual pain
COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@@H]1c1cccc([N+](=O)[O-])c1,nimodipine,Launched,calcium channel blocker,CFTR|NR3C2,hematology,hemorrhage
O=[N+]([O-])c1cncn1CCN1CCOCC1,nimorazole,Launched,bacterial DNA inhibitor,,oncology,head and neck squamous cell carcinoma (HNSCC)
Cc1ncc(CNC(=O)N(CCCl)[NH2+][O-])c(N)n1,nimustine,Launched,DNA alkylating agent,,,
Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C,ningetinib-tosylate,Preclinical,protein tyrosine kinase inhibitor,,,
COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1,nintedanib,Launched,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FGFR1|FGFR2|FGFR3|FGFR4|FLT1|FLT4|KDR|PDGFRA|PDGFRB,pulmonary,idiopathic pulmonary fibrosis (IPF)
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,niraparib,Launched,PARP inhibitor,PARP1,oncology,primary peritoneal cancer (PPC)
O=C1NCCN1c1ncc([N+](=O)[O-])s1,niridazole,Launched,phosphofructokinase inhibitor,,infectious disease,schistosomiasis
C=C(NC(=O)[C@@H](NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H]1CS[C@H](C)[C@@H]2NC(=O)[C@@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]3CS[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H]4CS[C@H](C)[C@H](NC(=O)[C@H]5CSC[C@H](NC(=O)/C(=C/C)NC(=O)[C@H](N)[C@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NC(=C)C(=O)N[C@H](CC(C)C)C(=O)N5)C(=O)N5CCC[C@@H]5C(=O)NCC(=O)N4)C(=O)NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N3)[C@@H](C)SC[C@@H](NC2=O)C(=O)N[C@H](Cc2cnc[nH]2)C(=O)N1)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)O,nisin,Phase 1,bacterial cell wall synthesis inhibitor,,,
COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)[C@@H]1c1ccccc1[N+](=O)[O-],nisoldipine,Launched,calcium channel blocker,CACNA1C|CACNA1D|CACNA1F|CACNA1S,cardiology,hypertension
CNCC[C@@H](Oc1ccccc1OC)c1ccccc1,nisoxetine,Phase 1,norepinephrine reuptake inhibitor,SLC6A2|SLC6A3|SLC6A4,,
O=[N+]([O-])c1ccc([As](=O)(O)O)cc1,nitarsone,Launched,,,dermatology,blackhead disease
CC(=O)Oc1ccccc1C(=O)Nc1ncc([N+](=O)[O-])s1,nitazoxanide,Launched,pyruvate ferredoxin oxidoreductase inhibitor,,gastroenterology,diarrhea
CC(=O)C(=Cc1cc(O)c(O)c([N+](=O)[O-])c1)C(C)=O,nitecapone,Phase 2,catechol O methyltransferase inhibitor,COMT,,
CCN(Cc1ccc(Cl)nc1)/C(=C/[N+](=O)[O-])NC,nitenpyram,Launched,,,infectious disease,flea control
CC(=O)Nc1ncc([N+](=O)[O-])s1,nithiamide,Preclinical,bacterial DNA inhibitor,,,
O=C1CCCC(=O)C1=C(O)c1ccc(C(F)(F)F)cc1[N+](=O)[O-],nitisinone,Launched,hydroxyphenylpyruvate dioxygenase inhibitor,,metabolism,tyrosinemia
CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1c1cccc([N+](=O)[O-])c1,nitrendipine,Launched,calcium channel blocker,CACNA1D|CACNA2D1|KCNN4,cardiology,hypertension
CCN(CC)CCOC(=O)C1(c2ccc([N+](=O)[O-])cc2)CCCC1,nitrocaramiphen,Preclinical,cholinergic receptor antagonist,CHRM1,,
C[C@@H](C(=O)OCCCCO[N+](=O)[O-])c1ccc(-c2ccccc2)c(F)c1,nitroflurbiprofen,Preclinical,cyclooxygenase inhibitor,,,
O=C1CN(/N=C/c2ccc([N+](=O)[O-])o2)C(=O)N1,nitrofurantoin,Launched,DNA inhibitor,,infectious disease,urinary tract infections|pyelonephritis
NC(=O)N/N=C/c1ccc([N+](=O)[O-])o1,nitrofurazone,Launched,bacterial DNA inhibitor,,infectious disease,first-aid antibiotic
NC(=O)c1cc([N+](=O)[O-])cc([N+](=O)[O-])c1,nitromide,Launched,,,infectious disease,coccidiosis
CNC(=O)N(C)[NH2+][O-],nitrosodimethylurea,Preclinical,DNA synthesis inhibitor,,,
O=[N+]([O-])c1ccc(O)c2ncccc12,nitroxoline,Launched,cathepsin inhibitor,METAP2,infectious disease,urinary tract infections
CN/C(=C\[N+](=O)[O-])NCCSCc1csc(CN(C)C)n1,nizatidine,Launched,histamine receptor antagonist,HRH2,gastroenterology,duodenal ulcer disease|erosive esophagitis (EE)|ulcerative esophagitis (UE)|gastroesophageal reflux disease (GERD)
CCN(CC)Cc1nccn1-c1ccc([N+](=O)[O-])cc1C(=O)c1ccccc1Cl,nizofenone,Launched,ion channel antagonist,,neurology/psychiatry,stroke
O=C(NCc1ccccn1)Nc1nnc(-c2ccco2)o1,NK-252,Preclinical,nuclear factor erythroid derived|like (NRF2) activator,NFE2L2,,
Cl[Ru+3](Cl)(Cl)(Cl)([n+]1cc2ccccc2[nH]1)[n+]1cc2ccccc2[nH]1,NKP-1339,Phase 1,HSP inhibitor,,,
Nc1ncc2c(n1)C[C@@H](c1ccco1)CC2=O,NKY-80,Preclinical,adenylyl cyclase inhibitor,ADCY5,,
O[C@@H](C[C@H]1c2ccccc2-c2cncn21)C1CCCCC1,NLG919,Phase 1,"indoleamine 2,3-dioxygenase inhibitor",IDO1,,
C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O,NM107,Phase 2,RNA polymerase inhibitor,,,
CN[C@H](CC(=O)O)C(=O)O,NMDA,Preclinical,glutamate receptor agonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,,
CN1CCN(c2ccc(OC(F)(F)F)c(Nc3ncc4c(n3)-c3c(c(C(N)=O)nn3CCO)CC4)c2)CC1,NMS-1286937,Phase 2,PLK inhibitor,FLT3|PLK1|PLK2|PLK3,,
Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(S(C)(=O)=O)cc1,NMS-873,Preclinical,ATPase inhibitor,VCP,,
CN1CCC(NC(=O)c2cc(-c3c(O)cc(O)cc3Oc3ccc([N+](=O)[O-])cc3)on2)CC1,NMS-E973,Preclinical,HSP inhibitor,,,
CCc1cccc(CC)c1NC(=O)c1nn(C)c2c1CCc1cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC(F)(F)F)nc1-2,NMS-P715,Preclinical,protein kinase inhibitor,,,
CCCCCCCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,NN-DNJ,Preclinical,glucosidase inhibitor,GBA,,
COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc32)CC1,NNC-05-2090,Preclinical,GABA uptake inhibitor|GAT inhibitor,SLC6A12,,
CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1,NNC-55-0396,Preclinical,T-type calcium channel blocker,CATSPER1|CATSPER2|CATSPER3|CATSPER4,,
COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O,NNC-63-0532,Preclinical,opioid receptor agonist,OPRL1,,
O=C(O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1,NNC-711,Preclinical,GABA uptake inhibitor,SIGMAR1|SLC6A1,,
CC(=O)Oc1ccccc1C(=O)Oc1cccc(CO[N+](=O)[O-])c1,NO-ASA,Phase 2,cyclooxygenase inhibitor,PTGS2,,
COc1ccc(-c2cc(=O)c3c(OC)c(OC)c(OC)c(OC)c3o2)cc1OC,nobiletin,Preclinical,MEK inhibitor,MAP2K1,,
COC(=O)Nc1nc2ccc(C(=O)c3cccs3)cc2[nH]1,nocodazole,Preclinical,tubulin polymerization inhibitor,HPGDS,,
Cc1ccc2[nH]c(N)nc(=O)c2c1Sc1ccncc1,nolatrexed,Phase 3,thymidylate synthase inhibitor,TYMS,,
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C,nomegestrol-acetate,Launched,progesterone receptor agonist,PGR,endocrinology,contraceptive
CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1,nonivamide,Launched,TRPV agonist,TRPV1,rheumatology|neurology/psychiatry,rheumatoid arthritis|muscle pain
CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1,nonoxynol-9,Launched,membrane integrity inhibitor,,endocrinology,contraceptive
Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4,nor-binaltorphimine,Preclinical,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,,
CNCCC=C1c2ccccc2C=Cc2ccccc21,norcyclobenzaprine,Preclinical,adrenergic receptor agonist|serotonin receptor antagonist,,,
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=C/C(=N/O)CC[C@@H]4[C@H]3CC[C@@]21CC,norelgestromin,Launched,,PGR,endocrinology,contraceptive
NC[C@H](O)c1ccc(O)c(O)c1,norepinephrine,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|PAH|SLC18A1|SLC18A2,cardiology|allergy|neurology/psychiatry,hypertension|urticaria|headache|seasonal affective disorder
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C,norethindrone,Launched,progesterone receptor agonist,PGR,obstetrics/gynecology,endometriosis
C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C,norethindrone-acetate,Launched,progesterone receptor agonist,PGR,endocrinology|orthopedics|obstetrics/gynecology,menopause|osteoporosis|vaginal atrophy
C#C[C@]1(OC(=O)CCCCCC)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C,norethisterone-enanthate,Launched,contraceptive agent,,endocrinology,contraceptive
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=C(CCC(=O)C4)[C@H]3CC[C@@]21C,noretynodrel,Launched,progestogen hormone,PGR,endocrinology,contraceptive
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21,norfloxacin,Launched,bacterial DNA gyrase inhibitor,TOP2A,infectious disease|urology,urinary tract infections|gonorrhea|prostatitis
NCC[C@@H](Oc1ccc(C(F)(F)F)cc1)c1ccccc1,norfluoxetine,Phase 1,selective serotonin reuptake inhibitor (SSRI),HTR2B,,
C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=C/C(=N/O)CC[C@@H]4[C@H]3CC[C@@]21CC,norgestimate,Launched,progesterone receptor agonist,ESR1|PGR,endocrinology,contraceptive
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC,norgestrel,Launched,progesterone receptor agonist,AR|ESR1|PGR|SRD5A1,endocrinology,contraceptive
c1cncc([C@H]2CCCN2)c1,nornicotine,Preclinical,acetylcholine receptor agonist,,,
CNCCC=C1c2ccccc2CCc2ccccc21,nortriptyline,Launched,tricyclic antidepressant,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD2|HRH1|HTR1A|HTR2A|HTR2C|HTR6|KCNJ10|PGRMC1|SIGMAR1|SLC6A2|SLC6A4,neurology/psychiatry,depression
CC(C)C[C@@H](N)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O,norvancomycin,Preclinical,,,,
COc1ccc2c(c1OC)C(=O)O[C@@H]2[C@H]1c2c(cc3c(c2OC)OCO3)CCN1C,noscapine,Launched,bradykinin receptor antagonist|tubulin polymerization inhibitor,SIGMAR1,pulmonary,cough suppressant
N[C@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O)C(=O)NCC(=O)O)C(=O)O,NOV-002,Phase 3,,GSR,,
CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C,novobiocin,Launched,bacterial DNA gyrase inhibitor,,obstetrics/gynecology,mastitis
C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)C(=O)CC[C@@H]12,NPC-01,Phase 3,steroid,,,
CC(C)C[C@@H](NC(=O)OCC1c2ccccc2-c2ccccc21)C(=O)O,NPC-15199,Phase 2,ICAM1 antagonist,PPARG,,
O=C(O)c1cc([N+](=O)[O-])ccc1NCCCc1ccccc1,NPPB,Preclinical,chloride channel blocker,ANO1|CLCN2|CLCN7|TRPA1,,
CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N,NPS-2143,Preclinical,calcium receptor antagonist,CASR,,
CC(C)(Cc1ccccc1)NC(=O)c1cnc2ccccc2n1,NPS-2407,Preclinical,glutamate receptor antagonist,,,
Cc1c(NC(=O)N2CCOCC2)ccc2c1c1ccccc1n2C(C)C,NPY-5RA972,Preclinical,neuropeptide receptor antagonist,NPY5R,,
CCOC(=O)c1c2c3c(cccc3[nH]c1=O)C(=O)c1ccccc1-2,NQDI-1,Preclinical,caspase inhibitor,CASP3,,
C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1,NS-018,Phase 1/Phase 2,JAK inhibitor,JAK1|JAK2|JAK3|TYK2,,
FC(F)(F)c1cc(NC(=S)Nc2ccc(Br)cc2-c2nn[nH]n2)cc(C(F)(F)F)c1,NS-11021,Preclinical,calcium-activated potassium channel activator,KCNMA1,,
CC(C)(O)c1ccc2c(c1)ncn2-c1cccc(-c2ccccc2C#N)c1,NS-11394,Preclinical,GABA receptor agonist,,,
O=C(Nc1cc(C(F)(F)F)ccc1O)Nc1cc(C(F)(F)F)ccc1O,NS-1643,Preclinical,voltage-gated potassium channel activator,KCNH2|KCNH6|KCNMA1,,
Nc1ncc(Cc2ccc(Br)cc2)s1,NS-19504,Preclinical,calcium-activated potassium channel activator,KCNMA1,,
O=C1Nc2c(ccc(Cl)c2Cl)/C1=N/O,NS-309,Preclinical,calcium-activated potassium channel activator,KCNN1|KCNN2|KCNN3|KCNN4,,
O=C(Nc1cccc(C(F)(F)F)c1)Nc1ccc(Br)cc1-c1nn[nH]n1,NS-3623,Preclinical,voltage-gated potassium channel activator,KCNH2,,
CN1[C@@H]2CC[C@H]1C=C(c1sccc1Br)C2,NS-3861,Preclinical,acetylcholine receptor agonist,CHRNA3|CHRNB4,,
O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)Nc1c(Br)cc(Br)cc1-c1nn[nH]n1,NS-5806,Preclinical,voltage-gated potassium channel activator,KCND3,,
Cc1c(-c2ccccc2F)[nH]c(N)c1C#N,NS-8,Phase 2,potassium channel agonist,KCNMA1,,
c1ccc2c(c1)CCC[C@H]2Nc1nc2ccccc2[nH]1,NS-8593,Preclinical,calcium-activated potassium channel modulator,KCNN1|KCNN2|KCNN3,,
N#Cc1cccc(-c2nc(-c3cccnc3)no2)c1,NS-9283,Preclinical,acetylcholine receptor allosteric modulator,CHRNA4,,
CCN(CC)CCC[C@@H](C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1,NSC-23766,Preclinical,Ras GTPase inhibitor,,,
C/C(=N\NC(=S)N1CCC1)c1ccccn1,NSC-319726,Preclinical,p53 activator,,,
O=Nc1ccc(O)c2ncccc12,NSC-3852,Preclinical,HDAC inhibitor,HDAC1,,
CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1,NSC-405020,Preclinical,matrix metalloprotease inhibitor,MMP1,,
C=C(C)[C@@H]1CC[C@]2(CO)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12,NSC-4644,Phase 2,ACAT inhibitor|sterol regulatory element binding protein (SREBP) inhibitor,PYGM,,
Clc1ccc2c(NCCNc3ccnc4cc(Cl)ccc34)ccnc2c1,NSC-5844,Preclinical,CC chemokine receptor agonist,CCR1,,
COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12,NSC-625987,Preclinical,CDK inhibitor,CDK2|CDK4,,
Cc1ccc(/C=C2\CNC/C(=C\c3ccc(C)cc3)C2=O)cc1,NSC-632839,Preclinical,ubiquitin specific protease inhibitor,SENP2|USP1|USP2|USP7,,
O=[N+]([O-])c1cc([N+](=O)[O-])c(/C=C/c2ccc(Cl)c(Cl)c2)cc1/C=C/c1ccc(Cl)c(Cl)c1,NSC-636819,Preclinical,histone demethylase inhibitor,KDM4A|KDM4B,,
O=C1C(Cl)=C(NCCN2CCOCC2)C(=O)c2ncccc21,NSC-663284,Preclinical,CDC inhibitor,CDC25A|CDC25B|CDC25C,,
Cc1ccc(S(=O)(=O)c2ccc([N+](=O)[O-])o2)cc1,NSC-697923,Preclinical,ubiquitin-conjugating enzyme inhibitor,UBE2N,,
O=C1C(SCCO)=C(SCCO)C(=O)c2ccccc21,NSC-95397,Preclinical,CDC inhibitor,CDC25A|CDC25B,,
CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1,NSC-9965,Preclinical,acetylcholine receptor antagonist,CHRNA4|CHRNB2,,
CC(C)CCNc1ncccc1C(=O)N1CCN(Cc2ccccc2)CC1,NSI-189,Phase 2,neurotrophic agent,,,
CC1=C(c2ccc(NC3=C(C)C(=O)CC3)cc2)NNC(=O)C1,NSP-805,Preclinical,phosphodiesterase inhibitor,,,
Oc1cc(CNC(=S)/C=C/c2cc(O)c(O)c(Br)c2)cc(O)c1O,NT157,Preclinical,IGF-1 inhibitor,IGF1R,,
O=[N+]([O-])c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1,NTNCB,Preclinical,neuropeptide receptor antagonist,NPY5R,,
Cc1ccc(S(=O)(=O)Nc2ccc3c(c2)c(C(=O)C(F)(F)F)cn3CC(=O)N[C@@H](CC(C)C)C(=O)O)cc1,NTRC-824,Preclinical,neurotensin receptor antagonist,NTSR2,,
O=C(O)c1c(Sc2ccccc2)c2cc(Cl)ccc2n1Cc1ccc(Cl)cc1,nTZDpa,Preclinical,PPAR receptor agonist,PPARG,,
Cc1nc(=O)c2cccc(O)c2[nH]1,NU-1025,Preclinical,PARP inhibitor,PARP1,,
Nc1nc(OCC2CCCCC2)c2[nH]cnc2n1,NU-2058,Preclinical,cyclin D inhibitor,CCNA2|CDK2,,
Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1,NU-6027,Preclinical,CDK inhibitor,CCNA2|CDK2,,
O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12,NU-7026,Preclinical,DNA dependent protein kinase inhibitor|mTOR inhibitor|PI3K inhibitor,PRKDC,,
O=c1cc(N2CCOCC2)oc2c(-c3cccc4c3sc3ccccc34)cccc12,NU-7441,Preclinical,DNA dependent protein kinase inhibitor,PRKDC,,
O=C1N=C2SCCN2C(=O)[C@H]1Cc1ccc(Cl)cc1,nuclomedone,Phase 3,immunosuppressant,,,
COc1ccc(C2=N[C@@H](c3ccc(Cl)cc3)[C@@H](c3ccc(Cl)cc3)N2C(=O)N2CCNC(=O)C2)c(OC(C)C)c1,nutlin-3,Preclinical,MDM inhibitor,MDM2|TP53,,
CN1CCC(C(=O)N2c3ccccc3NC(=O)c3cccnc32)CC1,nuvenzepine,Preclinical,acetylcholine receptor antagonist,,,
O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1,NVP-231,Preclinical,ceramidase inhibitor,CERK,,
Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@H](CN2CCCC2)C1,NVP-ADW742,Preclinical,insulin growth factor receptor inhibitor,IGF1R,,
Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1,NVP-AEW541,Preclinical,IGF-1 inhibitor,IGF1R|INSR,,
CCNC(=O)c1noc(-c2cc(C(C)C)c(O)cc2O)c1-c1ccc(CN2CCOCC2)cc1,NVP-AUY922,Phase 2,HSP inhibitor,HSP90AA1|HSP90AB1,,
Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,NVP-BEZ235,Phase 3,mTOR inhibitor|PI3K inhibitor,ATR|MTOR|PIK3CA|PIK3CD|PIK3CG,,
CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1,NVP-BGJ398,Phase 3,FGFR inhibitor,FGFR1|FGFR2|FGFR3|FGFR4|KDR,,
Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1Nc1nc(-c2cccnc2)nc2c1cnn2C,NVP-BHG712,Preclinical,ephrin inhibitor,EPHB4,,
Fc1cc(-c2cccc3ncc(-c4cnn(C5CCNCC5)c4)nc23)cc(F)c1CN1CCOCC1,NVP-BSK805,Preclinical,JAK inhibitor,JAK2,,
Cn1cc(-c2ccc3ncc(Cc4ccc5ncccc5c4)n3n2)cn1,NVP-BVU972,Preclinical,MET inhibitor,MET,,
N#Cc1ccc(NCCNCC(=O)N2CCC[C@H]2C#N)nc1,NVP-DPP728,Phase 2,dipeptidyl peptidase inhibitor,DPP4,,
COc1cccc(-c2cc(F)ccc2[C@H]2Cc3nc(N)nc(C)c3C(=O)N2)n1,NVP-HSP990,Phase 1,HSP inhibitor,HSP90AA1|HSP90AB1,,
CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl,NVP-TAE226,Preclinical,protein tyrosine kinase inhibitor,PTK2,,
COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,NVP-TAE684,Preclinical,ALK tyrosine kinase receptor inhibitor,ALK|INSR,,
COc1ccc(C(=O)C2CCN(CC(=O)N(Cc3nc(=O)c4c([nH]3)CCOC4)CC3CC3)CC2)cc1,NVP-TNKS656,Preclinical,tankyrase inhibitor,TNKS2,,
CC(C)NC(=O)N1CC[C@H](NC2=Nc3cc(F)ccc3N(CC(F)F)c3ccc(Cl)cc32)C1,NVS-PAK1-1,Preclinical,p21 activated kinase inhibitor,PAK1,,
CC(C)(C)/[N+]([O-])=C/c1ccc(S(=O)(=O)O)cc1S(=O)(=O)O,NXY-059,Phase 3,free radical scavenger,,,
C[C@@H]1[C@H](O)[C@@H](C)/C=C/C=C/CC/C=C/C=C/C=C/C=C/[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)C[C@@H]2O[C@](O)(C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)O[C@H]1C)C[C@H](O)[C@H]2C(=O)O,nystatin,Launched,fungal ergosterol inhibitor,,infectious disease,esophageal candidiasis|skin infections|yeast infection
C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(OC)cc(C)cc1OC,O-1918,Preclinical,cannabinoid receptor antagonist,,,
O=C(Nc1nc(=O)n(Cc2ccc(Cl)cc2)s1)c1ccc(Cl)cc1,O-304,Preclinical,AMPK activator,,,
Cc1cc(C)c(S(=O)(=O)Nc2ccccc2C(F)(F)F)c(C)c1,o-3M3FBS,Preclinical,phospholipase activator,,,
CC(=O)OC[C@H](N)C(=O)O,O-acetyl-L-serine,Preclinical,,PTGS1,,
O=C(O)c1ccccc1S,o-mercapto-benzoic-acid,Preclinical,,,,
COc1ccc(COc2ccc(CC#N)cc2)cc1,O4I1,Preclinical,Oct inducer,POU5F1,,
Nc1nc(OCc2ccccc2)c2[nH]cnc2n1,O6-benzylguanine,Phase 3,O6-alkylguanine-DNA alkyltransferase inhibitor,MGMT,,
O=C(Nc1cc2cc[nH]c2cn1)c1ccccc1,OAC1,Preclinical,Oct activator,,,
O=C(Nc1ccc2[nH]ccc2c1)c1ccccc1,OAC2,Preclinical,Oct activator,POU5F1,,
COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C,obatoclax,Phase 3,BCL inhibitor,BCL2,,
CC[C@H]1[C@@H](O)[C@H]2[C@H]3CC[C@@H]([C@@H](C)CCC(=O)O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12,obeticholic-acid,Launched,FXR agonist,NR1H4,gastroenterology,primary biliary cholangitis
O/N=C/c1cc[n+](COC[n+]2ccc(/C=N/O)cc2)cc1,obidoxime,Launched,cholinesterase reactivator,ACHE,critical care|neurology/psychiatry,poison antidote|nerve gas poisoning
Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(=O)O,OC000459,Phase 2,CRTH receptor antagonist,PTGDR2,,
Cc1nc2c(C)cccn2c(=O)c1CCN1CCC(c2noc3cc(F)ccc23)CC1,ocaperidone,Preclinical,serotonin receptor antagonist,,,
C[C@@H]1CC(=O)c2c(ccc3c2C(=O)c2cccc(O)c2C3=O)C1,ochromycinone,Phase 1,STAT inhibitor,STAT3,,
O=C(c1ccccn1)c1cnn2c(-c3ccncc3)ccnc12,ocinaplon,Phase 3,GABA receptor modulator,GABRA1|GABRA2|GABRA3|GABRA5,,
CC(C)c1ccc(C(=O)NCCOc2ccc(C(=O)O)cc2)cc1,OCO-1112,Phase 2,cholesterol inhibitor,,,
C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C,octamethyltrisiloxane,Preclinical,,,,
CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(=NCCCCCCCC)cc2)cc1,octenidine,Launched,membrane integrity inhibitor,,infectious disease,gram-negative bacterial infections|gram-positive bacterial infections
CCCC[C@@H](CC)COC(=O)/C=C/c1ccc(OC)cc1,octinoxate,Launched,,,dermatology,sunscreen lotion
CCCC[C@@H](CC)COC(=O)c1ccccc1O,octisalate,Launched,,,dermatology,sunscreen lotion
CCCC[C@@H](CC)COC(=O)C(C#N)=C(c1ccccc1)c1ccccc1,octocrylene,Launched,,,dermatology,sunscreen lotion
CC(C)CCC[C@@H](C)N,octodrine,Preclinical,antitumor agent,,,
NCC(O)c1ccc(O)cc1,octopamine,Preclinical,trace amine associated receptor agonist,F10|TAAR1,,
C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](NC(=O)[C@@H](N)Cc2ccccc2)CSSC[C@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,octreotide,Launched,somatostatin receptor agonist,SSTR2|SSTR3|SSTR5,gastroenterology|endocrinology|oncology,diarrhea|acromegaly|carcinoid tumors
CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1,odanacatib,Phase 3,cathepsin inhibitor,CTSK,,
O=c1onc2cnc3ccccc3n12,ODQ,Preclinical,guanylyl cyclase inhibitor,GUCY1A2|GUCY1A3|GUCY1B3,,
COc1cc2c(cc1NS(=O)(=O)c1ccc(Br)cc1C)n(C)c(=O)n2C,OF-1,Preclinical,bromodomain inhibitor,BRD1,,
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,ofloxacin,Launched,bacterial DNA gyrase inhibitor,,infectious disease|otolaryngology|gastroenterology|endocrinology,respiratory tract infections|sinusitis|skin infections|bone and joint infections|intra-abdominal infections|diarrhea|fever|urinary tract infections
N[C@H]1C[C@@H]1c1ccc(-c2cccc(O)c2)cc1,OG-L002,Preclinical,histone lysine demethylase inhibitor,KDM1A,,
Nc1nc(NCc2ccccc2)nc(-c2ccccc2CO)n1,ogerin,Preclinical,G protein-coupled receptor modulator,,,
CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1,oglemilast,Phase 2,phosphodiesterase inhibitor,,,
N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O,oglufanide,Phase 2,VEGF antagonist,,,
CN1CCN(c2ccc(-c3cccc(CN4CCOCC4)c3)cc2NC(=O)c2c[nH]c(=O)cc2C(F)(F)F)CC1,OICR-9429,Preclinical,WDR5/MLL interaction inhibitor,WDR5,,
Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|HRH1|HRH2|HRH4|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR3A|HTR5A|HTR6|HTR7,neurology/psychiatry,schizophrenia|bipolar disorder
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,olaparib,Launched,PARP inhibitor,PARP1|PARP2,oncology,ovarian cancer
CCCCCCCC/C=C\CCCCCCCC(=O)NCCc1ccc(O)c(O)c1,OLDA,Preclinical,TRPV agonist,GPR119,,
CCCCCCCC/C=C\CCCCCCCC(N)=O,oleamide,Preclinical,cannabinoid receptor agonist,HTR7|PLA2G2A,,
CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@@H](C5=CC(=O)OC5)[C@@H](OC(C)=O)C[C@]43O)C2)O[C@@H](C)[C@@H]1O,oleandrin,Phase 1,Na/K-ATPase inhibitor,,,
CC1(C)CC[C@]2(C(=O)O)CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]2C1,oleanolic-acid,Preclinical,G protein-coupled receptor agonist,GPBAR1,,
CCCCCCCC/C=C\CCCCCCCC(=O)NCCO,oleoylethanolamide,Preclinical,cannabinoid receptor agonist|glucose dependent insulinotropic receptor agonist|potassium channel blocker|PPAR receptor agonist,CNR1|GPR119|GPR55|PPARA,,
CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4=C/C(=N/O)CC[C@]4(C)[C@H]3CC[C@]12C,olesoxime,Phase 2/Phase 3,apoptosis stimulant,,,
C/C=C1\[C@H](O[C@H]2O[C@@H](CO)[C@@H](O)[C@@H](O)[C@@H]2O)OC=C(C(=O)OC)[C@H]1CC(=O)OCCc1ccc(O)c(O)c1,oleuropein,Phase 2,estrogen receptor agonist,GPER1,,
CC[C@H]1/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]2[C@H](C)[C@H](CC1)O[C@]1(CC[C@H](C)[C@H](C[C@@H](C)O)O1)[C@H]2C,oligomycin-A,Preclinical,ATP synthase inhibitor|ATPase inhibitor,ATP5A1,,
CCCc1nc(C(C)(C)O)c(C(=O)O)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,olmesartan,Launched,angiotensin receptor antagonist,AGTR1,cardiology,hypertension
CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,olmesartan-medoxomil,Launched,angiotensin receptor antagonist,AGTR1,cardiology,hypertension
C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccsc23)c1,olmutinib,Launched,Bruton's tyrosine kinase (BTK) inhibitor|EGFR inhibitor,BTK|EGFR,oncology,non-small cell lung cancer (NSCLC)
COc1ccc2c(c1OCc1ccccc1)C[C@@H](C(=O)O)N(C(=O)C(c1ccccc1)c1ccccc1)C2,olodanrigan,Phase 2,angiotensin antagonist,,,
Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc21,olomoucine,Preclinical,CDK inhibitor,CDK1|CDK2|CDK5|MAPK1,,
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21,olopatadine,Launched,histamine receptor antagonist,HRH1|S100A1|S100A12|S100A13|S100A2|S100B,ophthalmology,conjunctivitis
Cc1[nH]c(=O)c(C#N)cc1-c1ccc2nccn2c1,olprinone,Launched,phosphodiesterase inhibitor,PDE3A,cardiology,congestive heart failure
O=C(O)c1cc(/N=N/c2ccc(O)c(C(=O)O)c2)ccc1O,olsalazine,Launched,cyclooxygenase inhibitor,IFNG|TPMT,gastroenterology,ulcerative colitis
Cc1c(-c2cnccn2)ssc1=S,oltipraz,Phase 3,nuclear factor erythroid derived|like (NRF2) activator,ANG,,
CCCCCCCCCCCCCCOc1ccc(C(=O)OCC(=O)N(C)CC(=O)OCC)o1,olumacostat-glasaretil,Phase 3,acetyl-CoA carboxylase inhibitor,,,
CCCCCCCC/C=C\CCCCCCCC(=O)NCc1ccc(O)c(OC)c1,olvanil,Preclinical,TRPV agonist,CNR1|GPR119|TRPV1,,
CN(C)c1cc(CNCC(C)(C)C)c(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(=O)[C@H](C(N)=O)C(=O)[C@@]3(O)C(=O)[C@@H]1C2=O,omadacycline,Launched,bacterial 30S ribosomal subunit inhibitor,,infectious disease,pneumonia
O=C(N[C@H]1CCS[C@H]2CCC[C@@H](C(=O)O)N2C1=O)[C@@H](S)Cc1ccccc1,omapatrilat,Preclinical,metalloproteinase inhibitor,ACE|MME,,
CS(=O)(=O)n1cc2c(n1)CN([C@H]1CO[C@H](c3cc(F)ccc3F)[C@@H](N)C1)C2,omarigliptin,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus
COC(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1ccc([C@@H]2CC[C@@H](c3ccc(NC(=O)[C@@H]4CCCN4C(=O)[C@@H](NC(=O)OC)C(C)C)cc3)N2c2ccc(C(C)(C)C)cc2)cc1)C(C)C,ombitasvir,Launched,HCV inhibitor,,infectious disease,hepatitis C
COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO,ombrabulin,Phase 3,tubulin polymerization inhibitor,,,
CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](CO)Cc1ccc(O)cc1,OMDM-2,Preclinical,FAAH inhibitor,GPR119,,
COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1,omecamtiv-mecarbil,Phase 3,cardiac myosin activator,MYBPC3,,
O=C(O)CCCCCCCCCCCCCCc1ccc(I)cc1,omega-(4-iodophenyl)pentadecanoic-acid,Preclinical,,,,
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC,omega-3-acid-esters,Launched,cholesterol inhibitor,,,
COc1ccc2nc([S@@](=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,omeprazole,Launched,ATPase inhibitor,ATP4A|CLCN2,gastroenterology,heartburn
COc1ccc2c(c1)nc([S@@](=O)Cc1ncc(C)c(OC)c1C)n2[Mg]n1c([S@@](=O)Cc2ncc(C)c(OC)c2C)nc2cc(OC)ccc21,omeprazole-magnesium,Launched,proton pump inhibitor,ATP4A|ATP4B,gastroenterology,gastroesophageal reflux disease (GERD)|heartburn
COc1ccc2nc(SCc3ncc(C)c(OC)c3C)[nH]c2c1,omeprazole-sulfide,Phase 1,ATPase inhibitor,,,
CC(C)[C@]12O[C@H]1[C@@H]1O[C@]13[C@]1(O[C@H]1C[C@H]1C4=C(CC[C@@]13C)C(=O)OC4)[C@@H]2OC(=O)CCC(=O)O,omtriptolide,Preclinical,ERK1 and ERK2 phosphorylation inhibitor,,,
COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(N)c2)c(OC)c1,ON-01500,Preclinical,apoptosis stimulant,,,
CN1CCN(c2ccc(Nc3ncc4cc(C#N)c(=O)n(C5CCCC5)c4n3)cc2)CC1,ON123300,Preclinical,CDK inhibitor,CDK4|NUAK1|PDGFRB,,
Cc1ccccc1CN1C(=O)C2=C(CCN(Cc3ccccc3)C2)N2CCN=C12,ONC201,Phase 2,AKT inhibitor|MAP kinase inhibitor,TNFSF10,,
O=Cc1cn(Cc2ccc(Cl)cc2)c2ccccc12,oncrasin-1,Preclinical,apoptosis stimulant,,,
Cc1nccn1C[C@H]1CCc2c(c3ccccc3n2C)C1=O,ondansetron,Launched,serotonin receptor antagonist,HTR3A|HTR3B,gastroenterology,nausea|vomiting
CC#CC(=O)N1CC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,ONO-4059,Phase 1,Bruton's tyrosine kinase (BTK) inhibitor,BTK,,
CCOCOC[C@H](C[C@H](C)C(=O)NO)NC(=O)c1ccc(Oc2ccccc2)cc1,ONO-4817,Phase 1,matrix metalloprotease inhibitor,MMP8,,
Cc1csc(S(=O)(=O)N(CC(C)C)c2cc3c(cc2OCc2ccc(C(=O)O)cc2)CCC3)n1,ONO-8130,Preclinical,prostanoid receptor antagonist,PTGER1,,
C[C@@H](C(=O)Nc1cc(C#N)ccc1CCCC(=O)O)c1ccc(F)c2ccccc12,ONO-AE3-208,Preclinical,prostanoid receptor antagonist,PTGER4,,
COc1ccc(C[C@H](NC(=O)[C@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)C(=O)[C@@]2(C)CO2)cc1,ONX-0914,Preclinical,proteasome inhibitor,,,
NCCONC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O,OP-0595,Preclinical,beta lactamase inhibitor,,,
CC(=O)NCCCOc1ccc(C(=O)N2CCC(N3C(=O)CCc4ccccc43)CC2)cc1,OPC-21268,Phase 1,vasopressin receptor antagonist,AVPR1A|AVPR2|OXTR,,
Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(-c2cc(O)c(O)c([N+](=O)[O-])c2)n1,opicapone,Phase 3,catechol O methyltransferase inhibitor,COMT,,
OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc32)CC1,opipramol,Launched,sigma receptor agonist,,neurology/psychiatry,generalized anxiety disorder (GAD)
COC[C@H](NC(=O)c1cnc(C)s1)C(=O)N[C@@H](COC)C(=O)N[C@@H](Cc1ccccc1)C(=O)[C@@]1(C)CO1,oprozomib,Phase 1/Phase 2,proteasome inhibitor,,,
O=[N+]([O-])c1cc(O)c(O)c([N+](=O)[O-])c1,OR-486,Preclinical,catechol O methyltransferase inhibitor,COMT,,
Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O,orantinib,Phase 3,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,AURKA|AURKB|EGFR|FGFR1|FGFR2|KDR|PDGFRA|PDGFRB,,
C[C@@H]1CN(c2c(F)c(F)c3c(=O)c(C(=O)O)cn(C4CC4)c3c2F)C[C@H](C)N1,orbifloxacin,Launched,bacterial DNA gyrase inhibitor,,infectious disease,urinary tract infections
CC(C)C[C@H](N[C@@H](Cc1cncn1Cc1cc(Cl)cc(Cl)c1)C(=O)O)C(=O)O,ORE1001,Phase 1/Phase 2,angiotensin converting enzyme inhibitor,ACE2,,
FC(F)(F)c1ccc(N2CCNCC2)nc1Cl,ORG-12962,Phase 2,serotonin receptor agonist,HTR2A|HTR2B|HTR2C,,
COc1cc(C(=O)NCC2(N(C)C)CCCC2)cc(OC)c1OCc1ccccc1,ORG-25543,Preclinical,glycine transporter inhibitor,GLRB|SLC6A5,,
O=C1c2cccnc2OC[C@@H]2CCCN12,ORG-26576,Phase 2,glutamate receptor modulator,,,
CCc1c(C(=O)NCCc2ccc(N3CCCCC3)cc2)[nH]c2ccc(Cl)cc12,ORG-27569,Preclinical,cannabinoid receptor modulator,CNR1,,
CC1(CN)Cc2ccccc2C1,ORG-9768,Phase 1,adrenergic receptor antagonist,ADRA2A,,
C=C1C(=O)[C@]23[C@H](O)[C@H]1CC[C@H]2[C@@]12CO[C@]3(O)[C@@H](O)[C@@H]1C(C)(C)CC[C@@H]2O,oridonin,Preclinical,BCL inhibitor,BCL2,,
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O[C@H]3C[C@](C)(N)[C@@H](O)[C@H](C)O3)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(NCc3ccc(-c4ccc(Cl)cc4)cc3)[C@@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O,oritavancin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,skin infections
CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,orlistat,Launched,lipase inhibitor,CNR1|DAGLA|DAGLB|FASN|LIPF|PNLIP,endocrinology,weight-loss aid
COc1ccc2c(c1)OC(C)(C)[C@@H](c1ccccc1)[C@@H]2c1ccc(OCCN2CCCC2)cc1,ormeloxifene,Launched,selective estrogen receptor modulator (SERM),,endocrinology,contraceptive
Cc1ncc([N+](=O)[O-])n1C[C@@H](O)CCl,ornidazole,Launched,antiprotozoal agent,,infectious disease,protozoan infection
NCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,ornipressin,Preclinical,vasoconstrictor,,,
Cl.NCCC[C@@H](N)C(=O)O,ornithine,Launched,NFkB pathway modulator,GPRC6A,,
O=C(O)c1cc(=O)[nH]c(=O)[nH]1,orotic-acid,Phase 2,,DHODH,,
CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)O,orphanin-fq,Phase 1,opioid receptor agonist,OPRL1|OPRM1,,
Cc1ccccc1[C@@H](OCCN(C)C)c1ccccc1,orphenadrine,Launched,acetylcholine receptor antagonist,,neurology/psychiatry,muscle pain
CNC(=O)c1ccc2cc([C@]3(O)CCn4cncc43)ccc2c1,orteronel,Phase 3,androgen biosynthesis inhibitor|androgen receptor antagonist|cytochrome P450 inhibitor,CYP17A1,,
NC1CCC(N[C@@H]2C[C@H]2c2ccccc2)CC1,ORY-1001,Phase 1/Phase 2,histone lysine demethylase inhibitor,KDM1A,,
CCC(CC)O[C@@H]1C=C(C(=O)O)C[C@H](N)[C@H]1NC(C)=O,oseltamivir-carboxylate,Launched,neuraminidase inhibitor,,infectious disease,influenza A virus infection
CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1,oseltamivir-phosphate,Launched,neuraminidase inhibitor,CES1|NEU1|NEU2,infectious disease,influenza A virus infection
c1ccc2c(c1)OC[C@H](CNCCCOc1ccc3c(c1)OCO3)O2,osemozotan,Phase 2/Phase 3,serotonin receptor agonist,HTR1A,,
COc1cccc2cc(-c3nc([C@H]4CC[C@H](C(=O)O)CC4)n4ncnc(N)c34)[nH]c12,OSI-027,Phase 1,mTOR inhibitor,MTOR,,
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCO)cc23)c1,OSI-420,Preclinical,EGFR inhibitor,EGFR,,
O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12,OSI-930,Phase 1,KIT inhibitor|VEGFR inhibitor,FLT1|KDR|KIT,,
N#Cc1ccc([C@H]2CCc3cncn32)c(F)c1,osilodrostat,Launched,cytochrome P450 inhibitor,,,
C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,osimertinib,Launched,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC)
OCCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1,ospemifene,Launched,selective estrogen receptor modulator (SERM),ESR1|ESR2,obstetrics/gynecology|endocrinology,vaginal atrophy|dyspareunia|menopause
C[C@](O)(COc1ccc(C#N)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,ostarine,Phase 3,androgen receptor modulator,AR,,
COc1ccc2ccc(=O)oc2c1CC=C(C)C,osthol,Preclinical,calcium channel blocker,,,
CO/N=C1/C[C@@H](C(=O)NC[C@@H](O)c2ccccc2)N(C(=O)c2ccc(-c3ccccc3C)cc2)C1,OT-R-antagonist-1,Preclinical,oxytocin receptor antagonist,AVPR1A|OXTR,,
COC(=O)[C@H](Cc1cccc(C(=N)N)c1)[C@@H](C)NC(=O)c1ccc(-c2cc[n+]([O-])cc2)cc1,otamixaban,Phase 3,coagulation factor inhibitor,F10,,
CCN(CC)C[C@H]1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc21,otenzepad,Phase 3,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,,
CCCCCCCCOc1ccccc1C(=O)Nc1ccc(C(=O)OCC[N+](C)(CC)CC)cc1,otilonium,Launched,acetylcholine receptor antagonist,CACNA1C,gastroenterology,irritable bowel syndrome
CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1,OTS167,Phase 1/Phase 2,maternal embryonic leucine zipper kinase inhibitor,MELK,,
Cc1cc(O)c(-c2ccc([C@@H](C)CN)cc2)c2c1[nH]c(=O)c1sccc12,OTS514,Preclinical,TOPK inhibitor,,,
Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n1-2,OTX015,Phase 1/Phase 2,bromodomain inhibitor,BRD2|BRD3|BRD4,,
C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@@H](C6=CC(=O)OC6)CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)[C@H](O)[C@H](O)[C@H]1O,ouabain,Launched,ATPase inhibitor,ATP1A1,cardiology,hypertension|cardiac arrythmia
Fc1ccccc1CNCc1ccc(-c2ccnc3[nH]ccc23)cc1,OXA-06,Preclinical,rho associated kinase inhibitor,ROCK1|ROCK2,,
CC(=O)N1C[C@H](O)C[C@H]1C(=O)O,oxaceprol,Preclinical,anti-inflammatory agent,,,
Cc1onc(-c2ccccc2)c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O,oxacillin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,staphylococcal infections
O=C1CCCCCCCCCCCCCCO1,oxacyclohexadecan-2-one,Preclinical,protein kinase inhibitor,,,
O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O,oxaliplatin,Launched,DNA inhibitor,,oncology,colorectal cancer
CN1CCCN=C1/C=C/c1cccc(O)c1,oxantel,Launched,anthelmintic agent,,infectious disease,gastrointestinal parasites
O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1,oxaprozin,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,osteoarthritis|rheumatoid arthritis
O=c1[nH]c2ccccc2n1CCCN1CCN(C(c2ccccc2)c2ccccc2)CC1,oxatomide,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis
NC(=O)N1c2ccccc2CC(=O)c2ccccc21,oxcarbazepine,Launched,sodium channel blocker,SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,seizures
CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1,oxelaidin,Launched,antitussive,,pulmonary,cough suppressant
CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc1ccccc1)C(C)(C)Cc1ccccc1,oxethazaine,Launched,local anesthetic,,neurology/psychiatry,local anesthetic
Cc1noc(C)c1-c1cc(O)cc([C@@H](O)c2ccccc2)c1,OXF-BD-02,Preclinical,bromodomain inhibitor,BRD4,,
COC(=O)Nc1nc2ccc([S@@](=O)c3ccccc3)cc2[nH]1,oxfendazole,Launched,anthelmintic agent,,infectious disease,lungworms|tapeworm|gastrointestinal roundworms
N[C@@H](C(=O)O)c1ccc(O)cc1,oxfenicine,Phase 1,carnitine palmitoyltransferase inhibitor,CPT1A|CPT1B,,
CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1,oxibendazole,Launched,tubulin polymerization inhibitor,TUBB|TUBB4B,infectious disease,strongyles
Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,oxiconazole,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,tinea pedis|tinea cruris|tinea corporis
NCCc1cc(O)c(O)cc1O,oxidopamine,Preclinical,neurotoxin,,,
O=C(O)c1ccc[n+]([O-])c1,oxiniacic-acid,Preclinical,,,,
O=c1[nH]c2ccccc2n1C1CCN(CCOc2ccccc2)CC1,oxiperomide,Phase 2,dopamine receptor antagonist,,,
NC(=O)CN1C[C@H](O)CC1=O,oxiracetam,Launched,acetylcholine receptor agonist,,neurology/psychiatry,senile dementia
CCN(CC)CCc1nc(-c2ccccc2)no1,oxolamine,Launched,antitussive,,pulmonary,cough suppressant
CCn1cc(C(=O)O)c(=O)c2cc3c(cc21)OCO3,oxolinic-acid,Preclinical,bacterial DNA gyrase inhibitor,,,
O=C(O)c1nc(=O)[nH]c(=O)[nH]1,oxonic-acid,Preclinical,uricase inhibitor,,,
C[N+](C)(C)CC#CCN1CCCC1=O,oxotremorine-M,Preclinical,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4,,
O=C1CCCN1CC#CCN1CCCC1,oxotremorine-sesquifumarate,Preclinical,cholinergic receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4,,
C=CCOc1ccccc1OC[C@H](O)CNC(C)C,oxprenolol,Launched,adrenergic receptor antagonist,ADRB1,cardiology,angina pectoris|hypertension|cardiac arrythmia
COc1ccc(C(=O)c2ccccc2)c(O)c1,oxybenzone,Launched,lipase inhibitor,LIPE,dermatology,sunscreen lotion
CCCCOc1cc(C(=O)OCCN(CC)CC)ccc1N,oxybuprocaine,Launched,local anesthetic,SCN10A,neurology/psychiatry,local anesthetic
CCN(CC)CC#CCOC(=O)[C@](O)(c1ccccc1)C1CCCCC1,oxybutynin,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3,urology,urinary incontinence
O=C(Nc1cc(Cl)cc(Cl)c1O)c1c(O)c(Cl)cc(Cl)c1Cl,oxyclozanide,Launched,,,infectious disease,fascioliasis
COc1cccc(C(=O)CCN[C@@H](C)[C@H](O)c2ccccc2)c1,oxyfedrine,Launched,adrenergic receptor agonist,,cardiology,angina pectoris
O=C1CCC[C@@H]2[C@H]3CCC[N@+]4([O-])CCC[C@@H](CN12)[C@@H]34,oxymatrine,Launched,,,,
Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,oxymetazoline,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|HTR1B|HTR1D|HTR2C,otolaryngology,nasal congestion
CN1CCCN=C1COC(=O)[C@](O)(c1ccccc1)C1CCCCC1,oxyphencyclimine,Launched,cholinergic receptor antagonist,,gastroenterology,peptic ulcer disease (PUD)
CC[N+](C)(CC)CCOC(=O)C(O)(c1ccccc1)C1CCCCC1,oxyphenonium,Launched,cholinergic receptor antagonist,CHRM1|CHRM3,gastroenterology,peptic ulcer disease (PUD)
O=c1nc2[nH][nH]cc-2c(=O)[nH]1,oxypurinol,Phase 2/Phase 3,xanthine oxidase inhibitor,XDH,,
Oc1cccc2cccnc12,oxyquinoline,Launched,chelating agent,METAP2,dermatology,cosmetic
CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12,oxytetracycline,Launched,bacterial 30S ribosomal subunit inhibitor,,infectious disease|urology,chlamydia|urinary tract infections|skin infections|ear infections|gonorrhea|urethritis|Lyme disease
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,oxytocin,Launched,oxytocin receptor agonist,AVPR1A|AVPR1B|AVPR2|OXTR,obstetrics/gynecology,labor induction
O=C(O)/C=C/c1ccc(Cn2ccnc2)cc1,ozagrel,Launched,thromboxane synthase inhibitor,TBXAS1,neurology/psychiatry,stroke
CC(C)Oc1ccc(-c2nc(-c3cccc4c3CC[C@@H]4NCCO)no2)cc1C#N,ozanimod,Phase 3,sphingosine 1-phosphate receptor agonist,S1PR1,,
CNc1ncc(-c2ccc3c(=O)c(C(=O)O)cn(C4CC4)c3c2C)cc1C,ozenoxacin,Phase 3,antiinfective drug,,,
CN1C(=O)[C@H](N2CCCCC2)S/C1=C\C(=O)O,ozolinone,Phase 3,diuretic,,,
CCCCCOC(=O)c1ccc(N(C)C)cc1,p-dimethylinamyl-benzoate,Preclinical,,,,
CC(=O)c1cc([N+](=O)[O-])c(Sc2ccc(F)cc2F)s1,P22077,Preclinical,ubiquitin specific protease inhibitor,USP7,,
CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@@H]1CO,P276-00,Phase 2,CDK inhibitor,CDK1|CDK4|CDK9,,
CC(=O)c1cc([N+](=O)[O-])c(Sc2cccc(Cl)c2Cl)s1,P5091,Preclinical,ubiquitin specific protease inhibitor,USP7,,
O[C@@H](CNc1ccccc1)Cn1c2ccc(Br)cc2c2cc(Br)ccc21,P7C3,Preclinical,NAMPT inhibitor,NAMPT,,
CCCCCCOc1cc2c(cc1N(C)c1ncc(C(=O)O)cn1)C(C)(C)CCC2(C)C,PA-452,Preclinical,retinoid receptor antagonist,RXRA,,
C=CCc1cccc(/C=N/NC(=O)CN2CCN(Cc3ccccc3)CC2)c1O,PAC-1,Phase 1,caspase activator,CASP3,,
CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O,paclitaxel,Launched,tubulin polymerization inhibitor,BCL2|MAP2|MAP4|MAPT|NR1I2|TLR4|TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,oncology,ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)
C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1,pacritinib,Phase 3,FLT3 inhibitor|JAK inhibitor,FLT3|JAK1|JAK2|JAK3,,
COCc1nn2c(CN3C[C@@H](CC(F)(F)Cl)CC3=O)c(C(F)(F)F)nc2s1,padsevonil,Phase 3,antiepileptic,,,
C[C@@]12C[C@@]3(O)O[C@@H](O1)[C@]1(COC(=O)c4ccccc4)[C@H]3C[C@@]12O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,paeoniflorin,Preclinical,anticonvulsant,,,
COc1ccc(C(C)=O)c(O)c1,paeonol,Preclinical,anti-inflammatory agent,,,
CON=C(N)c1ccc(-c2ccc(-c3ccc(C(N)=NOC)cc3)o2)cc1,pafuramidine,Phase 3,DNA synthesis inhibitor,,,
CC(C)CCC(=O)C[C@H]1c2ccccc2C(=O)N1c1ccc2ccc(Cl)nc2n1,pagoclone,Phase 2/Phase 3,GABA receptor agonist,,,
CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,palbociclib,Launched,CDK inhibitor,CDK4|CDK6,oncology,breast cancer
O=P(O)(NCCCl)NCCCl,palifosfamide,Phase 3,DNA alkylating agent,,,
Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCC[C@@H]2O,paliperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,DRD2|HTR2A,neurology/psychiatry,schizophrenia
COc1cc2c(cc1OC)-c1cc3ccc(OC)c(OC)c3c[n+]1CC2,palmatine-chloride,Preclinical,dopamine synthesis inhibitor,CYP3A4,,
CCCCCC/C=C\CCCCCCCC(=O)O,palmitoleic-acid,Preclinical,,,,
CCCCCCCCCCCCCCCC(=O)O[C@@H](CC(=O)O)C[N+](C)(C)C,palmitoylcarnitine,Preclinical,protein kinase inhibitor,,,
CCCCCCCCCCCCCCCC(=O)NCCO,palmitoylethanolamide,Launched,cannabinoid receptor agonist,CNR2|GPR119|GPR55,,
COc1ccc(COc2cc3oc(=O)c4cc([C@@H](C)O)ccc4c3cc2OC)cc1,palomid-529,Phase 1,AKT inhibitor|mTOR inhibitor,MTOR,,
O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2,palonosetron,Launched,serotonin receptor antagonist,HTR3A,gastroenterology,nausea|vomiting
Cc1cc(NC(=O)NCCN2CCC(O)(Cc3ccccc3)CC2)c2ccccc2n1,palosuran,Phase 2,urotensin receptor antagonist,UTS2R,,
CC1(C)CCC(C)(C)c2cc(Cn3cccn3)c(/C=C/c3ccc(C(=O)O)cc3)cc21,palovarotene,Phase 3,retinoid receptor agonist,RARG,,
C[C@]12CCCN1CC1=NNC(=O)c3cc(F)cc4[nH]c2c1c34,pamiparib,Phase 3,PARP inhibitor,,,
CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1[N+]1(C)CCCCC1,pancuronium,Launched,acetylcholine receptor antagonist,CHRM2|CHRM3|CHRNA1|CHRNA2,critical care|neurology/psychiatry,endotracheal intubation|muscle relaxant
C=C(N)N1CC[C@H](SC2=C(C(=O)O)N3C(=O)[C@H]([C@@H](C)O)[C@H]3C2)C1,panipenem,Preclinical,antibacterial ,,,
Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1,panobinostat,Launched,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC4|HDAC6|HDAC7|HDAC8|HDAC9,hematologic malignancy,multiple myeloma
CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO,pantethine,Launched,coenzyme A precursor,,,
COc1ccnc(C[S@@](=O)c2nc3ccc(OC(F)F)cc3[nH]2)c1OC,pantoprazole,Launched,ATPase inhibitor,ATP4A,gastroenterology,gastroesophageal reflux disease (GERD)|erosive esophagitis (EE)|Zollinger-Ellison syndrome
CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)O,pantothenic-acid,Launched,coenzyme A precursor,,,
NC(=O)CN1CC[C@@H](NC(=O)[C@@H]2CCCN2)C1=O,PAOPA,Preclinical,dopamine receptor modulator,DRD2,,
COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC,papaverine,Launched,phosphodiesterase inhibitor,PDE10A|PDE4B|PDE5A,cardiology|hematology|gastroenterology,myocardial infarction|angina pectoris|pulmonary embolism (PE)|colitis|vascular spasm
CCc1cccc2c1c(O)c(C(=O)N(CC)c1ccccc1)c(=O)n2C,paquinimod,Phase 2,S100A9 inhibitor,,,
Cc1ccc(S(N)(=O)=O)cc1,para-toluenesulfonamide,Phase 3,,CA12|CA2|CA6|CA9,,
CC(=O)Nc1ccc(O)cc1,paracetamol,Launched,cyclooxygenase inhibitor,FAAH|PTGS1|PTGS2|TRPV1,neurology/psychiatry|endocrinology,pain relief|fever
Oc1ccc(Cl)cc1,parachlorophenol,Launched,antiinfective drug,,infectious disease,first-aid antiseptic
CC[C@@]1(C)OC(=O)N(C)C1=O,paramethadione,Launched,anticonvulsant,CACNA1G,neurology/psychiatry,seizures
Cn1c(=O)[nH]c2ncn(C)c2c1=O,paraxanthine,Phase 1,adenosine receptor antagonist,,,
CCCCc1ccc2nc(NC(=O)OC)[nH]c2c1,parbendazole,Preclinical,tubulin polymerization inhibitor,TUBB,,
CC(=O)Nc1ccc(O[C@]2(C)OC(=O)c3ccccc3O2)cc1,parcetasal,Preclinical,anti-inflammatory agent,,,
CN1CCN(c2cccc3[nH]c(=O)oc23)CC1,pardoprunox,Phase 3,dopamine receptor agonist|serotonin receptor agonist,DRD2|DRD3|DRD4|HTR1A|HTR7,,
CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1,parecoxib,Launched,cyclooxygenase inhibitor,LTF,neurology/psychiatry,pain relief
CCOc1ccc(C(=O)OCCN(CC)CC)cc1,parethoxycaine,Preclinical,local anesthetic,,,
C#CCN(C)Cc1ccccc1,pargyline,Launched,monoamine oxidase inhibitor,MAOA|MAOB,cardiology,hypertension
C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@]12C,paricalcitol,Launched,vitamin D receptor agonist,VDR,nephrology|endocrinology,chronic kidney disease (CKD)|hyperthyroidism
Cc1cnc(C(=O)N[C@H]2CCCCC/C=C\[C@@H]3C[C@@]3(C(=O)NS(=O)(=O)C3CC3)NC(=O)[C@@H]3C[C@@H](Oc4nc5ccccc5c5ccccc45)CN3C2=O)cn1,paritaprevir,Launched,HCV inhibitor,,infectious disease,hepatitis C
NC[C@@H]1O[C@H](O[C@H]2[C@@H](O)[C@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)O[C@@H]2CO)[C@H](N)[C@@H](O)[C@@H]1O,paromomycin,Launched,bacterial 30S ribosomal subunit inhibitor,,infectious disease,amebiasis
Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1,paroxetine,Launched,selective serotonin reuptake inhibitor (SSRI),CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HTR2A|SLC6A2|SLC6A4,neurology/psychiatry,depression|obsessive compulsive disorder (OCD)|generalized anxiety disorder (GAD)|panic disorders|posttraumatic stress disorder|social anxiety disorder
CCC(=O)c1ccc(O)cc1,paroxypropione,Launched,gonadotropin inhibitor,,,
CCOc1c([C@H](C)n2nc(C)c3c(N)ncnc32)cc(Cl)c(F)c1[C@@H]1CNC(=O)C1,parsaclisib,Phase 2,PI3K inhibitor,,,
C=C1C(=O)O[C@H]2[C@H]1CC/C(C)=C/CC[C@@]1(C)O[C@@H]21,parthenolide,Phase 1,NFkB pathway inhibitor,,,
C=C1C(=O)O[C@H]2[C@H]1CC/C(C)=C\CC[C@@]1(C)O[C@@H]21,parthenolide-(-),Preclinical,NFkB pathway inhibitor,HDAC1,,
C=C1C(=O)O[C@@H]2[C@H]3O[C@]3(C)CC/C=C(\C)CC[C@@H]12,parthenolide-(alternate-stereo),Preclinical,NFkB pathway inhibitor,IKBKB|RELA,,
NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O,pasireotide,Launched,somatostatin receptor agonist,SSTR1|SSTR2|SSTR3|SSTR5,endocrinology,Cushing's syndrome|acromegaly
NCc1cc(Oc2cccc(C(=O)N3C[C@@H](O)[C@H](F)C3)c2)nc(C(F)(F)F)c1,PAT-1251,Phase 1,lysyl oxidase inhibitor,,,
CC[C@H](NC(=O)c1c(NS(C)(=O)=O)c(-c2ccccc2)nc2ccccc12)c1ccccc1,pavinetant,Phase 2,neurokinin receptor antagonist,,,
Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,pazopanib,Launched,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,CSF1R|FGF1|FGFR1|FGFR3|FLT1|FLT4|ITK|KDR|KIT|PDGFRA|PDGFRB|SH2B3,oncology,renal cell carcinoma (RCC)|soft tissue sarcoma (STS)
C[C@H]1COc2c(C3(N)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,pazufloxacin,Launched,topoisomerase inhibitor,,infectious disease,pneumonia|peritonitis|bacterial septicemia
CCCCCc1cccc(CC(=O)O)c1,PBI-4050,Phase 2/Phase 3,free fatty acid receptor agonist,,,
CN(C)Cc1ccc2c(Cl)cc(Cl)c(O)c2n1,PBT-1033,Preclinical,chelating agent,,,
COC(=O)C1=C(C)NC(C)=C(C(=O)OCCSc2ccccc2)[C@@H]1C,PCA-4248,Phase 1,platelet activating factor receptor antagonist,PTAFR,,
CN(C)Cc1c(C(=O)NCCOc2ccc(C(=O)NO)cc2)oc2ccccc12,PCI-24781,Phase 3,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC6,,
N=C(N)c1ccc2nc(-c3cc(CC(=O)N[C@@H](CC(=O)O)C(=O)O)cc(-c4cc(S(N)(=O)=O)ccc4O)c3O)[nH]c2c1,PCI-27483,Phase 2,ERK1 and ERK2 phosphorylation inhibitor,,,
Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2C1CCCC1,PCI-29732,Preclinical,Bruton's tyrosine kinase (BTK) inhibitor,BTK,,
COc1ccc(Cn2ccc3ccc(C(=O)NO)cc32)cc1,PCI-34051,Preclinical,HDAC inhibitor,HDAC1|HDAC10|HDAC6|HDAC8,,
CC1(C)Oc2ccc(C#N)cc2[C@@H](OC2=CC(=O)CC2)[C@@H]1O,PCO-400,Phase 1,potassium channel activator,KCNJ8,,
O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F,PD-0325901,Phase 2,MEK inhibitor,MAP2K1,,
CCOC(=O)c1c(C)[nH]c2ccc3c(c12)CN1CCc2cc(OC)ccc2[C@H]1O3,PD-102807,Preclinical,acetylcholine receptor antagonist,CHRM4,,
O=C(O)c1ccccc1Nc1ccc(CCc2ccc(Cl)c(Cl)c2)cc1,PD-118057,Preclinical,potassium channel activator,KCNH2,,
Cc1cc(Cn2cnc3c2C[C@@H](C(=O)O)N(C(=O)C(c2ccccc2)c2ccccc2)C3)ccc1N(C)C,PD-123319,Phase 1,angiotensin antagonist,AGTR2,,
CCCN1CCO[C@@H]2c3cc(O)ccc3OC[C@H]21,PD-128907,Preclinical,dopamine receptor agonist,DRD2|DRD3,,
COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,PD-153035,Phase 1,EGFR inhibitor,EGFR|KDR,,
COc1ccc(C(=O)/C(Cc2cc(OC)c(OC)c(OC)c2)=C(\C(=O)O)c2ccc3c(c2)OCO3)cc1,PD-156707,Preclinical,endothelin receptor antagonist,EDNRA|EDNRB,,
CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,PD-158780,Preclinical,EGFR inhibitor,EGFR,,
CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+](=O)[O-],PD-160170,Preclinical,neuropeptide receptor antagonist,NPY1R,,
CCN(CC)CCCCNc1ncc2cc(-c3c(Cl)cccc3Cl)c(NC(=O)NC(C)(C)C)nc2n1,PD-161570,Preclinical,FGFR inhibitor,FGFR1,,
CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1,PD-166285,Preclinical,SRC inhibitor,EGFR|FGFR1|PDGFRB|PKMYT1|SRC|WEE1,,
CC(C)[C@H](NS(=O)(=O)c1ccc(-c2ccc(Br)cc2)cc1)C(=O)O,PD-166793,Preclinical,collagenase inhibitor|metalloproteinase inhibitor,MMP13|MMP2|MMP3,,
Cc1cccc(C(=O)NCN2CCN(c3ccccc3C#N)CC2)c1,PD-168077,Preclinical,dopamine receptor agonist,DRD2,,
C=CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,PD-168393,Preclinical,EGFR inhibitor,EGFR|ERBB2|SRC,,
Cc1ccc(N2CCN(CC[C@H]3NC(=O)c4ccccc43)CC2)cc1C,PD-168568,Preclinical,dopamine receptor antagonist,DRD2|DRD4,,
CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1,PD-173074,Preclinical,FGFR inhibitor|VEGFR inhibitor,FGFR1|FGFR2|FGFR3|FGFR4|FLT1|FLT4|KDR|PDGFRA|PDGFRB,,
CC(C)C[C@@H](C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C)N(C)Cc1ccc(C(C)(C)C)cc1,PD-173212,Preclinical,calcium channel blocker,CACNA1B,,
O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl,PD-184352,Phase 2,MEK inhibitor,MAP2K1|MAP3K1|MAP3K2,,
Cc1cc(I)ccc1Nc1c(C(=O)NOCC2CC2)cc(F)c(F)c1F,PD-198306,Preclinical,MAP kinase inhibitor|MEK inhibitor,MAP2K1|MAP2K2,,
O=C(NOC[C@H](O)CO)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F,PD-318088,Preclinical,MEK inhibitor,,,
O=C1NC(=O)c2c1c(-c1ccccc1)cc1[nH]c3ccc(O)cc3c21,PD-407824,Preclinical,PKC inhibitor,WEE1,,
Cc1sc(N)c(C(=O)c2cccc(C(F)(F)F)c2)c1C,PD-81723,Preclinical,adenosine receptor agonist,ADORA1,,
COc1cccc(-c2cc(=O)c3ccccc3o2)c1N,PD-98059,Preclinical,MEK inhibitor,AKT1|CHEK1|GSK3B|LCK|MAP2K1|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|RAF1|ROCK1|RPS6KB1|SGK1,,
COc1cc(OCc2cccc(-c3ccccc3)c2C)cc(OC)c1CN1CCCC[C@H]1C(=O)O,PD1-PDL-inhibitor-1,Preclinical,programmed death ligand inhibitor,CD274,,
Cc1cc(Cn2c(=O)n(Cc3cnc(C)s3)c(=O)c3cc(S(=O)(=O)NC4(C)CC4)ccc32)n(C)n1,PDD-00017273,Preclinical,PARG inhibitor,,,
Cc1ncc(C)n2nc([C@@H]3C[C@H]3c3nc4c5cccnc5ccn4c3C)nc12,PDE10-IN-1,Preclinical,phosphodiesterase inhibitor,PDE10A,,
CCCCCCCCCCCCCCCc1cccc(OCC(=O)NCCO)c1,PDP-EA,Preclinical,FAAH activator,FAAH,,
NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2C[C@@H]3C[C@H]1C[C@@](O)(C3)C2,peficitinib,Launched,JAK inhibitor,JAK1|JAK2|JAK3,rheumatology,rheumatoid arthritis
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21,pefloxacin,Launched,bacterial DNA gyrase inhibitor,TOP2A,infectious disease|urology,gastrointestinal infections|urethritis|gonorrhea|urinary tract infections
O=c1[nH]c2ccccc2c(=O)n1CCCN1CCN(c2ccccc2)CC1,pelanserin,Phase 2,serotonin receptor antagonist,HTR2A,,
CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,pelitinib,Phase 2,EGFR inhibitor,EGFR,,
Cc1nc(=O)c(C#N)c(NCc2cccnc2)[nH]1,pelrinone,Phase 2,phosphodiesterase inhibitor,,,
CC[C@@H](Oc1cccc(CN(CCCOc2ccc(OC)cc2)c2nc3ccccc3o2)c1)C(=O)O,pemafibrate,Phase 3,PPAR receptor agonist,,,
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,pemetrexed,Launched,dihydrofolate reductase inhibitor|thymidylate synthase inhibitor,ATIC|DHFR|GART|TYMS,oncology,non-small cell lung cancer (NSCLC)|mesothelioma
Cc1cccn2c(=O)c(-c3nn[nH]n3)cnc12,pemirolast,Launched,mediator release inhibitor,HRH1,pulmonary,asthma
CN1C(C)(C)CCCC1(C)C,pempidine,Launched,ganglionic blocker,,cardiology,hypertension
CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1,penbutolol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|HTR1A|HTR1B,cardiology,hypertension
Nc1nc(=O)c2ncn(CCC(CO)CO)c2[nH]1,penciclovir,Launched,DNA directed DNA polymerase inhibitor,,dental,cold sore
OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,penfluridol,Launched,T-type calcium channel blocker,CACNA1G,neurology/psychiatry,schizophrenia
CC(C)(S)[C@@H](N)C(=O)O,penicillamine-(racemic),Launched,,,,
CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(=O)O,penicillin-v-potassium,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,pneumonia|ear infections|skin infections|throat infections|cholera|scarlet fever
CCCCCCCCCCCCCCCCCCCCCCCCC(=O)O,pentacosanoic-acid,Preclinical,,,,
CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,pentagastrin,Launched,CCK receptor agonist,CCKBR,gastroenterology,anacidity diagnostic|gastric hypersecretion diagnostic
N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1,pentamidine,Launched,anti-pneumocystis agent,TRDMT1,infectious disease,pneumonia
O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CCN(CC(=O)O)CC(=O)O,pentetic-acid,Phase 2,chelating agent,,,
C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1,pentolinium,Launched,cholinergic receptor antagonist,CHRNA10|CHRNA3|CHRNA4|CHRNB4,cardiology,hypertension
OC[C@H]1O[C@@H](n2cnc3c2NC=NC[C@H]3O)C[C@@H]1O,pentostatin,Launched,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor,ADA,hematologic malignancy,hairy cell leukemia
CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,pentoxifylline,Launched,phosphodiesterase inhibitor,ADORA1|ADORA2A|ADORA2B|ADRA2B|NT5E|PDE10A|PDE1A|PDE1B|PDE1C|PDE2A|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A|PDE6A|PDE6B|PDE6C|PDE6D|PDE6G|PDE6H|PDE7A|PDE7B|PDE8A|PDE8B|PDE9A|TNF,cardiology,claudication
COc1ccc([C@@H](O)c2cc(-c3ncnc4cc(N5CCOCC5)ccc34)c(F)cc2Cl)nn1,peposertib,Phase 1/Phase 2,DNA dependent protein kinase inhibitor,,,
CC(C)CC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)[C@@H](O)CC(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)[C@@H](O)CC(=O)O)C(C)C)C(C)C,pepstatin,Preclinical,aspartic protease inhibitor,CTSB|CTSD|CTSL|REN,,
CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(=O)O)C[C@H]1NC(=N)N,peramivir,Launched,neuraminidase inhibitor,,infectious disease,influenza A virus infection
NC(=S)N/N=C/c1ccncc1,perchlozone,Launched,,,infectious disease,tuberculosis
CC(C)=CCC/C(C)=C/CC/C(C)=C/C=C/C(C)=C/C(=O)O,peretinoin,Phase 3,retinoid receptor agonist,RXRA,,
FC1(F)C(F)(F)C(F)(F)C2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C1(F)F,perfluorodecalin,Launched,,,dermatology,cosmetic
CCCCCCCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F,perfluorohexyloctane,Launched,,,,
C1CCC(C(C[C@H]2CCCCN2)C2CCCCC2)CC1,perhexiline,Launched,carnitine palmitoyltransferase inhibitor,CPT1A,cardiology,angina pectoris
CCCCCCCCCCCCCCCCCCOP(=O)(O)OC1CC[N+](C)(C)CC1,perifosine,Phase 3,AKT inhibitor,AKT1,,
CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC,perindopril,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|myocardial infarction|coronary artery disease (CAD)
CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)O,perindoprilat,Phase 2,angiotensin converting enzyme inhibitor,ACE,,
CC1(C)[C@@H](C=C(Cl)Cl)[C@@H]1C(=O)OCc1cccc(Oc2ccccc2)c1,permethrin,Launched,,,infectious disease,lice
O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(c2nsc3ccccc23)CC1,perospirone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,DRD2|DRD3|DRD4,neurology/psychiatry,schizophrenia|bipolar disorder
OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,perphenazine,Launched,dopamine receptor antagonist,CALM1|DRD1|DRD2|HRH1|HTR2A|HTR2C|HTR6|HTR7,neurology/psychiatry|gastroenterology,schizophrenia|nausea|vomiting
CO[C@H]1[C@@H](O)[C@@H](C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@@H](C5=CC(=O)OC5)CC[C@]43O)C2)[C@@H]1O,peruvoside,Phase 1,cardiac glycoside,,,
O=c1c2c(c1=O)N(CCP(=O)(O)O)CCCN2,perzinfotel,Phase 2,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B,,
O[C@@H](Cc1ccncc1)C(Cl)(Cl)Cl,PETCM,Preclinical,caspase activator,CASP3,,
NS(=O)(=O)OC[C@@H]1C[C@@H](n2ccc3c(N[C@H]4CCc5ccccc54)ncnc32)C[C@@H]1O,pevonedistat,Phase 3,nedd activating enzyme inhibitor,NAE1|UBA3,,
FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1,pexidartinib,Launched,tyrosine kinase inhibitor,CSF1R|FLT3|KIT,,
Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)NCc2cc(F)ccc2Oc2ccc3c(cnn3CCO)c2)cc1,pexmetinib,Phase 1,MAP kinase inhibitor|TIE tyrosine kinase inhibitor,MAPK14|TEK,,
Cc1cc(Oc2c(C3CC3)nn(CS(C)(=O)=O)c2C)cc(C)c1C#N,PF-02413873,Phase 1,progesterone receptor antagonist,,,
Cn1cc(-c2ccncc2)c(-c2ccc(OCc3ccc4ccccc4n3)cc2)n1,PF-02545920,Phase 2,phosphodiesterase inhibitor,PDE10A,,
CCCOCCn1c(=O)c(N2CCN(CCO)CC2)nc2cnc(-c3ccc(OC)nc3)cc21,PF-03049423,Phase 2,phosphodiesterase inhibitor,PDE5A,,
CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(C(C)(C)CNCC(C)(C)C)cn1,PF-03084014,Phase 3,gamma secretase inhibitor,,,
Cc1nc(Nc2[nH]nc3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)c2sccc2n1,PF-03758309,Phase 1,p21 activated kinase inhibitor,PAK4,,
CC(=O)NCC(=O)N1[C@@H]2CC[C@H]1c1ccc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)cc12,PF-03814735,Phase 1,Aurora kinase inhibitor,AURKA|AURKB,,
N#Cc1ccc(N2N=C3c4ccc(C(=O)O)cc4CCC3[C@@H]2C2CCCC2)cc1Cl,PF-03882845,Phase 1,mineralocorticoid receptor antagonist,,,
O=C(NCC(=O)N1CC[C@H](N[C@H]2CC[C@@](O)(c3ccc(-c4ncccn4)cn3)CC2)C1)c1cccc(C(F)(F)F)c1,PF-04136309,Phase 2,CC chemokine receptor antagonist,,,
OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1,PF-04217903,Phase 1,c-Met inhibitor,MET,,
COc1ccc2cc(OCC3(C(=O)O)CN(C(=O)c4ccc(F)cc4)C3)ccc2c1,PF-04418948,Phase 1,prostaglandin inhibitor,PTGER2,,
C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc(=O)c2cnn(C3CCOCC3)c2[nH]1,PF-04447943,Phase 2,phosphodiesterase inhibitor,PDE9A,,
O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1,PF-04457845,Phase 2,FAAH inhibitor,FAAH,,
Nc1ncnc2c1C(=O)N(c1ccc([C@H]3CC[C@H](CC(=O)O)CC3)cc1)CCO2,PF-04620110,Phase 1,diacylglycerol O acyltransferase inhibitor,DGAT1,,
COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cn1,PF-04691502,Phase 2,mTOR inhibitor|PI3K inhibitor,MTOR|PIK3CA,,
CC(C)(N)c1nc(-c2ccc(OC(F)(F)F)cc2)c[nH]1,PF-04885614,Preclinical,voltage-gated sodium channel blocker,SCN10A,,
Cc1cnc(NC(=O)c2cc(Oc3cnc(C(=O)N(C)C)nc3)c3cc(C)oc3c2)cn1,PF-04937319,Phase 2,glucokinase activator,GCK,,
OC1(CN2CCC(COc3noc4cccc(O[C@@H]5CCOC5)c34)CC2)CCOCC1,PF-04995274,Phase 1,serotonin receptor agonist,,,
Nc1[nH]ncc1-c1cc(Cl)ccc1Oc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl,PF-05089771,Preclinical,sodium channel blocker,,,
Cc1nc2ccc(C(=O)N3CCC4(CC3)CC(=O)c3c(cnn3C(C)C)C4)cc2[nH]1,PF-05175157,Phase 2,acetyl-CoA carboxylase inhibitor,,,
Cc1nc(-c2cnn(C)c2-c2ccc(C(F)(F)F)cn2)c2c(N3CCC3)ncnn12,PF-05180999,Phase 1,phosphodiesterase inhibitor,,,
Cc1cc(-c2ccc3c(c2)CC[C@H]3N2CC3(CCN(C(=O)Cc4cn5cc(C)sc5n4)CC3)C2)ncn1,PF-05190457,Phase 2,growth hormone secretagogue receptor inverse agonist,GHSR,,
CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1,PF-05212384,Phase 2,mTOR inhibitor|PI3K inhibitor,MTOR|PIK3CA,,
C[C@@H]1CNS(=O)(=O)N(c2ccc3c(C#N)nccc3c2)C1,PF-06260414,Phase 1,androgen receptor modulator,,,
CC(C)(CO)n1cc(C(=O)c2cncc(NC(=O)Cc3ccc(Cl)cn3)c2)c2cnc(N)nc21,PF-06273340,Phase 1,tyrosine kinase receptor inhibitor,,,
COc1ccc(Cl)cc1-c1cc(=O)[nH]c(=S)n1CC(N)=O,PF-06282999,Phase 1,myeloperoxidase inhibitor,,,
C[C@@H](C(N)=O)[C@H](N)c1nc2cc(C(C)(C)C)ccc2[nH]1,PF-06305591,Phase 1,sodium channel blocker,,,
O=C(O)c1c[nH]c2cc(Cl)c(-c3ccc(C4(O)CCC4)cc3)cc12,PF-06409577,Phase 1,protein kinase activator,,,
Cc1cc(Oc2nccc3[nH]ncc23)ccc1-c1c(C)ncnc1C,PF-06412562,Phase 1,dopamine receptor partial agonist,,,
N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1,PF-06447475,Preclinical,serine/threonine kinase inhibitor,LRRK2,,
C=CC(=O)N1C[C@H](COc2nc(Nc3cnn(C)c3)nc3[nH]cc(Cl)c23)[C@@H](OC)C1,PF-06459988,Phase 2,receptor tyrosine protein kinase inhibitor,,,
C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21,PF-06463922,Launched,ALK tyrosine kinase receptor inhibitor,ALK|FES|ROS1,oncology,non-small cell lung cancer (NSCLC)
CC[C@@H]1[C@H](F)C(=O)N[C@@H]1COc1nccc2cc(C(N)=O)c(OC)cc12,PF-06650833,Phase 1,kinase inhibitor,,,
C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C,PF-06651600,Phase 2/Phase 3,JAK inhibitor,,,
C=CC(=O)N[C@@H]1CN(c2nc(Nc3cn(C)nc3OC)c3ncn(C)c3n2)C[C@H]1F,PF-06747775,Phase 2,EGFR inhibitor,,,
C[C@H]1C[C@H]2CSC(N)=N[C@@]2(c2nc(NC(=O)c3ccc(OC(F)F)cn3)cs2)CO1,PF-06751979,Phase 1,beta secretase inhibitor,,,
O=C1C[C@H](c2c[nH]c3ccc(F)cc23)C(=O)N1,PF-06840003,Phase 1,"indoleamine 2,3-dioxygenase inhibitor",,,
C[C@@]1(O)CCC[C@H]1n1c(=O)c(C(F)F)cc2cnc(NC3CCN(S(C)(=O)=O)CC3)nc21,PF-06873600,Phase 2,CDK inhibitor,,,
O=C(N[C@H]1CCCC[C@H]1C(=O)O)c1cnn2c(O)cc(-c3ccccc3)nc12,PF-06928215,Preclinical,cyclic GMP-AMP synthase inhibitor,,,
COCc1nnc(N2CC(Oc3ccc(F)cc3Cl)C2)n1-c1ccc(OC)nc1,PF-3274167,Phase 2,oxytocin receptor antagonist,AVPR1A|OXTR,,
O=C(Nc1cccnc1)N1CCC(Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1,PF-3845,Preclinical,FAAH inhibitor,FAAH,,
Cn1nccc1-c1ccc(Sc2cccc(C3(C(N)=O)CCOCC3)c2)cc1,PF-4191834,Preclinical,lipoxygenase inhibitor,,,
CCN(CC)Cc1ccc(C(=O)N(CCc2ccccc2OC)[C@@H]2CCNC2)cc1,PF-429242,Preclinical,SREBP inhibitor,MBTPS1,,
CN(c1ccccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O,PF-431396,Preclinical,focal adhesion kinase inhibitor,PTK2|PTK2B,,
CCc1cncnc1N1CCN(Cc2nc3ccc(C(F)(F)F)cc3[nH]2)CC1,PF-4708671,Preclinical,ribosomal protein inhibitor,RPS6KB1,,
Cn1cc(-c2[nH]c3cc(NC(=O)[C@H](N)C4CCCCC4)cc4c3c2C=NNC4=O)cn1,PF-477736,Phase 1,CHK inhibitor,CHEK1|CHEK2,,
Nc1ncnc2c1c(COc1cccc(Cl)c1)nn2C1CCOCC1,PF-4800567,Preclinical,casein kinase inhibitor,CSNK1D|CSNK1E,,
Cc1ccc(-c2c(-c3nn(C)c4ncnc(N5CC[C@H](N6CCCCC6)C5)c34)cnn2C)cc1,PF-4981517,Preclinical,cytochrome P450 inhibitor,CYP3A4,,
CC(F)(F)CN1CCOc2c(nn(-c3ccccc3Cl)c2-c2ccc(Cl)cc2)C1=O,PF-514273,Preclinical,cannabinoid receptor antagonist,,,
Cc1cnc(-c2cc(N3CCN(C(=O)CCS(C)(=O)=O)CC3)ncc2Cl)c(C)c1,PF-5274857,Preclinical,smoothened receptor antagonist,SMO,,
CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O,PF-562271,Phase 1,focal adhesion kinase inhibitor,PTK2|PTK2B,,
CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4c(c3)CCC(=O)N4)ncc2C(F)(F)F)c1,PF-573228,Preclinical,focal adhesion kinase inhibitor,CDK1|CDK2|CDK7|GSK3B|IKBKB,,
Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCCCC2)n1,PF-670462,Preclinical,casein kinase inhibitor,CSNK1D|CSNK1E,,
O=C(Nc1ccccc1)N1CCC(Cc2cnc3ccccc3c2)CC1,PF-750,Preclinical,FAAH inhibitor,FAAH,,
O=C(CCN1CCN(C(=O)OCc2cc(Cl)cc(Cl)c2)CC1)c1ccc2[nH]c(=O)oc2c1,PF-8380,Preclinical,autotaxin inhibitor,ENPP2,,
N#Cc1ccc(-c2ccc(S(=O)(=O)Nc3cccc(N)n3)cc2)cc1,PF-915275,Phase 1,11-beta hydroxysteroid dehydrogenase inhibitor,HSD11B1,,
COc1ccccc1S(=O)(=O)Nc1ccc2c(c1)CN(C)C(=O)N2,PFI-1,Preclinical,bromodomain inhibitor,BRD4,,
O=C(/C=C/N1C[C@H]2C[C@@H]1CN2c1ccccn1)c1ccccc1O,PFI-3,Preclinical,bromodomain inhibitor,PBRM1|SMARCA4,,
COc1ccccc1C(=O)Nc1cc2c(cc1N1CCCC1)n(C)c(=O)n2C,PFI-4,Preclinical,bromodomain inhibitor,BRPF1,,
O=C(/C=C/c1ccc2ccccc2n1)c1ccncc1,PFK-015,Phase 1,phosphofructokinase inhibitor,PFKFB3,,
O=C(/C=C/c1ccc2ccc(C(F)(F)F)cc2n1)c1ccncc1,PFK-158,Phase 1,phosphofructokinase inhibitor,PFKFB3,,
C[C@@H](C(=O)O[C@H]1C[C@H]2CC[C@@H](C1)N2C)c1ccc(Br)cc1,PG-9,Preclinical,acetylcholine receptor agonist,,,
N#C[C@H](c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1)c1nc2ccccc2s1,PGL5001,Phase 2,JNK inhibitor,MAPK10|MAPK8|MAPK9,,
CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1,PH-797804,Phase 2,p38 MAPK inhibitor,MAPK11|MAPK14,,
O=C(N[C@H]1CN2CCC1CC2)c1cc2ccoc2cn1,PHA-543613,Preclinical,nicotinic receptor agonist,,,
O=C(N[C@H]1CN2CCC1CC2)c1ccc2c(c1)OCCO2,PHA-568487,Preclinical,nicotinic receptor agonist,CHRNA7,,
Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1,PHA-665752,Preclinical,c-Met inhibitor,MET,,
CCc1cccc(CC)c1NC(=O)N1Cc2n[nH]c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1,PHA-680632,Preclinical,Aurora kinase inhibitor,AURKA|AURKB|AURKC,,
O=C1NCCc2[nH]c(-c3ccncc3)cc21,PHA-767491,Preclinical,CDC inhibitor,CDK1|RPS6KB1,,
CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C,PHA-793887,Phase 1,CDK inhibitor,CDK1|CDK2|CDK4|CDK5|CDK7|CDK9,,
CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2,PHA-848125,Phase 2,CDK inhibitor|growth factor receptor inhibitor,CDK2|CDK4|CDK7|NTRK1,,
O=C(Nc1ccccc1)[C@]12C[C@H]1/C(=N\O)c1ccccc1O2,PHCCC,Preclinical,glutamate receptor agonist,GRM1|GRM4,,
CCOc1ccc(N=C(C)Nc2ccc(OCC)cc2)cc1,phenacaine,Launched,local anesthetic,,neurology/psychiatry,local anesthetic
NC(=O)NC(=O)Cc1ccccc1,phenacemide,Launched,sodium channel blocker,SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,epilepsy|seizures
Cc1cc(=O)n(-c2ccccc2)n1C,phenazone,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief
Nc1ccc(/N=N/c2ccccc2)c(N)n1,phenazopyridine,Launched,local anesthetic,SCN1A,infectious disease,urinary tract infections
NNCCc1ccccc1,phenelzine,Launched,monoamine oxidase inhibitor,ABAT|AOC3|GAD2|GPT|GPT2|MAOA|MAOB|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,depression
C[C@@H](Oc1ccccc1)C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O,phenethicillin,Launched,bacterial cell wall synthesis inhibitor,,,
S=C=NCCc1ccccc1,phenethyl-isothiocyanate,Phase 2,anticancer agent,CYP2E1,,
CN1CCC2=C(C1)[C@H](c1ccccc1)c1ccccc12,phenindamine,Launched,histamine receptor antagonist,HRH1,allergy|otolaryngology,allergic rhinitis|common cold
O=C1c2ccccc2C(=O)C1c1ccccc1,phenindione,Launched,vitamin K antagonist,VKORC1,hematology,deep vein thrombosis (DVT)
CN(C)CC[C@@H](c1ccccc1)c1ccccn1,pheniramine,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis|urticaria
Oc1ccccc1,phenol,Preclinical,,CA1|CA12|CA14|CA2|CA4|CA9,otolaryngology,pharyngitis
O=S1(=O)OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2ccccc21,phenolsulfonphthalein,Launched,,,,
c1ccc2c(c1)Nc1ccccc1S2,phenothiazine,Preclinical,dopamine receptor antagonist,,,
CC(C)=C[C@H]1[C@@H](C(=O)OCc2cccc(Oc3ccccc3)c2)C1(C)C,phenothrin,Launched,,,infectious disease,lice
CC(COc1ccccc1)N(CCCl)Cc1ccccc1,phenoxybenzamine,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C,cardiology|endocrinology,hypertension|pheochromocytoma
NC(=O)OCCCc1ccccc1,phenprobamate,Launched,muscle relaxant,,neurology/psychiatry,anxiety|muscle relaxant
CC[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O,phenprocoumon,Launched,vitamin K antagonist,VKORC1,hematology,thrombosis|pulmonary embolism (PE)
CN1CC[C@@]2(C)c3cc(OC(=O)Nc4ccccc4)ccc3N(C)[C@@H]12,phenserine,Phase 3,acetylcholinesterase inhibitor|beta amyloid synthesis inhibitor,ACHE|BCHE,,
CN1C(=O)C[C@H](c2ccccc2)C1=O,phensuximide,Launched,succinimide antiepileptic,,neurology/psychiatry,seizures
Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1,phentolamine,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C,endocrinology|cardiology,pheochromocytoma|hypertension
Nc1ccc(C(=O)Oc2ccccc2)c(O)c1,phenyl-aminosalicylate,Launched,,,infectious disease,tuberculosis
O=C(Oc1ccccc1)c1ccccc1O,phenyl-salicylate,Launched,antiseptic,,urology,interstitial cystitis (IC)
NC(=O)CC[C@H](NC(=O)Cc1ccccc1)C(=O)O,phenylacetylglutamine,Phase 2,DNA methylase inhibitor|protein synthesis inhibitor,,,
O=S(=O)(O)c1ccc2nc(-c3ccccc3)[nH]c2c1,phenylbenzimidazole-sulfonic-acid,Launched,,,dermatology,sunscreen lotion
O=C(O)CCCc1ccccc1,phenylbutyrate,Launched,HDAC inhibitor,HDAC1,metabolism,urea cycle disorders
CNC[C@H](O)c1cccc(O)c1,phenylephrine,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D,otolaryngology|gastroenterology|cardiology,nasal congestion|hemorrhoids|hypotension
OCCc1ccccc1,phenylethyl-alcohol,Preclinical,,,,
NC(=O)CN1C[C@H](c2ccccc2)CC1=O,phenylpiracetam,Launched,noradrenaline uptake inhibitor,,neurology/psychiatry,anxiety|fatigue|depression
O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1,phenytoin,Launched,hydantoin antiepileptic,SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,seizures
CCn1c2ccccc2c2cc(CNC)ccc21,PhiKan-083,Preclinical,p53 stabilizing agent,TP53,,
O=C(CCc1ccc(O)cc1)c1c(O)cc(O)cc1O,phloretin,Launched,sodium/glucose cotransporter inhibitor,AQP9|CLCN3|SLC23A1,,
O=C(CCc1ccc(O)cc1)c1c(O)cc(O)cc1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,phlorizin,Preclinical,sodium/glucose cotransporter inhibitor,SLC5A1|SLC5A11|SLC5A2|SLC5A3,,
Oc1cc(O)cc(O)c1,phloroglucin,Launched,,,neurology/psychiatry,spasms
Cc1cc(-c2nc3cc(F)ccc3s2)ccc1NC(=O)[C@@H](N)CCCCN,phortress,Phase 1,aryl hydrocarbon receptor ligand,AHR,,
On1ncc(C2CCNCC2)c1-c1cccc(-c2ccccc2)c1,PHP-501,Preclinical,GABA receptor antagonist,GABRA1|GABRB2|GABRG2,,
CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nncs2)cc1,PHT-427,Preclinical,AKT inhibitor|pyruvate dehydrogenase inhibitor,AKT2|PDPK1,,
CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(=O)O)cc1,phthalylsulfacetamide,Preclinical,,,,
O=C(O)c1ccccc1C(=O)Nc1ccc(S(=O)(=O)Nc2nccs2)cc1,phthalylsulfathiazole,Launched,dihydropteroate synthetase inhibitor,,infectious disease|gastroenterology,dysentry|colitis
Oc1ccc(-c2c(-c3ccccc3)nn3c(C(F)(F)F)cc(C(F)(F)F)nc23)cc1,PHTPP,Preclinical,estrogen receptor antagonist,ESR2,,
CNC(=O)Oc1ccc2c(c1)[C@]1(C)CCN(C)[C@@H]1N2C,physostigmine,Launched,acetylcholinesterase inhibitor|cholinesterase inhibitor,ACHE|BCHE,cardiology|neurology/psychiatry|ophthalmology|gastroenterology,hypotension|Alzheimer's disease|glaucoma|gastroparesis
CC1=C(C/C=C(\C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C(=O)c2ccccc2C1=O,phytonadione,Launched,,BGLAP|GGCX,hematology,vitamin K deficiency|anticoagulation reversal
CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO,phytosphingosine,Phase 1,,,,
Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,PI-103,Preclinical,mTOR inhibitor|PI3K inhibitor,MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG|PRKDC,,
Nc1ccc(-c2cccc3c(=O)cc(N4CCOCC4)oc23)cc1,PI-828,Preclinical,PI3K inhibitor,,,
Nc1cc(C(F)(F)F)c(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,PI3K-IN-2,Phase 2,PI3K inhibitor,,,
COc1ncc(-c2nc(N3CCOCC3)nc3c(CN4CCC(C(C)(C)O)CC4)cc(F)cc23)cc1NS(C)(=O)=O,PI3Kd-IN-2,Preclinical,PI3K inhibitor,,,
COc1ccc(-c2sc(NC(=O)C(C)(C)C)nc2C)cc1S(=O)(=O)Nc1ccc(O)cc1,PI4KIII-beta-inhibitor-1,Preclinical,PI4K inhibitor,PI4K2B,,
CN1CCN(c2ccc3nc(-c4ccc5nc(-c6ccc(O)cc6)[nH]c5c4)[nH]c3c2)CC1,pibenzimol,Phase 2,DNA inhibitor,,,
CCCCN1CCC(CNC(=O)c2c3n(c4ccccc24)CCCO3)CC1,piboserod,Phase 2,serotonin receptor antagonist,HTR2B|HTR4,,
CNC(=S)[C@@]1(c2ccccn2)CCCS1,picartamide,Phase 2,H+/K+-ATPase inhibitor,ATP4A,,
Oc1cc(O)cc(/C=C/c2ccc(O)c(O)c2)c1,piceatannol,Preclinical,SYK inhibitor,ATP5A1|ATP5B|ATP5C1|IRF3,,
COc1ccc(C(=O)Nc2c(Cl)cncc2Cl)cc1OC1CCCC1,piclamilast,Phase 2,phosphodiesterase inhibitor,PDE4A|PDE4B|PDE4C|PDE4D,,
NCc1cccnc1,picolamine,Preclinical,,,,
O=C(O)c1ccccn1,picolinic-acid,Phase 2,chelating agent,,,
OCc1ccccn1,piconol,Preclinical,,,,
COc1ccc(C(=O)NCc2cccnc2)cc1C(=O)NCc1cccnc1,picotamide,Launched,thromboxane receptor antagonist|thromboxane synthase inhibitor,TBXA2R,hematology,thrombosis
CC(C)(O)[C@H]1[C@H]2OC(=O)[C@@H]1[C@@]1(O)C[C@H]3O[C@]34C(=O)O[C@@H]2[C@]41C,picrotin,Phase 2,GABA receptor antagonist,GLRA1|GLRA2|GLRA3|GLRB,,
C=C(C)[C@@H]1[C@H]2OC(=O)[C@H]1[C@]1(O)C[C@H]3O[C@]34C(=O)O[C@H]2[C@]14C,picrotoxinin,Preclinical,GABA receptor antagonist,GLRA1|GLRA2|GLRA3|GLRB|HTR3A|HTR3B,,
O=C1CC[C@@H](C(=O)O)N1,pidolic-acid,Launched,,ADAM28|AMY1A|AMY2A|AMY2B|ANG|CCL8|HCRT|IGLC1|KRTAP5-2|TFF2|VEGFA,dermatology,xerosis cutis
O=C1CC[C@@H](C(=O)N2CSC[C@H]2C(=O)O)N1,pidotimod,Launched,interferon receptor agonist|interleukin receptor agonist,,infectious disease,immune adjuvant
Cc1ccc(C(=O)Cn2c3c(sc2=N)CCCC3)cc1,pifithrin-alpha,Preclinical,TP53 inhibitor,TP53,,
Cc1ccc(-c2cn3c4c(sc3n2)CCCC4)cc1,pifithrin-cyclic,Preclinical,TP53 inhibitor,TP53,,
NS(=O)(=O)C#Cc1ccccc1,pifithrin-mu,Preclinical,HSP inhibitor,HSPA1A|TP53,,
Cc1ccccc1-n1c(Cn2ncc3c(N)ncnc32)nc2cccc(C)c2c1=O,PIK-293,Preclinical,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,,
Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc32)nc2cccc(C)c2c1=O,PIK-294,Preclinical,PI3K inhibitor,PIK3CB|PIK3CD|PIK3CG,,
Cc1ccc([N+](=O)[O-])cc1S(=O)(=O)N(C)/N=C/c1cnc2ccc(Br)cn12,PIK-75,Preclinical,DNA protein kinase inhibitor|PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG|PRKDC,,
CC(=O)Nc1nc(C)c(-c2ccc(Cl)c(S(=O)(=O)NCCO)c2)s1,PIK-93,Preclinical,PI3K inhibitor,PI4KB|PIK3C3|PIK3CG,,
O=C(O)CCCNC(=O)c1cccnc1,pikamilone,Phase 1,,,,
Cc1ccnc(NC(=O)[C@H](C)c2cccc(C(=O)c3ccccc3)c2)c1,piketoprofen,Launched,cyclooxygenase inhibitor,,neurology/psychiatry,pain relief
COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1,pilaralisib,Phase 2,PI3K inhibitor,,,
CC[C@@H]1C(=O)OC[C@@H]1Cc1cncn1C,pilocarpine,Launched,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,ophthalmology|cardiology,glaucoma|hypertension
Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2,pilsicainide,Launched,sodium channel blocker,SCN5A,cardiology,cardiac arrythmia
Nc1nccc(-c2ccc3noc(-c4ccc(Cl)cc4)c3c2)n1,PIM-1-Inhibitor-2,Preclinical,Pim kinase inhibitor,PIM1,,
C[C@@H]1C[C@H](N)C[C@H](c2ccncc2NC(=O)c2ccc(F)c(-c3c(F)cccc3F)n2)C1,PIM-447,Phase 1,Pim kinase inhibitor,,,
CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1,pimavanserin,Launched,serotonin receptor inverse agonist,DRD2|HTR2A,neurology/psychiatry,Parkinson's Disease
CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@H](Cl)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,pimecrolimus,Launched,calcineurin inhibitor,,dermatology,eczema
CN1CCC(=C2c3ccccc3Sc3ccccc32)CC1,pimethixene,Launched,antihistamine,,neurology/psychiatry|allergy,attention-deficit/hyperactivity disorder (ADHD)|anxiety|sleep cycle support|allergic rhinitis
COc1ccc(-c2nc3ccc(C4=NNC(=O)C[C@H]4C)cc3[nH]2)cc1,pimobendan,Launched,calcium sensitizer|phosphodiesterase inhibitor,PDE3A,cardiology,congestive heart failure
O=C(O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,pimodivir,Phase 3,antiviral,,,
O=[N+]([O-])c1nccn1C[C@@H](O)CN1CCCCC1,pimonidazole,Phase 3,,,,
O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,pimozide,Launched,dopamine receptor antagonist,CACNA1I|CALM1|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR2A|KCNA10|KCNH2,neurology/psychiatry,Tourette's disorder
C[C@@H](NC(=NC#N)Nc1ccncc1)C(C)(C)C,pinacidil,Launched,ATP channel activator|potassium channel activator,ABCC8|ABCC9,cardiology,hypertension
CC1(C)[C@@H]2C[C@@H](O)[C@@](C)(O)[C@H]1C2,pinanediol,Preclinical,,,,
COc1cc(Br)c(C[N+]2(CCOCC[C@H]3CC[C@@H]4C[C@H]3C4(C)C)CCOCC2)cc1OC,pinaverium,Launched,T-type calcium channel blocker,CACNA1C,gastroenterology,irritable bowel syndrome
Cc1cccc(C)c1NC(=O)CN1CCCCCC1,pincainide,Phase 1,antiarrhythmic,,,
CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12,pindolol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|HTR1A|HTR2A|HTR2B,cardiology,hypertension
CC(C)NC[C@H](O)COc1cccc2[nH]ccc12,pindolol-(-),Phase 2,adrenergic receptor antagonist|serotonin receptor antagonist,HTR1A,,
CO[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H]1O,pinitol,Phase 2,gamma secretase inhibitor,,,
O=C1C[C@@H](c2ccccc2)Oc2cc(O)cc(O)c21,pinocembrin,Phase 2,cytochrome P450 inhibitor,CYP1B1,,
CCc1ccc(CCOc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc1,pioglitazone,Launched,insulin sensitizer|PPAR receptor agonist,PPARG|TRPM3,endocrinology,diabetes mellitus
NC(=O)C1(N2CCCCC2)CCN(CCCC(=O)c2ccc(F)cc2)CC1,pipamperone,Launched,dopamine receptor antagonist,DRD2|HRH1|HTR1A|HTR1B|HTR1D|HTR2A,neurology/psychiatry,schizophrenia
CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H](N3CC[N+](C)(C)CC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CC[N+](C)(C)CC1,pipecuronium,Launched,neuromuscular blocker,CHRM2|CHRM3|CHRNA2,neurology/psychiatry,anesthetic
CCn1cc(C(=O)O)c(=O)c2cnc(N3CCNCC3)nc21,pipemidic-acid,Launched,topoisomerase inhibitor,,infectious disease,gram-negative bacterial infections
CC[N@@+]1(C)CCC[C@H](OC(=O)C(O)(c2ccccc2)c2ccccc2)C1,pipenzolate,Launched,cholinergic receptor antagonist,CHRM1,neurology/psychiatry,spasms
CC(=O)c1ccc2c(c1)N(CCCN1CCC(CCO)CC1)c1ccccc1S2,piperacetazine,Launched,dopamine receptor antagonist,,neurology/psychiatry,schizophrenia
CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H]2SC(C)(C)[C@@H]3C(=O)O)c2ccccc2)C(=O)C1=O,piperacillin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,intra-abdominal infections|skin infections|pelvic inflammatory disease|pneumonia
Clc1ccc2c(N3CCN(CCCN4CCN(c5ccnc6cc(Cl)ccc56)CC4)CC3)ccnc2c1,piperaquine-phosphate,Launched,antimalarial agent,,infectious disease,malaria
C1CNCCN1,piperazine,Launched,benzodiazepine receptor agonist,GABRB3,infectious disease,gastrointestinal roundworms
O=C1CNC(=O)CN1,piperazinedione,Phase 2,DNA synthesis inhibitor,,,
CCN1CCC[C@H](OC(=O)C(c2ccccc2)c2ccccc2)C1,piperidolate,Launched,acetylcholine receptor antagonist,CHRM1,neurology/psychiatry,spasms
O=C(/C=C/C=C/c1ccc2c(c1)OCO2)N1CCCCC1,piperine,Phase 1,monoamine oxidase inhibitor,MAOA|MAOB|TRPV1,,
CCCCOCCOCCOCc1cc2c(cc1CCC)OCO2,piperonyl-butoxide,Launched,cytochrome P450 inhibitor,,infectious disease,lice
O=C(CCBr)N1CCN(C(=O)CCBr)CC1,pipobroman,Launched,DNA alkylating agent,,hematology,polycythemia vera|thrombocythemia
CN1CCN(c2cc3c(nn2)Oc2ccccc2N3C)CC1,pipofezine,Preclinical,selective serotonin reuptake inhibitor (SSRI),,,
CN(C)S(=O)(=O)c1ccc2c(c1)N(CCCN1CCC(CCO)CC1)c1ccccc1S2,pipotiazine,Launched,dopamine receptor antagonist,DRD1|DRD2|HTR1A|HTR2A,neurology/psychiatry,schizophrenia
CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1,pipotiazine-palmitate,Launched,dopamine receptor antagonist|serotonin receptor antagonist,DRD1|DRD2|HTR1A|HTR2A,neurology/psychiatry,schizophrenia
NC(=O)CN1CCCC1=O,piracetam,Launched,acetylcholine receptor agonist,GRIA1|GRIA2|GRIA3|GRIA4,neurology/psychiatry,senile dementia
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O[C@@H]2CCCCO2)[C@H](C)O1,pirarubicin,Launched,topoisomerase inhibitor,TOP2A,oncology,breast cancer
O=C(O)c1cc(=O)c2c3nc4ccccc4oc-3cc(=O)c2[nH]1,pirenoxine,Launched,AGE inhibitor,,ophthalmology,cataracts
Cc1nc2ccccn2c(=O)c1CCN1CCC(C(=O)c2ccc(F)cc2)CC1,pirenperone,Preclinical,serotonin receptor antagonist,HTR2A|HTR7,,
CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc32)CC1,pirenzepine,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,gastroenterology,peptic ulcer disease (PUD)
NS(=O)(=O)c1cc(C(=O)O)cc(N2CCCC2)c1Oc1ccccc1,piretanide,Launched,glucocorticoid receptor agonist,SLC12A1|SLC12A2,cardiology,hypertension|edema
Cc1ccc(=O)n(-c2ccccc2)c1,pirfenidone,Launched,TGF beta receptor inhibitor,FURIN|TNF,pulmonary,idiopathic pulmonary fibrosis (IPF)
c1cnc(N2CCN(Cc3ccc4c(c3)OCO4)CC2)nc1,piribedil,Launched,dopamine receptor agonist,ADRA1A|ADRA2A|ADRA2C|DRD2|DRD3|DRD4|HTR1A|HTR2B,neurology/psychiatry,Parkinson's Disease|dizziness
CC1(C)[C@@H]2CC[C@@]1(C)C(=O)N(CCCCN1CCN(c3ccccn3)CC1)C2=O,piricapiron,Phase 2,dopamine receptor antagonist|serotonin receptor antagonist,HTR2A,,
Cc1cccc(Nc2cc(Cl)nc(SCC(=O)O)n2)c1C,pirinixic-acid,Preclinical,PPAR receptor agonist,PPARA,,
Cc1ccc2c(c1)c1c3n2CCN[C@H]3CCC1,pirlindole,Launched,monoamine oxidase inhibitor,MAOA,neurology/psychiatry,depression
C[C@@H]1CCC[C@H](C)N1CCC[C@@](O)(c1ccccc1)c1ccccn1,pirmenol,Preclinical,acetylcholine receptor inhibitor,,,
Cc1cc(C[C@H](C)CC(C)(C)C)n(O)c(=O)c1,piroctone-olamine,Launched,,,infectious disease,fungal infection
CCOC(=O)c1ccc(OCCC2CCN(c3ccc(C)nn3)CC2)cc1,pirodavir,Phase 2,,,,
CCn1cc(C(=O)O)c(=O)c2cnc(N3CCCC3)nc21,piromidic-acid,Phase 2,bacterial DNA gyrase inhibitor,,,
CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O,piroxicam,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,osteoarthritis|rheumatoid arthritis
CCc1[nH]c(=O)[nH]c1C(=O)c1ccncc1,piroximone,Phase 2,phosphodiesterase inhibitor,PDE3A,,
COc1cc(C(=O)OCc2cccc(COC(=O)c3cc(OC)c(OC)c(OC)c3)n2)cc(OC)c1OC,pirozadil,Preclinical,hypolipidemic,,,
O=c1[nH]c2ccccc2c2cc(CO)nn12,pirquinozol,Phase 1,histamine release inhibitor,,,
O=C1C(c2ccccn2)=[N+]([O-])c2ccccc21,PIT,Preclinical,purinergic receptor antagonist,P2RY1,,
O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1,pitavastatin,Launched,HMGCR inhibitor,HMGCR,endocrinology,hyperlipidemia
Clc1ccc(CCCOCCCN2CCCCC2)cc1,pitolisant,Launched,histamine receptor antagonist,HRH3,,
CC(C)(C)C(=O)NCCCC(=O)O,pivagabine,Launched,corticotropin releasing factor receptor antagonist,CRHR1|CRHR2,neurology/psychiatry,depression
CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1(C)C,pivampicillin,Launched,bacterial cell wall synthesis inhibitor,,pulmonary|infectious disease,bronchitis|pneumonia|gynecologic infections
CCCC(=O)OCOC(=O)C(C)(C)C,pivanex,Phase 2,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC8,,
CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2C(=O)[C@@H](/N=C/N3CCCCCC3)[C@H]2SC1(C)C,pivmecillinam,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,urinary tract infections|gram-negative bacterial infections
NCCNc1ccc(NCCN)c2c1C(=O)c1ccncc1C2=O,pixantrone,Launched,topoisomerase inhibitor,TOP2A,hematologic malignancy,non-Hodgkin lymphoma (NHL)
CN1CCC(=C2c3ccccc3CCc3sccc32)CC1,pizotifen,Launched,serotonin receptor antagonist,HTR1A|HTR2A|HTR2C,neurology/psychiatry,migraine headache
CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1,PJ-34,Preclinical,PARP inhibitor,EEF2|PARP1|PARP15|PARP3,,
CC[C@@H](C)N(C)C(=O)c1cc2ccccc2c(-c2ccccc2Cl)n1,PK-11195,Phase 1,benzodiazepine receptor antagonist,TSPO,,
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1[nH]nc2c(F)c(F)ccc12,PK-44,Preclinical,dipeptidyl peptidase inhibitor,DPP4,,
CCCC(=O)C1CCN(c2ncnc3c2CN(C(=O)c2ccc(-c4ccccc4)cc2)CC3)CC1,PK-THPP,Preclinical,potassium channel blocker,KCNK9,,
C[C@@H](Nc1ncnc2[nH]c(-c3ccc(O)cc3)cc12)c1ccccc1,PKI-166,Phase 1,EGFR inhibitor,EGFR,,
O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3[C@@H]4CC[C@H]3COC4)n2)cc1,PKI-179,Phase 1,mTOR inhibitor|PI3K inhibitor,MTOR,,
Cc1cc(CCCOc2c(C)cc(-c3noc(C(F)(F)F)n3)cc2C)on1,pleconaril,Phase 3,,,,
c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1,plerixafor,Launched,CC chemokine receptor antagonist,ACKR3|CCR4|CXCR4,hematologic malignancy,non-Hodgkin lymphoma (NHL)|multiple myeloma
CO[C@H](C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1Cc2cc3cc(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@@H](O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1,plicamycin,Launched,alcohol dehydrogenase inhibitor,,oncology|endocrinology,testicular carcinoma|Paget's disease|hypercalcemia
CC(C)(C)c1nc[nH]c1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O,plinabulin,Phase 3,tubulin polymerization inhibitor,,,
N[C@@H](Cc1ccc(O)cc1)C(=O)O,plovamer-acetate,Phase 2,,TAT|TH|YARS|YARS2,,
CC1=CC(=O)c2c(O)cccc2C1=O,plumbagin,Preclinical,anticancer agent,,,
O=C(NNc1ccccc1)c1ccncc1,plurisin-1,Preclinical,stearoyl-CoA desaturase inhibitor,SCD,,
CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F,PLX4720,Preclinical,RAF inhibitor,BRAF|KDR,,
Cc1noc(C)c1-c1cnc2c(-c3ccc(C(=O)O)cc3)cn([C@@H](C)c3ccccn3)c2c1,PLX51107,Phase 1,bromodomain inhibitor,,,
FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)cc1,PLX647,Preclinical,receptor tyrosine protein kinase inhibitor,CSF1R|KIT,,
O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12,PLX8394,Phase 1/Phase 2,serine/threonine kinase inhibitor,BRAF,,
COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl,PNU-120596,Preclinical,acetylcholine receptor agonist,CHRNA7,,
CNC(=O)c1ccc2c(c1)CCO[C@H]2CCN1CCN(c2ccc(C(N)=O)cc2)CC1,PNU-142633,Phase 2,serotonin receptor agonist,HTR1D,,
CCCNCCc1ccc(NS(=O)(=O)c2ccc(OC(F)(F)F)cc2)cc1,PNU-177864,Preclinical,dopamine receptor antagonist,DRD3,,
Cn1c2c(c3ccccc31)CCNCC2,PNU-22394,Phase 2,serotonin receptor agonist,HTR2A|HTR2B|HTR2C|MAOA|MAOB,,
O=C(N[C@H]1CN2CCC1CC2)c1ccc(Cl)cc1,PNU-282987,Preclinical,cholinergic receptor agonist,CHRNA7,,
C1CCC(N=C(NC23CC4CC(CC(C4)C2)C3)N2CCOCC2)CC1,PNU-37883,Preclinical,ATP-sensitive potassium channel antagonist,,,
Cc1ccc(/C=N/NC(=O)c2ccccc2Oc2ccccc2)o1,PNU-74654,Preclinical,beta-catenin inhibitor,CTNNB1|TCF4,,
Cc1cc2c(N3CCCC3)nc(N3CCCC3)nc2n1C,PNU-89843,Preclinical,benzodiazepine receptor agonist,GABBR1,,
COc1ccc(OCc2ccc(COc3c(Cl)cccc3Cl)cc2)c(Cl)c1,pocapavir,Preclinical,Enterovirus capsid inhibitor,,,
COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OC,podophyllotoxin,Launched,microtubule inhibitor|tubulin polymerization inhibitor,IGF1R|TOP2A|TUBA4A|TUBB,infectious disease,genital warts
O=C1CCN[Zn]OC(=O)[C@H](Cc2cnc[nH]2)N1,polaprezinc,Preclinical,chelating agent,,,
CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,polidocanol,Launched,local anesthetic,,dermatology,varicose veins
OC[C@H]1O[C@@H](Oc2cc(O)cc(/C=C/c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,polydatin,Phase 2,ICAM1 expression inhibitor,ICAM1,,
O=c1nc[nH]c2c1ncn2[C@H]1O[C@H](COP(=O)(O)O)[C@H](O)[C@H]1O,polyinosine,Preclinical,immunostimulant,HPRT1|IMPDH2|PYGM,,
CC[C@@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H](C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](CCN)NC(=O)[C@@H](CCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O,polymyxin-B-sulfate,Launched,bacterial permeability inducer,,ophthalmology,eye infection
CN1[C@@H](CSCC(F)(F)F)Nc2cc(Cl)c(S(N)(=O)=O)cc2S1(=O)=O,polythiazide,Launched,sodium/chloride cotransporter inhibitor,SLC12A3,cardiology|gastroenterology|rheumatology|nephrology,edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|acute glomerulonephritis (AGN)|chronic renal failure|hypertension
Nc1cccc2c1C(=O)N([C@H]1CCC(=O)NC1=O)C2=O,pomalidomide,Launched,angiogenesis inhibitor|tumor necrosis factor production inhibitor,,hematologic malignancy,multiple myeloma
Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,ponatinib,Launched,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,ABL1|BCR|FGFR1|FGFR2|FGFR3|FGFR4|FLT3|KDR|KIT|LCK|LYN|PDGFRA|RET|SRC|TEK,hematologic malignancy,chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
CCC/N=C1\S/C(=C\c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C,ponesimod,Phase 3,sphingosine 1-phosphate receptor agonist,S1PR1,,
CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O,posaconazole,Launched,sterol demethylase inhibitor,CYP3A4,infectious disease,oropharyngeal candidiasis
C[C@]12CCC(=O)C=C1C=C[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@@]2(O)CCC(=O)O,potassium-canrenoate,Launched,mineralocorticoid receptor antagonist,NR3C2,cardiology,edema
Nc1ccc(C(=O)O)cc1,potassium-p-aminobenzoate,Launched,,,rheumatology|urology,scleroderma|dermatomyositis|Peyronie's disease
Cc1ncccc1OC[C@@H]1CCCN1,pozanicline,Phase 2,acetylcholine receptor antagonist,CHRNA4|CHRNB2,,
C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1,poziotinib,Phase 2,EGFR inhibitor,EGFR|ERBB2|ERBB4,,
Cc1ccc(-c2nn(C(C)(C)C)c3ncnc(N)c23)cc1,PP-1,Preclinical,SRC inhibitor,HCK|RET,,
Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1,PP-121,Preclinical,protein tyrosine kinase inhibitor,ABL1|EGFR|HCK|KDR|MTOR|PDGFRA|PIK3CA|PIK3CB|PIK3CD|PIK3CG|PRKDC|SRC,,
CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc21,PP-2,Preclinical,SRC inhibitor,ABL1|LCK|RIPK2|SRC,,
CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21,PP242,Preclinical,mTOR inhibitor,MTOR|PASK,,
CCCc1c(-c2ccc(O)cc2)nn(-c2ccc(O)cc2)c1-c1ccc(O)cc1,PPT,Preclinical,estrogen receptor agonist,ESR1,,
COc1ccccc1-c1c[nH]c2ncc(-c3cncc(C(=O)N(C)C)c3)cc12,PPY-A,Preclinical,Abl kinase inhibitor,ABL1|BCR,,
COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12,PQ-401,Preclinical,IGF-1 inhibitor,IGF1R,,
N#CSc1cc(SC#N)c(N)nc1N,PR-619,Preclinical,DUB inhibitor,,,
Nc1ncnc2c1ncn2CCOC[P@@]1(=O)OCC[C@@H](c2cccc(Cl)c2)O1,pradefovir,Phase 2,cytochrome P450 activator,,,
C#CC[C@H](Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,pralatrexate,Launched,dihydrofolate reductase inhibitor,DHFR,hematologic malignancy,peripheral T-cell lymphoma (PTCL)
C[n+]1ccccc1/C=N/O,pralidoxime,Launched,acetylcholinesterase inhibitor,ACHE|BCHE,critical care,organophosphate poisoning
C[n+]1ccccc1CN=O,pralidoxime-chloride,Launched,acetylcholinesterase inhibitor,ACHE|BCHE,pulmonary,respiratory depression
C[C@H](NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H](C)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O,pralmorelin,Launched,growth hormone releasing peptide ligand agonist,,,
CCCN[C@H]1CCc2nc(N)sc2C1,pramipexole,Launched,dopamine receptor agonist,ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C,neurology/psychiatry,Parkinson's Disease
CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C,pramiracetam,Launched,acetylcholine receptor agonist,,neurology/psychiatry,senile dementia
CCCCOc1ccc(OCCCN2CCOCC2)cc1,pramoxine,Launched,topical anesthetic,,dermatology,corticosteroid-responsive dermatoses
COC(=O)C1=C(C)NC(C)=C(C(=O)OC/C=C/c2ccccc2)[C@@H]1c1cccc([N+](=O)[O-])c1,pranidipine,Phase 2,calcium channel blocker,CACNA1C,,
O=C(Nc1cccc2c(=O)cc(-c3nn[nH]n3)oc12)c1ccc(OCCCCc2ccccc2)cc1,pranlukast,Launched,leukotriene receptor antagonist,CYSLTR1|CYSLTR2|IL5|MUC2|NFKB1|RNASE3|TNF,pulmonary,bronchospasm|asthma
C[C@@H](C(=O)O)c1ccc2c(c1)Cc1cccnc1O2,pranoprofen,Launched,cyclooxygenase inhibitor,,neurology/psychiatry,pain relief
CC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@@H]3[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]32)C1,prasterone-acetate,Preclinical,,,,
CC(=O)Oc1cc2c(s1)CCN([C@@H](C(=O)C1CC1)c1ccccc1F)C2,prasugrel,Launched,purinergic receptor antagonist,P2RY12,cardiology,myocardial infarction|acute coronary syndrome (ACS)
COc1ccc(C(=O)c2c(C)n(CCN3CCOCC3)c3ccccc23)cc1,pravadoline,Preclinical,cyclooxygenase inhibitor,CNR1|CNR2,,
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,pravastatin,Launched,HMGCR inhibitor,HMGCR|SLCO1B1,endocrinology|cardiology,hypercholesterolemia|myocardial infarction|hyperlipidemia
O=C(C1CCCCC1)N1CC(=O)N2CCc3ccccc3[C@H]2C1,praziquantel,Launched,anthelmintic agent,,infectious disease,gastrointestinal parasites|cystic hydatid disease|schistosomiasis
COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC,prazosin,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|KCNH2|KCNH6|KCNH7,cardiology,hypertension
O=C(OCCN1CCOCC1)C1(c2ccccc2)CCCCC1,PRE-084,Preclinical,sigma receptor agonist,SIGMAR1,,
CCCN1CCC[C@H](c2cccc(O)c2)C1,preclamol,Phase 2,dopamine receptor agonist,DRD2,,
CCOC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@H]3[C@@H](O)C[C@@]21C,prednicarbate,Launched,phospholipase activator,PLA2G1B,dermatology|ophthalmology|neurology/psychiatry,eczema|contact dermatitis|itching
C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO,prednisolone,Launched,glucocorticoid receptor agonist,NR3C1|NR3C2|SERPINA6,ophthalmology|dermatology|infectious disease,conjunctivitis|rosacea|punctate keratitis|shingles|iritis|cyclitis
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,prednisolone-acetate,Launched,glucocorticoid receptor agonist,NR3C1,ophthalmology|dermatology|infectious disease,conjunctivitis|rosacea|punctate keratitis|shingles|iritis|cyclitis
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@H]3[C@@H](O)C[C@@]21C,prednisolone-acetate,Launched,glucocorticoid receptor agonist,NR3C1,ophthalmology|dermatology|infectious disease,conjunctivitis|rosacea|punctate keratitis|shingles|iritis|cyclitis
C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)O,prednisolone-hemisuccinate,Preclinical,glucocorticoid receptor agonist,NR3C1,,
C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)(O)O,prednisolone-sodium-phosphate,Launched,glucocorticoid receptor agonist,NR3C1,allergy|pulmonary|ophthalmology|infectious disease|rheumatology|endocrinology|neurology/psychiatry|gastroenterology|hematology,allergic rhinitis|asthma|contact dermatitis|mycosis|lupus|hypercalcemia|thyroiditis|congenital adrenal hyperplasia|multiple sclerosis|ulcerative colitis|enteritis|thrombocythemia|pneumonia|meningitis|psoriatic arthritis|rheumatoid arthritis
CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@H]3[C@@H](O)C[C@@]21C,prednisolone-tebutate,Launched,anti-inflammatory agent,,,
C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO,prednisone,Launched,glucocorticoid receptor agonist,HSD11B1|NR3C1,endocrinology|rheumatology|infectious disease|dermatology|ophthalmology|hematology|gastroenterology|neurology/psychiatry,congenital adrenal hyperplasia|hypercalcemia|rheumatoid arthritis|psoriatic arthritis|ankylosing spondylitis|bursitis|osteoarthritis|epicondylitis|dermatomyositis|psoriasis|mycosis|conjunctivitis|anemia|ulcerative colitis|enteritis|multiple sclerosis|meningitis
CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,pregnenolone,Launched,glutamate receptor modulator,SULT2B1,rheumatology,rheumatoid arthritis
CC(=O)[C@H]1CC[C@H]2[C@H]3CC=C4C[C@@H](OC(=O)CCC(=O)O)CC[C@]4(C)[C@@H]3CC[C@]12C,pregnenolone-succinate,Preclinical,GABA receptor negative allosteric modulator,CYP17A1,,
COCCOc1ccc(N2CCN(CCn3ncc4c3nc(N)n3nc(-c5ccco5)nc43)CC2)cc1,preladenant,Phase 3,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,presatovir,Phase 2,RSV fusion inhibitor,,,
O=[N+]([O-])c1cn2c(n1)OC[C@@H](OCc1ccc(OC(F)(F)F)cc1)C2,pretomanid,Launched,nitric oxide donor,FASN,,
OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1,pridinol,Launched,muscle relaxant,,neurology/psychiatry,muscle relaxant
CCCN1CCC(c2cccc(S(C)(=O)=O)c2)CC1,pridopidine,Phase 2,dopamine receptor antagonist,,,
CCCN[C@@H](C)C(=O)Nc1ccccc1C,prilocaine,Launched,local anesthetic,SCN5A,neurology/psychiatry,anesthetic
O=C1C2CCN(CC2)C1(CO)CO,PRIMA1,Preclinical,TP53 inhibitor,ACHE,,
COc1cc(N[C@@H](C)CCCN)c2ncccc2c1,primaquine,Launched,antimalarial agent|DNA inhibitor,,infectious disease,malaria
CCC1(c2ccccc2)C(=O)NCNC1=O,primidone,Launched,GABA receptor antagonist,CHRNA4|CHRNA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA2|GRIK2|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,seizures
C=Cc1cc(O)cc2nc(-c3ccc(O)c(F)c3)oc12,prinaberel,Phase 2,estrogen receptor agonist,ESR2|NCOA1,,
CC1(C)SCCN(S(=O)(=O)c2ccc(Oc3ccncc3)cc2)[C@H]1C(=O)NO,prinomastat,Phase 3,matrix metalloprotease inhibitor,,,
C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O,priralfinamide,Phase 3,sodium channel blocker,CACNA1B,,
CC(C)N[C@H](C)Cc1ccc(O)cn1,prisotinol,Phase 2,,,,
Cc1nc(N(C)C(=O)Cc2ccc(-c3ccccn3)cc2)sc1S(N)(=O)=O,pritelivir,Phase 2,helicase primase inhibitor,,,
CCOc1ccccc1-n1c(CN2CCNCC2)nc2ccccc2c1=O,PRLX-93936,Phase 1/Phase 2,voltage-dependent anion selective channel protein inhibitor,,,
CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCN(C2COC2)CC1,PRN1008,Preclinical,Bruton's tyrosine kinase (BTK) inhibitor,,,
C=CC(=O)N1CCN(CCCn2c(=O)c(-c3c(Cl)c(OC)cc(OC)c3Cl)cc3cnc(NC)nc32)CC1,PRN1371,Phase 1,protein tyrosine kinase inhibitor,,,
COCc1c[n+]([O-])c(C)cn1,proacipimox,Phase 1,cholesterol inhibitor,,,
CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1,proadifen,Preclinical,nitric oxide synthase inhibitor,NOS1,,
CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1,probenecid,Launched,uricosuric blocker,PANX1|SLC22A11|SLC22A6|SLC22A8|SLCO1C1,nephrology|rheumatology,hyperuricemia|gout
CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1,probucol,Launched,atherogenesis inhibitor,ABCA1|ABCB11|CES1,cardiology,coronary artery disease (CAD)
CCN(CC)CCNC(=O)c1ccc(N)cc1,procainamide,Launched,sodium channel blocker,DNMT1|SCN5A,cardiology,ventricular arrhythmias|ventricular tachycardia (VT)
CCN(CC)CCOC(=O)c1ccc(N)cc1,procaine,Launched,HMGCR inhibitor,CHRNA2|GRIN3A|HTR3A|KCNMA1|KCNMB1|KCNMB2|KCNMB3|KCNMB4|KCNN1|KCNN2|KCNN3|KCNN4|MAOA|MAOB|RYR1|RYR2|SCN10A|SLC6A3,neurology/psychiatry,anesthetic
CNNCc1ccc(C(=O)NC(C)C)cc1,procarbazine,Launched,monoamine oxidase inhibitor,,hematologic malignancy,Hodgkin's lymphoma
CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,procaterol,Launched,adrenergic receptor agonist,ADRB2,pulmonary,asthma
CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,prochlorperazine,Launched,dopamine receptor antagonist,DRD1|DRD2|DRD3|DRD4,gastroenterology,nausea|vomiting
O=C(O)CCc1nc2ccccc2[nH]1,procodazole,Preclinical,immunostimulant,,,
Oc1cc(O)c2c(c1)O[C@H](c1ccc(O)c(O)c1)[C@H](O)[C@H]2c1c(O)cc(O)c2c1O[C@H](c1ccc(O)c(O)c1)[C@@H](O)C2,procyanidin-B-2,Phase 2,,,,
COc1cc(N[C@@H](C)CCCN)c2ncccc2c1,procyclidine,Launched,acetylcholine receptor antagonist,,neurology/psychiatry,parkinsonism|Parkinson's Disease|akathisia|dystonia
O=C1N[C@H](C(=O)O)CS1,procysteine,Phase 3,glutathione synthase stimulant,,,
CCN(CC)[C@@H](C)CN1c2ccccc2Sc2ccccc21,profenamine,Launched,butyrylcholinesterase inhibitor|cholinergic receptor antagonist,CHRM1,neurology/psychiatry,Parkinson's Disease
Nc1ccc2cc3ccc(N)cc3nc2c1,proflavine-hemisulfate,Phase 2,topical anesthetic,F2,,
CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,progesterone,Launched,progesterone receptor agonist,CATSPER1|CATSPER2|CATSPER3|CATSPER4|CYP17A1|ESR1|NR3C2|OPRK1|PGR|TRPC5,obstetrics/gynecology|endocrinology,infertility|amenorrhea
CCCN(CCC)C(=O)[C@@H](CCC(=O)OCCCN1CCN(CCOC(=O)Cc2c(C)n(C(=O)c3ccc(Cl)cc3)c3ccc(OC)cc23)CC1)NC(=O)c1ccccc1,proglumetacin,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief
CC(C)NC(=N)N=C(N)Nc1ccc(Cl)cc1,proguanil,Launched,dihydrofolate reductase inhibitor,DHFR,infectious disease,malaria
CC(C)C[C@@H](NC(=O)[C@H]1CCCN1)C(=O)NCC(N)=O,prolylleucylglycinamide,Phase 2,melanocyte-stimulating hormone release inhibitor,,,
CN(C)CCCN1c2ccccc2Sc2ccccc21,promazine,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|ADRA1D|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|HRH1|HTR2A|HTR2C,neurology/psychiatry,schizophrenia
CCCOc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](OC)CC[C@@H]12,promestriene,Launched,estrogen receptor agonist,ESR1,endocrinology,androgenetic alopecia
CC(CN1c2ccccc2Sc2ccccc21)N(C)C,promethazine,Launched,histamine receptor antagonist,HRH1,neurology/psychiatry|allergy,sedative|allergic rhinitis
CCN(CC)CC(=O)Oc1ccc(NC(C)=O)cc1,propacetamol,Launched,cyclooxygenase inhibitor,PTGS2,endocrinology|neurology/psychiatry,fever|pain relief
CCCNC[C@@H](O)COc1ccccc1C(=O)CCc1ccccc1,propafenone,Launched,antiarrhythmic,ADRB1|ADRB2|KCNA5|KCNH2,cardiology,atrial fibrillation (AF)|ventricular tachycardia (VT)|ventricular arrhythmias
CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc21)C(C)C,propantheline,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4,gastroenterology,peptic ulcer disease (PUD)
CCC(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-],propatylnitrate,Launched,,,cardiology,angina pectoris
CCCn1cnc2c1c(=O)n(CCCCC(C)=O)c(=O)n2C,propentofylline,Launched,adenosine reuptake inhibitor|phosphodiesterase inhibitor,PDE1A,neurology/psychiatry,stroke
CC[N+](C)(CC)CCC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc21,propidium-iodide,Preclinical,,ACHE,,
O=C1CCO1,propiolactone,Launched,,,infectious disease,antiseptic
CCCOC(C(=O)OC1CCN(C)CC1)(c1ccccc1)c1ccccc1,propiverine,Launched,acetylcholine receptor antagonist,CHRM1,urology,urinary incontinence
CC(C)c1cccc(C(C)C)c1O,propofol,Launched,benzodiazepine receptor agonist,FAAH|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|SCN2A|SCN4A,neurology/psychiatry,anesthetic
CNC(=O)Oc1ccccc1OC(C)C,propoxur,Launched,,,infectious disease,flea control
CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC,propoxycaine,Launched,local anesthetic,,neurology/psychiatry,anesthetic
CC(C)NCC(O)COc1cccc2ccccc12,propranolol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2,cardiology|neurology/psychiatry,hypertension|angina pectoris|migraine headache
CC(C)NC[C@@H](O)COc1cccc2ccccc12,propranolol-(R),Preclinical,adrenergic receptor antagonist,ADRB2|ADRB3,,
CC(C)NC[C@H](O)COc1cccc2ccccc12,propranolol-(S),Preclinical,adrenergic receptor antagonist,ADRB1|HTR1A|HTR5A|SLC10A1,,
CCCOC(=O)c1ccccc1,propyl-benzoate,Launched,,,,
CN[C@@H](C)CC1CCCCC1,propylhexedrine,Launched,adrenergic receptor agonist,,otolaryngology|endocrinology|allergy,nasal congestion|fever|allergic rhinitis
CCCOC(=O)c1ccc(O)cc1,propylparaben,Launched,,,,
CCCc1cc(=O)[nH]c(=S)[nH]1,propylthiouracil,Launched,thyroid peroxidase inhibitor,DIO1|TPO,endocrinology,hyperthyroidism|Grave's disease|goiter
Cc1c(C(C)C)c(=O)n(-c2ccccc2)n1C,propyphenazone,Preclinical,anti-inflammatory agent,,,
Cc1ccc2c(-c3ccccc3)nc(=O)n(C(C)C)c2c1,proquazone,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief
C[C@@H]1O[C@@H](O[C@@H]2C=C3CC[C@@H]4[C@H](CC[C@]5(C)[C@@H](c6ccc(=O)oc6)CC[C@]45O)[C@@]3(C)CC2)[C@H](O)[C@H](O)[C@H]1O,proscillaridin-A,Launched,,,cardiology,congestive heart failure|cardiac arrythmia
CCCc1cc(C(N)=S)ccn1,protionamide,Launched,,,infectious disease,tuberculosis
NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,protirelin,Launched,thyrotropin releasing hormone receptor agonist,TRHR,radiology,thyroid function diagnostic
C=CC1=C(C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)C(C)=C5C=C)c(C)c4CCC(=O)O)c(CCC(=O)O)c3C,protoporphyrin-IX,Preclinical,heme oxygenase inhibitor,HMOX1,,
CNCCCC1c2ccccc2C=Cc2ccccc21,protriptyline,Launched,tricyclic antidepressant,SLC6A2|SLC6A4,neurology/psychiatry,depression
Cc1noc(COc2ccccc2OC[C@@H](O)CNC(C)(C)C)n1,proxodolol,Launched,adrenergic receptor antagonist,,,
c1ccc(COCCCc2cnc[nH]2)cc1,proxyfan,Preclinical,histamine receptor modulator,HRH3,,
CCCOc1ccc(C(=O)OCCN(CC)CC)cc1N,proxymetacaine,Launched,sodium channel blocker,SCN10A|SCN5A,neurology/psychiatry,anesthetic
C[C@@H](O)Cn1cnc2c1c(=O)n(C)c(=O)n2C,Proxyphylline,Launched,,,pulmonary,asthma
CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1,PRT062070,Phase 2/Phase 3,JAK inhibitor|SYK inhibitor,SYK,,
NC(=O)c1cnc(N[C@@H]2CCCC[C@@H]2N)nc1Nc1cccc(-n2nccn2)c1,PRT062607,Phase 2,SYK inhibitor,FGR|MAP3K9|SYK,,
O=C1C(=Cc2cccnc2)C(=O)c2ccccc21,PRT4165,Preclinical,polycomb repressive complex inhibitor,PRC1,,
COCCCN1CCC(NC(=O)c2cc(Cl)c(N)c3c2OCC3)CC1,prucalopride,Launched,serotonin receptor agonist,HTR4,gastroenterology,constipation
Cc1oc(=O)oc1CN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)c2n3[C@@H](C)S2)CC1,prulifloxacin,Launched,bacterial DNA gyrase inhibitor,,infectious disease|pulmonary|gastroenterology,urinary tract infections|bronchitis|diarrhea
N#Cc1c[nH]c2c(C(=O)N3CCN(CCc4ccc(F)cc4)CC3)cccc12,pruvanserin,Phase 2,serotonin receptor antagonist,HTR2A|HTR2C,,
COc1cc(Cl)cc([C@H](C)Nc2cc(N3CCNCC3)ccc2S(C)(=O)=O)c1OC,PRX-07034,Phase 1,serotonin receptor antagonist,,,
N#Cc1cc(CN2CCC(Nc3ncnc4sc(Cl)cc34)CC2)ccc1F,PRX-08066,Phase 2,serotonin receptor antagonist,HTR2B,,
Cc1c(N2C(=O)[C@@H]3[C@H](O)CCN3C2=O)ccc(C#N)c1Cl,PS178990,Phase 1,androgen receptor modulator,AR,,
Nc1c(S(=O)(=O)O)cc(Nc2cccc3ccccc23)c2c1C(=O)c1ccccc1C2=O,PSB-06126,Preclinical,NTPDase inhibitor,ENTPD3,,
CC[C@@H]1CN2C(=O)N(C)c3[nH]c(-c4ccccc4)nc3C2=N1,PSB-11,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA3,,
CCCn1c(=O)[nH]c2nc(-c3ccc(S(=O)(=O)O)cc3)[nH]c2c1=O,PSB-1115,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2B|ADORA3,,
CCCCn1c(=O)c2[nH]c([C@@]34C[C@@H]5C[C@@H](C[C@H]3C5)C4)nc2n(CCCO)c1=O,PSB-36,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
CCCn1c(=O)[nH]c2nc(-c3ccc(S(=O)(=O)N4CCN(c5ccc(Cl)cc5)CC4)cc3)[nH]c2c1=O,PSB-603,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O,PSI-6130,Phase 1,RNA polymerase inhibitor,,,
O=C(O)c1c(O)c(Cc2ccc(Cl)cc2)nc2c3c(ccc12)CCCC3,PSI-697,Phase 1,P selectin inhibitor,,,
CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,PSI-7976,Preclinical,HCV inhibitor,,,
CCCCC1CCC(c2nc(-c3ccncc3)no2)CC1,PSN-375963,Preclinical,glucose dependent insulinotropic receptor agonist,GPR119,,
O=C(Nc1ccc(Cl)cc1)Nc1cccc(-c2cccc(N3CCCC3)n2)c1,PSNCBAM-1,Preclinical,cannabinoid receptor modulator,CNR1,,
O=c1ccc2cc3ccoc3cc2o1,psoralen,Launched,,MAOA|MAOB,dermatology,psoriasis|eczema|vitiligo
CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)C(F)(F)C2,PT-2385,Phase 1,hypoxia inducible factor inhibitor,EPAS1,,
Cc1nc2cc(F)c(F)cc2n1-c1cncc(Nc2ccc(C(F)(F)F)cc2)n1,PTC-028,Preclinical,BMI-1 inhibitor,,,
COc1cc(Br)c(Nc2nc(-c3c(C)nc4ncccn34)cs2)c(Br)c1,PTC-209,Preclinical,BMI-1 inhibitor,,,
COc1cc(/C=C/c2ccc(O)cc2)cc(OC)c1,pterostilbene,Phase 2/Phase 3,cyclooxygenase inhibitor|PPAR receptor agonist,PTGS2,,
CC(C)NCCCn1c(Sc2cc3c(cc2I)OCO3)nc2c(N)ncnc21,PU-H71,Phase 1,HSP inhibitor,HSP90AA1,,
O=c1c(-c2ccc(O)cc2)coc2c([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c(O)ccc12,puerarin,Phase 2,serotonin receptor antagonist,,,
O=C(N[C@H]1CN2CCC1CC2)c1c[nH]c2ccsc2c1=O,pumosetrag,Phase 2,serotonin receptor agonist,HTR3A|HTR4,,
c1ccc2c(Oc3nc(Nc4ccc(N5CCOCC5)cc4)c4ncn(C5CCCCC5)c4n3)cccc2c1,purmorphamine,Preclinical,smoothened receptor agonist,SMO,,
COc1ccc(C[C@H](N)C(=O)N[C@H]2[C@@H](O)[C@H](n3cnc4c(N(C)C)ncnc43)O[C@@H]2CO)cc1,puromycin,Preclinical,protein synthesis inhibitor,NHP2L1|RPL10L|RPL11|RPL13A|RPL15|RPL19|RPL23|RPL23A|RPL26L1|RPL3|RPL37|RPL8|RSL24D1,,
CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1,purvalanol-A,Preclinical,CDK inhibitor,CDK1|CDK2|CDK4|CDK5|CSNK1G3|RPS6KA1|SRC,,
CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(=O)O)c(Cl)c2)c2ncn(C(C)C)c2n1,purvalanol-B,Preclinical,tyrosine kinase inhibitor,CDK2|CDK4|CDK5|MAPK1|MAPK3|SRPK2,,
CC[C@@H](C)SSc1ncc[nH]1,PX-12,Phase 2,thioredoxin inhibitor,CNR1|TXN,,
N[C@@H](Cc1ccc([N+]([O-])(CCCl)CCCl)cc1)C(=O)O,PX-478,Phase 1,hypoxia inducible factor inhibitor,,,
C[C@H]1CC[C@@]2(OC1)O[C@H]1C[C@H]3[C@@H]4CC[C@@H]5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]3(C)[C@H]1[C@@H]2C,PYM50028,Phase 2,neurotrophic agent,,,
CCOC(=O)c1ccc(N2NC(=O)/C(=C/c3ccc([N+](=O)[O-])o3)C2=O)cc1,PYR-41,Preclinical,ubiquitin activating enzyme inhibitor,,,
O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O,pyrantel,Launched,acetylcholine receptor agonist|nicotinic receptor agonist,,infectious disease,gastrointestinal roundworms
CN1CCCN=C1/C=C/c1cccs1,pyrantel-pamoate,Launched,neuromuscular blocker,,infectious disease,hookworm|tapeworm
NC(=O)c1cnccn1,pyrazinamide,Launched,fatty acid synthase inhibitor,FASN,infectious disease,tuberculosis
N=C(N)NC(=O)c1cnccn1,pyrazinoylguanidine,Phase 1,diuretic,,,
O=C1c2ccccc2-c2[nH]nc3cccc1c23,pyrazolanthrone,Preclinical,JNK inhibitor,MAPK10|MAPK8|MAPK8IP1|MAPK9|TTK,,
COc1ccc2nc3c([N+](=O)[O-])ccc4c3c(c2c1)NN4CCCN(C)C,pyrazoloacridine,Phase 2,topoisomerase inhibitor,TOP1|TOP2A,,
C=C/C=C\CC1=C(C)[C@@H](OC(=O)[C@@H]2[C@@H](C=C(C)C)C2(C)C)CC1=O,pyrethrins,Launched,,,infectious disease,flea control
Cc1ncc(CO)c(C=O)c1O,pyridoxal,Launched,,PDXK,neurology/psychiatry,epilepsy
Cc1ncc(CO)c(/C=N/NC(=O)c2ccncc2)c1O,pyridoxal-isonicotinoyl-hydrazone,Phase 2,apoptosis stimulant,,,
Cc1ncc(CO)c(CN)c1O,pyridoxamine,Phase 3,AGE inhibitor,,,
Cc1ncc(CO)c(CO)c1O,pyridoxine,Launched,vitamin B,DDC|PDXK,metabolism,vitamin B6 deficiency
CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1,pyrimethamine,Launched,dihydrofolate reductase inhibitor,DHFR|SLC47A1,infectious disease,malaria
O=S(=O)(NCC1CC1)c1ccc(Nc2nccc(N3CCCc4cc(O)ccc43)n2)cc1,pyrintegrin,Preclinical,integrin signaling activator,,,
Cc1ncc(CSSCc2cnc(C)c(O)c2CO)c(CO)c1O,pyritinol,Launched,,,rheumatology|neurology/psychiatry,rheumatoid arthritis|senile dementia
COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1,pyronaridine,Phase 3,antimalarial agent,,,
CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/[C@H]1CCCN1C,pyrotinib,Phase 3,kinase inhibitor,,,
O=C(CCCCCCC(=O)Nc1cccnc1)NO,pyroxamide,Phase 1,HDAC inhibitor,HDAC1,,
S=C(S)N1CCCC1,pyrrolidine-dithiocarbamate,Preclinical,NFkB pathway inhibitor,HSD11B1|RELA,,
Cc1cc(/C=C/c2ccc3cc(N(C)C)ccc3[n+]2C)c(C)n1-c1ccccc1,pyrvinium-pamoate,Launched,androgen receptor antagonist,AR,infectious disease,pinworm
CC(C)c1ccc(CC(=O)N2CCN(c3ccc(C#N)nn3)CC2)cc1,PZ-2891,Preclinical,pantothenate kinase activator,,,
CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(N2CCC(c3ccc(OC(F)(F)F)cc3)CC2)cc1,Q-203,Phase 2,ATP synthase inhibitor,,,
CC1C(=O)N=C2Nc3cccc(Cl)c3CN21,quazinone,Phase 2,phosphodiesterase inhibitor,PDE3A|PDE3B,,
O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,quercetin,Launched,polar auxin transport inhibitor,ATP5A1|ATP5B|ATP5C1|HCK|HIBCH|PIK3CG|PIM1|STK17B|UGT3A1,neurology/psychiatry|allergy,fatigue|allergic rhinitis|drowsiness
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,quetiapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2C|HTR3A|HTR6|HTR7|SLC6A2,neurology/psychiatry,schizophrenia|bipolar disorder
CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12,quiflapon,Phase 2,leukotriene synthesis inhibitor,ALOX5|ALOX5AP,,
CCCN1C[C@@H](NS(=O)(=O)N(CC)CC)C[C@@H]2Cc3c(O)cccc3C[C@H]21,quinagolide,Launched,dopamine receptor agonist,DRD2,endocrinology,hyperprolactinemia
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O,quinapril,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|congestive heart failure|angioedema
C[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O,quinaprilat,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|angioedema
CCCN1CCC[C@@H]2Cc3nc(N)ncc3C[C@H]21,quinelorane,Phase 3,dopamine receptor agonist,DRD2|DRD3,,
C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(OC5CCCC5)ccc4[C@H]3CC[C@@]21C,quinestrol,Launched,estrogen receptor agonist,ESR1|ESR2,endocrinology,menopause
CC[C@H]1NC(=O)c2cc(S(N)(=O)=O)c(Cl)cc2N1,quinethazone,Launched,thiazide diuretic,,cardiology,hypertension
C=C[C@H]1C[N@@]2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12,quinidine,Launched,sodium channel blocker,KCNA5|KCNA7|KCNH1|KCNH2|KCNH5|KCNK1|KCNK6|SCN5A|SLC29A4,infectious disease|cardiology,malaria|atrial fibrillation (AF)|ventricular arrhythmias
C=C[C@H]1C[N@@]2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12,quinine,Launched,hemozoin biocrystallization inhibitor,GP9|KCNB2|KCNN4|SLC29A4,infectious disease,malaria
C=C[C@H]1C[N@@]2CC[C@H]1C[C@@H]2[C@@H](OC(=O)OCC)c1ccnc2ccc(OC)cc12,quinine-ethyl-carbonate,Launched,,,infectious disease,malaria
O=C(O)c1cccnc1C(=O)O,quinolinic-acid,Preclinical,glutamate receptor agonist,,,
CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21,quinpirol-(-),Phase 2,dopamine receptor agonist,DRD1|DRD2|DRD3|DRD4|HTR1A|HTR2A|HTR2B|HTR2C,,
c1ccc2nc(N3CCNCC3)ccc2c1,quipazine,Preclinical,serotonin receptor agonist,HTR1A|HTR1D|HTR2A|HTR2B|HTR2C|HTR3A|HTR3B|HTR6|SLC6A4,,
CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1,quizartinib,Phase 3,FLT3 inhibitor,CSF1R|FLT3|KIT|PDGFRA|PDGFRB|RET,,
Cc1cccc(C)c1NC(=O)C[N+](C)(C)C,QX-222,Preclinical,sodium channel blocker,,,
CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C,QX-314,Preclinical,sodium channel blocker,MAPK14|TGFBR1,,
CCCN(CCC)c1cc(C)nc2c(-c3cnc(N(C)C)cc3C)c(C)nn12,R-121919,Preclinical,CRF receptor antagonist,,,
[N-]=[N+]=N[C@]1(CO)O[C@@H](n2ccc(N)nc2=O)[C@H](O)[C@@H]1O,R-1479,Phase 1,HCV inhibitor,,,
O=S(=O)(c1ccccc1F)N1CCOc2c(N3CCNCC3)cccc21,R-1485,Phase 1,serotonin receptor antagonist,HTR6,,
Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21,R-1487,Phase 1,p38 MAPK inhibitor,,,
Cc1cccc(-c2n[nH]cc2-c2ccc(F)c(-c3cnn(CCO)c3)c2)n1,R-268712,Preclinical,serine/threonine kinase inhibitor,TGFBR1,,
Nc1nc(Nc2ccc3c(c2)CC[C@@H](N2CCCC2)CC3)nn1-c1cc2c(nn1)-c1ccccc1CCC2,R-428,Phase 2,AXL kinase inhibitor,AXL,,
Cc1nc2sccn2c(=O)c1CCN1CCC(=C(c2ccccc2)c2ccc(F)cc2)CC1,R-59022,Preclinical,diacylglycerol kinase inhibitor|protein kinase inhibitor,DGKA,,
COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1,R-96544,Preclinical,serotonin receptor antagonist,HTR2A,,
Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1,R112,Phase 1,SYK inhibitor,SYK,,
O=C(NO)c1cnc(N2CCN(S(=O)(=O)c3ccc4ccccc4c3)CC2)nc1,R306465,Phase 1,HDAC inhibitor,,,
COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC,R406,Phase 1,SYK inhibitor,RET|SYK,,
COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N,R547,Phase 1,CDK inhibitor,CDK1|CDK2|CDK4|CDK7,,
COCCCOc1ccnc(C[S@@](=O)c2nc3ccccc3[nH]2)c1C,rabeprazole,Launched,ATPase inhibitor|gastrin inhibitor,ATP4A,gastroenterology,gastroesophageal reflux disease (GERD)|duodenal ulcer disease|Zollinger-Ellison syndrome
CC(C)(C)c1cc(C(C)(C)C)c2c(c1)[C@](O)(C(F)(F)F)C(=O)O2,rac-BHFF,Preclinical,GABA receptor positive allosteric modulator,GABBR1,,
CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1,racecadotril,Launched,enkephalinase inhibitor,MME,gastroenterology,diarrhea
CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC,raclopride,Launched,dopamine receptor antagonist,DRD2|DRD3|HTR1A,,
C[C@@H](CCc1ccc(O)cc1)NC[C@@H](O)c1ccc(O)cc1,ractopamine,Launched,adrenergic receptor agonist,,endocrinology,weight-gain aid
Cc1c(N[C@@H](c2nnc(-c3ccc(C#N)cc3)o2)[C@H](C)O)ccc(C#N)c1Cl,RAD140,Phase 1,androgen receptor modulator,,,
C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(Cl)c1,radafaxine,Phase 2,dopamine-norepinephrine reuptake inhibitor,SLC6A3,,
CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(CNCc4cn[nH]n4)cc3)c(F)c2)C(=O)O1,radezolid,Phase 2,bacterial 30S ribosomal subunit inhibitor|bacterial 50S ribosomal subunit inhibitor,,,
O=C(Nc1ccc2[nH]c(=O)oc2c1)C(=O)N1CCC(Cc2ccc(F)cc2)CC1,radiprodil,Phase 2,acetylcholine receptor antagonist,,,
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1,radotinib,Phase 3,Bcr-Abl kinase inhibitor,,,
Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21,RAF265,Phase 2,RAF inhibitor|VEGFR inhibitor,BRAF,,
Cc1ncc(NC(=O)c2cccc(C(F)(F)F)c2)cc1-c1cnc(OC2CCOCC2)c(N2CCOCC2)c1,RAF709,Preclinical,RAF inhibitor,,,
O=C(O)COC[C@H]1CC[C@H](COC(=O)N(c2ccccc2)c2ccc(Cl)cc2)CC1,ralinepag,Phase 3,IP1 prostacyclin receptor agonist,,,
O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,raloxifene,Launched,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),ESR1|ESR2,orthopedics|oncology,osteoporosis|breast cancer
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,raltegravir,Launched,HIV integrase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)
Cc1nc(=O)c2cc(CN(C)c3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)s3)ccc2[nH]1,raltitrexed,Launched,thymidylate synthase inhibitor,FPGS|TYMS,oncology,mesothelioma
O=C(O)CCn1c2c(c3ccccc31)C[C@H](NS(=O)(=O)c1ccc(F)cc1)CC2,ramatroban,Launched,prostanoid receptor antagonist,PTGDR2|TBXA2R,cardiology|pulmonary,coronary artery disease (CAD)|asthma
CCC(=O)NCC[C@@H]1CCc2ccc3c(c21)CCO3,ramelteon,Launched,melatonin receptor agonist,MTNR1A|MTNR1B,neurology/psychiatry,insomnia
Cc1c(NC(C)C)c(=O)n(-c2ccccc2)n1C,ramifenazone,Launched,cyclooxygenase inhibitor,,neurology/psychiatry|endocrinology,pain relief|fever
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,ramipril,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension
Cn1cc(C(=O)[C@@H]2CCc3nc[nH]c3C2)c2ccccc21,ramosetron,Launched,serotonin receptor antagonist,HTR3A,gastroenterology,nausea|vomiting|irritable bowel syndrome
O=C1C[C@@]2(C(=O)N1)C(=O)N(Cc1ccc(Br)cc1F)C(=O)c1cccn12,ranirestat,Phase 3,aldose reductase inhibitor,AKR1B1,,
CN=C(C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1,ranitidine,Launched,histamine receptor antagonist,HRH2,gastroenterology,heartburn
COc1ccccc1OC[C@@H](O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1,ranolazine,Launched,sodium channel blocker,SCN10A|SCN9A,cardiology,chronic stable angina
C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(N)=O)[C@@H](C)O,rapastinel,Phase 2,glutamate receptor agonist,,,
C#CCN[C@@H]1CCc2ccccc21,rasagiline,Launched,monoamine oxidase inhibitor,BCL2|MAOB,neurology/psychiatry,Parkinson's Disease
COC(=O)[C@H]1[C@H]2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@H]2CC[C@@H]1O,rauwolscine,Preclinical,adrenergic receptor antagonist,ADRA2A|ADRA2B|ADRA2C|HTR1B|HTR1D|HTR1E|HTR2B,,
Cn1nccc1Nc1nccc(-c2ccn([C@H](CO)c3ccc(Cl)c(F)c3)c(=O)c2)n1,ravoxertinib,Phase 1,ERK1 and ERK2 phosphorylation inhibitor,MAPK1|MAPK3,,
C[C@@H](c1nc(-c2ccc(C#N)cc2)cs1)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,ravuconazole,Phase 2,sterol demethylase inhibitor,,,
COc1ccc(OC)c([C@H]2c3c(-c4ccc5ccccc5c4)n[nH]c3OC(=N)C2C#N)c1,RBC8,Preclinical,Ral GTPase inhibitor,RALA|RALB,,
O=C(N[C@H](Cc1cc(=O)[nH]c2ccccc12)C(=O)O)c1ccc(Cl)cc1,rebamipide,Launched,free radical scavenger,FPR1,gastroenterology,peptic ulcer disease (PUD)|gastritis
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1,rebastinib,Phase 1/Phase 2,Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor,ABL1|BCR|FGR|FLT3|HCK|LYN|SRC,,
CCOc1ccccc1O[C@H](c1ccccc1)[C@H]1CNCCO1,reboxetine,Launched,adrenergic receptor antagonist,SLC6A2,neurology/psychiatry,depression
COc1cc2nc(N3CCN(C(=O)COc4c(OC)cccc4C(C)C)CC3)nc(N)c2cc1OC,Rec-15/2615,Phase 2,adrenergic receptor antagonist,ADRA1A,,
COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1,refametinib,Phase 2,MEK inhibitor,MAP2K1|MAP2K2,,
CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1,regadenoson,Launched,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,radiology,myocardial perfusion imaging (MPI)
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,regorafenib,Launched,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,ABL1|BRAF|DDR2|EPHA2|FGFR1|FGFR2|FLT1|FLT4|FRK|KDR|KIT|MAPK11|NTRK1|PDGFRA|PDGFRB|RAF1|RET|TEK,oncology,colorectal cancer|gastrointestinal stromal tumors (GIST)
COc1ccc(S(=O)(=O)N2c3ccc(Cl)cc3[C@](O)(c3ccccc3Cl)[C@@H]2C(=O)N2CCC[C@H]2C(N)=O)cc1OC,relcovaptan,Phase 2,vasopressin receptor antagonist,AVPR1A|AVPR1B|AVPR2|OXTR,,
O=C(NC1CCNCC1)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O,relebactam,Launched,beta lactamase inhibitor,,,
CONC(=O)Nc1ccc(-c2sc3c(c2CN(C)C)c(=O)n(-c2ccc(OC)nn2)c(=O)n3Cc2c(F)cccc2F)cc1,relugolix,Phase 3,gonadotropin releasing factor hormone receptor antagonist,,,
C[C@@](Cc1ccccc1)(NC(=O)CN)c1ccccc1,remacemide,Phase 3,glutamate receptor antagonist,GRIN1,,
COC(=O)c1ccc(OC(=O)CCCCCCC(=O)NO)cc1,remetinostat,Phase 2,HDAC inhibitor,,,
COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc21,remimazolam,Phase 3,benzodiazepine receptor agonist,GABBR1,,
N#Cc1ccc(-c2csc(NN=C3CCCC3)n2)cc1,remodelin,Preclinical,transferase inhibitor,NAT10,,
CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O,repaglinide,Launched,insulin secretagogue,ABCC8|KCNJ11|PPARG,endocrinology,diabetes mellitus
CC(C)Cc1ccc([C@@H](C)C(=O)NS(C)(=O)=O)cc1,reparixin,Phase 3,CC chemokine receptor antagonist,CXCR1|CXCR2,,
C[C@H]1CNC(=O)c2cnn3ccc(nc23)N[C@H](C)c2cc(F)ccc2O1,repotrectinib,Phase 1/Phase 2,receptor tyrosine protein kinase inhibitor,,,
Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1,repsox,Preclinical,TGF beta receptor inhibitor,TGFBR1,,
CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl,resatorvid,Phase 3,toll-like receptor inhibitor,TLR4,,
COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC,reserpine,Launched,vesicular monoamine transporter inhibitor,SLC18A1|SLC18A2,cardiology,hypertension
C[C@]12CC[C@H](O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](c3ccc(=O)oc3)C[C@H]3O[C@]132,resibufogenin,Phase 2,Na/K-ATPase inhibitor,,,
CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O,resiquimod,Phase 3,toll-like receptor agonist,TLR7|TLR8,,
CC(C)c1cc(Oc2c(Cl)cc(-n3nc(C#N)c(=O)[nH]c3=O)cc2Cl)nnc1O,resmetirom,Phase 3,thyroid hormone receptor agonist,,,
CN(C)Cc1ccc(S(=O)(=O)n2ccc(/C=C/C(=O)NO)c2)cc1,resminostat,Phase 2,HDAC inhibitor,HDAC1|HDAC3|HDAC6|HDAC8,,
Oc1cccc(O)c1,resorcinol,Launched,phosphodiesterase inhibitor,CA12|CA14|CA2|PTGS1,dermatology,acne vulgaris (AV)|eczema|psoriasis|seborrheic dermatitis
CC(=O)Oc1cccc(O)c1,resorcinol-monoacetate,Launched,antiseptic,,,
Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1,resveratrol,Launched,cytochrome P450 inhibitor|SIRT activator,CSNK2A1|NQO2|PTGS1|PTGS2,,
COC(=O)c1nc(C(F)(F)F)n2c1CN(C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F)CC2,retagliptin,Phase 1,dipeptidyl peptidase inhibitor,,,
C=C[C@]1(C)C[C@@H](OC(=O)CS[C@@H]2C[C@H]3CC[C@@H](C2)N3C)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,retapamulin,Launched,protein synthesis inhibitor,,infectious disease,impetigo
C=CCNc1c(O)cc2c(O)c1C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)N2,retaspimycin,Phase 3,HSP inhibitor,HSP90AA1,,
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=O)C(C)(C)CCC1,retinaldehyde,Launched,,,dermatology,cosmetic
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/CO)C(C)(C)CCC1,retinol,Launched,retinoid receptor ligand,ALDH1A1|ALDH1A2|ALDH1A3|DHRS3|DHRS4|LRAT|NR2C2|RBP1|RBP3|RDH11|RDH12|RDH13|RDH14|RDH5|RDH8|RETSAT|RHO|RLBP1|RXRA|RXRB|RXRG,dermatology,cosmetic|acne vulgaris (AV)|keratosis
CC(=O)OC/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C,retinyl-acetate,Launched,,,,
CCCCCCCCCCCCCCCC(=O)OC/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C,retinyl-palmitate,Launched,,,,
CCCCC[C@@H](O)c1cccc(OCc2ccc3ccccc3n2)c1,REV-5901,Phase 2,leukotriene receptor antagonist|lipoxygenase inhibitor,ALOX5,,
Cc1nc(Nc2ccc(F)cc2)nc(N2CCc3ccccc3[C@H]2C)c1C,revaprazan,Launched,potassium-competitive acid antagonist,ATP4A,gastroenterology,gastritis
CN(CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)C(=O)c1ccc(CN2CCC(C(N)=O)CC2)cc1,revefenacin,Launched,cholinergic receptor antagonist,,,
O=C(NCCCN1CCOCC1)c1cnn2c(-c3ccccc3)cc(-c3ccccc3)nc12,reversan,Preclinical,MRP inhibitor,ABCC1,,
c1nc2nc(Nc3ccc(N4CCOCC4)cc3)nc(NC3CCCCC3)c2[nH]1,reversine,Preclinical,Aurora kinase inhibitor,AURKB|INCENP|MAP2K1,,
O=c1c(O[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,reynoutrin,Preclinical,antioxidant,,,
O=C(O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O,RG108,Preclinical,DNA methyltransferase inhibitor,DNMT1|DNMT3B,,
COc1cc2c(cc1F)C(c1ccccc1Cl)=NC1C(C)=NNC1=N2,RG1530,Phase 1,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FGFR1|FGFR2,,
Cc1ccc(C(=O)NCCCCCC(=O)Nc2ccccc2N)cc1,RG2833,Phase 1,HDAC inhibitor,HDAC1|HDAC3,,
CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@@H]1C(=O)Nc2ccccc2-c2ccccc21,RG4733,Phase 2,gamma secretase inhibitor,PSEN1,,
CCOc1cc(C(C)(C)C)ccc1C1=N[C@@](C)(c2ccc(Cl)cc2)[C@@](C)(c2ccc(Cl)cc2)N1C(=O)N1CCN(CCCS(C)(=O)=O)CC1,RG7112,Phase 1,MDM inhibitor,MDM2,,
CCc1nc(C)cn2nc(-c3cc(=O)n4cc(C5CCN(C)CC5)cc(C)c4n3)cc12,RG7800,Preclinical,RNA splicing modifier,,,
COCCCOc1cc2c(cc1OC)-c1cc(=O)c(C(=O)O)cn1[C@H](C(C)C)C2,RG7834,Preclinical,antiviral,,,
COCCN1CCN(Cc2ccc(-c3n[nH]c4c3C(=O)c3c(NC(=O)NN5CCOCC5)cccc3-4)cc2)CC1,RGB-286638,Phase 1,CDK inhibitor,CDK1|CDK2|CDK3|CDK4|CDK5|CDK6|CDK7|CDK9|FLT3|GSK3B|JAK2|MAP3K7|MAPK9,,
Nc1cc(F)ccc1NC(=O)/C=C/c1cnn(C/C=C/c2ccccc2)c1,RGFP966,Preclinical,HDAC inhibitor,HDAC3,,
C[C@H](CCOc1cccc(CC(=O)O)c1)N(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1,RGX-104,Phase 1,LXR agonist,,,
O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1,RHC-80267,Preclinical,triacylglycerol lipase inhibitor,DAGLA|DAGLB,,
O=C(O)c1cc(O)c2c(c1)C(=O)c1cccc(O)c1C2=O,rhein,Phase 1,,HSP90AA1,,
COc1cc(O)c2c(c1)C(=O)c1cc(C)cc(O)c1C2=O,rheochrysidin,Preclinical,protein tyrosine kinase inhibitor,PTPN1,,
COC(=O)c1ccccc1-c1c2ccc(N)cc2[o+]c2cc(N)ccc12,rhodamine-123,Phase 1,,,,
O=C1C(Cl)=C(N2CCOCC2)C(=O)N1c1ccc(Cl)c(Cl)c1,RI-1,Preclinical,,RAD51,,
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,ribavirin,Launched,antiviral,ADK|ENPP1|IMPDH1|IMPDH2|NT5C2,infectious disease,hepatitis C
OC[C@@H](O)[C@@H](O)[C@@H](O)CO,ribitol,Preclinical,,,,
CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,ribociclib,Launched,CDK inhibitor,CDK4|CDK6,oncology,breast cancer
Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C,riboflavin,Launched,vitamin B,BLVRB|RFK,gastroenterology,jaundice
Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@H](O)[C@H](O)[C@H](O)COP(=O)(O)O)c2cc1C,riboflavin-5-phosphate-sodium,Launched,,BLVRB|DHODH|DPYD|HAO1|HAO2|MT-ND1|NOS1|PNPO|POR|PPCDC|RFK|RPS6KA4|SGK1,,
CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@H](Cn1c2nc(=O)[nH]c(=O)c-2nc2cc(C)c(C)cc21)OC(=O)CCC,riboflavin-tetrabutyrate,Preclinical,antioxidant,,,
NC[C@H]1O[C@H](O[C@H]2[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)[C@@H](O)[C@H](N)C[C@@H]2N)[C@H](N)[C@@H](O)[C@@H]1O,ribostamycin,Launched,bacterial 30S ribosomal subunit inhibitor,P4HB,infectious disease,human immunodeficiency virus (HIV-1)
NC[C@H]1O[C@H](O[C@H]2[C@@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)[C@@H](O)[C@H](N)C[C@@H]2N)[C@H](N)[C@@H](O)[C@@H]1O,ribostamycin-sulfate,Launched,bacterial 30S ribosomal subunit inhibitor,,infectious disease,gram-negative bacterial infections
CCCCCC[C@@H](O)C/C=C\CCCCCCCC(=O)O,ricinoleic-acid,Launched,prostanoid receptor agonist,PTGER3,,
c1cc(-c2nc3ccc(-c4ccc5nc(-c6ccncc6)[nH]c5c4)cc3[nH]2)ccn1,ridinilazole,Phase 3,antibacterial,,,
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(c3C2=O)C2=NC3(CCN(CC(C)C)CC3)NC2=C(NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C4=O,rifabutin,Launched,protein synthesis inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,rifampin,Launched,RNA polymerase inhibitor,NR1I2|SLCO1A2|SLCO1B1|SLCO1B3,infectious disease,tuberculosis|meningitis
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(cc(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,rifamycin,Launched,DNA directed RNA polymerase inhibitor,SLCO1A2|SLCO1B1|SLCO1B3|SLCO2B1,infectious disease,tuberculosis|leprosy
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(cc(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,rifamycin-sv,Phase 3,RNA synthesis inhibitor,,,
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C6CCCC6)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,rifapentine,Launched,RNA polymerase inhibitor,CYP2C8|CYP2C9|CYP3A4,infectious disease,tuberculosis
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,rifaximin,Launched,RNA synthesis inhibitor,,gastroenterology,diarrhea|irritable bowel syndrome|hepatic encephalopathy (HE)
COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1,rigosertib,Phase 3,cell cycle inhibitor|PLK inhibitor,PLK1,,
COCCN1CCC(N(Cc2ccc(-c3ccc(C(F)(F)F)cc3)cc2)C(=O)Cn2c(SCc3cccc(F)c3F)cc(=O)c3ccccc32)CC1,rilapladib,Phase 2,phospholipase inhibitor,,,
C1COC(NC(C2CC2)C2CC2)=N1,rilmenidine,Launched,adrenergic receptor agonist|imidazoline receptor agonist,ADRA2A,cardiology,hypertension
Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,rilpivirine,Launched,non-nucleoside reverse transcriptase inhibitor,NR1I2|SCN10A,infectious disease,human immunodeficiency virus (HIV-1)
Nc1nc2ccc(OC(F)(F)F)cc2s1,riluzole,Launched,glutamate inhibitor,KCNK10|KCNK2|KCNK4|KCNN4|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A|SLC7A11,neurology/psychiatry,amyotrophic lateral sclerosis (ALS)
C[C@@H](N)C12CC3CC(CC(C3)C1)C2,rimantadine,Launched,antiviral|RNA synthesis inhibitor,,infectious disease,influenza A virus infection
C[C@@H]1CN(CCCn2c3ccccc3c3ccccc32)C[C@H](C)N1,rimcazole,Phase 1,sigma receptor antagonist,SIGMAR1,,
N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F,rimegepant,Launched,calcitonin antagonist,CALCA,,
Cc1cc(S(C)(=O)=O)c(S(C)(=O)=O)cc1C(=O)NC(=N)N,rimeporide,Phase 1,sodium/hydrogen exchanger inhibitor,,,
CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,rimexolone,Launched,glucocorticoid receptor agonist,NR3C1|SERPINA6,ophthalmology,anterior uveitis
COC(=O)N(C)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncccc23)nc1N,riociguat,Launched,guanylate cyclase stimulant,GUCY1A2|GUCY1A3|GUCY1B2|GUCY1B3,cardiology,hypertension
COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1OC(F)F,riodipine,Phase 2,calcium channel blocker,,,
C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12,ripasudil,Launched,rho associated kinase inhibitor,ROCK1|ROCK2,ophthalmology,glaucoma|ocular hypertension
CCn1nc(C)c2c1C(c1ccccc1)=NCC(=O)N2,ripazepam,Phase 2,benzodiazepine receptor agonist,GABRA1,,
CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21,ripretinib,Phase 3,receptor tyrosine protein kinase inhibitor,,,
Cc1cn2nc(-c3cc(=O)n4cc(N5CCNC6(CC6)C5)ccc4n3)cc(C)c2n1,risdiplam,Phase 2/Phase 3,RNA splicing inhibitor,,,
Cc1ccc(COC(=O)N2CC[C@H](CNc3ncccn3)[C@H](F)C2)cc1,rislenemdaz,Preclinical,ionotropic glutamate receptor antagonist,,,
Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,risperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2C|HTR6|HTR7,neurology/psychiatry,schizophrenia|bipolar disorder|irritability
OCc1ccc(-c2ccc(-c3ccc(CO)s3)o2)s1,RITA,Preclinical,MDM inhibitor,MDM2,,
Cc1nc2sccn2c(=O)c1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1,ritanserin,Phase 3,serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7,,
CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,ritonavir,Launched,HIV protease inhibitor,CYP1A2|CYP2B6|CYP2C19|CYP2C8|CYP2C9|CYP2D6|CYP2E1|CYP3A4|CYP3A5|CYP3A7,infectious disease,human immunodeficiency virus (HIV-1)
CNCC/C=C/c1cccnc1,rivanicline,Phase 2,acetylcholine receptor agonist,CHRNA4|CHRNB2|CXCL8,,
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,rivaroxaban,Launched,coagulation factor inhibitor,F10,neurology/psychiatry|hematology|cardiology,stroke|systemic embolism|atrial fibrillation (AF)|deep vein thrombosis (DVT)|pulmonary embolism (PE)
CCN(C)C(=O)Oc1cccc([C@H](C)N(C)C)c1,rivastigmine,Launched,acetylcholinesterase inhibitor,ACHE|BCHE,neurology/psychiatry,Alzheimer's disease|Parkinson's Disease|senile dementia
CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12,rizatriptan,Launched,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F,neurology/psychiatry,migraine headache
O=C(NCc1cccc(O)c1)Nc1nc(-c2ccncc2)cs1,RKI-1447,Preclinical,rho associated kinase inhibitor,CDC42BPA|DMPK|LIMK1|MYLK|PAK1|PKN1|ROCK1|ROCK2,,
O=c1c2ccccc2nc2n1CCCCC2,RLX,Preclinical,,,,
Cc1nc(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)c(CO)nc1-c1cccc(Cl)c1Cl,RMC-4550,Preclinical,SHIP2 phosphatase inhibitor,,,
CN1CCN(C(=O)CN[C@@H]2C[C@H]2c2ccc(OCc3ccccc3)cc2)CC1,RN-1,Preclinical,histone demethylase inhibitor,KDM1A,,
CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl,RN-1734,Preclinical,TRPV antagonist,TRPV4,,
O=[N+]([O-])c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1,RN-1747,Preclinical,TRPV agonist,TRPV4,,
COc1cc2c(cc1O)[C@H](CCc1ccc(Cl)cc1)N(C)CC2,Ro-04-5595,Preclinical,glutamate receptor antagonist,GRIN2B,,
Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C)c2cc1C=O,Ro-08-2750,Preclinical,NGF binding inhibitor,NGF|NGFR,,
Cc1ncc(CN2CC=C(c3ccccc3)CC2)c(N)n1,Ro-10-5824,Preclinical,dopamine receptor agonist,DRD4,,
O=[S@@](c1ccccc1)c1ccc2nnnn2n1,Ro-106-9920,Preclinical,NFkB pathway inhibitor,,,
CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1,Ro-1138452,Preclinical,prostanoid receptor antagonist,PTGIR,,
CCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(N=[N+]=[N-])ccc1-2,Ro-15-4513,Preclinical,GABA benzodiazepine site receptor inverse agonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB2|GABRG2,,
CN1Cc2c(C(=O)OC(C)(C)C)ncn2-c2ccsc2C1=O,Ro-19-4605,Preclinical,GABA benzodiazepine site receptor inverse agonist,GABRA1|GABRA2|GABRA3|GABRA5,,
CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC,Ro-20-1724,Preclinical,phosphodiesterase inhibitor,PDE3A|PDE4A|PDE4B|PDE4C|PDE4D,,
C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1,Ro-25-6981,Preclinical,glutamate receptor antagonist|monamine transporter modulator,GRIN2B,,
CS(=O)(=O)c1ccc([C@@H](CC2CCCC2)C(=O)Nc2nccs2)cc1,Ro-28-1675,Preclinical,glucokinase activator,GCK,,
COc1cc(Cc2cnc(N)nc2N)c(C(C)C)cc1OC,Ro-3,Preclinical,purinergic receptor antagonist,P2RX3,,
O=C1N=C(NCc2cccs2)S/C1=C\c1ccc2ncccc2c1,Ro-3306,Preclinical,CDK inhibitor,CDK1,,
CCCN(CCC)Cc1nc(-c2ncn3c2CN(C)C(=O)c2cc(F)ccc2-3)no1,Ro-48-6791,Preclinical,GABA receptor modulator,,,
C=CCN(C)CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1,Ro-48-8071,Preclinical,oxidosqualene cyclase inhibitor,LSS,,
O=C(NOCCO)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F,Ro-4987655,Phase 1,MEK inhibitor,MAP2K1,,
CN(C)CCn1cc(C(=O)N2CCC3(CC2)OCc2ccccc23)c2ccc(Cl)cc21,Ro-5028442,Phase 1,vasopressin receptor antagonist,,,
CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F,Ro-5126766,Phase 1,MEK inhibitor|RAF inhibitor,BRAF|MAP2K1|MAP2K2|RAF1,,
Cc1c(F)cccc1[C@H]1COC(N)=N1,Ro-5263397,Preclinical,trace amine associated receptor agonist,,,
C[C@H](N)Cn1ccc2cc(F)c(Cl)cc21,Ro-60-0175,Preclinical,serotonin receptor agonist,HTR2A|HTR2B|HTR2C,,
COc1ccc(S(=O)(=O)Nc2nc(-c3cccc([N+](=O)[O-])c3)cs2)cc1OC,Ro-61-8048,Preclinical,kynurenine 3-monooxygenase inhibitor,KMO,,
Cc1ccc(S(=O)(=O)N2CCC[C@H]2c2ccc(F)cc2)cc1,Ro-67-7476,Preclinical,glutamate receptor positive allosteric modulator,GRM1,,
Nc1ccc(-c2nc3ccc(-c4nc5ccc(N)cc5[nH]4)cc3[nH]2)cc1,Ro-90-7501,Preclinical,beta amyloid protein neurotoxicity inhibitor,APP,,
[N-]=[N+]=N[C@]1(CO)O[C@@H](n2ccc(N)nc2=O)[C@@H](O)[C@@H]1O,Ro-9187,Preclinical,HCV inhibitor,,,
NC(=O)c1ccc(F)c2c1C[C@@H](N(C1CCC1)C1CCC1)CO2,robalzotan,Phase 2,serotonin receptor antagonist,HTR1A,,
COCCNc1cc(NC(=O)N2CCCc3cc(CN4CCN(C)CC4=O)c(C=O)nc32)ncc1C#N,roblitinib,Preclinical,FGFR inhibitor,,,
C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,rociletinib,Phase 3,EGFR inhibitor,EGFR,,
C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1,rocuronium,Launched,acetylcholine receptor antagonist,CHRM2|CHRNA2|HTR3A,neurology/psychiatry,anesthetic
O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1,roflumilast,Launched,phosphodiesterase inhibitor,PDE4A|PDE4B|PDE4C|PDE4D,pulmonary,chronic obstructive pulmonary disease (COPD)|bronchitis
COCc1c(-c2cc3cc(C)cc(OC)c3s2)c2c(N)ncnn2c1CN1CCNC(=O)C1,rogaratinib,Phase 2/Phase 3,FGFR inhibitor,,,
C[C@@H](OC[C@@]1(c2ccccc2)CC[C@]2(CCC(=O)N2)CN1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,rolapitant,Phase 3,neurokinin receptor antagonist,,,
COc1ccc([C@H]2CNC(=O)C2)cc1OC1CCCC1,rolipram,Phase 3,phosphodiesterase inhibitor,,,
CN(C)[C@@H]1C(=O)C(C(=O)NCN2CCCC2)=C(O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12,rolitetracycline,Launched,bacterial 30S ribosomal subunit inhibitor,,infectious disease,gram-negative bacterial infections|gram-positive bacterial infections
O=C(CN1CCC(CN2Cc3ccccc3C2=O)CC1)c1ccc(F)cc1,roluperidone,Phase 2,,,,
O=C1CCC2CCC(=O)N12,rolziracetam,Phase 2,,,,
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,romidepsin,Launched,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9,hematologic malignancy,cutaneous T-cell lymphoma (CTCL)
Cn1c([N+](=O)[O-])cnc1COC(N)=O,ronidazole,Launched,antiprotozoal agent,,infectious disease,histomoniasis|dysentry
CCCN(CCC)CCc1cccc2c1CC(=O)N2,ropinirole,Launched,dopamine receptor agonist,ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C,neurology/psychiatry,Parkinson's Disease|restless leg syndrome
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,ropivacaine,Launched,sodium channel blocker,SCN10A,neurology/psychiatry,anesthetic
CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1,roquinimex,Phase 3,angiogenesis inhibitor|tumor necrosis factor production inhibitor,,,
CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/[C@]2(C)O[C@H]2[C@@H]1C,rosamicin,Phase 2,protein synthesis inhibitor,,,
CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,roscovitine,Phase 2,CDK inhibitor,CDK2|CDK9,,
O=C(O)c1c(Cl)c(Cl)c(Cl)c(Cl)c1-c1c2cc(I)c(=O)c(I)c-2oc2c(I)c(O)c(I)cc12,rose-bengal,Launched,contrast agent|immunostimulant,,radiology,diagnostic agent
O=C1OC2(c3cc(I)c(O)c(I)c3Oc3c2cc(I)c(O)c3I)c2c(Cl)c(Cl)c(Cl)c(Cl)c21,rose-bengal-lactone,Launched,coloring agent,,ophthalmology,staining agent
C=C1CC[C@H]2[C@H](CN)[C@@H]([C@@]3(C)CC[C@H](O)C[C@@H]3CO)CC[C@]12C,rosiptor,Phase 2,SHIP1 phosphatase activator,,,
O=C(/C=C/c1ccc(O)c(O)c1)O[C@H](Cc1ccc(O)c(O)c1)C(=O)O,rosmarinic-acid,Launched,GABA transaminase inhibitor,MCL1|TYR,,
CCn1cc(C(=O)O)c(=O)c2ccc(-c3ccncc3)cc21,rosoxacin,Launched,topoisomerase inhibitor,,infectious disease,urinary tract infections
C[C@]12CC[C@H](O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(c3ccoc3)CC[C@]12O,rostafuroxine,Phase 2,ATPase inhibitor,ATP1A1,,
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,rosuvastatin,Launched,HMGCR inhibitor,HMGCR,endocrinology|cardiology,hyperlipidemia|dyslipidemia|hypertriglyceridemia|hypercholesterolemia|atherosclerosis
CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1,rotigotine,Launched,dopamine receptor agonist,ADRA2B|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A,neurology/psychiatry,Parkinson's Disease|restless leg syndrome
COc1cc2c(cc1OC)[C@@H]1Cc3ccc(OC)c(OC)c3CN1CC2,rotundine,Launched,serotonin receptor agonist,DRD1|DRD2|DRD3|HTR1A,neurology/psychiatry,anxiety|sedative
CCOC(=O)Cn1nc(C(F)(F)F)cc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,rovazolac,Preclinical,LXR agonist,,,
O=[N+]([O-])c1cc([As](=O)(O)O)ccc1O,roxarsone,Launched,antiprotozoal agent,,endocrinology,weight-gain aid
CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1,roxatidine-acetate,Launched,histamine receptor antagonist,HRH2,gastroenterology,Zollinger-Ellison syndrome|erosive esophagitis (EE)|gastroesophageal reflux disease (GERD)|gastritis
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)/C(=N\OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,roxithromycin,Launched,bacterial 50S ribosomal subunit inhibitor,MLNR,infectious disease,respiratory tract infections|urinary tract infections|skin infections
CC(C)Oc1ccc(-c2nc(-c3cccc4c3CC[C@H]4NCCC(=O)O)no2)cc1C#N,RP-001,Preclinical,sphingosine 1-phosphate receptor agonist,S1PR1,,
COc1ccccc1CC(=N)N1C[C@@H]2C(=O)CCC(c3ccccc3)(c3ccccc3)[C@@H]2C1,RP67580,Preclinical,,,,
O=C(O)c1ccc(S(=O)(=O)N(Cc2ccc(OC(F)(F)F)cc2)c2ncc(C(F)(F)F)cc2Cl)cc1,RQ-00203078,Preclinical,transient receptor potential channel antagonist,TRPM8,,
O=C(CBr)N1CC([N+](=O)[O-])([N+](=O)[O-])C1,RRx-001,Phase 3,glucose 6-phosphate dehydrogenase inhibitor,G6PD,,
C[C@@H](NC(=O)[C@@H]1CSCN1C(=O)c1ccccc1)c1ccccc1,RS-0481,Phase 2,immunostimulant,,,
Cc1c[nH]c(=O)n(CCCN2CCN(c3ccccc3OCC(F)(F)F)CC2)c1=O,RS-100329,Preclinical,adrenergic receptor antagonist,ADRA1A|ADRA1D,,
COc1cc(OC)c(C(=O)CCCCN2CCC3(CC2)NC(=O)NC3=O)cc1NS(=O)(=O)c1ccc(C(F)(F)F)cc1,RS-102221,Preclinical,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,,
O=C1Nc2ccccc2C2(CCN(CCc3ccc(C(F)(F)F)cc3)CC2)O1,RS-102895,Preclinical,CCR antagonist,CCR2,,
CC(C)c1cc(-c2ccc(F)c3ccccc23)nc(N)n1,RS-127445,Phase 1,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,,
CC(C)n1cnc2c(C(=O)N[C@H]3C[N@]4CC[C@@H]3CC4)cc(Cl)cc21,RS-16566,Preclinical,serotonin receptor antagonist,,,
CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1,RS-17053,Preclinical,adrenergic receptor antagonist,ADRA1A|ADRA1D,,
COc1cc(N)c(Cl)cc1C(=O)OCCCN1CCCCC1,RS-23597-190,Preclinical,serotonin receptor antagonist,HTR4,,
COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1,RS-39604,Preclinical,serotonin receptor antagonist,HTR4,,
Clc1cccc2c1CN(C1=NCCN1)C2,RS-45041-190,Preclinical,imidazoline receptor agonist,,,
Cc1ccc2c(c1)C1(CCN(CCc3nc(-c4ccccc4)oc3C)CC1)OC(=O)N2,RS-504393,Preclinical,CC chemokine receptor antagonist,CCL2|CCR2,,
Cn1cc(C(=O)C(=O)N[C@H]2C[N@]3CC[C@@H]2CC3)c2ccccc21,RS-56812,Preclinical,serotonin receptor partial agonist,HTR3A,,
CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1,RS-67333,Preclinical,serotonin receptor partial agonist,HTR4,,
COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1,RS-67506,Preclinical,serotonin receptor partial agonist,HTR4,,
CCS(=O)(=O)N1CCC[C@@H]2CN3CCc4cc(OC)ccc4[C@@H]3C[C@@H]21,RS-79948,Preclinical,adrenergic receptor antagonist,ADRA2A,,
O=C(Nc1ccccc1F)N[C@H]1N=C(c2ccccc2)c2ccccc2NC1=O,RSV604,Phase 2,RSV replication inhibitor,,,
CC1(C)CC[C@]2(NC(=O)C(C)(F)F)CC[C@]3(C)[C@H](C(=O)C=C4[C@@]5(C)C=C(C#N)C(=O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]2C1,RTA-408,Phase 2,nitric oxide production inhibitor,NFE2L2,,
COc1ccc2[nH]cc(C3=CCNCC3)c2c1,RU-24969,Phase 1,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A|HTR6,,
CCC[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(=O)O)[C@H]12,RU-28318,Phase 2,cytochrome P450 inhibitor,NR3C2,,
CC(C)N[C@@H]1CCn2c(=O)[nH]c3cccc(c32)[C@H]1O,RU-42173,Phase 2,adrenergic receptor agonist,ADRB2,,
CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=O)N1CCCCO,RU-58841,Phase 2,androgen receptor antagonist,AR,,
CC[C@@H](C)CNCC(=O)N1CCc2sccc2[C@@H]1COc1cccc(C)c1,RU-SKI-43,Preclinical,hedgehog pathway inhibitor,HHAT,,
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c([N+](=O)[O-])cccc3nc2-1,rubitecan,Phase 3,topoisomerase inhibitor,TOP1,,
CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1,ruboxistaurin,Phase 3,PKC inhibitor,,,
CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,rucaparib,Phase 3,PARP inhibitor,PARP1|PARP2,,
CCCCc1ccc(O)cc1O,rucinol,Phase 1,tyrosinase inhibitor,TYR,,
NC(=O)c1cn(Cc2c(F)cccc2F)nn1,rufinamide,Launched,voltage-gated sodium channel blocker,GRM5|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,seizures
CN1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn4c3c2SCC4)CC1,rufloxacin,Launched,bacterial DNA gyrase inhibitor,,infectious disease,gram-negative bacterial infections
Cc1cncc(CN2CCC(=C3c4ccc(Cl)cc4CCc4cccnc43)CC2)c1,rupatadine,Launched,histamine receptor antagonist|platelet activating factor receptor antagonist,HRH1|PTAFR,allergy,allergic rhinitis|urticaria
O=c1c2ccccc2nc2n1CCc1c-2[nH]c2ccccc12,rutaecarpine,Preclinical,cyclooxygenase inhibitor,PTGS2,,
C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O,rutin,Launched,antioxidant|capillary stabilizing agent|nitric oxide scavenger,AKR1C3,rheumatology|otolaryngology|gastroenterology|neurology/psychiatry|allergy,joint pain|nasal congestion|constipation|irritability|allergic rhinitis
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,ruxolitinib,Launched,JAK inhibitor,JAK1|JAK2|JAK3|TYK2,hematologic malignancy|hematology,myelofibrosis|polycythemia vera
N#CC[C@@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,ruxolitinib-(S),Preclinical,JAK inhibitor,JAK1|JAK2,,
COCCN(CCOC)C(=O)CCCC#Cc1cccc2nc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(Cc3ccccc3Cl)c(=O)c12,RV1729,Phase 1,PI3K inhibitor,,,
C=CCn1c(=O)n([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2[nH]c(N)nc(=O)c21,RWJ-21757,Phase 2,toll-like receptor agonist,TLR7,,
Cc1c(C(=O)NCCCO)cnn1-c1nc(-c2cccc(C(F)(F)F)c2)cs1,RWJ-50271,Preclinical,integrin inhibitor,ICAM1,,
OCCC#Cc1nc(-c2ccc(F)cc2)c(-c2ccncc2)n1CCCc1ccccc1,RWJ-67657,Phase 1,MAP kinase inhibitor,MAPK14|PTGS2,,
Nc1ccn([C@@H]2C(F)=C(CO)[C@@H](O)[C@H]2O)c(=O)n1,RX-3117,Phase 1/Phase 2,CDK inhibitor|DNA synthesis inhibitor,CDK2|DNMT1,,
CO[C@@]1(C2=NCCN2)COc2ccccc2O1,RX-821002,Preclinical,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C,,
Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1,ryuvidine,Preclinical,histone lysine methyltransferase inhibitor,CDK2|CDK4,,
Cc1oc2ccccc2c1CNC(=O)NCc1cccs1,S-07662,Preclinical,CAR antagonist,NR1I3,,
CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@]12C,S-111,Phase 2,PARP inhibitor,PARP1,,
COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1,S-14506,Preclinical,serotonin receptor agonist,HTR1A,,
O=C([C@@H]1C[C@@H]2CCCC[C@@H]2N1C(=O)[C@@H]1C[C@H]1c1ccccc1)N1CCSC1,S-17092,Preclinical,prolyl endopeptidase inhibitor,,,
Cc1ccc(C#Cc2ccc(S(=O)(=O)N[C@H](Cc3c[nH]c4ccccc34)C(=O)O)s2)cc1,S-3304,Phase 1/Phase 2,matrix metalloprotease inhibitor,,,
NC(=O)c1ccc(OCCCN2C[C@H]3CCC[C@H]3C2)cc1,S-38093,Preclinical,histamine receptor antagonist,,,
CC(C)SC(=N)N,S-isopropylisothiourea,Preclinical,nitric oxide synthase inhibitor,NOS3,,
N[C@@H](CCC(=O)N[C@@H](CS[N+][O-])C(=O)NCC(=O)O)C(=O)O,S-nitrosoglutathione,Phase 1,nitric oxide stimulant,PTPN1,,
N[C@@H](CSS(=O)(=O)O)C(=O)O,S-sulfo-L-cysteine,Preclinical,glutamate receptor agonist,,,
N[C@H](CSC(c1ccccc1)(c1ccccc1)c1ccccc1)C(=O)O,S-trityl-L-cysteine,Preclinical,mitotic kinesin inhibitor,,,
c1ccc2c(c1)CC(N1CCN(c3cccc4c3OCCO4)CC1)C2,S15535,Preclinical,serotonin receptor agonist,,,
O=S1(=O)N[C@H]2CCCN2c2ccccc21,S18986,Phase 2,glutamate receptor modulator,GRIA1|GRIA2|GRIA3|GRIA4,,
COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(C(F)(F)F)c1,S1P1-agonist-III,Preclinical,sphingosine kinase inhibitor,S1PR1,,
COC(=O)C(Cc1ccc(OCCn2c(=O)sc3cc(C(=O)c4ccccc4)ccc32)cc1)C(=O)OC,S26948,Preclinical,PPAR receptor agonist,PPARG,,
Cc1cc(C)cc(NC(=O)Nc2ccc(OS(N)(=O)=O)cc2)c1,S4,Preclinical,carbonic anhydrase inhibitor,CA12|CA9,,
O=C1Nc2ccc(CN3C(=O)CSC3=O)cc2/C1=C/c1cc(CN2CCOCC2)c[nH]1,S49076,Preclinical,tyrosine kinase inhibitor,,,
Cc1c(-c2c(-c3ccc(F)o3)sc3ncnc(O[C@H](Cc4ccccc4OCc4ccnn4CC(F)(F)F)C(=O)O)c23)ccc(OCCN2CCN(C)CC2)c1Cl,S63845,Preclinical,MCL1 inhibitor,,,
CNC(=O)COC(=O)NCCC1CCN(c2cccc(C)n2)CC1,SA-47,Preclinical,FAAH inhibitor,FAAH,,
O=C1NS(=O)(=O)c2ccccc21,saccharin,Launched,DNA polymerase inhibitor,CA1|CA12|CA2|CA9,,
NC[C@@H](CS(=O)(=O)O)c1ccc(Cl)cc1,saclofen,Preclinical,GABA receptor antagonist,GABBR1|GABBR2|KCTD12|KCTD16|KCTD8,,
CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O,sacubitril,Launched,neprilysin inhibitor,MME,cardiology,congestive heart failure
C[C@H](C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O)C(=O)O,sacubitrilat,Preclinical,neprilysin inhibitor,,,
O=C1C(=C(O)/C=C/c2ccc(O)cc2)C(=O)[C@@](O)([C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C(=O)/C1=C/[C@H]1C(=O)C(=C(O)/C=C/c2ccc(O)cc2)C(=O)[C@](O)([C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C1=O,safflower-yellow,Preclinical,anti-inflammatory agent,,,
C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O,safinamide,Launched,dopamine reuptake inhibitor|glutamate inhibitor|monoamine oxidase inhibitor,MAOB,neurology/psychiatry,Parkinson's Disease
CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO,safingol,Phase 1,PKC inhibitor,TRPM3,,
CC1=C(C=O)C(C)(C)CC=C1,safranal,Phase 2,benzodiazepine receptor agonist,GABBR1,,
CN[C@H]1CC[C@H](N(Cc2cccc(-c3ccncc3)c2)C(=O)c2sc3ccccc3c2Cl)CC1,SAG,Preclinical,smoothened receptor agonist,SMO|TRPC6,,
O=C(/C=C/c1ccccc1)N[C@@H](NC(=S)Nc1ccc(Cl)cc1)C(Cl)(Cl)Cl,sal003,Preclinical,eukaryotic translation initiation factor inhibitor,EIF2A,,
COc1ccc(NS(=O)(=O)c2ccc(N=Nc3ccc(O)c(C(=O)O)c3)cc2)nn1,salazodine,Phase 2,,,,
OCc1ccccc1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,salicin,Phase 1,anti-inflammatory agent,,,
OCc1ccccc1O,salicyl-alcohol,Preclinical,,,,
NC(=O)c1ccccc1O,salicylamide,Launched,analgesic agent,,neurology/psychiatry|endocrinology,pain relief|fever
O=C(Nc1ccccc1)c1ccccc1O,salicylanilide,Preclinical,other antibiotic,,,
O=C(O)c1ccccc1O,salicylic-acid,Launched,cyclooxygenase inhibitor|prostanoid receptor antagonist,AKR1C1|ASIC3|PTGS1|PTGS2,dermatology|endocrinology|neurology/psychiatry,acne vulgaris (AV)|fever|pain relief
OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O,salidroside,Preclinical,beta amyloid protein neurotoxicity inhibitor,APP,,
CC[C@@H](C(=O)[C@@H](C)[C@@H](O)[C@H](C)[C@@H]1O[C@@H]([C@@H](CC)C(=O)O)CC[C@@H]1C)[C@H]1O[C@]2(C=C[C@@H](O)[C@]3(CC[C@@](C)([C@H]4CC[C@](O)(CC)[C@H](C)O4)O3)O2)[C@H](C)C[C@@H]1C,salinomycin,Launched,,,infectious disease,coccidiosis
CC(C)=CCC/C(C)=C/CC/C(C)=C/CSc1ccccc1C(=O)O,salirasib,Phase 2,mTOR inhibitor,TRPA1,,
OCc1cc([C@@H](O)CNCCCCCCOCCCCc2ccccc2)ccc1O,salmeterol,Launched,adrenergic receptor agonist,ADRB2,pulmonary,asthma|chronic obstructive pulmonary disease (COPD)|bronchospasm
C[C@@]1(C(=O)O)NCCc2cc(O)c(O)cc21,salsolinol-1-carboxylic-acid,Preclinical,,,,
O=C(/C=C/c1ccccc1)N[C@@H](NC(=S)Nc1cccc2cccnc12)C(Cl)(Cl)Cl,salubrinal,Preclinical,eukaryotic translation initiation factor inhibitor,EIF2S1,,
O=C(/C=C/c1ccc(O)c(O)c1/C=C/c1ccc(O)c(O)c1)O[C@H](Cc1ccc(O)c(O)c1)C(=O)O,salvianolic-acid-A,Phase 1,matrix metalloprotease inhibitor,,,
O=C(/C=C/c1ccc(O)c2c1[C@@H](C(=O)O[C@H](Cc1ccc(O)c(O)c1)C(=O)O)[C@H](c1ccc(O)c(O)c1)O2)O[C@H](Cc1ccc(O)c(O)c1)C(=O)O,salvianolic-acid-B,Phase 2,EGFR inhibitor|metalloproteinase inhibitor,MMP9,,
COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C,salvinorin-A,Phase 1,opioid receptor agonist,OPRD1|OPRK1|OPRM1,,
O=S(=O)(c1cccc2ccccc12)c1n[nH]c2ccc(N3CCNCC3)cc12,SAM-315,Preclinical,serotonin receptor antagonist,,,
CCCCCCN1CCC(C(=O)N(C)CC)(c2ccccc2)CC1,sameridine,Preclinical,opioid receptor modulator,,,
COCCNC(=O)Cn1cnc([N+](=O)[O-])n1,sanazole,Phase 1,,,,
CN(C)[C@@H]1C(=O)[C@@H](C(N)=O)C(=O)[C@@]2(O)C(=O)[C@H]3C(=O)c4c(O)cccc4C[C@H]3C[C@@H]12,sancycline,Preclinical,antitumor agent,,,
NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c12,sangivamycin,Phase 1,DNA inhibitor,,,
C[n+]1cc2c3c(ccc2c2ccc4cc5c(cc4c21)OCO5)OCO3,sanguinarium-chloride,Phase 1,apoptosis stimulant,CASP3,,
Cc1nn(-c2ccccc2)c(C)c1/C=N/N1CCN(Cc2ccccc2)CC1,SANT-1,Preclinical,smoothened receptor antagonist,SHH|SMO,,
CCOc1cc(C(=O)Nc2ccc(Cl)c(-c3nc4ccccc4[nH]3)c2)cc(OCC)c1OCC,SANT-2,Preclinical,smoothened receptor antagonist,SHH|SMO,,
CCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N)c(=O)n1,sapacitabine,Phase 3,DNA synthesis inhibitor,,,
C[C@H](O)[C@H](O)[C@H]1CNc2[nH]c(N)nc(=O)c2N1,sapropterin,Launched,phenylalanine 4-hydroxylase stimulant,NOS3|PAH|TH|TPH1,metabolism,hyperphenylalaninemia (HPA)
CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1,saquinavir,Launched,HIV protease inhibitor,CYP3A4,infectious disease,human immunodeficiency virus (HIV-1)
COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)c3ccc(C)c(OC)c3)cc2)cc(OC)c1,SAR-245409,Phase 1/Phase 2,PI3K inhibitor,MTOR|PIK3CG,,
CCn1c(N)c(C(=O)NC)c(=O)c2ccc(C#C[C@@](C)(O)COC)nc21,SAR131675,Preclinical,VEGFR inhibitor,FLT4,,
C[C@@H]1COCCN1c1cc(=O)n2c(n1)N(Cc1cncc(Cl)c1)[C@H](C(F)(F)F)CC2,SAR405,Preclinical,PI3K inhibitor,PIK3C3,,
CC(C)(C)C[C@@H]1N[C@@H](C(=O)N[C@H]2CC[C@H](O)CC2)[C@H](c2cccc(Cl)c2F)[C@]12C(=O)Nc1cc(Cl)ccc12,SAR405838,Phase 1,MDM inhibitor,MDM2,,
O=c1[nH]ccc2cc(OC3CCNCC3)ccc12,SAR407899,Phase 2,rho associated kinase inhibitor,ROCK1,,
CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1,saracatinib,Phase 2/Phase 3,SRC inhibitor,ABL1|LCK|SRC|YES1,,
O=C(O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O,sarafloxacin,Launched,bacterial DNA gyrase inhibitor,,infectious disease,gram-negative bacterial infections|gram-positive bacterial infections
CNCC(=O)O,sarcosine,Phase 2,glycine transporter inhibitor,SLC6A9,,
N=C(N)N/N=C1\CCc2c(C(=N)N)cccc21,sardomozide,Preclinical,S-adenosylmethionine decarboxylase inhibitor,,,
CCc1noc(C)c1-c1[nH]c2ccccc2c1[C@@H](O)CN(C)C,sari-59-801,Phase 1,,,,
CCO[C@@H](Cc1ccc(OCCn2c(C)ccc2-c2ccc(SC)cc2)cc1)C(=O)O,saroglitazar,Launched,PPAR receptor agonist,PPARA|PPARG,endocrinology|cardiology|gastroenterology,diabetes mellitus|dyslipidemia|non-alcoholic steatohepatitis (NASH)
COc1cccc(CCc2ccccc2OC[C@@H](CN(C)C)OC(=O)CCC(=O)O)c1,sarpogrelate,Launched,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,endocrinology|cardiology|rheumatology,diabetes mellitus|angina pectoris|Raynaud's disease|atherosclerosis|Buerger's disease
O=C(Oc1ccccc1C(=O)O)c1ccccc1O,sasapyrine,Launched,NFkB pathway inhibitor,PTGS1|PTGS2,rheumatology,osteoarthritis|rheumatoid arthritis
C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21,savolitinib,Phase 3,c-Met inhibitor,MET,,
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)[C@@]12C[C@@H]3C[C@@H](C[C@@](O)(C3)C1)C2,saxagliptin,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus
Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc21,SB-200646,Preclinical,serotonin receptor antagonist,HTR2B|HTR2C,,
Oc1ccc(-c2nc(-c3ccncc3)c(-c3ccc(F)cc3)[nH]2)cc1,SB-202190,Preclinical,p38 MAPK inhibitor,AKT1|ALOX5|CHEK1|GSK3B|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|ROCK1|RPS6KB1|SGK1,,
O=C(OCCN1CCCCC1)c1c[nH]c2ccccc12,SB-203186,Preclinical,serotonin receptor antagonist,HTR4,,
C[S@@](=O)c1ccc(-c2nc(-c3ccncc3)c(-c3ccc(F)cc3)[nH]2)cc1,SB-203580,Preclinical,p38 MAPK inhibitor,AKT1|ALOX5|CHEK1|CYP2D6|CYP3A4|GAK|GSK3B|LCK|MAPK1|MAPK10|MAPK11|MAPK12|MAPK14|MAPK8|MAPK9|PRKCA|RAF1|RIPK2|ROCK1|RPS6KB1|SGK1|SRC|TNF,,
CC#CCOC(=O)c1c(C)nc2sc3c(c2c1N)CC[C@H](O)C3,SB-205384,Preclinical,GABA receptor modulator,GABRA3|GABRA5|GABRA6,,
Cn1ccc2cc3c(cc21)CCN3C(=O)Nc1cccnc1,SB-206553,Preclinical,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,,
COc1ccc(NC(=O)c2ccc(-c3ccc(-c4noc(C)n4)cc3C)cc2)cc1OCCN(C)C,SB-216641,Preclinical,serotonin receptor antagonist,HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C,,
Cn1cc(C2=C(c3ccc(Cl)cc3Cl)C(=O)NC2=O)c2ccccc21,SB-216763,Preclinical,glycogen synthase kinase inhibitor,CCNA2|CDK2|GSK3A|GSK3B,,
O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1[C@H]1CC[C@H]3O1,SB-218078,Preclinical,CHK inhibitor,CHEK1,,
COC(=O)[C@H](NC(=O)c1cc(-c2ccccc2)nc2ccccc12)c1ccccc1,SB-218795,Preclinical,tachykinin antagonist,TACR3,,
CSc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cccnc1)CC2,SB-221284,Preclinical,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,,
CC[C@H](NC(=O)c1c(C)c(-c2ccccc2)nc2ccccc12)c1ccccc1,SB-222200,Preclinical,tachykinin antagonist,TACR3,,
O=C(Nc1ccc([N+](=O)[O-])cc1O)Nc1ccccc1Br,SB-225002,Preclinical,CC chemokine receptor antagonist,CXCR2,,
COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cc(F)cc(-c3cccnc3)c1)CC2,SB-228357,Preclinical,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,,
Cc1nc2c(-c3cnc(N)nc3)nc(N3CCOCC3)nc2n1C(C)C,SB-2343,Phase 1,mTOR inhibitor|PI3K inhibitor,MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG,,
COc1nccc(-c2c(-c3ccc(F)cc3)ncn2[C@H]2CC[C@H](O)CC2)n1,SB-239063,Preclinical,p38 MAPK inhibitor,MAPK11|MAPK14|PTGS2,,
COc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1,SB-242235,Phase 1,p38 MAPK inhibitor,HSPB1|MAPK14,,
Cc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2,SB-243213,Phase 1,serotonin receptor inverse agonist,HTR2A|HTR2B|HTR2C|HTR6,,
COc1ccc(NS(=O)(=O)c2ccc(I)cc2)cc1N1CCN(C)CC1,SB-258585,Preclinical,serotonin receptor antagonist,HTR6,,
Cc1ccccc1N(C)C(=O)c1ccc([S@@](=O)c2nccs2)c([N+](=O)[O-])c1,SB-268262,Preclinical,calcitonin antagonist,CALCA,,
CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1,SB-269970,Preclinical,serotonin receptor antagonist,HTR7,,
COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1,SB-271046,Phase 1,serotonin receptor antagonist,HTR6,,
CCOC(=O)[C@H](Cc1ccc([N+](=O)[O-])cc1)NC(=O)c1ccccc1,SB-297006,Preclinical,CC chemokine receptor antagonist,CCR3,,
COC(=O)[C@H](Cc1ccc([N+](=O)[O-])cc1)NC(=O)c1cccc2ccccc12,SB-328437,Preclinical,CCR antagonist,,,
Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1,SB-334867,Preclinical,orexin receptor antagonist,HCRTR1|HCRTR2,,
COc1cccc(NC(=O)/C=C/c2ccc(Cl)cc2)c1,SB-366791,Preclinical,TRPV antagonist,TRPV1,,
COc1ccc(S(=O)(=O)Nc2cc(Cl)cc(Cl)c2OC)cc1N1CCNCC1,SB-399885,Preclinical,serotonin receptor antagonist,HTR6,,
Cc1cc(NC(=O)Nc2ccc(N(C)C)cc2)c2cc(F)cc(F)c2n1,SB-408124,Preclinical,orexin receptor antagonist,HCRTR1|HCRTR2,,
O=C1NC(=O)C(c2ccccc2[N+](=O)[O-])=C1Nc1ccc(O)c(Cl)c1,SB-415286,Preclinical,glycogen synthase kinase inhibitor,GSK3A|GSK3B|RPS6KB1,,
NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1,SB-431542,Preclinical,TGF beta receptor inhibitor,ACVR1C|TGFBR1,,
CCN(CCNC(=O)Nc1ccccc1Br)c1cccc(C)c1,SB-452533,Preclinical,TRPV antagonist,TRPV1,,
Cc1cccc(-c2nc(C(C)(C)C)[nH]c2-c2ccc3c(c2)OCO3)n1,SB-505124,Preclinical,ALK tyrosine kinase receptor inhibitor,TGFBR1,,
Cc1cccc(-c2nc(C(C)(C)C)[nH]c2-c2ccc3nccnc3c2)n1,SB-525334,Preclinical,TGF beta receptor inhibitor,TGFBR1,,
CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1,SB-590885,Preclinical,RAF inhibitor,BRAF,,
Cc1cccc2c1CC[C@H](CN1CCC(c3c(Cl)cccc3Cl)CC1)C[C@@H]2O,SB-612111,Preclinical,nociceptin/orphanin FQ receptor antagonist,OPRL1,,
Cc1nc(C(=O)N2CCCC[C@H]2CNC(=O)c2cccc3occc23)c(-c2ccc(F)cc2)s1,SB-649868,Phase 2,orexin receptor antagonist,,,
COc1cc(Br)c(S(=O)(=O)Nc2ccc(Cl)c(O[C@@H]3CCN(C)C3)c2)cc1OC,SB-657510,Preclinical,urotensin receptor antagonist,UTS2R,,
COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(=O)O)cc1,SB-683698,Phase 1,integrin antagonist,ITGA4|ITGAV|ITGB1|ITGB7,,
O=C(Nc1ccccc1Br)N[C@@H]1CCN(c2ccc(C(F)(F)F)cn2)C1,SB-705498,Phase 2,TRPV antagonist,TRPV1,,
COc1cc(Br)c(S(=O)(=O)Nc2ccc(C(F)(F)F)c(O[C@@H]3CCN(C)C3)c2)cc1OC,SB-706375,Preclinical,urotensin receptor antagonist,UTS2R,,
O=S(=O)(c1ccccc1)c1cnc2c(N3CCNCC3)cccc2c1,SB-742457,Phase 3,serotonin receptor antagonist,HTR6,,
Cc1ccc(C(=O)N(CCCN)[C@@H](c2oc3cc(Cl)ccc3c(=O)c2Cc2ccccc2)C(C)C)cc1,SB-743921,Phase 1/Phase 2,kinesin-like spindle protein inhibitor,KIF11,,
CCn1c(-c2nonc2N)nc2cncc(CNC3CCNCC3)c21,SB-747651A,Preclinical,kinase inhibitor,AKT1|AKT3|ROCK1|RPS6KA5|RPS6KB1,,
COc1ccc(S(=O)(=O)N2CCCN(S(=O)(=O)c3ccc(OC)c(OC)c3)CC2)cc1OC,SB-756050,Phase 1,G protein-coupled receptor agonist,GPBAR1,,
CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21,SB-772077B,Preclinical,rho associated kinase inhibitor,ROCK1|ROCK2,,
CCCCc1nc2cc(/C=C/C(=O)NO)ccc2n1CCN(CC)CC,SB-939,Phase 3,HDAC inhibitor,HDAC1|HDAC10|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC9,,
COc1ccc(CCNCc2ccc(OCc3ccc(Cl)nc3)c(OC)c2)cc1OC,SBE-13,Preclinical,PLK inhibitor,PLK1,,
O=C(CCCCCCC(=O)NO)NO,SBHA,Preclinical,HDAC inhibitor,HDAC1|HDAC3,,
CCS(=O)(=O)c1ncc(Cl)c(C(=O)Oc2cccc(C)c2)n1,SBI-115,Preclinical,G protein-coupled receptor antagonist,,,
CCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12,SC-10,Preclinical,protein kinase activator,PRKCA,,
COc1cccc(-c2ccc(NC(=O)C3=C(C(=O)O)CCC3)c(F)c2)c1,SC-12267,Phase 2,dihydroorotate dehydrogenase inhibitor,IL17A,,
O=C(NNc1nc2cc(F)ccc2n2cccc12)c1cnccn1,SC-144,Preclinical,P glycoprotein inhibitor,,,
CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc21,SC-19220,Preclinical,prostanoid receptor antagonist,PTGER1,,
NS(=O)(=O)c1ccc(-n2nc(C(F)(F)F)cc2-c2ccc(Cl)cc2)cc1,SC-236,Preclinical,cyclooxygenase inhibitor,PTGS2,,
O=C(CCc1ccncc1)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc21,SC-51089,Preclinical,prostanoid receptor antagonist,PTGER1,,
COc1ccc(-n2nc(C(F)(F)F)cc2-c2ccc(Cl)cc2)cc1,SC-560,Preclinical,cyclooxygenase inhibitor,PTGS1,,
O=S(=O)(NCCCCCCc1ccccc1)c1cccc2c(Cl)cccc12,SC-9,Preclinical,protein tyrosine kinase activator,PRKCA,,
C=C1C(=O)O[C@@H]2/C=C(/C)C[C@H]3C=C(C[C@H](OC(=O)/C(C)=C\C)[C@@H]12)C(=O)O3,scabertopin,Preclinical,anticancer agent,,,
CN=c1nc(-c2ccccc2)n(-c2ccccc2)s1,SCH-202676,Preclinical,G protein-coupled receptor modulator,CHRM1|CHRM2|DRD1|DRD2,,
Cc1ccccc1C(c1ccccc1C)N1[C@@H]2CC[C@H]1C[C@](O)(c1ccccc1)C2,SCH-221510,Preclinical,nociceptin/orphanin FQ receptor agonist,OPRL1,,
CN1CCc2cc(Cl)c(O)cc2[C@@H](c2ccccc2)C1,SCH-23390,Preclinical,dopamine receptor antagonist,DRD1|DRD5|HTR2C|KCNJ4|KCNJ6,,
Cc1nc2c(OCc3ccccc3)cccn2c1CC#N,SCH-28080,Phase 1,ATPase inhibitor,ATP4A,,
COc1ccc2nc3n[nH]c(C)c3c(NCCOCCO)c2c1,SCH-51344,Preclinical,MTH1 inhibitor,NUDT1,,
Nc1nc2c(cnn2CCc2ccccc2)c2nc(-c3ccco3)nn12,SCH-58261,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
Cn1cc(-c2cnn3c(N)c(Br)c([C@@H]4CCCNC4)nc23)cn1,SCH-900776,Phase 2,CHK inhibitor,CDK2|CHEK1,,
COc1cc2c(c(OC)c1OC)-c1c(cc3c(c1OC)OCO3)C[C@@H](C)[C@@H](C)C2,schisandrin-B,Preclinical,antioxidant,ATR,,
COc1cc2c(c(OC)c1OC)-c1c(cc3c(c1OC)OCO3)C[C@H](C)[C@@](C)(O)C2,schisandrol-B,Phase 3,lipid peroxidase inhibitor,,,
C=CC(C)(O)CC[C@@H]1[C@@]2(C)CCCC(C)(C)[C@@H]2CC[C@@]1(C)O,sclareol,Preclinical,,,,
CC1(C)CCC[C@]2(C)[C@H]3CC(=O)O[C@]3(C)CC[C@@H]12,sclareolide,Launched,other antifungal,,,
CN1[C@@H]2C[C@@H](O)C[C@H]1[C@@H]1O[C@@H]12,scopine,Launched,,,,
CN1[C@@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12,scopolamine,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|SI,neurology/psychiatry|gastroenterology,motion sickness|vomiting|nausea
C[N@+]1([O-])[C@@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12,scopolamine-N-oxide,Preclinical,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4,,
O=C(CN1C(=O)c2ccccc2S1(=O)=O)Nc1ccc(O)cc1,SCP-1,Phase 1,analgesic agent,,,
O=C(CCCCCN1C(=O)c2cccc3cccc(c23)C1=O)NO,scriptaid,Preclinical,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9,,
O=C(N/N=C/c1ccccc1O)c1ccccc1O,SCS,Preclinical,,,,
O=C(CO)N1CCC(c2[nH]nc(-c3ccc(Cl)cc3)c2-c2ccncn2)CC1,SD-0006,Phase 2,p38 MAPK inhibitor,,,
NC(=O)c1ccc2[nH]ccc2c1,SD-169,Preclinical,p38 MAPK inhibitor,MAPK14,,
Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1,SD-208,Preclinical,TGF beta receptor inhibitor,TGFBR1,,
COCCN1CCC(C(=O)NO)(S(=O)(=O)c2ccc(Oc3ccc(OC(F)(F)F)cc3)cc2)CC1,SD-2590,Preclinical,matrix metalloprotease inhibitor,MMP1|MMP13|MMP2,,
C=C(C)CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(O)[C@H]1C5,SDM25N,Preclinical,opioid receptor antagonist,OPRD1,,
CCN(CC)CCOC(=O)c1cc(Cl)c(N)cc1OC,SDZ-205-557,Preclinical,serotonin receptor antagonist,HTR3A|HTR3B,,
CC(C)OC(=O)c1cc2c(OC[C@@H](O)CNC(C)(C)C)cccc2[nH]1,SDZ-21009,Preclinical,adrenergic receptor antagonist|serotonin receptor antagonist,HTR1A|HTR1B,,
N[C@@H](Cc1cc(-c2ccc(Cl)cc2Cl)cc(CP(=O)(O)O)c1O)C(=O)O,SDZ-220-040,Preclinical,glutamate receptor antagonist,GRIN1,,
N[C@@H](Cc1cc(CP(=O)(O)O)cc(-c2ccccc2Cl)c1)C(=O)O,SDZ-220-581,Preclinical,glutamate receptor antagonist,GRIN1,,
CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+](=O)[O-],SDZ-NKT-343,Phase 1,tachykinin antagonist,TACR1,,
CN1CC[C@@H]2CN3CCc4cccc(c43)[C@@H]2C1,SDZ-SER-082,Preclinical,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,,
CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc21,SDZ-WAG-994,Phase 2,adenosine receptor agonist,ADORA1,,
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CC[C@@H](O)C(C)(C)O)CC[C@@H]12,secalciferol,Launched,vitamin D receptor agonist,VDR,critical care,bone fracture
O=C1c2cc(Cl)ccc2O[C@H]2CCON12,seclazone,Phase 1,anti-inflammatory agent,,,
C/C(=N\NC(=O)c1cccc(S(=O)(=O)N2CCN(C)CC2)c1)c1cc(Cl)ccc1O,seclidemstat,Phase 1,histone demethylase inhibitor,,,
Cc1ncc([N+](=O)[O-])n1C[C@@H](C)O,secnidazole,Launched,acetylcholinesterase inhibitor|microtubule inhibitor,,infectious disease,protozoan infection
COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc(O)c(OC)c2)ccc1O,secoisolariciresinol-(-),Phase 2,,,,
COc1cc(C[C@@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)Cc2ccc(O)c(OC)c2)ccc1O,secoisolariciresinol-diglucoside,Phase 2,antioxidant,,,
O=C1C=C2C=C[C@@H]3C[C@@]2(O1)[C@H]1CCCCN31,securinine,Preclinical,GABA receptor antagonist|TP53 activator,GABRA1,,
C=C1C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]2(C)[C@@]1(OC(C)=O)C(C)=O,segesterone-acetate,Launched,progesterone receptor agonist,PGR,,
CCO[C@H](COc1ccc(C(F)(F)F)cc1)CSc1ccc(OCC(=O)O)c(C)c1,seladelpar,Phase 3,PPAR receptor agonist,,,
CO[C@H]1C[C@H](O[C@@H]2/C(C)=C/C[C@@H]3C[C@@H](C[C@]4(CC[C@H](C)[C@@H](C5CCCCC5)O4)O3)OC(=O)[C@@H]3C=C(C)/C(=N/O)[C@H]4OC/C(=C\C=C\[C@@H]2C)[C@]43O)O[C@@H](C)[C@@H]1O,selamectin,Launched,nematocide,,infectious disease,flea control
C#CCN(C)[C@H](C)Cc1ccccc1,selegiline,Launched,monoamine oxidase inhibitor,MAOA|MAOB,neurology/psychiatry,Parkinson's Disease
[O-][n+]1cccc(-c2nc3c(Cl)cccc3cc2[C@@H](Nc2ncnc3cccnc23)C(F)(F)F)c1,seletalisib,Preclinical,PI3K inhibitor,,,
CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(-c2ccccc2)n1,selexipag,Launched,IP1 prostacyclin receptor agonist|platelet aggregation inhibitor,PTGIR,pulmonary,pulmonary arterial hypertension (PAH)
O=C(O)[C@H]1C[C@@H](CP(=O)(O)O)CCN1,selfotel,Phase 3,glutamate receptor antagonist,GRIN2A|GRIN2B|GRIN2C|GRIN2D,,
O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,selinexor,Launched,exportin antagonist,XPO1,hematologic malignancy,multiple myeloma
C[C@@H]1CCc2ncc(F)cc2[C@H]2CCCN2c2ccn3ncc(c3n2)C(=O)N1,selitrectinib,Phase 1/Phase 2,protein tyrosine kinase inhibitor,,,
Cc1cc(F)c(C(=O)Nc2cccc(-c3nncn3C(C)C)n2)cc1-n1cnc(C2CC2)c1,selonsertib,Phase 2,MAP kinase activator,,,
Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21,selumetinib,Phase 3,MEK inhibitor,MAP2K1,,
CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@@H]1C(=O)N(C)CCc2ccccc21,semagacestat,Phase 3,gamma secretase inhibitor,PSEN1,,
CC(=NNC(=N)N)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(C(C)=NNC(=N)N)cc(C(C)=NNC(=N)N)c2)cc(C(C)=NNC(=N)N)c1,semapimod,Phase 2,cytokine production inhibitor|p38 MAPK inhibitor,MAPK14,,
Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1,semaxanib,Phase 3,VEGFR inhibitor,FGFR1|FLT1|KDR|KIT|PDGFRA|PDGFRB|RET,,
CC1CCC(NC(=O)N(CCCl)[NH2+][O-])CC1,semustine,Phase 3,DNA alkylating agent,,,
CN(C)c1cccc(Oc2cnc(Nc3cccc(O)c3)nc2)c1,SEN-1269,Preclinical,beta amyloid inhibitor,APP,,
NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1,senicapoc,Phase 3,intermediate conductance potassium channel blocker,KCNN4,,
O=C(O)c1cc(O)c2c(O)c3c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)cccc3c(-c3c4cc(C(=O)O)cc(O)c4c(O)c4c(O[C@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)cccc34)c2c1,sennoside-A,Launched,glycoside agonist,,gastroenterology,constipation
O=C(O)c1cc(O)c2c(O)c3c(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cccc3c(-c3c4cc(C(=O)O)cc(O)c4c(O)c4c(O[C@H]5O[C@@H](CO)[C@@H](O)[C@@H](O)[C@@H]5O)cccc34)c2c1,sennoside-protonated,Preclinical,,,,
C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/C=C/C(O)(CC)CC)CC[C@@H]23)C[C@@H](O)C[C@@H]1O,seocalcitol,Phase 3,vitamin D receptor agonist,VDR,,
O=C(O)c1cc2occc2[nH]1,SEP-227900,Phase 1,D-amino acid oxidase Inhibitor,DAO,,
CC1=C(C)C(=O)C([C@@H](CCCCCC(=O)O)c2ccccc2)=C(C)C1=O,seratrodast,Launched,prostanoid receptor antagonist,TBXA2R,pulmonary,asthma
c1ccc2c(CCNc3ccc(Nc4ccncc4)cc3)c[nH]c2c1,serdemetan,Phase 1,MDM inhibitor,MDM2,,
NCCc1c[nH]c2ccc(O)cc12,serotonin,Launched,growth factor receptor activator,DRD1|DRD5|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR3A|HTR3B|HTR4|HTR5A|HTR6|HTR7|SLC36A1,neurology/psychiatry,anxiety|depression|sleeplessness
Clc1ccc([C@@H](Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1,sertaconazole,Launched,sterol demethylase inhibitor,,infectious disease,tinea pedis
CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,sertraline,Launched,selective serotonin reuptake inhibitor (SSRI),SLC6A3|SLC6A4,neurology/psychiatry|obstetrics/gynecology,depression|obsessive compulsive disorder (OCD)|panic disorders|posttraumatic stress disorder|premenstrual syndrome|social anxiety disorder
c1cc2c(cc1[C@H]1OC[C@H]3[C@@H]1CO[C@@H]3c1ccc3c(c1)OCO3)OCO2,sesamin,Preclinical,NFkB pathway inhibitor,,,
O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)c1cccc3ccccc13)CC2,setipiprant,Phase 3,prostaglandin inhibitor,PTGDR2,,
CN1CCC2=C(C1)c1ccccc1Cc1ccccc12,setiptiline,Launched,adrenergic receptor antagonist,HRH1|HTR2A|HTR2C,neurology/psychiatry,depression
CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@@H](C)NC1=O,setmelanotide,Phase 3,melanocortin receptor agonist,,,
FC(F)(F)c1cccc(-c2noc(-c3cc(-c4ccccc4)c(C(F)(F)F)s3)n2)c1,SEW-2871,Preclinical,lysophospholipid receptor agonist,S1PR1,,
CCOc1ccc(NC(=S)N2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,SF-11,Preclinical,neuropeptide receptor antagonist,MCOLN3|NPY2R,,
CC(C)N(CCCNC(=O)Nc1ccc(C(C)(C)C)cc1)C[C@H]1O[C@@H](n2cc(Br)c3c(N)ncnc32)[C@H](O)[C@@H]1O,SGC-0946,Preclinical,histone lysine methyltransferase inhibitor,,,
O=C(NCC(=O)N1CCCC1)Nc1ccc2cnccc2c1,SGC-707,Preclinical,protein arginine N-methyltransferase inhibitor,PRMT3,,
COc1ccc(CCc2nc3cc(-c4c(C)noc4C)ccc3n2C[C@H](C)N2CCOCC2)cc1Cl,SGC-CBP30,Preclinical,bromodomain inhibitor,CREBBP|EP300,,
Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1,SGI-1027,Preclinical,DNA methyltransferase inhibitor,DNMT1|DNMT3A|DNMT3B,,
CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1,SGI-1776,Phase 1,Pim kinase inhibitor,FLT3|PIM1|PIM2|PIM3,,
CCCCP(=O)(O)CCCN,SGS-742,Preclinical,GABA receptor antagonist,GABBR1|GABBR2,,
Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1,SGX523,Phase 1,hepatocyte growth factor receptor inhibitor,MET,,
O=C(NCc1ccc(F)cc1)N1CCN2C(=O)OC(c3ccccc3)(c3ccccc3)[C@@H]2C1,SHA-68,Preclinical,neuropeptide receptor antagonist,NPSR1,,
O=C(O)C1=C[C@@H](O)[C@H](O)[C@H](O)C1,shikimic-acid,Preclinical,,,,
CC1(N)CCN(c2cnc(-c3cccc(Cl)c3Cl)c(N)n2)CC1,SHP099,Preclinical,protein tyrosine kinase inhibitor,PTPN11,,
CN1CCC[C@@H]1CCSc1ccc(O)cc1,SIB-1553A,Phase 2,acetylcholine receptor agonist,CHRNB4,,
C=C1C=CC(=O)C(=NNc2ccccc2)N1,SIB-1757,Preclinical,glutamate receptor antagonist,GRM5,,
Cc1cccc(/C=C/c2ccccc2)n1,SIB-1893,Preclinical,glutamate receptor antagonist,GRM4|GRM5,,
CCOC(=O)[C@@H](C)Oc1cccc2c(=O)n(CC(=O)Nc3ccc4c(c3)OCCO4)ccc12,SID-7969543,Preclinical,steroidogenic factor antagonist,NR5A1,,
CN/C(=N\c1ccc(C2=NNC(=O)C[C@@H]2C)cc1)NC#N,siguazodan,Phase 1,phosphodiesterase inhibitor,PDE3A,,
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,sildenafil,Launched,phosphodiesterase inhibitor,PDE5A|PDE6G|PDE6H|SLCO1B1|SLCO1B3,urology,erectile dysfunction
COc1cc([C@H]2Oc3cc([C@H]4Oc5cc(O)cc(O)c5C(=O)[C@@H]4O)ccc3O[C@@H]2CO)ccc1O,silibinin,Launched,cytochrome P450 inhibitor,ALOX5,gastroenterology,hepatic cirrhosis
C[C@H](Cc1cc2c(c(C(N)=O)c1)N(CCCO)CC2)NCCOc1ccccc1OCC(F)(F)F,silodosin,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D,urology,benign prostatic hyperplasia (BPH)
Nc1ccc(S(=O)(=O)N([Ag])c2ncccn2)cc1,silver-sulfadiazine,Launched,PABA antagonist,,critical care,sepsis
COc1cc([C@H]2Oc3ccc([C@H]4Oc5cc(O)cc(O)c5C(=O)[C@@H]4O)cc3O[C@@H]2CO)ccc1O,silymarin,Launched,,,,
COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6CC6)C[C@H]5/C=C\CCCCN(C)C(=O)[C@@H]4C3)cc(-c3nc(C(C)C)cs3)nc2c1C,simeprevir,Launched,HCV inhibitor,CYP1A2|CYP3A4,infectious disease,hepatitis C
Cc1n[nH]cc1-c1cc2[nH]c([C@H]3CC4CCN3CC4)nc(=O)c2s1,simurosertib,Preclinical,kinase inhibitor,,,
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,simvastatin,Launched,HMGCR inhibitor,HMGCR|ITGB2,endocrinology|cardiology|neurology/psychiatry,hypercholesterolemia|coronary heart disease|myocardial infarction|stroke|hyperlipidemia
CSCC[C@H](NC(=O)[C@H](Cc1ccc(OS(=O)(=O)O)cc1)NC(=O)[C@@H](N)CC(=O)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,sincalide,Preclinical,cholecystokinin agonist,,,
Nc1ncnc2c1ncn2[C@@H]1O[C@H](C[C@@H](N)CC[C@H](N)C(=O)O)[C@@H](O)[C@H]1O,sinefungin,Preclinical,DNA methyltransferase inhibitor|RNA synthesis inhibitor,CARM1,,
COC1=C[C@@H]2[C@@H]3Cc4ccc(OC)c(O)c4[C@]2(CCN3C)CC1=O,sinomenine,Preclinical,angiogenesis inhibitor,,,
CN1CCN(c2ncc(-c3cc(Cl)cc(Cl)c3Cl)c(N)n2)CC1,sipatrigine,Phase 2,voltage-gated sodium channel blocker,CACNA1D|SCN10A|SCN1A|SCN3A|SCN4A|SCN5A|SCN9A,,
CCc1cc(/C(C)=N/OCc2ccc(C3CCCCC3)c(C(F)(F)F)c2)ccc1CN1CC(C(=O)O)C1,siponimod,Launched,sphingosine 1-phosphate receptor modulator,S1PR1,neurology/psychiatry,multiple sclerosis
Fc1ccc(-n2cc(CCCCN3CCC4(CC3)OCc3ccccc34)c3ccccc32)cc1,siramesine,Phase 2,sigma receptor antagonist,ADRA1A|ADRA1B|ADRA1D,,
COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1,siremadlin,Preclinical,MDM inhibitor,,,
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,sirolimus,Launched,mTOR inhibitor,FKBP1A|MTOR,transplant|pulmonary,organ rejection|lymphangioleiomyomatosis
Cc1cc(C)nc(SCC(=O)Nc2ncc(Cc3cccc4ccccc34)s2)n1,SirReal-2,Preclinical,SIRT inhibitor,SIRT2,,
C[C@@H](NC(=O)c1ccccc1/N=C/c1c(O)ccc2ccccc12)c1ccccc1,sirtinol,Preclinical,SIRT inhibitor,SIRT1|SIRT2,,
COc1cc2c(cc1OC)CN(C(=O)/C=C/c1c(-c3ccccc3)n(C)c3ncccc13)CC2,SIS3,Preclinical,serine/threonine kinase inhibitor,SMAD3|TGFBR1,,
CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O,sisomicin,Launched,protein synthesis inhibitor,,ophthalmology,conjunctivitis|punctate keratitis
CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O,sisomicin-sulfate,Launched,bacterial 30S ribosomal subunit inhibitor,,infectious disease,gram-negative bacterial infections
N[C@@H]1CN(c2c(F)cc3c(=O)c(C(=O)O)cn([C@@H]4C[C@@H]4F)c3c2Cl)CC12CC2,sitafloxacin,Launched,bacterial DNA gyrase inhibitor,,infectious disease,buruli ulcer
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,sitagliptin,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus
CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C,sitosterol,Preclinical,,,,
COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)cc4F)c3s2)nc1,sitravatinib,Phase 3,receptor tyrosine protein kinase inhibitor,,,
CC(C)(C)C(=O)Oc1ccc(S(=O)(=O)Nc2ccccc2C(=O)NCC(=O)O)cc1,sivelestat,Launched,elastase inhibitor,CELA1|ELANE,pulmonary,acute lung injury
CCOc1cc(/C=C2/C(=O)N(c3ccccc3)N=C2C)cc(Cl)c1OCC(=O)OC,SJ-172550,Preclinical,MDM inhibitor,MDM4,,
N#Cc1cc(NC(=O)[C@H]2c3ccccc3C(=O)N(CC(F)(F)F)[C@@H]2c2cccnc2)ccc1F,SJ-733,Phase 1,ATPase inhibitor,,,
C=C1C[C@H]2C=Nc3cc(OCCCOc4cc5c(cc4OC)C(=O)N4CC(=C)C[C@H]4C=N5)c(OC)cc3C(=O)N2C1,SJG-136,Phase 2,DNA intercalating agent,,,
C=CCN1CC[C@]2(C)c3cc(O)ccc3C[C@H]1[C@H]2C,SK&F-10047-(+),Phase 1,sigma receptor agonist,SIGMAR1,,
Nc1nc2c(ccc3ccccc32)s1,SKA-31,Preclinical,potassium channel activator,KCNN4,,
O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OC[C@H](O)CO)cc21,skepinone-L,Preclinical,p38 MAPK inhibitor,MAPK14,,
Oc1cc2c(cc1O)[C@H](c1ccccc1)CNCC2,SKF-38393,Preclinical,dopamine receptor agonist,CALY|DRD1|DRD5,,
C=CCN1CCc2cc(O)c(O)cc2[C@H](c2ccccc2)C1,SKF-77434,Preclinical,dopamine receptor agonist,DRD1,,
Oc1cc2c(c(Cl)c1O)CCNCC2c1ccccc1,SKF-81297,Preclinical,dopamine receptor agonist,DRD1|DRD5,,
CN1CCc2cc(Br)c(O)cc2[C@H](c2ccccc2)C1,SKF-83566,Preclinical,dopamine receptor antagonist,DRD1|DRD5,,
Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1,SKF-86002,Preclinical,p38 MAPK inhibitor,ALOX5|MAPK14,,
O=C(O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1,SKF-89976A,Preclinical,GABA uptake inhibitor,SLC6A1,,
CN(C)CCCCSC(=N)N,SKF-91488,Preclinical,histamine N-methyltransferase inhibitor,HNMT,,
COc1ccc(CCCO[C@@H](Cn2ccnc2)c2ccc(OC)cc2)cc1,SKF-96365,Preclinical,calcium channel blocker,CYP3A4|PKD2|TRPC1|TRPC3|TRPC4|TRPC5|TRPV2,,
Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1,SKI-II,Preclinical,sphingosine kinase inhibitor,SPHK1,,
CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21,SKLB-1028,Preclinical,Abl kinase inhibitor|EGFR inhibitor|FLT3 inhibitor,,,
COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC,SKLB1002,Preclinical,VEGFR inhibitor,KDR,,
C/N=C(/NS(=O)(=O)c1ccc(Cl)cc1)N1C[C@H](c2ccccc2)C(c2ccc(Cl)cc2)=N1,SLV-319-(+/-),Phase 2,cannabinoid receptor antagonist,CNR1|DRD2|HTR1A,,
O[C@H]1CC[C@H](Nc2nc(-c3ccccc3)nc3[nH]ccc23)CC1,SLV-320,Phase 2,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
NC(=O)C1N=CNC1=O,SM-108,Phase 2,,,,
CN[C@@H](C)C(=O)N[C@H]1CCCC[C@H]2CC[C@@H](C(=O)N[C@@H](c3ccccc3)c3cn(CCCCc4ccc(CCCCn5cc([C@@H](NC(=O)[C@@H]6CC[C@@H]7CCCC[C@H](NC(=O)[C@H](C)NC)C(=O)N76)c6ccccc6)nn5)cc4)nn3)N2C1=O,SM-164,Preclinical,XIAP inhibitor,BIRC2|BIRC3|XIAP,,
CC[C@H](Oc1ccc(Cl)cc1)C(=O)O[C@H]1C[C@H]2CC[C@@H](C1)N2C,SM-21,Preclinical,sigma receptor antagonist,PGRMC1,,
C=CCNc1ncnc2ccc(Br)cc12,SMER-28,Preclinical,autophagy inducer,SNCA,,
O=C1NC(=O)/C(=C/c2cccc(C(F)(F)F)c2)S1,SMI-4a,Preclinical,Pim kinase inhibitor,PIM1,,
Cc1cc(C)c(C2=NO[C@@H]3[C@H]4CC[C@H](C4)[C@H]23)c(C)c1,SN-2,Preclinical,transient receptor potential channel agonist,MCOLN3,,
CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,SN-38,Launched,topoisomerase inhibitor,TOP1,oncology,colorectal cancer
CCOC(=O)[C@H]1CS[C@H](Cc2ccc(OCc3ccc([N+](=O)[O-])cc3)cc2)N1,SN-6,Preclinical,sodium/calcium exchange inhibitor,,,
COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)[C@@H]1c1ccc([N+](=O)[O-])cc1,SNAP-5089,Preclinical,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CACNA1C|CACNA1D,,
Cc1ccc(NC(=O)C(C)C)cc1C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1,SNAP-94847,Preclinical,,ADRA1A|DRD2,,
C=CCN1C[C@H](C)N([C@H](c2ccc(C(=O)N(CC)CC)cc2)c2cccc(OC)c2)C[C@H]1C,SNC-80,Preclinical,,OPRD1,,
CC(C)=CCc1c(O)cc(O)c2c(=O)c(O)c(-c3ccc(C(F)(F)F)cc3)oc12,SNG-1153,Preclinical,selective estrogen receptor modulator (SERM),ESR1,,
O=C(Nc1cccc(Cl)c1)Nc1ncc(CCNc2ncnc3ccsc23)s1,SNS-314,Phase 1,Aurora kinase inhibitor,AURKA|AURKB|AURKC,,
CC1(C)CC(=O)c2c(C(F)(F)F)nn(-c3ccc(C(N)=O)c(N[C@H]4CC[C@H](O)CC4)c3)c2C1,SNX-2112,Phase 1,HSP inhibitor,,,
CC1(C)CC(=O)c2c(C(F)(F)F)nn(-c3ccc(C(N)=O)c(N[C@H]4CC[C@H](OC(=O)CN)CC4)c3)c2C1,SNX-5422,Phase 1/Phase 2,HSP inhibitor,HSP90AA1|HSP90AB1,,
Cc1cc(OCC(=O)O)cc(C)c1Cc1ccc(O)c(C(C)C)c1,sobetirome,Phase 1/Phase 2,thyroid hormone receptor agonist,THRA|THRB,,
CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C,soblidotin,Phase 2,microtubule inhibitor,,,
CC1=CC[C@@H](C(C)(C)O)C[C@@H]1O,sobrepin,Launched,mucolytic agent,,pulmonary,chest congestion
CC(C)COC(=O)OCN1C(=O)CN(CCN2CC(=O)N(COC(=O)OCC(C)C)C(=O)C2)CC1=O,sobuzoxane,Launched,topoisomerase inhibitor,,hematologic malignancy,peripheral T-cell lymphoma (PTCL)
O=C(O)[C@@H](O)Cc1ccc(O)c(O)c1,sodium-danshensu,Preclinical,,,,
Cc1cc(S(=O)(=O)O)c2c(C)ccc(C(C)C)cc1-2,sodium-gualenate,Launched,antacid,,gastroenterology|otolaryngology,peptic ulcer disease (PUD)|pharyngitis
N#C[Fe-2](C#N)(C#N)(C#N)(C#N)[N+][O-],sodium-nitroprusside,Launched,nitric oxide donor,,cardiology,hypertension|congestive heart failure
O=S(=O)(O)Oc1ccc(C(c2ccc(OS(=O)(=O)O)cc2)c2ccccn2)cc1,sodium-picosulfate,Launched,,,gastroenterology,constipation
O=C(O)[C@@H]1O[Sb]2(O)(O[Sb]34(O)O[C@H]([C@H](O)CO)[C@H](O3)[C@H](C(=O)O)O4)O[C@H]([C@H](O)CO)[C@@H]1O2,sodium-stibogluconate,Launched,tyrosine phosphatase inhibitor,PTPN6,infectious disease,leishmaniasis
Cc1c(S(=O)(=O)O)oc2c1C(=O)C(=O)c1c-2ccc2c1CCCC2(C)C,sodium-tanshinone-II-A-sulfonate,Phase 2,potassium channel activator,,,
CCCC[C@@H](CC)CC[C@@H](CC(C)C)OS(=O)(=O)O,sodium-tetradecyl-sulfate,Launched,,PROC,dermatology,varicose veins
CC(C)=CCOc1ccc(/C=C/C(=O)c2ccc(OCC=C(C)C)cc2OCC(=O)O)cc1,sofalcone,Launched,mucus protecting agent,CBR1,gastroenterology,peptic ulcer disease (PUD)
CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,sofosbuvir,Launched,HCV inhibitor,,infectious disease,hepatitis C|hepatitis C
CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@@](C)(O)[C@@H]1O)Oc1ccccc1,sofosbuvir-impurity-m,Preclinical,antiviral,,,
CNc1cccc(NC(=O)N[C@@H]2N=C(c3ccccn3)c3ccccc3N(CC(=O)C(C)(C)C)C2=O)c1,sograzepide,Phase 2,gastrin inhibitor,,,
C[C@@H]1CC[C@@]2(NC1)O[C@@H]1C[C@H]3[C@H]4CC=C5C[C@H](O[C@H]6O[C@@H](CO)[C@@H](O[C@H]7O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O[C@H]6O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]6O)CC[C@@]5(C)[C@@H]4CC[C@@]3(C)[C@H]1[C@@H]2C,solamargine,Phase 3,apoptosis inhibitor,,,
CC1(C)CN(C(=O)c2ccc(-c3cccc4nc(NC(=O)C5CC5)nn34)cc2)C1,solcitinib,Phase 1,JAK inhibitor,JAK1,,
O=C(O[C@H]1C[N@]2CC[C@@H]1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1,solifenacin-succinate,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,urology,urinary incontinence|urinary frequency
CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cc(-c4cccc(N)c4)nn3)C(=O)O[C@]12C,solithromycin,Phase 3,protein synthesis inhibitor,,,
NC(=O)OC[C@H](N)Cc1ccccc1,solriamfetol,Launched,dopamine reuptake inhibitor,,neurology/psychiatry,narcolepsy
CC(C)(N)CC12CC3CC(CC(C3)C1)C2,somantadine,Phase 1,antiviral,,,
C[C@H](N)C(=O)NCC(=O)N[C@H]1CSSC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O,somatostatin,Launched,somatostatin receptor agonist,OPRD1|OPRM1|SSTR1|SSTR2|SSTR3|SSTR4|SSTR5,hematology,hemorrhage
NS(=O)(=O)c1ccc(N2CCN(CC[C@@H]3OCCc4ccccc43)CC2)cc1,sonepiprazole,Phase 2,dopamine receptor antagonist,,,
Cc1c(C(=O)Nc2ccc(N3C[C@@H](C)O[C@@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1,sonidegib,Launched,smoothened receptor antagonist,SMO,oncology,basal cell carcinoma (BCC)
O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34,sophocarpine,Phase 3,,,,
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,sorafenib,Launched,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,BRAF|DDR2|FGFR1|FLT1|FLT3|FLT4|KDR|KIT|PDGFRB|RAF1|RET,oncology,renal cell carcinoma (RCC)|thyroid cancer|hepatocellular carcinoma (HCC)
COCCO[C@@H]1c2ccn3c(C)c(C)nc3c2N[C@H](c2ccccc2)[C@H]1O,soraprazan,Preclinical,proton pump inhibitor,,,
C/C=C/C=C/C(=O)O,sorbic-acid,Launched,,,,
O=C1NC(=O)[C@@]2(CCOc3ccc(F)cc32)N1,sorbinil,Phase 3,aldose reductase inhibitor,AKR1B1,,
CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O,sorbitan-monostearate,Preclinical,,,,
OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CO,sorbitol,Launched,mucolytic agent,,gastroenterology,constipation
CCOc1ccc(Cc2cc([C@@H]3O[C@H](SC)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,sotagliflozin,Phase 3,sodium/glucose cotransporter inhibitor,SLC5A1|SLC5A2,,
CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1,sotalol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|KCNH2,cardiology,atrial fibrillation (AF)|ventricular arrhythmias
CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1,sotrastaurin,Phase 2,PKC inhibitor,PRKCA|PRKCB|PRKCD|PRKCE|PRKCH|PRKCQ,,
O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cnc(Cl)nc1C(F)(F)F,SP-100030,Preclinical,NFkB pathway inhibitor,JUN|NFKB1,,
COc1ccc2[nH]c3c(-c4cccc5ccccc45)nccc3c2c1,SP-141,Preclinical,ubiquitin ligase inhibitor,MDM2,,
COCCOCCOc1ccc(C2=N[C@@](C)(C(=O)O)CS2)c(O)c1,SP-420,Phase 1,,,,
CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O,spaglumic-acid,Launched,glutamate receptor antagonist,GRM3,allergy,allergic conjunctivitis|allergic rhinitis
O=C(O)C[C@@H](NC(=O)CP(=O)(O)O)C(=O)O,sparfosate,Phase 3,aspartate carbamoyltransferase inhibitor,CA2|CA4,,
CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2S(=O)(=O)Nc2noc(C)c2C)c(COCC)c1,sparsentan,Phase 3,angiotensin receptor antagonist,,,
C1CCN2C[C@@H]3C[C@@H](CN4CCCC[C@@H]34)[C@H]2C1,sparteine-(-),Launched,,,,
C1CCN2C[C@H]3C[C@H](CN4CCCC[C@@H]34)[C@H]2C1,sparteine-(+),Launched,,,,
C1CCN2C[C@@H]3C[C@H](CN4CCCC[C@@H]34)[C@H]2C1,sparteine-sulfate,Launched,,,,
Fc1ccc(CNc2ncnc3ccc(F)cc23)cc1,spautin-1,Preclinical,deubiquitinase inhibitor,USP10|USP13,,
CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@@]3(O)C(=O)C[C@@H](C)O[C@H]3O[C@@H]2[C@H]1O,spectinomycin,Launched,bacterial 30S ribosomal subunit inhibitor,,pulmonary,airsacculitis|chronic respiratory disease
NCCCCNCCCN,spermidine,Preclinical,glutamate receptor modulator,KCNJ4|TXNRD1,,
NCCCNCCCCNCCCN,spermine,Preclinical,,CA14|CA4|CA6|CA9|CASR|GRIN1|GRIN2A|KCNJ4|ODC1|SMOX|SMS|TRPM4|TRPM5,,
CCCCCCCCCCCCC/C=C/[C@@H](O)[C@@H](N)COP(=O)(O)OCC[N+](C)(C)C,sphingosylphosphorylcholine,Preclinical,gene expression stimulant,GPR12,,
O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1,spiperone,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|ADRA1D|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1D|HTR2A|HTR2B|HTR2C|HTR6|HTR7,neurology/psychiatry,schizophrenia
CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1,spiradoline,Phase 2,opioid receptor agonist,OPRK1,,
CO[C@@H]1[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O[C@H]2CC[C@H](N(C)C)[C@@H](C)O2)/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]1O,spiramycin,Launched,bacterial 50S ribosomal subunit inhibitor,,infectious disease,toxoplasmosis|soft tissue infection
O=C(CCBr)N1CC[N+]2(CC1)CC[N+]1(CCN(C(=O)CCBr)CC1)CC2,spirobromin,Phase 1,,,,
CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@H]12,spironolactone,Launched,mineralocorticoid receptor antagonist,AR|CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1F|CACNA1G|CACNA1H|CACNA1I|CACNA1S|CACNA2D1|CACNA2D2|CACNA2D3|CACNB1|CACNB2|CACNB3|CACNB4|CACNG1|CYP11B2|NR3C1|NR3C2|PGR|SHBG,endocrinology|cardiology|gastroenterology|rheumatology,hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia
O=C1NCN(c2ccccc2)C12CCN(C[C@H]1COc3ccccc3O1)CC2,spiroxatrine,Preclinical,serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|HTR1A|HTR2B,,
O=C1CCc2c(ccc3ccccc23)O1,splitomycin,Preclinical,SIRT inhibitor,SIRT1,,
COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(-c2ccncc2)nc1OC,SPP301,Phase 3,endothelin receptor antagonist,EDNRA,,
CC(C)n1nc(C#Cc2ccccc2)c2c(N)ncnc21,SPP86,Preclinical,receptor tyrosine protein kinase inhibitor,RET,,
CC(C)=CCC/C(C)=C/CNCCNC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2,SQ-109,Phase 3,bacterial cell wall synthesis inhibitor,FDFT1,,
Nc1ncnc2c1ncn2[C@H]1CCCO1,SQ-22536,Preclinical,adenylyl cyclase inhibitor,ADCY1,,
CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@H]4C[C@@H](NCCCNCCCCN)CC[C@]4(C)[C@H]3CC[C@]12C)OS(=O)(=O)O,squalamine,Phase 3,antiviral,,,
CCCCOc1c(OCCCC)c(=O)c1=O,squaric-acid-dibutyl-ester,Preclinical,oxidative stress inducer,,,
O=C(Nc1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)c1ccc(C(F)(F)F)cc1,SR-1078,Preclinical,retinoid receptor agonist,RORA|RORC,,
CC1=C(/C=C/C(=C/C=C/C(C)=C/C(=O)O)c2ccc(C)cc2)C(C)(C)CCC1,SR-11302,Preclinical,,,,
CC(C)Oc1cccc(CC(=O)N2CCC[C@](CC[N+]34CCC(c5ccccc5)(CC3)CC4)(c3ccc(Cl)c(Cl)c3)C2)c1,SR-140333,Phase 2,neurokinin receptor antagonist,TACR1,,
Cc1c(C)n(Cc2ccc(-c3ccccc3C(=O)O)cc2)c2ccc(C(=O)N[C@@H](C)c3ccc([N+](=O)[O-])cc3)cc12,SR-1664,Preclinical,PPAR receptor ligand,PPARG,,
OC(c1ccc(-c2ccc(CN3CCN(Cc4ccncc4)CC3)cc2)c(F)c1)(C(F)(F)F)C(F)(F)F,SR-2211,Preclinical,retinoid receptor inverse agonist,RORC,,
O=C(O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1,SR-2640,Phase 2,leukotriene receptor antagonist,CYSLTR1,,
O=C(O)Cn1c(C(=O)Nc2nc(-c3ccccc3Cl)cs2)cc2ccccc21,SR-27897,Phase 2,CCK receptor antagonist,CCKAR,,
Cc1ccc(-c2ncn(-c3ccc(Nc4nccc(-c5cccc(N6CCOCC6)c5)n4)cc3)n2)cn1,SR-3306,Preclinical,JNK inhibitor,MAPK10|MAPK8|MAPK9,,
COc1ccc(CCN(C)CCCOc2ccc(S(=O)(=O)c3c(C(C)C)c4ccccc4n3C)cc2)cc1OC,SR-33805,Phase 1,calcium channel blocker,,,
COc1cc(NC(=O)c2cccc(-n3cc(NC(=O)Nc4cccc(C)c4)cn3)c2)cc(OC)c1OC,SR-3576,Preclinical,JNK inhibitor,MAPK10,,
CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)[C@H]1COc2ccccc2O1,SR-3677,Preclinical,rho associated kinase inhibitor,ROCK2,,
NC1CCN(c2cccc(Cl)n2)CC1,SR-57227A,Phase 2,serotonin receptor agonist,HTR3A,,
CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc21,SR-59230A,Preclinical,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,,
c1ccc2c(c1)CCCc1cc(NCCN3CCOCC3)nnc1-2,SR-95639A,Preclinical,acetylcholine receptor agonist,CHRM1,,
COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC,SRC-kinase-inhibitor-I,Preclinical,SRC inhibitor,CSK|LCK|RIPK2,,
O=C(Nc1cc(C(F)(F)F)ccc1N1CCCCC1)c1ccncc1,SRPIN340,Preclinical,serine arginine protein kinase inhibitor,SRPK1|SRPK2,,
O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1,SRT1720,Preclinical,SIRT activator,SIRT1,,
Cc1nc(-c2cccnc2)sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1,SRT2104,Phase 2,SIRT activator,SIRT1,,
C[C@H](Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO,SRT3190,Preclinical,CC chemokine receptor antagonist,,,
COc1c(C)c(C(=O)c2ccc(N)c(C(=O)O)c2)n2ccccc12,SSR128129E,Preclinical,,,,
O=C(Oc1ccc(Br)cc1)N1CC[N@]2CC[C@@H]1CC2,SSR180711,Phase 2,acetylcholine receptor agonist,CHRNA7,,
COc1ccc2cc(S(=O)(=O)N[C@H](CC(=O)N[C@H](Cc3ccc(CN4[C@H](C)CCC[C@@H]4C)cc3)C(=O)N(C)C(C)C)c3ccc4c(c3)OCO4)ccc2c1,SSR240612,Preclinical,bradykinin receptor antagonist,,,
CCCCc1nc(N)c2nc(-n3nccn3)n(C)c2n1,ST-1535,Preclinical,adenosine receptor antagonist,,,
Oc1ccc2ccccc2c1Cc1c(O)ccc2ccccc12,ST-1859,Phase 1,antiamyloidogenic agent,,,
NC(=O)[C@H]1CCS[C@@H]2C[C@]3(CCCN3C(=O)Cc3ccc(NC(=O)COc4ccc(Cl)cc4Cl)cc3)C(=O)N12,ST-2825,Preclinical,myeloid differentiation primary response inhibitor,MYD88,,
CCc1cccc(CC)c1NC1=NCCN1,ST-91,Preclinical,adrenergic receptor agonist,,,
Cc1cccc(/C=N/Nc2cc(N3CCOCC3)nc(OCCc3ccccn3)n2)c1,STA-5326,Phase 2,interleukin synthesis inhibitor,IL12A,,
Cc1ccc(S(=O)(=O)OCC(=O)Nc2ccc(C(=O)O)c(O)c2)cc1,STAT3-inhibitor-VI,Preclinical,STAT inhibitor,STAT3,,
O=C(O)Cc1nn(Cc2ccc(Br)cc2F)c(=O)c2ccccc12,statil,Preclinical,aldose reductase inhibitor,,,
O=[N+]([O-])c1ccc2c(c1)S(=O)(=O)C=C2,stattic,Preclinical,,,,
Cc1cn([C@H]2C=C[C@@H](CO)O2)c(=O)[nH]c1=O,stavudine,Launched,DNA directed DNA polymerase inhibitor|nucleoside reverse transcriptase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)
CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(-c3csc4ccccc34)nc21,stemregenin-1,Preclinical,aryl hydrocarbon receptor antagonist,AHR,,
C[C@@H](SC(=O)c1cccs1)C(=O)NCC(=O)O,stepronin,Launched,mucolytic agent,,,
CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@H](O)C[C@]12C,stetaderm,Launched,,,,
O=S(=O)(/N=C/c1c(O)ccc2ccccc12)c1cccs1,STF-083010,Preclinical,serine/threonine kinase inhibitor,ERN1,,
Cc1ccc(S(=O)(=O)Cc2nc(-c3ccc(C(=O)NCc4cccnc4)cc3)oc2C)cc1,STF-118804,Preclinical,NAMPT inhibitor,NAMPT,,
CC(C)(C)c1ccc(S(=O)(=O)NCc2ccc(C(=O)Nc3cccnc3)cc2)cc1,STF-31,Preclinical,NAMPT inhibitor,NAMPT|SLC2A1,,
Cc1cccc(Nc2nc(-c3ccncc3)cs2)c1,STF-62247,Preclinical,autophagy inducer,,,
CC[C@H](/C=C/[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C,stigmasterol,Preclinical,,,,
CC(C)(C)[C@@H](O)/C=C/c1ccc2c(c1)OCO2,stiripentol,Launched,GABA uptake inhibitor,GABRA3,neurology/psychiatry,epilepsy
Cc1ccc2c(c1)[C@H]1CN(C)CC[C@H]1N2,stobadine,Phase 2,adrenergic receptor antagonist,ADRA1A,,
CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](NC(=N)N)[C@@H](O)[C@@H]3NC(=N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O,streptomycin,Launched,bacterial 30S ribosomal subunit inhibitor,,infectious disease,tuberculosis
CN([NH2+][O-])C(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O,streptozotocin,Launched,DNA alkylating agent,,oncology,pancreatic cancer
N#Cc1c(N2C=C(O)O[Sr]OC(O)=C2)sc2c1CC(=O)O[Sr]OC2=O,strontium-ranelate,Launched,bone formation stimulant|bone resorption inhibitor,CASR,orthopedics|rheumatology,osteoporosis|osteoarthritis
O=C1C[C@@H]2OCC=C3CN4CC[C@]56c7ccccc7N1[C@H]5[C@H]2[C@H]3C[C@H]46,strychnine,Preclinical,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|CHRNA10|CHRNA9|GLRA1|GLRA2|GLRA3|GLRB,,
Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,SU014813,Phase 2,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,KDR,,
Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)c(C)c1C(=O)N1CCN(C)CC1,SU11274,Preclinical,hepatocyte growth factor receptor inhibitor|tyrosine kinase inhibitor,MET,,
Cc1[nH]c(/C=C2\C(=O)Nc3cc(-c4ccccc4)ccc32)c(C)c1CCC(=O)O,SU16f,Preclinical,PDGFR tyrosine kinase receptor inhibitor,PDGFRB,,
Nc1nnc(Sc2ncc([N+](=O)[O-])s2)s1,SU3327,Preclinical,JNK inhibitor,MAPK8,,
CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1,SU4312,Preclinical,PDGFR tyrosine kinase receptor inhibitor|tyrosine kinase inhibitor|VEGFR inhibitor,KDR|PDGFRB,,
COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2,SU9516,Preclinical,CDK inhibitor,CDK1|CDK2|CDK4|CDK5,,
CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(N)=O,substance-P,Phase 1,neurokinin receptor antagonist,TACR1|TACR2|TACR3,,
O=C(O)CCC(=O)O,succinic-acid,Launched,,ALDH5A1|ASPH|BBOX1|HSD17B6|OXCT1|OXCT2|P3H1|P3H2|P3H3|P4HA1|P4HA2|PLOD1|PLOD3|SDHA|SDHB|SDHC|SDHD|SLC13A1|SLC13A2|SLC13A3|SLC25A10|SUCLA2|SUCLG1|SUCLG2|SUCNR1|TMLHE,,
CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(OC(=O)CCC(=O)O)c(C(C)(C)C)c1,succinobucol,Phase 2/Phase 3,antioxidant,VCAM1,,
C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,succinylcholine-chloride,Launched,,CHRFAM7A|CHRM1|CHRM2|CHRM3|CHRNA1|CHRNA10,neurology/psychiatry,muscle relaxant
O=C(O)CCC(=O)Nc1ccc(S(=O)(=O)Nc2nccs2)cc1,succinylsulfathiazole,Phase 2,dihydrofolate reductase inhibitor,DHFR,,
O=S(=O)(OC[C@H]1O[C@@](COS(=O)(=O)O[Al](O)O)(O[C@H]2O[C@H](COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@H]2OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O)O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O,sucralfate,Launched,antacid,,gastroenterology,duodenal ulcer disease
OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl,sucralose,Launched,,,,
OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O,sucrose,Launched,,ACTA1|ATOX1|C22orf28|LYZ,,
CC(=O)OC[C@H]1O[C@@](COC(C)=O)(O[C@H]2O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]2OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O,sucrose-octaacetate,Preclinical,,,,
Cc1ccccc1/N=N/c1ccc(/N=N/c2c(O)ccc3ccccc23)c(C)c1,sudan-IV,Preclinical,,,,
CONC(=O)Nc1ccc(-c2sc3c(c2CN(C)Cc2ccccc2)c(=O)n(-c2ccccc2)c(=O)n3Cc2c(F)cccc2F)cc1,sufugolix,Preclinical,gonadotropin releasing factor hormone receptor antagonist,,,
O=C(O)CCSC[C@@H]1O[C@H]2O[C@@H]3[C@@H](O)[C@H](O)[C@H](O[C@@H]4[C@@H](O)[C@H](O)[C@H](O[C@@H]5[C@@H](O)[C@H](O)[C@H](O[C@@H]6[C@@H](O)[C@H](O)[C@H](O[C@@H]7[C@@H](O)[C@H](O)[C@H](O[C@@H]8[C@@H](O)[C@H](O)[C@H](O[C@@H]9[C@@H](O)[C@H](O)[C@H](O[C@@H]1[C@@H](O)[C@@H]2O)O[C@H]9CSCCC(=O)O)O[C@H]8CSCCC(=O)O)O[C@H]7CSCCC(=O)O)O[C@H]6CSCCC(=O)O)O[C@H]5CSCCC(=O)O)O[C@H]4CSCCC(=O)O)O[C@H]3CSCCC(=O)O,sugammadex,Launched,neuromuscular blockade reversal agent,,,
CC1(C)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O,sulbactam,Launched,beta lactamase inhibitor,,infectious disease,skin infections|intra-abdominal infections|gynecologic infections
CC(C)(C)C(=O)OCOC(=O)[C@H]1N2C(=O)C[C@H]2S(=O)(=O)C1(C)C,sulbactam-pivoxil,Launched,beta lactamase inhibitor,,infectious disease,skin infections
S=C1SCN(Cc2ccccc2)CN1Cc1ccccc1,sulbentine,Preclinical,other antifungal,,,
C/C(=C(/CCOC(=O)C(C)C)SS/C(CCOC(=O)C(C)C)=C(\C)N(C=O)Cc1cnc(C)nc1N)N(C=O)Cc1cnc(C)nc1N,sulbutiamine,Launched,acetylcholine receptor antagonist,,neurology/psychiatry,asthenia
Clc1ccc(CS[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1,sulconazole,Launched,sterol demethylase inhibitor,,infectious disease,tinea pedis|tinea cruris|tinea corporis
Nc1ccc(S(=O)(=O)NC(=O)c2ccccc2)cc1,sulfabenzamide,Launched,bacterial antifolate,,infectious disease,gram-negative bacterial infections|gram-positive bacterial infections
CC(=O)NS(=O)(=O)c1ccc(N)cc1,sulfacetamide,Launched,PABA antagonist,,ophthalmology,conjunctivitis
Nc1ccc(S(=O)(=O)Nc2ccc(Cl)nn2)cc1,sulfachlorpyridazine,Launched,bacterial antifolate,,infectious disease,urinary tract infections
Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1,sulfadiazine,Launched,bacterial antifolate,,infectious disease|ophthalmology,malaria|meningitis|urinary tract infections|conjunctivitis|trachoma|chancroid
COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC,sulfadoxine,Launched,dihydropteroate synthase inhibitor,,infectious disease,malaria
Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C,sulfafurazole,Launched,bacterial antifolate,,infectious disease,urinary tract infections
N=C(N)NS(=O)(=O)c1ccc(N)cc1,sulfaguanidine,Launched,bacterial antifolate,,infectious disease,urinary tract infections
Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1,sulfamerazine,Launched,bacterial antifolate,,infectious disease,coccidiosis|cholera
COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1,sulfameter,Launched,dihydrofolate reductase inhibitor,DHFR,infectious disease,urinary tract infections
Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1,sulfamethazine,Launched,PABA antagonist,,gastroenterology,enteritis
Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1,sulfamethizole,Launched,bacterial antifolate,,infectious disease,urinary tract infections
Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1,sulfamethoxazole,Launched,PABA antagonist,,infectious disease|gastroenterology,pneumonia|enteritis|urinary tract infections
COc1nccnc1NS(=O)(=O)c1ccc(N)cc1,sulfametopyrazine,Launched,PABA antagonist,,infectious disease,malaria|urinary tract infections|respiratory tract infections
COc1cc(NS(=O)(=O)c2ccc(N)cc2)ncn1,sulfamonomethoxine,Launched,bacterial antifolate,,infectious disease,urinary tract infections
Cc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C,sulfamoxole,Launched,PABA antagonist,,infectious disease,urinary tract infections
Nc1ccc(S(N)(=O)=O)cc1,sulfanilamide,Launched,carbonic anhydrase inhibitor,CYP2C19|CYP2C9|CYP2D6|CYP2E1|CYP3A4,infectious disease,vulvovaginal candidiasis
Nc1ccc(S(=O)(=O)O[Zn]OS(=O)(=O)c2ccc(N)cc2)cc1,sulfanilate-zinc,Preclinical,,,,
CC(=O)Nc1ccc(S(=O)(=O)Nc2ccc([N+](=O)[O-])cc2)cc1,sulfanitran,Launched,,,infectious disease,coccidiosis
Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,sulfaphenazole,Launched,dihydropteroate synthetase inhibitor,DHPS,infectious disease,urinary tract infections
Nc1ccc(S(=O)(=O)Nc2ccccn2)cc1,sulfapyridine,Launched,PABA antagonist,,infectious disease,gram-negative bacterial infections|gram-positive bacterial infections
Nc1ccc(S(=O)(=O)Nc2cnc3ccccc3n2)cc1,sulfaquinoxaline,Launched,vitamin K antagonist,,infectious disease,coccidiosis
O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O,sulfasalazine,Launched,cyclooxygenase inhibitor,ACAT1|ALOX5|CHUK|IKBKB|PLA2G1B|PPARG|PTGS1|PTGS2|SLC46A1|SLC7A11|TBXAS1,gastroenterology,ulcerative colitis
Nc1ccc(S(=O)(=O)Nc2nccs2)cc1,sulfathiazole,Launched,dihydropteroate synthase inhibitor,,infectious disease,gram-negative bacterial infections|gram-positive bacterial infections
Cc1cc2cc(Oc3ccnc(Nc4cccc(CS(=O)(=O)NCCN(C)C)c4)n3)ccc2[nH]1,sulfatinib,Phase 1,tyrosine kinase inhibitor,,,
O=C1C(CC[S@](=O)c2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1,sulfinpyrazone,Launched,uricosuric blocker,ABCC1|FPR1|SLC22A12,rheumatology,gout
Cc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(C)n1,sulfisomidin,Preclinical,antibacterial,,,
CC(=O)N(c1onc(C)c1C)S(=O)(=O)c1ccc(N)cc1,sulfisoxazole-acetyl,Launched,folic acid antagonist,,infectious disease|otolaryngology,meningitis|urinary tract infections|otitis|trachoma
C[S@@](=O)CCCCN=C=S,sulforaphane,Phase 2,anticancer agent|aryl hydrocarbon receptor antagonist,NFE2L2,,
CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc([S@@](C)=O)cc1,sulindac,Launched,cyclooxygenase inhibitor,AKR1B1,rheumatology,osteoarthritis|rheumatoid arthritis|ankylosing spondylitis
COc1cc(O)c(C(=O)c2ccccc2)cc1S(=O)(=O)O,sulisobenzone,Launched,,,dermatology,sunscreen lotion
COc1cc([S@@](C)=O)ccc1-c1nc2ncccc2[nH]1,sulmazole,Phase 1,adenosine receptor antagonist,,,
COc1cc(C(=S)N2CCOCC2)cc(OC)c1OC,sulmetozine,Launched,gastrin inhibitor,GAST,gastroenterology,peptic ulcer disease (PUD)
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@H]3CC[S@@](=O)C3)S[C@H]12,sulopenem,Phase 3,antibacterial,,,
COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1,sulphadimethoxine,Launched,dihydropteroate synthetase inhibitor,,infectious disease,gram-negative bacterial infections|gram-positive bacterial infections
CCN1CCC[C@@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC,sulpiride,Launched,dopamine receptor antagonist,,neurology/psychiatry,schizophrenia
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)OCOC(=O)[C@@H]1N2C(=O)C[C@H]2S(=O)(=O)C1(C)C,sultamicillin,Launched,antibacterial ,,infectious disease,gram-negative bacterial infections|gram-positive bacterial infections
NS(=O)(=O)c1ccc(N2CCCCS2(=O)=O)cc1,sultiame,Phase 3,carbonic anhydrase inhibitor,CA2,,
CCN1CCC[C@H]1CNC(=O)c1cc(S(=O)(=O)CC)ccc1OC,sultopride,Preclinical,dopamine receptor antagonist,,,
CN[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1,sumanirole,Phase 3,dopamine receptor agonist,DRD2,,
CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1,sumatriptan,Launched,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR5A|HTR6|HTR7,neurology/psychiatry,migraine headache
Cc1c(C)c(NCC(=O)N(C)C2CCN(Cc3ccc(C(N)=O)cc3)CC2)c(C)c(C)c1N,SUN-11602,Preclinical,fibroblast growth factor mimetic,FGFR1,,
C/C(=N\c1ccccc1N)c1c(C)cc(=O)n(O)c1O,SUN-B-8155,Preclinical,calcitonin agonist,CALCR,,
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,sunitinib,Launched,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,CSF1R|FGFR1|FLT1|FLT3|FLT4|KDR|KIT|PDGFRA|PDGFRB|RET,oncology,gastrointestinal stromal tumors (GIST)|renal cell carcinoma (RCC)|neuroendocrine tumors of pancreatic origin (PNET)
CCOC[C@@H](O)COc1ccc(NC(=O)CC[S+](C)C)cc1,suplatast,Launched,histamine release inhibitor|immunoglobulin inhibitor,,rheumatology,Kimura's disease
Cc1ccc(C(=O)Nc2ccc(S(=O)(=O)O)c3cc(S(=O)(=O)O)cc(S(=O)(=O)O)c23)cc1NC(=O)c1cccc(NC(=O)Nc2cccc(C(=O)Nc3cc(C(=O)Nc4ccc(S(=O)(=O)O)c5cc(S(=O)(=O)O)cc(S(=O)(=O)O)c45)ccc3C)c2)c1,suramin,Launched,DNA synthesis inhibitor,F2|FSHR|P2RY1|P2RY11|P2RY13|P2RY2|PLA2G2A|RYR1|RYR2|SIRT5,infectious disease,African trypanosomiasis|onchocerciasis
Cn1nc(-c2cccc(F)c2)n(C)c1=S,suritozole,Phase 2,GABA receptor inverse agonist,GABBR1,,
CC(=O)NC[C@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1,sutezolid,Phase 2,protein synthesis inhibitor,,,
CCCCC1(COC(=O)CCC(=O)O)C(=O)N(c2ccccc2)N(c2ccccc2)C1=O,suxibuzone,Launched,cyclooxygenase inhibitor,,rheumatology|neurology/psychiatry,joint pain|muscle pain
O[C@H]1[C@H]2[C@H](O)CCCN2C[C@H]1O,swainsonine,Phase 2,alpha mannosidase inhibitor,MAN2A1,,
CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(C(=O)N3CCC(Cc4ccc(F)cc4)CC3)cc12,SX-011,Preclinical,MAP kinase inhibitor,MAPK14,,
CC(=O)N(C)Cc1ccc2c(c1)OCO2,SY-640,Phase 2,,,,
CCCNC(=O)N1N=C(c2ccc(N)cc2)c2cc3c(cc2[C@@H]1C)OCO3,SYM-2206,Preclinical,glutamate receptor antagonist,GRIA1|GRIA2|GRIA3|GRIA4,,
O=c1n(Cl)c(=O)n(Cl)c(=O)n1Cl,symclosene,Preclinical,,,,
CNC[C@@H](O)c1ccc(O)cc1,synephrine,Launched,adrenergic receptor agonist,ADRA1A,otolaryngology,sinusitis
O=C(Nc1ccncc1)c1cc([N+](=O)[O-])ccc1Cl,T-0070907,Preclinical,PPAR receptor antagonist,PPARG,,
COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1,T-0156,Preclinical,phosphodiesterase inhibitor,PDE5A,,
CNc1nc(NCc2ncccn2)c2c(-c3ccc4ncccc4c3)c[nH]c2n1,T-025,Preclinical,CLK inhibitor,,,
O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,T-0901317,Preclinical,LXR agonist,NCOA1|NCOA2|NR1H2|NR1H3|NR1I2|RXRB,,
COC(=O)OC[C@H]1O[C@@H](Oc2cc(C)cc(O)c2C(=O)CCc2ccc3occc3c2)[C@H](O)[C@@H](O)[C@@H]1O,T-1095,Preclinical,sodium/glucose cotransporter inhibitor,,,
O=C(O)CCc1cc(C(=O)c2ccc(OC3CCCC3)cc2O)ccc1OCc1ccc2c(=O)[nH]oc2c1,T-5224,Phase 2,AP inhibitor,JUN,,
Cc1cc(C(=O)Nc2cccc(C(=O)Nc3cccc(C(F)(F)F)c3)c2)on1,T-5601640,Preclinical,LIM kinase inhibitor,LIMK2,,
Nc1sc2c(c1C(=O)c1ccc(Cl)cc1)CCCC2,T-62,Phase 2,adenosine receptor modulator,ADORA2A,,
Fc1ccc(-c2ccc3c(c2)[nH]c2ccncc23)cn1,T-807,Phase 2,PET radiotracer,,,
Fc1ccc(-c2[nH]c(-c3c(F)cccc3F)nc2-c2ccncc2)cc1,TA-01,Preclinical,casein kinase inhibitor|MAP kinase inhibitor,CSNK1D|CSNK1E|MAPK14,,
CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)/C=C/CC(C)(C)N,tabimorelin,Phase 2,growth hormone secretagogue receptor agonist,GHSR,,
C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CC[C@@H](O)C(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O,tacalcitol,Launched,vitamin D receptor agonist,VDR,dermatology,psoriasis|chapped lips
CC(=O)Nc1ccc(C(=O)Nc2ccccc2N)cc1,tacedinaline,Phase 3,HDAC inhibitor,HDAC1,,
Nc1c2c(nc3ccccc13)CCCC2,tacrine,Launched,acetylcholinesterase inhibitor,ACHE|BCHE,neurology/psychiatry,Alzheimer's disease
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,tacrolimus,Launched,calcineurin inhibitor,FKBP1A,transplant,organ rejection
CN1CC(=O)N2[C@H](c3ccc4c(c3)OCO4)c3[nH]c4ccccc4c3C[C@@H]2C1=O,tadalafil,Launched,phosphodiesterase inhibitor,PDE11A|PDE5A,urology,erectile dysfunction
O=C(O)c1ccc2nc(-c3cc(Cl)cc(Cl)c3)oc2c1,tafamidis-meglumine,Launched,transthyretin amyloid inhibitor,TTR,neurology/psychiatry,familial amyloid polyneuropathy (FAP)
COc1cc(C)c2c(Oc3cccc(C(F)(F)F)c3)c(OC)cc(N[C@@H](C)CCCN)c2n1,tafenoquine,Launched,antimalarial agent,,infectious disease,malaria
CC(C)OC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/C(F)(F)COc2ccccc2)[C@H](O)C[C@@H]1O,tafluprost,Launched,prostaglandin inhibitor,PTGFR,ophthalmology,glaucoma|ocular hypertension
O=C(CO)[C@@H](O)[C@@H](O)[C@H](O)CO,tagatose,Launched,phosphorylase inhibitor,PYGL,,
COc1cn(-c2ccc(-n3cccn3)cc2F)nc(-c2ccnn2-c2ccccc2)c1=O,TAK-063,Phase 2,phosphodiesterase inhibitor,PDE10A,,
CC(=O)N1CCC(C(=O)N(CCCN2CCC(Cc3ccc(C(N)=O)cc3)CC2)c2ccc(C)c(Cl)c2)CC1,TAK-220,Phase 1,CC chemokine receptor antagonist,CCR5,,
NS(=O)(=O)OC[C@H]1C[C@@H](Nc2ccnc3cc(-c4cccc(SC(F)(F)F)c4)nn23)[C@H](O)[C@@H]1O,TAK-243,Phase 1,ubiquitin activating enzyme inhibitor,,,
CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21,TAK-285,Phase 1,EGFR inhibitor,ERBB2,,
Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1,TAK-593,Phase 1,VEGFR inhibitor,PDGFRA,,
N#Cc1c(Oc2ccc(F)c(NC(=O)Cc3cccc(C(F)(F)F)c3)c2)ccc2nc(NC(=O)C3CC3)sc12,TAK-632,Preclinical,RAF inhibitor,BRAF,,
Cn1cc(-c2nc(N[C@@H]3CCCC[C@@H]3N)c(F)c3c2C(=O)NC3)cn1,TAK-659,Phase 2,spleen associated tyrosine kinase inhibitor,,,
CCc1nc(-c2cccc(C)c2)c(-c2ccnc(NC(=O)c3ccccc3)c2)s1,TAK-715,Phase 2,p38 MAPK inhibitor,MAPK14,,
Cn1c(=O)c(F)c(Nc2ccc(I)cc2F)c2c(=O)n(C[C@@H](O)CO)cnc21,TAK-733,Phase 1,MEK inhibitor,MAP2K1,,
Cc1ccc(-c2ccc3c(c2)C=C(C(=O)Nc2ccc(C[N+](C)(C)C4CCOCC4)cc2)CCC3)cc1,TAK-779,Preclinical,CC chemokine receptor antagonist,,,
Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3c(c2)OC[C@H]3CC(=O)O)c1,TAK-875,Phase 3,insulin secretagogue,FFAR1,,
CCS(=O)(=O)c1cccc(-c2cc(C(=O)NC3CCN(C)CC3)c(C)c3[nH]c4ncc(C)cc4c23)c1,TAK-901,Phase 1,Aurora kinase inhibitor,AURKB,,
COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2c(n1)N(C1CCCC1)CC(F)(F)C(=O)N2C,TAK-960,Phase 1,PLK inhibitor,PLK1,,
CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O,talabostat,Phase 3,dipeptidyl peptidase inhibitor|fibroblast activation protein inhibitor,DPP4,,
CN(C(=O)c1ccc(F)cc1C(F)(F)F)C1CCN(c2nnc(-c3ccnn3C)c3ccccc23)CC1,taladegib,Phase 2,smoothened receptor antagonist,DHH|IHH|SMO,,
CC(=O)N1N=C(c2ccc(N)cc2)c2cc3c(cc2C[C@H]1C)OCO3,talampanel,Phase 2,glutamate receptor antagonist,GRIA1|GRIA2|GRIA3|GRIA4,,
C=Cc1c(C)c2cc3nc(c(CC(=O)N[C@@H](CC(=O)O)C(=O)O)c4nc(cc5[nH]c(cc1[nH]2)c(C)c5CC)C(C)=C4C(=O)O)[C@@H](CCC(=O)O)[C@@H]3C,talaporfin,Phase 3,photosensitizing agent,,,
CCC(CC)[C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1,talarozole,Phase 2,cytochrome P450 inhibitor,CYP26A1,,
Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1,talazoparib,Launched,PARP inhibitor,PARP2,oncology,breast cancer
CC(C)(C)NC[C@@H](O)COc1ccc(NC(=O)NC2CCCCC2)cc1,talinolol,Launched,adrenergic receptor antagonist,ADRB1,cardiology,hypertension
C=CCN1CCc2nc(N)sc2CC1,talipexole,Launched,adrenergic receptor agonist|dopamine receptor agonist,ADRA2A|DRD2|HTR3A,infectious disease,genitial herpes
C[C@@H]1CN(Cc2ccc(F)cc2)[C@@H](C)CN1C(=O)c1cc2c(C(=O)C(=O)N(C)C)cn(C)c2cc1Cl,talmapimod,Phase 2,p38 MAPK inhibitor,IL1B|MAPK11|MAPK14|MT-CO2|TNF,,
CC[C@H](NC(=O)c1c(O)c(-c2ccccc2)nc2ccccc12)c1ccccc1,talnetant,Phase 2,tachykinin antagonist,TACR2|TACR3,,
O=C1O[C@H](OC(=O)c2cccnc2Nc2cccc(C(F)(F)F)c2)c2ccccc21,talniflumate,Launched,cyclooxygenase inhibitor,CLCA1,neurology/psychiatry,pain relief
CNCCC[C@@]1(c2ccccc2)OC(C)(C)c2ccccc21,talopram,Phase 2,adrenergic inhibitor,SLC6A2,,
C#CCO[C@H]1CN2CCC1CC2,talsaclidine,Phase 2/Phase 3,acetylcholine receptor agonist,,,
CN1C(=O)C[C@@H](C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N2CCC[C@H]2C(N)=O)NC1=O,taltirelin,Launched,thyrotropin releasing hormone receptor agonist,TRHR,neurology/psychiatry,spinocerebellar ataxia
CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](/C=C(\C)C(=O)O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1,taltobulin,Phase 1,tubulin polymerization inhibitor,,,
COC(=O)[C@H](CCCNC(=N)N)NS(=O)(=O)c1ccc(C)cc1,TAME,Preclinical,,,,
CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21,tamibarotene,Launched,retinoid receptor agonist,RARA|RARB,hematologic malignancy,acute promyelocytic leukemia (APL)
Nc1nc(-n2cccn2)nc(-n2cccn2)c1Br,taminadenant,Phase 1/Phase 2,adenosine receptor antagonist,,,
CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,tamoxifen,Launched,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),EBP|ESR1|ESR2|GPER1|PRKCA|PRKCB|PRKCD|PRKCE|PRKCG|PRKCI|PRKCQ|PRKCZ,oncology,breast cancer
CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1,tamsulosin,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D,urology,benign prostatic hyperplasia (BPH)
Cn1c(C#N)ccc1-c1ccc2c(c1)C(C)(C)OC(=S)N2,tanaproget,Phase 2,progesterone receptor agonist,PGR,,
O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1CCCCN1CCN(c2ncccn2)CC1,tandospirone,Launched,serotonin receptor agonist,HTR1A,neurology/psychiatry,generalized anxiety disorder (GAD)|dysthymic disorder
COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1,tandutinib,Phase 2,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,CSF1R|FLT3|KIT|PDGFD|PDGFRB,,
C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)NC(=CC1=O)C2=O,tanespimycin,Phase 3,HSP inhibitor,HSP90AA1,,
COc1ccc(-c2cc(=O)c3c(OC)c(OC)c(OC)c(OC)c3o2)cc1,tangeritin,Preclinical,cell cycle inhibitor,,,
O=C(OC[C@H]1O[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1,tannic-acid,Launched,PARG inhibitor,ANO1,gastroenterology,constipation
Cc1coc2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12,tanshinone-I,Phase 2,AP inhibitor,IFNG,,
Cc1coc2c1C(=O)C(=O)c1c-2ccc2c1CCCC2(C)C,tanshinone-IIA,Phase 2/Phase 3,anti-inflammatory agent|interleukin inhibitor,IL1B|NR1I2|TNF,,
CC(C)c1c(O)cc(/C=C/c2ccccc2)cc1O,tapinarof,Phase 3,aryl hydrocarbon receptor agonist,,,
O=C(O)COc1cccc(CN(Cc2ccc(-n3cccn3)cc2)S(=O)(=O)c2cccnc2)c1,taprenepag,Phase 2,prostaglandin receptor agonist,PTGER2,,
O=C(O[C@H]1C[N@]2CC[C@@H]1CC2)N(Cc1cc(F)c(F)c(F)c1)c1cccc(F)c1,tarafenacin,Phase 2,acetylcholine receptor antagonist,CHRM3,,
C[C@H](NC(=O)C(C)(C)Oc1ccc(C(F)(F)F)cn1)[C@@H](Cc1ccc(Cl)cc1)c1cccc(C#N)c1,taranabant,Phase 3,cannabinoid receptor inverse agonist,CNR1,,
CNC(=N)NCCC[C@H](N)C(=O)O,targinine,Phase 3,nitric oxide synthase inhibitor,NOS3,,
COc1cc2c(cc1OC)CN(CCc1ccc(NC(=O)c3cc(OC)c(OC)cc3NC(=O)c3cnc4ccccc4c3)cc1)CC2,tariquidar,Phase 3,P glycoprotein inhibitor,ABCB1,,
CN(C)CCNc1nc2cc(O)ccc2c2c1C(=O)c1ccccc1-2,TAS-103,Phase 1,topoisomerase inhibitor,TOP1,,
Cc1nc(-c2cn3c(n2)-c2ccc(-c4cnn(C(C)(C)C(N)=O)c4)cc2OCC3)n(C(C)C)n1,taselisib,Phase 3,PI3K inhibitor,PIK3CA,,
CCC(=O)NC[C@@H]1C[C@H]1c1cccc2c1CCO2,tasimelteon,Launched,melatonin receptor agonist,MTNR1A|MTNR1B,neurology/psychiatry,Non-24-Hour Sleep-Wake Disorder
O=C(NS(=O)(=O)c1ccc(Br)s1)c1ccc(Cl)cc1Cl,tasisulam,Phase 3,apoptosis stimulant,,,
COc1cccc2c1c(O)c(C(=O)N(C)c1ccc(C(F)(F)F)cc1)c(=O)n2C,tasquinimod,Phase 3,angiogenesis inhibitor|S100A9 inhibitor,HDAC4,,
c1cnc(SCc2cccnc2)nc1,tasuldine,Phase 3,mucolytic agent,,,
NCCS(=O)(=O)O,taurine,Launched,antioxidant,,neurology/psychiatry,anxiety|irritability|sleeplessness
C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C,taurocholate,Phase 1,G protein-coupled receptor agonist,CEL|FABP6|SLCO1C1,,
C[C@H](CCC(=O)NCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C,tauroglycocholate,Preclinical,membrane permeability enhancer,,,
O=S1(=O)CCN(CN2CCS(=O)(=O)NC2)CN1,taurolidine,Launched,apoptosis stimulant,,infectious disease,catheter-related bloodstream infection
OB1OCc2cc(F)ccc21,tavaborole,Launched,leucyl-tRNA synthetase inhibitor,,infectious disease,onychomycosis
NCCCC[C@@H]1NC(=O)[C@H](CCC(=O)O)NC(=O)c2cc([N+](=O)[O-])ccc2OCC[C@@H](C(=O)NCC(=O)O)NC1=O,tavilermide,Phase 3,tyrosine kinase partial agonist,,,
O=C1c2c(O)cc(O)cc2O[C@H](c2ccc(O)c(O)c2)[C@H]1O,taxifolin,Phase 2,opioid receptor antagonist,ADIPOR2,,
CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1,tazarotene,Launched,retinoid receptor agonist,RARA|RARB|RARG|RXRB,dermatology,cosmetic|sunscreen lotion
CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,tazemetostat,Launched,histone lysine methyltransferase inhibitor,EZH2,,
C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O,tazobactam,Launched,beta lactamase inhibitor,,infectious disease,pneumonia
O=[N+]([O-])c1cn2c(n1)OC[C@@H](OCc1ccc(-c3ccc(OC(F)(F)F)cc3)nc1)C2,TBA-354,Phase 1,,,,
N[C@@H](C(=O)O)[C@@H](OCc1ccccc1)C(=O)O.N[C@H](C(=O)O)[C@H](OCc1ccccc1)C(=O)O,TBOA-(DL),Preclinical,excitatory amino acid transporter inhibitor,SLC1A1|SLC1A2|SLC1A3|SLC1A6|SLC1A7,,
Cc1cc(Nc2cc(C)c(C#N)c(N[C@@H](C)CCCC(C)(C)O)n2)[nH]n1,TC-A-2317,Preclinical,Aurora kinase inhibitor,AURKA,,
CC(C)(C)c1ccc(C(=O)Nc2cn3cc(-n4ccnc4)ccc3n2)cc1,TC-ASK-10,Preclinical,MAP kinase inhibitor,MAP3K5|MAP3K6,,
O=C(O)CCN(O)C(=O)CCCCCCCCC1CC1,TC-E-5002,Preclinical,histone demethylase inhibitor,KDM2A|KDM4A|KDM4C|KDM5A|KDM6A|KDM7A|PHF8,,
CC1CCN([C@@H](c2ccc(F)cc2)c2ccc([C@@H](C)C(=O)O)cc2-c2ccc(C(F)(F)F)cc2)CC1,TC-E-5006,Preclinical,gamma secretase modulator,APP,,
CCn1c(=O)n([C@H]2CCCN(c3nccc(-c4cc5ccccc5o4)n3)C2)c2ccccc21,TC-F-2,Preclinical,FAAH inhibitor,FAAH,,
CC(C)c1c(NC(=O)Nc2ccc(Cl)cc2)c(=O)n(-c2ccccc2)n1C,TC-FPR-43,Preclinical,formyl peptide receptor agonist,FPR2,,
Cc1sc(C)c2c1CCC=C2c1cnc[nH]1,TC-G-1000,Preclinical,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C,,
COC1CCN(c2cccc(-c3cc(NC(C)=O)nc(-n4nc(C)cc4C)n3)n2)CC1,TC-G-1004,Preclinical,adenosine receptor antagonist,ADORA2A,,
Cc1ccc(C)c(Oc2ccncc2C(=O)N2CCN(C3CC3)c3ccccc32)c1,TC-G-1005,Preclinical,G protein-coupled receptor agonist,GPBAR1,,
CNc1nc(NCc2ccc(NS(C)(=O)=O)cc2Cl)cc(-c2ccccn2)n1,TC-G-1008,Preclinical,G protein-coupled receptor agonist,GPR39,,
Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1,TC-H-106,Preclinical,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC8,,
CC1(C)SCN(S(=O)(=O)c2ccccc2)[C@@H]1C(=O)N[C@@H](CNC(=O)NCc1ccccc1)C(=O)O,TC-I-15,Preclinical,integrin inhibitor,ITGA2|ITGB1,,
O=C(Nc1ccc(F)cc1)N1CCc2ccccc2[C@@H]1c1ccc(C(F)(F)F)cc1,TC-I-2000,Preclinical,transient receptor potential channel antagonist,TRPM8,,
FC(F)(F)c1ccccc1-c1cc(C(F)(F)F)c2[nH]c(C3=NOC4(CCCCC4)C3)nc2c1,TC-I-2014,Preclinical,transient receptor potential channel antagonist,TRPM8,,
COc1cccc(-n2nc(C(=O)O)cc2-c2ccc(C3CCCCC3)c(Cl)c2)c1,TC-LPA5-4,Preclinical,lysophosphatidic acid receptor antagonist,LPAR5,,
CC(C)(C)Nc1nc(Nc2ccc(C(N)=O)cc2)cc(N)c1C#N,TC-Mps1-12,Preclinical,monopolar spindle 1 kinase inhibitor,TTK,,
CC(=O)Nc1cccc(Nc2ncnc(N3CCC(OCc4ccc(OC(F)(F)F)cc4)CC3)n2)c1C,TC-N-1752,Preclinical,sodium channel blocker,SCN9A,,
COc1cccc(OC)c1-c1cc(C(=O)N[C@@H](CC(C)C)C(=O)O)nn1-c1ccnc2cc(Cl)ccc12,TC-NTR1-17,Preclinical,neurotensin agonist,NTSR1,,
COc1cc(OC)cc(C(=O)NNC(=O)Nc2cccc3ccccc23)c1,TC-O-9311,Preclinical,G protein-coupled receptor agonist,GPR139,,
Cc1cc(C(=O)N2Cc3cnn(C)c3Nc3ccccc32)ccc1CNC(=O)N1CCC[C@H]1C(=S)N1CCCN(C)CC1,TC-OT-39,Preclinical,oxytocin receptor agonist|vasopressin receptor agonist,AVPR1A|OXT,,
Cc1cccc(C)c1-n1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n2c3ccccc3nc12,TC-S-7003,Preclinical,SRC inhibitor,LCK,,
COc1ncc2cc(C(=O)Nc3cc(C(=O)NCc4cccc(Cl)c4)ccc3Cl)c(=O)[nH]c2n1,TC-S-7004,Preclinical,DYRK inhibitor,DYRK1A|DYRK1B,,
C[C@H](Nc1cc2c(-c3ccc4c(c3)OCO4)noc2cn1)c1ccccc1,TC-S-7005,Preclinical,PLK inhibitor,PLK2,,
N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1,TC-S-7006,Preclinical,MAP kinase inhibitor,MAP3K8,,
O=[N+]([O-])c1c(Nc2cc(F)cc(Cl)c2)ccc2nonc12,TC-S-7009,Preclinical,hypoxia inducible factor inhibitor,EPAS1,,
O=C(O)C1CN(Cc2ccc(-c3nc4cc(Cc5ccccc5F)ccc4s3)c(F)c2)C1,TC-SP-14,Preclinical,sphingosine 1-phosphate receptor agonist,S1PR1,,
O[C@@]12[C@H]3[C@@H]4[C@@H]5C[C@@H]6[C@@H]4[C@@H]3[C@@H]([C@@H]6[C@@H]51)N2CCc1cccc(F)c1,TC1,Preclinical,beta-secretase inhibitor,BACE1,,
CCOc1cncc(/C=C/CCNC)c1,TC2559,Preclinical,acetylcholine receptor agonist,CHRNA4,,
O=C1CC(=O)c2c(Cl)c(Cl)c(Cl)c(Cl)c21,TCID,Preclinical,,,,
O=C(NNC(=O)c1ccc(CNS(=O)(=O)c2ccc(F)c(Cl)c2)cc1)c1ccccc1,TCN201,Preclinical,glutamate receptor antagonist,GRIN2A,,
Nc1nccc(/C=C/c2ccccc2)n1,TCN238,Preclinical,glutamate receptor positive allosteric modulator,GRM4,,
Cc1nnc(-c2ccc3occ(-c4ccc([S@](C)=O)cc4)c3c2)o1,TCS-2002,Preclinical,glycogen synthase kinase inhibitor,GSK3B,,
CC(C)(O)C(=O)N1CCN(c2ccc(C(F)(F)F)c(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c2)CC1,TCS-21311,Preclinical,JAK inhibitor,JAK3,,
O=C(NO)c1ccc2[nH]c(=O)c(CCCc3ccccc3)nc2c1,TCS-2210,Preclinical,neural stem cell inducer,,,
Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2CCOC[C@H]2C(=O)N2CCC(CC(=O)O)CC2)cc1,TCS-2314,Preclinical,integrin inhibitor,ITGA4|ITGB1,,
O=C(O)COc1ccc(/C=C2\SC(=O)NC2=O)cc1,TCS-3035,Preclinical,G protein-coupled receptor agonist,GPR35,,
COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC,TCS-359,Preclinical,FLT3 inhibitor,FLT3,,
CC[C@@H](C)c1ccc(NC(=O)Cn2cnc3c2c(=O)n(C)c(=O)n3C)cc1,TCS-5861528,Preclinical,transient receptor potential channel antagonist,TRPA1,,
CC(C)C(=O)SCCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)NC12CC3CC(CC(C3)C1)C2,TCS-HDAC6-20b,Preclinical,HDAC inhibitor,HDAC6,,
COc1cc2c(cc1OC)CN(C(=O)[C@@H](NCc1ccncc1)C(C)(C)C)CC2,TCS-OX2-29,Preclinical,orexin receptor antagonist,HCRTR2,,
N#Cc1c(-c2ccccc2)cc(-c2cc(Br)ccc2O)[nH]c1=O,TCS-PIM-1-1,Preclinical,Pim kinase inhibitor,PIM1,,
CCC[n+]1cc(Br)cc(C(=O)N(CCC(=O)NCCOC(=O)N2CCc3ccccc3C2)c2ccccc2)c1,TCV-309,Preclinical,platelet activating factor receptor antagonist,,,
OC[C@H]1O[C@@H](S[C@@H]2O[C@H](CO)[C@H](O)[C@H](n3cc(-c4cccc(F)c4)nn3)[C@H]2O)[C@H](O)[C@@H](n2cc(-c3cccc(F)c3)nn2)[C@H]1O,TD139,Phase 2,anti-inflammatory agent,,,
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)OCOC(=O)C(C)(C)C)=C(SC3CN(C4=NCCS4)C3)[C@H](C)[C@H]12,tebipenem,Launched,bacterial cell wall synthesis inhibitor,CNR1,infectious disease|otolaryngology,pneumonia|otitis
OC[C@H]1O[C@@H](n2cnc3c(N[C@@H]4CCOC4)ncnc32)[C@H](O)[C@@H]1O,tecadenoson,Phase 2,adenosine receptor agonist,ADORA1,,
COc1cccc([C@@H](C)NCCCc2ccccc2Cl)c1,tecalcet,Phase 2,calcium-sensing receptor agonist,CASR,,
Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc32)cc1,tecastemizole,Phase 3,histamine receptor antagonist,KCNH2,,
O=C(NN1C(=O)[C@@H]2[C@@H]3C=C[C@@H]([C@H]4C[C@@H]34)[C@@H]2C1=O)c1ccc(C(F)(F)F)cc1,tecovirimat,Launched,orthopoxvirus egress inhibitor,,infectious disease,smallpox
Cn1nnc(-c2ccc(-c3ccc(N4C[C@H](CO)OC4=O)cc3F)cn2)n1,tedizolid,Launched,bacterial 50S ribosomal subunit inhibitor,,infectious disease,skin infections
Cn1nnc(-c2ccc(-c3ccc(N4C[C@H](COP(=O)(O)O)OC4=O)cc3F)cn2)n1,tedizolid-phosphate,Launched,protein synthesis inhibitor,,infectious disease,skin infections
Fc1ccccc1-c1nc2ccn(Cc3ccc(-c4ccc(C(F)(F)F)cc4C(F)(F)F)nn3)cc-2n1,tegobuvir,Phase 3,HCV inhibitor|protease inhibitor,,,
CCCCCCCCCC(=O)N[C@H]1[C@H](Oc2c3cc4cc2Oc2ccc(cc2Cl)[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2NC(C)=O)[C@@H]2NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H]4NC(=O)[C@@H](Cc5ccc(c(Cl)c5)O3)NC(=O)[C@@H](N)c3ccc(O)c(c3)Oc3cc(O)cc4c3)c3ccc(O)c(c3)-c3c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc3[C@H](C(=O)O)NC2=O)O[C@H](CO)[C@@H](O)[C@@H]1O,teicoplanin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections
CCCCC/C=C/CCC(=O)N[C@H]1[C@H](Oc2c3cc4cc2Oc2ccc(cc2Cl)[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2NC(C)=O)[C@@H]2NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H]4NC(=O)[C@@H](Cc5ccc(c(Cl)c5)O3)NC(=O)[C@H](N)c3ccc(O)c(c3)Oc3cc(O)cc4c3)c3ccc(O)c(c3)-c3c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc3[C@@H](C(=O)O)NC2=O)O[C@H](CO)[C@@H](O)[C@@H]1O,teicoplanin-A2-1,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections
CC(=O)N[C@@H]1[C@H](O[C@@H]2c3ccc(c(Cl)c3)Oc3cc4cc(c3O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3NC(=O)CCCCCCCC(C)C)Oc3ccc(cc3Cl)C[C@H]3NC(=O)[C@H](N)c5ccc(O)c(c5)Oc5cc(O)cc(c5)[C@H](NC3=O)C(=O)N[C@@H]4C(=O)N[C@@H]3C(=O)N[C@@H]2C(=O)N[C@@H](C(=O)O)c2cc(O)cc(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)c2-c2cc3ccc2O)O[C@H](CO)[C@@H](O)[C@@H]1O,teicoplanin-A2-3,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections
O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(Cc2ccc(Cl)cc2)C1,teijin-compound-1,Preclinical,CC chemokine receptor antagonist,CCR2,,
CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1,telaprevir,Launched,HCV inhibitor,CTSA|PGR,infectious disease,hepatitis C
CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1,telatinib,Phase 2,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,KDR,,
Cc1cn([C@@H]2C[C@@H](O)[C@H](CO)O2)c(=O)[nH]c1=O,telbivudine,Launched,DNA polymerase inhibitor,,infectious disease,hepatitis B
O=C(N[C@@H]1CC[C@@H](c2cccc(F)c2F)CN(CC(F)(F)F)C1=O)N1CCC(n2c(=O)[nH]c3ncccc32)CC1,telcagepant,Phase 3,calcitonin antagonist,CALCRL|RAMP1,,
Cc1scc2c1N(C(=O)CN1CCN(C)CC1)c1ccccc1NC2=O,telenzepine,Phase 3,acetylcholine receptor antagonist,CHRM1,,
CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C,telithromycin,Launched,bacterial 30S ribosomal subunit inhibitor|bacterial 50S ribosomal subunit inhibitor,CYP1A2|CYP2D6|CYP3A4|CYP3A5|CYP3A7,infectious disease,pneumonia
CCOC(=O)N1CSC[C@@H]1C(=O)O,telmesteine,Launched,mucolytic agent,,pulmonary,cough suppressant
CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,telmisartan,Launched,angiotensin receptor antagonist,AGTR1|PPARG,cardiology,hypertension
Cc1ccn(-c2cc(Cl)ccc2[C@@H](Oc2cc(-c3ccc(C[C@H](N)C(=O)O)cc3)nc(N)n2)C(F)(F)F)n1,telotristat,Launched,tryptophan hydroxylase inhibitor,TPH1,gastroenterology,diarrhea
CCOC(=O)[C@@H](N)Cc1ccc(-c2cc(O[C@H](c3ccc(Cl)cc3-n3ccc(C)n3)C(F)(F)F)nc(N)n2)cc1,telotristat-ethyl,Launched,tryptophan hydroxylase inhibitor,TPH1,gastroenterology,diarrhea
CCCCCCCCCCCCCCCCCC(=O)NCCCCOn1c(CCCC)nc2c(N)nc3ccccc3c21,telratolimod,Preclinical,toll-like receptor agonist,,,
COc1cccc(C(=O)Nc2ccc(OCCN3CCOCC3)c(-c3ccnn3C)c2)c1,temanogrel,Preclinical,serotonin receptor antagonist,,,
COP(=S)(OC)Oc1ccc(Sc2ccc(OP(=S)(OC)OC)cc2)cc1,temefos,Launched,cholinesterase inhibitor,,,
CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@H](c2cccs2)CN(CC(=O)O)C1=O,temocapril,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology|nephrology,hypertension|congestive heart failure|diabetic nephropathy|coronary artery disease (CAD)
Oc1cccc(-c2c3nc(c(-c4cccc(O)c4)c4[nH]c(c(-c5cccc(O)c5)c5ccc([nH]5)c(-c5cccc(O)c5)c5nc2C=C5)CC4)C=C3)c1,temoporfin,Launched,radical formation stimulant,,oncology,head and neck squamous cell carcinoma (HNSCC)
Cn1nnc2c(C(N)=O)ncn2c1=O,temozolomide,Launched,DNA alkylating agent,MGMT,oncology,glioblastoma|astrocytoma
CC1(C)CC(O)CC(C)(C)N1O,tempol,Phase 2,free radical scavenger,,,
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,temsirolimus,Launched,mTOR inhibitor,MTOR,oncology,renal cell carcinoma (RCC)
Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@@H](CC(=O)NCCCN1CCN(C)CC1)c1nnc(C)n1-2,TEN-010,Preclinical,bromodomain inhibitor,,,
CC[C@H](Nc1ncnc2nc[nH]c12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1,tenalisib,Phase 2,PI3K inhibitor,,,
CN1Cc2c(Cl)cc(Cl)cc2[C@H](c2cccc(S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c3cccc([C@@H]4CN(C)Cc5c(Cl)cc(Cl)cc54)c3)c2)C1,tenapanor,Launched,sodium/hydrogen exchanger inhibitor,,,
COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2n1,tenatoprazole,Phase 2,ATPase inhibitor,IDO1,,
Cc1cc(N2CCN([C@@H]3CN[C@H](C(=O)N4CCSC4)C3)CC2)n(-c2ccccc2)n1,teneligliptin,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus
NC(=O)N1C(=O)[C@@H](C(=O)c2cccs2)c2cc(Cl)ccc21,tenidap,Phase 3,cyclooxygenase inhibitor,KCNJ4|PTGS1,,
O=C1NCCN[C@@H]1c1cccs1,tenilsetam,Phase 3,AGE inhibitor,,,
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](c6cccs6)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,teniposide,Launched,topoisomerase inhibitor,TOP2A|TOP2B,hematologic malignancy,acute lymphoblastic leukemia (ALL)
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,tenofovir,Launched,HIV integrase inhibitor|nucleoside reverse transcriptase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)|hepatitis B
CC(C)OC(=O)[C@@H](C)NP(=O)(CO[C@@H](C)Cn1cnc2c(N)ncnc21)Oc1ccccc1,tenofovir-alafenamide,Launched,nucleoside reverse transcriptase inhibitor,,infectious disease,hepatitis B
CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C,tenofovir-disoproxil,Launched,nucleoside reverse transcriptase inhibitor,CYP1A2,infectious disease,human immunodeficiency virus (HIV-1)|hepatitis B
CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(C(C)(C)C)cc2)cc1,tenovin-1,Preclinical,SIRT inhibitor|TP53 activator,SIRT1,,
CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(C(C)(C)C)cc2)cc1,tenovin-6,Preclinical,SIRT inhibitor,SIRT1|SIRT2|SIRT3,,
CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O,tenoxicam,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology|orthopedics,rheumatoid arthritis|osteoarthritis|ankylosing spondylitis|tendinitis|bursitis|periarthritis
O=C1/C(=C/c2cccs2)CCC/C1=C\c1cccs1,tenylidone,Preclinical,,,,
COc1ccc(-n2nc(CCC(=O)N(C)O)cc2-c2ccc(Cl)cc2)cc1,tepoxalin,Launched,cyclooxygenase inhibitor|lipoxygenase inhibitor,ALOX5,rheumatology|orthopedics,rheumatoid arthritis|hip dysplasia
Cn1c2cc([S@@](C)=O)sc2c2cnn(Cc3cccc(N)c3)c(=O)c21,TEPP-46,Preclinical,pyruvate kinase isozyme activator,PKM,,
CC(=O)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C,teprenone,Launched,mucus protecting agent,,dermatology,cosmetic
COc1ccc(C[C@@H](C)[C@@H](C)Cc2ccc(OC)c(OC)c2)cc1OC,terameprocol,Phase 1/Phase 2,lipoxygenase inhibitor,BIRC5|CDK1,,
COc1cc2nc(N3CCN(C(=O)[C@H]4CCCO4)CC3)nc(N)c2cc1OC,terazosin,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D,urology|cardiology,benign prostatic hyperplasia (BPH)|hypertension
CN(C/C=C/C#CC(C)(C)C)Cc1cccc2ccccc12,terbinafine,Launched,fungal squalene epoxidase inhibitor,SQLE,infectious disease,tinea pedis|tinea cruris|tinea corporis
CC(C)(C)NC[C@@H](O)c1cc(O)cc(O)c1,terbutaline,Launched,adrenergic receptor agonist,ADRB2,pulmonary,bronchospasm|bronchitis|emphysema
C#CC1(OC[C@H](O)CN2CCN(c3cccc(C(F)(F)F)c3)CC2)CCCCC1,terciprazine,Phase 1,,,,
CC(C)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,terconazole,Launched,sterol demethylase inhibitor,,infectious disease,vulvovaginal candidiasis
CCN(CC)C(=O)N[C@H]1C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,terguride,Launched,dopamine receptor agonist|serotonin receptor antagonist,ADRA1A|ADRA2A|ADRA2B|ADRA2C|DRD2|DRD3|DRD4|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C,neurology/psychiatry,Parkinson's Disease
CC(=O)[C@@H](C#N)C(=O)Nc1ccc(C(F)(F)F)cc1,teriflunomide,Launched,dihydroorotate dehydrogenase inhibitor,DHODH,neurology/psychiatry,multiple sclerosis
NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,terlipressin,Launched,vasopressin receptor agonist,AVPR1A,cardiology,hypotension
O=c1n(C[C@H]2CO2)c(=O)n(C[C@H]2CO2)c(=O)n1C[C@H]1CO1,teroxirone,Phase 1,DNA inhibitor,,,
CC(C)(O)[C@H]1CC[C@](C)(O)CC1,terpene,Preclinical,,,,
C[C@H]1C(=O)C(=O)[C@@H]2O[C@@H]2C1=O,terreic-acid-(-),Preclinical,Bruton's tyrosine kinase (BTK) inhibitor,BTK,,
Cc1ccc2c(c1CCC(=O)O)CC[C@@H](NS(=O)(=O)c1ccc(Cl)cc1)C2,terutroban,Phase 3,prostanoid receptor antagonist,TBXA2R,,
CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(=O)O,tesaglitazar,Phase 3,insulin sensitizer|PPAR receptor agonist,PPARA|PPARG,,
CCOc1ccc(-c2nc(-c3cccc(C(=O)O)n3)cs2)cc1OCC,tetomilast,Phase 2,phosphodiesterase inhibitor,PDE4D,,
COc1cc2c(cc1OC)[C@@H]1CC(=O)[C@@H](CC(C)C)CN1CC2,tetrabenazine,Launched,vesicular monoamine transporter inhibitor,SLC18A1|SLC18A2,infectious disease|neurology/psychiatry,cholera|Huntington's disease
CCCCNc1ccc(C(=O)OCCN(C)C)cc1,tetracaine,Launched,membrane integrity inhibitor,SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,anesthetic
CN(C)[C@@H]1C(=O)[C@H](C(N)=O)C(=O)[C@@]2(O)C(=O)[C@@H]3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12,tetracycline,Launched,bacterial 30S ribosomal subunit inhibitor,,infectious disease|dermatology,respiratory tract infections|pneumonia|skin infections|urinary tract infections|acne vulgaris (AV)|plague|psittacosis
CCCCCCCCCCCCCCSCC(=O)O,tetradecylthioacetic-acid,Phase 2,lipid peroxidase inhibitor,,,
NCCNCCNCCNCCN,tetraethylenepentamine,Phase 2/Phase 3,superoxide dismutase inhibitor,SOD1|SOD2,,
Nc1nc(=O)c2c([nH]1)NC[C@H](CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2,tetrahydrofolic-acid,Launched,,FOLR2,,
COc1ccc(C[C@H]2NCCc3cc(OC)c(OC)cc32)cc1OC,tetrahydropapaverine,Preclinical,,,,
O=C1N[C@H](O)CCN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,tetrahydrouridine,Phase 2,cytidine deaminase inhibitor,CDA,,
c1ccc2c(c1)CCC[C@@H]2C1=NCCN1,tetrahydrozoline,Launched,adrenergic receptor agonist,,ophthalmology,eye irritation
CN(C)C(=S)SC(=S)N(C)C,tetramethylthiuram-monosulfide,Preclinical,,,,
c1ccc([C@H]2CN3CCSC3=N2)cc1,tetramisole,Launched,immunostimulant,ALPPL2|CHRNA3,infectious disease,gastrointestinal parasites
COc1ccc2cc1Oc1ccc(cc1)C[C@H]1c3cc(c(OC)cc3CCN1C)Oc1c(OC)c(OC)cc3c1[C@H](C2)N(C)CC3,tetrandrine,Preclinical,calcium channel blocker,SLC6A3,,
N[C@@H](C(=O)O)c1nn[nH]n1,tetrazol-5-yl-glycine-(RS),Preclinical,glutamate receptor agonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,,
c1cc2c(cc1C1CCCCC1)c1c3n2CCNC3CCC1,tetrindole,Phase 3,monoamine oxidase inhibitor,MAOA,,
O=C1C(=O)C(O)C(=O)C(=O)C1O,tetroquinone,Preclinical,,,,
CC(C)(CO)c1cc2cc(NC(=O)C3(c4ccc5c(c4)OC(F)(F)O5)CC3)c(F)cc2n1C[C@@H](O)CO,tezacaftor,Launched,CFTR channel agonist,,pulmonary,cystic fibrosis
O=C(Nc1ccc(N2CCC(C(=O)N3CCOCC3)CC2)cc1)c1cnc(Oc2ccccc2)nc1,TFC-007,Preclinical,prostaglandin inhibitor,HPGDS,,
CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21,TG-003,Preclinical,CLK inhibitor,CLK1|CLK4|DYRK1A|DYRK1B,,
CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1,TG-02,Phase 1/Phase 2,CDK inhibitor|FLT3 inhibitor|JAK inhibitor,CDK1|CDK2|CDK7|CDK9|FLT3|JAK2,,
Cc1cc(-c2cc(O)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12,TG-100572,Preclinical,SRC inhibitor|VEGFR inhibitor,KDR|SRC,,
Nc1nc(N)c2nc(-c3cccc(O)c3)cnc2n1,TG-100713,Preclinical,PI3K inhibitor,,,
Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12,TG-100801,Phase 2,SRC inhibitor|VEGFR inhibitor,CSK|FGFR1|FLT1|FLT4|KDR|SRC,,
Cc1cnc(Nc2ccc(N3CCN(C)CC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1,TG-101209,Preclinical,JAK inhibitor,JAK2|JAK3,,
Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1,TG100-115,Phase 1/Phase 2,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,,
CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F,TGR-1202,Phase 3,PI3K inhibitor,,,
Cc1cc([C@@H](C)Nc2ccccc2)c2nc(N3CCOCC3)cc(=O)n2c1,TGX-221,Preclinical,PI3K inhibitor,PIK3CB|PIK3CD,,
Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+](=O)[O-],TH-302,Phase 3,DNA alkylating agent,,,
Nc1nc(NC2CC2)cc(-c2cccc(Cl)c2Cl)n1,TH-588,Preclinical,MTH1 inhibitor,NUDT1,,
COc1cc(C[C@H]2c3cc(OC)c(OC)cc3CCN2C)c(Oc2cc3c(cc2OC)-c2c(OC)c(OC)cc4c2[C@H](C3)N(C)CC4)cc1OC,thaliblastine,Phase 2,DNA inhibitor,,,
O=C1CC[C@H](N2C(=O)c3ccccc3C2=O)C(=O)N1,thalidomide,Launched,tumor necrosis factor production inhibitor,TNF,oncology,myeloma
O=c1c(O)cc([C@H]2Oc3cc(O)cc(O)c3C[C@H]2O)c2cc([C@H]3Oc4cc(O)cc(O)c4C[C@H]3O)cc(O)c(O)c1-2,theaflavin,Preclinical,antiviral,,,
Cn1cnc2c1c(=O)[nH]c(=O)n2C,theobromine,Launched,phosphodiesterase inhibitor,ADORA1|ADORA2A|PDE4B,,
CCNC1=N[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]2S1,thiamet-g,Preclinical,GLCNAC phosphotransferase inhibitor,MGEA5,,
Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1,thiamine,Launched,vitamin B,SLC19A2|SLC19A3|TPK1,metabolism,thiamine deficiency
Cc1ncc(C[n+]2csc(CCOP(=O)(O)OP(=O)(O)O)c2C)c(N)n1,thiamine-pyrophosphate,Launched,,,hematology,anemia
CS(=O)(=O)c1ccc([C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl)cc1,thiamphenicol,Launched,bacterial 50S ribosomal subunit inhibitor,,infectious disease,pelvic inflammatory disease
C=CCC1([C@H](C)CCC)C(=O)NC(=S)NC1=O,thiamylal,Launched,glutamate receptor antagonist,GABRA1,neurology/psychiatry,sedative
O=C(NCc1ccccc1)c1csc(Nc2ccncn2)n1,thiazovivin,Preclinical,rho associated kinase inhibitor,,,
CCSc1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2,thiethylperazine,Launched,dopamine receptor antagonist,DRD1|DRD2|DRD4,gastroenterology,nausea
COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2c(c1OC)-c1ccc(SC)c(=O)cc1[C@@H](NC(C)=O)CC2,thiocolchicoside,Launched,GABA receptor antagonist,GABRA1|GABRB2|GABRG2|GLRA1|GLRB,neurology/psychiatry,muscle relaxant
O=C(O)CCCC[C@H]1CCSS1,thioctic-acid,Launched,reducing agent,ACHE|PTGS2,nephrology,diabetic nephropathy
OCCSCCO,thiodiglycol,Preclinical,,,,
Nc1nc2nc[nH]c2c(=S)[nH]1,thioguanine,Launched,purine antagonist,IMPDH1|IMPDH2,hematologic malignancy,acute myeloid leukemia (AML)
CC[Hg]Sc1ccccc1C(=O)O,thiomersal,Launched,other antibiotic,OXCT1,infectious disease,preservative
CCC[C@@H](C)C1(CC)C(=O)NC(=S)NC1=O,thiopental,Launched,GABA receptor antagonist,FAAH,neurology/psychiatry,anesthetic
S=C(NC1CCCCC1)N1CCC([C@H]2C=NC=N2)CC1,thioperamide,Preclinical,histamine receptor antagonist,HRH3|HRH4,,
COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC,thiophanate,Preclinical,,,,
CN1CCN(CCCN2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1,thioproperazine,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|DRD1|DRD2|HTR1A|HTR2A,neurology/psychiatry,schizophrenia
O=C(O)CNC(=O)[C@@H](CS)Cc1ccccc1,thiorphan,Phase 1,membrane metalloendopeptidase inhibitor,MME,,
C=C(NC(=O)C(=C)NC(=O)c1csc(C2=N[C@@H]3c4csc(n4)[C@H]4NC(=O)c5csc(n5)[C@H]([C@](C)(O)[C@@H](C)O)NC(=O)[C@H]5CSC(=N5)/C(=C/C)NC(=O)[C@H]([C@@H](C)O)NC(=O)c5csc(n5)[C@]3(CC2)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)N[C@@H]2C=Cc3c([C@H](C)O)cc(nc3[C@H]2O)C(=O)O[C@@H]4C)n1)C(N)=O,thiostrepton,Launched,FOXM1 inhibitor|protein synthesis inhibitor,FOXM1,obstetrics/gynecology,mastitis
S=P(N1CC1)(N1CC1)N1CC1,thiotepa,Launched,cytochrome P450 inhibitor,CYP2B6|CYP3A4,oncology,breast cancer|ovarian cancer|bladder cancer
CN1CCN(CC/C=C2/c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1,thiothixene,Launched,dopamine receptor antagonist,DRD1|DRD2|HRH1|HTR2A,neurology/psychiatry,schizophrenia
CN(C)C(=S)SSC(=S)N(C)C,thiram,Launched,,JAK2,ophthalmology,contact dermatitis
CNc1ccc(-c2ccc3cc(OC[C@H](O)CF)ccc3n2)cn1,THK5351,Phase 2,PET radiotracer ,,,
CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1,thonzonium,Launched,ATPase inhibitor,,infectious disease,ear infections
COc1ccc(CN(CCN(C)C)c2ncccn2)cc1,thonzylamine,Launched,antihistamine,,neurology/psychiatry,itching
CC(O)(C(=O)O)[C@@H](CC(=O)O)C(=O)O.CC(O)(C(=O)O)[C@H](CC(=O)O)C(=O)O.[NaH].[NaH].[NaH].[NaH].[NaH].[NaH],threo-2-methylisocitrate-(DL),Preclinical,isocitrate lyase substrate,,,
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(C)=O)C(C)C)[C@@H](C)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)O)C(C)C)C(C)C)[C@@H](C)O)[C@@H](C)O,thymalfasin,Launched,immune response modulator,,infectious disease,hepatitis B|hepatitis C
Cc1ccc(C(C)C)c(O)c1,thymol,Launched,GABA receptor positive allosteric modulator,TRPA1,infectious disease,ringworm|antiseptic
Cc1cc(OI)c(C(C)C)cc1-c1cc(C(C)C)c(OI)cc1C,thymol-iodide,Preclinical,,,,
CC(C)[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O,thymopentin,Launched,immune response stimulator,,,
CN(C)C/C=C/C(=O)Nc1ccc(C(=O)Nc2cccc(Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)c2)cc1,THZ1,Preclinical,CDK inhibitor,CDK7,,
CN(C)CCCC(=O)Nc1ccc(C(=O)Nc2cccc(Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)c2)cc1,THZ1-R,Preclinical,CDK inhibitor,CDK7,,
CN(C)C/C=C/C(=O)Nc1cccc(C(=O)Nc2cccc(Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)c2)c1,THZ2,Preclinical,CDK inhibitor,CDK7,,
c1ccc2[nH]c(-c3cscn3)nc2c1,tiabendazole,Launched,angiogenesis inhibitor,,infectious disease,gastrointestinal roundworms|hookworm
Cc1ccsc1C(=CCCN1CCC[C@@H](C(=O)O)C1)c1sccc1C,tiagabine,Launched,GABA uptake inhibitor,SLC6A1,neurology/psychiatry,seizures
CN1c2ccccc2[C@@H](NCCCCCCC(=O)O)c2ccc(Cl)cc2S1(=O)=O,tianeptine,Launched,selective serotonin reuptake enhancer (SSRE),OPRD1|OPRK1|OPRM1,neurology/psychiatry|pulmonary|gastroenterology,depression|asthma|irritable bowel syndrome
CCN(CC)CCNC(=O)c1cc(S(C)(=O)=O)ccc1OC,tiapride,Launched,dopamine receptor antagonist,DRD2|DRD3,neurology/psychiatry,dyskinesia|abstinence from alcohol|psychosis
C[C@@H](C(=O)O)c1ccc(C(=O)c2ccccc2)s1,tiaprofenic-acid,Launched,cyclooxygenase inhibitor,PTGS2,rheumatology,rheumatoid arthritis
O=C(Cn1c(=O)sc2ccc(Cl)cc21)N1CCN(CCO)CC1,tiaramide,Launched,anti-inflammatory agent,,pulmonary,asthma
C#C[C@]1(O)CC[C@@H]2[C@H]3[C@H](C)CC4=C(CCC(=O)C4)[C@H]3CC[C@@]21C,tibolone,Launched,androgen receptor agonist|estrogen receptor agonist|progesterone receptor agonist,ESR1,obstetrics/gynecology,endometriosis
Cc1ccccc1CN1C2=NCCN2C(=O)C2=C1CCN(Cc1ccccc1)C2,TIC10,Phase 2,AKT inhibitor|TRAIL modulator,AKT1|MAPK1,,
CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,ticagrelor,Launched,purinergic receptor antagonist,P2RY12,cardiology,acute coronary syndrome (ACS)|myocardial infarction
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(=O)O)c3ccsc3)C(=O)N2[C@H]1C(=O)O,ticarcillin,Launched,lactamase inhibitor,,infectious disease,gram-negative bacterial infections
Clc1ccccc1CN1CCc2sccc2C1,ticlopidine,Launched,purinergic receptor antagonist,P2RY12,hematology|neurology/psychiatry,thrombosis|stroke
O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1,tideglusib,Phase 2,glycogen synthase kinase inhibitor,GSK3B,,
COc1ccc2cc(-c3[nH]c(-c4ccc([S@@](C)=O)cc4)nc3-c3ccncc3)ccc2c1,tie2-kinase-inhibitor,Preclinical,TIE tyrosine kinase inhibitor,KDR|MAPK14,,
CC1(NC2=NS(=O)(=O)c3sc(Cl)cc3N2)CC1,tifenazoxide,Phase 1,ATP-sensitive potassium channel agonist,ABCC8|KCNJ11,,
CN(C)c1cc(NC(=O)CNC(C)(C)C)c(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(=O)[C@@H](C(N)=O)C(=O)[C@@]3(O)C(=O)[C@H]1C2=O,tigecycline,Launched,bacterial 30S ribosomal subunit inhibitor,,infectious disease,skin infections|pneumonia|intra-abdominal infections
CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]2O)[C@@H](CCN2C[C@H](C)C[C@H](C)C2)C[C@@H](C)C(=O)/C=C/C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC,tilmicosin,Launched,bacterial 50S ribosomal subunit inhibitor,,pulmonary,bovine respiratory disease (BRD)
CCN(CC)CCOc1ccc2c(c1)C(=O)c1cc(OCCN(CC)CC)ccc1-2,tilorone,Launched,interferon inducer,,infectious disease|gastroenterology|neurology/psychiatry,influenza A virus infection|diarrhea|hepatitis B|multiple sclerosis|urinary tract infections|virus herpes simplex (HSV)|hepatitis C
O=P(O)(O)C(Sc1ccc(Cl)cc1)P(=O)(O)O,tiludronate,Launched,bone resorption inhibitor|osteoclast inhibitor,ATP6V1A|MMP2|PTPN1,orthopedics,navicular syndrome
CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(=O)O,timofibrate,Phase 2,cholesterol inhibitor|lipase clearing factor inhibitor,LPL,,
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,timolol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2,ophthalmology,ocular hypertension|glaucoma
O=C(O)[C@H]1CSCN1,timonacic,Launched,antioxidant,,,
c1ccc2c(SC3=NCCN3)c[nH]c2c1,tinazoline,Launched,adrenergic receptor agonist,,,
CCS(=O)(=O)CCn1c([N+](=O)[O-])cnc1C,tinidazole,Launched,antiprotozoal agent,,infectious disease|obstetrics/gynecology,giardiasis|amebiasis|bacterial vaginosis|trichomoniasis
CCOC(=O)c1c(N)sc2c1CCN(Cc1ccccc1)C2,tinoridine,Launched,anti-inflammatory agent,,neurology/psychiatry,pain relief
Clc1ccc([C@H](Cn2ccnc2)OCc2ccsc2Cl)c(Cl)c1,tioconazole,Launched,sterol demethylase inhibitor,,infectious disease,yeast infection
Nc1nc(=S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1,tioguanine,Launched,purine antagonist,,hematologic malignancy,acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)|chronic myeloid leukemia (CML)
C[C@@H](S)C(=O)NCC(=O)O,tiopronin,Launched,chelating agent|reducing agent,,urology,kidney stones
CN=C(NC#N)NCCSCc1csc(NC(=N)N)n1,tiotidine,Phase 2,histamine receptor antagonist,HRH2,,
C[N+]1(C)[C@@H]2C[C@@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@H]1[C@@H]1O[C@@H]12,tiotropium,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3,pulmonary,chronic obstructive pulmonary disease (COPD)|bronchitis|emphysema
O=c1oc2cc(O)ccc2s1,tioxolone,Preclinical,carbonic anhydrase inhibitor,CA2,,
CCCc1c(SCCCOc2ccc(C(C)=O)c(OCCCC(=O)O)c2CCC)ccc(C(C)=O)c1O,tipelukast,Phase 2,leukotriene receptor antagonist,,,
Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)cc(=O)n2C,tipifarnib,Phase 3,farnesyltransferase inhibitor,FNTA|FNTB,,
N=C1CCCN1Cc1[nH]c(=O)[nH]c(=O)c1Cl,tipiracil,Launched,thymidine phosphorylase inhibitor,,oncology,colorectal cancer
O=C(O)C(=O)c1cn(Cc2ccccc2)c2ccc(-c3ccc(OC(F)(F)F)cc3)cc12,tiplaxtinin,Phase 1,plasminogen activator inhibitor,SERPINE1,,
CCC[C@@]1(CCc2ccccc2)CC(=O)[C@@H]([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(C(F)(F)F)cn3)c2)C(=O)O1,tipranavir,Launched,HIV protease inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)
CSc1ccccc1OC[C@@H](O)CNC(C)C,tiprenolol,Phase 2,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,,
C[N@+]12CCCC[C@@H]1CCC(=C(c1cccs1)c1cccs1)C2,tiquizium,Launched,acetylcholine receptor antagonist,,neurology/psychiatry,spasms
Nc1n[n+]([O-])c2ccccc2[n+]1[O-],tirapazamine,Phase 3,DNA inhibitor,,,
C#Cc1cnc2[nH]c(=O)n(C(CC)CC)c2n1,tirasemtiv,Phase 2,troponin activator,,,
O=C(O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1,tiratricol,Launched,thyroid hormone stimulant,THRA|THRB,endocrinology,Refetoff syndrome
CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(=O)O,tirofiban,Launched,platelet aggregation inhibitor|structural glycoprotein antagonist,ITGA2B|ITGB3,cardiology,myocardial infarction|refactory angina
Cl[Ti](Cl)(C1C=CC=C1)C1C=CC=C1,titanocene-dichloride,Phase 2,apoptosis stimulant,,,
O=C1NC(=O)[C@@H](c2cn3c4c(cccc24)CCC3)[C@@H]1c1c[nH]c2ccccc12,tivantinib,Phase 3,tyrosine kinase inhibitor,MET,,
COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,tivozanib,Launched,VEGFR inhibitor,FLT1|FLT4|KDR|KIT|PDGFRA|PDGFRB,oncology,renal cell carcinoma (RCC)
Clc1ccc2nsnc2c1NC1=NCCN1,tizanidine,Launched,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C|NISCH,neurology/psychiatry,spasms
Cc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1,TMC-353121,Phase 2,RSV fusion inhibitor,,,
COc1ccc2c(c1)C=C1Cn3c-2c(C2CCCCC2)c2ccc(cc23)C(=O)NS(=O)(=O)N(C)CCOCCN(C)C1=O,TMC647055,Phase 2,RNA polymerase inhibitor,,,
O=C(NC(=O)c1c(F)cccc1Cl)NC1c2ccccc2-c2ccccc21,TMN-355,Preclinical,cyclophilin inhibitor,PPIA,,
CCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1,TMPH,Preclinical,,,,
COc1cc(/C=C/c2ccc(OC)cc2OC)cc(OC)c1,TMS,Preclinical,,,,
CO[C@@H]1[C@H](OC(=O)NC(=O)CCl)CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C,TNP-470,Phase 2,methionine aminopeptidase inhibitor,METAP2,,
NC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](N)C[C@@H]1O,tobramycin,Launched,bacterial 30S ribosomal subunit inhibitor,,infectious disease,bacterial septicemia|respiratory tract infections|meningitis|skin infections|urinary tract infections
Cc1cccc(C)c1NC(=O)[C@@H](C)N,tocainide,Launched,sodium channel blocker,SCN5A,cardiology,cardiac arrythmia
Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NCCN1CCCC1,toceranib,Launched,protein tyrosine kinase inhibitor,FLT1|FLT3|KDR|PDGFRA|PDGFRB,oncology,cutaneous mast cell tumors
Cc1c(C)c2c(c(C)c1OC(=O)CCC(=O)OCCO)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2,tocofersolan,Launched,antioxidant,,cardiology,cerebral cholesterosis
CCOC(=O)NNc1nncc2ccccc12,todralazine,Launched,antihypertensive agent,,cardiology,hypertension
C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,tofacitinib,Launched,JAK inhibitor,JAK1|JAK2|JAK3,rheumatology,rheumatoid arthritis
CCC1=C(C)NN=C(c2ccc(OC)c(OC)c2)c2cc(OC)c(OC)cc21,tofisopam,Launched,cytochrome P450 inhibitor|phosphodiesterase inhibitor,CYP3A4,neurology/psychiatry,anxiety|abstinence from alcohol
CCc1ccc(Cc2ccc3c(c2)[C@]2(OC3)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1,tofogliflozin,Launched,sodium/glucose cotransporter inhibitor,GCK,endocrinology,diabetes mellitus
Cc1ccccc1OC[C@@H](O)CNCCOc1ccc(C(N)=O)cc1,tolamolol,Phase 3,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,,
Cc1ccc(S(=O)(=O)NC(=O)NN2CCCCCC2)cc1,tolazamide,Launched,ATP channel blocker,ABCC8|KCNJ1|KCNJ10|KCNJ11,endocrinology,diabetes mellitus
c1ccc(CC2=NCCN2)cc1,tolazoline,Launched,adrenergic receptor antagonist,ADRA1A|ADRA2A|ADRA2B|ADRA2C|HRH1|HRH2,neurology/psychiatry,reverse sedative
CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1,tolbutamide,Launched,ATP channel blocker,ABCC8|KCNJ1|KCNJ11|KCNJ8,endocrinology,diabetes mellitus
Cc1c(Cl)cccc1Nc1ccccc1C(=O)O,tolfenamic-acid,Launched,cyclooxygenase inhibitor|prostanoid receptor antagonist,,neurology/psychiatry,migraine headache
Cc1cccc(Oc2cnc(=O)[nH]c2)c1,tolimidone,Phase 2,SRC activator,LYN|SRC,,
Cc1ccc(C(=O)c2ccc(CC(=O)O)n2C)cc1,tolmetin,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,rheumatoid arthritis|osteoarthritis
Cc1cccc(N(C)C(=S)Oc2ccc3ccccc3c2)c1,tolnaftate,Launched,fungal squalene epoxidase inhibitor,,infectious disease,tinea pedis|tinea corporis
Cc1ccc(NC2=NCCN2)c(Cl)c1,tolonidine,Launched,adrenergic receptor antagonist,ADRA2A,,
Cc1cc2nc3ccc(=[N+](C)C)cc-3sc2cc1N,tolonium,Launched,,,hematology,methemoglobinemia
Cc1cccc(N2C[C@@H](CO)OC2=O)c1,toloxatone,Launched,monoamine oxidase inhibitor,MAOA|MAOB,neurology/psychiatry,depression
Cc1ccc(C(=O)[C@@H](C)CN2CCCCC2)cc1,tolperisone,Launched,voltage-gated sodium channel blocker,CYP2C19|CYP2D6,neurology/psychiatry|infectious disease|rheumatology|cardiology,muscle relaxant|multiple sclerosis|encephalomyelitis|ankylosing spondylitis|atherosclerosis|Raynaud's disease
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1,tolterodine,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,urology,urinary incontinence|urinary frequency
Cc1cc(-n2c(=O)[nH]c(=O)n(C)c2=O)ccc1Oc1ccc(SC(F)(F)F)cc1,toltrazuril,Launched,antiprotozoal agent,,infectious disease,coccidiosis
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc32)c(C)c1,tolvaptan,Launched,vasopressin receptor antagonist,AVPR1A|AVPR2,endocrinology|cardiology|gastroenterology,hyponatremia|congestive heart failure|hepatic cirrhosis
CN(C)c1cccc2c(S(=O)(=O)Nc3ccc(NC(=O)C(C)(C)CO)cc3)cccc12,tomeglovir,Preclinical,antiviral,,,
CCCc1c(OCCCCc2nn[nH]n2)ccc(C(C)=O)c1O,tomelukast,Phase 3,leukotriene receptor antagonist,CYSLTR1,,
Cc1cc(Nc2cc(N)ncn2)c(=O)n2c1C(=O)NC21CCCCC1,tomivosertib,Phase 2,MAPK-interacting kinase inhibitor,,,
CC(=O)c1ccc2c(c1)[C@H](NC(=O)c1ccc(F)c(Cl)c1)[C@H](O)C(C)(C)O2,tonabersat,Phase 2,gap junction modulator|nitric oxide production inhibitor,,,
C[C@](O)(CNC(=O)C(F)(F)F)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,topilutamide,Preclinical,androgen receptor antagonist,,,
CC1(C)O[C@@H]2[C@@H](CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@H]23)O1,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,CA1|CA12|CA2|CA4|CA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA1|GRIA2|GRIA3|GRIA4|GRIK1|GRIK2|GRIK3|GRIK4|GRIK5|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,epilepsy|migraine headache
N#Cc1cc(-c2nnc(-c3ccncc3)[nH]2)ccn1,topiroxostat,Launched,xanthine oxidase inhibitor,XDH,rheumatology|nephrology,gout|hyperuricemia
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,topotecan,Launched,topoisomerase inhibitor,TOP1|TOP1MT,oncology,small cell lung cancer|cervical cancer
Cc1cccc(Nc2ccncc2S(=O)(=O)NC(=O)NC(C)C)c1,torasemide,Launched,electrolyte reabsorption inhibitor|thromboxane receptor antagonist,SLC12A1,cardiology,edema|congestive heart failure|hypertension
CCOC(=O)N1c2ccc(C(F)(F)F)cc2[C@@H](N(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)C(=O)OC)C[C@H]1CC,torcetrapib,Phase 3,cholesteryl ester transfer protein inhibitor,CETP,,
Nc1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,torcitabine,Phase 2,DNA polymerase inhibitor,DCK|TK2,,
CN(C)CCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1,toremifene,Launched,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),ESR1,oncology,breast cancer
CCC(=O)N1CCN(c2ccc(-n3c(=O)ccc4cnc5ccc(-c6cnc7ccccc7c6)cc5c43)cc2C(F)(F)F)CC1,torin-1,Preclinical,mTOR inhibitor,MTOR,,
Nc1ccc(-c2ccc3ncc4ccc(=O)n(-c5cccc(C(F)(F)F)c5)c4c3c2)cn1,torin-2,Preclinical,mTOR inhibitor,MTOR,,
CC(C)C[C@@H](C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1)[C@H](O)C(=O)NO,tosedostat,Phase 2,peptidase inhibitor,ANPEP|LAP3|NPEPPS,,
N[C@H]1CCN(c2nc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2F)C1,tosufloxacin,Launched,bacterial DNA gyrase inhibitor,,infectious disease,gram-negative bacterial infections
N#Cc1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c12,toyocamycin,Phase 1,serine/threonine kinase inhibitor,ERN1,,
COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12,tozadenant,Phase 3,adenosine receptor antagonist,ADORA2A,,
Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)[nH]n1,tozasertib,Phase 2,Aurora kinase inhibitor|Bcr-Abl kinase inhibitor|FLT3 inhibitor|JAK inhibitor,AURKA|AURKB|AURKC|LCK,,
CC(C)(O)c1ccn2c(-c3ccc(F)c(-c4ccc(F)cc4C#N)c3)cnc2c1F,TP-003,Preclinical,GABA receptor inverse agonist,GABRA1|GABRA2|GABRA3|GABRA5,,
CN1CCN(Cc2ccc(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)N(C)C)n3)cc2)CC1,TP-0903,Phase 1/Phase 2,AXL kinase inhibitor,AXL,,
CC(C)(O)[C@H]1CC[C@H](Nc2ccc3ncc(-c4cccc(C(F)(F)F)c4)n3n2)CC1,TP-3654,Phase 1,"1,4,5-trisphosphate inhibitor",,,
NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O,TPCA-1,Preclinical,IKK inhibitor,IKBKB,,
O=S(=O)(O)c1ccc(-c2c3nc(c(-c4ccc(S(=O)(=O)O)cc4)c4ccc([nH]4)c(-c4ccc(S(=O)(=O)O)cc4)c4nc(c(-c5ccc(S(=O)(=O)O)cc5)c5ccc2[nH]5)C=C4)C=C3)cc1,TPPS4,Phase 1,,,,
COc1cc2c(cc1O)CCN[C@]21CS[C@@H]2c3c(OC(C)=O)c(C)c4c(c3[C@H](COC1=O)N1[C@@H]2[C@H]2c3c(cc(C)c(OC)c3O)C[C@@H]([C@@H]1O)N2C)OCO4,trabectedin,Phase 3,antitumor agent,,,
O=[N+]([O-])OC[C@H]1O[C@@H](n2cnc3c(NC4CCCC4)ncnc32)[C@H](O)[C@@H]1O,trabodenoson,Phase 3,adenosine receptor agonist,,,
CCCCNc1c(C(=O)OCC)c(C)nc2c1cnn2CC,tracazolate,Phase 2,GABA receptor modulator,GABRA1,,
O=C(c1ccccc1Cl)c1cccnc1-c1nnn(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c1-c1ccncc1,tradipitant,Phase 3,neurokinin receptor antagonist,,,
Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1cccn1,TRAM-34,Preclinical,potassium channel antagonist,KCNN4,,
N#CC(c1ccccc1)(c1ccccc1)c1ccccc1Cl,TRAM-39,Preclinical,calcium-activated potassium channel activator,KCNN4,,
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,trametinib,Launched,MEK inhibitor,MAP2K1|MAP2K2,oncology,melanoma
NCCCS(=O)(=O)O,tramiprosate,Phase 3,beta amyloid protein neurotoxicity inhibitor,APP,,
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@H]2CCCC[C@@H]21,trandolapril,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|myocardial infarction
NC[C@H]1CC[C@H](C(=O)O)CC1,tranexamic-acid,Launched,antifibrinolytic|plasminogen activator inhibitor,PLG,hematology,hemophilia
COc1ccc(/C=C/C(=O)Nc2ccccc2C(=O)O)cc1OC,tranilast,Launched,angiogenesis inhibitor,HPGDS|HRH1,pulmonary,asthma
CCCCC/C=C\C=C\CCCCCCCCC(=O)O,"trans-10,cis-12-conjugated-linoleic-acid",Launched,,,,
CCCCCCCC/C=C/C(=O)O,trans-2-undecenoic-acid,Preclinical,,,,
O=C(O)C1CCC(c2cc3cccnc3c(-c3cccc(F)c3)n2)CC1,"trans-4-[8-(3-fluorophenyl)-1,7-naphthyridin-6-yl]cyclohexanecarboxylic-acid",Preclinical,,,,
COc1ccc(/C=C/C(=O)O)cc1,trans-4-methoxycinnamic-acid,Preclinical,,,,
CC(/C=C/C=C(\C)C(=O)O)=C\C=C\C=C(C)\C=C\C=C(/C)C(=O)O,transcrocetinate,Preclinical,glutamate receptor antagonist,,,
N[C@H]1C[C@@H]1c1ccccc1,tranylcypromine,Launched,monoamine oxidase inhibitor,KDM1A|MAOA|MAOB,neurology/psychiatry,depression
CCn1c(=O)n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c2ccccc21,trap-101,Preclinical,nociceptin/orphanin FQ receptor antagonist|opioid receptor antagonist,OPRL1,,
CCN(CC)c1cc(C)nc2ncnn12,trapidil,Launched,PDGFR tyrosine kinase receptor inhibitor,PDGFRA,cardiology,coronary artery disease (CAD)
CC(C)OC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)COc2cccc(C(F)(F)F)c2)[C@H](O)C[C@@H]1O,travoprost,Launched,prostanoid receptor agonist,PTGFR,ophthalmology,ocular hypertension|glaucoma
C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(c2ccccc2)CC1,traxoprodil,Phase 2,glutamate receptor antagonist,GRIN2B,,
O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12,trazodone,Launched,adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor,ADRA1A|ADRA2A|HRH1|HTR1A|HTR2A|HTR2B|HTR2C|SLC6A4,neurology/psychiatry,depression
C[C@H]1Oc2ccccc2C[C@@H]1N(C)C,trebenzomine,Phase 2,,,,
Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2cc(F)ccc2C#N)c1=O,trelagliptin,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus
C(#CCN1CCCC1)CN1CCCC1,tremorine,Preclinical,acetylcholine receptor agonist,,,
CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O,treosulfan,Launched,DNA synthesis inhibitor,,oncology,ovarian cancer
CCOc1cc(OCC)c(C(=O)CCC(=O)O)cc1OCC,trepibutone,Launched,cholinergic receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4,gastroenterology,irritable bowel syndrome
CCCCC[C@H](O)CC[C@@H]1[C@H]2Cc3cccc(OCC(=O)O)c3C[C@H]2C[C@H]1O,treprostinil,Launched,prostanoid receptor agonist,P2RY12|PPARD|PTGIR,pulmonary,pulmonary arterial hypertension (PAH)
COc1cc2c(cc1OC)-c1c/c(=N\c3c(C)cc(C)cc3C)n(C)c(=O)n1CC2,trequinsin,Phase 1,phosphodiesterase inhibitor,PDE5A,,
NC(=O)c1cc(N2CC2)c([N+](=O)[O-])cc1[N+](=O)[O-],tretazicar,Phase 2,DNA replication inhibitor,NQO2,,
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1,tretinoin,Launched,retinoid receptor agonist|retinoid receptor ligand,ALDH1A1|ALDH1A2|GPRC5A|NR0B1|NR2C2|PPARD|RARA|RARB|RARG|RARRES1|RORB|RORC|RXRB|RXRG,hematologic malignancy,acute promyelocytic leukemia (APL)
CC(=O)OCC(COC(C)=O)OC(C)=O,triacetin,Launched,,,,
C[C@]12C=CC(=O)C=C1CC[C@H]1[C@@H]3C[C@@H](O)[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@]12F,triamcinolone,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,triamcinolone-acetonide,Launched,glucocorticoid receptor agonist|immunosuppressant,NR3C1|SERPINA6,dermatology,corticosteroid-responsive dermatoses
CC(C)(C)CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C,triamcinolone-hexacetonide,Launched,anti-inflammatory agent,,,
Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1,triamterene,Launched,sodium channel blocker,SCNN1A|SCNN1B|SCNN1D|SCNN1G,endocrinology|cardiology,hypokalemia|hypertension|edema
NC(=S)N/N=C/c1ncccc1N,triapine,Phase 2,ribonucleotide reductase inhibitor,RRM1|RRM2,,
CCO[C@H]1O[C@H]([C@@H](COCc2ccccc2)OCc2ccccc2)[C@H](OCc2ccccc2)[C@H]1O,tribenoside,Launched,anti-inflammatory agent|capillary stabilizing agent,,,
O=C(Nc1ccc(Br)cc1)c1cc(Br)cc(Br)c1O,tribomsalan,Preclinical,,,,
CCCC(=O)OCC(COC(=O)CCC)OC(=O)CCC,tributyrin,Phase 1,HDAC inhibitor,,,
CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC,tricaprylin,Launched,,,dermatology,cosmetic
NS(=O)(=O)c1cc2c(cc1Cl)N[C@H](C(Cl)Cl)NS2(=O)=O,trichlormethiazide,Launched,chloride channel blocker,PTGS1|PTGS2|SLC12A1,cardiology,hypertension|edema
CC(/C=C/C(=O)NO)=C\[C@@H](C)C(=O)c1ccc(N(C)C)cc1,trichostatin-a,Phase 1,HDAC inhibitor,HDAC1|HDAC10|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9,,
CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23,triciribine,Phase 1/Phase 2,AKT inhibitor,AKT1|AKT2|AKT3,,
CN1N=C(N)c2cn([C@@H]3O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]3O)c3ncnc1c23,triciribine-phosphate,Phase 1/Phase 2,AKT inhibitor,,,
CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1,triclabendazole,Launched,microtubule inhibitor,DNMT1,infectious disease,tapeworm
O=C(Nc1ccc(Cl)cc1)Nc1ccc(Cl)c(Cl)c1,triclocarban,Launched,other antibiotic,,infectious disease,first-aid antiseptic
Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl,triclosan,Launched,antibacterial agent,DNMT1,infectious disease,first-aid antiseptic
CC[N+](CC)(CC)CC[C@](O)(c1ccccc1)C1CCCCC1,tridihexethyl,Launched,acetylcholine receptor antagonist,,gastroenterology|ophthalmology,peptic ulcer disease (PUD)|nystagmus
NCCNCCNCCN,trientine,Launched,chelating agent,CA14,metabolism,Wilson's disease
CO/N=C(/C(=O)OC)c1ccccc1CO/N=C(\C)c1cccc(C(F)(F)F)c1,trifloxystrobin,Preclinical,mitochondrial electron transport inhibitor,,,
CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,trifluoperazine,Launched,dopamine receptor antagonist,ADRA1A|CALM1|CALY|DRD2|DRD4|HRH1|HTR2A|HTR2C|S100A4|TNNC1,neurology/psychiatry,schizophrenia
CN(C)CCCN1c2ccccc2Sc2ccc(C(F)(F)F)cc21,triflupromazine,Launched,dopamine receptor antagonist,CHRM1|CHRM2|DRD1|DRD2|HTR2B,neurology/psychiatry|gastroenterology,psychosis|nausea|vomiting
O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1C(F)(F)F,trifluridine,Launched,DNA directed DNA polymerase inhibitor|thymidylate synthase inhibitor,TYMS,infectious disease,virus herpes simplex (HSV)
CC(=O)Oc1cc(C(F)(F)F)ccc1C(=O)O,triflusal,Launched,cyclooxygenase inhibitor|platelet aggregation inhibitor|thromboxane synthase inhibitor,NFKB1|NOS2|PDE10A|PTGS1,neurology/psychiatry|cardiology,stroke|myocardial infarction|atrial fibrillation (AF)
C[n+]1cccc(C(=O)O)c1,trigonelline,Phase 1,,,,
O[C@](CCN1CCCCC1)(c1ccccc1)C1CCCCC1,trihexyphenidyl,Launched,acetylcholine receptor antagonist,CHRM1,neurology/psychiatry,parkinsonism
CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,trilaciclib,Phase 2,CDK inhibitor,,,
C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(=O)[C@H](C#N)C[C@]35C)[C@@H]1CC[C@@H]2O,trilostane,Launched,3beta-hydroxy-delta5-steroid dehydrogenase inhibitor,,endocrinology,Cushing's syndrome
FC(F)(F)c1ccccc1-n1ccnc1,TRIM,Preclinical,,,,
CC[C@@](COC(=O)c1cc(OC)c(OC)c(OC)c1)(c1ccccc1)N(C)C,trimebutine,Launched,opioid receptor agonist,OPRD1|OPRK1|OPRM1,gastroenterology,irritable bowel syndrome
COc1ccc(CN2CCNCC2)c(OC)c1OC,trimetazidine,Launched,3-ketoacyl CoA thiolase inhibitor,ACAA2,cardiology,angina pectoris
CN1C(=O)OC(C)(C)C1=O,trimethadione,Launched,oxazolidine antiepileptic,CACNA1G|CACNA1H|CACNA1I,neurology/psychiatry,seizures
COc1cc(C(=O)NCc2ccc(OCCN(C)C)cc2)cc(OC)c1OC,trimethobenzamide,Launched,histamine receptor antagonist,DRD2,gastroenterology,vomiting|nausea|gastroenteritis
COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC,trimethoprim,Launched,dihydrofolate reductase inhibitor,DHFR|TYMS,infectious disease|gastroenterology,urinary tract infections|ear infections|diarrhea
COc1cc(C[C@H]2NCCc3cc(O)c(O)cc32)cc(OC)c1OC,trimethoquinol,Launched,adrenergic receptor antagonist,ADRB2|ADRB3,pulmonary,asthma
C=CC(=O)OCC(CC)(COC(=O)C=C)COC(=O)C=C,trimethylolpropane-triacrylate,Preclinical,,,,
COc1cc(C(=O)N2CCOCC2)cc(OC)c1OC,trimetozine,Launched,sedative,,neurology/psychiatry,sedative
COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC,trimetrexate,Phase 3,dihydrofolate reductase inhibitor,DHFR,,
C[C@@H](CN(C)C)CN1c2ccccc2CCc2ccccc21,trimipramine,Launched,norepinephrine reputake inhibitor|tricyclic antidepressant,SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,depression
Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1,trioxsalen,Launched,DNA synthesis inhibitor,,dermatology,vitiligo|eczema
CN(C)CCN(Cc1ccccc1)c1ccccn1,tripelennamine,Launched,histamine receptor antagonist,HRH1,pulmonary|allergy,asthma|allergic rhinitis|urticaria
Cc1ccc(/C(=C\CN2CCCC2)c2ccccn2)cc1,triprolidine,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis
CC(C)C(C)(C)C,triptan,Phase 1,serotonin receptor agonist,HTR1B|HTR1D,,
CC(C)[C@]12O[C@H]1[C@@H]1O[C@]13[C@]1(O[C@H]1C[C@H]1C4=C(CC[C@@]13C)C(=O)OC4)[C@@H]2O,triptolide,Phase 3,RNA polymerase inhibitor,RELA,,
CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,triptorelin,Launched,gonadotropin releasing factor hormone receptor agonist,GNRHR,oncology|endocrinology|obstetrics/gynecology,prostate cancer|breast cancer|precocious puberty|endometriosis|myoma|gender dysphoria
O=c1[nH]c(=O)n(Cl)c(=O)n1Cl,troclosene,Launched,,,,
CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@H]4C[C@@H](NCCCNCCCCNCCCN)CC[C@]4(C)[C@H]3CC[C@]12C)OS(=O)(=O)O,trodusquemine,Phase 1,tyrosine phosphatase inhibitor,,,
NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)O,trofinetide,Phase 2,cytokine production inhibitor,IFNG|IL6|TNF,,
O=[P@]1(N(CCCl)CCCl)OCCCN1CCCl,trofosfamide,Launched,DNA alkylating agent,,oncology,medulloblastoma
CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O,troleandomycin,Launched,protein synthesis inhibitor,,infectious disease|pulmonary|otolaryngology,pneumonia|bronchitis|tonsillitis|sinusitis
Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(C(=O)O)O2,trolox,Launched,antioxidant,,,
O=C(O)c1ccccc1NCCc1ccccc1,tromaril,Launched,prostanoid receptor antagonist,,ophthalmology,eye inflammation
NC(CO)(CO)CO,trometamol,Launched,,AMD1|CANT1|DCN|NEIL1|VEGFA,,
Cc1cc(C)cc(C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)c1,"tropanyl-3,5-dimethylbenzoate",Preclinical,serotonin receptor antagonist,HTR3A|HTR3B,,
COc1ccc2c(c1)c(CC(=O)OC[C@@H](C(=O)O)c1ccccc1)c(C)n2C(=O)c1ccc(Cl)cc1,tropesin,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,,
CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1,tropicamide,Launched,acetylcholine receptor antagonist,CHRM3|CHRM4,ophthalmology,mydriasis diagnostic|cycloplegia diagnostic
O=C(O)c1cc(F)c2nc(N3[C@@H]4CC[C@H]3C[C@@H](OCc3c(-c5ccccc5OC(F)(F)F)noc3C3CC3)C4)sc2c1,tropifexor,Phase 2,FXR agonist,,,
CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)c1c[nH]c3ccccc13)C2,tropisetron,Launched,serotonin receptor antagonist,GLRA1|GLRA2|GLRB|HTR3A|HTR4,gastroenterology,nausea|vomiting
O=C(O[C@H]1C[C@H]2CC[C@@H](C1)[N+]21CCCC1)C(O)(c1ccccc1)c1ccccc1,trospium,Launched,acetylcholine receptor antagonist,CHRM1,urology,urinary incontinence|urinary frequency
CCC(CO)(C(=O)OC1C[C@H]2CC[C@@H](C1)[N+]2(C)C)c1ccccc1,troventol,Phase 1,,,,
S=C(NCCc1ccccn1)Nc1ccc(Br)cn1,trovirdine,Phase 1,non-nucleoside reverse transcriptase inhibitor,,,
C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(OCCO)c(OCCO)c4)oc4cc(OCCO)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O,troxerutin,Launched,antioxidant,,,
COc1cc(C(=O)N[C@H]2CCCNC2)cc(OC)c1OC,troxipide,Launched,glucosamine synthetase stimulant,,gastroenterology,gastroesophageal reflux disease (GERD)
COc1ccsc1CNCC[C@@]1(c2ccccn2)CCOC2(CCCC2)C1,TRV130,Phase 3,opioid receptor agonist,OPRM1,,
O=C1c2ccccc2-n2c1nc1ccccc1c2=O,tryptanthrin,Preclinical,cyclooxygenase inhibitor,IDO1,,
N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O,tryptophan,Launched,serotonin receptor partial agonist,CASR|IDO1|SLC36A1|WARS|WARS2,neurology/psychiatry|gastroenterology,anxiety|bloating|constipation|fatigue|sleeplessness
[O-][N+]CNc1ccc(N2CCOCC2)c(Cl)c1,TS-011,Preclinical,delayed vasospasm antagonist,,,
C/C(=C\c1ccc(C(=O)O)cc1)c1ccc2c(c1)C(C)(C)CCC2(C)C,TTNPB,Phase 1,retinoid receptor agonist,RARA|RARB|RARG,,
Cc1ccc(-c2csc3ncnc(SCCC(=O)O)c23)cc1,TTP-22,Preclinical,casein kinase inhibitor,CSNK2A1,,
CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC,TU-2100,Phase 2,,,,
CCCCC[C@@H](C)N,tuaminoheptane,Launched,,,otolaryngology,nasal congestion
CN1CCc2c(c3ccccc3n2Cc2ccc(C(=O)NO)cc2)C1,tubastatin-A,Preclinical,HDAC inhibitor,HDAC6,,
COc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C,tubocurarine,Launched,acetylcholine receptor antagonist,ACHE|CHRNA2|HTR3A|HTR3B|KCNN1|KCNN2|KCNN3|ZACN,neurology/psychiatry,anesthetic
Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,tucatinib,Phase 3,EGFR inhibitor,ERBB2,,
Nc1cc(F)ccc1NC(=O)c1ccc(CNC(=O)/C=C/c2cccnc2)cc1,tucidinostat,Phase 3,HDAC inhibitor,,,
C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)O,tuftsin,Preclinical,macrophage activator,,,
N#CCc1ccccc1C#Cc1ccc(CCC(=O)O)c(F)c1,TUG-770,Preclinical,free fatty acid receptor agonist,FFAR1,,
Cc1ccc(-c2ccc(F)cc2COc2ccc(CCC(=O)O)cc2)cc1,TUG-891,Preclinical,free fatty acid receptor agonist,FFAR4,,
CC(C)(C)NC[C@H](O)c1ccccc1Cl,tulobuterol,Launched,adrenergic receptor agonist,ADRB2,pulmonary,asthma
O=C1c2cc3nnn(CCc4cccc(F)c4)c(=O)c3cc2OCN1C1CC1,tulrampator,Phase 2,antidepressant ,,,
CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(S(=O)(=O)c3ccccc3C(C)(C)C)cc2)c(O)c(O)c1O,TW-37,Preclinical,BCL inhibitor,BCL2|BCL2L1|MCL1,,
Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1,TWS-119,Preclinical,glycogen synthase kinase inhibitor,GSK3B|JUN|MYC,,
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)O,TXA127,Phase 2,angiotensin receptor agonist,,,
CC(C)(C)C(=O)C(=NNc1ccc(Cl)cc1)Nc1ccc(Cl)cc1,TY-52156,Preclinical,sphingosine 1-phosphate receptor antagonist,S1PR3,,
CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC,tylosin,Launched,protein synthesis inhibitor,,infectious disease|gastroenterology,gram-positive bacterial infections|colitis
Cc1ccc(C(C)C)c(OCC2=NCCN2)c1,tymazoline,Launched,,,allergy,allergic rhinitis
CC(C)(C)c1cc(C=C(C#N)C#N)cc(C(C)(C)C)c1O,tyrphostin-A9,Preclinical,protein tyrosine kinase inhibitor|tyrosine kinase inhibitor,,,
COc1cc2ncc(-c3ccccc3)nc2cc1OC,tyrphostin-AG-1296,Preclinical,FLT3 inhibitor,FLT3,,
COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC,tyrphostin-AG-1478,Preclinical,EGFR inhibitor,EGFR|MAPK14,,
N#CC(C#N)=Cc1ccc(O)c(O)c1,tyrphostin-AG-18,Preclinical,EGFR inhibitor|tyrosine kinase inhibitor,EGFR,,
N#C/C(=C\c1ccc(O)c(O)c1)C(=O)Nc1ccccc1,tyrphostin-AG-494,Preclinical,EGFR inhibitor,EGFR,,
COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2nc3ccccc3s2)c1O,tyrphostin-AG-825,Preclinical,protein tyrosine kinase inhibitor,ERBB2,,
C[C@H](NC(=O)/C(C#N)=C/c1ccc(O)c(O)c1)c1ccccc1,tyrphostin-AG-835,Preclinical,protein tyrosine kinase inhibitor,EGFR,,
CC(C)(C)c1cc(/C=C(\C#N)C(N)=S)cc(C(C)(C)C)c1O,tyrphostin-AG-879,Preclinical,tyrosine kinase inhibitor,ERBB2|KDR|NTRK1,,
N#C/C(=C\c1ccc(O)c(O)c1)C(N)=O,tyrphostin-AG-99,Preclinical,tyrosine kinase inhibitor,EGFR,,
CSC(=N)C(C#N)C(C#N)C(=N)SC,U-0124,Preclinical,MEK inhibitor,,,
N#CC(C(=N)Sc1ccccc1N)C(C#N)C(=N)Sc1ccccc1N,U-0126,Preclinical,MEK inhibitor,AKT1|CHEK1|GSK3B|LCK|MAP2K1|MAP2K2|MAP2K7|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|RAF1|ROCK1|RPS6KB1|SGK1,,
CC(C)C(=O)c1ccc(O)c(O)c1,U-0521,Preclinical,catechol O methyltransferase inhibitor,COMT,,
NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1,U-104,Phase 1/Phase 2,carbonic anhydrase inhibitor,CA1|CA12|CA2|CA9,,
CCN(CC)CCO[C@H]1CC[C@@]2(C)C(=CC[C@@H]3[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]32)C1,U-18666A,Preclinical,oxidosqualene cyclase inhibitor,,,
CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@H]1CCCC[C@@H]1N1CCCC1,U-50488-(-),Preclinical,opioid receptor agonist,OPRK1,,
CN(C(=O)c1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@@H]1N1CCCC1,U-54494A,Preclinical,opioid receptor agonist,OPRK1,,
C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O,U-75799E,Phase 1,growth hormone releasing factor agonist,GHSR,,
CCCN(CCC)C1Cc2cc(OC)c(OC)cc2C1,U-99194,Preclinical,dopamine receptor antagonist,DRD3,,
N[C@@H](CCNCc1ccc(Cl)cc1)C(=O)N1CCCCC1,UAMC-00039,Preclinical,dipeptidyl peptidase inhibitor,DPP4|DPP7,,
Clc1ccc(C2=CCC[C@H]3CC[C@@H]2N3)cn1,UB-165,Preclinical,acetylcholine receptor agonist,CHRNA3|CHRNA4|CHRNB2,,
CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(=O)O,ubenimex,Launched,leukotriene synthesis inhibitor,LTA4H|RNPEP,hematologic malignancy,acute myeloid leukemia (AML)
N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(=O)O)c1=O)C(=O)O,UBP-296,Preclinical,glutamate receptor antagonist,GRIK1,,
N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(=O)O)c1=O)C(=O)O,UBP-302,Preclinical,glutamate receptor antagonist,GRIK1,,
Cc1cn(C[C@H](N)C(=O)O)c(=O)n(Cc2ccsc2C(=O)O)c1=O,UBP-310,Preclinical,glutamate receptor antagonist,GRIK1|GRIK5,,
Oc1c(CN2CCCC2)cc(COCc2ccccc2)c2cccnc12,UC-112,Preclinical,XIAP inhibitor,XIAP,,
c1ccc(C(NCc2cccnc2)(c2ccccc2)c2ccccc2)cc1,UCL-2077,Preclinical,slow afterhyperpolarization channel blocker,,,
CCCOc1ccc(S(=O)(=O)NCC[C@@H]2CCCN2C)cc1-c1nc2c(CCC)nn(C)c2c(=O)[nH]1,udenafil,Launched,phosphodiesterase inhibitor,,urology,erectile dysfunction
CCCCNNC(=O)c1ccc(Br)cc1,UF-010,Preclinical,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC8,,
CCCCOC(=O)c1ccccc1Nc1cccc(C(F)(F)F)c1,ufenamate,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,dermatology,eczema|dermatitis
CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C,UH-232-(+),Preclinical,dopamine receptor antagonist,DRD2|DRD3|DRD4|HTR1A,,
Cc1cc(CCC[C@H](CC(=O)NO)C(=O)N[C@H](C(=O)N[C@H](C)c2ccccc2)C(C)(C)C)ccc1-c1ccccc1,UK-356618,Preclinical,metalloproteinase inhibitor,MMP13|MMP14|MMP2|MMP3|MMP9,,
NC(=O)c1noc([C@H](CCCC2CCCCC2)CC(=O)NO)n1,UK-383367,Phase 1,procollagen C-endopeptidase inhibitor,BMP1,,
N#C/C(=C\c1cn(-c2ccccc2)c2ccccc12)C(=O)O,UK-5099,Preclinical,monocarboxylate transporter inhibitor,SLC16A1,,
CCOC(=O)N1CCN(C(=O)[C@H](Cc2cccc(C(=N)N)c2)NS(=O)(=O)c2c(C(C)C)cc(C(C)C)cc2C(C)C)CC1,uki-1,Preclinical,urokinase inhibitor,,,
C[C@H]1Sc2c(C(=O)O)c(=O)c3cc(F)c(N4CCNCC4)cc3n21,ulifloxacin,Launched,,,infectious disease,gram-negative bacterial infections|gram-positive bacterial infections
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,ulipristal,Launched,progesterone receptor antagonist,PGR,endocrinology,contraceptive
OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2,umeclidinium,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3,pulmonary,chronic obstructive pulmonary disease (COPD)|bronchitis|emphysema
CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(c23)C1=O,unbs-5162,Phase 1,CC chemokine receptor antagonist,,,
COc1cc2c(NC3CCN(C)CC3)nc(N3CCCN(C)CC3)nc2cc1OCCCN(C)C,UNC0224,Preclinical,histone lysine methyltransferase inhibitor,EHMT1|EHMT2,,
COc1cc2c(NC3CCN(C)CC3)nc(N3CCCN(C)CC3)nc2cc1OCCOCCN(C)C,UNC0321,Preclinical,histone lysine methyltransferase inhibitor,EHMT2,,
COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(N3CCCN(C(C)C)CC3)nc2cc1OCCCN1CCCCC1,UNC0631,Preclinical,histone lysine methyltransferase inhibitor,EHMT2,,
COc1cc2c(NC3CCN(C(C)C)CC3)nc(C3CCCCC3)nc2cc1OCCCN1CCCC1,UNC0638,Preclinical,histone lysine methyltransferase inhibitor,EHMT1|EHMT2,,
COc1cc2c(NC3CCN(C(C)C)CC3)nc(N3CCC(F)(F)CC3)nc2cc1OCCCN1CCCC1,UNC0642,Preclinical,histone lysine methyltransferase inhibitor,EHMT1|EHMT2,,
COc1cc2c(NC3CCN(C4CCCCC4)CC3)nc(N3CCCN(C(C)C)CC3)nc2cc1OCCCN1CCCCC1,UNC0646,Preclinical,histone lysine methyltransferase inhibitor,EHMT2,,
COc1cc2c(N(C)C3CCN(C(C)C)CC3)nc(C3CCCCC3)nc2cc1OCCCN1CCCC1,UNC0737,Preclinical,histone lysine methyltransferase inhibitor,EHMT1|EHMT2,,
O=C(c1ccc(C(=O)N2CCC(N3CCCC3)CC2)c(Nc2ccccc2)c1)N1CCC(N2CCCC2)CC1,UNC1215,Preclinical,L3MBTL antagonist,L3MBTL3,,
CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(-c2ccc(N3CCN(C(C)C)CC3)nc2)cc2c1cnn2C(C)C,UNC1999,Preclinical,histone lysine methyltransferase inhibitor,EZH2,,
CCCCNc1ncc2c(-c3ccc(CN4CCN(C)CC4)cc3)cn([C@H]3CC[C@H](O)CC3)c2n1,UNC2025,Preclinical,FLT3 inhibitor|MER tyrosine kinase inhibitor,FLT3|MERTK,,
CCCCNc1ncc(-c2ccc(CN3CCOCC3)cn2)c(N[C@H]2CC[C@H](O)CC2)n1,UNC2250,Preclinical,MER tyrosine kinase inhibitor,MERTK,,
O=C(NCC(=O)N1CCCCC1)Nc1ccc2nnsc2c1,UNC2327,Preclinical,protein arginine N-methyltransferase inhibitor,PRMT3,,
NC(=O)c1nc(Nc2ccccc2)sc1NC(=O)C1CCCCC1,UNC3230,Preclinical,phosphatidyl-inositol activator,PIP5K1C,,
O=C(c1cncc(Br)c1)N1CCC(N2CCCC2)CC1,UNC669,Preclinical,L3MBTL antagonist,L3MBTL1,,
O=C(c1cccc(Br)c1)N1CCC(N2CCCC2)CC1,UNC926,Preclinical,MBT inhibitor,L3MBTL1,,
CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12,upadacitinib,Launched,JAK inhibitor,,,
CCOC(=O)N1CCN(C(=O)[C@H](Cc2cccc(C(=N)NO)c2)NS(=O)(=O)c2c(C(C)C)cc(C(C)C)cc2C(C)C)CC1,upamostat,Phase 2,serine protease inhibitor,,,
O=C(COc1cccc2c(=O)[nH]ccc12)c1ccccc1,UPF-1069,Preclinical,PARP inhibitor,PARP2,,
CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(Cl)[C@@H]1O)Oc1ccccc1,uprifosbuvir,Preclinical,antiviral,,,
Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl,uprosertib,Phase 2,AKT inhibitor,AKT1|AKT2|AKT3,,
O=c1cc[nH]c(=O)[nH]1,uracil,Launched,,DPYD|UCKL1,,
O=c1[nH]cc(N(CCCl)CCCl)c(=O)[nH]1,uracil-mustard,Launched,DNA synthesis inhibitor,,hematologic malignancy,non-Hodgkin lymphoma (NHL)
COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1,urapidil,Launched,adrenergic receptor antagonist,HTR1A,cardiology,hypertension
NC(=O)c1cccc(-c2cccc(OC(=O)NC3CCCCC3)c2)c1,URB597,Phase 1,FAAH inhibitor,FAAH|FAAH2|TRPA1,,
NC(N)=O,urea,Launched,hydroxy radical formation stimulant,ARG1|CA2|CTNNB1,dermatology,psoriasis|xerosis cutis|ichthyosis vulgaris|eczema|keratosis|dermatitis
O=c1[nH]c(=O)c2[nH]c(=O)[nH]c2[nH]1,uric-acid,Phase 3,,PYGL,,
O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1,uridine,Phase 2,dopamine receptor agonist,LSM6|TYMP,,
O=c1ccn([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1,uridine-5'-triphosphate,Launched,purinergic receptor activator,P2RY11|P2RY2|P2RY4|P2RY6|UCK2,,
CC(=O)OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O,uridine-triacetate,Launched,,,nephrology,orotic aciduria
CN1CCN(Cc2ccc(-c3cnc4[nH]cc(-c5ccc6[nH]ccc6c5)c4c3)cc2)CC1,URMC-099,Preclinical,mixed lineage kinase inhibitor,CDKL2|DAPK3|FLT3|LRRK2|MAP3K10|MAP3K11|MAP3K2|MAP3K9|SRPK2,,
O=c1oc2cc(O)ccc2c2ccc(O)cc12,urolithin-A,Phase 3,antioxidant,,,
C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,ursodeoxycholyltaurine,Phase 3,cholesterol inhibitor,,,
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,ursodiol,Launched,nuclear factor erythroid derived|like (NRF2) activator,AKR1C2|NR1H4,gastroenterology,gallstones
C[C@H]1[C@H](C)CC[C@]2(C(=O)O)CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@]43C)[C@H]12,ursolic-acid,Phase 2/Phase 3,ATPase inhibitor|NFkB pathway inhibitor|STAT inhibitor,HSD11B1|PLA2G1B|PTPN1|PYGM,,
CC(=O)c1c(O)c(C)c(O)c2c1OC1=CC(=O)C(=C(C)O)C(=O)[C@@]12C,usniacin-(+),Preclinical,MAP kinase activator,PTPN1,,
CC(=O)c1c(O)c(C)c(O)c2c1OC1=CC(=O)C(=C(C)O)C(=O)[C@]12C,usniacin-(+),Preclinical,MAP kinase activator,PTPN1,,
COc1cc(CN2CCN(c3ccc(F)cc3)CC2)cc(OC)c1OC,V-51,Phase 1,adrenergic receptor antagonist,,,
O=C(O)C[C@@H]1CC[C@H](NC(=O)Cc2cccs2)B(O)O1,vaborbactam,Launched,beta lactamase inhibitor,,,
O=C(O)CNC(=O)c1ncc(-c2cccc(Cl)c2)cc1O,vadadustat,Phase 3,hypoxia inducible factor prolyl hydroxylase inhibitor,,,
CC(C)[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O,val-tyr,Preclinical,angiotensin converting enzyme inhibitor,,,
CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)nc(N)[nH]c21,valaciclovir,Launched,DNA polymerase inhibitor,,infectious disease,shingles|virus herpes simplex (HSV)
COc1cc2c(cc1OC)[C@H]1C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN1CC2,valbenazine,Launched,vesicular monoamine transporter inhibitor,,neurology/psychiatry,dyskinesia
CC[C@@H](C)[C@@H](C(=O)OCC[N+](C)(CC)CC)c1ccccc1,valethamate,Launched,acetylcholine receptor antagonist,CHRM1|CHRM4|CHRM5,obstetrics/gynecology,labor induction
CC(C)[C@H](N)C(=O)OC[C@@H](CO)OCn1cnc2c(=O)nc(N)[nH]c21,valganciclovir,Launched,DNA synthesis inhibitor,,infectious disease,cytomegalovirus (CMV)
C=C[C@]1(C)C[C@@H](OC(=O)CSC(C)(C)CNC(=O)[C@H](N)C(C)C)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,valnemulin,Launched,bacterial 50S ribosomal subunit inhibitor,,infectious disease|gastroenterology,dysentry|colitis|pneumonia
CC[C@@H](C)[C@@H](CC)C(N)=O,valnoctamide,Launched,arachidonic acid acylation inhibitor|benzodiazepine receptor agonist,,neurology/psychiatry,sleeplessness
CCCC(CCC)C(=O)O,valproic-acid,Launched,benzodiazepine receptor agonist|HDAC inhibitor,ABAT|ACADSB|ALDH5A1|HDAC1|HDAC2|HDAC9|OGDH|SCN10A|SCN11A|SCN1A|SCN1B|SCN2A|SCN2B|SCN3A|SCN3B|SCN4A|SCN4B|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,epilepsy|seizures|seizures
CCCC(CCC)C(N)=O,valpromide,Launched,epoxide hydolase inhibitor,,neurology/psychiatry,epilepsy
CCCC(CCC)C(=O)NCC(N)=O,valrocemide,Phase 2,,,,
CCCCC(=O)OCC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)C1)C(=O)c1c(OC)cccc1C3=O,valrubicin,Launched,DNA inhibitor|topoisomerase inhibitor,TOP2A,oncology,bladder cancer
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,valsartan,Launched,angiotensin receptor antagonist,AGTR1,cardiology,hypertension|congestive heart failure|congestive heart failure
C/C=C/C[C@@H](C)C(=O)[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,valspodar,Phase 3,P glycoprotein inhibitor,ABCB1,,
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O,vancomycin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,endocarditis
COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,vandetanib,Launched,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,EGFR|EPHA1|EPHA10|EPHA2|EPHA3|EPHA4|EPHA5|EPHA6|EPHA7|EPHA8|EPHB1|EPHB2|EPHB3|EPHB4|EPHB6|ERBB2|ERBB3|ERBB4|FLT1|FLT4|KDR|PTK6|RET|SRC|TEK|VEGFA,oncology,medullary thyroid cancer (MTC)
COc1cc(C=O)ccc1O,vanillin,Preclinical,,ABAT|ALDH5A1,,
COc1cc(CCC(C)=O)ccc1O,vanillylacetone,Preclinical,,,,
CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)OCC(C)(C)CCCCc1cccc3c1CN(C3)C(=O)O2)C(=O)NS(=O)(=O)C1CC1,vaniprevir,Phase 3,serine protease inhibitor,,,
COc1cc(C(=S)N2CCOCC2)ccc1O,vanitiolide,Preclinical,,,,
Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1,vanoxerine,Phase 3,dopamine reuptake inhibitor,SLC6A3,,
CCOc1noc2cc(OCCC3CCN(c4ccc(C)nn4)CC3)ccc12,vapendavir,Phase 2,antiviral,,,
CCCc1nc(C)c2c(=O)nc(-c3cc(S(=O)(=O)N4CCN(CC)CC4)ccc3OCC)[nH]n12,vardenafil,Launched,phosphodiesterase inhibitor,PDE5A|PDE6G|PDE6H,urology,erectile dysfunction
c1cnc2cc3c(cc2n1)[C@@H]1CNC[C@H]3C1,varenicline,Launched,acetylcholine receptor agonist,CHRNA3|CHRNA4|CHRNA6|CHRNA7,neurology/psychiatry,smoking cessation
CCc1c(C(=O)C(N)=O)c2c(OCC(=O)O)cccc2n1Cc1ccccc1,varespladib,Phase 3,secretory phospholipase inhibitor,PLA2G2A,,
N=C(N)NCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,vasopressin,Launched,vasopressin receptor agonist,AVPR1A|AVPR1B|AVPR2|OXTR,gastroenterology,abdominal distension
Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1,vatalanib,Phase 3,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,EGFR|FLT1|FLT4|KDR|PDGFRB,,
CS(=O)(=O)NCCN1C(=O)NC[C@]12CCN1CCc3c(oc4ccccc34)[C@@H]1C2,vatinoxan,Preclinical,adrenergic receptor antagonist,,,
CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1,VBY-825,Preclinical,cathepsin inhibitor,CTSB|CTSL|CTSS,,
CO[C@H]1CC[C@H](N(c2cc(C3=CCCCC3)sc2C(=O)O)C(=O)[C@H]2CC[C@H](C)CC2)CC1,VCH-916,Phase 1,HCV inhibitor,,,
CS(=O)(=O)c1ccc(-c2cnc(N)c(C(=O)Nc3ccccc3)n2)cc1,VE-821,Preclinical,ATR kinase inhibitor,ATR,,
CNCc1ccc(-c2cc(-c3nc(-c4ccc(S(=O)(=O)C(C)C)cc4)cnc3N)on2)cc1,VE-822,Phase 2,ATR kinase inhibitor,ATM|ATR|MTOR|PIK3CG,,
NC(=O)[C@H]1CCN(c2ncnc(N)c2F)C[C@@H]1N1CCC[C@@H](Nc2cc(Cl)cc(C(F)(F)F)c2)C1=O,vecabrutinib,Phase 1/Phase 2,Bruton's tyrosine kinase (BTK) inhibitor,,,
CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CCCCC1,vecuronium,Launched,acetylcholine receptor antagonist,CHRNA2,neurology/psychiatry,muscle relaxant
C[C@H](C(=O)O)c1ccc(C2CCCCC2)c2ccccc12,vedaprofen,Launched,anti-inflammatory agent,PTGS2,neurology/psychiatry|endocrinology,pain relief|fever
O=Cc1c(O)cccc1OCCCCC(=O)O,velaresol,Preclinical,,,,
CCC[C@@H](N(NC(=O)c1cccc(OC)c1CC)C(=O)c1cc(C)cc(C)c1)C(C)(C)C,veledimex,Phase 2,cytochrome P450 inhibitor,,,
O=C(O)[C@@H](c1ccc(OCc2ccc3ccccc3n2)cc1)C1CCCC1,veliflapon,Phase 3,leukotriene synthesis inhibitor,ALOX5AP,,
C[C@]1(c2nc3cccc(C(N)=O)c3[nH]2)CCCN1,veliparib,Phase 3,PARP inhibitor,PARP1|PARP2,,
CC(C)(C)S(=O)(=O)N[C@H]1CC[C@H](C(=O)Nc2ccc(C(F)(F)F)cn2)CC1,velneperit,Phase 2,neuropeptide receptor antagonist,NPY5R,,
COC[C@H]1C[C@@H](c2nc(-c3ccc4c(c3)COc3cc5c(ccc6[nH]c([C@@H]7CC[C@H](C)N7C(=O)[C@@H](NC(=O)OC)C(C)C)nc65)cc3-4)c[nH]2)N(C(=O)[C@H](NC(=O)OC)c2ccccc2)C1,velpatasvir,Launched,antiviral,,infectious disease,hepatitis C
CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F,vemurafenib,Launched,RAF inhibitor,BRAF|RAF1,oncology,melanoma
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,venetoclax,Launched,BCL inhibitor,BCL2,hematologic malignancy,chronic lymphocytic leukemia (CLL)
COc1ccc([C@@H](CN(C)C)C2(O)CCCCC2)cc1,venlafaxine,Launched,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotoninâ__orepinephrine reuptake inhibitor (SNRI),SLC6A2|SLC6A4,neurology/psychiatry,depression|generalized anxiety disorder (GAD)|panic disorders|social anxiety disorder
N#Cc1ccc(COC[C@H]2O[C@@H](n3c(NCc4ccc(Cl)c(Cl)c4)nc4c(N)ncnc43)[C@H](O)[C@@H]2O)cc1,VER-155008,Preclinical,HSP inhibitor,HSPA1A,,
CCNC(=O)c1[nH]nc(-c2cc(Cl)c(O)cc2O)c1-c1ccc(OC)cc1,VER-49009,Preclinical,HSP inhibitor,HSP90AA1,,
C=CCN1CCC[C@H]1CNC(=O)c1cc(S(N)(=O)=O)cc(OC)c1OC,veralipride,Preclinical,dopamine receptor antagonist,,,
COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,verapamil,Launched,calcium channel blocker,CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1F|CACNA1G|CACNA1I|CACNA1S|CACNB1|CACNB2|CACNB3|CACNB4|CYP3A4|KCNA10|KCNA7|KCNH2|KCNJ11|NALCN|SCN5A|SLC29A4|SLC6A4,cardiology,hypertension
C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)/C=C/c2ccc(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O,verbascoside,Phase 2/Phase 3,NFkB pathway inhibitor|PKC inhibitor,,,
CC(C)(C)c1ccc(S(=O)(=O)Nc2ccc(Cl)cc2C(=O)c2cc[n+]([O-])cc2)cc1,vercirnon,Phase 3,CC chemokine receptor antagonist,CCR9,,
O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1ccccn1,verdinexor,Preclinical,exportin antagonist,,,
CC(C)OCCn1c(=S)[nH]c(=O)c2[nH]ccc21,verdiperstat,Phase 3,myeloperoxidase inhibitor,,,
COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N,vericiguat,Phase 3,guanylate cyclase stimulant,,,
CC(C)(Sc1ccncc1-c1ccc(C#N)c2ccccc12)C(=O)O,verinurad,Phase 2,urate transporter inhibitor,SLC22A12,,
COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC,vernakalant,Launched,potassium channel blocker,KCNA5,cardiology,atrial fibrillation (AF)
C=CC1=C(C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)C(C)=C5CCC(=O)O)c(CCC(=O)OC)c4C)[C@@]1(C)C3=CC=C(C(=O)OC)[C@H]1C(=O)OC,verteporfin,Launched,photosensitizing agent,,ophthalmology,macular degeneration
CN1C(N)=N[C@](C)(c2cc(NC(=O)c3ccc(F)cn3)ccc2F)CS1(=O)=O,verubecestat,Phase 3,beta secretase inhibitor,,,
COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1,verubulin,Phase 2,tubulin polymerization inhibitor,TUBB,,
CC[C@H](Nc1cc(C)nc2c(-c3ccc(OC)cc3C)c(C)nn12)c1nc(C)no1,verucerfont,Phase 2,corticotropin releasing factor receptor antagonist,,,
O[C@@H]1CCCC[C@H]1N1CCC(c2ccccc2)CC1,vesamicol,Preclinical,acetylcholinesterase inhibitor,SLC18A3,,
COc1ccc(C(=O)N2CCN(c3ccc4c(c3)CCC(=O)N4)CC2)cc1OC,vesnarinone,Launched,phosphodiesterase inhibitor,KCNH2|PDE3A,cardiology,congestive heart failure
O=C(O)C[C@H]1CC(c2ccccc2)=NO1,VGX-1027,Phase 1,tumor necrosis factor receptor antagonist,TLR4,,
COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C,vicriviroc,Phase 3,CC chemokine receptor antagonist,CCR5,,
Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,vidarabine,Launched,antiviral,ADA,infectious disease,virus herpes simplex (HSV)|varicella-zoster virus (VZV)
C=C[C@@H](N)CCC(=O)O,vigabatrin,Launched,GABA aminotransferase inhibitor,ABAT|SLC32A1,neurology/psychiatry,seizures|spasms
O=C(O)C(c1ccccc1)(c1ccccc1)c1ccccc1.OCc1cc([C@@H](O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl)ccc1O,vilanterol,Launched,adrenergic receptor agonist,ADRB2,pulmonary,chronic obstructive pulmonary disease (COPD)
N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1,vilazodone,Launched,serotonin reuptake inhibitor,DRD2|DRD3|HRH1|HTR1A|HTR4|SLC6A4,neurology/psychiatry,depression
N#C[C@@H]1CCCN1C(=O)CN[C@@]12C[C@@H]3C[C@@H](C[C@@](O)(C3)C1)C2,vildagliptin,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus
CCOc1ccccc1OC[C@H]1CNCCO1,viloxazine,Launched,norepinephrine reuptake inhibitor,SLC6A2,neurology/psychiatry,depression
CC[C@]1(O)C[C@@H]2C[N@@](CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,vinblastine,Launched,microtubule inhibitor|tubulin polymerization inhibitor,JUN|TUBA1A|TUBB|TUBD1|TUBE1|TUBG1,hematologic malignancy|infectious disease|oncology,Hodgkin's lymphoma|true histiocytic lymphoma (THL)|mycosis|small lymphocytic lymphoma (SLL)|testicular carcinoma|Kaposi sarcoma
CC[C@]12CCCN3CCc4c(n(c5ccccc45)C(=O)C1)[C@@H]32,vinburnine,Launched,adrenergic receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4,neurology/psychiatry,stroke
CC[C@]1(O)C[C@@H]2C[N@@](CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,vincristine,Launched,tubulin polymerization inhibitor,TUBA4A|TUBB,hematologic malignancy,acute lymphoblastic leukemia (ALL)
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,vindesine,Launched,tubulin polymerization inhibitor,TUBB|TUBB1,oncology,breast cancer|non-small cell lung cancer (NSCLC)|melanoma
CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)C[N@](CCc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32,vinflunine,Launched,microtubule inhibitor,,oncology,bladder cancer
CCC1=C[C@@H]2C[N@](C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,vinorelbine,Launched,tubulin polymerization inhibitor,TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,oncology,non-small cell lung cancer (NSCLC)
CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c(n1c1ccccc41)[C@@H]32,vinpocetine,Launched,phosphodiesterase inhibitor|sodium channel blocker,PDE1A|PDE1C,neurology/psychiatry,stroke|senile dementia
NCCC[C@H](N)CC(=O)N[C@H]1CNC(=O)[C@H]([C@H]2C[C@H](O)N=C(N)N2)NC(=O)C(C=NC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC1=O,viomycin,Launched,protein synthesis inhibitor,,infectious disease,tuberculosis
Cc1cc(Cn2nnc3c(-c4ccco4)nc(N)nc32)ccc1N,vipadenant,Phase 1,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1,vismodegib,Launched,hedgehog pathway inhibitor|smoothened receptor antagonist,SMO,oncology,basal cell carcinoma (BCC)
CC1=C(C)C(=O)C(CCCCCCCCCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)=CC1=O,visomitin,Preclinical,antioxidant,,,
C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4/[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)(O)O[C@H]1[C@@H](O)[C@@H](n6cnc7cc(C)c(C)cc76)O[C@@H]1CO)[C@H]5CC(N)=O)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O,vitamin-B12,Launched,,,hematology,megaloblastic anemia
Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2,vitamin-E,Launched,LDL oxidation inhibitor|PKC inhibitor,ALOX5|DGKA|NR1I2|PPP2CA|PPP2CB|PRKCA|PRKCB|SEC14L2|SEC14L3|SEC14L4,,
NC(=O)[C@@H]1CC[C@H](c2ccc(OCc3ccccc3F)cc2)N1,vixotrigine,Phase 2,sodium channel blocker,,,
Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H](C(C)C)N2Cc3ccccc3C2=O)cc1,VL285,Preclinical,PROTAC,,,
C=CC(=O)N1CC/C(=C\c2ccc(F)c([N+](=O)[O-])c2)C(=O)/C(=C/c2ccc(F)c([N+](=O)[O-])c2)C1,VLX1570,Phase 1/Phase 2,deubiquitinase inhibitor,,,
C/C(=N/Nc1nnc2c(n1)[nH]c1c(C)cccc12)c1ccccn1,VLX600,Phase 1,antitumor agent|ubiquitin C-terminal hydrolase inhibitor,TP53|USP14,,
CC(=NNc1nnc2c(n1)[nH]c1c(C)cccc12)c1ccccn1,VLX600,Phase 1,antitumor agent|ubiquitin C-terminal hydrolase inhibitor,TP53|USP14,,
C=C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,voclosporin,Phase 3,calcineurin inhibitor,,,
OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O,voglibose,Launched,glucosidase inhibitor,MGAM,endocrinology,diabetes mellitus|hyperglycemia
CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C,volasertib,Phase 3,PLK inhibitor,PLK1,,
COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC,volinanserin,Phase 3,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C|KCNH2,,
CNCc1cc(-c2ccccc2F)n(S(=O)(=O)c2cccnc2)c1,vonoprazan,Launched,potassium-competitive acid antagonist,ATP4A,gastroenterology,peptic ulcer disease (PUD)
CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1,vorapaxar,Launched,thrombin inhibitor,F2R,cardiology,myocardial infarction|peripheral artery disease (PAD)
C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F,vorasidenib,Preclinical,isocitrate dehydrogenase inhibitor,,,
CN[C@H]1CN(c2ccc3c(=O)c(C(=O)O)cn(-c4nccs4)c3n2)C[C@@H]1OC,voreloxin,Phase 3,topoisomerase inhibitor,TOP2A,,
C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,voriconazole,Launched,cytochrome P450 inhibitor,CYP2C19|CYP2C9|CYP3A4|CYP3A5|PTGS1,infectious disease,esophageal candidiasis|aspergillosis|skin infections
O=C(CCCCCCC(=O)Nc1ccccc1)NO,vorinostat,Launched,HDAC inhibitor,HDAC1|HDAC10|HDAC11|HDAC2|HDAC3|HDAC5|HDAC6|HDAC8|HDAC9,hematologic malignancy,cutaneous T-cell lymphoma (CTCL)
Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1,vortioxetine,Launched,serotonin receptor agonist|serotonin receptor antagonist,HTR1A|HTR1B|HTR2A|HTR2C|HTR3A|HTR5A|HTR6|HTR7|SLC6A4,neurology/psychiatry,depression
CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccc(C(F)(F)F)cc4Cl)oc23)[C@@H]1CO,voruciclib,Phase 1,CDK9 inhibitor,,,
CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O,voxelotor,Launched,hemoglobin modulator,,,
CCn1c(=O)c(-c2cc[nH]n2)cc2c(C)nc(N)nc21,voxtalisib,Phase 2,mTOR inhibitor|PI3K inhibitor,MTOR|PIK3CA,,
O=C(O)CCc1c[nH]c2ccccc12,VP-20629,Phase 1,beta amyloid antagonist,PLA2G2E|SLC36A1,,
CNC(=O)c1ccccc1Nc1cc(Nc2ccc(N3CCOCC3)cc2OC)ncc1C(F)(F)F,VS-4718,Phase 1,focal adhesion kinase inhibitor,,,
CC(C)[C@](O)(c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1)c1cn[nH]n1,VT-464,Phase 2,cytochrome P450 inhibitor,CYP17A1,,
CN[C@H](CNC(=O)N1CCC[C@@H]([C@@H](OCCNC(=O)OC)c2cccc(Cl)c2)C1)C[C@H]1CCCOC1,VTP-27999,Phase 1,renin inhibitor,REN,,
C[C@@H](CN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1)NC(=O)c1ccc2ccccc2c1,VU0155069,Preclinical,phospholipase inhibitor,PLD1,,
COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc32)cc1,VU0238429,Preclinical,acetylcholine receptor allosteric modulator,CHRM5,,
Cc1csc(NC(=O)CSc2ccc(-c3ccccc3)nn2)n1,VU0240551,Preclinical,potassium/chloride cotransporter inhibitor,SLC12A5,,
CCCCOc1ccc(C(=O)Nc2ccc(F)cc2F)cc1,VU0357121,Preclinical,glutamate receptor positive allosteric modulator,GRM5,,
O=C(NC1CCC1)c1ccc(C#Cc2cccc(F)c2)nc1,VU0360172,Preclinical,glutamate receptor positive allosteric modulator,GRM5,,
COc1cc(NC(=O)c2ccccn2)ccc1Cl,VU0361737,Preclinical,glutamate receptor positive allosteric modulator,GRM4,,
O=C(Nc1ccc(S(=O)(=O)Nc2ccccc2Cl)c(Cl)c1)c1ccccn1,VU0364439,Preclinical,glutamate receptor positive allosteric modulator,GRM4,,
O=C(NCCN1CCC2(CC1)C(=O)NCN2c1cccc(F)c1)c1ccc2ccccc2c1,VU0364739,Preclinical,phospholipase inhibitor,PLD2,,
O=C(Nc1cccc(Cl)c1)c1ccccn1,VU0364770,Preclinical,glutamate receptor positive allosteric modulator,GRM4,,
O=C(Nc1ccc(Oc2ccc(Cl)cn2)c(Cl)c1)c1ccccn1,VU0422288,Preclinical,glutamate receptor positive allosteric modulator,GRM3,,
Cc1cc(C)c2c(N)c(C(=O)NCc3ccc(Cl)cc3)sc2n1,VU10010,Preclinical,acetylcholine receptor allosteric modulator,CHRM4,,
COc1ccc(CNC(=O)c2sc3nc(C)cc(C)c3c2N)cc1,VU152100,Preclinical,acetylcholine receptor allosteric modulator,CHRM4,,
O=C(Nc1cc(-c2ccccc2)nn1-c1ccccc1F)c1ccc([N+](=O)[O-])cc1,VU1545,Preclinical,glutamate receptor positive allosteric modulator,GRM5,,
O=C(Nc1cc(-c2ccccc2)nn1-c1ccccc1)c1ccc([N+](=O)[O-])cc1,VU29,Preclinical,glutamate receptor potentiator,GRM5,,
O=[N+]([O-])c1ccc2nc(COCc3nc4ccc([N+](=O)[O-])cc4[nH]3)[nH]c2c1,VU591,Preclinical,potassium channel blocker,KCNJ1,,
CN1CCN(c2nc3ccccc3nc2Cl)CC1,VUF10166,Preclinical,serotonin receptor antagonist,HTR3A|HTR3B,,
CN1CCN(c2cc(-c3ccccc3)nc(N)n2)CC1,VUF10460,Preclinical,histamine receptor agonist,HRH4,,
COc1cc(C(=O)N(CC[C@H]2CCCN2C)C/C(C)=C/c2ccccc2F)cc(OC)c1OC,VUF11207,Preclinical,CC chemokine receptor agonist,ACKR3,,
Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1,VX-11e,Preclinical,MAP kinase inhibitor,MAPK1,,
CC(C)(C)C#Cc1cc(N(C(=O)[C@H]2CC[C@H](C)CC2)[C@H]2CC[C@@H](O)CC2)c(C(=O)O)s1,VX-222,Phase 2,HCV inhibitor,,,
NC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F,VX-702,Phase 2,p38 MAPK inhibitor,IL1B|IL6|MAPK11|MAPK12|MAPK14|TNF,,
O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl,VX-745,Phase 2,p38 MAPK inhibitor,MAPK11|MAPK12|MAPK14,,
CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C,VX-765,Phase 2,caspase inhibitor,CASP1,,
COc1ccc2c(c1)[C@H](C(=O)N(Cc1ccc(N(C)C)cc1)c1ccc(C(C)C)cc1)CCC2,W-54011,Preclinical,anaphylatoxin chemotactic receptor antagonist,C5AR1,,
Cn1nc(-c2ccc(C(F)(F)F)cc2)nc2c(=O)n(C)c(=O)nc1-2,walrycin-B,Preclinical,transcriptional regulatory protein WalR,,,
CC(=O)C[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O,warfarin,Launched,vitamin K antagonist,VKORC1,hematology|cardiology,deep vein thrombosis (DVT)|pulmonary embolism (PE)|atrial fibrillation (AF)|myocardial infarction
COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1,WAY-100635,Phase 1,serotonin receptor antagonist,HTR1A,,
O=C1Nc2cc(Cl)c(Cl)cc2N2CCNC[C@H]12,WAY-161503,Preclinical,serotonin receptor agonist,HTR2C,,
Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(C(=O)NO)c1,WAY-170523,Preclinical,metalloproteinase inhibitor,MMP13,,
Oc1ccc(-c2nc3cc(O)cc(Br)c3o2)cc1,WAY-200070,Preclinical,estrogen receptor agonist,ERBB2|ERBB3|ERBB4|ESR2,,
CC(C)(C)c1ccc(-c2nc3c(N4CCN(Cc5ccc6nccnc6c5)CC4)cccc3[nH]2)cc1,WAY-207024,Preclinical,gonadotropin releasing factor hormone receptor antagonist,GNRHR|HRH2|TACR2,,
CN(C)CCn1cc(S(=O)(=O)c2cccc(F)c2)c2cccnc21,WAY-208466,Preclinical,serotonin receptor agonist,DRD2|HTR2A|HTR2C|HTR6|HTR7,,
N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(=O)O,WAY-213613,Preclinical,glutamate inhibitor,SLC1A2,,
Cn1c(C#N)ccc1-c1cc(F)c2c(c1)C(C)(C)C(=O)N2,WAY-255348,Preclinical,progesterone receptor antagonist,,,
O=S(=O)(NC1CCNCC1)c1cc(S(=O)(=O)c2ccccc2)ccc1C(F)(F)F,WAY-316606,Preclinical,secreted frizzled related protein inhibitor,SFRP1,,
CC(C)OC(=O)C1=CN(C(=O)c2ccc(F)c(F)c2)CC(C)(C)c2c1[nH]c1ccccc21,WAY-362450,Phase 1,FXR agonist,NR1H4,,
c1cncc(CN2CCC(n3ncc4c(N5CCOCC5)nc(-c5ccc6[nH]ccc6c5)nc43)CC2)c1,WAY-600,Preclinical,mTOR inhibitor,MTOR,,
c1cc2c3c(c1)c1c(n3CCNC2)CCCC1,WAY-629,Preclinical,serotonin receptor agonist,HTR2C,,
COc1cccc(OC)c1OCCNC[C@H]1COc2ccccc2O1,WB-4101,Preclinical,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|HTR1A,,
COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1,WDR5-0103,Preclinical,histone lysine methyltransferase inhibitor,WDR5,,
Cc1ccc(-c2nn(C(C)(C)CNC(=O)c3ncccc3C)c3ncnc(N)c23)cc1,WEHI-345-analog,Preclinical,SRC inhibitor,,,
COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2ccnc(Nc3ccc(N4CCN(C)CC4)cc3)n2)c(OC)c1,WH-4-023,Preclinical,SRC inhibitor,LCK|SRC,,
COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC,WHI-P154,Preclinical,JAK inhibitor,EGFR|JAK1|JAK2|JAK3,,
COc1ccc(-n2c(SCCCN3C(=O)c4cccc5cccc(c45)C3=O)nnc2-c2ccncc2)cc1,WIKI4,Preclinical,tankyrase inhibitor|WNT pathway inhibitor,TNKS2,,
O=C(NCCCCCCCCNC(=O)C(Cl)Cl)C(Cl)Cl,WIN-18446,Preclinical,aldehyde dehydrogenase inhibitor,ALDH1A2,,
CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N/C(=N/C2CCCCC2)NC2CCCCC2)cc1,WIN-64338,Preclinical,bradykinin receptor antagonist,BDKRB2,,
CN(C)C[C@@H](O)Cn1c2ccc(Br)cc2c2cc(Br)ccc21,wiskostatin,Preclinical,actin related protein inhibitor|neural Wiskott-Aldrich syndrome protein inhibitor,WASL,,
Cc1cc(-c2ccc(CC(=O)Nc3ccc(-c4cccnc4)cc3)cc2)ccn1,wnt-c59,Preclinical,porcupine inhibitor,PORCN,,
COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C(C3=O)[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O,wortmannin,Preclinical,PI3K inhibitor,PI4KA|PI4KB|PIK3CA|PIK3CD|PIK3CG|PIK3R1|PLK1|PRKDC,,
C[C@H](NC(=O)/C(C#N)=C/c1cccc(Br)n1)c1ccccc1,WP1066,Phase 1,STAT inhibitor,STAT3,,
CCC[C@H](NC(=O)/C(C#N)=C/c1cccc(Br)n1)c1ccccc1,WP1130,Preclinical,deubiquitinase inhibitor,JAK2|UCHL5|USP14|USP9X,,
O=C(O)Cn1nnnc1-c1ccsc1,WP921,Preclinical,,,,
CC1(C)N=C(N)N=C(N)N1OCCCOc1cc(Cl)c(Cl)cc1Cl,WR99210,Preclinical,dihydrofolate reductase inhibitor,TYMS,infectious disease,malaria
CCOC(=O)c1ccc(-c2ccc(OC(=O)N(C)Cc3cccc(-c4ccncc4)c3)cc2)cc1,WWL-113,Preclinical,carboxylesterase inhibitor,CES3,,
CN(Cc1cccc(-c2ccccc2)c1)C(=O)Oc1ccc(-c2ccc(C(N)=O)cc2)cc1,WWL-123,Preclinical,monoacylglycerol lipase inhibitor,ABHD6,,
CCOC(=O)C(=O)Nc1cccc(OC)c1C(N)=O,WY-16922,Phase 1,histamine release inhibitor,,,
CNC(=O)Nc1ccc(-c2nc(N3C[C@H]4CC[C@@H](C3)O4)c3cnn(C4CCC5(CC4)OCCO5)c3n2)cc1,WYE-125132,Preclinical,mTOR inhibitor,MTOR,,
COC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)OC)CC4)c3n2)cc1,WYE-354,Preclinical,mTOR inhibitor,MTOR,,
COC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5cccnc5)CC4)c3n2)cc1,WYE-687,Preclinical,mTOR inhibitor,MTOR,,
C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)ncc2Cl)c1,WZ-3146,Preclinical,EGFR inhibitor,EGFR,,
C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1,WZ-4002,Preclinical,EGFR inhibitor,EGFR|ERBB2,,
CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1,WZ4003,Preclinical,AMPK inhibitor,NUAK1|NUAK2,,
C=CC(=O)Nc1cccc(Sc2nc(Nc3ccc(N4CCN(C)CC4)cc3)ncc2Cl)c1,WZ8040,Preclinical,EGFR inhibitor,EGFR,,
c1ccc(NCc2ccc(CNc3ccccn3)cc2)nc1,WZ811,Preclinical,CC chemokine receptor antagonist,CXCR4,,
FC(F)(F)c1cccc(C2=CCN(CCc3ccc4ccccc4c3)CC2)c1,xaliproden,Phase 3,serotonin receptor agonist,HTR1A,,
O=C(NCCNCC(O)COc1ccc(O)cc1)N1CCOCC1,xamoterol,Phase 3,adrenergic receptor agonist,ADRB1,,
CCCCCCOc1nsnc1C1=CCCN(C)C1,xanomeline,Phase 3,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR6|HTR7,,
O=c1c2ccccc2oc2ccccc12,xanthone,Preclinical,antimalarial agent,,,
O=c1nc(-c2ccc(C(F)(F)F)cc2)[nH]c2c1CSCC2,XAV-939,Preclinical,tankyrase inhibitor,TNKS|TNKS2,,
CCN(Cc1ccccc1)C(=O)Cn1c(=O)n(C)c2cnc(-c3ccccc3)nc21,XBD173,Phase 2,benzodiazepine receptor ligand,TSPO,,
CCc1c(C(=O)Nc2cc(S(=O)(=O)N(CC)CC)ccc2O)[nH]c(C)c1C(C)=O,XD-14,Preclinical,bromodomain inhibitor,BRD2|BRD3|BRD4|BRDT,,
O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc21,XE-991,Preclinical,potassium channel blocker,KCNQ1|KCNQ2|KCNQ3|KCNQ4|KCNQ5,,
O=C(O)c1ccccc1-c1ccc(C(F)(F)F)cc1,xenalipin,Phase 2,,,,
Cc1cccc(OC[C@@H](O)CNC(C)(C)C)c1C,xibenolol,Phase 3,adrenergic receptor antagonist,,,
Cc1cccc(C)c1NC(=O)/N=C1/CCCN1C,xilobam,Phase 1,,,,
Cc1cccc(C)c1NC(=O)c1cc(S(N)(=O)=O)c(Cl)cc1O,xipamide,Launched,carbonic anhydrase inhibitor,SLC12A3,cardiology,edema|hypertension
O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)[C@@H]1CCCN1,XL019,Phase 1,JAK inhibitor,JAK1|JAK2|JAK3,,
CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2F)c(C(C)(C)c2c(Cl)cccc2Cl)n1,XL041,Preclinical,LXR agonist,,,
Cc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2Nc2ccc3nsnc3c2)cc1,XL147,Phase 2,PI3K inhibitor,PIK3CA|PIK3CD|PIK3CG,,
CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)n[nH]3)cc(N3CCN(C)CC3)n2)on1,XL228,Phase 1,Abl kinase inhibitor|insulin growth factor receptor inhibitor|SRC inhibitor,IGF1R|SRC,,
Cc1c(C(=O)N2CCOc3ccc(-c4ccc(N)nc4)cc3C2)ccc(S(C)(=O)=O)c1F,XL388,Preclinical,mTOR inhibitor,MTOR,,
COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1,XL647,Phase 3,EGFR inhibitor|VEGFR inhibitor,EGFR|EPHB4|ERBB2|FLT4|KDR,,
CC[C@@H](C)Nc1cc(C(=O)N[C@H]2C[C@H]3CC[C@@H](C2)N3c2ccc(C(=O)C3CC3)cn2)c(C)cc1C(N)=O,XL888,Phase 1,HSP inhibitor,,,
CCOc1cc(C(=O)N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(C1CCCC1)c1ccccc1C(=O)N2C,XMD17-109,Preclinical,MAP kinase inhibitor,MAPK7,,
CCOc1cc(N2CCC(O)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C,XMD8-92,Preclinical,MAP kinase inhibitor,DCLK2|MAPK7|PLK4|TNK1,,
Cc1cccc(C)c1NC1=NCCCS1,xylazine,Launched,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C,neurology/psychiatry,anesthetic
Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1,xylometazoline,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C,otolaryngology|allergy,nasal congestion|allergic rhinitis
O=C[C@H](O)[C@@H](O)[C@H](O)CO,xylose,Launched,,,,
OCC[N+]12CN3CN(CN(C3)C1)C2,Y-11,Preclinical,focal adhesion kinase inhibitor,PTK2,,
CC(C)N1CCN(c2ccc(C(=O)c3c(-c4ccc(O)cc4)sc4cc(O)ccc34)cc2)CC1,Y-134,Preclinical,estrogen receptor antagonist,ESR1|ESR2,,
CC(=O)N(O)[C@@H]1c2cc(C#N)ccc2OC(C)(C)[C@H]1O,Y-26763,Phase 1,potassium channel activator,KCNJ8,,
CC(=O)N(OCc1ccccc1)[C@@H]1c2cc(C#N)ccc2OC(C)(C)[C@H]1O,Y-27152,Phase 1,potassium channel activator,KCNJ8,,
C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1,Y-27632,Preclinical,rho associated kinase inhibitor,PKIA|PKN2|PRKACA|PRKCE|ROCK1|ROCK2,,
CC(C)c1ccc(C(=O)c2cccs2)c(SCCCCCCCCN(C)C)n1,Y-29794,Preclinical,prolyl endopeptidase inhibitor,PREP,,
Cc1c(C(=O)Nc2ccc(N3CCC(N4CCOCC4)CC3)c(C#N)c2)cnn1-c1ccc(Cl)cc1,Y-320,Preclinical,interleukin inhibitor,IL17A,,
C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1,Y-39983,Phase 2,rho associated kinase inhibitor,ROCK1|ROCK2,,
Cc1cccc(COc2cccc(/C=C3\C(=O)NN(c4ccccc4)C3=O)c2)c1,Y16,Preclinical,rho associated kinase inhibitor,RHOA,,
OCc1ccc(-c2nn(Cc3ccccc3)c3ccccc23)o1,YC-1,Preclinical,guanylyl cyclase activator,GUCY1A2|GUCY1A3|GUCY1B3|HIF1A,,
Cc1nc2ccc(Oc3ccc(F)cc3)cc2c(=O)n1C[C@H]1CCCN(C(C)C)C1,YIL-781,Preclinical,ghrelin receptor antagonist,GHSR,,
COc1ccc(C(=O)C[C@@]2(O)C(=O)Nc3c(Cl)ccc(Cl)c32)cc1,YK-4-279,Preclinical,apoptosis inhibitor,EWSR1|FLI1,,
O=c1ccccn1CC1(O)CCN(Cc2ccccc2)CC1,YL0919,Preclinical,selective serotonin reuptake inhibitor (SSRI),,,
Cc1cccc(NC(=O)N[C@@H]2N=C(c3ccccc3)c3ccccc3N(CC(=O)c3ccccc3C)C2=O)c1,YM-022,Phase 2,CCK receptor antagonist,CCKBR,,
COCCn1c2c([n+](Cc3cnccn3)c1C)C(=O)c1ccccc1C2=O,YM-155,Phase 2,survivin inhibitor,BIRC5,,
Nc1ccc(C(=O)Nc2cccc(-c3nc(N4CCOCC4)c4oc5ncccc5c4n3)c2)cn1,YM-201636,Preclinical,PI3K inhibitor,,,
Nc1cccc(CNC(=O)c2ccc(Oc3ccc(OCc4cccc(F)c4)cc3)nc2)c1,YM-244769,Preclinical,sodium/calcium exchange inhibitor,,,
Cc1c(C(=O)N(C)C2CCCCC2)sc2nc3ccc(N)cc3n12,YM-298198,Preclinical,glutamate receptor antagonist,GRM1,,
Cc1c(C(=O)NC2CCCCC2)sc2nc3ccc(N)cc3n12,YM-298198-desmethyl,Preclinical,glutamate receptor antagonist,GRM1,,
N#Cc1ccc(N(Cc2ccc(Br)cc2)n2cnnc2)cc1,YM-511,Phase 2,aromatase inhibitor,CYP19A1,,
Cc1nnsc1C(=O)Nc1ccc(-n2nc(C(F)(F)F)cc2C(F)(F)F)cc1,YM-58483,Preclinical,calcium channel blocker,TRPC3|TRPC5|TRPM4,,
Cc1cc(C)c(NC(=O)N(Cc2ccc3c(c2)Cc2ccccc2-3)C2CCCCCC2)c(C)c1,YM-750,Phase 1,ACAT inhibitor,SOAT1,,
COc1cc2c(cc1OC)-c1cc3nc4ccccc4nc3n1C(C)(C)C2,YM-90709,Preclinical,IL5 inhibitor,CSF2RB|IL5RA,,
CCc1ccc2c(-c3cccc(Cl)c3)nc(=O)n(CC)c2n1,YM-976,Phase 1,phosphodiesterase inhibitor,PDE4A,,
C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@@H]1C(=O)N(C)c2ccccc2-c2ccccc21,YO-01027,Preclinical,gamma secretase inhibitor,,,
Clc1cccc(Cl)c1CSc1nnc(-c2cnccn2)s1,yoda-1,Preclinical,piezo channel activator,PIEZO1,,
COC(=O)[C@@H]1[C@H]2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O,yohimbine,Launched,adrenergic receptor antagonist,ADRA2A|ADRA2B|ADRA2C|DRD2|DRD3|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR7|KCNJ1|KCNJ10|KCNJ11|KCNJ12|KCNJ14|KCNJ15|KCNJ8,cardiology,cardiac arrythmia|bradycardia
COc1ccc(CCN(C)CCc2ccc(OC)c(OC)c2)cc1OC,YS-035,Preclinical,calcium channel blocker,,,
CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCCCC2)[C@@H]1c1cccc([N+](=O)[O-])c1,YS-201,Preclinical,calcium receptor antagonist,,,
CCOC(=O)c1cc2ccc(O)cc2oc1=O,YZ9,Preclinical,phosphofructokinase inhibitor,MIF|PFKFB3,,
O=C(CC(c1ccccc1)c1ccccc1)N1CCN(C(c2ccccc2)c2ccccc2)CC1,Z160,Phase 2,N-type calcium channel blocker,CACNA2D1,,
COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CN2CCC1CC2,zacopride,Phase 2,serotonin receptor antagonist,HTR3A|HTR3B|HTR4|HTR5A,,
COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12,zafirlukast,Launched,leukotriene receptor antagonist,CYSLTR1|CYSLTR2,pulmonary,asthma
Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1,zalcitabine,Launched,nucleoside reverse transcriptase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)
C[C@@]1(CN2CCC(n3c(=O)[nH]c4ccccc43)CC2)OCc2ccccc2-n2cccc21,zaldaride,Phase 3,calmodulin antagonist,CALM1,,
Cc1nc(-c2csc(NC(=N)N)n2)c[nH]1,zaltidine,Phase 3,histamine receptor antagonist,HRH2,,
C[C@@H](C(=O)O)c1ccc2c(c1)CC(=O)c1ccccc1S2,zaltoprofen,Launched,cyclooxygenase inhibitor,,endocrinology|neurology/psychiatry,fever|pain relief
c1ccc(C(O[C@@H]2CCCN(CCc3ccc4c(c3)OCO4)C2)c2ccccc2)cc1,zamifenacin,Phase 3,acetylcholine receptor antagonist,CHRM3,,
CC(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CO)OC(C(=O)O)=C[C@@H]1NC(=N)N,zanamivir,Launched,neuraminidase inhibitor,NEU2,infectious disease,influenza A virus infection
C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,zanubrutinib,Launched,Bruton's tyrosine kinase (BTK) inhibitor,,,
CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1,zaprinast,Phase 2,phosphodiesterase inhibitor,GPR35|PDE1A|PDE4D|PDE5A|PDE9A,,
COc1cc(-c2ccc(=O)[nH]n2)ccc1OC(F)F,zardaverine,Phase 2,phosphodiesterase inhibitor,PDE4D,,
COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC,zatebradine,Phase 3,HCN channel blocker,HCN1|HCN2|HCN3|HCN4,,
Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1,ZCL-278,Preclinical,CDC inhibitor,CDC42,,
N#Cc1cccc([C@@H]2C=C(C(F)(F)F)NC3=C2C(=O)CCC3)c1,ZD-0947,Preclinical,potassium channel activator,,,
O=C(O)Cc1ccc(OCCNC[C@H](O)c2ccccc2)cc1,ZD-2079,Phase 2,adrenergic receptor agonist,ADRB3,,
COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1,ZD-7114,Phase 1,adrenergic receptor agonist,ADRB3,,
CCc1cc2c(c(CC)n1)CCC(=O)N2Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,ZD-7155,Preclinical,angiotensin receptor antagonist,AGTR1,,
CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1,ZD-7288,Phase 2,HCN channel blocker,HCN1|HCN2|HCN3|HCN4,,
C/C(=C\CNc1ncnc2nc[nH]c12)CO,zeatin,Phase 1,,,,
O=c1ncccn1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,zebularine,Preclinical,DNA methyltransferase inhibitor,CDA|DNMT1,,
COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(-c2nnco2)cc1,zibotentan,Phase 3,endothelin receptor antagonist,EDNRA,,
Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,zidovudine,Launched,nucleoside reverse transcriptase inhibitor,TERT,infectious disease,human immunodeficiency virus (HIV-1)|acquired immunodeficiency syndrome (AIDS)
C[C@H](c1cc2ccccc2s1)N(O)C(N)=O,zileuton,Launched,leukotriene synthesis inhibitor|lipoxygenase inhibitor,ALOX5,pulmonary,asthma
CC(C)N[C@H]1CCn2c(=O)[nH]c3cccc(c32)[C@@H]1O,zilpaterol,Launched,adrenergic receptor agonist,ADRB2,endocrinology,weight-gain aid
Cc1cc(N2CCCCC2)nn2cnnc12,zindotrine,Phase 2,phosphodiesterase inhibitor,,,
O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1,ziprasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR3A|HTR6|HTR7|SLC6A4,neurology/psychiatry,schizophrenia|bipolar disorder
CCc1nc2c(C)cc(N3CCN(CC(=O)N4CC(O)C4)CC3)cn2c1N(C)c1nc(-c2ccc(F)cc2)c(C#N)s1,ziritaxestat,Phase 3,autotaxin inhibitor,,,
CCCCCS(=O)(=O)CCCCCCCCCCn1c(-c2ccc(O)cc2)c(C)c2cc(O)ccc21,ZK-164015,Preclinical,estrogen receptor antagonist,ESR1|ESR2,,
O=c1[nH]c2cc(C(F)(F)F)c(N3CCOCC3)cc2n(CP(=O)(O)O)c1=O,ZK-200775,Phase 2,kainate receptor antagonist,,,
C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O,ZK-811752,Phase 2,CC chemokine receptor antagonist,CCR1,,
CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC,ZK-93423,Phase 3,benzodiazepine receptor agonist,GABRA1|GABRA2|GABRA3|GABRA5|GABRB2|GABRG2,,
CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C,ZK-93426,Phase 1,benzodiazepine receptor antagonist,GABRA1|GABRA2|GABRA3|GABRA5,,
CC(C)(C)c1ccc(-c2nc3ccccc3[nH]2)cc1,ZLN005,Preclinical,,,,
Cc1ccc(OCCSc2ncccn2)c(Br)c1,ZLN024,Preclinical,AMPK activator,PRKAA1|PRKAB1|PRKAG1,,
C[C@@](O)(C(=O)Nc1ccc(S(=O)(=O)c2ccccc2)cc1)C(F)(F)F,ZM-226600,Preclinical,Kir6 channel (KATP) activator,,,
Nc1nc(NCCc2ccc(O)cc2)nc2nc(-c3ccco3)nn12,ZM-241385,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC,ZM-306416,Preclinical,Abl kinase inhibitor|SRC inhibitor|VEGFR inhibitor,EGFR|FLT1|FLT4|KDR,,
Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O,ZM-323881,Preclinical,VEGFR inhibitor,KDR,,
Cc1ccc(NC(=O)c2cccc(N(C)C)c2)cc1NC(=O)c1ccc(O)cc1,ZM-336372,Preclinical,RAF inhibitor,BRAF|LCK|MAPK14|RAF1,,
CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1,ZM-39923,Preclinical,JAK inhibitor,JAK1|JAK3,,
COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1,ZM-447439,Preclinical,Aurora kinase inhibitor,AURKA|AURKB,,
C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@@H](Sc2ccccc2)C[C@H]1C(=O)O,zofenopril-calcium,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension
c1cc(CN2CCCCC2)cc(OCCCNc2nc3ccccc3s2)c1,zolantidine,Preclinical,histamine receptor antagonist,,,
C[C@@H]1CN2c3c(cc4c(N5C(=O)OC[C@@H]5C)noc4c3F)CC3(C(=O)NC(=O)NC3=O)[C@H]2[C@H](C)O1,zoliflodacin,Phase 3,antibacterial ,,,
CS(=O)(=O)c1ccc(-c2cn3ccccc3n2)cc1,zolimidine,Launched,mucus protecting agent,,gastroenterology,peptic ulcer disease (PUD)|gastroesophageal reflux disease (GERD)
CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12,zolmitriptan,Launched,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F,neurology/psychiatry,migraine headache
Cc1nn(C)c2c1C(c1cccc(Cl)c1)=NCCN2,zometapine,Phase 2,,,,
NC(N)=NC(=O)c1cnn(-c2cccc3ncccc23)c1C1CC1,zoniporide,Phase 3,sodium/hydrogen exchanger inhibitor,SLC9A1,,
NS(=O)(=O)Cc1noc2ccccc12,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,CA1|CA10|CA11|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|CA5B|CA6|CA7|CA8|CA9|CACNA1G|CACNA1H|CACNA1I|MAOA|MAOB|SCN10A|SCN11A|SCN1A|SCN1B|SCN2A|SCN2B|SCN3A|SCN3B|SCN4A|SCN4B|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,seizures|epilepsy
O=C(O)Cc1nn(Cc2nc3cc(C(F)(F)F)ccc3s2)c(=O)c2ccccc12,zopolrestat,Phase 2,,AKR1B1|AKR1B10,,
O[C@@H](COc1cccc2ncccc12)CN1CCN([C@@H]2c3ccccc3[C@@H]3[C@H](c4ccccc42)C3(F)F)CC1,zosuquidar,Phase 3,P glycoprotein inhibitor,ABCB1|ABCB4,,
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@H](n3cnnn3)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,zotarolimus,Launched,mTOR inhibitor,FKBP1A,cardiology,coronary artery restenosis
CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc21,zotepine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,ADRA2B|DRD2|DRD3|DRD4|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR6|HTR7|SLC6A2|SLC6A4,neurology/psychiatry,schizophrenia
Nc1nc2cc(Cl)ccc2o1,zoxazolamine,Phase 2,myorelaxant,,,
O=C1N=C2C=CC=CN2C12Cc1ccccc1C2,ZSET1446,Preclinical,nicotinic receptor agonist,,,
FC(F)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,ZSTK-474,Phase 1/Phase 2,PI3K inhibitor,PIK3CB|PIK3CD|PIK3CG,,
OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(Cl)cc32)CC1,zuclopenthixol,Launched,dopamine receptor antagonist,ADRA1A|ADRA2A|DRD1|DRD2|DRD5|HRH1|HTR2A,neurology/psychiatry,schizophrenia|bipolar disorder
C[C@@]1(O)CC[C@H]2[C@H](CC[C@@H]3[C@@H]2CC[C@]2(C)[C@@H](C(=O)Cn4cc(C#N)cn4)CC[C@@H]32)C1,zuranolone,Phase 3,GABA receptor agonist,,,